<SEC-DOCUMENT>0001213900-23-024298.txt : 20230330
<SEC-HEADER>0001213900-23-024298.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330075428
ACCESSION NUMBER:		0001213900-23-024298
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Can-Fite BioPharma Ltd.
		CENTRAL INDEX KEY:			0001536196
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36203
		FILM NUMBER:		23777187

	BUSINESS ADDRESS:	
		STREET 1:		10 BAREKET STREET, KIRYAT MATALON
		STREET 2:		P.O. BOX 7537
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951778
		BUSINESS PHONE:		972 39241114

	MAIL ADDRESS:	
		STREET 1:		10 BAREKET STREET, KIRYAT MATALON
		STREET 2:		P.O. BOX 7537
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951778
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2022_canfitebio.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 11:16:42 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:canf="http://www.confite.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form <ix:nonNumeric contextRef="c0" name="dei:DocumentType">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric>
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Or</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Or</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Or</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric>
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date
of event requiring this shell company report________________________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the transition period from</b>__________ to ___________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
File No. <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-36203</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><span style="font-family: Times New Roman, Times, Serif"><b>Can-Fite
BioPharma Ltd.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>(Exact
name of Registrant as specified in its charter)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Can-Fite
BioPharma Ltd., an Israeli Limited Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>(Translation
of Registrant&#8217;s name into English)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif"><b>Israel</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>(Jurisdiction
of incorporation or organization)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">10
Bareket Street</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Kiryat Matalon</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine3">P.O. Box 7537</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Petah-Tikva</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">4951778</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>(Address
of principal executive offices)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName">Motti
Farbstein</ix:nonNumeric><br/>
Chief Operating and Financial Officer<br/>
Tel: +<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">972</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">(3) 924-1114</ix:nonNumeric><br/>
Fax: +<ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelFaxNumber">972 (3) 924-9378</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelEmailAddress">motti@canfite.co.il</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1">10
Bareket Street</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2">Kiryat Matalon</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine3">P.O. Box 7537</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown">Petah-Tikva</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">4951778</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
registered or to be registered pursuant to Section 12(b) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American Depositary Shares, each representing 300 Ordinary Shares, no par value *</b></span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CANF</b></span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NYSE American</b></span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
registered or to be registered pursuant to Section 12(g) of the Act:<br/>
<b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Ordinary
shares not for trading, but only in connection with the registration of the American Depositary Shares.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered
by the annual report (December 31, 2022): <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction> ordinary shares are outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>
&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934. Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such a shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 16%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 16%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 21%"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided
pursuant to Section 13(a) of the Exchange Act &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#1006;
The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
reflect the correction of an error to previously issued financial statements. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-0">U.S. GAAP</span> &#9746;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#9744;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as issued by the International Accounting Standards Board &#9744;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow. Item 17 &#9744;&#160;&#160;Item 18 &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 12%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1.</b></span></td>
    <td style="width: 80%; text-align: justify"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identity of Directors, Senior Management and Advisers.</span></a></td>
    <td style="width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2.</b></span></td>
    <td style="text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Statistics and Expected Timetable</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3.</b></span></td>
    <td style="text-align: justify"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4.</b></span></td>
    <td style="text-align: justify"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information on the Company</span></a></td>
    <td style="text-align: center">44</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4A.</b></span></td>
    <td style="text-align: justify"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 5.</b></span></td>
    <td style="text-align: justify"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and Financial Review and Prospects</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 6.</b></span></td>
    <td style="text-align: justify"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Senior Management and Employees</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 7.</b></span></td>
    <td style="text-align: justify"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders and Related Party Transactions</span></a></td>
    <td style="text-align: center">130</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 8.</b></span></td>
    <td style="text-align: justify"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information</span></a></td>
    <td style="text-align: center">131</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 9.</b></span></td>
    <td style="text-align: justify"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offer and Listing</span></a></td>
    <td style="text-align: center">131</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 10.</b></span></td>
    <td style="text-align: justify"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Information</span></a></td>
    <td style="text-align: center">132</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 11.</b></span></td>
    <td style="text-align: justify"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">149</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 12.</b></span></td>
    <td style="text-align: justify"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities Other Than Equity Securities</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2" style="text-align: justify"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 13.</b></span></td>
    <td style="text-align: justify"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults, Dividend Arrearages and Delinquencies</span></a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 14.</b></span></td>
    <td style="text-align: justify"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Modifications to the Rights of Security Holders and Use of Proceeds</span></a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 15.</b></span></td>
    <td style="text-align: justify"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16.</b></span></td>
    <td style="text-align: justify"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</span></a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16A.</b></span></td>
    <td style="text-align: justify"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Financial Expert</span></a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16B.</b></span></td>
    <td style="text-align: justify"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics</span></a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16C.</b></span></td>
    <td style="text-align: justify"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16D.</b></span></td>
    <td style="text-align: justify"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemptions from the Listing Standards for Audit Committees</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16E.</b></span></td>
    <td style="text-align: justify"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16F.</b></span></td>
    <td style="text-align: justify"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Registrant&#8217;s Certifying Accountant</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16G.</b></span></td>
    <td style="text-align: justify"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16H.</b></span></td>
    <td style="text-align: justify"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosure</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16I.</b></span></td>
    <td style="text-align: justify"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART III</b></span></a></td>
    <td style="text-align: center">155</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 17.</b></span></td>
    <td style="text-align: justify"><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">155</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 18.</b></span></td>
    <td style="text-align: justify"><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">155</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 19.</b></span></td>
    <td style="text-align: justify"><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">155</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INTRODUCTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Can-Fite is a clinical-stage
biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and
inflammatory diseases and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment
of cancer, inflammatory, autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor,
or A3AR, as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a
low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline
of drug candidates are synthetic, highly specific agonists and allosteric modulators targeting the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have been
trading on the Tel Aviv Stock Exchange, or TASE, under the symbol &#8220;CFBI&#8221; since October 2005. On October 2, 2012, our ADSs
began trading over the counter, or OTC, in the United States under the symbol &#8220;CANFY&#8221; and on November 19, 2013, our ADSs began
trading on the NYSE American under the symbol &#8220;CANF.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Can-Fite&#8221; refer to Can-Fite BioPharma
Ltd. and its consolidated subsidiary. References to &#8220;ordinary shares&#8221;, &#8220;ADSs&#8221;, &#8220;warrants&#8221; and &#8220;share
capital&#8221; refer to the ordinary shares, ADSs, warrants and share capital, respectively, of Can-Fite.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">References to &#8220;U.S. dollars&#8221;, &#8220;dollars&#8221;, &#8220;USD&#8221;,
and &#8220;$&#8221; are to currency of the United States of America, and references to &#8220;NIS&#8221; are to New Israeli Shekels. References
to &#8220;ordinary shares&#8221; are to our ordinary shares, no par value. We report financial information under generally accepted accounting
principles in the United States, or U.S. GAAP.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
U.S. dollar translations of NIS amounts presented in this Annual Report on Form 20-F for the year ended on December 31, 2022 are translated
using the rate of NIS 3.519 to $1.00, the exchange rate reported by the Bank of Israel on December 30, 2022, U.S. dollar translations
of NIS amounts presented in this Annual Report on Form 20-F for the year ended on December 31, 2021 are translated using the rate of NIS
3.11 to $1.00, the exchange rate reported by the Bank of Israel on December 31, 2021, and U.S. dollar translations of NIS amounts presented
in this Annual Report on Form 20-F for the year ended on December 31, 2020 are translated using the rate of NIS 3.215 to $1.00, the exchange
rate reported by the Bank of Israel on December 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 9, 2023, we effected
a change in the ratio of our ADSs to ordinary shares from one (1) ADS representing thirty (30) ordinary shares to a new ratio of one (1)
ADS representing three hundred (300) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-ten reverse ADS
split. All ADS and related option and warrant information presented in this Annual Report on Form 20-F have been retroactively adjusted
to reflect the reduced number of ADSs and the increase in the ADS price which resulted from this action. Unless otherwise indicated, in
this Annual Report on Form 20-F fractional ADSs have been rounded to the nearest whole number.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORWARD LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
20-F contains forward-looking statements, about our expectations, beliefs or intentions regarding, among other things, our product development
efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should&#8221;
or &#8220;anticipate&#8221; or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited
to, various filings made by us with the U.S. Securities and Exchange Commission, or the SEC, press releases or oral statements made by
or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred,
these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially
from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
20-F identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking
statements, particularly those set forth under the heading &#8220;Risk Factors.&#8221; The risk factors included in this Annual Report
on Form 20-F are not necessarily all of the important factors that could cause actual results to differ material<span style="font-family: Times New Roman, Times, Serif">ly
from those expressed in any of our forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance
on such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied
in such forward-looking statements include, but are not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable
    terms, or at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainties
    of cash flows and inability to meet working capital needs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical development, commercialization and market acceptance of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic partnerships and other corporate collaborations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and strategic plans for our business and product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our
    ability to operate our business without infringing the intellectual property rights of others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitive
    companies, technologies and our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    related to unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated
    liquidity risk;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    related to not satisfying the continued listing requirements of NYSE American; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements
    as to the impact of the political and security situation in Israel on our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this Annual Report on Form
20-F and are expressly qualified in their entirety by the cautionary statements included in this Annual Report on Form 20-F. We undertake
no obligations to update or revise forward-looking st</span>atements to reflect events or circumstances that arise after the date made
or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPLANATORY NOTE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market data and certain industry
data and forecasts used throughout this Annual Report on Form 20-F were obtained from sources we believe to be reliable, including market
research databases, publicly available information, reports of governmental agencies and industry publications and surveys. We have relied
on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable
based on our management&#8217;s knowledge of the industry. Forecasts are particularly likely to be inaccurate, especially over long periods
of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the third-party
forecasts we cite. Statements as to our market position are based on the most currently available data. While we are not aware of any
misstatements regarding the industry data presented in this Annual Report on Form 20-F, our estimates involve risks and uncertainties
and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; in this Annual
Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PART
I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 1. </b></span><b>Identity
of Directors, Senior Management and Advisers.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 2. </b></span><b>Offer
Statistics and Expected Timetable.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 3. </b></span><b>Key
Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. [Reserved]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Capitalization and Indebtedness.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Reasons for the Offer and Use of Proceeds.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should carefully consider
the risks we describe below, in addition to the other information set forth elsewhere in this Annual Report on Form 20-F, including our
consolidated financial statements and the related notes beginning on page F-1, before deciding to invest in our ordinary shares and American
Depositary Shares, or ADSs. These material risks could adversely impact our results of operations, possibly causing the trading price
of our ordinary shares and ADSs to decline, and you could lose all or part of your investment.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal factors and
uncertainties that make investing in our ordinary shares risky, include, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Financial Positi<span style="font-family: Times New Roman, Times, Serif">on
and Capital Requirements</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred operating losses since our inception and anticipate that we will continue to incur substantial operating losses for
    the foreseeable future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or
    difficult to obtain and will dilute current shareholders&#8217; ownership interests.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Risks
Related to Our Business and Regulatory Matters</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not yet commercialized any products or technologies, and we may never become profitable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates are at various stages of clinical and preclinical development and may never be commercialized.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
    of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be unable to develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current pipeline is based on our platform technology utilizing the Gi protein associated A3AR, as a potent therapeutic target and
    currently includes three molecules, Piclidenoson, Namodenoson and CF602 product candidates, of which Piclidenoson is the most advanced.
    Failure to develop these molecules will have a material adverse effect on us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    trials are very expensive, time-consuming and difficult to design and implement, and, as a result, we may suffer delays or suspensions
    in future trials which would have a material adverse effect on our ability to generate revenues.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    manufacture of our product candidates is a chemical synthesis process and if one of our materials suppliers encounters problems manufacturing
    our products, our business could suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not currently have sales, marketing or distribution capabilities or experience, and we are unable to effectively sell, market
    or distribute our product candidates now and we do not expect to be able to do so in the future. The failure to enter into agreements
    with third parties that are capable of performing these functions would have a material adverse effect on our business and results
    of operations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on key members of our management and key consultants and will need to add and retain additional leading experts. Failure to
    retain our management and consulting team and add additional leading experts could have a material adverse effect on our business,
    results of operations or financial condition.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates will remain subject to ongoing regulatory requirements even if they receive marketing approval, and if we fail
    to comply with these requirements, we could lose these approvals, and the sales of any approved commercial products could be suspended.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to successfully grow and expand our business. Failure to manage our growth effectively will have a material adverse
    effect on our business, results of operations and financial condition.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    cannabinoid initiative is uncertain and may not yield commercial results and is subject to significant regulatory risks.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    or the third parties upon whom we depend may be adversely affected by natural disasters and/or health epidemics, and our business
    continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Risks
Related to Our Intellectual Property</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    expiry of a patent that we licensed from the National Institute of Health, or NIH, and the consequent loss of composition of matter
    exclusivity that we had by virtue of this license may diminish our proprietary position.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    license from Leiden University intellectual property, which protects certain small molecules which target the A3AR, in furtherance
    of our platform technology, and we could lose our rights to this license if a dispute with Leiden University arises or if we fail
    to comply with the financial and other terms of the license.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    failure to obtain or maintain patents, licensing agreements, including our current licensing agreements, and other intellectual property
    could impact our ability to compete effectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
    patent protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to
    expend substantial sums and management resources.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to protect the intellectual property rights of the third parties from whom we license certain of our intellectual property
    or with whom we have entered into other strategic relationships.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore, may be unable to prevent our
    competitors from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation
    for their inventions irrespective of their agreements with us, which in turn could impact our future profitability.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Risks
Related to Our Industry</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect the healthcare industry to face increased limitations on reimbursement as a result of healthcare reform, which could adversely
    affect third-party coverage of our products and how much or under what circumstances healthcare providers will prescribe or administer
    our products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    employees, principal investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities,
    including non-compliance with regulatory standards.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Risks
Related to Our Operations in Israel</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    conduct our operations in Israel and therefore our results may be adversely affected by political, economic and military instability
    in Israel and its region.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    a certain portion of our expenses is incurred in currencies other than U.S. dollars, our results of operations may be harmed by currency
    fluctuations and inflation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Risks
Related to Our Ordinary Shares and ADSs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market conditions
    and adverse developments with respect to financial institutions and associated liquidity risk.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business could be negatively impacted by unsolicited takeover proposals, by shareholder activism or by proxy contests relating to
    the election of directors or other matters.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of additional equity securities may adversely affect the market price of our ADSs or ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our ordinary shares and ADSs is subject to fluctuation, which could result in substantial losses by our investors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not satisfy the NYSE American requirements for continued listing. If we cannot satisfy these requirements, the NYSE American
    could delist our securities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC
    and NYSE American requirements, which may result in less protection than is accorded to investors under rules applicable to domestic
    issuers.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Risks Related to Our Financial Position and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have incurred operating
losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. Since our incorporation in 1994, we have been focused on research and development activities with a view to
developing our product candidates, CF101, also known as Piclidenoson, CF102, also known as Namodenoson, and CF602. We have financed our
operations primarily through the sale of equity securities (both in private placements and in public offerings on the TASE and NYSE American)
and payments received under out-licensing agreements and have incurred losses in each year since our inception in 1994. We have historically
incurred substantial net losses, including net losses of approximately $10.1 million in 2022, $12.6 million in 2021, and $14.4 million
in 2020. As of December 31, 2022, we had an accumulated deficit of approximately $150.8 million. We do not know whether or when we will
become profitable. To date, we have not commercialized any products or generated any revenues from product sales and accordingly we do
not have a revenue stream to support our cost structure. Our losses have resulted principally from cost<span style="font-family: Times New Roman, Times, Serif">s
incurred in development and discovery activities. We expect to continue to incur losses for the foreseeable future, and these losses
will likely increase as we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
    and manage pre-clinical development and clinical trials for our current and new product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement
    internal systems and infrastructures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to license additional technologies to develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    management and other personnel; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">move
    towards commercialization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
our product candidates fail in clinical trials or do not gain regulatory clearance or approval, or if our product candidates do not achieve
market acceptance, we may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability
on a q</span>uarterly or annual basis. Our inability to achieve and then maintain profitability would negatively affect our business,
financial condition, results of operations and cash flows. Moreover, our prospects must be considered in light of the risks and uncertainties
encountered by an early-stage company and in highly regulated and competitive markets, such as the biopharmaceutical market, where regulatory
approval and market acceptance of our products are uncertain. There can be no assurance that our efforts will ultimately be successful
or result in revenues or profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We will need to raise
additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and
will dilute current shareholders&#8217; ownership interests.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, we
had cash and cash equivalents of $3.0 million and short-term deposits of $5.0 million. In January 2023, we raised approximately $7.5 million
in gross proceeds (approximately $6.7 million net of issuance costs) from a registered direct offering and a concurrent private placement.
We believe that our existing financial resources will be sufficient to meet our requirements for the next twelve months from the date
of issuance of this Annual Report on Form 20-F. We have expended and believe that we will continue to expend substantial resources for
the foreseeable future developing our product candidates. These expenditures will include costs associated with research and development,
manufacturing, conducting preclinical experiments and clinical trials and obtaining regulatory approvals, as well as commercializing any
products approved for sale. Because the outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably
estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. In addition,
other unanticipated costs may arise. As a result of these and other factors currently unknown to us, we will require additional funds,
through public or private equity or debt financings or other sources, such as strategic partnerships and alliances and licensing arrangements.
In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have
sufficient funds for our current or future operating plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
will depend on many factors, including the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development, and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review of our
product candidates, the number and development requirements of other product candidates that we pursue, and the costs of activities,
such as product marketing, sales, and distribution. Because of the numerous risks and uncertainties associated with the development and
commercialization of our product candidates, we are u<span style="font-family: Times New Roman, Times, Serif">nable to estimate the amounts
of increased capital outlays and operating expenditures associated with our anticipated clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future capital requirements depend on many factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of research and development investment required to develop our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure to obtain regulatory approval or achieve commercial success of our product candidates, including Piclidenoson, Namodenoson
    and CF602;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our preclinical studies and clinical trials for our earlier stage product candidates, and any decisions to initiate clinical
    trials if supported by the preclinical results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing and outcome of regulatory review of our product candidates that progress to clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to partner or sub-license any of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending intellectual
    property-related claims;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales and distribution
    costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing our product candidates and any products we successfully commercialize;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and amount of sales of, or royalties on, our future products, if any;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expenses needed to attract and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    product liability or other lawsuits related to our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or invest in businesses, products or technologies and other strategic relationships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of financing unanticipated working capital requirements and responding to competitive pressures; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    minimum shareholders&#8217; equity requirements and complying with other continue listing standards under the NYSE American Company
    Guide</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additional
funds may not be available when we need them, on terms that are acceptable to us, or at all. General market conditions may make it very
difficult for us to seek fina</span>ncing from the capital markets and the Russian invasion of Ukraine could impact the availability
or cost of future financings. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce
or terminate preclinical studies, clinical trials or other research and development activities for one or more of our product candidates
or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary
to commercialize our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may incur substantial costs
in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees,
printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain
securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Raising additional capital
may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product
candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing
shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect shareholder rights. Debt
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such
as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through strategic partnerships and
alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates,
or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when
needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Business and Regulatory
Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have not yet commercialized
any products or technologies, and we may never become profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet commercialized
any products or technologies, and we may never be able to do so. We do not know when or if we will complete any of our product development
efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved
products. Even if we are successful in developing products that are approved for marketing, we will not be successful unless these products
gain market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance of these products
will depend on a number of factors, inc<span style="font-family: Times New Roman, Times, Serif">luding:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of regulatory approvals in the countries, and for the uses, we seek;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    competitive environment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    establishment and demonstration in the medical community of the safety and clinical efficacy of our products and their potential
    advantages over existing therapeutic products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enter into distribution and other strategic agreements with pharmaceutical and biotechnology companies with strong marketing
    and sales capabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    adequacy and success of distribution, sales and marketing efforts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and reimbursement policies of government and third-party payors, such as insurance companies, health maintenance organizations
    and other plan administrators.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Physicians,
patients, thirty-party payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of
third-pa</span>rty payors, cover any of our products or products incorporating our technologies. As a result, we are unable to predict
the extent of future losses or the time required to achieve profitability, if at all. Even if we successfully develop one or more products
that incorporate our technologies, we may not become profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our product candidates
are at various stages of clinical and preclinical development and may never be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates are
at various stages of clinical development and may never be commercialized. The progress and results of any future pre-clinical testing
or future clinical trials are uncertain, and the failure of our product candidates to receive regulatory approvals will have a material
adverse effect on our business, operating results and financial condition to the extent we are unable to commercialize any products. None
of our product candidates has received regulatory approval for commercial sale. In addition, we face the risks of failure inherent in
developing therapeutic products. Our product candidates are not expected to be commercially available for several years, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to receive FDA approval
or approval from foreign regulatory authorities to market a product candidate or to distribute our products, we must demonstrate thorough
pre-clinical testing and thorough human clinical trials that the product candidate is safe and effective for its intended uses (e.g.,
treatment of a specific condition in a specific way subject to contraindications and other limitations). If the FDA, or foreign regulatory
authorities, determine that data from our pre-clinical testing and clinical trials are not sufficient to support approval, the FDA, or
foreign regulatory authorities, may require additional pre-clinical testing or clinical trials for our product candidates. Even if we
comply with all FDA requests, the FDA may ultimately reject one or more of our New Drug Applications, or NDA, or grant approval for a
narrowly intended use that is not commercially feasible. We might not obtain regulatory approval for our drug candidates in a timely manner,
if at all. Failure to obtain FDA approval of any of our drug candidates in a timely manner or at all will severely undermine our business
by reducing the number of salable products and, therefore, corresponding product revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Results of earlier clinical
trials may not be predictive of the results of later-stage clinical trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of preclinical
studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Also, interim
results, if at all, during a clinical trial do not necessarily predict final results. Product candidates in later stages of clinical trials
may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical trials.
For example, our former subsidiary OphthaliX Inc, or OphthaliX, announced top-line results of a Phase III study with Piclidenoson for
dry-eye syndrome in which Piclidenoson did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary
efficacy endpoints, OphthaliX released top-line results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma
in which no statistically significant differences were found between the Piclidenoson treated group and the placebo group in the primary
endpoint of lowering intraocular pressure, or IOP. In addition, two Phase IIb studies in rheumatoid arthritis, utilizing Piclidenoson
in combination with methotrexate, a generic drug commonly used for treating rheumatoid arthritis patients, or MTX, failed to reach their
primary endpoints and we ended our Phase III ACROBAT study after the independent data monitoring committee, or IDMC recommended in a pre-planned
interim analysis not to continue this study. A Phase II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although
positive data from further analysis of the Phase II/III study suggests Piclidenoson as a potential systemic therapy for patients with
moderate-severe psoriasis. Furthermore, a Phase II study for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first
line treatment did not meet its primary endpoint although it showed superiority in overall survival in the largest study subpopulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies in the pharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding
promising results in earlier studies. Any delay in, or termination or suspension of, our clinical trials will delay the requisite filings
with the FDA, the EMA or other foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates and
generate product revenues. If the clinical trials do not support our product claims, the completion of development of such product candidates
may be significantly delayed or abandoned, which will significantly impair our ability to generate product revenues and will materially
adversely affect our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This drug candidate development
risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are
developed from preclinical through early to late stage clinical trials towards approval and commercialization, it is customary that various
aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize
processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical
trials, approval and commercialization, such changes do carry the risk that they will not achieve these intended objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in our planned clinical
trials or future clinical trials could cause our product candidates to perform differently, including causing toxicities, which could
delay completion of our clinical trials, delay approval, if any, of our product candidates, and/or jeopardize our ability to commence
product sales and generate revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We might be unable to
develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if regulatory authorities
approve our product candidates, they may not be commercially successful. Our product candidates may not be commercially successful because
government agencies and other third-party payors may not cover the product or the coverage may be too limited to be commercially successful;
physicians and others may not use or recommend our products, even following regulatory approval. A product approval, assuming one issues,
may limit the uses for which the product may be distributed thereby adversely affecting the commercial viability of the product. Third
parties may develop superior products or have proprietary rights that preclude us from marketing our products. We also expect that at
least some of our product candidates will be expensive, if approved. Patient acceptance of and demand for any product candidates for which
we obtain regulatory approval or license will depend largely on many factors, including but not limited to the extent, if any, of reimbursement
of costs by government agencies and other third-party payors, pricing, the effectiveness of our marketing and distribution efforts, the
safety and effectiveness of alternative products, and the prevalence and severity of side effects associated with our products. If physicians,
government agencies and other third-party payors do not accept our products, we will not be able to generate significant revenue. In addition,
government regulators and legislative bodies in the U.S. are considering numerous proposals that may result in limitations on the prices
at which we could charge customers for our products if we have products that are ultimately approved for sale. At this time, we are unable
to predict how these potential legislative changes might affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our current pipeline
is based on our platform technology utilizing the Gi protein associated A3AR, as a potent therapeutic target and currently includes three
molecules, Piclidenoson, Namodenoson and CF602 product candidates, of which Piclidenoson is the most advanced. Failure to develop these
molecules will have a material adverse effect on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current pipeline is based
on a platform technology where we target the A3AR with highly selective ligands, or small signal triggering molecules that bind to specific
cell surface receptors, such as the A3AR, including Piclidenoson, Namodenoson and CF602. A3ARs are structures found in cell surfaces that
record and transfer messages from small molecules or ligands, such as Piclidenoson, Namodenoson and CF602 to the rest of the cell. Piclidenoson
is the most advanced of our drug candidates. As such, we are currently dependent on only three molecules for our potential commercial
success, and any safety or efficacy concerns related to such molecules would have a significant impact on our business. Failure to develop
our drug candidates, in whole or in part, will have a material adverse effect on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Clinical trials are
very expensive, time-consuming and difficult to design and implement, and, as a result, we may suffer delays or suspensions in future
trials which would have a material adverse effect on our ability to generate revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials are
very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Regulatory
authorities, such as the FDA, may preclude or prohibit clinical trials from proceeding. Additionally, the <span style="font-family: Times New Roman, Times, Serif">clinical
trial process is time-consuming, failure can occur at any stage of the trials, and we may encounter problems that cause us to abandon
or repeat clinical trials. The commencement and completion of clinical trials may be delayed by several factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    safety issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-acceptance
    of an IND by the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination
    of dosing issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of effectiveness or efficacy during clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to manufacture sufficient quantities of drug candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in formulation or manufacturing changes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of third-party suppliers to perform final manufacturing steps for the drug substance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of patient recruitment and enrollment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to retain patients in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of healthy volunteers and patients to conduct trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to monitor patients adequately during or after treatment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to reach an agreement with contract research organizations or clinical trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of institutional review boards, or IRBs, to approve our clinical trial protocols or suspension or termination of our clinical trial
    by the IRB, DSMB, or the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of institutional review boards to approve our clinical trial protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of clinical investigators and institutional review boards to follow our clinical trial protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of clinical investigators or sites to maintain necessary licenses or permits or comply with good clinical practices, or GCP, or other
    regulatory requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">debarment
    of a clinical investigator by FDA or other similar suspension or exclusion by a regulatory authority; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of sufficient funding to finance the clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have experienced the risks involved with conducting clinical trials, including but not limited to, increased expense and delay and failure
to meet end points of the trial. For example, OphthaliX, announced top-line results of a Phase III study with Piclidenoson for dry-eye
syndr</span>ome in which Piclidenoson did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary
efficacy endpoints and OphthaliX released top-line results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma
in which no statistically significant differences were found between the Piclidenoson treated group and the placebo group in the primary
endpoint of lowering IOP. In addition, two Phase IIb studies in rheumatoid arthritis, utilizing Piclidenoson in combination with MTX
failed to reach their primary end points and we ended our Phase III ACROBAT study after the IDMC recommended in a pre-planned interim
analysis not to continue this study. A Phase II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although positive
data from further analysis of the Phase II/III study suggests Piclidenoson as a potential systemic therapy for patients with moderate-severe
psoriasis. Furthermore, a Phase II study of Namodenoson for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first
line treatment did not meet its primary endpoint although it showed superiority in overall survival in the largest study subpopulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we or regulatory
authorities may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or
if the regulatory authorities find deficiencies in our regulatory submissions or the conduct of these trials. Any suspension of clinical
trials will delay possible regulatory approval, if any, increase costs, and adversely impact our ability to develop products and generate
revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We seek to partner with
third-party collaborators with respect to the development and commercialization of Piclidenoson and for any other product candidate, and
we may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and
commercialize our product candidates successfully, if at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy relies
in part on partnering with pharmaceutical companies to complement our internal development efforts. We will be competing with many other
companies as we seek partners for Piclidenoson, Namodenoson and for any other product candidate and we may not be able to compete successfully
against those companies. If we are not able to enter into collaboration arrangements for Piclidenoson, Namodenoson and for any other
product candidate, we may be required to undertake and fund further development, clinical trials, manufacturing and commercialization
activities solely at our own expense and risk. If we are unable to finance and/or successfully execute those expensive activities, or
we delay such activities due to capital availability, our business could be materially and adversely affected, and potential future product
launch could be materially delayed, be less successful, or we may be forced to discontinue clinical development of these product candidates.
The proc<span style="font-family: Times New Roman, Times, Serif">ess of establishing and maintaining collaborative relationships is difficult,
time-consuming and involves significant uncertainty, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaboration partner may shift its priorities and resources away from our product candidates due to a change in business strategies,
    or a merger, acquisition, sale or downsizing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing
    issues, a change in business strategy, a change of control or other reasons;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaboration partner may not devote sufficient capital or resources towards our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaboration partner may change the success criteria for a drug candidate thereby delaying or ceasing development of such candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones
    tied to such activities, thereby impacting our ability to fund our own activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaboration partner could develop a product that competes, either directly or indirectly, with our drug candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing,
    distribution or sale of a product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet
    demand requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    partner may exercise a contractual right to terminate a strategic alliance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    dispute may arise between us and a partner concerning the research, development or commercialization of a drug candidate resulting
    in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or arbitration
    which may divert management attention and resources; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    partner may use our products or technology in such a way as to invite litigation from a third party.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any collaborative partners
we enter into agreements with in the future may shift their priorities and resources away from our product candidates or seek to renegotiate
or terminate their relationships with us. If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our
research, clinical development, manufacturing or commercialization efforts related to that collaboration could be delayed or terminated,
or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of
our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition
terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates,
undertake development and commercialization activities at our own expense or find alternative sources of capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we acquire or license
additional technology or product candidates, we may incur a number of costs, may have integration difficulties and may experience other
risks that could harm our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may acquire and license
additional product candidates and technologies. Any product candidate or technology we license from others or acquire will likely require
additional development efforts prior to commercial sale, including extensive pre-clinical or clinical testing, or both, and approval by
the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical
product development, including the possibility that the product candidate or product developed based on licensed technology will not be
shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any product
candidate that we develop based on acquired or licensed technology that is granted regulatory approval will be manufactured or produced
economically, successfully commercialized or widely accepted in the marketplace. Moreover, integrating any newly acquired product candidates
could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may not succeed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The manufacture of our
product candidates is a chemical synthesis process and if one of our materials suppliers encounters problems manufacturing our products,
our business could suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and foreign regulators
require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance
with requirements that the FDA or foreign regulators establish. We do not intend to engage in the manufacture of our products other than
for pre-clinical and clinical studies, but we or our materials suppliers may face manufacturing or quality control problems causing product
production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s or
foreign regulators&#8217; requirements necessary to continue manufacturing our drug substance. Drug manufacturers are subject to ongoing
periodic unannounced inspections by the FDA, the U.S. Drug Enforcement Agency, or DEA, and corresponding foreign regulators to ensure
strict compliance with requirements and other governmental regulations and corresponding foreign standards. Any failure to comply with
DEA requirements or FDA or foreign regulatory requirements could adversely affect our clinical research activities and our ability to
develop our product candidates, and delay possible regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We do not currently
have sales, marketing or distribution capabilities or experience, and we are unable to effectively sell, market or distribute our product
candidates now and we do not expect to be able to do so in the future. The failure to enter into agreements with third parties that are
capable of performing these functions would have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
and we do not expect to develop, sales, marketing and distribution capabilities. If we are unable to enter into agreements with third
parties to perform these functions, we will not be able to successfully market any of our platforms or product candidates. In order to
successfully market any of our platform or product candidates, we must make arrangements with third parties to perform these services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we do not intend to develop
a marketing and sales force with technical expertise and supporting distribution capabilities, we will be unable to market any of our
product candidates directly. To promote any of our potential products through third parties, we will have to locate acceptable third parties
for these functions and enter into agreements with them on acceptable terms, and we may not be able to do so. Any third-party arrangements
we are able to enter into may result in lower revenues than we could achieve by directly marketing and selling our potential products.
In addition, to the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the
efforts of such third parties, as well as the terms of our agreements with such third parties, which cannot be predicted in most cases
at this time. As a result, we might not be able to market and sell our products in the United States or overseas, which would have a material
adverse effect on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We will to some extent
rely on third parties to implement our manufacturing and supply strategies. Failure of these third parties in any respect could have a
material adverse effect on our business, results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our current and future
manufacturing and supply strategies are unsuccessful, then we may be unable to conduct and complete any future pre-clinical or clinical
trials or commercialize our product candidates in a timely manner, if at all. Completion of any potential future pre-clinical or clinical
trials and commercialization of our product candidates will require access to, or development of, facilities to manufacture a sufficient
supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial
purposes on our own and do not intend to develop or acquire facilities for the manufacture of product candidates for commercial purposes
in the foreseeable future. We may rely on contract manufacturers to produce sufficient quantities of our product candidates necessary
for any pre-clinical or clinical testing we undertake in the future. Such contract manufacturers may be the sole source of production
and they may have limited experience at manufacturing, formulating, analyzing, filling and finishing our types of product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also intend to rely on
third parties to supply the requisite materials needed for the manufacturing of our active pharmaceutical ingredients, or API. There may
be a limited supply of these requisite materials. We might not be able to enter into agreements that provide us assurance of availability
of such components in the future from any supplier. Our potential suppliers may not be able to adequately supply us with the components
necessary to successfully conduct our pre-clinical and clinical trials or to commercialize our product candidates. In particular, the
continued spread of COVID-19 globally could result in the inability of our suppliers to deliver components or raw materials on a timely
basis or at all. If we cannot acquire an acceptable supply of the requisite materials to produce our product candidates, we will not be
able to complete pre-clinical and clinical trials delaying possible regulatory approval, and adversely impacting our ability to develop
products, and will not be able to market or commercialize our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We depend on key members
of our management and key consultants and will need to add and retain additional leading experts. Failure to retain our management and
consulting team and add additional leading experts could have a material adverse effect on our business, results of operations or financial
condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent on
our executive officers and other key management and technical personnel. Our failure to retain our Chief Executive Officer, Pnina Fishman,
Ph.D., who has developed much of the technology we utilize today, or any other key management and technical personnel, could have a material
adverse effect on our future operations. Our success is also dependent on our ability to attract, retain and motivate highly trained technical,
and management personnel, among others, to continue the development and commercialization, if approved, of our current and future product
candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success also depends on
our ability to attract, retain and motivate personnel required for the development, maintenance and expansion of our activities. There
can be no assurance that we will be able to retain our existing personnel or attract additional qualified employees or consultants. The
loss of key personnel or the inability to hire and retain additional qualified personnel in the future could have a material adverse effect
on our business, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We face significant
competition and continuous technological change, and developments by competitors may render our products or technologies obsolete or non-competitive.
If we cannot successfully compete with new or existing products, our marketing and sales will suffer and we may not ever be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will compete against fully
integrated pharmaceutical and biotechnology companies and smaller companies that are collaborating with larger pharmaceutical companies,
academic institutions, government agencies and other public and private research organizations. In addi<span style="font-family: Times New Roman, Times, Serif">tion,
many of these competitors, either alone or together with their collaborative partners, operate larger research and development programs
than we do, and have substantially greater financial resources than we do, as well as significantly greater experience in:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    drugs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undertaking
    pre-clinical testing and human clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    FDA approval, addressing various regulatory matters and other regulatory approvals of drugs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">formulating
    and manufacturing drugs; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching,
    marketing and selling drugs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
our competitors develop and commercialize products faster than we do, or develop and commercialize products that are superior to our
product candidates, our commercial opportunities will be reduced or eliminated. The extent to which any of our product candidates achieve
market acceptance will depend on competitive factors, many of which are beyond our control. Competition in the biotechnology and biopharmaceutical
industry is intense and has been accentuated by the rapid pace of technology development. Our competitors include large integrated pharmaceutical
companies, biotechnology companies that currently have drug and target discovery efforts, universities, and public and private research
institutions. Almost all of these entities have substantially greater research and development capabilities and financial, scientific,
manufacturing, marketing and sales resources than we do. These organizations also compete with us to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    parties for acquisitions, joint ventures or other collaborations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">license
    proprietary technology that is competitive with the technology we are developing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    funding; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    and hire scientific talent and other qualified personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may succeed
in developing and commercializing products earlier and obtaining regulatory approvals from the FDA or foreign regulators more rapidly
than we do. Our competitors may also develop products or technologies that are superior to those we are developing, and render our product
candidates or technologies obsolete or non-competitive. If we cannot successfully compete with new or existing products, our marketing
and sales will suffer and we may not ever be profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors currently
include companies with marketed products and/or an advanced research and development pipeline. The major competitors in the psoriasis
therapeutic field include Amgen, J&amp;J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, UCB and more. Competitors in the
HCC field include companies such as Bayer, Exelixis, Merck, Roche, Eisai, Astrazenca, Beigene, Novartis, and Bristol-Myers Squibb. Competitors
in the NASH field include companies such as Gilead, Genfit, Galmed, Intercept, Madrigal, Akero, 89Bio, Viking, and Terns. Competitors
in the erectile dysfunction field include Pfizer, Eli Lilly, Bayer, and Petros Pharmaceuticals. See &#8220;Item 4. Information on the
Company&#8212;B. Business Overview&#8212;Competition.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, several companies
have reported the commencement of research projects related to the A3AR. Such companies include CV Therapeutics Inc. (which was acquired
by Gilead), King Pharmaceuticals R&amp;D Inv. (which was acquired by Pfizer), Hoechst Marion Roussel Inc. (which was acquired by Aventis),
Novo Nordisk A/S and Inotek Pharmaceuticals. However, to the best of our knowledge, there is no approved drug currently on the market,
which is similar to our A3AR agonists, nor are we aware of any allosteric modulator in the A3AR product pipeline similar to our allosteric
modulator with respect to chemical profile and mechanism of action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may suffer losses
from product liability claims if our product candidates cause harm to patients.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of our product candidates
could cause adverse events. Although a pooled safety analysis from clinical trials encompassing more than 1,600 humans dosed with Piclidenoson
through the completion of our Phase II rheumatoid arthritis and psoriasis trials indicated that Piclidenoson is generally well-tolerated
at doses up to 4.0 mg administered twice daily for up to 12-48 weeks, there were incidences (less than or equal to 5%) of adverse events
in eight completed and fully analyzed trials in inflammatory disease. Such adverse events included nausea, diarrhea, abdominal pain, vomiting,
constipation, common bacterial and viral syndromes (such as tonsillitis, otitis and respiratory and urinary tract infections), abdominal
pain, vomiting, myalgia, arthralgia, dizziness, headache and pruritus. We observed an even lower incidence (less than or equal to 2%)
of serious adverse events, although only one type of event was reported in more than a single Piclidenoson-treated subject, which was
exacerbation of chronic obstructive lung disease reported in two subjects. Notwithstanding the foregoing, the placebo group in such studies
had a higher incidence of overall adverse events than the pooled Piclidenoson groups. In addition, in normal volunteers, Piclidenoson
at doses 3-4-fold higher than those to be used in therapeutic trials, but not at therapeutic doses, was associated with prolongation of
the electrocardiographic QT intervals. No new safety concerns have been identified and no novel or unexpected safety concerns have appeared
over 48 weeks of treatment in more recent trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is also a risk that
certain adverse events may not be observed in clinical trials, but may nonetheless occur in the future. If any of these adverse events
occur, they may render our product candidates ineffective or harmful in some patients, and our sales would suffer, materially adversely
affecting our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, potential adverse
events caused by our product candidates could lead to product liability lawsuits. If product liability lawsuits are successfully brought
against us, we may incur substantial liabilities and may be required to limit the marketing and commercialization of our product candidates.
Our business exposes us to potential product liability risks, which are inherent in the testing, manufacturing, marketing and sale of
pharmaceutical products. We may not be able to avoid product liability claims. Product liability insurance for the pharmaceutical and
biotechnology industries is generally expensive, if available at all. If, at any time, we are unable to obtain sufficient insurance coverage
on reasonable terms or to otherwise protect against potential product liability claims, we may be unable to clinically test, market or
commercialize our product candidates. A successful product liability claim brought against us in excess of our insurance coverage, if
any, may cause us to incur substantial liabilities, and, as a result, our business, liquidity and results of operations would be materially
adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our product candidates
will remain subject to ongoing regulatory requirements even if they receive marketing approval, and if we fail to comply with these requirements,
we could lose these approvals, and the sales of any approved commercial products could be suspended.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive regulatory
approval to market a particular product candidate, the product will remain subject to extensive regulatory requirements, including requirements
relating to manufacturing, labelling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping.
Even if regulatory approval of a product is granted, the approval may be subject to limitations on the uses for which the product may
be marketed or the conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor
the safety or efficacy of the product, which could negatively impact us or our collaboration partners by reducing revenues or increasing
expenses, and cause the approved product candidate not to be commercially viable. In addition, as clinical experience with a drug expands
after approval, typically because it is used by a greater number and more diverse group of patients after approval than during clinical
trials, side effects and other problems may be observed after approval that were not seen or anticipated during pre-approval clinical
trials or other studies. Any adverse effects observed after the approval and marketing of a product candidate could result in limitations
on the use of or withdrawal of any approved products from the marketplace. Absence of long-term safety data may also limit the approved
uses of our products, if any. If we fail to comply with the regulatory requirements of the FDA and other applicable U.S. and foreign
regulatory authorities, or previously unknown problems with any approved commer<span style="font-family: Times New Roman, Times, Serif">cial
products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions
or other setbacks, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictions
    on the products, manufacturers or manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warning
    or other enforcement letters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Civil
    or criminal penalties, fines and injunctions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    seizures or detentions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Import
    or export bans or restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voluntary
    or mandatory product recalls and related publicity requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suspension
    or withdrawal of regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    or partial suspension of production; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refusal
    to approve pending applications for marketing approval of new products or supplements to approved applications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or our collaborators
are slow or unable to adapt to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, marketing
approval for our product candidates may be lost or cease to be achievable, resulting in decreased revenue from milestones, product sales
or royalties, which would have a material adverse effect on our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We deal with hazardous
materials and must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our activities and those of
our third-party manufacturers on our behalf involve the controlled storage, use and disposal of hazardous materials, including corrosive,
explosive and flammable chemicals and other hazardous compounds. We and our manufacturers are subject to U.S. federal, state, and local,
and Israeli and other foreign laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by these
laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In addition, if we develop
a manufacturing capacity, we may incur substantial costs to comply with environmental regulations and would be subject to the risk of
accidental contamination or injury from the use of hazardous materials in our manufacturing process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of an accident,
government authorities may curtail our use of these materials and interrupt our business operations. In addition, we could be liable for
any civil damages that result, which may exceed our financial resources and may seriously harm our business. Although our Israeli insurance
program covers certain unforeseen sudden pollutions, we do not maintain a separate insurance policy for any of the foregoing types of
risks. In addition, although the general liability section of our life sciences policy covers certain unforeseen, sudden environmental
issues, pollution in the United States and Canada is excluded from the policy. In the event of environmental discharge or contamination
or an accident, we may be held liable for any resulting damages, and any liability could exceed our resources. In addition, we may be
subject to liability and may be required to comply with new or existing environmental laws regulating pharmaceuticals or other medical
products in the environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Environmental, social
and corporate governance (ESG) issues, including those related to climate change and sustainability, may have an adverse effect on our
business, financial condition and results of operations and damage our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is an increasing focus
from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and
legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet regulatory requirements
or investor, customer, consumer, employee or other shareholders&#8217; evolving expectations and standards for responsible corporate citizenship
in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management,
employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation,
brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with
us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers, consumers, investors
and other shareholders are increasingly focusing on environmental issues, including climate change, energy and water use, plastic waste
and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory requirements to reduce
or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements may result in
increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products
and packaging, other components of our products and their environmental impact on sustainability, or increased customer and consumer concerns
or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with
these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not adapt to or comply
with new regulations, including the SEC&#8217;s published proposed rules that would require companies to provide significantly expanded
climate-related disclosures in their periodic reporting, which may require us to incur significant additional costs to comply and impose
increased oversight obligations on our management and board of directors, or fail to meet evolving investor, industry or stakeholder expectations
and concerns regarding ESG issues, investors may reconsider their capital investment in our Company, we may become subject to penalties,
and customers and consumers may choose to stop purchasing our products, if approved for commercialization, which could have a material
adverse effect on our reputation, business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our business and operations
may be materially adversely affected in the event of computer system failures or security breaches.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures, our internal computer systems, and those of our contract research organizations, or CROs, and other third parties
on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, natural disasters, fire, terrorism,
war, and telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a
material disruption of our drug development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the
extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate
disclosure of confidential or proprietary information, including protected health information or personal data of employees or former
employees, access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development
of our drug candidates could be delayed. We may also be vulnerable to cyber-attacks by hackers or other malfeasance. This type of breach
of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or
result in legal proceedings. Further, these cybersecurity breaches may inflict reputational harm upon us that may result in decreased
market value and erode public trust.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may not be able to
successfully grow and expand our business. Failure to manage our growth effectively will have a material adverse effect on our business,
results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to successfully
grow and expand. Successful implementation of our business plan will require management of growth, including potentially rapid and substantial
growth, which will result in an increase in the level of responsibility for management personnel and place a strain on our human and capital
resources. To manage growth effectively, we will be required to continue to implement and improve our operating and financial systems
and controls to expand, train and manage our employee base. Our ability to manage our operations and growth effectively requires us to
continue to expend funds to enhance our operational, financial and management controls, reporting systems and procedures and to attract
and retain sufficient numbers of talented personnel. If we are unable to scale up and implement improvements to our control systems in
an efficient or timely manner, or if we encounter deficiencies in existing systems and controls, then we will not be able to make available
the products required to successfully commercialize our technology. Failure to attract and retain sufficient numbers of talented personnel
will further strain our human resources and could impede our growth or result in ineffective growth. Moreover, the management, systems
and controls currently in place or to be implemented may not be adequate for such growth, and the steps taken to hire personnel and to
improve such systems and controls might not be sufficient. If we are unable to manage our growth effectively, it will have a material
adverse effect on our business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we are unable to
obtain adequate insurance, our financial condition could be adversely affected in the event of uninsured or inadequately insured loss
or damage. Our ability to effectively recruit and retain qualified officers and directors could also be adversely affected if we experience
difficulty in obtaining adequate directors&#8217; and officers&#8217; liability insurance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to obtain
insurance policies on terms affordable to us that would adequately insure our business and property against damage, loss or claims by
third parties. To the extent our business or property suffers any damages, losses or claims by third parties, which are not covered or
adequately covered by insurance, our financial condition may be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to maintain
sufficient insurance as a public company to cover liability claims made against our officers and directors. Our insurance costs have increased
for directors&#8217; and officers&#8217; liability insurance, and we may be required to incur further substantial increased costs to maintain
the same or similar coverage or be forced to accept reduced coverage in future. If we are unable to adequately ensure our officers and
directors, we may not be able to retain or recruit qualified officers and directors to manage us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our cannabinoid initiative
is uncertain and may not yield commercial results and is subject to significant regulatory risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing formulations
of cannabis components for the treatment of diseases in which there is an overexpression of A3A<span style="font-family: Times New Roman, Times, Serif">R.
While we believe there are substantial business opportunities for us in this field, there can be no assurance that our activities will
be successful, or that any research and development and product testing efforts will result in commercially saleable products, or that
the market will accept or respond positively to our products. In addition, our current and potential involvement in cannabis-related
activity may expose us to legal and reputational risks. Such risks include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical-use
    cannabis remains illegal under U.S. federal law, and therefore, strict enforcement of federal laws regarding medical -use cannabis
    would likely result in our inability to market any products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    has not approved a marketing application for the treatment of any disease or condition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in laws, regulations and guidelines related to cannabis may result in significant additional compliance costs for us or limit our
    ability to operate in certain jurisdictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    banks will not accept deposits from or provide other bank services to businesses involved with cannabis and U.S. federal money laundering
    laws make it a federal crime to engage in financial transactions involving the proceeds of some form of unlawful activity; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    parties with whom we do business may perceive that they are exposed to reputational risk as a result of our cannabis-related business
    activities and may ultimately elect not to do business with us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Complying with laws and regulations
relating to cannabinoids is evolving, complex and expensive, and may divert management&#8217;s attention and resources from other aspects
of our business. Failure to maintain compliance with such laws and regulations may result in regulatory action that could have a material
adverse effect on our business, results of operations and financial condition. The DEA, FDA or state agencies may seek civil penalties,
refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could
lead to criminal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We or the third parties
upon whom we depend may be adversely affected by natural disasters and/or health epidemics, and our business continuity and disaster recovery
plans may not adequately protect us from a serious disaster.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Natural disasters could severely
disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If
a natural disaster, power outage, health epidemic or other event occurred that prevented us from using all or a significant portion of
our office, manufacturing and/or lab spaces, that damaged critical infrastructure, such as the manufacturing facilities of our third-party
contract manufacturers, CROs, clinical sites, third parties ongoing activities and schedules or that otherwise disrupted operations, it
may be difficult or, in certain cases, impossible for us to continue our plans and business for a substantial period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In late 2019, a novel strain
of COVID-19, also known as coronavirus, was reported in Wuhan, China and began spreading to various parts of the world. Epidemics such
as this can adversely impact our business and that of third parties with whom we engage as they can cause disruptions, such as travel
bans, quarantines, and interruptions to access the trial sites and supply chain, which could result in material delays and complications
with respect to our research and development programs and clinical trials. If there are future outbreaks of COVID-19 this may result in
a period of business disruption in these and other areas impacting our business, including the establishment of contractual relationships
with investigators enrolling subjects in our clinical trials, the continuity of care provided by these institutions to the subjects we
seek to enroll and their ability to support industry-funded research as a means of caring for their subjects, supply of these sites with
study materials, and the enrollment of subjects and their adherence with study requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The disaster recovery and
business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial
expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse
effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The expiry of a patent
that we licensed from the National Institute of Health, or NIH, and the consequent loss of composition of matter exclusivity that we had
by virtue of this license may diminish our proprietary position.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the expiry
in June 2015 of a patent that provided composition of matter protection over Piclidenoson and Namodenoson, that we licensed from the NIH,
we no longer enjoy composition of matter patent exclusivity relating to Piclidenoson and Namodenoson. Nevertheless, because Piclidenoson
and Namodenoson may each be a new chemical entity, or NCE, following approval of an NDA, we, if we are the first applicant to obtain NDA
approval, may be entitled to five years of data exclusivity in the United States with respect to such NCEs. Analogous data and market
exclusivity provisions, of varying duration, may be available in Europe and other foreign jurisdictions. We also have rights under our
pharmaceutical use issued patents with respect to Piclidenoson and Namodenoson and under our Piclidenoson manufacturing process patents,
which provide patent exclusivity within our field of activity until the mid- to late-2020s. While we believe that we may be able to protect
our exclusivity through such use patent portfolio and such period of exclusivity, the lack of composition of matter patent protection
may diminish our ability to maintain a proprietary position for our intended uses of Piclidenoson or Namodenoson. Moreover, we cannot
be certain that we will be the first applicant to obtain an FDA approval for any indication of Piclidenoson or Namodenoson and we cannot
be certain that we will be entitled to NCE exclusivity. In addition, we have discontinued the prosecution of a family of pending patent
applications under joint ownership of us and NIH pertaining to the use of A3AR agonists for the treatment of uveitis. Such diminution
of our proprietary position could have a material adverse effect on our business, results of operation and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We license from Leiden
University intellectual property, which protects certain small molecules which target the A3AR, in furtherance of our platform technology,
and we could lose our rights to this license if a dispute with Leiden University arises or if we fail to comply with the financial and
other terms of the license.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have licensed intellectual
property from Leiden University pursuant to a license agreement. The license agreement imposes certain payment, reporting, confidentiality
and other obligations on us. In the event that we were to breach any of the obligations and fail to cure, Leiden University would have
the right to terminate the license agreement. In addition, Leiden University has the right to terminate the license agreement upon our
bankruptcy, insolvency, or receivership. If any dispute arises with respect to our arrangements with Leiden University, such dispute may
disrupt our operations and may have a material adverse impact on us if resolved in a manner that is unfavorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The failure to obtain
or maintain patents, licensing agreements, including our current licensing agreements, and other intellectual property could impact our
ability to compete effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To compete effectively, we
need to develop and maintain a proprietary position with regard to our own technologies, intellectual property, licensing agreements,
product candidates and business. Legal standards relating to the validity and scope of claims in the biotechnology and biopharmaceutical
fields are still evolving. Therefore, the degree of future protection for our proprietary rights in our core tec<span style="font-family: Times New Roman, Times, Serif">hnologies
and any products that might be made using these technologies is also uncertain. The risks and uncertainties that we face with respect
to our patents and other proprietary rights include the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">while
    some of our patents or patents that we in-licensed have issued, the pending patent applications we have filed may not result in issued
    patents or may take longer than we expect to result in issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    third party may initiate an inter parties review, or IPR, proceedings in the U.S.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to interference proceedings in the U.S.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    third party may initiate opposition proceedings in foreign countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    patents that are issued may not provide meaningful protection;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to develop additional proprietary technologies that are patentable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    companies may challenge patents licensed or issued to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    companies may independently develop similar or alternative technologies, or duplicate our technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    companies may design around patents we have in-licensed or developed; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
    of patents is complex, uncertain and expensive.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
patent rights covering our products and methods are not sufficiently broad or not issued at all by the United States Patent and Trademark
Office, or the USPTO, or by foreign patent offices, we may not have adequate protection against competitors with similar products and
technologies. Furthermore, if the USPTO or foreign patent offices issue patents to us or our licensors, others may challenge the patents
or design around the patents, or the pate</span>nt office or the courts may invalidate the patents. Thus, any patents we own or license
from third parties may not provide any protection against our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
patents will be issued as a result of any pending applications, and we cannot be certain that any of our issued patents will give us adequate
protection from competing products. For example, issued patents, including the patents in-licensed by us, may be circumvented or challenged,
declared invalid or unenforceable, or narrowed in scope. In addition, since publication of discoveries in the scientific or patent literature
often lags behind actual discoveries, we cannot be certain that we were the first to make our inventions or to file patent applications
covering those inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that others
may obtain issued patents that could prevent us from commercializing our products or require us to obtain licenses requiring the payment
of significant fees or royalties in order to enable us to conduct our business. As to those patents that we have in-licensed, our rights
depend on maintaining our obligations to the licensor under the applicable license agreement, and we may be unable to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents and
patent applications, we depend upon trade secrets and proprietary know-how to protect our proprietary technology. We require our employees,
consultants, advisors and collaborators to enter into confidentiality agreements that prohibit the disclosure of confidential information
to any other parties. We require our employees and consultants to disclose and assign to us their ideas, developments, discoveries and
inventions. These agreements may not, however, provide adequate protection for our trade secrets, know-how or other proprietary information
in the event of any unauthorized use or disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Costly litigation may
be necessary to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property
rights of others.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may face significant expense
and liability as a result of litigation or other proceedings relating to patents and other intellectual property rights of others. In
the event that another party has also filed a patent application or been issued a patent relating to an invention or technology claimed
by us in pending applications, we may be required to participate in an interference proceeding declared by the USPTO to determine priority
of invention, which could result in substantial uncertainties and costs for us, even if the eventual outcome were favorable to us. We,
or our licensors, also could be required to participate in interference proceedings involving issued patents and pending applications
of another entity. An adverse outcome in an interference proceeding could require us to cease using the technology or to license rights
from prevailing third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost to us of any patent
litigation or other proceeding relating to our own or in-licensed patents or patent applications, even if resolved in our favor, could
be substantial. Our ability to enforce our patent protection could be limited by our financial resources, and may be subject to lengthy
delays. If we are unable to effectively enforce our proprietary rights, or if we are found to infringe the rights of others, we may be
in breach of our License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A third party may claim that
we are using inventions claimed by their patents and may go to court to stop us from engaging in our normal operations and activities,
such as research, development and the sale of any future products. Such lawsuits are expensive and would consume time and other resources.
There is a risk that the court will decide that we are infringing the third party&#8217;s patents and will order us to stop the activities
claimed by the patents, redesign our products or processes to avoid infringement or obtain licenses (which may not be available on commercially
reasonable terms). In addition, there is a risk that a court will order us to pay the other party damages for having infringed their patents
and possibly also their legal fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, there is no guarantee
that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed by the patent, or
that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition, third parties may, in the
future, assert other intellectual property infringement claims against us with respect to our product candidates, technologies or other
matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We rely on confidentiality
agreements that could be breached and may be difficult to enforce, which could result in third parties using our intellectual property
to compete against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe that
we take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure of confidential
information to third parties, as well as agreements that purport to require the disclosure and assignment to us of the rights to the
ideas, developments, discoveries and inventions of our employees and consultants while we employ them, the agreements can be difficult
and costly to enforce. Although we seek to obtain these types of agreements from our contractors, consultants, advisors and research
collaborators, to the extent that employees and consultants utilize or independently develop intellectual property in connection with
any of our projects, disputes may arise as to the intellectual property rights associated with our products. If a dispute arises, a court
may determine that the right belongs to a third party. In addition, enforcement of our rights can be costly and unpredictable. We also
rely on trade secrets <span style="font-family: Times New Roman, Times, Serif">and proprietary know-how that we seek to protect in part
by confidentiality agreements with our employees, contractors, consultants, advisors or others. Despite the protective measures we employ,
we still face the risk that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">these
    agreements may be breached;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">these
    agreements may not provide adequate remedies for the applicable type of breach;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    trade secrets or proprietary know-how will otherwise become known; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors will independently develop similar technology or proprietary information.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>International patent
protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to spend substantial
sums and management resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent law outside the United
States is different than in the United States. Further, the laws of some foreign countries may not protect our intellectual property rights
to the same extent as the laws of the United States, if at all. A failure to obtain sufficient intellectual property protection in any
foreign country could materially and adversely affect our business, results of operations and future prospects. Moreover, we may participate
in opposition proceedings to determine the validity of our foreign patents or our competitors&#8217; foreign patents, which could result
in substantial costs and divert management&#8217;s resources and attention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although most jurisdictions
in which we have applied for, intend to apply for, or have been issued patents have patent protection laws similar to those of the United
States, some of them do not. For example, we expect to do business in Brazil and India in the future. However, the Brazilian drug regulatory
agency, ENVISA, has the authority to nullify patents on the basis of its perceived public interest and the Indian patent law does not
allow patent protection for new uses of pharmaceuticals (many of our current patent applications are of such nature). Additionally, due
to uncertainty in patent protection law, we have not filed applications in many countries where significant markets exist, including Indonesia,
Pakistan, Russia, African countries and Taiwan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may be unable to
protect the intellectual property rights of the third parties from whom we license certain of our intellectual property or with whom we
have entered into other strategic relationships.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our intellectual
property rights are currently licensed from Leiden University, and, in the future, we wish to continue to license intellectual property
from Leiden University and/or other universities and/or strategic partners. Such third parties may determine not to protect the intellectual
property rights that we license from them and we may be unable to defend such intellectual property rights on our own or we may have to
undertake costly litigation to defend the intellectual property rights of such third parties. There can be no assurances that we will
be able to obtain licenses to such third party intellectual property or otherwise have the right to use through similar strategic relationships.
Any loss or limitations on use with respect to our right to use such intellectual property licensed from third parties or otherwise obtained
from third parties with whom we have entered into strategic relationships could have a material adverse effect on our business, results
of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Under applicable U.S.
and Israeli law, we may not be able to enforce covenants not to compete and therefore, may be unable to prevent our competitors from benefiting
from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective
of their agreements with us, which in turn could impact our future profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally enter into confidentiality
and non-competition agreements with our employees and certain key consultants, or our employment and consulting agreements contain confidentiality
and non-competition provisions. These agreements, to the extent they are in place and in effect, prohibit our employees and certain key
consultants, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period
of time and maintain confidentiality of our know-how and trade secrets, as long as they do not enter the public domain. We may be unable
to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict
our competitors from benefitting from the expertise our former employees or consultants developed while working for us. For example, Israeli
courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities
of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts,
such as the secrecy of a company&#8217;s confidential commercial information or the protection of its intellectual property. If we cannot
demonstrate that such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our
former employees or consultants and our ability to remain competitive may be diminished.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Chapter 8 to
the Israeli Patents Law, 5727-1967, or the Patents Law, deals with inventions made in the course of an employee&#8217;s service and during
his or her term of employment, whether or not the invention is patentable, or service inventions. Section 134 of the Patents Law provides
that if there is no agreement that explicitly determines whether the employee is entitled to compensation for the service inventions and
the extent and terms of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory committee
of the Israeli Patents Office. Although our employees have agreed to assign to us service invention rights, we may face claims demanding
remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration
or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Intellectual property
rights do not necessarily addre<span style="font-family: Times New Roman, Times, Serif">ss all potential threats to our competitive advantage.</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others
    may be able to make compounds that are the same as or similar to our product candidates but that are not covered by the claims of
    the patents that we own or have exclusively licensed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    or our licensors or any future strategic partners might not have been the first to make the inventions covered by the issued patent
    or pending patent application that we own or have exclusively licensed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our
    inventions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is possible that our pending patent applications will not lead to issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable,
    as a result of legal challenges by our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
    learned from such activities to develop competitive products for sale in our major commercial markets; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not develop additional proprietary technologies that are patentable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor
or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved
in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are subject to government
regulations and we may experience delays in obtaining required regulatory approvals in the United States and the regulatory authorities
in foreign jurisdiction in which we intend to market our proposed product candidates, of which there can be no assurance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Various aspects of our operations
are subject to foreign, federal, state or local laws, and rules and regulations, any of which may change from time to time. We are not
permitted to market our product candidates as prescription pharmaceutical products in the United States until we receive approval of a
New Drug Application, or NDA, from the Food and Drug Administration, or FDA, or in any foreign countries until we receive the requisite
approval from such countries. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert
management resources and attention and, consequently, could adversely affect our business operations and financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in regulatory approval,
limitations in regulatory approval and withdrawals of regulatory approval may have a material adverse effect on us. In the United States,
the FDA generally requires the completion of clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical
development to ensure its quality before an NDA is approved. If we experience significant delays in testing or receiving approvals or
sign-offs to conduct clinical trials, our product development costs, or our ability to license product candidates, will increase. If
the FDA grants regulatory approval to market a product, this approval will be limited to those disease states and conditions and populations
for which the product has demonstrated, through clinical trials, to be safe and effective. Any product approvals that we receive in the
future could also include significant restrictions on the use or marketing of our products. Product approvals, if granted, can be withdrawn
for failure to comply with regulatory requirements or upon the occurrence of adverse events following commercial introduction of the
products. Failure to comply with applicable FDA or other applicable regulatory requirements may result in criminal prosecution, civil
penalties, recall or seizure of products, total or partial suspension of production or injunction, as well as other regulatory action
against our product candidates or us. If approval is withdrawn for a product, or if a product were seized or recalled, we would be unable
to sell or license that pr<span style="font-family: Times New Roman, Times, Serif">oduct and our revenues would suffer. In addition,
outside the United States, our ability to market any of our potential products is contingent upon receiving market application authorizations
from the appropriate regulatory authorities and these foreign regulatory approval processes include all of the risks associated with
the FDA approval process described above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
success depends on our receipt of the regulatory approvals described above, and the issuance of such regulatory approvals is uncertain
and subject to a number of risks, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may disagree with the number, design, size, conduct or implementation of our clinical trials or any of our collaborators&#8217;
    clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may disagree with our interpretation of data from preclinical studies or clinical trials or the use of results from studies
    that served as precursors to our current or future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of toxicology studies may not support the filing of an Investigational New Drug Application, or IND, or NDA for our product
    candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities or Institutional Review Boards, or IRBs, may disagree with the design or implementation
    of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to provide acceptable evidence of our product candidates&#8217; safety and efficacy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our clinical trials may not be satisfactory or may not meet the level of statistical or clinical significance required
    by the FDA, European Medicines Agency, or EMA, or other regulatory agencies for us to receive marketing approval for any of our product
    candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dosing of our product candidates in a particular clinical trial may not be at an optimal level;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    in our clinical trials may suffer adverse effects for reasons that may or may not be related to our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials may not be sufficient to support the submission of an NDA, or other submission to obtain regulatory
    approval in the United States or elsewhere;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers
    with which we contract for clinical and commercial supplies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering
    our clinical data insufficient for approval of our product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining regulatory
approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon, among other things,
the type, complexity and novelty of the product candidates involved, the jurisdiction in which regulatory approval is sought and the substantial
discretion of the regulatory authorities. Changes in regulatory approval policies during the development period, changes in or the enactment
of additional statutes or regulations, or changes in regulatory review for a submitted product application may cause delays in the approval
or rejection of an application. Regulatory approval obtained in one jurisdiction does not necessarily mean that a product candidate will
receive regulatory approval in all jurisdictions in which we may seek approval, but the failure to obtain approval in one jurisdiction
may negatively impact our ability to seek approval in a different jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Clinical testing is
expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business model depends
entirely on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. Our
product candidates are in the early stages of development and as of the date of this Annual Report on Form 20-F. We may not be successful
in obtaining approval from the FDA or comparable foreign regulatory authorities to start or continue clinical trials for any of our product
candidates. Moreover, there is no guarantee that we will receive approval to commence human clinical trials or that our clinical trials
will be successful or that we will continue clinical development in support of an approval from the FDA or comparable foreign regulatory
authorities for any indication. We note that most product candidates never reach the clinical development stage and even those that do
commence clinical development have only a small chance of successfully completing clinical development and gaining regulatory approval.
Success in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim
results of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can occur at any
stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay
or prevent our ability to receive regulatory approval or commercialize our product candidates. Therefore, our business currently depends
entirely on the successful development, regulatory approval and commercialization of our product candidates, which may never occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The results of previous
clinical trials may not be predictive of future results, our progress in trials for one product candidate may not be indicative of progress
in trials for other product candidates, and our trials may not be designed so as to support regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no products
approved for sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical
development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide,
or regulators may require us, to conduct additional clinical or non-clinical testing. We will be required to demonstrate with substantial
evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before
we can obtain regulatory approvals for their commercial sale. Success in early clinical trials does not mean that future clinical trials
will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to
the satisfaction of the FDA and other regulatory authorities despite having progressed through initial clinical trials. Product candidates
that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical trials. Similarly,
the outcome of non-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim
results of a clinical trial do not necessarily predict final results. Progress in trials of one product candidate does not indicate that
we will make similar progress in additional trials for that product candidate or in trials for our other product candidates. A number
of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant
setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The design of a clinical trial
can determine whether its results will support approval of a product. We may be unable to design and/or execute a clinical trial to support
regulatory approval. Flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed.
In addition, we or our investigators may have little control over whether subjects comply with important aspects of clinical trial protocols.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances, there can
be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors,
including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other
trial protocols, modifications in the formulation throughout the course of development and the rate of dropout among clinical trial participants.
While we have not had any serious adverse events in our clinical trials to date that are believed to be related to our oral product candidates,
we may need to change future trial designs in response to adverse events that occur during future clinical development. We do not know
whether any Phase 2, Phase 3 or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate
efficacy and safety to obtain regulatory approval to market our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Even if we receive regulatory
approval for any of our product candidates, we may not be able to successfully commercialize the product and the revenue that we generate
from its sales, if any, may be limited</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If approved for marketing,
the commercial success of our product candidates will depend upon each product&#8217;s acceptance by the medical communit<span style="font-family: Times New Roman, Times, Serif">y,
including physicians, patients and health care payors. The degree of market acceptance for any of our product candidates will depend
on a number of factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    of clinical safety and efficacy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience, dosing burden and ease of administration;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any adverse effects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of physicians to prescribe our product candidates, and the target patient population to try new therapies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
    of our product candidates compared to competing products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    introduction of any new products that may in the future become available targeting indications for which our product candidates may
    be approved;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    procedures or therapies that may reduce the incidences of any of the indications in which our product candidates may show utility;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    and cost-effectiveness;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inclusion or omission of our product candidates in applicable therapeutic guidelines;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our own or any future collaborators&#8217; sales and marketing strategies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in approved labeling from regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare
    and Medicaid, private health insurers and other third-party payors or to receive the necessary pricing approvals from government
    bodies regulating the pricing and usage of therapeutics; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing approvals.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our product candidates
are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we may not generate
sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party
payors on the benefits of our product candidates may require significant resources and may never be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even if we obtain
regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize our product candidates
successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability
to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited or subject to
restrictions or post-approval commitments that render our product candidates not commercially viable. For example, regulatory authorities
may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to
charge for any of our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or
may approve any of our product candidates with a label that does not include the labeling claims necessary or desirable for the successful
commercialization of that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions on approvals
or require risk management plans or a REMS to assure the safe use of the drug. Moreover, product approvals may be withdrawn for non-compliance
with regulatory standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially
harm the commercial success of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Even if we obtain marketing
approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result
in significant additional expense. Additionally, our product candidates could be subject to labeling and other restrictions and withdrawal
from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated
problems with our product candidates</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain regulatory
approval for any of our product candidates for an indication, the FDA or foreign equivalent may still impose significant restrictions
on their indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming
post-approval studies, including Phase 4 clinical trials, and post-market surveillance to monitor safety and efficacy. Our product candidates
will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution, safety
surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market information. These requirements
include registration with the FDA, as well as continued compliance with current Good Clinical Practices regulations, or cGCPs, for any
clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual
review and periodic inspections by the FDA and other regulatory authorities for compliance with current Good Manufacturing Practices,
or cGMPs, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has the authority
to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution or use
of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting
treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or enrollment in a registry.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to sales and
marketing activities related to our product candidates, advertising and promotional materials must comply with FDA rules in addition to
other applicable federal, state and local laws in the United States and similar legal requirements in other countries. In the United States,
the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug Marketing Act. Application
holders must obtain FDA approval for product and manufacturing changes, depending on the nature of the change. We may also be subject,
directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback
Statute, U.S. False Claims Act, and similar state laws, which impact, among other things, our proposed sales, marketing, and scientific/educational
grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans
Affairs, or other government drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations.
All of these activities are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar
requirements exist in many of these areas in other countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if any of our
product candidates are approved for a particular indication, our product labeling, advertising and promotion would be subject to regulatory
requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products.
In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling.
If we receive marketing approval for our product candidates, physicians may nevertheless legally prescribe our products to their patients
in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject
to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion
of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The
federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several
companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions
under which specified promotional conduct is changed or curtailed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or a regulatory agency
discover previously unknown problems with a product candidate, such as adverse events of unanticipated severity or frequency, problems
with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable regulatory requirements,
we may be subject to the following administrative or judicial sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
    of warning letters or untitled letters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    holds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties or monetary fines;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    of any ongoing clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license
    approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or imposition of restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention or refusal to permit the import or export of product.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The occurrence of any event
or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. Adverse regulatory action,
whether pre- or post-approval, can also potentially lead to product liability claims and increase our product liability exposure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United
States or abroad, and compliance with such regulation may be expensive and consume substantial financial and management resources. If
we or any future marketing collaborators or contract manufacturers are slow or unable to adapt to changes in existing requirements or
the adoption of new requirements or policies or are not able to maintain regulatory compliance, it could delay or prevent the promotion,
marketing or sale of our products, which would adversely affect our business and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Obtaining and maintaining
regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval
of our product candidates in other jurisdictions</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining and maintaining
regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory
approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect
on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable
regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate
in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different
from those in the United States, including additional preclinical studies or clinical trials, as clinical studies conducted in one jurisdiction
may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate
must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to
charge for our products is also subject to approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could
delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory requirements
in international markets and/ or to receive applicable marketing approvals, our target market will be reduced and our ability to realize
the full market potential of our product candidates will be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Even though we may apply
for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that in some cases
our dry powder drug products may qualify for the FDA&#8217;s orphan drug status. There is no guarantee that the FDA will grant any future
application for orphan drug designation for any of our product candidates, which would make us ineligible for the additional exclusivity
and other benefits of orphan drug designation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition
that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing
and making a drug available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan
drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten
the duration of regulatory review and approval process. In addition to the potential period of exclusivity, orphan designation makes a
company eligible for grant funding of up to $500,000 per year for four years to defray costs of clinical trial expenses, tax credits for
clinical research expenses and potential exemption from the FDA application user fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product that has orphan
designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is
entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market the same drug for the same indication
for seven years, except in limited circumstances, such as (i) the drug&#8217;s orphan designation is revoked; (ii) its marketing approval
is withdrawn; (iii) the orphan exclusivity holder consents to the approval of another applicant&#8217;s product; (iv) the orphan exclusivity
holder is unable to assure the availability of a sufficient quantity of drug; or (v) a showing of clinical superiority to the product
with orphan exclusivity by a competitor product. If a drug designated as an orphan product receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan drug exclusivity. There can be no assurance that we will receive orphan
drug designation for any of our product candidates in the indications for which we think they might qualify, if we elect to seek such
applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Current and future legislation
may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices
we may obtain</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States and some
foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system
that could prevent or delay marketing approval for our product candidates, restrict or regulate post-approval activities and affect our
ability to profitably sell our product candidates. Legislative and regulatory proposals have been made to expand post-approval requirements
and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will
be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing
approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval
process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing
testing and other requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare
coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for drugs. In
addition, this legislation authorized Medicare Part D prescription drug plans to use formularies where they can limit the number of drugs
that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products,
we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives and other provisions of
this legislation could decrease the coverage and price that we receive for our product candidates and could seriously harm our business.
While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment
limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may result in a similar
reduction in payments from private payors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 or, collectively, the ACA, is
a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies
against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on
the health industry and impose additional health policy reforms. The ACA revised the definition of &#8220;average manufacturer price&#8221;
for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the law imposed a significant annual
fee on companies that manufacture or import branded prescription drug products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the U.S. Congress enacted the Budget Control
Act of 2011, or the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted
in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to
the statute, will remain in effect through 2027 absent additional congressional action. However, pursuant to the CARES Act, and subsequent
legislation, these reductions were suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. In January 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new
laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers
for our drugs, if approved, and accordingly, our financial operations. If government spending is further reduced, anticipated budgetary
shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact
the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which
may delay our ability to develop, market and sell any product candidates we may develop. In addition, any significant spending reductions
affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes
or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act,
could have an adverse impact on our anticipated product revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been judicial and
Congressional challenges to certain aspects of the ACA, and we expect such challenges to continue. In 2017, the U.S. Congress enacted
the Tax Cuts and Jobs Act, or the 2017 Tax Act, which eliminated the tax-based shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual
mandate.&#8221; On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed
the implementation of certain fees mandated by the ACA, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored
insurance plans and the annual fee imposed on certain health insurance providers based on market share. The Bipartisan Budget Act of 2018,
or the BBA, among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans. In July
2018, the Centers for Medicare and Medicaid Services, or CMS, published a final rule permitting further collections and payments to and
from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome
of federal district court litigation, regarding the method CMS uses to determine this risk adjustment. Litigation and legislation over
the ACA are likely to continue, with unpredictable and uncertain results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, recently there has
been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products. There have been
several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring
more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs
under Medicare, and reform government program reimbursement methodologies for drugs. On September 24, 2020, the FDA released a final rule
providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department
of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical
manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required
by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain
fixed fee arrangements between pharmacy benefit managers and manufacturers. On August 16, 2022, President Biden signed the Inflation Reduction
Act of 2022, which includes several provisions to lower prescription drug costs for people with Medicare, including price negotiation
requirements for drugs covered under Medicare, rebate requirements when drug prices rise faster than inflation, and a cap on out-of-pocket
spending for Medicare Part D enrollees. At the state level, legislatures have increasingly passed legislation and implemented regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 20, 2020, the
HHS Office of Inspector General finalized further modifications to the federal Anti-Kickback Statute. Under the final rules, the HHS Office
of Inspector General added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements
among clinicians, providers, and others, yet removed safe harbor protection for price reductions from pharmaceutical manufacturers to
plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule
also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements
between pharmacy benefit managers and manufacturers. This rule (with exceptions) became effective January 19, 2021. We continue to evaluate
what effect, if any, these rules will have on our business. CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer
advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to
include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater
than $35 for a monthly supply or usual course of treatment. Prescription drugs and biological products that are in violation of these
requirements will be included on a public list. Any adopted health reform measure could reduce the ultimate demand for our products, if
approved, or put pressure on our product pricing. Individual states in the United States have also become increasingly active in passing
legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in
their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be
adopted in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The delivery of healthcare
in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively
a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and
approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare
budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant
health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products,
this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our
ability to commercialize any products for which we obtain marketing approval. Both in the United States and in the EU, legislative and
regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical
products. We do not know whether additional legislative changes will be enacted, or whether the regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Any termination or
<span style="font-family: Times New Roman, Times, Serif">suspension of, or delays in the commencement or completion of, any necessary
studies of any of our product candidates for any indications could result in increased costs to us, delay or limit our ability to generate
revenue and adversely affect our commercial prospects</span></i></b><span style="font-family: Times New Roman, Times, Serif">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
commencement and completion of clinical studies can be delayed for a number of reasons, including delays related to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or a comparable foreign regulatory authority failing to grant permission to proceed and placing the clinical study on hold;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    for clinical testing failing to enroll or remain enrolled in our trials at the rate we expect;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    facility manufacturing any of our product candidates being ordered by the FDA or other government or regulatory authorities to temporarily
    or permanently shut down due to violations of cGMP requirements or other applicable requirements, or cross-contaminations of product
    candidates in the manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    changes to our manufacturing process that may be necessary or desired;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    choosing an alternative treatment for the indications for which we are developing our product candidates, or participating in competing
    clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    experiencing severe or unexpected drug-related adverse effects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports
    from clinical testing on similar technologies and products raising safety and/or efficacy concerns;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators losing their license or permits necessary to perform our clinical trials, not performing our clinical trials
    on our anticipated schedule or employing methods consistent with the clinical trial protocol, cGMP requirements, or other third parties
    not performing data collection and analysis in a timely or accurate manner;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspections
    of clinical study sites by the FDA, comparable foreign regulatory authorities, or IRBs finding regulatory violations that require
    us to undertake corrective action, result in suspension or termination of one or more sites or the imposition of a clinical hold
    on the entire study, or that prohibit us from using some or all of the data in support of our marketing applications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations
    of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or any
    of the data produced by such contractors in support of our marketing applications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one
    or more IRBs refusing to approve, suspending or terminating the study at an investigational site, precluding enrollment of additional
    subjects, or withdrawing its approval of the trial, reaching agreement on acceptable terms with prospective contract research organizations,
    or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different
    CROs and trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deviations
    of the clinical sites from trial protocols or dropping out of a trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding
    new clinical trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of the CRO to execute any clinical trials for any reason; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government
    or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of a trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product development costs
for any of our product candidates will increase if we have delays in testing or approval or if we need to perform more or larger clinical
studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to amend study protocols
to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable foreign regulatory authorities,
and IRBs for reexamination, which may impact the costs, timing or successful completion of that study. If we experience delays in completion
of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing entities, or any of our clinical study sites suspend
or terminate any of our clinical studies of any of our product candidates, its commercial prospects may be materially harmed and our ability
to generate product revenues will be delayed. Any delays in completing our clinical trials will increase our costs, slow down our development
and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our
business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, termination or suspension
of, or a delay in the commencement or completion of, clinical studies may also ultimately lead to the denial of regulatory approval of
our product candidates. In addition, if one or more clinical studies are delayed, our competitors may be able to bring competing products
to market before we do, and the commercial viability of any of our affected product candidates could be significantly reduced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we or any of our
independent contractors, consultants, collaborators, manufacturers, or service providers fail to comply with healthcare and data privacy
laws and regulations, we or they could be subject to enforcement actions, which could result in penalties and affect our ability to develop,
market and sell our product candidates and may harm our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are or may in the future
be subje<span style="font-family: Times New Roman, Times, Serif">ct to federal, state, and foreign healthcare and data privacy laws and
regulations pertaining to, among other things, fraud and abuse of patients&#8217; rights. These laws and regulations include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully soliciting, offering, receiving, or paying any
    remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending
    the purchase or order of any item or service for which payment may be made, in whole or in part, under a federal healthcare program
    such as Medicare and Medicaid. Liability may be established without a person or entity having actual knowledge of the federal Anti-Kickback
    Statute or specific intent to violate it. This statute has been interpreted to apply broadly to arrangements between pharmaceutical
    manufacturers on the one hand and prescribers, patients, purchasers and formulary managers on the other. In addition, the ACA amended
    the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting from a
    violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims
    Act, or the FCA. A conviction for violation of the Anti-Kickback Statute requires mandatory exclusion from participation in federal
    healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities
    from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty
    if they do not qualify for an exemption or safe harbor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FCA prohibits, among other things, knowingly presenting, or causing to be presented claims for payment of government funds that are
    false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false
    or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay
    money to the federal government. This statute also permits a private individual acting as a &#8220;whistleblower&#8221; to bring
    actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. The FCA prohibits
    anyone from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented,
    for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or
    fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. This law
    also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S. federal agencies are
    requiring nonmonetary remedial measures, such as corporate integrity agreements in FCA settlements. The U.S. Department of Justice
    announced in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more aggressive approach in pursuing individuals
    as FCA defendants in addition to the corporations. On October 28, 2021, the Biden Administration announced that it would continue
    the policies set forth in the &#8220;Yates&#8221; memo. FCA liability is potentially significant in the healthcare industry because
    the statute provides for treble damages and mandatory penalties of $5,500 to $11,000 per false claim or statement ($12,537 to $25,076
    per false claim or statement for penalties assessed after May 9, 2022 for violations occurring after November 2, 2015. Government
    enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA
    for a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that
    the customers would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them
    to prescribe products; engaging in promotion for &#8220;off-label&#8221; uses; and submitting inflated best price information to
    the Medicaid Rebate Program;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal False Statements Statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making
    any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing
    the same to contain any materially false, fictitious or fraudulent statement or entry, in connection with the delivery of or payment
    for healthcare benefits, items, or services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Civil Monetary Penalties Law authorizes the imposition of substantial civil monetary penalties against an entity, such as
    a pharmaceutical manufacturer, that engages in activities including, among others (1) knowingly presenting, or causing to be presented,
    a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting
    with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable
    by a federal healthcare program; (3) violations of the federal Anti-Kickback Statute; (4) knowingly offering or transferring remuneration
    to a Medicare or Medicaid beneficiary or recipient to influence the beneficiary&#8217;s or recipient&#8217;s selection of a particular
    provider, practitioner, or supplier for the order or receipt of any item or service; or (5) failing to report and return a known
    overpayment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly
    and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully
    falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of,
    or payment for, healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not
    need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act, which imposes requirements on certain types
    of people and entities relating to the privacy, security, and transmission of individually identifiable health information, and requires
    notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health
    information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for
    which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, to report annually to the
    Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value to physicians, other healthcare
    providers and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their
    immediate family members, which is published in a searchable form on an annual basis;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws that may be broader
    in scope and also apply to commercial insurers and other non-federal payor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requirements
    for mandatory corporate regulatory compliance programs, and laws relating to patient data privacy and security. Other state laws
    require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant
    compliance guidance promulgated by the federal government; require drug manufacturers to report information related to payments and
    other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws govern
    the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and
    often are not preempted by HIPAA, thus complicating compliance efforts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the European Union, the General Data Protection Regulation, or the GDPR, Regulation EU 2016/679, which was adopted in May 2016 and
    has become applicable on May 25, 2018. The GDPR is further intended to harmonize data protection requirements across the European
    Union member states by establishing new and expanded operational requirements for entities that collect, process or use personal
    data generated in the European Union, including consent requirements for disclosing the way personal information will be used, information
    retention requirements, and notification requirements in the event of a data breach.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    California Consumer Privacy Act of 2018, or CCPA, effective as of January 1, 2020, gives California residents expanded rights to
    access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed
    information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private
    right of action for data breaches, that is expected to increase data breach litigation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, failure to comply with the Israeli Privacy Protection Law of 1981, and its regulations, as well as the guidelines of the
    Israeli Privacy Protection Authority, may expose us to administrative fines, civil claims (including class actions) and in certain
    cases criminal liability. Current pending legislation may result in a change of the current enforcement measures and sanctions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any such healthcare laws and regulations, we may be subject to penalties, including administrative, civil and criminal
penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain
approvals from the FDA or foreign regulatory authorities, or exclusion from participation in government contracting, healthcare reimbursement
or other government programs, including Medicare and Medicaid, any of which could adversely our financial results. Any action against
us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention
from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable
laws and regulations may be costly to us in terms of money, time and resources.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our employees, principal
investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities, including non-compliance
with regulatory standards.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also exposed to the
risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging in fraud or
other misconduct. Misconduct by employees, independent contractors, principal investigators, consultants, commercial partners and vendors
could include intentional failures to comply with EU regulations, to provide accurate information to the EMA or EU Member States authorities
or to comply with manufacturing or quality standards we have or will have established. In particular, sales, marketing and business arrangements
in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices such as promotion of products by medical practitioners. The EU Member States in which we operate have different
statutory provisions regulating the cooperation of pharmaceutical companies with healthcare professionals. In addition to these statutory
provisions, codes of conduct issued by business associations or other non-statutory standards may be applicable to our activities. Both
statutory provisions and non-statutory codes or standards restrict payments or other benefits provided to healthcare professionals, and
in case of non-compliance, may result in severe sanctions such as bans, administrative fines, criminal fines or even imprisonment. The
advertising of medicinal products for human use in the EU is regulated by Title VIII of European Directive 2001/83/EC. These provisions
have been implemented into the law of the EU member States. Such laws inter alia restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct could also involve
the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious and
irreparable harm to our reputation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This could also apply with
respect to data privacy. In the EU, the EU Directive 95/46/EEC was replaced by the GDPR on May 25, 2018. The GDPR as an EU regulation
does not have to be implemented into Member States&#8217; national law, but applies directly in all Member States since May 25, 2018.
It applies to companies with an establishment in the European Economic Area (EEA) and to certain other companies not in the EEA that offer
or provide goods or services to individuals located in the EEA or monitor individuals located in the EEA. The GDPR implements more stringent
operational requirements for controllers of personal data, including, for example, expanded disclosures about how personal information
is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded)
data, increased cyber security requirements, mandatory data breach notification requirements and higher standards for controllers to demonstrate
that they have obtained a valid legal basis for certain data processing activities. The GDPR provides that EU Member States may continue
to make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result
in continued or new differences between Member States, limit our ability to use and share personal data or could cause our costs to increase,
and harm our business and financial condition. We are also subject to evolving and strict rules on the transfer of personal data out of
the European Union to the United States. Further prospective revision of the Directive on privacy and electronic communications (Directive
2002/58/EC), or ePrivacy Directive, may affect our marketing communications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our actual or alleged failure
to comply with this regulation, or to protect personal data, could result in enforcement actions and significant penalties against us,
which could result in negative publicity, increase our operating costs, subject us to claims or other remedies and have a material adverse
effect on our business, financial condition, and results of operations. It is not always possible to identify and deter misconduct by
employees or other parties. The precautions we take to detect and prevent such activity may not protect us from legal or regulatory action
resulting from a failure to comply with applicable laws or regulations. Misconduct by our employees, principal investigators, consultants,
commercial partners or vendors could result in significant financial penalties, criminal sanctions, civil law claims and/or negative media
coverage, and thus have a material adverse effect on our business, including through the imposition of significant fines or other sanctions,
and our reputation. In particular, failure to comply with EU laws, including failure under the GDPR, ePrivacy Directive and other laws
relating to the security of personal data may result in fines up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover
of the preceding financial year, if greater, and other administrative penalties including criminal liability, which may be onerous and
adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the GDPR and related laws
may also give risk to increase risk of private actions, including a new form of class action that is available under the GDPR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We conduct our operations
in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel and its region.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our headquarters, all of our
operations and some of our suppliers and third party contractors are located in central Israel and our key employees, officers and most
of our directors are residents of Israel. Accordingly, political and economic instability, war or acts of terrorism or natural disasters,
emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency, including for
example, the COVID-19 outbreak), may directly affect our business. Since the establishment of the State of Israel in 1948, a number of
armed conflicts have taken place between Israel and its Arab neighbors. Any hostilities involving Israel or the interruption or curtailment
of trade within Israel or between Israel and its trading partners could adversely affect our operations and results of operations and
could make it more difficult for us to raise capital. During the winter of 2008, winter of 2012 and the summer of 2014, Israel was engaged
in an armed conflict with Hamas, a militia group and political party operating in the Gaza Strip, and during the summer of 2006, Israel
was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite militia group and political party. Israel faces political
tension with respect to its relationships with Turkey, Iran and certain Arab neighbor countries. In addition, recent conflicts involved
missile strikes against civilian targets in various parts of Israel, and negatively affected business conditions in Israel. Recent political
uprisings and social unrest in various countries in the Middle East and North Africa are affecting the political stability of those countries.
This instability may lead to deterioration of the political relationships that exist between Israel and these countries, and have raised
concerns regarding security in the region and the potential for armed conflict. Any armed conflicts, terrorist activities or political
instability in the region could adversely affect business conditions and could harm our results of operations. For example, any major
escalation in hostilities in the region could result in a portion of our employees and service providers being called up to perform military
duty for an extended period of time. Parties with whom we do business have sometimes declined to travel to Israel during periods of heightened
unrest or tension, forcing us to make alternative arrangements when necessary. In addition, the political and security situation in Israel
may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their
commitments under those agreements pursuant to force majeure provisions in such agreements. Any future deterioration in the political
and security situation in Israel will negatively impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance does
not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although the Israeli
government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure
you that this government coverage will be maintained. Any losses or damages incurred by us could have a material adverse effect on our
business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm
our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, in the past, the
State of Israel and Israeli companies have been subjected to an economic boycott. Several countries still restrict business with the State
of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial
condition or the expansion of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israel&#8217;s most recent
general elections were held on April 9, 2019, September 17, 2019, March 2, 2020, March 23, 2021 and November 1, 2022. In addition, proposed
judicial reform has sparked widespread protests across Israel. Uncertainty surrounding future elections and the outcome of the judicial
reform in Israel may continue and the political situation in Israel may further deteriorate. Actual or perceived political instability
in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy
and, in turn, our business, financial condition, results of operations and growth prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our operations may be
disrupted as a result of the obligation of Israeli citizens to perform military service.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many Israeli citizens, including
Motti Farbstein, our Chief Operating and Financial Officer, are obligated to perform one month, and in some cases more, of annual military
reserve duty until they reach the age of 40 (or older, for reservists with certain occupations) and, in the event of a military conflict,
may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military
reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such
call-ups, which may include the call-up of Motti Farbstein. Such disruption could materially adversely affect our business, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Because a certain portion
of our expenses is incurred in currencies other than U.S. dollars, our results of operations may be harmed by currency fluctuations and
inflation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Company&#8217;s functional
and presentation currency is U.S. dollar To date, we have not engaged in hedging transactions. Although the Israeli rate of inflation
has not had a material adverse effect on our financial condition during 2020, 2021 or 2022 to date, we may, in the future, decide to enter
into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of the currencies
mentioned above in relation to U.S. dollars. These measures, however, may not adequately protect us from material adverse effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>It may be difficult
to enforce a U.S. judgment against us and our officers and directors named in this Annual Report on Form 20-F in Israel or the United
States, or to serve process on our officers and directors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated in Israel.
All of our executive officers and directors listed in this Annual Report on Form 20-F reside outside of the United States, and all of
our assets and most of the assets of our executive officers and directors are located outside of the United States. Therefore, a judgment
obtained against us or most of our executive officers and all of our directors in the United States, including one based on the civil
liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli
court. It also may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities
law claims in original actions instituted in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Your rights and responsibilities
as a shareholder will be governed by Israeli law which may differ in some respects from the rights and responsibilities of shareholders
of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of the holders of our shareholders are governed by our Amended and Restated Articles of Association
and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in typical
U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith toward the company and other
shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of
shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share
capital, mergers and acquisitions and interested party transactions requiring shareholder approval. In addition, a shareholder who knows
that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive
officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the
implications of these provisions that govern shareholders&#8217; actions. These provisions may be interpreted to impose additional obligations
and liabilities of our shareholders that are not typically imposed on shareholders of U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Provisions of Israeli
law may delay, prevent or otherwise impede a merger with, or an acquisition of, our Company, which could prevent a change of control,
even when the terms of such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions. For example,
a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each merging company
with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies approved the
merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a full tender offer
can only be completed if the acquirer receives at least 95% of the issued share capital; provided that, pursuant to an amendment to the
Companies Law, 5759-1999, as amended, or the Israeli Companies Law, effective as of May 15, 2011, a majority of the offerees that do not
have a personal interest in such tender offer shall have approved the tender offer; except that, if the total votes to reject the tender
offer represent less than 2% of our issued and outstanding share capital, in the aggregate, approval by a majority of the offerees that
do not have a personal interest in such tender offer is not required to complete the tender offer, and the shareholders, including those
who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition
the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder that accepts
the offer may not seek appraisal rights and the acquirer or the company published all required information with respect to the tender
offer prior to the tender offer&#8217;s response date).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel
exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent
as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent
on the fulfillment of numerous conditions, including, in some cases, requirement for a holding period of two years from the date of the
transaction during which sales and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain
share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition
of the shares has occurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other similar provisions
could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be
beneficial to us or to our shareholders. See &#8220;Description of the Offered Securities&#8212;Articles of Association.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Inflation could adversely&#160;affect our
business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While inflation&#160;in the
United States and global markets has been relatively low in recent years, during 2021 and 2022, the economy in the United States and global
markets encountered a material increase in the level of inflation. The impact of COVID-19, geopolitical developments such as the Russia-Ukraine
conflict and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity,
including whether inflation will continue and how long, and at what rate. Increases in&#160;inflation raise our costs for commodities,
labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms
may adversely&#160;impact our financial condition. Additionally, increases in inflation, along with the uncertainties surrounding COVID-19,
geopolitical developments and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and
uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing.
A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of operations
or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Ordinary Shares and ADSs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our business, operating
results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments
with respect to financial institutions and associated liquidity risk. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business depends on the
economic health of the global economies. If the conditions in the global economies remain uncertain or continue to be volatile, or if
they deteriorate, including as a result of the impact of military conflict, such as the war between Russia and Ukraine, terrorism or other
geopolitical events, our business, operating results and financial condition may be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, increases in
inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and
failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, along
with the uncertainties surrounding COVID-19, geopolitical developments and global supply chain disruptions, have caused, and may in the
future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly
or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a material adverse impact
on our financial condition, results of operations or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More recently, the closures
of SVB and Signature Bank and their placement into receivership with the FDIC created bank-specific and broader financial institution
liquidity risk and concerns. Although the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that
depositors at SVB and Signature Bank would have access to their funds, even those in excess of the standard FDIC insurance limits, under
a systemic risk exception, future adverse developments with respect to specific financial institutions or the broader financial services
industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term working capital needs, and create
additional market and economic uncertainty. There can be no assurance that future credit and financial market instability and a deterioration
in confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn,
liquidity shortages, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and
credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause short-term liquidity risk
and also make any necessary debt or equity financing more difficult, more costly, more onerous with respect to financial and operating
covenants and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material
adverse effect on our growth strategy, financial performance and stock price and could require us to alter our operating plans. In addition,
there is a risk that one or more of our service providers, financial institutions, manufacturers, suppliers and other partners may be
adversely affected by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>There can be no assurance
that we will not be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in 2023 or in any subsequent year.
If we are a PFIC, there may be negative tax consequences for U.S. taxpayers that are holders of our ordinary shares, ADSs, Warrants, or
Pre-funded Warrants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be treated as a PFIC
for U.S. federal income tax purposes in any taxable year in which either (i) at least 75% of our gross income is &#8220;passive income&#8221;
or (ii) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive
income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our analysis of our
income, assets, and operations, we believe that we were not a PFIC for 2022. Because the PFIC determination is highly fact intensive,
there can be no assurance that we will not be a PFIC in 2023 or in any other taxable year. If we were to be characterized as a PFIC for
U.S. federal income tax purposes in any taxable year during which a U.S. shareholder owns our ordinary shares, ADSs, Warrants, or Pre-funded
Warrants, then &#8220;excess distributions&#8221; to such U.S. shareholder, and any gain realized on the sale or other disposition of
our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, as applicable, will be subject to special rules. Under these rules: (i) the
excess distribution or gain would be allocated ratably over the U.S. shareholder&#8217;s holding period for the ordinary shares (or ADSs,
Warrants, or Pre-funded Warrants, as the case may be); (ii) the amount allocated to the current taxable year and any period prior to the
first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (iii) the amount allocated to each
of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that
year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such
other taxable year. Certain of the adverse consequences of PFIC status can be mitigated if a U.S. shareholder makes an election to treat
us as a &#8220;qualified electing fund,&#8221; or QEF, or makes a &#8220;mark-to-market&#8221; election. A QEF election is unavailable
with respect to our Warrants, and a mark-to-market election is unavailable with respect to our Warrants and Pre-funded Warrants. In addition,
if the U.S. Internal Revenue Service, or IRS, determines that we are a PFIC for a year with respect to which we have determined that we
were not a PFIC, it may be too late for a U.S. shareholder to make a timely QEF or mark-to-market election. U.S. shareholders who hold
our ordinary shares, ADSs, Warrants or Pre-funded Warrants during a period when we are a PFIC will be subject to the foregoing rules,
even if we cease to be a PFIC in subsequent years, subject to exceptions for U.S. shareholders who made a timely QEF or mark-to-market
election (to the extent available). A U.S. shareholder can make a QEF election by completing the relevant portions of and filing IRS Form
8621 in accordance with the instructions thereto. Upon request, we intend to annually furnish U.S. shareholders with information needed
in order to complete IRS Form 8621 (which form would be required to be filed with the IRS on an annual basis by the U.S. shareholder)
and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries that we control is a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Provisions of our charter
documents and Israeli law may discourage, delay, prevent or otherwise impede a merger with, or an acquisition of, our Company, which could
prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in articles of
association may discourage, delay, prevent or otherwise impede a merger, acquisition or other change in control of us that shareholders
may consider favorable, including transactions in which they might otherwise receive a premium for their ADSs. On February 20, 2020, we
amended our articles of association to establish a staggered board of directors, which divides the board into three groups, with directors
in each group serving a three-year term. The existence of a staggered board can make it more difficult for shareholders to replace or
remove incumbent members of our Board of Directors. As such, these provisions could also limit the price that investors might be willing
to pay in the future for our ADSs, thereby depressing the market price of our ADSs. In addition, because our Board of Directors is responsible
for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace
or remove our current management by making it more difficult for shareholders to replace members of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Israeli corporate
law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions
involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions.
For example, a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each
merging company with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies
approved the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a full
tender offer can only be completed if the acquirer receives at least 95% of the issued share capital; provided that, pursuant to an amendment
to the Companies Law, 5759-1999, as amended, or the Israeli Companies Law, effective as of May 15, 2011, a majority of the offerees that
do not have a personal interest in such tender offer shall have approved the tender offer; except that, if the total votes to reject the
tender offer represent less than 2% of our issued and outstanding share capital, in the aggregate, approval by a majority of the offerees
that do not have a personal interest in such tender offer is not required to complete the tender offer, and the shareholders, including
those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer,
petition the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder
that accepts the offer may not seek appraisal rights).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel
exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent
as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent
on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which sales
and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the
tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our business could be
negatively impacted by unsolicited takeover proposals, by shareholder activism or by proxy contests relating to the election of directors
or other matters.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be negatively
affected as a result of an unsolicited takeover proposal, by shareholder activism or a proxy contest. During 2019, an activist shareholder
sought to make changes to our Board of Directors, among other matters, which ultimately resulted in us entering into a settlement agreement
with the shareholder, and for which considerable costs were incurred and absorbed significant time and attention by management and the
Board of Directors. A future proxy contest, unsolicited takeover proposal, or other shareholder activism relating to the election of directors
or other matters would most likely require us to incur significant legal fees and proxy solicitation expenses and require significant
time and attention by management and our Board of Directors. The potential of a proxy contest, unsolicited takeover proposal, or other
shareholder activism could interfere with our ability to execute our strategic plan, give rise to perceived uncertainties as to our future
direction, result in the loss of potential business opportunities or make it more difficult to attract and retain qualified personnel,
any of which could materially and adversely affect our business and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Issuance of additional
equity securities may adversely affect the market price of our ADSs or ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently authorized
to issue 5,000,000,000 ordinary shares, no par value. As of the date of this Annual Report on Form 20-F, we had 1,224,837,393 ordinary
shares issued and outstanding and we had no preferred shares outstanding. As of the date of this Annual Report, we also had warrants to
purchase 1,222,016,340 ordinary shares and options to purchase 26,987,000 ordinary shares outstanding, of which options to purchase 13,852,625
ordinary shares are currently fully vested or vest within the next 60 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that ADSs or
ordinary shares are issued or options and warrants are exercised, holders of our ADSs and our ordinary shares will experience dilution.
In addition, in the event of any future issuances of equity securities or securities convertible into or exchangeable for ADSs or ordinary
shares, holders of our ADSs or our ordinary shares may experience dilution. We also consider from time to time various strategic alternatives
that could involve issuances of additional ADSs or ordinary shares, including but not limited to acquisitions and business combinations,
but do not currently have any definitive plans to enter into any of these transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have no plans to
pay dividends on our ordinary shares, and you may not receive funds without selling our ADSs or ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any cash dividends on our ordinary shares, nor do we expect to pay any cash dividends on our ordinary shares for the foreseeable future.
We currently intend to retain any additional future earnings to finance our operations and growth and for future stock repurchases and,
therefore, we have no plans to pay cash dividends on our ordinary shares at this time. Any future determination to pay cash dividends
on our ordinary shares will be at the discretion of our Board of Directors and will be dependent on our earnings, financial condition,
operating results, capital requirements, any contractual restrictions, and other factors that our Board of Directors deems relevant. Accordingly,
you may have to sell some or all of our ADSs or ordinary shares in order to generate cash from your investment. You may not receive a
gain on your investment when you sell our ADSs or ordinary shares and may lose the entire amount of your investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The market price of
our ordinary shares and ADSs is subject to fluctuation, which could result in substantial losses by our investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market in general
and the market price of our ordinary shares on the TASE and our ADSs on the NYSE American is subject to fluctuation, and changes in <span style="font-family: Times New Roman, Times, Serif">our
share price may be unrelated to our operating performance. The market price of our ordinary shares and ADSs are and will be subject to
a number of factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of technological innovations or new products by us or others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration
    or terminations of licenses, research contracts or other collaboration agreements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    concern as to the safety of drugs we, our licensees or others develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    volatility of market prices for shares of biotechnology companies generally;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of research and development projects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    in clinical and preclinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departure
    of key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning intellectual property rights or regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our and our competitors&#8217; results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in earnings estimates or recommendations by securities analysts, if our ordinary shares or ADSs are covered by analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in government regulations or patent decisions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    by our licensees; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions and other factors, including factors unrelated to our operating performance, such as natural disasters and political
    and economic instability, including wars, terrorism, political unrest, results of certain elections and votes, emergence of a pandemic,
    or other widespread health emergencies (or concerns over the possibility of such an emergency, including for example, the COVID-19
    outbreak), boycotts, adoption or expansion of government trade restrictions, and other business restrictions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors and any corresponding
price fluctuations may materially and adversely affect the market price of our ordinary shares and our ADSs and result in substantial
losses by our investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, market prices
for securities of biotechnology and pharmaceutical companies historically have been very volatile. The market for these securities has
from time to time experienced significant price and volume fluctuations for reasons unrelated to the operating performance of any one
company. See also Risk Factors&#8212;Risks Relating to Ownership of Our Ordinary Shares and ADSs &#8220;<i>Our business, operating results
and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with
respect to financial institutions and associated liquidity risk.</i>&#8221; In the past, following periods of market volatility, shareholders
have often instituted securities class action litigation and we have been named in the past in a lawsuit requesting recognition as a class
action, in which we ultimately prevailed. If we were involved in securities litigation, it could have a substantial cost and divert resources
and attention of management from our business, even if we are successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future sales of our ordinary
shares or ADSs could reduce the market price of our ordinary shares and ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Substantial sales of
our ordinary shares or our ADSs either on the TASE or on the NYSE American, as applicable, may cause the market price of our ordinary
shares or our ADSs to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales by us or our security-holders
of substantial amounts of our ordinary shares or our ADSs, or the perception that these sales may occur in the future, could cause a reduction
in the market price of our ordinary shares or our ADSs. The issuance of any additional ordinary shares or ADSs, or any securities that
are exercisable for or convertible into our ordinary shares or our ADSs, may have an adverse effect on the market price of our ordinary
shares or our ADSs, as applicable, and will have a dilutive effect on our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may not satisfy the
NYSE American requirements for continued listing. If we cannot satisfy these requirements, the NYSE American could delist our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs are listed on the
NYSE American under the symbol &#8220;CANF.&#8221; To continue to be listed on the NYSE American, we are required to satisfy a number
of conditions, including maintaining a share price and shareholders&#8217; equity above certain thresholds. If we are delisted from the
NYSE American, trading in our securities may be conducted, if available, on the OTC Markets or, if available, via another market. In the
event of such delisting, our shareholders would likely find it significantly more difficult to dispose of, or to obtain accurate quotations
as to the value of our securities, and our ability to raise future capital through the sale of our securities could be severely limited.
In addition, if our securities were delisted from the NYSE American, our ADSs could be considered a &#8220;penny stock&#8221; under the
U.S. federal securities laws. Additional regulatory requirements apply to trading by broker-dealers of penny stocks that could result
in the loss of an effective trading market for our securities. Moreover, if our ADSs were delisted from the NYSE American, we will no
longer be exempt from certain provisions of the Israeli Securities Law, and therefore will have increased disclosure requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>ADS holders are not
shareholders and do not have shareholder rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as Depositary, delivers our ADSs. Each ADS represents two of our ordinary shares. ADS holders will not be treated as shareholders and
do not have the rights of shareholders. The Depositary will be the holder of the shares underlying our ADSs. Holders of ADSs will have
ADS holder rights. A deposit agreement among us, the Depositary, ADS holders and the beneficial owners of ADSs sets out ADS holder rights
as well as the rights and obligations of the Depositary. New York law governs the deposit agreement and our ADSs. Our shareholders have
shareholder rights. Israeli law and our Amended and Restated Articles of Association govern shareholder rights. ADS holders do not have
the same voting rights as our shareholders. Shareholders are entitled to our notices of general meetings and to attend and vote at our
general meetings of shareholders. At a general meeting, every shareholder present (in person or by proxy, attorney or representative)
and entitled to vote has one vote. This is subject to any other rights or restrictions which may be attached to any shares. ADS holders
may instruct the Depositary how to vote the number of deposited shares their ADSs represent.&#160;<i>Otherwise, you won&#8217;t be able
to exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough in advance to withdraw
the shares. Th</i>e Depositary will notify ADS holders of shareholders&#8217; meetings and arrange to deliver our voting materials to
them if we ask it to. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the Depositary
how to vote. For instructions to be valid, they must reach the Depositary by a date set by the Depositary. The Depositary will try, as
far as practical, subject to the laws of Israel and our Amended and Restated Articles of Association or similar documents, to vote or
to have its agents vote the shares or other deposited securities as instructed by ADS holders. The Depositary will only vote or attempt
to vote as instructed. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the Depositary
to vote your shares. In addition, the Depositary and its agents are not responsible for failing to carry out voting instructions or for
the matter of carrying out voting instructions. Th<i>is means that you may not be able to exercise your right to vote and there may be
nothing you can do if your shares are not voted as requested.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADS holders do not have the
same rights to receive dividends or other distributions as our shareholders. Subject to any special rights or restrictions attached to
a share, the directors may determine that a dividend will be payable on a share and fix the amount, the time for payment and the method
for payment (although we have never declared or paid any cash dividends on our ordinary shares and we do not anticipate paying any cash
dividends in the foreseeable future). Dividends and other distributions payable to our shareholders with respect to our ordinary shares
generally will be payable directly to them. Any dividends or distributions payable with respect to ordinary shares deposited in the ADS
facility will be paid to the Depositary, which has agreed to pay to ADS holders the cash dividends or other distributions it or the custodian
receives on shares or other deposited securities, after deducting its fees and expenses. ADS holders will receive these distributions
in proportion to the number of ordinary shares their ADSs represent. In addition, there may be certain circumstances in which the Depositary
may not pay ADS holder&#8217;s amounts distributed by us as a dividend or distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our ordinary shares
and our ADSs are traded on different markets and this may result in price variations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have traded
on the TASE since October 2005 and our ADSs have been listed on the NYSE American since November 2013. Trading on these markets will take
place in different currencies (U.S. dollars on the NYSE American and NIS on the TASE), and at different times (resulting from different
time zones, different trading days and different public holidays in the United States and Israel). The trading prices of our securities
on these two markets may differ due to these and other factors. Any decrease in the price of our securities on one of these markets could
cause a decrease in the trading price of our securities on the other market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have incurred significant
additional increased costs as a result of the listing of our ADSs for trading on the NYSE American, and our management is required to
devote substantial time to new compliance initiatives as well as to compliance with ongoing U.S. and Israeli reporting requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company in the
United States, we incur additional significant accounting, legal and other expenses that we did not incur before becoming a reporting
company in the United States. We also incur costs associated with corporate governance requirements of the SEC and the NYSE American Company
Guide, as well as requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act as
a result of our ADSs being listed on the NYSE American. These rules and regulations have increased our legal and financial compliance
costs, introduced new costs such as investor relations, stock exchange listing fees and shareholder reporting, and made some activities
more time consuming and costly. Since we are no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business
Startups Act of 2012, and are no longer able to take advantage of certain exemptions from various reporting requirements that are applicable
to public companies that are &#8220;emerging growth companies&#8221; and that were applicable to us prior to January 1, 2020, we may incur
additional compliance costs in the future. The implementation and testing of such processes and systems may require us to hire outside
consultants and incur other significant costs. Any future changes in the laws and regulations affecting public companies in the United
States and Israel, including Section 404 and other provisions of the Sarbanes-Oxley Act, the rules and regulations adopted by the SEC
and the NYSE American Company Guide, as well as applicable Israeli reporting requirements, for so long as they apply to us, may result
in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly
for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced
policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements
could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors, our Board committees
or as executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>As a foreign private
issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC and NYSE American requirements,
which may result in less protection than is accorded to investors under rules applicable to domestic issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we will be permitted to follow certain home country corporate governance practices instead of those otherwise required under the NYSE
American Company Guide for domestic issuers. For instance, we may follow home country practice in Israel with regard to, among other things,
composition and function of the audit committee and other committees of our Board of Directors and certain general corporate governance
matters. In addition, in certain instances we will follow our home country law, instead of the NYSE American Company Guide, which requires
that we obtain shareholder approval for certain dilutive events, such as an issuance that will result in a change of control of the company,
certain transactions other than a public offering, involving issuances of a 20% or more interest in the company and certain acquisitions
of the stock or assets of another company. We comply with the director independence requirements of the NYSE American Company Guide, including
the requirement that a majority of the Board of Directors be independent. Following our home country governance practices as opposed to
the requirements that would otherwise apply to a U.S. company listed on the NYSE American may provide less protection than is accorded
to investors under the NYSE American Company Guide applicable to domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a foreign
private issuer, we are exempt from the rules and regulations under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange
Act, related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from
the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required
under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly
as domestic companies whose securities are registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Because we became a
reporting company under the Exchange Act by means of filing a Form 20-F, we may have difficulty attracting the attention of research analysts
at major brokerage firms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we did not become
a reporting company by conducting an underwritten initial public offering in the United States, we may have difficulty attracting the
attention of security analysts at major brokerage firms in order for them to provide coverage of our company. The failure to receive research
coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we are unable to
satisfy the requirements of Section 404 of the Sarbanes-Oxley Act as they apply to a foreign private issuer that is listed on a U.S. exchange,
or our internal control over financial reporting is not effective, the reliability of our financial statements may be questioned and our
share price and the ADS price may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the requirements
of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires companies subject to the reporting requirements of the U.S.
securities laws to do a comprehensive evaluation of its and its subsidiaries&#8217; internal control over financial reporting. To comply
with this statute, we must document and test our internal control procedures and our management and issue a report concerning our internal
control over financial reporting. In addition, as long as we do not become an accelerated or large accelerated filer, we are exempt from
the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. Under this exemption, our auditor will not be required
to attest to and report on our management&#8217;s assessment of our internal control over financial reporting until the date we are no
longer a non-accelerated filer. We will need to prepare for compliance with Section 404 by strengthening, assessing and testing our system
of internal controls to provide the basis for our report. However, the continuous process of strengthening our internal controls and complying
with Section 404 is complicated and time-consuming. Furthermore, as our business continues to grow both domestically and internationally,
our internal controls will become more complex and will require significantly more resources and attention to ensure our internal controls
remain effective overall. During the course of the testing, our management may identify material weaknesses or significant deficiencies,
which may not be remedied in a timely manner to meet the deadline imposed by the Sarbanes-Oxley Act. If our management cannot favorably
assess the effectiveness of our internal control over financial reporting, or our independent registered public accounting firm identifies
material weaknesses in our internal controls, investor confidence in our financial results may weaken, and the market price of our securities
may suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;&#160;</b></span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 4. </b></span><b>Information
on the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. History and Development of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal name is Can-Fite
BioPharma Ltd. and our commercial name is &#8220;Can-Fite.&#8221; We are a company limited by shares organized under the laws of the State
of Israel. Our principal executive offices are located at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778 Israel. Our telephone
number is +972 (3) 924-1114.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were founded on September
11, 1994 by Pnina Fishman, Ph.D., our Chief Executive Officer and a director, and Ilan Cohn, Ph.D., our Chairman of the Board of Directors,
under the name Can-Fite Technologies Ltd. On January 7, 2001, we changed our name to Can-Fite BioPharma Ltd. We completed our initial
public offering in Israel in October 2005 and our ordinary shares are traded on the TASE under the symbol &#8220;CFBI.&#8221; On October
2, 2012, our ADSs began trading over the counter in the United States under the symbol &#8220;CANFY&#8221; and on November 19, 2013, our
ADSs began trading on the NYSE American under the symbol &#8220;CANF.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2011, through
a series of transactions, we spun-off our activity in the ophthalmic field to our now former subsidiary, OphthaliX, a Delaware corporation
and successor-in-interest to Denali Concrete Management, Inc., a Nevada corporation, whose common shares were traded in the United States
on OTC under the symbol &#8220;OPLI.&#8221; In the spin-off transactions, we granted an exclusive license for the use of our Piclidenoson
drug candidate in the ophthalmic field, or the License Agreement, to Eye-Fite Ltd., an Israel limited company, or Eye-Fite, and transferred
our issued and outstanding ordinary shares in Eye-Fite to OphthaliX in exchange for an 86.7% interest in OphthaliX. In connection with
the spin-off transactions, OphthaliX completed a series of private placement financing transactions. Following the spin-off transactions
and the private placement financing transactions, we held approximately 82% interest in OphthaliX. In July 2016, OphthaliX released top-line
results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma. In this trial, no statistically significant differences
were found between the Piclidenoson treated group and the placebo group in the primary endpoint of lowering IOP. High IOP is a characteristic
of glaucoma. Piclidenoson was found to have a favorable safety profile and was generally well-tolerated. Based on these overall results,
OphthaliX saw no immediate path forward in glaucoma and ceased active business operations. Subsequently, on May 21, 2017, OphthaliX and
a wholly owned private Israeli subsidiary of OphthaliX, Bufiduck Ltd, or the Merger Sub, and Wize Pharma Ltd., or Wize Israel, an Israeli
company formerly listed on the TASE entered into an Agreement and Plan of Merger, or the Merger Agreement, providing for the merger of
the Merger Sub with and into Wize Israel, with Wize Israel becoming a wholly-owned subsidiary of OphthaliX and the surviving corporation
of the merger, or the Merger. On November 16, 2017, the Merger was completed. As a result of the Merger, our ownership of OphthaliX, immediately
post-Merger, became approximately 8% of the outstanding shares of common stock. In addition, immediately prior to the Merger, OphthaliX
sold on an &#8220;as is&#8221; basis to us all the ordinary shares of Eye-Fite in exchange for the irrevocable cancellation and waiver
of all indebtedness owed by OphthaliX and Eye-Fite to us, including approximately $5 million of deferred payments owed by OphthaliX and
Eye-Fite to us and, as part of the purchase of Eye-Fite, we also assumed certain accrued milestone payments in the amount of $175,000
under a license agreement previously entered into with NIH. In addition, that certain License Agreement granted to OphthaliX by us and
a related services agreement was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital expenditures for
the years ended December 31, 2022, 2021 and 2020 were $9,000, 11,000 and $26,000, respectively. Our current capital expenditures are made
solely within Israel and primarily consist of the acquisition of computers and related communications equipment. Such capital expenditures
are financed internally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use our website (<i>http://www.canfite.com</i>)
as a channel of distribution of Company information. The information we post on our website may be deemed material. Accordingly, investors
should monitor the website, in addition to following our press releases, SEC filings and public conference calls and webcasts. The contents
of our website are not, however, a part of this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Business Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical company
that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and
erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune,
and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target.
A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting
that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators targeting the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product pipeline is based on the research
of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found in most body tissues, but are rarely
found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s research revealed that one reason
that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules which bind with high selectivity
to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression in tumor and inflammatory cells,
whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators, currently our pipeline of
drug candidates, bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate down-stream signal transduction
pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the inhibition of inflammatory cytokines.
Cytokines are proteins produced by cells that interact with cells of the immune system in order to regulate the body&#8217;s response
to disease and infection. Overproduction or inappropriate production of certain cytokines by the body can result in disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates, CF101, CF102 and CF602,
are being developed to treat cancer, liver and inflammatory diseases, as well as erectile dysfunction. CF101, also known as Piclidenoson,
is in an advance stage of clinical development for the treatment of autoimmune-inflammatory diseases, including psoriasis. During 2021,
we decided to stop developing Piclidenoson for the treatment of COVID-19 to focus on other indications. CF102, also known as Namodenoson,
is being developed for the treatment of HCC and has orphan drug designation for the treatment of HCC in the United States and Europe.
Namodenoson was granted Fast Track designation by the FDA as a second line treatment to improve survival for patients with advanced HCC
who have previously received Nexavar (sorafenib). Namodenoson is also being developed for the treatment of NASH, a disease for which no
FDA approved therapies currently exist. CF602 is our second generation allosteric drug candidate for the treatment of erectile dysfunction,
which has shown efficacy in the treatment of erectile dysfunction in preclinical studies and we are investigating additional compounds,
targeting A3AR, for the treatment of erectile dysfunction. Preclinical studies revealed that our drug candidates have potential to treat
additional inflammatory diseases, such as Crohn&#8217;s disease, oncological diseases, viral diseases, such as the JC virus, and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our pipeline of
d<span style="font-family: Times New Roman, Times, Serif">rug candidates represent a significant market opportunity. For instance, according
to iHealthcareAnalyst, the psoriasis drug market is forecasted to be worth $11.3 billion by 2025. According to DelveInsight, the HCC
drug market in the G8 countries (U.S., Germany, France, Italy, Spain, UK, Japan and China) is expected to reach $3.8 billion by 2027.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have in-licensed an allosteric modulator of the A3AR, CF602 from Leiden University. In addition, we have out-licensed the following product
candidates for indications that we are currently pursuing:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Piclidenoson
    for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis to Gebro Holding, or Gebro, for
    Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including Hong Kong, Macao and Taiwan), (iv) psoriasis
    to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma AG, or Ewopharma, for Central Eastern Europe,
    and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namodenoson
    for the treatment of (i) liver cancer and NASH to Chong Kun Dang Pharmaceuticals, or CKD, for South Korea, (ii) advanced liver cancer
    and NAFLD/NASH to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC and NASH to Ewopharma, for Central Eastern
    Europe and Switzerland.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, (i) we are preparing
a registration plan for the FDA protocol for our upcoming Phase III pivotal trial following a recent submission of a registration plan
to the EMA and successful completion of our Phase III trial for Piclidenoson in the treatment of psoriasis, (ii) we are conducting a pivotal
Phase III trial for Namodenoson in the treatment of advanced liver cancer which is open for enrollment, (iii) we are conducting a Phase
IIb study of Namodenoson in the treatment of NASH, (iv) we are investigating additional compounds, targeting the A3 adenosine receptor,
for the treatment of erectile dysfunction, and (v) we are conducting pre-clinical studies with formulations of cannabis components for
the treatment of diseases in which there is an overexpression of A3AR. Since inception, we have incurred significant losses in connection
with our research and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we believe characteristics of Piclidenoson,
as exhibited in our clinical studies to date, including its good safety profile, clinical activity, simple and less frequent delivery
through oral administration and its low cost of production, position it well against the competition in psoriasis markets, where treatments,
when available, often include injectable drugs, many of which can be highly toxic, expensive and not always effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Like Piclidenoson, Namodenoson has a good safety
profile, is orally administered and has a low cost of goods, which we believe may position it well in the HCC market, where no drug has
yet been approved by the FDAn for patients with advanced liver cancer disease defined as Child Pugh B7. In addition, pre-clinical studies
show Namodenoson&#8217;s novel mechanism of action which entails de-regulation of three key signaling pathways which mediate the etiology
and pathology of NAFLD/NASH and are responsible for the anti-inflammatory and anti-fibrogenic effect in the liver. Most recently, pre-clinical
data support Namodenoson&#8217;s potential utilization as an anti-obesity drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevertheless, other drugs on the market, new drugs
under development (including drugs that are in more advanced stages of development in comparison to our drug candidates) and additional
drugs that were originally intended for other purposes, but were found effective for purposes targeted by us, may all be competitive to
the current drugs in our pipeline. In fact, some of these drugs are well established and accepted among patients and physicians in their
respective markets, are orally bioavailable, can be efficiently produced and marketed, and are relatively safe. None of our product candidates
have been approved for sale or marketing and, to date, there have been no commercial sales of any of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategy is to build a fully integrated biotechnology
company that discovers, in-licenses and develops an innovative and effective small molecule drug portfolio of ligands that bind to a
specific therapeutic target for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. We continue to develop
and test our existing pipeline, while also testing other indications for our existi<span style="font-family: Times New Roman, Times, Serif">ng
drugs and examining, from time to time, the potential of other small molecules that may fit our platform technology of utilizing small
molecules to target the A3AR. We generally focus on drugs with global market potential and we seek to create global partnerships to effectively
assist us in developing our portfolio and to market our products. Our approach allows us to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    to advance our clinical and preclinical pipeline;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">test
    our products for additional indications which fit our molecules&#8217; mechanism of action;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    other small molecule drugs or ligands;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">focus
    on our product candidates closest to realizing their potential; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid
    dependency on a small number of small molecules and indications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Using this approach, we have successfully advanced
our product candidates for a number of indications into various stages of clinical development. Specific elements of our current strategy
include the following:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Successful development of our existing portfolio
of small molecule orally bioavailable drugs for the treatment of various diseases</b>. We intend to continue to develop our existing portfolio
of small molecule orally bioavailable drugs, both for existing targeted diseases, as well as other potential indications. Our drug development
will continue to focus on cancer, liver and inflammatory diseases and erectile dysfunction. We intend to focus most prominently on advancing
our product candidates that are in the most advanced stages, i.e., psoriasis with respect to Piclidenoson, and HCC and NASH with respect
to Namodenoson.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use our expertise with our platform technology
to evaluate in-licensing opportunities</b>. We continuously seek attractive product candidates and innovative technologies to in-license
or acquire. We intend to focus on product candidates that would be synergistic with our A3AR expertise. We believe that by pursuing selective
acquisitions of technologies in businesses that complement our own, we will be able to enhance our competitiveness and strengthen our
market position. We intend to utilize our expertise in A3AR and our pharmacological expertise to validate new classes of small molecule
orally bioavailable drugs. We will then seek to grow our product candidate portfolio by attempting to in-license those various candidates
and to develop them for a variety of indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Primarily develop products that target major
global markets</b>. Our existing product candidates are almost all directed at diseases that have major global markets. Our intent is
to continue to develop products that target diseases that affect significant populations using our platform technology. We believe these
arrangements will allow us to share the high development cost, minimize the risk of failure and enjoy our partners&#8217; marketing capabilities,
while also enabling us to treat a more significant number of persons. We believe further that this strategy will increase the likelihood
of advancing clinical development and potential commercialization of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Commercialize our product candidates throughout-licensing
arrangements</b>. We have entered into several out-licensing arrangements with leading pharmaceutical companies in the Far East, Canada
and Europe. We intend to continue to commercialize our product candidates throughout-licensing arrangements with third parties who may
perform any or all of the following tasks: completing development, securing regulatory approvals, manufacturing, marketing and sales.
We do not intend to develop our own manufacturing facilities or sales forces. If appropriate, we may enter into co-development and similar
arrangements with respect to any product candidate with third parties or commercialize a product candidate ourselves. We believe these
arrangements will allow us to share the high development cost, minimize the risk of failure and enjoy our partners&#8217; marketing capabilities.
We believe further that this strategy will increase the likelihood of advancing clinical development and potential commercialization of
our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Product Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth our current pipeline
of product candidates, including the target indication and status of each.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are preparing a registration plan for the FDA protocol for our upcoming
Phase III pivotal trial following a recent submission of a registration plan to the EMA and successful completion of our Phase III trial
for Piclidenoson in the treatment of psoriasis.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting a pivotal Phase III trial for Namodenoson in the treatment of advanced liver cancer which is open for enrollment.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting a Phase IIb study of Namodenoson in the treatment of NASH.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are investigating additional compounds, targeting the A3AR, for the treatment of erectile dysfunction.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing formulations of cannabis components for the treatment of diseases in which there is an overexpression of A3AR.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Piclidenoson (CF101)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson, our lead therapeutic product candidate,
is in development for the treatment of autoimmune-inflammatory diseases. Piclidenoson is a highly-selective, orally bioavailable small
molecule synthetic drug, which targets the A3AR. Based on our clinical studies to date, we believe that Piclidenoson has a favorable safety
profile and significant anti-inflammatory effects as a result of its capability to inhibit the production of inflammatory cytokines, such
as TNF-&#945;, IL-6 and IL-1, chemokines and MMPs, by modulating key proteins such as NF-&amp;kcy;B and PKB/AKT. Overall, these up-stream
events result in apoptosis of inflammatory cells. See Figure 1 below. Piclidenoson&#8217;s anti-inflammatory effect is mediated via the
A3AR, which is highly expressed in inflammatory cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Figure 1: Piclidenoson anti-inflammatory mechanism
of action</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is an autoimmune hereditary disease
that affects the skin. In psoriasis, immune cells move from the dermis to the epidermis, where they stimulate keratinocytes, or skin cells,
to proliferate. DNA acts as an inflammatory stimulus to stimulate receptors which produce cytokines, such as IL-1, IL-6, and TNF-&#945;,
and antimicrobial peptides. These cytokines and antimicrobial peptides signal more inflammatory cells to arrive and produce further inflammation.
In other words, psoriasis occurs when the immune system overreacts and mistakes the skin cells as a pathogen, and sends out faulty signals
that speed up the growth cycle of skin cells. Normally, skin cells grow gradually and flake off approximately every four weeks. New skin
cells grow to replace the outer layers of the skin as they shed. But in psoriasis, new skin cells move rapidly to the surface of the skin
in days rather than weeks. They build up and form thick patches called plaques.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are five types of psoriasis: plaque, guttate,
inverse, pustular and erythrodermic. The most common form, plaque psoriasis, is commonly seen as red and white hues of scaly patches appearing
on the top first layer of the epidermis, or skin. In plaque psoriasis, skin rapidly accumulates at these sites, which gives it a silvery-white
appearance. Plaques frequently occur on the skin of the lower back, elbows and knees, but can affect any area, including the scalp, palms
of hands, soles of feet and genitals. The plaques range in size from small to large. In contrast to eczema, psoriasis is more likely to
be found on the outer side of the joint. Some patients, though, have no dermatological symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is a chronic recurring condition that
varies in severity from minor localized patches to complete body coverage. Fingernails and toenails are frequently affected, known as
psoriatic nail dystrophy, and can be seen as an isolated symptom. Psoriasis can also cause inflammation of the joints, which is known
as psoriatic arthritis.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pre-Clinical Studies with Piclidenoson</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information below is based on the various
studies conducted with Piclidenoson, including preclinical studies. All of the studies were conducted by Can-Fite and/or by Can-Fite&#8217;s
partners or affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical studies are a set of experiments
carried out in animals to show that a certain drug does not evoke toxicity. Based on the animal studies and safety data, one can approach
the FDA and request permission to conduct a Phase I study in human beings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The toxicity of Piclidenoson has been evaluated
following 28-day, 90-day, six-month and nine-month good laboratory practice repeated-dose toxicity studies in male and female mice (28-day,
90-day and six-month), dogs (single-dose only), and monkeys (28-day, 90-day and nine-month). Even though the dose of Piclidenoson in these
studies was escalated to an exposure that is many folds higher than the dose used in human clinical studies, no toxic side effects were
identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effects on cardiovascular parameters were evaluated
in conscious instrumented monkeys and anesthetized dogs. These studies demonstrated no significant cardiovascular risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Genotoxicity studies were conducted in bacterial
and mammalian mutation assays <i>in vitro</i> (i.e., laboratory) and in an <i>in vivo</i> (i.e., animal) mouse micronucleus assay. These
studies were all negative, indicating no deleterious action on cellular genetic material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reproductive toxicology studies that we completed
in mice and rabbits did not reveal evidence of negative effects on male or female fertility. In mouse teratology studies, or studies for
abnormalities of physiological developments, craniofacial and skeletal abnormalities were observed at doses greater than 10 mg/kg; however,
no such effects were observed at 3 mg/kg demonstrating the safety of the drug in this concentration range. Teratogenicity, or any developmental
anomaly in a fetus, was not observed in rabbits given doses (greater than 13 mg/kg) that induced severe maternal toxicity in such rabbits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Studies of P450 enzymes, or enzymes that participate
in the metabolism of drugs, showed that Piclidenoson caused no P450 enzyme inhibition, or increased drug activity, or induction, or reduced
drug activity. Studies carried out with radiolabeled (C<sup>14</sup>) Piclidenoson in rats showed that the drug is excreted essentially
unchanged. These studies also showed that the drug is widely distributed in all body parts, except the central nervous system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical studies with skin cells, modeling
psoriasis in humans, Piclidenoson destroyed pathological skin cells. We observed that in a cell culture of human HaCaT cells, incubated
with Piclidenoson, cell apoptosis was induced with an increase in the caspase protein, known to mediate apoptotic responses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clinical Studies with Piclidenoson</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information below is based on the various
studies conducted with Piclidenoson, including clinical studies in patients with autoimmune-inflammatory and ophthalmic diseases. All
of the studies were conducted by Can-Fite and/or by Can-Fite&#8217;s partners or affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Phase I Clinical Studies of Piclidenoson</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson has been studied comprehensively
in normal volunteer trials to assess safety, pharmacokinetic metabolism and food interaction. Two Phase I studies in 40 healthy volunteers,
single dose and repeated dose, indicated that Piclidenoson is rapidly absorbed (reaching a maximal concentration within one to two hours)
with a half-life of eight to nine hours. Some mild adverse events (principally, increased heart rate) were observed at doses higher than
single doses of 10.0 mg and twice-daily doses of 5.0 mg. Such increase in heart rate was not accompanied by any change in QT intervals.
The drug showed linear kinetics, in that the concentration that results from the dose is proportional to the dose and the rate of elimination
of the drug is proportional to the concentration, and low inter-subject variability, meaning that the same dose of the drug does not produce
large differences in pharmacological responses in different individuals. A fed-fast Phase I study (with and without food) demonstrated
that food causes some attenuation in Piclidenoson absorption; accordingly, Piclidenoson is administered to patients on an empty stomach
in our trials. An additional Phase I study of the absorption, metabolism, excretion and mass balance of 4.0 mg (C<sup>14</sup>) Piclidenoson
was conducted in six healthy male subjects and demonstrated that Piclidenoson was generally well-tolerated in this group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the findings from Phase I clinical studies,
4.0 mg twice daily, or BID, was selected as the upper limit for initial Phase II clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in preparation for Phase III studies
of Piclidenoson to establish cardiac safety in humans prior to registration for marketing approval, we conducted a cardiodynamic trial
that was a placebo-controlled crossover study using precise methodology to determine the effect of Piclidenoson on electrocardiograms
of healthy volunteers. The primary objective of the trial was to assess whether Piclidenoson causes a delay in cardiac repolarization,
as manifested by prolongation of the QT interval of the electrocardiogram. A drug-induced delay in cardiac repolarization creates an electrophysiological
environment that can lead to the development of ventricular cardiac arrhythmias. In this study, Piclidenoson doses were up to 3-fold higher
than the highest dose expected to be used in our registration-directed clinical trials. Trial results showed that our highest projected
Piclidenoson dose had no clinically significant adverse electrocardiographic effects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Phase II, Phase II/III and Phase III Clinical
Studies of Piclidenoson</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson has completed eleven Phase II studies,
one Phase II/III study and three Phase III studies in different clinical indications including psoriasis, rheumatoid arthritis, glaucoma
and dry eye syndrome, or DES, in approximately 1,700 patients. These studies indicate that Piclidenoson has a favorable safety profile
at doses up to 4.0 mg BID for up to 48 weeks. In these studies, we did not observe a dose-response relationship between Piclidenoson and
adverse events. Moreover, we did not observe any clinically significant changes in vital signs, electrocardiograms, blood chemistry or
hematology. Furthermore, no new emergent safety signals have been observed in the completed or ongoing Phase III rheumatoid arthritis
and psoriasis trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced positive top-line results
from our Phase III COMFORT study of Piclidenoson in the treatment of moderate to serious psoriasis in which Piclidenoson met its primary
endpoint. Previously, Piclidenoson given as a standalone therapy reached the primary endpoint in Phase II clinical studies in DES; however,
a Phase III study of Piclidenoson for DES failed to reach the primary endpoint. We have observed positive data utilizing Piclidenoson
as a standalone drug in a Phase IIa clinical study in rheumatoid arthritis. In this study, we also observed a significant direct correlation
between A3AR expression prior to treatment and the patients&#8217; responses to Piclidenoson. However, we did not fully attain the primary
endpoint in this study as we did not observe a significant difference in responses between Piclidenoson and the placebo (which for this
study was 0.1 mg of Piclidenoson). Moreover, two Phase IIb studies in rheumatoid arthritis utilizing Piclidenoson in combination with
MTX, also failed to reach the primary endpoints. Based on this data, we believe that the failures in the Phase IIb studies in rheumatoid
arthritis may have been due to low A3AR expression in the MTX-treated patients. A Phase IIb of Piclidenoson given as a standalone therapy
in patients with A3AR expression levels above a certain threshold reached the primary endpoint in rheumatoid arthritis in December 2013.
Piclidenoson has been tested in Phase II trials to establish dose and activity (first, orally administered capsules and then tablets in
formulations of 1.0, 2.0 and 4.0 mg of Piclidenoson BID) in psoriasis (moderate to severe plaque psoriasis), rheumatoid arthritis and
DES (moderate to severe). A Phase II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although positive data
from further analysis of the Phase II/III study suggested Piclidenoson as a potential systemic therapy for patients with moderate-severe
psoriasis. In addition, a Phase II study of Piclidenoson for glaucoma showed no statistically significant differences between the Piclidenoson
treated group and the placebo group in the primary endpoint of lowering IOP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Psoriasis</i>: The rationale for utilizing
Piclidenoson to treat psoriasis stems from our pre-clinical pharmacology studies showing that Piclidenoson acts as an anti-inflammatory
agent via the inhibition of inflammatory cytokines, including TNF-&#945;, which plays a major role in the pathogenesis of psoriasis.
In addition, the A3AR is over-expressed in the tissue and PBMCs of patients with psoriasis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We completed an exploratory Phase II trial in
ten European and Israeli medical centers involving 76 patients. This study was a randomized, double-blind, placebo controlled and included
four cohorts of 1.0, 2.0, and 4.0 mg of Piclidenoson and a placebo for a 12-week period. The study objectives were efficacy and safety
of daily doses of Piclidenoson administered orally in patients with moderate-to-severe plaque-type psoriasis and the efficacy endpoints
were improvements in both the Psoriasis Area Sensitivity Index score, or PASI score, and the Physicians&#8217; Global Assessment score,
or PGA score. We concluded that Piclidenoson met such efficacy endpoints and was well-tolerated and effective in ameliorating disease
manifestations in these patients. The patient group receiving 2.0 mg Piclidenoson BID showed progressive improvement over the course of
the 12-week study in the PGA and PASI scores. Analysis of the mean change from baseline in the PASI score at week 12 revealed a statistically
significant difference between the 2.0 mg Piclidenoson BID treated group and the placebo group (p&lt;0.001 versus baseline and p=0.031
versus placebo). Analysis of the PGA score revealed that 23.5% of the patients treated with the 2.0 mg Piclidenoson BID achieved a score
of 0 or 1, in comparison to 0% in the placebo group (p&lt;0.05). The study also demonstrated linear improvement in patients in both PASI
and PGA. See Figure 2. No drug-related serious adverse events were evident during the study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Figure 2: Psoriasis efficacy by PGA and PASI</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are representative pictures of
a patient with plaque-type psoriasis on the upper and lower back treated with 2.0 mg Piclidenoson BID, both baseline and week 12.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A comparison between baseline and week 12 of
a patient treated with 2.0 mg CF101</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2015, we completed a Phase II/III
randomized, double-blind, placebo-controlled, dose-finding study of the efficacy and safety of Piclidenoson administered daily orally
in patients with moderate-to-severe plaque psoriasis. This clinical trial enrolled 326 patients in 17 clinical centers in the United States,
Europe and Israel, of which 103 patients were enrolled in the first study cohort and were treated for 6 months and 223 patients were enrolled
in the second study cohort and were treated for 8 months. The first study cohort was comprised of three arms with patients receiving:
1.0 mg of Piclidenoson; 2.0 mg of Piclidenoson; and placebo. All patients receiving placebo were switched to either 1.0 mg or 2.0 mg of
Piclidenoson after 12 weeks. Based on a positive safety and efficacy interim analysis of the first 103 patients who completed 24 weeks
of treatment in the trial, we decided to continue patient enrollment for the second stage of the study and the study protocol was amended
to extend the Piclidenoson 2.0 mg BID and placebo administration for a period of 32 weeks. The positive clinical effects of the Piclidenoson
2.0 mg BID dose relative to a placebo were observed in a variety of standard psoriasis assessment parameters, including PASI 75 and PGA
scores, with the responses accumulating steadily over the 24-week treatment period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, we announced the study did not
meet its primary endpoint of a statistically significant improvement in the PASI 75 score relative to placebo after 12 weeks of treatment.
Further analysis of the entire study period revealed that by 32 weeks of treatment with Piclidenoson, 33% of the patients achieved PASI
75 while the mean percent of improvement in PASI score was 57% (p&lt;0.001). This was a statistically significant cumulative and linear
improvement during weeks 16 to 32. Most significantly, by week 32 of the study, 20% of the study patients reached PASI 90, a result demonstrating
a response rate of 90% clearing of skin lesions. PASI 90 is one of the most stringent and difficult to meet clinical endpoints for measuring
responses to psoriasis treatments. Moreover, the PASI 90 subset analysis further suggests a higher and significant (p=0.026) Piclidenoson
response rate of 27% among patients previously untreated with systemic psoriasis therapy compared to patients pre-treated with systemic
drugs. We believe this presents the opportunity that Piclidenoson can be developed as a first-line systemic therapy for patients with
moderate-severe psoriasis and for patients who do not want to be treated with the current systemic drugs due to safety issues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Figure 3: Linear Effect of Piclidenoson on
PASI Scores through 32 Weeks of Treatment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced positive top-line results
from our Phase III COMFORT study of Piclidenoson in the treatment of moderate to serious psoriasis in which Piclidenoson met its primary
endpoint. The trial was a Phase III randomized, double-blind, placebo- and active-controlled study of the efficacy and safety of daily
Piclidenoson (CF101) administered orally in patients with moderate-to-severe plaque psoriasis. The primary objectives of this study were
to evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg twice daily (BID) in patients with moderate-to-severe plaque psoriasis, compared
with placebo, as determined by the proportion of subjects who achieve a PASI score response of &#8805;75% (PASI 75) at Week 16 (superiority);
and evaluate the safety of oral Piclidenoson in this patient population. The secondary objectives of this study are to evaluate the efficacy
of oral Piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve, respectively, PASI
50, Physician Global Assessment (PGA) score of 0 or 1, and improvement on the Psoriasis Disability Index (PDI) at Week 16 (superiority);
evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg BID, compared with Otezla (apremilast), as determined by the proportion of subjects
who achieve PASI 75, PGA score of 0 or 1, PASI 50, and improvement in PDI at Weeks 16 and 32 (non-inferiority); and evaluate the efficacy
and safety data for Piclidenoson through the extension period of up to 48 weeks of treatment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The study data showed that patients treated with
oral Piclidenoson 2 mg or 3 mg twice daily, had clinically equivalent efficacy responses. At week 16, patients receiving Piclidenoson
3mg demonstrated statistically significant improvement when compared with placebo, as measured by the PASI 75 response (representing a
75% reduction in psoriasis severity): Piclidenoson 3mg: 9.7% vs. placebo: 2.6% (P&lt; 0.04). Secondary endpoint parameters at week 32
comparing Piclidenoson to the active control drug, Otezla, revealed inferiority with respect to PASI 75 (17% vs. 26.2%, respectively)
and PASI 50 (34.1% vs. 49.5%, respectively), but revealed superiority of Piclidenoson as compared to Otezla in the Psoriasis Disability
Index (PDI) (20.5% vs. 10.3%, respectively, P&lt;0.05). A linear increase in the response of patients to Piclidenoson was achieved along
the study period, on week 48 reaching PASI 50 in 90% of patients, PASI 90 in 10% of patients and PDI improvement in 60% of patients. Piclidenoson
had an excellent safety profile overlapping that of the placebo treated patients, showing a better safety profile when compared to Otezla.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further analysis of the study data showed that
Piclidenoson had a significantly better tolerability profile than Otezla, as GI-related adverse events were 1% for Piclidenoson vs. 6%
for Otezla, nervous system disorders were 0.7% for Piclidenoson, 9.9% for Otezla and 3.3% for the placebo. The discontinuation rate was
significantly higher for Otezla vs. Piclidenoson. In the secondary endpoint of achieving a PASI 75 response (at week 32, in the whole
patient population, Piclidenoson was inferior to Otezla; however, in a sub-group analysis of patients who had PASI&gt;25 (more severe
psoriasis) at baseline, Piclidenoson had a comparable response to Otezla.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMFORT
serves as the first of two pivotal studies required for EMA-drug approval. In January 2023, we submitted a market registration plan to
the EMA for Piclidenoson in the treatment of moderate to severe psoriasis and a submission to the FDA is expected to follow. Registration
plans for both the EMA and FDA include final efficacy and safety results from the COMFORT study and the protocol for our planned Phase
III pivotal trial together with a request for registration advice from the regulators. Current chemistry, manufacturing, and controls
(CMC), nonclinical data, and human pharmacokinetic data are also included.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rheumatoid
Arthritis: </i>We previously conducted a Phase IIa blinded to dose study in 74 patients with rheumatoid arthritis, randomized to receive
Piclidenoson as a monotherapy in one of three doses-0.1 mg, 1.0 mg and 4.0 mg. The primary efficacy endpoint was ACR20 response at week
12, a criterion determined by the American College of Rheumatology that reflects 20% improvement in inflammation parameters. The study
data revealed maximal response at the 1.0 mg group, showing 55.6% with ACR20, 33.3% with 50% improvement, or ACR50, and 11.5% with 70%
improvement, or ACR70. Piclidenoson administered BID for 12 weeks resulted in improvement in signs and symptoms of rheumatoid arthritis
and was well-tolerated.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently,
two Phase IIb studies with Piclidenoson in combination with MTX were conducted. The study protocols were multicenter, randomized, double-blind,
placebo-controlled, parallel-group and dose-finding to determine the safety and efficacy of daily Piclidenoson administered orally when
added to weekly MTX in patients with active rheumatoid arthritis. The objectives of both studies were improvement in ACR20, ACR50, ACR70
and DAS28, or the Disease Activity Score of 28 Joints, and EULAR, or the European League Against Rheumatism, response criteria, as well
as a positive safety profile. The trials&#8217; primary endpoints were both ACR20. The first Phase IIb trial showed that the combined
treatment had an excellent safety profile, but no significant ACR20 response was observed between the rheumatoid arthritis group treated
with Piclidenoson and MTX and the group treated with MTX alone (the placebo group). However, the ACR50, ACR70 and the EULAR Good Values
in the combined treatment group were higher than those of the MTX placebo group. The study also indicated that the 1.0 mg Piclidenoson
dose was the most favorable dose, i.e., the dose yielded the highest ACR50 and EULAR Good Values as compared to the MTX placebo group.
The most commonly reported adverse events in this study included nausea, dizziness, headache and common bacterial and viral infections
and infestations. Following a decision of our Clinical Advisory Board in October 2007, an additional Phase IIb study was initiated. This
study was conducted in medical centers in Europe and Israel and included 230 patients who received the drug orally BID (0.1 and 1.0 mg
Piclidenoson tablets plus MTX versus a placebo, which was MTX alone) for 12 weeks. On April 30, 2009, we published preliminary results
of the Phase IIb study, which were later confirmed as the final results, also indicating that the study&#8217;s objectives were not achieved.
The most commonly reported adverse events in this study included nausea, myalgia and dizziness. The two Phase IIb studies failed to achieve
the primary endpoint of ACR20. A cross study analysis of the three rheumatoid arthritis clinical studies revealed that in the first Phase
IIa study, where Piclidenoson had been administered as a standalone drug, A3AR had been over-expressed in the patients&#8217; PBMCs prior
to Piclidenoson treatment, whereas A3AR had not been over-expressed in the Phase IIb patient population. We believe, based on the foregoing
data, that there may be a direct and statistically significant correlation between A3AR over-expression at baseline and patients&#8217;
response to Piclidenoson, and that Piclidenoson should be administered as a standalone drug and not in combination with MTX. Furthermore,
the correlation between A3AR expression levels prior to treatment and patients&#8217; response to the drug suggest that the A3AR may
be a predictive biomarker to be analyzed prior to Piclidenoson treatment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of the two Phase IIb studies, we conducted an additional Phase IIb clinical study with Piclidenoson as a stand-alone,
monotherapy treatment and not in combination with MTX. The trial was a 12-week multicenter, randomized, double-blind, placebo-controlled,
parallel-group study involving 79 patients to determine the safety and efficacy of Piclidenoson administered orally daily in patients
with active rheumatoid arthritis and elevated baseline expression levels of the A3AR in PBMCs. Enrolled patients had high baseline A3AR
biomarker expression (determined at 1.5-fold over a predetermined age-matched standard). This selection criteria was made following the
findings during previous Phase IIa and IIb rheumatoid arthritis studies showing a positive correlation between A3AR expression at baseline
and patients&#8217; response to the drug, potentially rendering A3AR expression as a predictive biomarker. The primary objectives of
this study were to determine the efficacy of oral Piclidenoson when administered daily as a standalone treatment for 12 weeks to patients
with active rheumatoid arthritis and elevated baseline expression levels of the A3AR in the patients&#8217; PBMCs, in comparison to a
placebo treatment, and to assess the safety of daily oral Piclidenoson under the circumstances of the trial. In December 2013, we announced
the results of the study in which Piclidenoson met all primary efficacy endpoints, showing statistically significant superiority over
placebo in reducing signs and symptoms of rheumatoid arthritis as compared to the placebo. The treatment had an ACR20 response rate of
49% for Piclidenoson compared to 25% for placebo (p=0.035), an ACR50 response rate of 19% for Piclidenoson compared to 9% for placebo,
and an ACR70 response rate of 11% for Piclidenoson compared to 3% for placebo. Similar to our observations in the previously reported
Piclidenoson psoriasis trials, the response of patients with rheumatoid arthritis was cumulative over time, suggesting a consistent anti-inflammatory
effect of Piclidenoson. Moreover, half of the rheumatoid arthritis patients treated with Piclidenoson showed clinically meaningful improvement.
Piclidenoson was very well-tolerated and showed no evidence of immunosuppression, and there were no severe treatment-emergent adverse
events during the study. A subgroup analysis of 16 patients with no prior systemic therapy showed a dramatic increase in the response
showing ACR20 of 75%, ACR50 of 50%, and ACR70 of 50%. See Figure 7. We believe this may be related to the fact that in this patient population
there is a full receptor expression since they had not been treated earlier with any systemic drugs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the end of 2017, we initiated the pivotal ACRobat Phase III trial of Piclidenoson to evaluate Piclidenoson as a first line treatment
and replacement for MTX. The trial was a randomized, double-blind, active and placebo-controlled, parallel-group study in approximately
500 patients in Europe, Israel and Canada. The primary endpoint of ACRobat was low disease activity after 12 weeks of treatment in patients
dosed with Piclidenoson compared to those dosed with MTX. Piclidenoson at 1.0 mg and 2.0 mg, or placebo, will be administered twice daily,
and MTX or placebo will be administered once weekly. Secondary endpoints include disease activity remission at week 24, ACR 20/50/70
response rates, European League Against Rheumatism good and moderate response rates and change from baseline for disease activity and
ACR responses. The total study duration was to be 24 weeks in order to provide more data on long term efficacy and safety. In October
2020, an independent data monitoring committee for an interim analysis recommended not to continue this study. Subsequently, we conducted
a detailed analysis of the interim results which showed that although Piclidenoson efficacy was significantly superior to placebo, the
study missed the primary endpoint which was non-inferiority vs. the comparator methotrexate. Accordingly, we decided to stop developing
Piclidenoson for the treatment of rheumatoid arthritis to focus on other indications.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Developments with Piclidenoson</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Topical
Piclidenoson </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, we announced we are developing a topical psoriasis treatment with Piclidenoson. In a preclinical model, imiquimod-induced
skin psoriasis, daily treatment with topical Piclidenoson significantly inhibited the disease as measured by PASI calculated based on
observation of erythema, thickness, scaling, and a score of skin lesions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Osteoarthritis</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Arthritis Foundation, osteoarthritis, or OA, is the most common arthritic disease. Currently, there is a shortage of effective
drugs for treating OA patients. Piclidenoson has induced a significant anti-inflammatory effect in experimental animal models with respect
to the treatment of OA. We have not yet filed an IND for this indication as Piclidenoson for the treatment of OA is not currently being
clinically tested in the United States and there are no near-term plans to do so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, we announced that the U.S. Patent and Trademark Office, or the PTO, has issued to us Patent #10,265,337 titled &#8220;Use
of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment&#8221; for Piclidenoson for the treatment of osteoarthritis in mammals.
We are evaluating potential partnerships with companies in the animal health pharmaceutical market that may in-license and develop Piclidenoson
for the companion animal market, a substantial and rapidly growing global market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2021, we signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the
development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. During 2022, Vetbiolix
completed dose-ranging pharmacokinetic (PK) studies in dogs and determined the optimal efficacy and safety dosage for a planned European
multicentric clinical study. Piclidenoson was well tolerated, with the PK data proportional to dose. Pre-clinical studies were also conducted
showing Piclidenoson has a very favorable safety profile. Based on these data, Vetbiolix has designed a European Multicentric Clinical
study protocol for dogs with osteoarthritis which has been approved by an ethical committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Namodenoson
(CF102)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namodenoson
is our second drug candidate and is under development for the treatment of HCC, hepatitis C virus, or HCV, or NAFLD, the precursor to
NASH. Namodenoson is also a small, orally bioavailable molecule, and an A3AR agonist, with high affinity and selectivity to the A3AR.
In comparison to the expression in adjacent normal liver tissue, the A3AR is over-expressed in tumor tissues of patients with HCC, and
the over-expression is also reflected in the patients&#8217; PBMCs. A3AR over-expression in the patients&#8217; tumor cells and PBMCs
is attributed to high expression of certain A3AR transcription factors. The binding of Namodenoson to the A3AR results in down-regulation,
or a decrease in the quantity of a cellular component, such as the number of receptors on a cell&#8217;s surface, of certain A3AR transcription
factors. Our studies have shown that this down-regulation leads to apoptosis of HCC cells. In our pre-clinical and clinical studies,
Namodenoson demonstrated anti-cancer, anti-viral and liver protective effects. As a result, we believe that Namodenoson can be used to
treat a variety of oncological and liver-related diseases and viruses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2012, the FDA granted an orphan drug status for the active moiety, or the part of the drug that is responsible for the physiological
or pharmacological action of the drug substance, of Namodenoson for the treatment of HCC. Subsequently, in October 2015, the EMA granted
Namodenoson orphan drug designation for the treatment of HCC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
orphan drug designation is a special designation for drug approval and marketing. The special designation is granted to companies that
develop a given drug for unique populations and for incurable and relatively rare diseases. The FDA orphan drug designation program provides
orphan status to drugs and biologics, which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases
or disorders that affect fewer than 200,000 people in the United States and in the EU not more than 5 per 10,000. Orphan drug designations
have enabled companies to achieve medical breakthroughs that may not have otherwise been achieved due to the economics of drug research
and development as this status lessens some of the regulatory burdens, for approval, including statistical requirements for efficacy,
safety and stability, in an effort to maintain development momentum. Orphan drug designation also results in additional marketing exclusivity
and could result in certain financial incentives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2015, the FDA granted Fast Track designation to Namodenoson as a second line treatment to improve survival for patients with
advanced HCC who have previously received Nexavar (sorafenib). Fast Track, aimed at getting important new drugs that meet an unmet need
to patients earlier, is expected to expedite the development of Namodenoson. Drugs that receive Fast Track designation benefit from more
frequent meetings and communications with the FDA to review the drug&#8217;s development plan to support approval. It also allows us
to submit parts of the NDA on a rolling basis for review as data becomes available.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel&#8217;s
Ministry of Health has previously approved Namodenoson for Compassionate Use for HCC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are general descriptions of the diseases with respect to which Namodenoson has underwent or is currently undergoing or being
prepared for clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>HCC:
</i>HCC is an oncological disease characterized by malignant tumors that grow on the surface or inside of the liver. This type of tumor
is refractory to chemotherapy and to other anti-cancer agents. HCC, like any other cancer, develops when there is a mutation to the cellular
machinery that causes the cell to replicate at a higher rate and/or results in the cell avoiding apoptosis. Chronic infections of Hepatitis
B and/or C can aid the development of HCC by repeatedly causing the body&#8217;s own immune system to attack the liver cells, some of
which are infected by the virus. While this constant cycle of damage followed by repair can lead to mistakes during repair which in turn
lead to carcinogenesis, this hypothesis is more applicable, at present, to HCV. Chronic HCV causes HCC through cirrhosis. In chronic
Hepatitis B, however, the integration of the virus into infected cells can directly induce a non-cirrhotic liver to develop HCC. Alternatively,
repeated consumption of large amounts of ethanol can have a similar effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Hepatitis
C:</i> HCV is an infectious disease affecting primarily the liver, caused by the Hepatitis C virus. The infection is often asymptomatic,
but chronic infection can lead to scarring of the liver and ultimately to cirrhosis, which is generally apparent after many years, and
chronic liver disease. The virus also increases the chance for HCC development. In some cases, those with cirrhosis will develop liver
failure, liver cancer or life-threatening esophageal and gastric varices, or dilated submucosal veins, which can be life-threatening.
HCV is spread primarily by blood-to-blood contact often associated with intravenous drug use, poorly sterilized medical equipment, transfusions,
and erectile intercourse.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NAFLD/NASH</i>:
NASH, also called &#8220;fatty liver,&#8221; is a condition in which fat builds up inside the liver causing inflammation. Prior to the
presence of inflammation, the disease is simply referred to as NAFLD, the most common form of liver disorder in the United States. The
accumulation of macroglobular fat inside the liver causes oxidative stress that reduces the efficiency of the liver and can lead to increased
liver enzymes such as alanine aminotransferase and aspartate aminotransferase. Loss of liver efficiency and oxidative stress leads to
inflammation, liver cell ballooning, and the development of NASH. Prolonged inflammation results in cirrhosis (scar tissue), liver failure,
or liver cancer. There are currently no drugs approved for the treatment of NASH.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Clinical
Studies with Namodenoson</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
pre-clinical pharmacology studies, Namodenoson inhibited the growth of HCC via the induction of tumor cell apoptosis. In addition, in
collaboration with leading virology labs, we observed that Namodenoson inhibited viral replication of HCV through the down-regulation
of viral proteins. Both of these findings served as a basis to further explore development of this drug for HCC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted several pre-clinical studies demonstrating robust anti-inflammatory, anti-fibrogenic and anti-steatotic effects, supporting
the development of Namodenoson for the NAFLD/NASH indication. Furthermore, the results indicated that Namodenoson was very well-tolerated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
pre-clinical studies, we evaluated the toxicity, stability, metabolism and other safety parameters of Namodenoson at doses much higher
than the doses that we currently administer to humans in our clinical trials of Namodenoson.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, Namodenoson revealed its capability to act as an anti NAFLD/NASH agent and data has shown as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the STAM model, Namodenoson significantly decreased the non-alcoholic fatty liver disease (NAFLd) activity score, NAS, demonstrating
    anti-inflammatory and anti steatotic effects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">In the carbon tetrachloride (ccl4) model, Namodenoson reversed alanine
aminotransferase (ALT) to normal values and significantly improved liver inflammation and fibrosis, as well as the adiponectin and leptin
levels.</p>

<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namodenoson
    mechanism of action entailed de-regulation of the Wnt/&#946;-catenin pathway in the liver extracts of the ccl4 model mice and in
    the LX2 HScs, manifested by a decreasing the expression of phosphoinositide 3-kinase (PI3K), NF-&#954;B.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Studies of Namodenoson</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information discussed below is based on the various studies conducted by Can-Fite with Namodenoson, including clinical studies in patients
with oncological and liver-related diseases and viruses.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
I Clinical Study</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namodenoson
completed a Phase I double-blind, randomized, placebo-controlled, ascending single dose trial to evaluate the safety, tolerability, and
pharmacokinetics of orally administered Namodenoson in healthy volunteers. The study was conducted in the United States under an open
IND. Namodenoson was found to be safe and well-tolerated with a half-life time of 12 hours. See Figure 8.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_003.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
8: Half-life of orally administered Namodenoson - Phase I Clinical Study</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
I/II and Phase II Clinical Studies</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">HCC</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namodenoson
completed two Phase I/II studies in Israel, one in patients with HCC and another in patients with HCV. The HCC Phase I/II study was an
open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered Namodenoson
in patients with advanced HCC. The primary objectives of the study were to determine the safety and tolerability, dose-limiting toxicities,
maximum tolerated dose, and recommended Phase II dose of orally administered Namodenoson in patients with advanced HCC; and to assess
the repeat-dose pharmacokinetics behavior of Namodenoson in those patients. The secondary objectives were to document any observed therapeutic
effect of Namodenoson in patients with HCC and to evaluate the relationship between PBMCs and the A3AR expression at baseline, as a biomarker,
and the effects of Namodenoson in patients with HCC. The study included 18 patients, nine of which were also carriers of HCV. The initial
dose of Namodenoson was 1.0 mg BID, with planned dose escalations in subsequent cohorts to 5.0 and 25.0 mg BID. This Phase I/II study
achieved its objectives, showing a good safety profile, or no material differences versus a placebo with respect to observed and patient-indicated
side effects, for Namodenoson and a linear pharmacokinetic drug profile, with no dose-limiting toxicities at any dose level. The median
overall survival time for the patients in this study was 7.8 months, which is encouraging data considering that (i) 67% of the patient
population in the study had previously progressed on Nexavar, produced by Onyx Pharmaceuticals and Bayer, and that Namodenoson was a
second line therapy for these patients and (ii) 28% of the patient population were Child-Pugh Class B patients (patients classified on
the Child Pugh scoring system for chronic liver disease as having significantly impaired liver function) whose overall survival time
is usually 3.5 to 5.5 months. Accordingly, we may also consider Namodenoson as a drug to be developed for this patient sub-population
of Child-Pugh Class B patients. Namodenoson had no adverse effect on routine measures of liver function over a six-month period in 12
patients treated for at least that duration. These findings are consistent with our pre-clinical Namodenoson data which demonstrated
a protective effect on normal liver tissue in an experimental model of liver inflammation. As such, Namodenoson may potentially be a
safer alternative to patients with cirrhosis and/or hepatic impairment. The study also demonstrated a direct relationship between A3AR
expression at baseline and patients&#8217; response to Namodenoson, suggesting A3AR as a predictive biological marker. We also observed
a decrease in the viral load of seven out of nine patients who were also carriers of HCV. The most commonly reported adverse events included
loss of appetite, ascites, nausea, diarrhea, constipation and pain. However, many of these events are expected in a population of patients
with advanced HCC. The most frequently reported drug-related adverse events included diarrhea, fatigue, loss of appetite, pain and weakness.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second Phase I/II study was a randomized, double-blind, placebo-controlled, dose-escalation study evaluating the safety, tolerability,
biological activity, and pharmacokinetics of orally administered Namodenoson in 32 subjects with chronic HCV genotype 1. Eligible subjects
were assigned in a 3:1 ratio (eight subjects in each cohort) to receive QD or BID treatment (1.0, 5.0 and 25.0 mg of Namodenoson) for
15 days with oral Namodenoson or with a placebo. Dose escalation occurred in four sequential cohorts. The study&#8217;s primary objectives
were to determine the safety and tolerability of orally administered Namodenoson in patients with chronic HCV genotype 1, to assess the
effects on HCV load during 15 days of treatment with Namodenoson and to assess the repeat-dose pharmacokinetic behavior of Namodenoson
under the conditions of this trial. The secondary objective of this trial was to perform an exploratory evaluation of the relationship
between A3AR in PBMCs at baseline and the clinical effects of Namodenoson on the study&#8217;s patients. Following the decrease in HCV
load that had been observed in HCV patients treated with Namodenoson in the parallel HCC study and the good safety profile of Namodenoson,
we received Israeli Institutional Review Board, or IRB, approval to extend the treatment period of the Phase I/II in patients with HCV
to four months with the 1.0 mg dose vs. the placebo. The results of this Phase I/II HCV study demonstrated a good safety profile and
a linear pharmacokinetic drug profile, however, no significant decrease in the viral load was observed. Notwithstanding, we did observe
in the parallel HCC study that seven out of the nine patients with both HCC and HCV experienced a decrease in viral load and that these
seven patients were treated with higher Namodenoson dosages than what was administered to the patients with chronic HCV genotype 1 only,
and not HCC, possibly explaining the difference in results. The most commonly reported adverse events included loss of appetite, ascites,
nausea, diarrhea, constipation and pain. However, many of these events are expected in a population of patients with advanced HCV. The
most frequently reported drug-related adverse events included diarrhea, fatigue, loss of appetite, pain and weakness.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2019, we completed a Phase II study in HCC patients. In January 2013, as part of our preparatory work for such study, we announced that
we believe that the optimal drug dose for the upcoming study is Namodenoson 25.0 mg. This dose was found to be the most effective dose
out of the three dosages tested (1.0 mg, 5.0 mg and 25.0 mg) in the previous Phase I/II study. We filed a patent application protecting
such optimal dose of Namodenoson for HCC. A publication summarizing the results of the Phase I/II study was published in &#8220;The Oncologist,&#8221;
a leading oncology scientific journal. We also highlighted that one patient has been treated with Namodenoson for over five years.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase II study was a randomized, double-blind, placebo controlled trial conducted in the United States, Europe and Israel to evaluate
the efficacy and safety of Namodenoson as a second-line treatment for advanced HCC in subjects with Child-Pugh B who failed Nexavar as
a first line treatment. Advanced HCC in patients with underlying cirrhosis is categorized into three subclasses based on the severity
of cirrhosis, starting with Child Pugh A, or CPA, mostly treated with Nexavar and progressing to Child Pugh B, or CPB, and Child Pugh
C, or CPC, for which there are no drugs on market with proven efficacy. In the study, we enrolled only patients with CPB stage liver
cancer with CBP stage patients being further divided into three categories of increasing severity, namely CPB7, CPB8, and CPB9. These
patients already failed first line Nexavar and were treated with Namodenoson (25mg), or placebo, as a second line treatment, twice daily,
using a 2:1 randomization. The primary endpoint of the study was median overall survival. Secondary endpoints included progression free
survival, partial response, and disease control rate. In March 2014, the study protocol was approved by the IRB at the Rabin Medical
Center in Israel and in December 2014, we dosed the first patient at the study&#8217;s Israeli site. In the third quarter of 2017, we
announced that we completed enrollment and randomization of all 78 patients and in March 2019, we announced top-line results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the study did not achieve the primary end point of overall survival in the whole population (n=78), superiority in overall survival was
found in the largest study subpopulation of CPB7 (n=56) and in secondary end points in the whole population, including objective response
measured by CT or MRI. Findings from the study include the following: (i) for the whole population (n=78), median overall survival was
4.1 months for Namodenoson vs. 4.3 months for placebo (HR: 0.82), (ii) pre-planned subpopulation analysis of the CPB7 patients (n=56),
revealed that the Namodenoson treated group (n=34) showed median overall survival of 6.8 months vs 4.3 months in placebo (n=22) [HR:
0.77 (95% CI 0.49-1.40)]; similarly, for this subgroup of patients, progression free survival was 3.5 months for the Namodenoson treated
group vs 1.9 (HR: 0.87) in the placebo group; (iv) 1-year survival in the CPB7 population was 44% for the Namodenoson treated group,
as compared to 18% for patients dosed with placebo (p=0.028); (v) objective response in the whole patient population measured by CT or
MRI, demonstrated that 9% treated by Namodenoson achieved partial response vs 0% in the placebo group, (vi) consistent with safety results
from previously completed clinical trials, Namodenoson was generally well-tolerated, with no treated patients being withdrawn for toxicity
and no cases of treatment-related deaths, (vii) disease control rate was 18.0% in the Namodenoson group vs 7.1% in the placebo group
(p=0.013) after four months of treatment, (viii) 32.0% of patients treated with Namodenoson completed at least 12 months of treatment
vs 14.3% who were treated with placebo (p=0.058), (vii) as of March 27, 2019, two patients in the Namodenoson group are ongoing after
30 months of treatment; these patients will continue to receive Namodenoson, and (ix) all nine patients with CBP9 cirrhosis, the most
severe grade allowed into the trial, were randomly assigned to the Namodenoson treatment group (OS=3.5 months), a fact which has distorted
the results in the whole population. Subgroup analyses using a variety of demographic and baseline disease characteristics, such as sex,
performance status, and HCC disease status indicate the overall survival advantage of Namodenoson over placebo persists in the vast majority
of the subgroups.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
paper titled &#8220;Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical
Trial&#8221; was published in the peer reviewed journal <i>Cancers</i> with respect to the Phase II HCC trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2021, we announced that two patients continued to receive Namodenoson treatment from our Phase II study of HCC after nearly
four years under an open label extension. Additional findings show disappearance of ascites, normal liver function and good quality of
life. In one patient stable disease has been recorded with disappearance of peritoneal carcinomatosis. Namodenoson continued to demonstrate
a good safety profile and was well tolerated with no severe adverse events reported. Furthermore, in December 2021, we reported that
the last patient treated under the open label extension experienced a complete response and treatment is ongoing under a compassionate
use program established in Romania in August 2022. Under treatment with Namodenoson, we reported that the patient survived six years,
during which time the clinical benefits of treatment have included the disappearance of ascites, normal liver function, and the disappearance
of peritoneal carcinomatosis leading to complete clearance of all cancer lesions.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, we held an End-of-Phase II Meeting with the FDA regarding our Phase II study of Namodenoson in the treatment of HCC. The
purpose of the meeting was to review the Phase II study data with the FDA and to present our proposed Phase III study design to the regulatory
agency. The FDA agreed with our proposed pivotal Phase III trial design to support an NDA submission and approval. Subsequently in June
2020, we concluded a meeting with the Scientific Advice Working Party of the EMA to discuss our planned Phase III study. Based on the
input received from the FDA and EMA, we plan on conducting a Phase III, randomized, double blind, placebo controlled trial of Namodenoson,
that will enroll approximately 450 patients with HCC and underlying CPB7 cirrhosis at multiple centers worldwide. Patients will be randomized
to oral treatment with either Namodenoson 25 mg or matching placebo given twice daily. The primary efficacy endpoint of the trial is
overall survival (OS), based on the favorable OS response seen in the Phase II trial in patients with HCC and CPB7 cirrhosis. Other oncology
trial efficacy outcomes, such as tumor radiographic response rates and median progression-free survival, as well as standard safety parameters,
will be assessed. The study is designed to support an NDA submission in the U.S. and a marketing authorization application, or MAA, in
Europe. The Phase III study is currently open for enrollment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, we initiated a compassionate use program in Israel for Namodenoson in the treatment of HCC, the most common form of liver
cancer. Our compassionate use program has enrolled and continues to treat patients. The compassionate use program, which enables liver
cancer patients not enrolled in our clinical study to be treated with Namodenoson, is being administered by Dr. Salomon Stemmer, the
Principal Investigator of the Company&#8217;s prior Phase II liver cancer study, and Professor at the Institute of Oncology, Rabin Medical
Center, Israel. In August 2022, Namodenoson was approved for compassionate use in Romania.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">NAFLD/NASH</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted a Phase II double-blind, placebo-controlled, dose-finding efficacy and safety study that enrolled 60 patients with NAFLD with
or without NASH in three clinical sites in Israel including Hadassah Medical Center, Jerusalem; Rabin Medical Center, Petach Tikva; and
Holy Family Hospital, Nazareth; with Prof. Rifaat Safadi as the Principal Investigator. Patients with evidence of an active inflammation
were treated twice daily with 12.5 mg (n=21) or 25 mg (n=19) of oral Namodenoson vs. placebo (n=20). The patients were treated for 12
weeks and followed-up until week 16. The study&#8217;s end points included among others alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) blood level, % of liver fat, liver stiffness, serum adiponectin, leptin and patient&#8217;s weight loss. In April
2020 we announced top-line data and in June 2020 we announced our final data analysis. As a whole, the data show that Namodenoson at
the 25 mg dose produced statistically significant results in all measures of efficacy, while also having a strong safety profile and
well tolerated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutically
significant positive data and trends were found as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Anti-Inflammatory
Effect</i>: Namodenoson significantly reduced two liver enzymes, AST and ALT, which are elevated in a damaged liver, and increased the
anti-inflammatory cytokine adiponectin known also to act as an anti-fibrotic factor. Serum adiponectin levels increased in the 25 mg
dose group by 220 ng/mL and the 12.5 mg dose group by 539 ng/mL (p=0.03). Adiponectin is a cytokine with robust anti-inflammatory and
anti-fibrotic effects that is used as a biomarker in NAFLD/NASH trials. In addition, a dose response decrease compared to placebo was
observed, indicating a reduction of hepatic inflammation was achieved: (i) % of patients who reached ALT normalization at follow up was
36.8% in the 25 mg dose vs. 10% in the placebo (p=0.038). In the 12.5 mg dose, 23.8% was recorded at follow up, (ii) ALT change from
baseline (CFB) and % change from baseline (PCFB) - in the 25 mg group, CFB decreased by 15.4 U/L (p=0.066) and PCFB by 22% (p=0.079)
compared to placebo (1.7 U/L, 3.0%, respectively); in the 12.5 mg group, a decrease CFB of 10.4 U/L and PCFB of 8.2% was recorded; and,
(iii) AST CFB and PCFB - in the 25 mg group, CFB decreased by 8.1 U/L (p=0.03) and PCFB by 17.9% (p=0.05) compared to placebo (increase
of 0.3 U/L, decrease of 1.3%, respectively). In the 12.5 mg group, a decrease in CFB of 7.4 U/L and PCFB of 8.1 % was recorded.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reduction
of Liver </i>Steatosis: In the Namodenoson 25 mg treated group, the proportion of patients with high steatosis scores declined from 37.5%
to 13.3% of the population, as compared to the placebo treated group in which the proportion of patients with high steatosis scores decreased
from 37.5% to 35.3% of the population, with p=0.08. Steatosis was assessed by Controlled Attenuation Parameter (CAP) measurement of the
FibroScan, a non-invasive marker of hepatic steatosis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NASH
- All Cases Resolved</i>: 25% of patients randomized into the Namodenoson 25 mg dosed group had NASH at baseline, as compared to none
in the placebo group, which comprised of patients who had NAFLD without NASH at baseline. Following 12 weeks of treatment, all NASH cases
were resolved in patients treated with 25 mg of Namodenoson, as compared to new NASH that developed in the placebo group representing
5% of that population, with p&lt;0.009. NASH was evaluated by FibroScan-AST (FAST) score, a noninvasive marker of NASH, the severe form
of NAFLD (equivalent to biopsy findings of NAS&#8805;4, F&#8805;2), measured by FibroScan elastography, CAP and serum AST.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Decrease
in Body </i>weight: A linear decrease in body weight was recorded in the 25 mg and 12.5 mg Namodenoson groups.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>A3
Adenosine Receptor (A3AR)</i>: The A3AR biomarker was stable, demonstrating the presence of the receptor after chronic treatment and
reflecting the validity of the target.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Safety</i>:
Namodenoson continued to be safe and very well tolerated with no drug emergent severe adverse effects and no hepatotoxicity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently conducting a Phase IIb study Namodenoson in the treatment of NASH, having announced first patient enrollment in January
2022. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH.
The primary efficacy objective of the trial is to evaluate the efficacy of Namodenoson as compared to placebo in 140 subjects with NASH,
as determined by a histological endpoint. Eligible subjects are randomly assigned in a 2:1 ratio to oral doses of Namodenoson 25 mg every
12 hours or a matching placebo for 36 weeks. . The protocol was developed in conjunction with Dr. Scott Friedman, Chief of the Division
of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle
Clinical Research, both of whom were involved in the design of Namodenoson&#8217;s Phase II study in NAFLD/NASH.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Developments with Namodenoson</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-Obesity</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, we announced new pre-clinical findings demonstrating that Namodenoson, inhibits lipid production and fat accumulation in
adipocytes (lipid producing cells). More specifically, Namodenoson showed a significant decrease in lipid production and fat accumulation
utilizing 3T3-L1 adipocytes, functioning as lipid producing cells and are also responsible for fat storage. Namodenoson was also shown
to inhibit the proliferation of adipocytes, further hampering the expansion of fat producing cells. These findings, together with the
safety profile of Namodenoson, support its potential utilization as an anti-obesity drug. A patent application for the utilization of
Namodenoson as an anti-obesity drug has been filed. In January 2020, we announced further pre-clinical data generated at the Hadassah
Medical Center by Dr. Rifaat Safadi&#8217;s lab that demonstrated that Namodenoson induces weight loss in experimental models and normalizes
glucose levels.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>JC
Virus</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2011, we announced that, in laboratory study, Namodenoson inhibited the reproduction of the JC virus, a type of polyomavirus, which
is dormant in approximately 70% to 90% of the world population. However, in patients treated with biological drugs, including monoclonal
antibody therapeutics, such as anti-TNFs or anti-CD20, JC virus replication may occur, resulting in development of progressive multifocal
leukoencephalopathy, or PML, which is characterized by progressive damage or inflammation of the white matter of the brain and, eventually,
death. The ability of Namodenoson to suppress the JC virus culture, as indicated in the laboratory study, may indicate that it may be
used for the treatment of PML as a combination therapy with biological drugs. As Namodenoson is already in various stages of clinical
development for other indications, its efficacy for this new application may be tested in clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pancreatic
Cancer</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, we announced that in pre-clinical studies, Namodenoson significantly inhibits the growth of pancreatic carcinoma as a stand-alone
treatment. In combination with the leading chemotherapy used in pancreatic cancer, gemcitabine, Namodenoson demonstrated a significant
additive effect. These pre-clinical studies were conducted on advanced pancreatic carcinoma patient cells. Namodenoson&#8217;s molecular
mechanism of action in pancreatic cancer involves the regulation of the NF-&#954;B /I&#954;B /STAT3-mediated pathway.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CF602</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allosteric modulator, CF602, is our third drug candidate in its pipeline. CF602 is an orally bioavailable small molecule, which enhances
the affinity of the natural ligand, adenosine, to its A3AR. The advantage of this molecule is its capability to target specific areas
where adenosine levels are increased. Normal body cells and tissues are refractory to allosteric modulators. This approach complements
the basic platform technology of Can-Fite, utilizing the Gi coupled protein A3AR as a potent target in inflammatory diseases. CF602 has
demonstrated proof of concept for anti-inflammatory activity in <i>in vitro</i> and <i>in vivo</i> studies performed by us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
clinical studies conducted with our product candidates, other than CF602, patients suffering from erectile dysfunction reported that
they returned to normal functioning following the treatment with such drugs. We believe that these findings are correlated with our platform
technology, which is the targeting of the A3AR. Adenosine, like nitric oxide, is a potent and short-lived vaso-relaxant that functions
via intracellular signaling (in particular, through cAMP) to promote smooth muscle relaxation. Recent studies conducted by others show
that adenosine functions to relax the corpus cavernosum and thereby promote penile erection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CF602
was tested in an experimental animal model of diabetic rats, which similar to diabetic patients, suffer from erectile dysfunction. Erectile
dysfunction was assessed by monitoring the ratio between intra-cavernosal pressure, or ICP, and mean arterial pressure, or MAP, as a
physiological index of erectile function. The ICP/MAP for the CF602 treated group improved by 118% over the placebo group. This data
is similar to that achieved earlier by sildenafil (Viagra) in preclinical studies. In addition, treatment with CF602 reversed smooth
muscle and endothelial damage, in a dose dependent manner, leading to the improvement in erectile dysfunction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
studies of CF602 have revealed that CF602 restores the impaired vascular endothelial growth factor system in the penis of diabetes mellitus
rats, thereby inducing an increase in nitric oxide resulting in significant improvement of penile erection compared to placebo. This
mechanism of action is similar to that of sildenafil, with CF602 demonstrating effects on erection superior to that demonstrated by sildenafil
in animal studies. Among the most important factors to affect erectile function is nitric oxide, which is released by endothelial cells
that line the corpus cavernosum and control smooth muscle relaxation and vascular inflow. It has been well established that release of
nitric oxide is diminished in diabetes.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, CF602 induced a dose-dependent, linear effect in a diabetic mellitus rat model after treatment with one single dose of CF602.
One hour after dosing, erectile function was measured. Statistically significant full recovery from erectile dysfunction took place in
rats treated with a 500 &#181;/kg dose.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, we announced new data from a preclinical study of CF602 in the treatment of erectile dysfunction, or ED, in a diabetes experimental
model. The study evaluated the efficacy of topically applied CF602 in a 4-cohort study with diabetic Sprague-Dawley (SD) rats receiving
placebo; 100nM CF602; 500nM CF602. Na&#239;ve rats served as a comparative negative control. ED was assessed by tracing ICP under cavernous
nerve stimulation. Treatment with CF602 at a dose of 500 nM resulted in statistically significant improvement of erectile dysfunction
compared to vehicle treated controls when measured in a two-way ANOVA followed by Bonferroni multiple comparisons post-hoc analysis (p&lt;0.001).
The improvement was even better than recorded for the na&#239;ve animals group. Efficacy was dose-dependent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the American Diabetes Association, approximately 30 million children and adults have diabetes mellitus in the United States. It is
estimated that 35-75% of men with diabetes mellitus suffer from erectile dysfunction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, a patent was granted to us by the USPTO covering A3AR ligands for use in the treatment of erectile dysfunction. The patent
addresses methods for treating erectile dysfunction with different A3AR ligands including our erectile dysfunction drug candidate, CF602.
With this new broader patent protection, we made a strategic decision to investigate additional compounds, owned by us, for the most
effective and safest profile in this indication and we are seeking to partner development of CF602.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cannabinoid-Based
Pharmaceuticals</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, we entered into a collaboration agreement with Univo, a medical cannabis company, to identify and co-develop specific
formulations of cannabis components for the treatment of diseases in which there is an overexpression of A3AR. Based on our recent scientific
findings, we have filed patents for the use of cannabinoid-based drugs to treat cancer, autoimmune, inflammatory and metabolic diseases.
Our most recent pre-clinical research revealed that cannabis derived CBD enriched fractions, supplied by Univo, inhibit the expansion
of human fat cells (pre-adipocytes) by 60%, a result that points towards the potential anti-obesity effect of this agent. Although it
is already documented that cannabis derived compounds possess anti-obesity effect, the novel data presented by us demonstrates the anti-obesity
effect at low nano-molar concentrations. Low CBD concentrations are known to be safe and well accepted in humans. Previously, we announced
pre-clinical findings demonstrating CBD&#8217;s robust anti-neoplastic effect in pre-clinical studies against liver cancer. The studies
were carried out on human liver cancer cells and utilized cannabinoid fractions enriched for CBD, in nano and pico molar concentrations.
Marked inhibition of Hep-3b, liver cancer cell proliferation was noted and was mediated via the A3 adenosine receptor. As of December
31, 2020, our collaboration agreement with Univo expired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, we completed the development of a biological cell-based in vitro assay which can identify clinically active cannabis derived
compounds that bind to and activate A3AR, thus enabling the development of pharmaceuticals that use a specific cannabis derived compound
to treat a variety of diseases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, we received approval from the Medical Cannabis Unit of Israel&#8217;s Ministry of Health to conduct pre-clinical studies
on the effect of nanomolar concentrations of cannabinoid fractions on the proliferation and functionality of cancer, inflammatory and
adipocyte cells (fat cells). This regulatory approval allows us to advance our cannabinoid program by evaluating the effect of cannabis
fractions at nanomolar concentrations binding with A3AR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2021, we announced the completion of a set of pre-clinical studies demonstrating that cannabis derived compounds bind to A3AR,
mediating therapeutic effects. CBD rich T3/C15 cannabis fraction inhibited the proliferation of LX-2 hepatic-stellate cells, the liver
cell type mediating the development of fibrosis. This inhibitory response was neutralized by an antagonist to the A3AR, demonstrating
that the anti-fibrotic effect was mediated via the A3AR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, we announced the completion of a set of pre-clinical studies demonstrating that a CBD rich T3/C15 cannabis fraction inhibited
the growth of liver HEP-3b hepatocellular carcinoma cells via the A3AR by inhibiting Wnt- and NF-kappa B-related regulatory pathways.
The Wnt signaling pathway is known to be highly active in controlling the growth of liver cancer cells. An A3AR antagonist, MRS1523 reversed
this effect demonstrating that the inhibitory effect is mediated via our target, A3AR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercial
Biomarker Test</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2015, we completed the development of a commercial predictive biomarker blood test kit for A3AR. The biomarker test can be used
at any molecular biology lab, where a small blood sample from a prospective patient would be tested and within just a few hours, results
indicate if the patient would benefit from treatment with our drugs, which are currently in clinical trials for rheumatoid arthritis,
psoriasis, and liver cancer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO previously issued to us a patent for the utilization of A3AR as a biomarker to predict patient response to our drug Piclidenoson
in autoimmune inflammatory indications.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In-Licensing
Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary description of our in-licensing agreement with Leiden University. Our previously granted license with NIH expired
in June 2015 with the expiration of certain patents. The description provided below does not purport to be complete and is qualified
in its entirety by the complete agreement, which is attached as an exhibit to this Annual Report on Form 20-F</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leiden
University Agreements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 2, 2009, we entered into a license agreement, or the Leiden University Agreement, with Leiden University. Leiden University
is affiliated with NIH and is the joint owner with NIH of the patents licensed pursuant to the Leiden University Agreement. The Leiden
University Agreement grants an exclusive license for the use of the patents of several compounds, including CF602, that comprise certain
allosteric compound drugs, and for the use, sale, production and distribution of products derived from such patents in the territory,
i.e., China and certain countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, Holland and
England). Subject to certain conditions, we may sublicense the Leiden University Agreement. However, the U.S. government has an irrevocable,
royalty-free, paid-up right to practice the patent rights throughout the territory on behalf of itself or any foreign government or international
organization pursuant to any existing or future treaty or agreement to which the U.S. government is a signatory and the U.S. government
may require us to grant sublicenses when necessary to fulfill health or safety needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Leiden University Agreement, we are committed to make the following payments: (i) a one-time concession commission of 25,000 Euros;
(ii) annual royalties of 10,000 Euros until clinical trials commence; (iii) 2% to 3% of net sales value, as defined in the Leiden University
Agreement, received by us; (iv) royalties of up to 850,000 Euros based on certain progress milestones in the clinical stages of the products
which are the subject of the patent under the Leiden University Agreement; and (v) if we sublicense the agreement, we will provide Leiden
University royalties at a rate of 2-3% of net sales value, as defined in the Leiden University Agreement, and 10% of certain consideration
received for granting the sublicense. In the event that we transfer to a transferee the aspect of our business involving the Leiden University
Agreement, we must pay to Leiden University an assignment royalty of 10% of the consideration received for the transfer of the agreement.
However, a merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement. In addition,
we have agreed to bear all costs associated with the prosecution of the patents and patent applications to which we are granted a license
under the Leiden University Agreement. As of December 31, 2022, we have paid approximately 155,000 Euros in royalties to Leiden University
in connection with the Leiden University Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Leiden University Agreement expires when the last of the patents expires in each country of the territory, unless earlier terminated
in accordance with the terms of the Leiden University Agreement. The last of such patents is set to expire on 2027. The termination rights
of the parties include, but are not limited to, (i) the non-defaulting party&#8217;s right to terminate if the defaulting party does
not cure within 90 days of written notice identifying the default and requesting remedy of the same; and (ii) Leiden University&#8217;s
right to terminate if we become insolvent, have a receiver appointed over our assets or initiate a winding-up. In addition, Leiden University
may terminate the agreement when it is determined, in consultation with NIH, that termination is necessary to alleviate health and safety
needs and certain other similar circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Out-Licensing
and Distribution Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are summary descriptions of certain out-licensing and distribution agreements of Piclidenoson and Namodenoson for the indications
we are currently investigating.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cipher
Pharmaceuticals Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 20, 2015, we entered into a Distribution and Supply Agreement with Cipher granting Cipher the exclusive right to distribute Piclidenoson
in Canada for the treatment of psoriasis and rheumatoid arthritis. In 2020, we ended our development of Piclidenoson for rheumatoid arthritis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Distribution and Supply Agreement, we are entitled to CAD 1.65 million upon execution of the agreement plus milestone payments upon
receipt of regulatory approval by the Therapeutic Products Directorate of Health Canada, or Health Canada, for Piclidenoson and the first
delivery of commercial launch quantities as follows (i) CAD 1 million upon the first approved indication for either psoriasis or rheumatoid
arthritis, and (ii) CAD 1 million upon the second approved indication for either psoriasis or rheumatoid arthritis. In addition, following
regulatory approval, we shall be entitled to a royalty of 16.5% of net sales of Piclidenoson in Canada and reimbursement for the cost
of manufacturing Piclidenoson. We are also entitled to a royalty payment for any authorized generic of Piclidenoson that Cipher distributes
in Canada. To date, we have received a total of $1.3 million from Cipher in an upfront payment.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are responsible for supplying Cipher with finished product for distribution and conducting product development activities while Cipher
is responsible for distributing, marketing and obtaining applicable regulatory approvals in Canada. The Distribution and Supply Agreement
has an initial term of fifteen years, automatically renewable for additional five-year periods and may be terminated in certain limited
circumstances including certain breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract
period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timeline to regulatory submissions to Health Canada will be determined by the completion of the remaining clinical trial program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CKD
Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2016, we entered into an exclusive Distribution Agreement with CKD for the exclusive right to distribute Namodenoson for
the treatment of liver cancer in South Korea, upon receipt of regulatory approvals. On February 25, 2019, the Distribution Agreement
was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in South Korea. The Distribution Agreement
further provides that we will deliver finished product to CKD and grant CKD a right of first refusal to distribute Namodenoson for other
indications for which we develop Namodenoson.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution Agreement provides for up to $3,000,000 in upfront and milestone payments payable with respect to the liver cancer indication
and up to $6,000,000 with respect to the NASH indication. In addition, we are entitled to a transfer price of the higher of the manufacturing
cost plus 10% or 23% of net sales of Namodenoson following commercial launch in South Korea. To date, we have received a total of $2,000,000
from CKD, $1,500,000 in upfront payments for the expansion of CKD&#8217;s existing agreement with us to include the rights to distribute
Namodenoson for the treatment of NASH in South Korea, and a further $500,000 for a milestone payment received in the third quarter of
2017 upon receipt by CKD of a positive result from the preliminary review by the MFDS on obtaining orphan drug designation in South Korea.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution Agreement has an initial term of 10 years from first commercial sale of Namodenoson for the treatment of liver cancer or
NASH and is renewable for additional 3-year periods unless either party gives notice of termination at least 6 months prior to the then
current term. The Distribution Agreement may be terminated by CKD upon 30 days prior written notice if we fail to successfully complete
our ongoing Phase II clinical trial for Namodenoson and we may terminate the Distribution Agreement upon 30 days prior written notice
if certain commercialization milestones are not met by CKD or certain minimum quantities of sales are not made during the contract period.
In addition, either party may terminate the Distribution Agreement in the event of an uncured material breach or insolvency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gebro
Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2018, we entered into a Distribution and Supply Agreement with Gebro, granting Gebro the exclusive right to distribute Piclidenoson
in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis. In 2020, we ended our development
of Piclidenoson for rheumatoid arthritis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Distribution and Supply Agreement, we are entitled to &#8364;1,500,000 upon execution of the agreement plus milestone payments upon
achieving certain clinical, launch and sales milestones, as follows: (i) &#8364;300,000 upon initiation of the ACRobat Phase III clinical
trial for the treatment of rheumatoid arthritis and &#8364;300,000 upon the initiation of the COMFORT Phase III clinical trial for the
treatment of psoriasis, (ii) between &#8364;750,000 and &#8364;1,600,000 following first delivery of commercial launch quantities of Piclidenson
for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300,000 and up to &#8364;4,025,000 upon meeting
certain net sales. In addition, following regulatory approval, we shall be entitled to double digit percentage royalties on net sales
of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. To date, we have received a total of &#8364;2,100,000
from Gebro in upfront and milestone payments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are initially responsible for supplying Gebro with finished product for distribution and obtaining EMA and Swissmedic marketing approval
while Gebro is responsible for distributing, marketing and obtaining pricing and reimbursement approvals in the territories. The Distribution
and Supply Agreement has an initial term of fifteen years, automatically renewable for additional five-year periods and may be terminated
in certain limited circumstances including certain breaches of the agreement and failure to achieve certain minimum quantities of sales
during the contract period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CMS
Medical Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2018, we entered into a License, Collaboration and Distribution Agreement with CMS for the exclusive right to develop, manufacture
and commercialize Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of HCC and NAFLD/NASH
in China (including Hong Kong, Macau and Taiwan).&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the License, Collaboration and Distribution Agreement, we are entitled to $2,000,000 upon execution of the agreement plus milestone payments
of up to $14,000,000 upon achieving certain regulatory milestones and payments of up to $58,500,000 upon achieving certain sales milestones,
as follows: (i) $500,000 upon the granting of the marketing authorization of Piclidenoson in the United States for rheumatoid arthritis;
(ii) $500,000 upon the granting of the marketing authorization of Piclidenoson in the European Union for rheumatoid arthritis; (iii)
$500,000 upon the granting of the marketing authorization of Piclidenoson in the United States for psoriasis; (iv) $500,000 upon the
granting of the marketing authorization of Piclidenoson in the European Union for psoriasis; (v) $500,000 upon the granting of the marketing
authorization of Namodenoson in the United States for HCC; (vi) $500,000 upon the granting of the marketing authorization of Namodenoson
in the European Union for HCC; (vii) $500,000 upon the granting of the marketing authorization of Namodenoson in the United States for
NAFLD/NASH; (viii) $500,000 upon the granting of the marketing authorization of Namodenoson in the European Union for NAFLD/NASH; (ix)
$2,500,000 upon the issuance of an imported drug license permitting the product to be imported into and marketed in China, or the IDL
and granting of marketing authorization of Piclidenoson in China for rheumatoid arthritis; (x) $2,500,000 upon the issuance of the IDL
and granting of marketing authorization of Piclidenoson in China for psoriasis; (xi) $2,500,000 upon the issuance of the IDL and granting
of marketing authorization of Namodenoson in China for HCC; (xii) $2,500,000 upon the issuance of the IDL and granting of marketing authorization
of Namodenoson in China for NAFLD/NASH; and (xiii) between $1,000,000 and up to $30,000,000 upon meeting certain net sales. In addition,
following regulatory approval, we shall be entitled to double-digit percentage royalties on net sales of Piclidenoson and Namodenoson
in the licensed territories. To date, we have received a total of $2,000,000 from CMS in upfront and milestone payments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the agreement, CMS will be responsible for the development of Piclidenoson and Namodenoson to obtain regulatory approval in China
and shall be further responsible for obtaining and maintaining regulatory approval in China for the indications described above. We may,
at the option of CMS, supply finished product to CMS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License, Collaboration and Distribution Agreement shall continue in force unless earlier terminated and may be terminated in certain
limited circumstances including certain breaches of the agreement and failure to achieve certain minimum quantities of sales during the
contract period. Following expiration of the term of the agreement, the license granted shall become non-exclusive, fully paid, royalty
free and irrevocable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kyongbo
Pharm Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2019, we entered into a License and Distribution Agreement with Kyongbo Pharm. Under the terms of agreement, Kyongbo Pharm, in
exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, made a total upfront payment
of $750,000 to us, with additional payments of up to $3,250,000 upon achievement of certain milestones. We will also be entitled to a
transfer price for delivering finished product to Kyongbo Pharm. To date, we have received a total of $750,000 from Kyongbo Pharm in
upfront and milestone payments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ewopharma
Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, we signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis
and Namodenoson in the treatment of liver diseases namely, HCC, the most common form of liver cancer, and NASH. Under the terms of the
distribution agreement, Ewopharma we received $2.25 million upfront and are entitled to up to an additional $40.45 million payable upon
the achievement of regulatory and sales milestones plus 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive
right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma
has the right to extend the distribution agreement to new indications that we may identify for its drug candidates. We will also be entitled
to a transfer price for delivering finished product to Ewopharma. To date, we have received a total of $2.25 million from Ewopharma in
upfront, milestone and royalty payments.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Vetbiolix
Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2021, we signed a development and commercialization agreement
with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in
companion animals including dogs and cats. Vetbiolix will have the exclusive right to Piclidenoson in the veterinary osteoarthritis market
for two years, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield
positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay us upfront
and milestone payments of &#8364;250,000, in addition to royalties on sales upon regulatory approval for veterinary use.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
Revenues by Category of Activity and Geographic Markets</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we have generated revenues from payments received pursuant to our out-licensing agreements with respect to Piclidenoson and Namodenoson.
See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, we recorded the following revenues: (i) $0.15 million for the as a result of recognition of a portion
of an advance payment received in January 2018 under the distribution agreement with Gebro; (ii) $0.20 million under the Distribution
Agreement with CKD which was due to the recognition of a portion of the advance payment received in December 2016 and April 2019 under
the Distribution Agreement with CKD; (iii) $0.09 million under the Distribution Agreement with Cipher; and (iv) $0.37 million under the
Distribution Agreement with Ewopharma.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, we recorded the following revenues: (i) $0.19 million as a result of recognition of a portion of an
advance payment received in January 2018 under the distribution agreement with Gebro; (ii) $0.20 million under the Distribution Agreement
with CKD which was due to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution
Agreement with CKD; and (iii) $0.11 million under the Distribution Agreement with Cipher; and (iv) $0.35 million under the Distribution
Agreement with Ewopharma.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2020, we recorded the following revenues: (i) $0.26 million for the as a result of recognition of a portion
of an advance payment received in January 2018 under the distribution agreement with Gebro; (ii) $0.35 million under the Distribution
Agreement with CKD which was due to the recognition of a portion of the advance payment received in December 2016 and April 2019 under
the Distribution Agreement with CKD; and (iii) $0.15 million under the Distribution Agreement with Cipher.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to generate future revenues through our current and potential future out-licensing arrangements with respect to Piclidenoson and
Namodenoson based on the progress we make in our clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and operations are generally not affected by seasonal fluctuations or factors.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Raw
Materials and Suppliers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the raw materials that we require to manufacture Piclidenoson, Namodenoson and CF602 are widely available from numerous
suppliers and are generally considered to be generic industrial chemical supplies. We do not rely on a single or unique supplier for
the current production of any therapeutic small molecule in our pipeline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently manufacturing our API through a leading CRO. The relevant suppliers of our drug products are compliant with both current
Good Manufacturing Practices, or cGMP, and current Good Laboratory Practices, or cGLP, and allow us to manufacture drug products for
our current clinical trials. We anticipate that we will continue to rely on third parties to produce our drug products for clinical trials
and commercialization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that our drug candidates, if approved, can be manufactured in sufficient commercial quantities, in compliance with
regulatory requirements and at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental
regulation in connection with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must
ensure that all of the processes, methods and equipment are compliant with cGMP for drugs on an ongoing basis, as mandated by the FDA
and other regulatory authorities, and conduct extensive audits of vendors, contract laboratories and suppliers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract
Research Organizations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
outsource certain preclinical and clinical development activities to CROs, which in pre-clinical studies work according to cGMP and cGLP.
We believe our clinical CROs comply with guidelines from the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, which attempt to harmonize the FDA and the EMA regulations and guidelines. We create and
implement the drug development plans and, during the preclinical and clinical phases of development, manage the CROs according to the
specific requirements of the drug candidate under development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing
and Sales</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any marketing or sales capabilities. We intend to license to, or enter into strategic alliances with, larger companies
in the pharmaceutical business, which are equipped to market and/or sell our products, if any, through their well-developed marketing
capabilities and distribution networks. We intend to out-license some or all of our worldwide patent rights to more than one party to
achieve the fullest development, marketing and distribution of any products we develop.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how,
to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy
is to seek to protect our proprietary position by, among other filing U.S. and foreign patent applications related to our proprietary
technology, inventions and improvements that we believe are important to the development of our business. We also rely on trade secrets,
know-how and continuing technological innovation to develop and maintain our proprietary position.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 30, 2023, we owned or exclusively licensed (from Leiden University) 18 patent families that, collectively, contain approximately
209 issued patents and pending patent applications in various countries around the world relating to our two clinical candidates, Piclidenoson
and Namodenoson, and our preclinical candidate, CF602. Patents related to our drug candidates may provide future competitive advantages
by providing exclusivity related to the composition of matter, formulation and method of administration of the applicable compounds and
could materially improve their value. The patent positions for our leading drug candidates are described below. In addition, we filed
a patent application which is currently pending in various countries around the world concerning the use of cannabinoids for treatment
of conditions associated with elevated expression of the A<sub>3</sub> adenosine receptor.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to our product candidates, we currently own patents and/or have patent applications pending in several countries around the world
for the following families of patents:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A3AR
    ligands to treat viral diseases - a family of patents which pertain to use of substances that bind to the A3AR for the treatment
    of viral diseases, such as AIDS and hepatitis, and which inhibit viral replication. Such patents were granted in the United States,
    in Europe (by the EPO and validated in France, Germany, Italy, Switzerland and the United Kingdom), Australia, China, Israel, Japan,
    Singapore, Canada and Hong Kong. These patents have a filing date of January 1, 2002 and a priority date of January 16, 2001 and
    expired in January 2022, other than the U.S. patent that will expire in 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A3AR
    ligands to treat RA - a patent which pertains to the use of A3AR agonists for the treatment of inflammatory arthritis, in particular
    rheumatoid arthritis. This patent was granted in the United States and is set to expire in 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">A3AR
as a predictive and follow up biomarker - a family of patents and patent applications which pertain to a method of identifying inflammation,
determining its severity, and determining and monitoring the efficacy of the anti-inflammatory treatment by determining the level of
A3AR expression in white blood cells as a biological marker for inflammation. These patents were granted in the United States, Europe
(by the EPO and validated in France, Germany, Italy, Spain, Switzerland and the United Kingdom), Australia, Israel, Japan, China, Mexico
and Canada. The patents are set to expire in 2025. There is a patent application pending in Brazil that was refused and the refusal may
be appealed until September 2025. Each of the patents and the patent application has a filing date of November 30, 2005 and a priority
date of December 2, 2004.&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
    dose to protect from psoriasis - a family of patents and patent applications which pertains to the use of a specific dose level of
    Piclidenoson (total daily dose of 4.0 mg) for the treatment of psoriasis. Such a patent was granted in Israel, Japan, the United
    States, South Korea and Europe (by the EPO and validated in in Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands,
    Spain, Sweden, Switzerland and the United Kingdom). The patent is set to expire in 2030, and in 2031 in the U.S. There is a patent
    application pending in India with a filing date of September 6, 2010 and a priority date of September 6, 2009.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Piclidenoson
    method of synthesis - a family of patents which pertain to the method for producing Piclidenoson. Such patents were granted in the
    United States, India, China, Japan, Israel and Europe (by the EPO and validated in Austria, Belgium, Denmark, Finland, France, Germany,
    Greece, Hungary, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey
    and the United Kingdom). These patents are set to expire in 2028 and in 2031 in the U.S. Each patent has a filing date of March 13,
    2008 and a priority date of March 14, 2007.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Osteoarthritis
    (OA) indication - a family of patents and patent applications which pertain to the use of A3AR agonists for the treatment of OA.
    Such patents were granted in Europe (by the EPO and validated in Austria, Belgium, Denmark, France, Germany, Italy, Spain, Sweden,
    Switzerland, Netherlands and the United Kingdom), U.S., Australia, Canada, South Korea, China, Israel, Japan and Mexico. The patents
    are set to expire in 2026. A patent application is pending in Brazil. These patents and patent applications have a filing date of
    November 29, 2006 and a priority date of November 30, 2005.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liver
    protection- a family of patents which pertains to the use of A3AR agonists for increasing liver cell division, intended to induce
    liver regeneration following injury or surgery. Such patents were granted in China, Israel, Japan, U.S. and Europe (by the EPO and
    validated in Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom
    and Turkey). Each patent in this family has a filing date of October 22, 2008 and a priority date of October 15, 2007.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erectile
    dysfunction - a family of patents and patent applications which pertain to treatment of erectile dysfunction. This family includes
    granted patents in the United States, Australia, China, Hong Kong, Canada, South Korea, Israel, Mexico and Japan and patent applications
    in Brazil and Europe. The patents and patent applications have a filing date of August 8, 2013 with priority dates of August 8, 2012
    and November 12, 2012.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAR
    T induced cytokine release syndrome - a family of patent applications which pertains to the use of A3AR ligands for managing cytokine
    release syndrome. This family includes patent applications in Israel and in the U.S., EP and HK claiming priority from this Israeli
    application. The US, EP and HK patent applications have a filing date of September 16, 2018 and the Israeli patent application has
    a filing date of September 17, 2017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAFLD/NASH
    - a family of patents and patent applications which pertain to the use of A3AR ligands for treatment of ectopic fat accumulation.
    This family includes granted patents in U.S., Israel, Europe (by the EPO and validated in Austria, Belgium, Bulgaria, Croatia, Czechia,
    Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, North Macedonia,
    Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom and Turkey), South Korea,
    Hong Kong, China, Japan and Mexico, and patent applications in Brazil and Canada. The patent applications have a filing date of November
    22, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obesity
    - a family of patent applications which pertains to the use of A3AR ligand for reducing level of adipocytes and specifically, for
    treating obesity. This family includes patent applications in Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, Korea
    U.S. and Hong Kong. These patent applications have a filing date of January 6, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cannabinoids
    - a family of patent applications pertaining to the use of cannabinoids for treating conditions and diseases that involve elevated
    expression of the A3AR. This family includes a patent application in Israel and in Australia, Brazil, Canada, China, Eurasia, Europe,
    India, Japan, Mexico, Korea, Singapore, South Africa, Thailand, and the U.S. claiming priority from this Israeli application. These
    patent applications have a filing date of January 14, 2021 while the Israeli patent application has a filing date of January 16,
    2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PD-1/PD-L1
    - an Israeli patent application pertaining to the use of PD-1/PD-L1 axis inhibitor in combination with an A3AR. This Israeli patent
    application has a filing date of January 29, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
    of advanced cancer - a family of patent applications that makes use of A3AR ligands, particularly Namodenoson, for the treatment
    of advanced solid cancer, including advanced liver cancer. This family includes patent applications in the US, Australia, Brazil,
    Canada, Turkey, Japan, South Korea and Mexico. The US application was filed on December 28, 2022 claiming priority from a provisional
    application that was filed on December 29, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
    of joint inflammation __ an Israeli patent application that makes use of A3AR ligands for the local treatment of articular arthritis.
    This patent application was filed on January 9, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
    of psoriasis __ an Israeli patent application that makes use of A3AR ligands for the treatment of psoriasis. This patent application
    was filed on June 29, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
    of pancreatic cancer __ an Israeli patent application that makes use of A3AR ligands for the treatment of pancreatic cancer, including
    advanced forms. This patent application was filed on January 23, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently hold an exclusive license from Leiden University of the Netherlands to a family of patents and patent applications that relate
to the allosteric modulators of the A3AR, which includes the allosteric modulator CF602. This exclusive license relates to patents that
were granted in the United States, China, Japan, South Korea, India and in Europe (validated in, Austria, Belgium, Denmark, France, Germany,
Italy, the Netherlands, Spain, Sweden, Switzerland and United Kingdom). These granted patents are set to expire in 2028.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our owned and licensed patents provide broad and comprehensive coverage of our technology, and we intend to aggressively
enforce our intellectual property rights if necessary to preserve such rights and to gain the benefit of our investment. However, as
a result of the termination of the NIH license agreement between Can-Fite and NIH in June 2015 due to patent expiration, we no longer
hold rights to a family of composition of matter patents relating to Piclidenoson and Namodenoson that were licensed from NIH. Nevertheless,
because Piclidenoson or Namodenoson may be a NCE following approval of an NDA, we, if we are the first applicant to obtain NDA approval,
may be entitled to five years of data exclusivity in the United States with respect to such NCEs. Analogous data and market exclusivity
provisions, of varying duration, may be available in Europe and other foreign jurisdictions. However, we cannot be certain that we will
be the first applicant to obtain an FDA approval for any indication of Piclidenoson or Namodenoson and we cannot be certain that we will
be entitled to NCE exclusivity. In addition, we have discontinued the prosecution of a family of pending patent applications under joint
ownership of Can-Fite and NIH pertaining to the use of A3AR agonists for the treatment of uveitis. Such diminution of our proprietary
position could have a material adverse effect on our business, results of operation and financial condition.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. Our ability to maintain
and solidify our proprietary position for our technology will depend on our success in obtaining effective claims and enforcing those
claims once granted. We do not know whether any of our patent applications or those patent applications that we license will result in
the issuance of any patents. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed,
circumvented or found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products
or the length of term of patent protection that we may have for our products. Neither we nor our licensors can be certain that we were
the first to invent the inventions claimed in our owned or licensed patents or patent applications. In addition, our competitors may
independently develop similar technologies or duplicate any technology developed by us, and the rights granted under any issued patents
may not provide us with any meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required
for development, testing and regulatory review of a potential product, before any of our products can be commercialized, any related
patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trade
Secrets</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek
to protect our proprietary technology and processes, in part, by confidentiality agreements and assignment of inventions agreements with
our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data
and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology
systems. While we have confidence in these individuals, organizations and systems, such agreements or security measures may be breached,
and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered
by competitors or others.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Board</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek advice from our Scientific Advisory Board on scientific and medical matters generally. We call for Scientific Advisory Board meetings
on an as-needed basis. The following table sets forth certain information with respect to our Scientific Advisory Board member.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position/Institutional
    Affiliation</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nabil
    Hanna, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
    Chief Science Officer of Biogen-Idec</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Advisory Board</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Clinical Advisory Board, which consists of six members, an oncologist, dermatologist, and three hepatologists, who play an active role
in consulting with us with respect to clinical drug development. We call for Clinical Advisory Board meetings on an as-needed basis.
The following table sets forth certain information with respect to our Clinical Advisory Board members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position/Institutional
    Affiliation</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Kim Papp</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head,
    Probity Medical Research Inc., Ontario, Canada</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Salomon Stemmer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Davidoff
    Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Scott Friedman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dean
    for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Arun Sanyal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor
    of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Rifaat Safadi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head
    of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center and Professor of Internal
    Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hadassah University in Israel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Stephen Harrison</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry is characterized by rapidly evolving technology, intense competition and a highly risky, costly and lengthy research
and development process. Adequate protection of intellectual property, successful product development, adequate funding and retention
of skilled, experienced and professional personnel are among the many factors critical to success in the pharmaceutical industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology platform is based on the finding that the A3AR is highly expressed in pathological cells, such as various tumor cell types
and inflammatory cells. We believe that targeting the A3AR with synthetic and highly selective A3AR agonists, such as Piclidenoson and
Namodenoson, and allosteric modulators, such as CF602, induces anti-cancer and anti-inflammatory effects. Currently, our drug candidates,
Piclidenoson, Namodenoson, and CF602 are being developed to treat autoimmune inflammatory indications, oncology, and liver diseases as
well as erectile dysfunction, including but not limited to psoriasis, HCC, and NASH. Preclinical studies have also indicated that our
drug candidates have the potential to treat additional inflammatory diseases, such as erectile dysfunction, Crohn&#8217;s disease, oncological
diseases and viral diseases, such as the JC virus, and obesity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the competition, however, we believe that our drug candidates have unique characteristics and advantages over certain drugs currently
available on the market and under development to treat these indications. We believe that our pipeline of drug candidates has exhibited
a potential for therapeutic success with respect to the treatment of autoimmune-inflammatory, oncological and liver diseases. We believe
that targeting the A3AR with synthetic and highly selective A3AR agonists, such as Piclidenoson and Namodenoson, and allosteric modulators,
such as CF602, induces anti-cancer and anti-inflammatory effects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the characteristics of Piclidenoson, as exhibited in our clinical studies to date, including its good safety profile, clinical
activity, simple and less frequent delivery through oral administration and its low cost of production, position it well against the
competition in the autoimmune-inflammatory markets, including the psoriasis markets, where treatments, when available, often include
injectable drugs, many of which can be highly toxic, expensive and not always effective. For example, while TNF inhibitor therapies transformed
the treatment for many patients, a substantial percentage of patients (40% to 60%) do not respond to either a DMARD or biologic therapies
(Simsek, 2010).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
pharmacology studies in different experimental animal models revealed that Piclidenoson acts as a DMARD, which, when coupled with its
good safety profile, makes it competitive in the psoriasis market. Our recent findings suggest that Piclidenoson might offer a superior
efficacy and tolerability profile, allowing patients to stay on drug longer and potentially leading to an improvement in response rate.
Like Piclidenoson, Namodenoson has a good safety profile, is orally administered and has a low cost of production, which we believe positions
it well in the HCC market, where only a handful of drugs have been approved by the FDA.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our human clinical data suggests that A3AR may be a biological marker in that high A3AR expression prior to treatment has been
predictive of good patient response to our drug treatment. In fact, as a result of our research we have developed a simple blood assay
to test for A3AR expression as a predictive biological marker. We hold a patent with respect to the intellectual property related to
such assay and are currently analyzing A3AR expression levels in our Phase III psoriasis trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the other hand, other drugs on the market, new drugs under development (including drugs that are in more advanced stages of development
in comparison to our drug pipeline) and additional drugs that were originally intended for other purposes, but were found effective for
purposes targeted by us, may all be competitive to the current drug candidates in our pipeline. In fact, some of these drugs are well
established and accepted among patients and physicians in their respective markets, are orally bioavailable, can be efficiently produced
and marketed, and are relatively safe. Moreover, other companies of various sizes engage in activities similar to ours. Most, if not
all, of our competitors have substantially greater financial and other resources available to them. Competitors include companies with
marketed products and/or an advanced research and development pipeline. The major competitors in the psoriasis therapeutic field include
Amgen, J&amp;J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers, UCB, and more. Competitors in the HCC field include companies such
as Bayer, Exelixis, Merck, Roche, Eisai, Astrazenca, Beigene, Novartis, and Bristol-Myers. Competitors in the NASH field include companies
such as Gilead, Genfit, Galmed, Intercept, Madrigal, Akero, 89Bio, Viking, and Terns. Competitors in the erectile dysfunction field include
Pfizer, Eli Lilly, Bayer, and Petros Pharmaceuticals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
several companies have reported the commencement of research projects related to the A3AR. Such companies include CV Therapeutics Inc.
(which was acquired by Gilead), King Pharmaceuticals R&amp;D Inv. (which was acquired by Pfizer), Hoechst Marion Roussel Inc., Novo Nordisk
A/S and Inotek Pharmaceuticals. However, to the best of our knowledge, there is no approved drug currently on the market which is similar
to our A3AR agonists, nor are we aware of any allosteric modulator in the A3AR product pipeline similar to our allosteric modulator with
respect to chemical profile and mechanism of action.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Piclidenoson
for the Treatment of Psoriasis</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Psoriasis
is a skin condition that affects 2% to 3% of the general population according to the National Psoriasis Foundation. The disease is manifested
by scaly plaques on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. Topical
agents are typically used for mild disease, phototherapy for moderate disease, and systemic agents for severe disease. For moderate to
severe cases, systemic biologic drugs, delivered via intravenous injection, or IV, have dominated the market. According to the National
Psoriasis Foundation, common side effects of biologics include respiratory infections, flu-like symptoms, and injection site reactions
while rare side effects include serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves
of the eyes, blood disorders, and certain types of cancer. We believe a significant need remains for novel oral and safe drugs for patients
who do not respond to existing therapies or for whom these therapies are unsuitable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psoriasis therapeutic market is dominated by biological drugs that are primarily administered via IV and have potential side effects.
In January 2015, the FDA approved Cosentyx (secukinumab) by Novartis. In March 2016, the FDA approved Taltz (ixekizumab) by Eli Lilly.
In April 2019, the FDA approved Skyrizi (risankizumab) by AbbVie. An oral small molecule inhibitor of phosphodiesterase 4, Otezla (Amgen),
has gained sizable market share as a result in part due to its convenience of oral dose and comparable efficacy to the biologic drugs.
Recently, a new oral inhibitor of TYK2 called SOTYKTU (Bristol) received U.S. FDA approval in September 2022. The psoriasis drug market
is forecast to grow to $32 billion by 2026, according to estimate by Evaluate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current common treatments for psoriasis include topical and systemic
drugs, steroids, immunosuppressive drugs such as Cyclosporine A by Novartis, MTX and biological drugs. Biological drugs, such as Enbrel
(etanercept) by Amgen and Pfizer, Remicade (infliximab) by Centocor, Humira (adalimumab) by Abbvie, Stelara (ustekinumab) by Janssen,
Otezla (aprelimast) byAmgen, Cosentyx (secukinumab) by Novartis and Taltz (ixekizumab) by Eli Lilly have significant side effects, are
expensive and patients are often not responsive. For example, some of these drugs have received an FDA &#8220;black box&#8221; warning
for increased risk of cancer in children and adolescents and risk of infection with Legionella and Listeria bacteria.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Namodenoson
for the Treatment of HCC</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the American Cancer Society, HCC is the fifth most common form of cancer death in the U.S., the most common form of liver cancer in
adults and the third most common cause of cancer-related mortality worldwide, particularly in Asia. According to the American Cancer
Society, more than 800,000 people are diagnosed with liver cancer each year throughout the world and more than 700,000 persons die from
liver cancer each year. Despite several new approvals in the HCC market, including immunotherapy agents, this remains a significant unmet
medical need where five year survival rates remain less than 20%. According to iHealthcareAnalyst, the HCC drug market is expected to
reach $6.3 billion by 2029.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
therapies are in advanced clinical development for HCC. Some drugs under development act as a single agent and some act in combination
with Nexavar or approved checkpoint inhibitors pembrolizumab, atezolizumab, and/or nivolumab. Moreover, some are first line treatments
while others are second line treatments. In addition, many existing approaches are used in the treatment of unresectable liver cancer,
including alcohol injection, radiofrequency ablation, chemoembolization, cryoablation and radiation therapy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Namodenoson
for the Treatment of NASH</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rates
of NAFLD and NASH are increasing in the United States in concert with increasing rates of obesity and diabetes. In fact, NASH is now
the third leading cause of liver transplant in the United States. It is estimated that 17-33% of Americans have fatty liver, with approximately
one-third going on to develop NASH. NASH is believed to affect 2-5% of adult Americans. Despite the progression of several interesting
clinical-stage candidates by companies such as Gilead, Genfit, Madrigal, Conatus, Galmed, Intercept, Akero, 89Bio, Viking, and Terns
as well as others, there are currently no FDA approved treatment options for NASH.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2019, Intercept Pharmaceuticals announced its Phase 3 results of their OCA drug for the treatment of liver fibrosis due to NASH
and Intercept reported that it submitted an NDA to the FDA seeking accelerated approval of OCA for NASH and an MAA to the EMA. In June
2020, the FDA issued a complete response letter, or the CRL, regarding the NDA of OCA for the treatment of NASH. Recently, Intercept
reported that it is in discussions with the FDA with respect to the potential resubmission of its NDA. If approved, OCA will become the
first approved NASH drug. In December 2022, Madrigal Pharmaceuticals reported positive results from its Phase 3 MAESTRO-NASH program
with oral, thyroid hormone receptor-&#946; agonist, resmetirom. Madrigal plans to seek U.S. FDA approval with resmetirom for the treatment
of NASH in 2023. By 2028, Vantage Market Research estimates the addressable pharmaceutical market for NASH will reach $21.9 billion in
size.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CF602
for the Treatment of Erectile Dysfunction</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Massachusetts Male Aging Study in 1994, 52% of the respondents between the ages of 40 and 70 years old reported some degree of
erectile dysfunction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
most popular class of drug to treat erectile dysfunction is the phosphodiesterase type 5, or PDE5, inhibitors. These drugs block the
degradative action of cyclic guanosine monophosphate, or GMP, specific PDE5 on cyclic GMP in the smooth muscle cells lining the blood
vessels supplying the corpus cavernosum of the penis. An erection is caused by increased blood flow into the penis resulting from the
relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide from nerve
terminals and endothelial cells, which stimulates the synthesis of cyclic GMP in smooth muscle cells. The inhibition of PDE5 enhances
erectile function by increasing the concentration of cyclic GMP in the corpus cavernosum and pulmonary arteries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfortunately,
the systemic side effects of PDE5 inhibitors include a decrease in sitting blood pressure. This has resulted in warnings and precautions
and contraindications of use in patients already taking antihypertensive agents like nitrates or alpha-blockers. A study published in
the American Journal of Medicine (Selvin E., et al., 2007) found that persons with a history of heart disease, hypertension, and diabetes
had a higher probability of impotence. A second study published in the same journal (Shah NP., et al, 2015) notes that vascular erectile
dysfunction is a powerful marker of increased cardiovascular risk. We believe a significant market opportunity exists targeting erectile
dysfunction patients contraindicated for use of the market leading products, Viagra and Cialis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
Research Future estimates the value of the erectile dysfunction therapeutic market to reach approximately $6.1 billion by 2030.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insurance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain insurance for our offices and laboratory in Petah-Tikva, Israel. Our insurance program covers approximately $0.85 million of
equipment and lease improvements against risk of loss. In addition, we maintain the following insurance: employer liability with coverage
of approximately $5.7 million; third party liability with coverage of approximately $0.87 million; fire insurance coverage of approximately
$0.43 million; natural disaster coverage of approximately $1.3 million; all risk coverage of approximately $0.02 million for electronic
equipment and machinery insurance for laboratory refrigerators; and directors&#8217; and officers&#8217; liability insurance with coverage
of $5.0 million per claim and $5.0 million in the aggregate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain worldwide product and clinical trial liability insurance with coverage of approximately $5 million with respect to the
Piclidenoson and Namodenoson drugs used in clinical trials. We also procure additional insurance for each specific clinical trial which
covers a certain number of trial participants and which varies based on the particular clinical trial. Certain of such policies are based
on the Declaration of Helsinki, which is a set of ethical principles regarding human experimentation developed for the medical community
by the World Medical Association, and certain protocols of the Israeli Ministry of Health.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
procure cargo marine coverage when we ship substances for our clinical studies. Such insurance is custom-fit to the special requirements
of the applicable shipment, such as temperature and/or climate sensitivity. If required, we ensure the substances to the extent they
are stored in central depots and at clinical sites.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our insurance policies are adequate and customary for a business of our kind. However, because of the nature of our business,
we cannot assure you that we will be able to maintain insurance on a commercially reasonable basis or at all, or that any future claims
will not exceed our insurance coverage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater
discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup
of contaminated sites. We believe that our business, operations and facilities are being operated in compliance in all material respects
with applicable environmental and health and safety laws and regulations. Our laboratory personnel in Israel have ongoing communication
with the Israeli Ministry of Environmental Protection in order to verify compliance with relevant instructions and regulations. In addition,
all of our laboratory personnel participate in instruction on the proper handling of chemicals, including hazardous substances before
commencing employment, and during the course of their employment with us. In addition, all information with respect to any chemical substance
that we use is filed and stored as a Material Safety Data Sheet, as required by applicable environmental regulations. Based on information
currently available to us, we do not expect environmental costs and contingencies to have a material adverse effect on us. The operation
of our testing facilities, however, entails risks in these areas. Significant expenditures could be required in the future if these facilities
are required to comply with new or more stringent environmental or health and safety laws, regulations or requirements. See &#8220;Item
4. Information on the Company&#8212;B. Business Overview&#8212;Government Regulation and Funding&#8212;Israel Ministry of the Environment&#8212;Toxin
Permit.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation and Funding</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a highly controlled regulatory environment. Stringent regulations establish requirements relating to analytical, toxicological
and clinical standards and protocols in respect of the testing of pharmaceuticals. Regulations also cover research, development, manufacturing
and reporting procedures, both pre- and post-approval. In many markets, especially in Europe, marketing and pricing strategies are subject
to national legislation or administrative practices that include requirements to demonstrate not only the quality, safety and efficacy
of a new product, but also its cost-effectiveness relating to other treatment options. Failure to comply with regulations can result
in stringent sanctions, including product recalls, withdrawal of approvals, seizure of products and criminal prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through preclinical studies and
clinical trials that our product candidates are safe and effective. Historically, the results from preclinical studies and early clinical
trials often have not accurately predicted results of later clinical trials. In addition, a number of pharmaceutical products have shown
promising results in clinical trials but subsequently failed to establish sufficient safety and efficacy results to obtain necessary
regulatory approvals. We have incurred, and will continue to incur substantial expense for and devote a significant amount of time to,
preclinical studies and clinical trials. Many factors can delay the commencement and rate of completion of clinical trials, including
the inability to recruit patients at the expected rate, the inability to follow patients adequately after treatment, the failure to manufacture
sufficient quantities of materials used for clinical trials, and the emergence of unforeseen safety issues and governmental and regulatory
delays. If a product candidate fails to demonstrate safety and efficacy in clinical trials, this failure may delay development of other
product candidates and hinder our ability to conduct related preclinical studies and clinical trials. Additionally, as a result of these
failures, we may also be unable to obtain additional financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
authorities in all major markets require that a new pharmaceutical product be approved or exempted from approval before it is marketed,
and have established high standards for technical appraisal which can result in an expensive and lengthy approval process. The time to
obtain approval varies by country and some products are never approved. The lengthy process of conducting clinical trials, seeking approval
and subsequent compliance with applicable statutes and regulations, if approval is obtained, are very costly and require the expenditure
of substantial resources. These regulatory requirements impact our operations and differ from one country to another, so that securing
the applicable regulatory approvals of one country does not imply the approval of another country. The approval procedures involve high
costs and are manpower intensive, usually extend over many years and require highly skilled and professional resources.<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the United States, European Union and Israeli regulatory processes follow below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>United
States</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act (FDCA), as amended, and the regulations
promulgated thereunder, and other federal and state statutes and regulations govern, among other things, the safety and effectiveness
standards for our products and the raw materials and components used in the production of, testing, manufacture, labeling, storage, record
keeping, approval, advertising and promotion of our products on a product-by-product basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with the applicable requirements at any time during the product development process, including preclinical testing,
clinical testing, the approval process or post-approval process, may subject an applicant to delays in the conduct of clinical trials,
regulatory review and approval, and/or administrative or judicial sanctions. These sanctions may include, but are not limited to, the
FDA&#8217;s refusal to allow an applicant to proceed with clinical testing, refusal to approve pending applications, license suspension
or revocation, withdrawal of an approval, warning letters, adverse publicity, customer notification, product recalls, product seizures,
refusal to grant export or import approval, total or partial suspension of production or distribution, consent decrees, injunctions,
fines, and civil or criminal investigations and penalties brought by the FDA or the U.S. Department of Justice, or other governmental
entities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
steps usually required to be taken before a new drug may be marketed in the U.S. generally include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices
    regulation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant
    changes are made;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent Institutional Review Board, or IRB, or ethics committee at each treatment site before the trial is commenced;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well controlled human clinical trials to establish the safety, purity and potency of the proposed drug product candidate
    for its intended purpose;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    of data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical
    development and proposed labeling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
    of and submission to the FDA of a New Drug Application, or NDA, after completion of all pivotal clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA Advisory Committee review, if applicable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced
    to assess compliance with cGMP standards and to assure that the facilities, methods and controls are adequate to preserve the drug
    product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good
    Clinical Practices, or GCP;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GCP requirement sand the integrity
    of clinical data in support of the NDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    of user fees and securing FDA approval of the NDA for the proposed indication for use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including risk evaluation and mitigation strategies, or REMS, and any post-approval studies
    required by the FDA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include <i>in vitro</i> and <i>in vivo</i> evaluation of the product candidate, its chemistry, formulation and stability, and animal
studies to assess potential safety and efficacy. Certain preclinical tests must be conducted in compliance with good laboratory practice,
or GLP, regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, requiring them to be replicated.
After laboratory analysis and preclinical testing, a sponsor files an IND application including the results of the preclinical testing,
manufacturing information and analytical data, with FDA. An IND is a request for authorization from FDA to administer an investigational
new drug or biological product to humans to begin human testing. An IND becomes effective 30 days after FDA receives it, unless the FDA
notifies the sponsor that the clinical trial is subject to a clinical hold. FDA also may impose a clinical hold at any time during a
clinical trial. A sponsor may not proceed with a clinical trial that is subject to a clinical hold until the clinical hold has been lifted.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated
under the supervision of a qualified principal investigator in accordance with CGP requirements. Clinical studies are conducted under
protocols detailing, among other things, the objectives of the study, what types of patients may enter the study, schedules of tests
and procedures, drugs, dosages, and length of study, as well as the parameters to be used in monitoring safety, and the efficacy criteria
to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the
IND process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial
under an IND. If a clinical trial outside the U.S. is not conducted under an IND, the sponsor may submit data from the clinical trial
to the FDA in support of an NDA so long as the clinical trial is conducted consistent with the spirit of GCP and in compliance with an
international guideline for the ethical conduct of clinical research known as the Declaration of Helsinki and/or the laws and regulations
of the country or countries in which the clinical trial is performed, whichever provides the greater protection to the participants in
the clinical trial.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IRB, either centrally or individually, must also review each clinical trial at each institution at which the clinical trial will be conducted.
The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects,
the possible liability of the institution, and, where appropriate, the protection of privacy of the human subjects. An IRB must operate
in compliance with the FDA regulations. The FDA, IRB, or the clinical trial sponsor, or the principal investigator may suspend or discontinue
a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with
FDA requirements or the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive
GCP rules and the requirements for informed consent. Additionally, some clinical studies are overseen by an independent group of qualified
experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group recommends whether
or not a trial may move forward at designated check points based on access to certain data from the study. The clinical study sponsor
may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Typically,
clinical trials are conducted in three sequential phases which are subject to numerous laws and regulatory requirements, including good
clinical practice requirements, or GCP, which include adequate monitoring, reporting, record keeping and informed consent. In Phase I,
small clinical trials are conducted, typically in healthy human volunteers, to determine the safety and proper dose ranges of product
candidates. In Phase II, clinical trials are generally conducted in patients with the targeted disease or condition to identify possible
adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose
tolerance and optimate dosage. Multiple Phase II clinical trials may be conducted by the sponsor to obtain information prior to beginning
larger and more costly Phase III clinical trials. In Phase III, clinical trials are conducted in an expanded population of patients with
the targeted disease or condition to demonstrate that a dose range of the product candidate is potentially effective and has an acceptable
safety profile. Phase III trials are designed to provide sufficient data for the statistically valid evidence of safety and efficacy
to support approval, and if approved, the basis for product labeling. Post-approval studies, sometimes referred to as Phase IV trials,
may be conducted, voluntarily or as a condition of approval, after initial product approval to obtain additional information about the
drugs risks and benefits in patients with the targeted disease or condition. The time and expense required for us to perform this clinical
testing can vary and is substantial. We cannot be certain that we will successfully complete Phase I, Phase II or Phase III testing of
our product candidates within any specific time period, if at all. Furthermore, the FDA, the Institutional Review Board responsible for
approving and monitoring the clinical trials at a given site, the Data Safety Monitoring Board, where one is used, or we may suspend
the clinical trials at any time on various grounds, including a finding that subjects or patients are exposed to unacceptable health
risk.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the clinical data from these clinical trials (Phases I, II and III) are deemed to support the safety and effectiveness of the candidate
product for its intended use, then we may proceed to seek to file with the FDA an NDA seeking approval to market a new drug for one or
more specified intended uses. We have not completed our clinical trials for any candidate product for any intended use and therefore,
we cannot ascertain whether the clinical data will support and justify filing an NDA. Nevertheless, if and when we are able to ascertain
that the clinical data supports and justifies filing an NDA, we intend to make such appropriate filings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the NDA is to provide the FDA with sufficient information so that it can assess whether it ought to approve the candidate
product for marketing in the U.S. for specific intended uses. Under the Prescription Drug User Fee Act, or PDUFA, the submission of an
NDA requires the payment of substantial user fees, which the FDA adjusts on an annual basis, unless a waiver is granted. Moreover, no
user fees are assessed on NDAs for products designated as orphan drugs, unless the product as a non-orphan indication for use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NDA normally contains, among other things, sections describing the chemistry, manufacturing, and controls, non-clinical pharmacology
and toxicology, human pharmacokinetics and bioavailability, microbiology, the results of the clinical trials, and the proposed labeling
which contains, among other things, the intended uses of the candidate product. FDA reviews the information submitted under the NDA to
determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is compliant
with cGMP requirements to assure and preserve the product&#8217;s identity, strength, quality and purity. Before accepting an NDA for
filing, FDA conducts a preliminary review of the NDA, within 60 days of submission, to determine whether it is sufficiently complete
to permit substantive review. Generally, under PDUFA guidelines, FDA has a goal of ten months from the date of acceptance of a standard
NDA for a new molecular entity to review and act on the submission. The FDA does not always meet its PDUFA goal dates for standard and
priority applications. The review process may often be significantly extended by FDA requests for additional information or clarification.
The review process and the PDUFA goal date may be extended by three months if the FDA requests, or the applicant otherwise provides additional
information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal
date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured.
The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP
requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving
an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
cannot take any action to market any new drug or biologic product in the United States until an appropriate marketing application has
been approved by the FDA. The FDA has substantial discretion over the approval process and may disagree with a manufacturer&#8217;s interpretation
of the data submitted. The process may be significantly extended by requests for additional information or clarification regarding information
already provided. As part of this review, the FDA may refer the application to an appropriate advisory committee. An advisory committee
is a panel comprised of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides
a recommendation as to whether an application should be approved and under what conditions. FDA is not bound by the recommendations of
an advisory committee; however, it takes into consideration the advisory committee&#8217;s recommendations when making decisions., typically
a panel of clinicians. As part of the approval process, FDA determines whether the manufacturer&#8217;s facilities and manufacturing
processes are in compliance with cGMP requirements and sufficient to ensure consistent production of the product within required specifications.
Prior to approving an NDA, FDA also may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of its evaluation of an NDA, FDA will issue an approval letter or a Complete Response Letter, or CRL. An approval letter
authorizes commercialization of the drug for specified indications. A CRL informs the manufacturer that the review cycle for an application
is complete and that the application is not ready for approval in its present form. A CRL typically identifies specific deficiencies
in the NDA that may require additional clinical data or other significant requirements related to clinical trials or manufacturing. If
FDA issues a CRL, the manufacturer must resubmit the NDA with all deficiencies addressed or withdraw the NDA. Even if all requested data
and information are submitted, FDA ultimately may not approve the NDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction
of these and other regulatory requirements typically takes several years, and the actual time required may vary substantially based upon
the type, complexity and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable
period of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve
any of our products on a timely basis, if at all. Success in preclinical or early stage clinical trials does not assure success in later-stage
clinical trials. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications or
uses and these limitations may adversely affect the commercial viability of the product. Delays in obtaining, or failures to obtain regulatory
approvals, would have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA approves a new product, it may limit the approved indications for use of the product. Additionally, the FDA may call for further
clinical trials (i.e., Phase IV trials) and require additional data on safety and effectiveness. FDA also may impose other conditions
on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, designed to ensure the safe use of the
drug. A REMS could include, among other things, medication guides, physician communication plans, restricted distribution methods, and
patient registries. Any of these limitations on approval or marketing could restrict our ability to successfully commercialize products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also required to gain separate approval for the use of an approved product as a treatment for indications other than those initially
approved. In addition, side effects or adverse events that are reported during clinical trials can delay, impede or prevent marketing
approval. Similarly, adverse events that are reported after marketing approval can result in additional limitations being placed on the
product&#8217;s use and, potentially, withdrawal of the product from the market. Any adverse event, either before or after marketing
approval, can result in product liability claims against us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an alternate path for FDA approval of new indications or new formulations of previously-approved products, a company may file a Section
505(b)(2) NDA, instead of a &#8220;stand-alone&#8221; or &#8220;full&#8221; NDA. Section 505(b)(2) of the FDCA, was enacted as part of
the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Amendments. Section 505(b)(2)
permits the submission of an NDA where at least some of the information required for approval comes from studies not conducted by or
for the applicant and for which the applicant has not obtained a right of reference. Some examples of products that may be allowed to
follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication.
The Hatch-Waxman Amendments permit the applicant to rely upon certain published nonclinical or clinical studies conducted for an approved
product or the FDA&#8217;s conclusions from prior review of such studies. The FDA may require companies to perform additional studies
or measurements to support any changes from the approved product. The FDA may then approve the new product for all or some of the labeled
indications for which the reference product has been approved, as well as for any new indication supported by the NDA. While references
to nonclinical and clinical data not generated by the applicant or for which the applicant does not have a right of reference are allowed,
all development, process, stability, qualification and validation data related to the manufacturing and quality of the new product must
be included in an NDA submitted under Section 505(b)(2).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the Section 505(b)(2) applicant is relying on the FDA&#8217;s conclusions regarding studies conducted for an already
approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s
Orange Book publication. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii)
the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after
patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. The Section 505(b)(2) application
also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed
in the Orange Book for the reference product has expired. Thus, the Section 505(b)(2) applicant may invest a significant amount of time
and expense in the development of its products only to be subject to significant delay and patent litigation before its products may
be commercialized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulating and auditing human clinical trials, the FDA regulates and inspects equipment, facilities, laboratories and processes
used in the manufacturing and testing of such products prior to providing approval to market a product. If, after receiving FDA approval,
we make a material change in manufacturing equipment, location or process, additional regulatory review and approval may be required.
We also must adhere to cGMP regulations and product-specific regulations enforced by the FDA through its facilities inspection program.
The FDA also conducts regular, periodic visits to re-inspect our equipment, facilities, laboratories and processes following the initial
approval. If, as a result of these inspections, the FDA determines that our equipment, facilities, laboratories or processes do not comply
with applicable FDA regulations and conditions of product approval, the FDA may seek civil, criminal or administrative sanctions and/or
remedies against us, including the suspension of our manufacturing operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have currently received no approvals to market our products from the FDA or other foreign regulators.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment
of a serious or life-threatening disease or condition, or in the event of an emergency. These programs are fast track designation, breakthrough
therapy designation and priority review designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
the FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products,
for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs
for such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate
review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available
if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective.
The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must
pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last
section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that
the designation is no longer supported by data emerging in the clinical trial process.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or FDASIA. This law established a new regulatory scheme
allowing for expedited review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough
therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease
or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA
may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development
process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review
process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an
efficient manner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide
a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents
a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased
effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented
enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new
subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and
to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Secretary of Health and Human Services may additionally authorize unapproved drugs and biologics to be marketed in the event an actual
or potential emergency has been designated by the U.S. government. After an emergency has been designated, the FDA may issue an Emergency
Use Authorization, or EUA, for the use of a specific product based on criteria established by the FDCA. An EUA is product specific and
is subject to specific conditions and restrictions. Once the emergency underlying the EUA ends, then the EUA terminates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to
comply with post-approval regulatory requirements, including any post-approval requirements that the FDA may have imposed as a condition
of approval. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety
and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and
certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject
to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including
cGMP regulations, which impose certain procedural and documentation requirements upon drug manufacturers. Accordingly, the sponsor and
its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain
compliance with cGMP regulations and other regulatory requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of
the product before it is released for distribution. If the product is subject to official release, the manufacturer must submit samples
of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the
manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some
products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity,
potency, and effectiveness of pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess
new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among
other things:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics
may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly
promoted off-label uses may be subject to significant liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Drug Designation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Orphan Drug Act, FDA may grant special status, or orphan designation, to a drug intended to treat a rare disease or condition,
which is a defined as a disease or condition that affects fewer than 200,000 individuals in the United States, or there is no reasonable
expectation that the sales of the product will offset the cost of developing and making the drug available in the United States. A request
for orphan drug designation must be filed before the NDA is filed. Following the grant of orphan designation, FDA will publicly disclose
the identity of the therapeutic drug candidate and its potential orphan use. Orphan designation does not shorten the duration of the
regulatory review and approval process. The fact that the FDA has designated a drug as an orphan drug for a particular intended use does
not mean that the drug has been approved for marketing. Only after an NDA has been approved by the FDA is marketing appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug candidate with orphan designation subsequently receives the first FDA approval for the disease or condition for which it has orphan
designation, the drug is entitled to a seven-year period of market exclusivity subject to certain exceptions (e.g., clinical superiority
of a subsequent product). This means that FDA may not approve another drug application authorizing another manufacturer to market the
same drug for the same indication for seven years. This does not preclude competitors from receiving approval of the same product that
has orphan exclusivity for a different indication or a different product for the same indication for which the orphan product has exclusivity.
The orphan designation of a drug also provides the sponsor with certain financial incentives including tax credit, waiver of PDUFA fees,
and access to certain grant funding for orphan products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2012, the FDA granted orphan drug status for the active moiety, or the part of the drug that is responsible for the physiological
or pharmacological action of the drug substance, of Namodenoson for the treatment of HCC. Subsequently, in October 2015, the EMA granted
Namodenoson orphan drug designation for the treatment of HCC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
U.S. Healthcare Laws and Compliance Requirements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
products distributed in the United States, we will also be subject to additional healthcare regulation and enforcement by the federal
government and the states in which we conduct our business. Applicable federal and state healthcare laws and regulations include the
following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal anti-kickback law, which governs federal healthcare programs (e.g., Medicare, Medicaid), makes it illegal to solicit, offer,
    receive or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription of
    a particular drug. Many states have similar laws that are not restricted to federal healthcare programs. A person or entity does
    not need to have actual knowledge of the federal anti-kickback statute or specific intent to violate it to have committed a violation;
    in addition, items or services resulting from a violation of the federal anti-kickback statute may constitute a false or fraudulent
    claim for purposes of the False Claims Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Ethics in Patient Referrals Act, commonly referred to as the Stark Law, and its corresponding regulations, prohibit physicians from
    referring patients for designated health services (including outpatient drugs) reimbursed under the Medicare or Medicaid programs
    to entities with which the physicians or their immediate family members have a financial relationship or an ownership interest, subject
    to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items
    or services provided to a referred beneficiary;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    and state false claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third
    party payers (including Medicare and Medicaid), claims for reimbursement, including claims for the sale of drugs or services, that
    are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services.
    If the government or a whistleblower were to allege that we violated these laws there could be a material adverse effect on us, including
    our stock price. Even an unsuccessful challenge could cause adverse publicity and be costly to respond to, which could have a materially
    adverse effect on our business, results of operations and financial condition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
    Insurance Portability and Accountability Act of 1996, imposes criminal and civil liability for executing a scheme to defraud any
    healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the
    privacy, security and transmission of individually identifiable health information. This statute also prohibits knowingly and willfully
    falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of
    or payment for healthcare benefits, items, or services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making
    any materially false statement in connection with the delivery of or payment for health care benefits, items or services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires specified manufacturers
    of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s
    Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS,
    information related to payments or other &#8220;transfers of value&#8221; made to physicians. All such reported information is publicly
    available; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state laws and regulations, such as state anti-kickback&#160;and false claims laws, may apply to sales or marketing arrangements
    and claims involving healthcare items or services reimbursed by non-governmental&#160;third-party&#160;payors, including private
    insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance
    guidelines and the relevant compliance guidance promulgated by the federal government.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
future business activities could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements
with third parties will comply with applicable laws and regulations will involve substantial costs. It is possible that governmental
authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other health care laws and regulations. A finding of liability under these laws can have significant adverse
financial implications for us and can result in payment of large penalties and possible exclusion from federal healthcare programs. We
will consult counsel concerning the potential application of these and other laws to our business and our sales, marketing and other
activities and will make good faith efforts to comply with them. However, given their broad reach and the increasing attention given
by law enforcement authorities, we cannot assure you that some of our activities will not be challenged or deemed to violate some of
these laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reimbursement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates in the United States may depend, in part, on the extent to which the costs of the product candidates may be
covered by third-party&#160;payers, such as government health programs, commercial insurance and managed health care organizations. These
third-party&#160;payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment
of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort.
The United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment&#160;programs,
including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment&#160;measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could
further limit our net revenue and results. If these third-party&#160;payers do not consider our product candidates to be cost-effective&#160;compared
to other available therapies, they may not cover our product candidates after approval as a benefit under their plans or, if they do,
the level of payment may not be sufficient to allow us to sell our product candidates on a profitable basis.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain
FDA, EMA or other comparable regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective.
A payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.
Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on
our investment in product development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a
reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness
of a particular product candidate to currently available therapies. The conduct of such studies could be expensive and result in delays
in our commercializing efforts. The EU provides options for its member states to restrict the range of drug products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states
may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of
the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but
monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become
very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries,
cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance
that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing
arrangements for any of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party
payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased
and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing
regulation may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which
we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Healthcare
Reform</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been and continue to be a number of significant legislative initiatives to contain healthcare costs. The
ACA was enacted in the United States in March 2010 and contains provisions that may reduce the profitability of drug products, including,
for example, increased rebates for drugs subject to the Medicaid Drug Rebate Program, extension of Medicaid rebates to Medicaid managed
care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share
of sales to federal health care programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions
to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013 and, due to subsequent legislative amendments to the
statute, will stay in effect through 2027, unless additional Congressional action is taken; however, pursuant to the CARES Act, and subsequent
legislation, these reductions were suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. In January 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers,
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These
new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on
customers for our drugs, if approved, and, accordingly, our financial operations.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products.
There have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce
the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. The FDA released a final rule
on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from
Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe
harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy
benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected
at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.
On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, which includes several provisions to lower prescription
drug costs for people with Medicare, including price negotiation requirements for drugs covered under Medicare, rebate requirements when
drug prices rise faster than inflation, and a cap on out-of-pocket spending for Medicare Part D enrollees. At the state level, legislatures
have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
a number of these, and other proposed measures may require authorization through additional legislation to become effective, Congress
has indicated that it will continue to seek new legislative measures to control drug costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMS
issued a final rule, effective on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological
products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition
Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of
treatment. Prescription drugs and biological products that are in violation of these requirements will be included on a public list.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing.
Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed
to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries
and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures
to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.
We expect that additional state and federal healthcare reform measures will be adopted in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional state and federal healthcare reform measures, as well as legal changes by foreign governments, will be adopted
in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result
in reduced demand for our product candidates or additional pricing pressures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>European
Union</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements
of other countries and jurisdictions regarding quality, safety and efficacy that govern, among other things, clinical trials, marketing
authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a product, the company
would need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions
and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other
countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country
or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country
or jurisdiction may negatively impact the regulatory process in others.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
and Marketing Authorization in the European Union</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Medicines Agency, or EMA, is the scientific agency of the European Union, or EU, that coordinates the evaluation and monitoring
of new and approved medicinal products such as drugs and biologics. It is responsible for the scientific evaluation of applications for
EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process governing approval of medicinal products in the European Union follows essentially the same lines as in the United States and,
likewise, generally involves satisfactorily completing each of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    laboratory tests, animal studies and formulation studies all performed in accordance with the applicable E.U. Good Laboratory Practice
    regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the relevant national authorities of a clinical trial application, or CTA, which must be approved before human clinical trials
    may begin;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the relevant competent authorities of a Marketing Authorisation Application, or MAA, which includes the data supporting safety
    and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed
    labelling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an inspection by the relevant national authorities of the manufacturing facility or facilities, including those of
    third parties, at which the product is produced to assess compliance with strictly enforced current cGMP;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the product.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
Studies</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal
studies, in order to assess the potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of
the compounds for testing must comply with the relevant E.U. and/or Member States&#8217; regulations and requirements. The results of
the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial Approval</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requirements
for the conduct of clinical trials in the European Union including Good Clinical Practice, or GCP, are implemented in the Clinical Trials
Directive 2001/20/EC and the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system
for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under
this system, approval must be obtained from the competent national authority of an E.U. member state in which a study is planned to be
conducted or in multiple member states if the clinical trial is to be conducted in a number of member states. To this end, a CTA is submitted,
which must be supported by an investigational medicinal product dossier, or IMPD, and further supporting information prescribed by Directive
2001/20/EC and Directive 2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started after
a competent ethics committee has issued a favorable opinion on the clinical trial application in that country.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials in the EU are now regulated under Regulation (EU) 536/2014, or the CTR. As opposed to the former law, Directive 2001/20/EC, or
CTD, which as an EU directive was not directly applicable in the member states, the CTR has immediate effect and does not have to be
transposed into national law. While national law transposing the CTD varied to a great extent, the CTR aims at significant further harmonization
of the law governing clinical trials in the EU. After significant delay, the CTR has now become applicable on January 31, 2022. The CTR
further harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System,
or CTIS, which includes a centralized EU portal and database for clinical trials. The exact timing of the Regulation&#8217;s application
depends on confirmation of full functionality of CTIS through an independent audit. The CTR will become applicable six months after the
European Commission publishes notice of this confirmation. The CTR provides inter alia:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consistent
    rules for conducting clinical trials throughout the EU;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making
    information on the authorization, conduct and results of each clinical trial carried out in the EU publicly available;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harmonized
    electronic submission and assessment process for clinical trials conducted in multiple member states;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved
    collaboration, information sharing and decision-making between and within member states;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased
    transparency of information on clinical trials; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Higher
    standards of safety for all participants in EU clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorization of a clinical trial (Phase I-III) in an EU member state requires the submission of a CTA via the EU Portal. The application
will be reviewed by the competent authorities of the member states where the trial is supposed to take place. The application and approval
process is conducted by the member states under the cooperation system set forth in the CTR. Particularities under member states&#8217;
national law still apply to some extent. In general, the CTA should include, among other documents, the study protocol, results of the
nonclinical studies and manufacturing information and analytical results. Also, the sponsor has to suggest one of the concerned member
states as reporting member state. The CTR aims at speeding up the validation and review of clinical trial applications and therefore
provides strict deadlines.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketing
Authorization</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
to market a product in the member states of the European Union proceeds under one of four procedures: a centralized authorization procedure,
a mutual recognition procedure, a decentralized procedure or a national procedure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Centralized
Authorization Procedure</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized procedure enables applicants to obtain a marketing authorization that is valid in all E.U. member states based on a single
application. Certain medicinal products, including products developed by means of biotechnological processes, must undergo the centralized
authorization procedure for marketing authorization which, if granted by the European Commission, is automatically valid in all 28 E.U.
member states. The EMA and the European Commission administer this centralized authorization procedure pursuant to Regulation (EC) No
726/2004.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Regulation (EC) No 726/2004, this procedure is inter alia mandatory for:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medicinal
    products developed by means of one of the following biotechnological processes:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recombinant
    DNA technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled
    expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hybridoma
    and monoclonal antibody methods;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advanced
    therapy medicinal products as defined in Article 2 of Regulation (EC) No. 1394/2007 on advanced therapy medicinal products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medicinal
    products for human use containing a new active substance that, on the date of effectiveness of this regulation, was not authorized
    in the European Union, and for which the therapeutic indication is the treatment of any of the following diseases:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquired
    immune deficiency syndrome;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neurodegenerative
    disorder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diabetes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">auto-immune
    diseases and other immune dysfunctions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">viral
    diseases; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medicinal
    products that are designated as orphan medicinal products pursuant to Regulation (EC) No 141/2000.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized authorization procedure is optional for other medicinal products if they contain a new active substance or if the applicant
shows that the medicinal product concerned constitutes a significant therapeutic, scientific or technical innovation or that the granting
of authorization is in the interest of patients in the European Union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administrative
Procedure</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized authorization procedure, the EMA&#8217;s Committee for Human Medicinal Products, or CHMP, serves as the scientific committee
that renders opinions about the safety, efficacy and quality of medicinal products for human use on behalf of the EMA. The CHMP is composed
of experts nominated by each member state&#8217;s national authority for medicinal products, with expert appointed to act as Rapporteur
for the co-ordination of the evaluation with the possible assistance of a further member of the Committee acting as a Co-Rapporteur.
After approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP has 210 days to adopt an opinion
as to whether a marketing authorization should be granted. The process usually takes longer in case additional information is requested,
which triggers clock-stops in the procedural timelines. The process is complex and involves extensive consultation with the regulatory
authorities of member states and a number of experts. When an application is submitted for a marketing authorization in respect of a
drug that is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation,
the applicant may pursuant to Article 14(9) Regulation (EC) No 726/2004 request an accelerated assessment procedure. If the CHMP accepts
such request, the time-limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time-limit
for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. Once the procedure
is completed, a European Public Assessment Report, or EPAR, is produced. If the opinion is negative, information is given as to the grounds
on which this conclusion was reached. After the adoption of the CHMP opinion, a decision on the MAA must be adopted by the European Commission,
after consulting the E.U. member states.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conditional
Approval</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
specific circumstances, E.U. legislation (Article 14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing
Authorisations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining
the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted
for product candidates (including medicines designated as orphan medicinal products) if (1) the risk-benefit balance of the product candidate
is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3)
the product fulfills unmet medical needs and (4) the benefit to public health of the immediate availability on the market of the medicinal
product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization
may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion
of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid
for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional
or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect
to the review by the CHMP of applications for a conditional marketing authorization.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketing
Authorization under Exceptional Circumstances</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Article 14(8) Regulation (EC) No 726/2004, products for which the applicant can demonstrate that comprehensive data (in line with the
requirements laid down in Annex I of Directive 2001/83/EC, as amended) cannot be provided (due to specific reasons foreseen in the legislation)
might be eligible for marketing authorization under exceptional circumstances. This type of authorization is reviewed annually to reassess
the risk-benefit balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization under
exceptional circumstances is aimed at the provision of information on the safe and effective use of the product and will normally not
lead to the completion of a full dossier/approval.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Market
Authorizations Granted by Authorities of E.U. Member States</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, if the centralized procedure is not followed, there are three alternative procedures as prescribed in Directive 2001/83/EC:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    decentralized procedure allows applicants to file identical applications to several E.U. member states and receive simultaneous national
    approvals based on the recognition by E.U. member states of an assessment by a reference member state;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    national procedure is only available for products intended to be authorized in a single E.U. member state; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    mutual recognition procedure similar to the decentralized procedure is available when a marketing authorization has already been
    obtained in at least one E.U. member state.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
marketing authorization may be granted only to an applicant established in the European Union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pediatric
Studies</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in
an EMA-approved Paediatric Investigation Plan, or PIP, covering all subsets of the paediatric population, unless the EMA has granted
a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements
for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation.
This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine
that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to
delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults.
The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases
that only affect the elderly population.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies
actually comply with the agreed studies and measures listed in each relevant PIP.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Periods
of Authorization and Renewals</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis
of a re-evaluation of the risk-benefit balance by the competent authority of the authorizing member state. To this end, the marketing
authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety
and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing
authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission
or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.
Any authorization which is not followed by the actual placing of the drug on the E.U. market (in case of centralized procedure) or on
the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Drug Designation and Exclusivity</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000, the European Commission can grant such orphan medicinal product designation
to products for which the sponsor can establish that it is intended for the diagnosis, prevention or treatment of a life-threatening
or chronically debilitating condition affecting not more than five in 10,000 people in the European Union, or a life threatening, seriously
debilitating or serious and chronic condition in the European Union and with regards to that without incentives it is unlikely that sales
of the drug in the European Union would generate a sufficient return to justify the necessary investment. In addition, the sponsor must
establish that there is no other satisfactory method approved in the European Union of diagnosing, preventing or treating the condition,
or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation is not a marketing authorization. It is a designation that provides a number of benefits, including fee reductions,
regulatory assistance, and the possibility to apply for a centralized E.U. marketing authorization, as well as ten years of market exclusivity
following a marketing authorization. During this market exclusivity period, neither the EMA, the European Commission nor the member states
can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal
product&#8221; is defined as a medicinal product containing a similar active substance or substances as those contained in an authorized
orphan medicinal product and that is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic
indication may be reduced to six years if, at the end of the fifth year, it is established that the orphan designation criteria are no
longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.
In addition, a competing similar medicinal product may in limited circumstances be authorized prior to the expiration of the market exclusivity
period, including if the marketing authorization holder is unable to supply sufficient quantities of the product or if the competing
product is shown to be safer, more effective or otherwise clinically superior to the already approved orphan drug. Furthermore, a product
can lose orphan designation, and the related benefits, prior to us obtaining a marketing authorization if it is demonstrated that the
orphan designation criteria are no longer met.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the MAA of a medicinal product designated as an orphan drug includes the results of all studies conducted in compliance with an agreed
PIP, and a corresponding statement is subsequently included in the marketing authorization granted, the ten-year period of market exclusivity
will be extended to twelve years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulatory
Data Protection</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.U.
legislation also provides for a system of regulatory data and market exclusivity. According to Article 14(11) of Regulation (EC) No 726/2004,
as amended, and Article 10(1) of Directive 2001/83/EC, as amended, upon receiving marketing authorization, new chemical entities approved
on the basis of a complete independent data package benefit from eight years of data exclusivity and an additional two years of market
exclusivity. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess
a generic (abbreviated) application. During the additional two-year period of market exclusivity, a generic marketing authorization can
be submitted, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be marketed until the expiration
of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of
those ten years, the marketing authorization holder, or MAH, obtains an authorization for one or more new therapeutic indications which,
during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing
therapies. Even if a compound is considered to be a new chemical entity and the innovator is able to gain the period of data exclusivity,
another company nevertheless could also market another version of the drug if such company obtained marketing authorization based on
an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. However, products designated
as orphan medicinal products enjoy, upon receiving marketing authorization, a period of ten years of orphan market exclusivity-see also
<i>Orphan Drug Designation and Exclusivity</i>. Depending upon the timing and duration of the E.U. marketing authorization process, products
may be eligible for up to five years&#8217; supplementary protection certificates, or SPCs, pursuant to Regulation (EC) No 469/2009.
Such SPCs extend the rights under the basic patent for the drug (see below sub <i>Patent Term Extension</i>).&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulatory
Requirements After a Marketing Authorization has been Obtained</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain authorization for a medicinal product in the European Union, we will be required to comply with a range of requirements applicable
to the manufacturing, marketing, promotion and sale of medicinal products:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pharmacovigilance
and other requirements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will, for example, have to comply with the E.U.&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization
studies and additional monitoring obligations can be imposed. Other requirements relate, for example, to the manufacturing of products
and APIs in accordance with good manufacturing practice standards. E.U. regulators may conduct inspections to verify our compliance with
applicable requirements, and we will have to continue to expend time, money and effort to remain compliant. Non-compliance with E.U.
requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric
population, can also result in significant financial penalties in the European Union. Similarly, failure to comply with the E.U.&#8217;s
requirements regarding the protection of individual personal data can also lead to significant penalties and sanctions. Individual E.U.
member states may also impose various sanctions and penalties in case we do not comply with locally applicable requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Manufacturing</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing of authorized drugs, for which a separate manufacturer&#8217;s license is mandatory, must be conducted in strict compliance
with the EMA&#8217;s Good Manufacturing Practices, or cGMP, requirements and comparable requirements of other regulatory bodies in the
European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their
safety and identity. The EMA enforces its current cGMP requirements through mandatory registration of facilities and inspections of those
facilities. The EMA may have a coordinating role for these inspections while the responsibility for carrying them out rests with the
member states competent authority under whose responsibility the manufacturer falls. Failure to comply with these requirements could
interrupt supply and result in delays, unanticipated costs and lost revenues, and could subject the applicant to potential legal or regulatory
action, including but not limited to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible
civil and criminal penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketing
and Promotion</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward
the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83/EC. The applicable
regulations aim to ensure that information provided by holders of marketing authorizations regarding their products is truthful, balanced
and accurately reflects the safety and efficacy claims authorized by the EMA or by the competent authority of the authorizing member
state. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential
civil and criminal penalties.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Term Extension</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to compensate the patentee for delays in obtaining a marketing authorization for a patented product, a supplementary certificate,
or SPC, may be granted extending the exclusivity period for that specific product by up to five years. Applications for SPCs must be
made to the relevant patent office in each E.U. member state and the granted certificates are valid only in the member state of grant.
An application has to be made by the patent owner within six months of the first marketing authorization being granted in the European
Union (assuming the patent in question has not expired, lapsed or been revoked) or within six months of the grant of the patent (if the
marketing authorization is granted first). In the context of SPCs, the term &#8220;product&#8221; means the active ingredient or combination
of active ingredients for a medicinal product and the term &#8220;patent&#8221; means a patent protecting such a product or a new manufacturing
process or application for it. The duration of an SPC is calculated as the difference between the patent&#8217;s filing date and the
date of the first marketing authorization, minus five years, subject to a maximum term of five years.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
six month pediatric extension of an SPC may be obtained where the patentee has carried out an agreed pediatric investigation plan, the
authorized product information includes information on the results of the studies and the product is authorized in all member states
of the European Union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>United
Kingdom</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
withdrawal of the United Kingdom (U.K.) from the E.U. took effect on January 1, 2021, and there are 27 member states remaining in the
E.U. As of January 1, 2021, the U.K. is a &#8220;third country&#8221; with regard to the EU (subject to the terms of the EU UK Trade
Agreement) and EU law ceased to apply directly in the UK. However, the U.K. has retained the E.U. regulatory regime with certain modifications
as standalone U.K. legislation. Therefore, the U.K. regulatory regime is currently similar to E.U. regulations, but the U.K. may adopt
changed regulations that may diverge from the E.U. legislative regime for medicines and their research, development and commercialization.
For a two-year period starting January 1, 2021, the U.K. has adopted transitional provisions, which <i>inter alia</i> apply to the importation
of medicines into the U.K. and rely on certain EMA marketing authorization application procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Israel</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Israel
Ministry of the Environment - Toxin Permit</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Israeli Dangerous Substance Law - 1993, the Ministry of the Environment may grant a permit in order to use toxic
materials. Because we utilize toxic materials in the course of operation of our laboratories, we were required to apply for a permit
to use these materials. Our current toxin permit will remain in effect until March 9, 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Licenses and Approvals</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a business license from the municipality of Petah-Tikva for a drug development research laboratory located at our offices in Petah
Tikva, Israel. In order to obtain this license, we also received approval from the Petah-Tikva Association of Towns Fire Department.
The business license is valid until December 31, 2025 and is in the process of being renewed. We also have a radioactive materials or
products containing radioactive materials license, which is valid until July 25, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Testing in Israel</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to conduct clinical testing on humans in Israel, special authorization must first be obtained from the ethics committee and general
manager of the institution in which the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical
Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), as amended
from time to time, and other applicable legislation. These regulations also require authorization from the Israeli Ministry of Health,
except in certain circumstances, and in the case of genetic trials, special fertility trials and similar trials, an additional authorization
of the overseeing institutional ethics committee. The institutional ethics committee must, among other things, evaluate the anticipated
benefits that are likely to be derived from the project to determine if it justifies the risks and inconvenience to be inflicted on the
human subjects, and the committee must ensure that adequate protection exists for the rights and safety of the participants as well as
the accuracy of the information gathered in the course of the clinical testing. Since we intend to perform a portion of the clinical
studies on certain of our product candidates in Israel, we will be required to obtain authorization from the ethics committee and general
manager of each institution in which we intend to conduct our clinical trials, and in most cases, from the Israeli Ministry of Health.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Israel
Ministry of Health</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel&#8217;s
Ministry of Health, which regulates medical testing, has adopted protocols that correspond, generally, to those of the FDA and the EMA,
making it comparatively straightforward for studies conducted in Israel to satisfy FDA and the European Medicines Agency requirements,
thereby enabling medical technologies subjected to clinical trials in Israel to reach U.S. and EU commercial markets in an expedited
fashion. Many members of Israel&#8217;s medical community have earned international prestige in their chosen fields of expertise and
routinely collaborate, teach and lecture at leading medical centers throughout the world. Israel also has free trade agreements with
the United States and the European Union.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Countries</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, the EU and Israel, we are subject to a variety of other regulations governing clinical
trials and commercial sales and distribution of drugs in other countries. Whether or not our products receive approval from the FDA,
approval of such products must be obtained by the comparable regulatory authorities of countries other than the United States before
we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country,
and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials
and product licensing vary greatly from country to country.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements that we and our collaborators must satisfy to obtain regulatory approval by government agencies in other countries prior
to commercialization of our products in such countries can be rigorous, costly and uncertain. In Canada and Australia, regulatory requirements
and approval processes are similar in principle to those in the United States. For example, in Canada, pharmaceutical product candidates
are regulated by the Food and Drugs Act and the rules and regulations promulgated thereunder, which are enforced by Health Canada. Before
commencing clinical trials in Canada, an applicant must complete preclinical studies and file a clinical trial application with Health
Canada. After filing a clinical trial application, the applicant must receive different clearance authorizations to proceed with Phase
1 clinical trials, which can then lead to Phase 2 and Phase 3 clinical trials. To obtain regulatory approval to commercialize a new drug
in Canada, a new drug submission, or NDS, must be filed with Health Canada. If the NDS demonstrates that the product was developed in
accordance with the regulatory authorities&#8217; rules, regulations and guidelines and demonstrates favorable safety and efficacy and
receives a favorable risk/benefit analysis, Health Canada issues a notice of compliance which allows the applicant to market the product.
Facilities, procedures, operations and/or testing of products are subject to periodic inspection by Health Canada and the Health Products
and Food Branch Inspectorate. In addition, Health Canada conducts pre-approval and post-approval reviews and plant inspections to determine
whether systems are in compliance with the good manufacturing practices in Canada, Drug Establishment Licensing requirements and other
provisions of the Food and Drug Regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
governments also have stringent post-approval requirements including those relating to manufacture, labeling, reporting, record keeping
and marketing. Failure to substantially comply with these on-going requirements could lead to government action against the product,
our company and/or our representatives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted, introduced and passed in governmental bodies that could significantly change the statutory provisions
governing the approval, manufacturing and marketing of products regulated by the FDA, the EMA, the Israeli Ministry of Health and other
applicable regulatory bodies to which we are subject. In addition, regulations and guidance are often revised or reinterpreted by the
national agency in ways that may significantly affect our business and our product candidates. It is impossible to predict whether such
legislative changes will be enacted, whether FDA, EMA or Israeli Ministry of Health regulations, guidance or interpretations will change,
or what the impact of such changes, if any, may be. We may need to adapt our business and product candidates and products to changes
that occur in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Organizational Structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate structure consists of Can-Fite and our wholly owned subsidiary, Can-Fite Biopharma Europe, incorporated in France.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Property, Plants and Equipment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are headquartered in Petah-Tikva, Israel. We lease one floor in one facility pursuant to a lease agreement with Eshkolit Nihul Nadlan
LTD, an Israeli limited company. Pursuant to a verbal agreement with the lessor, the lease can be terminated at any time by each of the
parties without a prior notice. The Petah-Tikva headquarters consists of approximately 300 square meters of space. Lease payments are
approximately NIS 20,447, or $5,810 (based on the exchange rate reported by the Bank of Israel on December 31, 2022), per month. If our
lease is terminated, we do not foresee significant difficulty in leasing another suitable facility. The current facility houses our administrative,
clinical and research operations. The research laboratory consists of approximately 150 square meters and includes a tissue culture laboratory
and a molecular biology laboratory. As of December 31, 2022, we did not have obligation to any lease payments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ITEM
4A. </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ITEM
5. </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and Financial Review and Prospects</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this section should be read in conjunction with our consolidated financial statements and related notes beginning on page
F-1 and the related information included elsewhere in this Annual Report on Form 20-F. Our financial statements are prepared in accordance
with U.S. GAAP. We maintain our accounting books and records in U.S. dollars and our functional currency is the U.S. dollar. Certain
amounts presented herein may not sum due to rounding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment of cancer, inflammatory,
autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic
target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal
cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are
synthetic, highly specific agonists and allosteric modulators targeting the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product pipeline is based
on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found in most body tissues,
but are rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s research revealed
that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules which bind
with high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression in tumor
and inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators,
currently our pipeline of drug candidates, bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate
down-stream signal transduction pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the
inhibition of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system in order
to regulate the body&#8217;s response to disease and infection. Overproduction or inappropriate production of certain cytokines by the
body can result in disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates, CF101,
CF102 and CF602, are being developed to treat cancer, liver and inflammatory diseases, as well as erectile dysfunction. CF101, also known
as Piclidenoson, is in an advance stage of clinical development for the treatment of autoimmune-inflammatory diseases, including psoriasis.
During 2021, we decided to stop developing Piclidenoson for the treatment of COVID-19 to focus on other indications. CF102, also known
as Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for the treatment of HCC in the United States
and Europe. Namodenoson was granted Fast Track designation by the FDA as a second line treatment to improve survival for patients with
advanced HCC who have previously received Nexavar (sorafenib). Namodenoson is also being developed for the treatment of NASH, a disease
for which no FDA approved therapies currently exist. CF602 is our second generation allosteric drug candidate for the treatment of erectile
dysfunction, which has shown efficacy in the treatment of erectile dysfunction in preclinical studies and we are investigating additional
compounds, targeting A3AR, for the treatment of erectile dysfunction. Preclinical studies revealed that our drug candidates have potential
to treat additional inflammatory diseases, such as Crohn&#8217;s disease, oncological diseases, viral diseases, such as the JC virus,
and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our pipeline of
drug candidates represent a significant market opportunity. For instance, according to iHealthcareAnalyst, the psoriasis drug market
is forecasted to be worth $11.3 billion by 2025. According to DelveInsight, the HCC drug market in the G8 countries (U.S., Germany, France,
Italy, Spain, UK, Japan and China) is expected to reach $3.8 billion by 2027.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have in-licensed an allosteric
modulator of the A3AR, CF602 from Leiden University. In addition, we have out-licensed the following product candidates for indications
that we are currently pursuing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Piclidenoson
    for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis to Gebro Holding, or Gebro, for
    Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including Hong Kong, Macao and Taiwan), (iv) psoriasis
    to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma AG, or Ewopharma, for Central Eastern Europe,
    and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namodenoson
    for the treatment of (i) liver cancer and NASH to Chong Kun Dang Pharmaceuticals, or CKD, for South Korea, (ii) advanced liver cancer
    and NAFLD/NASH to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC and NASH to Ewopharma, for Central Eastern
    Europe and Switzerland.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, (i) we are preparing
a registration plan for the FDA protocol for our upcoming Phase III pivotal trial following a recent submission to the EMA and successful
completion of our Phase III trial for Piclidenoson in the treatment of psoriasis, (ii) we are conducting a pivotal Phase III trial for
Namodenoson in the treatment of advanced liver cancer which is open for enrollment, (iii) we are conducting a Phase IIb study of Namodenoson
in the treatment of NASH, (iv) we are investigating additional compounds, targeting the A3 adenosine receptor, for the treatment of erectile
dysfunction, and (v) we are conducting pre-clinical studies with formulations of cannabis components for the treatment of diseases in
which there is an overexpression of A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we have
incurred significant losses in connection with our research and development. As of December 31, 2022, we had an accumulated deficit of
approximately $150.8 million. Although we have recognized revenues in connection with our existing out-licensing agreements with, Cipher,
CKD, Gebro and Ewopharma, and our historic out-licensing agreement with KD, CMS, Kyongbo and Seikagaku Corporation, or SKK, we expect
to generate losses in connection with the research and development activities relating to our pipeline of drug candidates. Such research
and development activities are budgeted to expand over time and will require further resources if we are to be successful. As a result,
we expect to incur operating losses, which may be substantial over the next several years, and we will need to obtain additional funds
to further develop or research and development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have funded our operations
primarily through the sale of equity securities (both in private placements and in public offerings) and payments received under our
existing out-licensing agreements with KD, Cipher, CKD Gebro, CMS, and Kyongbo and our historic out-licensing agreement with SKK. We
expect to continue to fund our operations over the next several years through our existing cash resources, potential future milestone
payments that we expect to receive from our licensees, interest earned on our investments, if any, and additional capital to be raised
through public or private equity offerings or debt financings. As of December 31, 2022, we had approximately $3.0 million of cash and
cash equivalents and $5.0 million of short-term deposits. A substantial part of this amount is designated for payments to be made in
relation to the ongoing treatment of patients who are currently enrolled in the Company&#8217;s on-going trials. In January 2023, we
raised approximately $7.5 million in gross proceeds (approximately $6.7 million net of issuance costs) from a registered direct offering
and a concurrent private placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenues</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenues to date have been generated primarily from payments under
our existing out-licensing agreements with, Cipher, CKD, Gebro, Kyongbo and Ewophrma, and our historic out-licensing agreement with Kwang
Dong and SKK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Kwang Dong License
Agreement, we are entitled to up-front and milestone payments of up to $1.5 million. In accordance with the Kwang Dong License Agreement,
we received an up-front payment of $0.3 million and a payment of $0.048 million as consideration for Kwang Dong&#8217;s purchase of our
ordinary shares in 2009 and a milestone payment of $0.2 million in 2010. Under the terms of the Kwang Dong License Agreement, in addition
to the payments mentioned above, we are entitled to certain additional payments based on the sale of raw materials, subject to the terms
and conditions of the respective agreements. To date, we have received a total of $0.5 million from Kwang Dong in an upfront payment.
See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement with Cipher we received CAD 1.65 million upon execution of the agreement and are entitled to milestone payments upon
receipt of regulatory approval by Health Canada for Piclidenoson and the first delivery of commercial launch quantities as follows (i)
CAD 1 million upon the first approved indication for either psoriasis or rheumatoid arthritis, and (ii) CAD 1 million upon the second
approved indication for either psoriasis or rheumatoid arthritis. In addition, following regulatory approval, we shall be entitled to
a royalty of 16.5% of net sales of Piclidenoson in Canada and reimbursement for the cost of manufacturing Piclidenoson. We are also entitled
to a royalty payment for any authorized generic of Piclidenoson that Cipher distributes in Canada. To date, we have received a total
of $1.3 million (CAD 1.65 million) from Cipher in an upfront payment. See &#8220;Item 4. Information on the Company&#8212;B. Business
Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
with CKD provides for up to $3,000,000 in upfront and milestone payments payable with respect to the liver cancer indication and up to
$6,000,000 with respect to the NASH indication. In addition, we are entitled to a transfer price of the higher of (a) the manufacturing
cost plus 10% or (b) 23% of net sales of Namodenoson following commercial launch in South Korea. To date, we have received a total of
$2,000,000 from CKD, comprising $1,500,000 in upfront payments for the expansion of CKD&#8217;s existing agreement with us to include
the rights to distribute Namodenoson for the treatment of NASH in South Korea, and a further $500,000 for a milestone payment received
in the third quarter of 2017 upon receipt by CKD of a positive result from the preliminary review by the MFDS, on obtaining orphan drug
designation in South Korea. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution
Agreements&#8221;.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we entered
into a Distribution and Supply Agreement with Gebro. The Distribution and Supply Agreement with Gebro provides that we are entitled to
&#8364;1,500,000 upon execution of the agreement plus milestone payments upon achieving certain clinical, launch and sales milestones,
as follows: (i) &#8364;300,000 upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364;300,000
upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#8364;750,000 and &#8364;1,600,000
following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis,
and (iii) between &#8364;300,000 and up to &#8364;4,025,000 upon meeting certain net sales. In addition, following regulatory approval,
we shall be entitled to double digit percentage royalties on net sales of Piclidenoson in the territories and payment for the manufacturing
Piclidenoson. To date, we have received a total of &#8364;2,100,000 from Gebro in upfront and milestone payments. See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, we entered
into a License, Collaboration and Distribution Agreement with CMS. Under the License, Collaboration and Distribution Agreement, we are
entitled to $2,000,000 upon execution of the agreement plus milestone payments of up to $14,000,000 upon achieving certain regulatory
milestones and payments of up to $58,500,000 upon achieving certain sales milestones. In addition, following regulatory approval, we
shall be entitled to double-digit percentage royalties on net sales of Piclidenoson and Namodenoson in the licensed territories. To date,
we have received a total of $2,000,000 from CMS in upfront and milestone payments. See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, we entered
into a License and Distribution Agreement with Kyongbo Pharm. Under the terms of agreement, Kyongbo Pharm, in exchange for exclusive
distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, made a total upfront payment of $750,000 to us,
with additional payments of up to $3,250,000 upon achievement of certain milestones. We will also be entitled to a transfer price for
delivering finished product to Kyongbo Pharm. To date, we have received a total of $750,000 from Kyongbo Pharm in upfront and milestone
payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we signed
an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in
the treatment of liver diseases namely, HCC, the most common form of liver cancer, and NASH. Under the terms of the distribution agreement,
Ewopharma we received $2.25 million upfront and are entitled to up to an additional $40.45 million payable upon the achievement of regulatory
and sales milestones plus 17.5% royalties on net sales. We will also be entitled to a transfer price for delivering finished product
to Ewopharma. To date, we have received a total of $2,250,000 from Ewopharma in upfront, milestone and royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terminated SKK
license agreement we received an aggregate of approximately $8.5 million from SKK. See &#8220;Item 4. Information on the Company&#8212;B.
Business&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain payments we have
received from SKK and KD have been subject to a 10% and 5% withholding tax in Japan and Korea, respectively, and certain payments we
may receive in the future, if at all, may also be subject to the same withholding tax in Korea. Receipt of any milestone payment under
our out-licensing agreements depends on many factors, some of which are beyond our control. We cannot assure you that we will receive
any of these future payments. We expect our revenues for the next several years, if any, to be derived primarily from payments under
our current out-license agreements and our public capital raising activities, as well as additional collaborations that we may enter
into in the future with respect to our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone
payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory
supplies and costs for facilities and equipment. We charge all research and development expenses to operations as they are incurred.
We expect our research and development expense to remain our primary expense in the near future as we continue to develop our products.
Increases or decreases in research and development expenditures are attributable to the number and/or duration of the pre-clinical and
clinical studies that we conduct.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table identifies
our current major research and development projects:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Project</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 56%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expected
    or Recent Near <br/>
    Term Milestone</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Piclidenoson</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working on a registration plan for both the EMA and
    FDA, including pivotal Phase III study protocol and submission of pre-clinical studies that have already accomplished</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission of Phase III pivotal trial in the US and
    Europe</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namodenoson</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase III in HCC</span></td>
    <td>&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enrollment ongoing</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase IIb study in NASH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrollment ongoing</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We record certain costs for
each development project on a &#8220;direct cost&#8221; basis, as they are recorded to the project for which such costs are incurred.
Such costs include, but are not limited to, CRO expenses, drug production for pre-clinical and clinical studies and other pre-clinical
and clinical expenses. However, certain other costs, including but not limited to, salary expenses (including salaries for research and
development personnel), facilities, depreciation, share-based compensation and other overhead costs are recorded on an &#8220;indirect
cost&#8221; basis, i.e., they are shared among all of our projects and are not recorded to the project for which such costs are incurred.
We do not allocate direct salaries to projects due to the fact that our project managers are generally involved in several projects at
different stages of development, and the related salary expense is not significant to the overall cost of the applicable projects. In
addition, indirect labor costs relating to our support of the research and development process, such as manufacturing, controls, pre-clinical
analysis, laboratory testing and initial drug sample production, as well as rent and other administrative overhead costs, are shared
by many different projects and have never been considered by management to be of significance in its decision-making process with respect
to any specific project. Accordingly, such costs have not been specifically allocated to individual projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is a summary
of the gross direct costs allocated to our main projects on an individual basis, as well as the gross direct costs allocated to our less
significant projects on an aggregate basis, for the years ended December 31, 2020, 2021 and 2022; and on an aggregate basis since project
inception:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(USD in thousands)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Costs</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Since&#160;Project</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Inception</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Piclidenoson</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,790</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">46,587</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Namodenoson</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,991</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,410</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">CF602</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,740</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other projects</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,199</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,129</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    gross direct project costs&#160;<sup>(1)</sup></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,506</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,063</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,179</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">71,866</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
                                            not include indirect project costs and overhead, such as payroll and related expenses (including
                                            stock-based compensation), facilities, depreciation and impairment of intellectual property,
                                            which are included in total research and development expenses in our financial statements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From our inception through
December 31, 2022, we have incurred research and development expenses of approximately $140.2 million. We expect that a large percentage
of our research and development expense in the future will be incurred in support of our current and future preclinical and clinical
development projects. Due to the inherently unpredictable nature of preclinical and clinical development processes and given the early
stage of our preclinical product development projects, we are unable to estimate with any certainty the costs we will incur in the continued
development of the product candidates in our pipeline for potential commercialization. Clinical development timelines, the probability
of success and development costs can differ materially from expectations. We expect to continue to test our product candidates in preclinical
studies for toxicology, safety and efficacy, and to conduct additional clinical trials for each product candidate. If we are not able
to enter into an out-licensing arrangement with respect to any product candidate prior to the commencement of later stage clinical trials,
we may fund the trials for the product candidates ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we are currently focused
on advancing each of our product development projects, our future research and development expenses will depend on the clinical success
of each product candidate, as well as ongoing assessments of each product candidate&#8217;s commercial potential. In addition, we cannot
forecast with any degree of certainty which product candidates may be subject to future out-licensing arrangements, when such out-licensing
arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we obtain results from
clinical trials, we may elect to discontinue or delay clinical trials for certain product candidates or projects in order to focus our
resources on more promising product candidates or projects. Completion of clinical trials by us or our licensees may take several years
or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of clinical trials
may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of sites included in the clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the length of time required to enroll suitable patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients that participate in the clinical
    trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the duration of patient follow-up;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development stage of the product candidate; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the efficacy and safety profile of the product candidate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research and
development expenses to increase in the future from current levels as we continue the advancement of our clinical trials and preclinical
product development and to the extent we in-license new product candidates. The lengthy process of completing clinical trials and seeking
regulatory approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical
trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development
expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not
able to estimate with any certainty when we would recognize any net cash inflows from our projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and Administrative Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of compensation for employees in executive and operational functions, including accounting, finance, legal,
business development, investor relations, information technology and human resources. Other significant general and administration costs
include facilities costs, professional fees for outside accounting and legal services, travel costs, insurance premiums and depreciation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial Expense and Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense and income
consists of interest earned on our cash and cash equivalents; bank fees and other transactional costs; expense or income resulting from
fluctuations of the NIS and other currencies, in which a portion of our assets and liabilities are denominated, against the U.S. dollar
(our functional currency).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our accounting policies and
their effect on our financial condition and results of operations are more fully described in our audited consolidated financial statements
included elsewhere in this Annual Report on Form 20-F. The preparation of financial statements in conformity with U.S. GAAP as issued
by the Financial Accounting Standards Board (FASB) requires management to make estimates and assumptions that in certain circumstances
affect the reported amounts of assets and liabilities, revenues and expenses and disclosure of contingent assets and liabilities. These
estimates are prepared using our best judgment, after considering past and current events and economic conditions. While management believes
the factors evaluated provide a meaningful basis for establishing and applying sound accounting policies, management cannot guarantee
that the estimates will always be consistent with actual results. In addition, certain information relied upon by us in preparing such
estimates includes internally generated financial and operating information, external market information, when available, and when necessary,
information obtained from consultations with third party experts. Actual results could differ from these estimates and could have a material
adverse effect on our reported results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the accounting
policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these
policies relate to the more significant areas involving management&#8217;s estimates and assumptions. We consider an accounting estimate
to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that
were highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial
condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Functional and Presentation Currency</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our functional and presentation currency is the U.S. dollar since the
USD is the primary currency of the economic environment in which we operate.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Principles of Consolidation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our financial statements
reflect the consolidation of the financial statements of companies that we control based on legal control or effective control. We fully
consolidate into our financial statements the results of operations of companies that we control. Legal control exists when we have the
power, directly or indirectly, to govern the financial and operating policies of an entity. The effect of potential voting rights that
are exercisable at the balance sheet date are considered when assessing whether we have legal control. In addition, we consolidate on
the basis of effective control even if we do not have voting control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue Recognition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generate income from out-licensing
and distribution agreements. See &#8220;Item 4. Information on the Company&#8212;B. Business&#8212;Out-Licensing and Distribution Agreements&#8221;.
Such income comprises of upfront license fees, milestone payments and potential royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize revenue in accordance
with ASC 606, &#8220;Revenue from Contracts with Customers&#8221; pursuant to which each required deliverable is evaluated to determine
whether it qualifies as a separate unit of accounting based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer.
The arrangement&#8217;s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the
relative selling price of each deliverable which is based on the Estimated Selling Price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contracts generally include
three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive
licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contracts also include
development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent that
it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. We
have not yet received the required regulatory approvals for our products and we have not yet recognized any sales-based royalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue from supply and distribution
agreements with customers are recognized over time as we satisfy the performance obligations. We usually accept long-term upfront payment
from our customers. Contract liabilities for those upfront payments are recognized as revenue over time. We have concluded that the abovementioned
agreements contain a single performance obligation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenues from milestone payments:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Contingent payments related
to milestones will be recognized upon satisfaction of the milestone and contingent payments related to royalties will be recognized in
the period that the related sales have occurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenues from royalties:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues from royalties will
be recognized as they accrue in accordance with the terms of the relevant agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-based Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for share-based
compensation arrangements in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which
requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The
value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods
in the Company&#8217;s consolidated statement of comprehensive loss. We recognize compensation expenses for the value of its awards granted
based on the vesting acceleration approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC
718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures
differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We selected the binomial
option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards. The determination
of the grant date fair value of options using an option pricing model is affected by estimates and assumptions regarding a number of
complex and subjective variables. These variables include the expected volatility of our share price over the expected term of the options,
share option exercise and forfeiture rate, risk-free interest rates, expected dividends and the price of our ordinary shares on the TASE.
As our ordinary shares are publicly traded on the TASE, we do not need to estimate the fair value of our ordinary shares. Rather, we
use the actual closing market price of our ordinary shares on the date of grant, as reported by the TASE although in the future may use
the closing market price of our ADSs on the date of grant, as reported by the NYSE American.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the assumptions
used in the binomial option pricing model change significantly, share-based compensation for future awards may differ materially compared
with the awards previously granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As for other service providers,
the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments.
In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured
by reference to the fair value of the equity instruments granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of equity-settled
transactions is recognized in statements of comprehensive loss, together with a corresponding increase in equity, during the period which
the service are to be satisfied, ending on the date on which the relevant employees or other service providers become fully entitled
to the award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we modify the conditions
on which equity-instruments are granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee or other service provider at the modification date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB
issued Accounting Standards Update No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#8217;s own equity. This guidance also eliminates the treasury stock method
to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The Company&#8217;s
adopted the standard effective January 1, 2022. Adoption of the new standard did not have a material impact on the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, the FASB issued
ASU No. 2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.
The ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges
of freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios.
The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods
after issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard
effective January 1, 2022. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Offerings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 9, 2020, we entered
into warrant exercise agreements, or the Exercise Agreements, with several accredited investors who are the holders, or the Holders,
of warrants issued in September 2015, October 2015, March 2018, January 2019, and April 2019 or the Public Warrants, to purchase our
ordinary shares, represented by ADS, pursuant to which the Holders agreed to exercise in cash their Public Warrants to purchase up to
an aggregate of 22,278,540 ordinary shares represented by 74,262 ADSs having exercise prices ranging from $129.0 to $787.50 per ADS issued
by us, at a reduced exercise price of $32.50 per ADS, resulting in gross proceeds of approximately $2.4 million. Closing occurred on
January 13, 2020. Under the Exercise Agreements, we also issued to the Holders new unregistered warrants to purchase up to 22,278,540
ordinary shares represented by 74,262 ADSs, or the Private Placement Warrants. The Private Placement Warrants are immediately exercisable,
expire five and one-half years from issuance date and have an exercise price of $34.50 per ADS, subject to adjustment as set forth therein.
The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement
registering the ADSs underlying the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 12, 2020, we
sold to certain institutional investors an aggregate of (i) 182,500 units, or Units, each Unit consisting of one ADS, and one warrant
to purchase one ADS, or the Warrant, at a price of $15.0 per Unit, and (ii) 150,833 pre-funded units, or the Pre-funded Units, each Pre-funded
Unit consisting of one pre-funded warrant to purchase one ADS, or the Pre-funded Warrant, and one Warrant, at a price of $14.90 per Pre-funded
Unit, in a public offering, resulting in gross proceeds of approximately $5.0 million. Each Pre-funded Warrant contained in a Pre-funded
Unit is immediately exercisable for one ADS at an exercise price of $0.001 per share and remains exercisable until exercised in full.
The Warrants included in the Units and the Pre-funded Units are immediately exercisable at a price of $15.0 per ADS, subject to adjustment
in certain circumstances, and expire five years from the date of issuance. We paid an aggregate of $315,000 in placement agent fees and
expenses and issued placement agent warrants to purchase 25,000 ADS on the same terms as the warrants except they have a term of five
years and have an exercise price of $18.75.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March, April and May 2020,
we issued an aggregate of 51,250,020 ordinary shares represented by 170,833 ADSs in exchange for exercise of warrants. Total consideration
received by us was approximately $2,562,000.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 12, 2020, we sold
to several institutional and accredited investors an aggregate of 117,073,200 ordinary shares represented by 390,244 ADSs in a registered
direct offering at $20.50 per ADS, resulting in gross proceeds of approximately $8.0 million. In addition, we issued to the investors
unregistered warrants to purchase up to an aggregate of 195,122 ADSs in a private placement. The warrants are immediately exercisable
and will expire four and one-half years from the issuance date at an exercise price of $25.0 per ADS, subject to adjustment as set forth
therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying
the warrants. We paid an aggregate of $600,000 in placement agent fees and expenses and issued unregistered placement agent warrants
to purchase up to 29,268 ADS on the same terms as the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2020, we sold
to several institutional and accredited investors an aggregate of 51,165,000 ordinary shares represented by 170,550 ADSs in a registered
direct offering at $20.0 per ADS, resulting in gross proceeds of approximately $3.4 million. In addition, we issued to the investors
unregistered warrants to purchase up to an aggregate of 85,275 ADSs in a private placement. The warrants are immediately exercisable
and will expire four and one-half years from the issuance date at an exercise price of $25.0 per ADS, subject to adjustment as set forth
therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying
the warrants. We paid an aggregate of $255,825 in placement agent fees and expenses and issued unregistered placement agent warrants
to purchase up to 12,791 ADS on the same terms as the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February and March 2021,
we issued 50,926,830 ordinary shares represented by 169,756 ADSs in exchange for exercise of warrants. Total consideration received by
us was approximately $2,744,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2021, we sold
to an institutional investor an aggregate of (i) 57,000,000 ordinary shares represented by 190,000 ADSs at $20.0 per ADS, and (ii) 93,000,000
ordinary shares represented by 310,000 ADSs issuable upon the exercise of pre-funded warrants, or Pre-funded Warrants, at a price of
$19.99 per Pre-funded Warrant, in a registered direct offering. The Pre-funded Warrants were exercised in full during 2021. In addition,
we issued to the investors unregistered warrants to purchase 150,000,000 ordinary shares represented by 500,000 ADSs in a private placement.
The warrants are immediately exercisable and will expire three years from the effectiveness of an initial resale registration statement
registering the ordinary shares issuable upon the exercise of the warrants. We paid on aggregate of $700,000 in placement agent fees
and expenses and issued placement agent warrants in an amount equal to 7.0% of the aggregate number of ADSs sold in the offering (or
warrants to purchase up to an aggregate of 35,000 ADSs), at an initial exercise price equal to $20.0 per ADS, on substantially the same
terms as the investor warrants, except that the placement agent warrants expire on the earlier of (i) the third-year anniversary of the
date on which an initial resale registration statement registering the ordinary shares (or the ADSs) issuable upon the exercise of the
warrants becomes effective and (ii) August 11, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 20, 2021, we
entered into a warrant exercise agreement, or the Exercise Agreement, with an institutional investor, or the Holder, of warrants
issued in August 2021, or the Warrants, to purchase ordinary shares, represented by ADS, pursuant to which the Holder agreed to
exercise in cash its Warrant to purchase up to an aggregate of 150,000,000 ordinary shares represented by 500,000 ADSs having an
exercise price of $20.0 per ADS, resulting in gross proceeds of $10.0 million. Closing occurred on December 23, 2021. Under the
Exercise Agreement, we also issued to the Holder new unregistered warrants to purchase up to 180,000,000 ordinary shares represented
by 600,000 ADSs, or the Private Placement Warrants. The Private Placement Warrants are immediately exercisable, expire five years
following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the
warrants and have an exercise price of $5.5 per ADS (following a reduction from $20.0 per ADS as a result of the January 2023
offering), subject to adjustment as set forth therein. We paid an aggregate of $875,000 in placement agent fees and expenses and
issued unregistered placement agent warrants to purchase 35,000 ADS on the same terms as the warrant.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2023, we sold
to an institutional investor (i) 90,000,000 ordinary shares represented by 300,000 ADSs at a purchase price of $5.50 per ADS, and (ii)
pre-funded warrants to Purchase up to 210,000,000 ordinary shares represented by 700,000 ADSs at an offering price of $5.499 per pre-funded
warrant, in a registered direct offering. The pre-funded warrants were exercised in full. In a concurrent private placement, we also
issued pre-funded warrants to purchase up to an aggregate of 109,091,100 ordinary shares represented by 363,637 ADS, at the same purchase
price as in the registered direct offering. We have also issued unregistered Series A warrants to purchase up to an aggregate of 409,091,100
ordinary shares represented by 1,363,637 ADSs for an exercise price of $ 0.02 per share and Series B warrants to purchase up to an aggregate
of 409,091,100 ordinary shares represented by 1,363,637 ADSs for an exercise price of $ 0.018 per share. In addition, we paid an aggregate
of $675 thousands in placement agent fees and expenses and issued 28,636,500 ordinary shares represented by 94,455 ADSs issuable upon
the exercise of placement agent warrants for an exercise price of $ 0.02 per share. The offerings closed on January 13, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the Year Ended December 31, 2022 to Year Ended December
31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for the year ended
December 31, 2022 were $0.81 million, a decrease of $0.04 million, or 5.1%, compared to $0.85 million for the year ended December 31,
2021. The decrease in revenues was mainly due to the recognition a higher portion of advance payments received under Ewopharma distribution
agreement entered in 2021 which was set off by recognition of a lower portion of advance payments received under distribution agreements
from Gebro, Chong Kun Dung Pharmaceuticals, and Cipher Pharmaceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Research and development
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses for the year ended December 31, 2022 were $7.76 million, a decrease of $2.09 million, or 21.2%, compared to $9.85 million for
the year ended December 31, 2021. Research and development expenses for the year ended December 31, 2022 comprised primarily of expenses
associated with the completion of the Phase III study of Piclidenoson for the treatment of psoriasis and two ongoing studies for Namodenoson,
a Phase III study in the treatment of advanced liver cancer and a Phase IIb study for NASH. The decrease is primarily due to the wrap
up of the Phase III study of Piclidenoson for the treatment of psoriasis in 2022. We expect that the research and development expenses
will increase through 2023 and beyond.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>General and administrative
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were $3.14 million for the year ended December 31, 2022 a decrease of $0.70 million, or 18%, compared to $3.84 million for the
year ended December 31, 2021. The decrease is primarily due to the decrease in professional services and public and investor relations
expenses. We expect that general and administrative expenses will remain at the same level through 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Financial income (expenses),
net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income (expense),
net for the year ended December 31, 2022 aggregated $(0.07) million compared to financial expense, net of $0.23 for the year ended December
31, 2021. The decrease in financial expense, net was mainly due to increase in the revaluation of our short-term investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the Year Ended December 31, 2021 to Year Ended December
31, 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Revenues
for the year ended December 31, 2021 were $0.85 million, an increase of $0.09 million, or 12%, compared to $0.76 million for the year
ended December 31, 2020. The increase in revenues was mainly due to the recognition a portion of advance payments received under Ewopharma
distribution agreement entered in 2021 which was set off by recognition of a lower portion of advance payments received under distribution
agreements from Gebro, Chong Kun Dung Pharmaceuticals, and Cipher Pharmaceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>Research
and development expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Research
and development expenses for the year ended December 31, 2021 were $9.85 million, a decrease of $2.1 million, or 17%, compared to $11.95
million for the year ended December 31, 2020. Research and developments expenses for the year ended 2021 comprised primarily of expenses
associated with two studies for Piclidenoson, a Phase III study in the treatment of psoriasis and a Phase II study in COVID-19 and Phase
II studies for Namodenoson in the treatment of liver cancer and NASH. The decrease is primarily due to costs incurred in 2020 associated
with Univo research project which was completed by the end of that year, a Phase III study of Piclidenoson for the treatment of rheumatoid
arthritis which was ongoing during 2020, partially offset by pre-clinical projects and the two ongoing studies of Piclidenoson. We expect
that the research and development expenses will increase through 2022 and beyond.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>General
and administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">General
and administrative expenses were $3.84 million for the year ended December 31, 2021 an increase of $0.89 million, or 30%, compared to
$2.95 million for the year ended December 31, 2020. The increase is primarily due to the increase in salaries and related benefits due
to the distribution of bonuses to employees, increase in public relationship expenses and insurance expenses. We expect that general
and administrative expenses will remain at the same level through 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>Financial
income (expenses), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Financial
income, net for the year ended December 31, 2021 aggregated $0.23 million compared to financial expense, net of $0.3 million for the
year ended December 31, 2020. The decrease in financial expense, net was mainly due to increase in the revaluation of our short-term
investment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we have
funded our operations primarily through public (in Israel and the United States) and private offerings of our equity securities and payments
received under our strategic licensing arrangements. As of December 31, 2022, we had approximately $3 million in cash and cash equivalents
and $5 million in short-term deposits. We have invested most of our available cash funds in ongoing cash accounts and short-term deposits.
In January 2023, we raised approximately $7.5 million in gross proceeds (approximately $6.7 million net of issuance costs) from a registered
direct offering and a concurrent private placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be able to use U.S.
taxes withheld as credits against Israeli corporate income tax when we have income, if at all, but there can be no assurance that we
will be able to realize the credits. In addition, we believe that we may be entitled to a refund of such withholding tax from the U.S.
government but there can be no assurance that we will be entitled to such a refund. For information regarding the revenues and expenses
associated with our licensing agreements, see &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing
and Distribution Agreements&#8221;, &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;In-Licensing Agreements&#8221;
and &#8220;Item 5. Operating and Financial Review and Prospects&#8212;Revenues.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $10.8 million for the year ended December 31, 2022, compared with net cash used in operating activities of $9.85 million
and $12.0 million for the years ended December 31, 2021 and 2020, respectively. The $0.95 million increase in the net cash used in operating
activities during 2022, compared to 2021, was primarily the result of $2.4 million decrease in net loss offset by a $2.2 million change
in deferred revenues, $0.7 million change in other accounts payable and a $0.4 million change in prepaid expenses and other current assets.
The $2.15 million decrease in the net cash used in operating activities during 2021, compared to 2020, was primarily the result of $1.8
million decrease in net loss, $1.95 million change in trade payables, $1.7 million change in deferred revenues and $0.8 million change
in other accounts payable, which were offset by a decrease of $4.1 million in prepaid expenses and other current assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities for the year ended December 31, 2022 was $9.5 million compared to net cash used in investing activities of $14.5 million and
$0.03 million for the years ended December 31, 2021 and December 31, 2020, respectively. Net cash provided by investing activities for
the year ended December 31, 2022 was primarily from withdrawal from short term deposit while in net cash used in investing activities
for the year ended December 31, 2021 was primarily from investment in short term deposit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was no net cash provided
by financing activities for the year ended December 31, 2022, compared to $20.4 million for the year ended December 31, 2021 and $17.7
million of net cash provided by financing activities for the year ended December 31, 2020. The decrease in net cash provided by financing
activities during 2022 compared to 2021 was due to decrease in issuance of shares and warrants, net of issuance expenses during 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Developing drugs, conducting
clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic
objectives. Although we believe our existing financial resources as of the date of issuance of this Annual Report on Form 20-F, will
be sufficient to fund our projected cash requirements at least through the end of the next twelve months, we will require significant
additional financing to fund our operations. Additional financing may not be available on acceptable terms, if at all. Our future capital
requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of research and
    development investment required to develop our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure to obtain regulatory
    approval or achieve commercial success of our product candidates, including Piclidenoson, Namodenoson and CF602;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of our preclinical
    studies and clinical trials for our earlier stage product candidates, and any decisions to initiate clinical trials if supported
    by the preclinical results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome
    of regulatory review of our product candidates that progress to clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing,
    filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending intellectual property-related
    claims;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of commercialization
    activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of manufacturing
    our product candidates and any products we successfully commercialize;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, receipt and amount of sales of, or royalties
    on, our future products, if any;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expenses needed to attract and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or other lawsuits related to
    our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which we acquire or invest in businesses,
    products or technologies and other strategic relationships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of financing
    unanticipated working capital requirements and responding to competitive pressures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining minimum shareholders&#8217;
    equity requirements under the NYSE American Company Guide; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of the COVID-19
    outbreak and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
continuing revenues, we expect to satisfy our future cash needs through payments received under our license agreements, debt or equity
financings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable
terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research
or development programs or our commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our significant contractual obligations in U.S. dollars as of December 31, 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than <br/> 1&#160;year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>1-3&#160;years</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>3-5&#160;years</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More than <br/> 5&#160;years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Contractual Obligations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">567,709</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">567,709</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leiden University milestones<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Car lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,547</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,716</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,831</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">671,251</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">632,090</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">39,161</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left">(1)</td><td style="text-align: justify">The obligations above do not include a potential milestone payment
of &#8364;50,000 upon the initiation of a Phase I study, &#8364;100,000 upon the initiation of a Phase II study, &#8364;200,000 upon the
initiation of a Phase III study or &#8364;500,000 upon marketing approval by any regulatory authority.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as described above,
we did not have any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment
or interests in other companies, as of December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Research and Development, Patents and Licenses, Etc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For information concerning
our research and development policies and a description of the amount spent during each of the last three fiscal years on company-sponsored
research and development activities, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212; Results of Operation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Trend Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development stage
company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization
efforts. As such, it is not possible for us to predict with any degree of accuracy any known trends, uncertainties, demands, commitments
or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability,
liquidity or capital resources, or that would cause reported financial information to not necessarily be indicative of future operating
results or financial conditions. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are
in this &#8220;Operating and Financial Review and Prospects.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Critical Accounting Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We prepare our financial
statements in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported amounts of assets,
liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have
used different accounting policies and estimates. Changes in the accounting estimates are reasonably likely to occur from period to period.
Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these
estimates and actual results, our financial condition or results of operations will be affected. Significant estimates include, but are
not limited to, those related to deferred revenue, revenue recognition, stock-based compensation and fair value of marketable debt securities.
For further significant accounting policies please see Note 2 to our audited consolidated financial statements of this annual report.
We believe that our accounting policies contained therein are critical in fully understanding and evaluating our financial condition
and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;<span style="text-transform: uppercase">&#160;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 6. </b></span><b>Directors,
Senior Management and Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Directors and Senior Management.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth our directors and senior management:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Member</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 53%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilan Cohn, Ph.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pnina Fishman, Ph.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motti Farbstein</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating and Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sari Fishman, Ph.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP of Business Development</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy Regev(1)(2)(3)(4)(5)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abraham Sartani, M.D.(4)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoseph Bornstein(1)(2)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaacov Goldman (1)(2)(3)(4)(5)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Compensation
    Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External Director under
    Israeli Law</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director under
    Israeli Law</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director under
    the NYSE American rules</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Ilan Cohn, Ph.D.</i></b>
Ilan Cohn, Ph.D. is a patent attorney and a founding partner at the patent attorney firm Cohn, de Vries, Stadler &amp; Co. since December
2020. Previously, Dr. Cohen was a senior partner at Reinhold Cohn and Partners, where he has been an attorney since 1986. Dr. Cohn co-founded
Can-Fite, served as its Chief Executive Officer until September 2004, served on our Board of Directors since 1994 and since May 30, 2013
serves as the Chairman of the Can-Fite Board of Directors. Dr. Cohn has also been a director of OphthaliX since November 21, 2011 and
until control was transferred. Dr. Cohn is a patent attorney with many years of experience in the biopharmaceutical field. He has served
on the Board of Directors of a number of life science companies, including Discovery Laboratories Inc. (formerly Ansan Pharmaceuticals),
a U.S. public company. Dr. Cohn has also been involved in the past in management of venture capital funds focused on investments in the
life sciences industry. Dr. Cohn served a number of years as a co-chairman of the Biotech Committee of the US-Israeli Science and Technology
Commission. Dr. Cohn is also currently a member of the Board of Directors of I.C.R.C. Management Ltd, RedDress Medical Ltd. and Feelter
Sales Tools Ltd. Dr. Cohn holds a Ph.D. in Biology from the Hebrew University of Jerusalem.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Pnina Fishman, Ph.D.
</i></b>Pnina Fishman, Ph.D. co-founded Can-Fite and has served as our Chief Executive Officer and served on our Board of Directors since
September 2005. Dr. Fishman is the scientific founder of Can-Fite and was previously a professor of Life Sciences and headed the Laboratory
of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center, Israel. Dr. Fishman has authored
or co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her past managerial
experience included seven years as Chief Executive Officer of Mor Research Application, the technology transfer arm of Clalit Health
Services, the largest healthcare provider in Israel. Mor Research Application was also the first clinical research organization in Israel.
Dr. Fishman currently also serves as a member of the Board of Directors of F.D Consulting Ltd., Eye-Fite Ltd. and Ultratrend. Dr. Fishman
holds a Ph.D. in Immunology from the Bar Ilan University in Ramat Gan, Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Motti Farbstein</i></b>.
Motti Farbstein has been with Can-Fite since 2003. Mr. Farbstein served as our Chief Operating Officer from August 2003 until May 2005
and from that date onwards he served as Chief Operating and Financial Officer. Mr. Farbstein also serves as a director of Eye-Fite Ltd.
since July 2011. Mr. Farbstein&#8217;s past managerial experience includes seven years as Vice President of Mor Research Application,
a company that managed the commercialization of the intellectual property of all hospitals and research centers affiliated with Clalit
Health Services, which is the largest healthcare provider in Israel and was Israel&#8217;s first clinical CRO. Mr. Farbstein also has
extensive experience in the data management of clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Sari Fishman, Ph.D</i>.
</b>Sari Fishman, Ph.D. has served as our Director Clinical Affairs from 2004 to 2014, Director of Business Development from 2014 to
2017 and since 2017 serves as VP of Business Development. Dr. Fishman gained her Ph.D. at the Bar-Ilan University, Ramat-Gan, Israel.
Dr. Sari Fishman is the daughter of Pnina Fishman, our Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Abraham Sartani, M.D.
</i></b>Abraham Sartani has served on our Board of Directors since 2001. Dr. Sartani has over 30 years of experience in the pharmaceuticals
industry and currently acts as a consultant to pharmaceutical and medical device companies. Dr. Sartani is a member of a number of scientific
and management societies and the author or co-author of numerous publications and patents in the urology, pain treatment and hypertension
fields. Dr. Sartani previously served on the Board of Directors of Akkadeas Pharma Srl (formerly Arkadia Pharma) and was a co-founder.
From 1985 until 2008, Dr. Sartani was the Vice-President of R&amp;D and Licensing and Group coordinator of B&amp;D of Recordati, a European
specialty pharmaceutical company. Prior to joining Recordati, from 1980 until 1985, Dr. Sartani was employed at Farmitalia-Carlo Erba,
serving in a number of capacities, including as the Medical Director for Europe. Currently, Dr. Sartani is a member of the board of directors
of BLV Pharma Group Srl, a privately owned Italian food supplements company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Guy Regev. </i></b>Guy
Regev has over fourteen years of experience in accounting, financial management and control and general management of commercial enterprises.
He has served on our Board of Directors since July 2011 and has served as a member of our Audit Committee and Compensation Committee
since February 2014. Mr. Regev has also been a director of OphthaliX since November 2011. Mr. Regev is currently the Chief Executive
Officer of Gaon Holdings Ltd, a publicly traded Israeli holding company traded on the TASE which focuses on three areas of operation
- Cleantech / Water, Financial Services, Retail/Trading. Mr. Regev is currently also the Chief Executive Officer of Middle East Tube
Company Ltd a publicly traded Israeli company traded on the TASE which focuses on steel pipe manufacturing and galvanization services.
Mr. Regev was the Chief Executive Officer of Shaked Global Group Ltd, a privately-held equity investment firm that provides value added
capital to environmental-related companies and technologies. Prior to joining Shaked, from 2001 to 2008, Mr. Regev was Vice President
of Commercial Business at Housing &amp; Construction Holding, or HCH, Israel&#8217;s largest infrastructure company. His duties included
being responsible for the consolidation and financial recovery of various business units within HCH. Prior to that, Mr. Regev carried
several roles within the group including as a Chief Financial Officer and later the Chief Executive Officer of Blue-Green Ltd., the environmental
services subsidiary of HCH. Between 1999 and 2001, Mr. Regev was a manager at Deloitte &amp; Touche, Israel. Mr. Regev holds an LLB degree
in Law (Israel) and is a licensed attorney and has been a licensed CPA since 1999. Mr. Regev is also a director of, The Green Way Ltd,
Shtang Construction and Engineering Ltd, R.I.B.E. Consulting &amp; Investment Ltd., Middle East Tube Company Ltd, Middle East Tube -
Industries 2001 Ltd, Middle East Tubes - Galvanizing (1994) Ltd, I-Solar Greentech Ltd, Plassim Infrastructure Ltd, Plassim Advanced
Solutions in Sanitation Ltd, Hakohav Valves Industries Metal (1987) Ltd, Metzerplas Agriculture Cooperative Ltd, B. Gaon Retail &amp;
Trading Ltd, Gaon Agro - Rimon Management Services Ltd, B. Gaon Business (2004) Ltd, Gaon Antan Investments Ltd, Or Asaf Investments
Ltd, Hamashbir Holdings (1999) Ltd, and AHAVA Holdings LTD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Yoseph Borenstein</i>.
</b>Yoseph Bornstein has played key roles in the Israeli biomed industry during the past 35 years. Mr. Bornstein is a co-founder of Microbot
Medical and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. He is also serving as a compensation
committee member and Audit committee member at Microbot Medical. Mr. Bornstein founded Shizim Ltd., a life science holding group in October
2000 and has served as its president since then. Mr. Bornstein is the Chairman of GCP Clinical Studies Ltd., a provider of clinical research
services and educational programs in Israel since January 2002. He is the Chairman of Biotis Ltd., that supplies bio-pharmaceutical industry,
since June 2000. In addition, he is the Chairman of Dolphin Medical Ltd, that supplies medical device industry, since April 2012. Mr.
Bornstein is a co-founder and director of XACT Robotics, developing a novel platform technology for robotic needle steering in minimally
invasive interventional procedures, and is the founder of ShizimXL &amp; ShizimVS, Innovation Centers. In October 1992, Mr. Bornstein
founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in
2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein served as the Biotechnology
Committee Chairman of the United States-Israel Science &amp; Technology Commission, or the USISTC, from September 2002 to February 2005
as well as a consultant for USISTF from September 2002 to February 2005. He is also the founder of ILSI-Israel Life Science Industry
Organization (who was integrated into Israel Advanced Technology Industries) and ITTN-Israel Tech Transfer Organization. Mr. Bornstein
was the General Manager of Bristol-Myers Squibb (Israel), until 1992. Mr. Bornstein holds a Bachelor of Science degree in Agriculture
from the Hebrew University of Jerusalem.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Yaacov Goldman</i></b>.
Yaacov Goldman has served as external director since August 2017. Mr. Goldman provides consulting services to companies in strategic-financial
areas, through his wholly owned company, Maanit-Goldman Management &amp; Investments (2002) Ltd. Mr. Goldman also serves as a director
of Avgol Industries 1953 Ltd., Mivne Real Estate (K.D) Ltd., Prashkovsky Investments and Construction Ltd., Wearable Devices Ltd., and
until May 2022, Fattal Propoerties (Europe). Mr. Goldman served as the Professional Secretary of the Peer Review Institute of the Certified
Public Accountants Institute in Israel from October 2004 until September 2008. Commencing in 1981, Mr. Goldman worked for Kesselman &amp;
Kesselman (Israeli member firm of PricewaterhouseCoopers) for 19 years, and from 1991 until 2000, as a partner and then senior partner
of such firm. From September 2000 until November 2001, Mr. Goldman served as managing director of Argoquest Holdings, LLC. Mr. Goldman
holds a B.A. degree in Economics and Accounting from Tel Aviv University and is a Certified Public Accountant (Israel).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Compensation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compensation of Directors and Senior Management</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
in the aggregate all compensation we paid to all of our office holders as a group</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8216;office holder&#8217;
as defined in the Companies Law includes a general manager, chief business manager, deputy general manager, vice general manager, any
other person fulfilling or assuming the responsibilities of any of the foregoing positions without regard to such person&#8217;s title,
as well as a director, or a manager directly subordinate to the general manager or the chief executive officer. As of December 31, 2022,
in addition to the seven members of the Board of Directors (including the Company&#8217;s Chief Executive Officer), the Company considers
two other individuals, including its Chief Financial Officer and its VP Business Development to be office holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salaries, fees,<br/> commissions,<br/>
    bonuses and<br/> options<br/> (thousand USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">All office holders as a group, consisting of 9
    persons</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,760</td><td style="width: 1%; text-align: left">*</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            amount includes approximately $0.1 million set aside or accrued to provide pension, severance,
                                            retirement or similar benefits or expenses, but does not include business travel, professional
                                            and business association dues and expenses reimbursed to office holders, and other benefits
                                            commonly reimbursed or paid by companies in our industry.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
information regarding compensation reflected in our financial statements for five most highly compensated office holders, as of December
31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value
    of<br/>
    Options<br/>
    Granted(4)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other(5)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and
    Position</b></span></td>
    <td>&#160;</td>
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(USD
    in thousands)</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 41%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pnina
    Fishman<br/>
    <i>Chief Executive Officer</i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">445</span></td>
    <td style="white-space: nowrap; width: 1%">(1)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">728</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motti
    Farbstein<br/>
    <i>Chief Financial Officer</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">298</span></td>
    <td style="white-space: nowrap">(2)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">471</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sari Fishman<br/>
    <i>VP Business Development</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">231</span></td>
    <td style="white-space: nowrap">(2)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">370</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaacov
    Goldman<br/>
    <i>External Director</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td>
    <td style="white-space: nowrap">(3)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy Regev<br/>
    <i>External Director</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td>
    <td style="white-space: nowrap">(3)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
                                            represents consulting fee.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary
                                            includes gross salary plus payment of social benefits made by us on behalf of such person.
                                            Such benefits may include, to the extent applicable, payments, contributions and/or allocations
                                            for savings funds (e.g., managers&#8217; life insurance policy), education funds (referred
                                            to in Hebrew as &#8220;keren hishtalmut&#8221;), pension, severance, risk insurances (e.g.,
                                            life, or work disability insurance), payments for social security payments and tax gross-up
                                            payments, vacation, medical insurance and benefits, convalescence or recreation pay and other
                                            benefits and perquisites consistent with our policies.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
                                            represents fees for Board service.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            value of options is the expense recorded in our financial statements for the period ended
                                            December 31, 2022 with respect to all options granted to such person. Assumptions and key
                                            variables used in the calculation of such amounts are discussed in Note 10 of our financial
                                            statements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
                                            represents cost of use of company car.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director other than
our Chief Executive Officer and Avraham Sartani, is entitled to the payment of annual fee of NIS 53,155 or $15,105 (based on the exchange
rate reported by the Bank of Israel on December 31, 2022), and payment of NIS 3,552 or $1,009 (based on the exchange rate reported by
the Bank of Israel on December 31, 2022) per meeting for participating in meetings of the Board and committees of the Board. The annual
fee shall not exceed the annual fee of an expert external director set forth in the Companies Regulations (Rules regarding Compensation
and Expenses of External Directors) 5760-2000 as adjusted by the Companies Regulations (Relief for Public Companies with Shares Listed
for Trading on a Stock Market Outside of Israel), 5760-2000. The compensation awarded for participating in resolutions that are adopted
without an actual convening (i.e., unanimous written resolutions) and for participating through telephone meetings will be reduced as
follows: (1) for resolutions that will be adopted without an actual convening, the participation compensation will be reduced by 50%;
and (2) for participation through telephone meetings, the participation compensation will be reduced by 40%. The participation compensation
and the annual fee is inclusive of all expenses incurred by our directors in connection with their participation in a meeting held at
our offices or with regard to resolutions resolved by written consent or teleconference. Avraham Sartani is entitled to a fee of $1,000
per meeting. In addition, our directors (other than our Chief Executive Officer and external directors) are entitled to reimbursement
for expenses related to their participation at meetings taking place not at our offices and outside their respective residency area.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Employment and Consulting Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into employment
or consulting agreements with our directors, senior management and key service providers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of proprietary information and inventions. However, the enforceability
of the noncompetition provisions may be limited under applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain agreements to which we are a party. The descriptions provided below do not purport to be complete and are qualified
in their entirety by the complete agreements, which are attached as exhibits to this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Service Management Agreement
with F.D. Consulting:</i>&#160;On June 27, 2002, we entered into a Service Management Agreement with F.D. Consulting, a company partially
owned by Pnina Fishman, pursuant to which Dr. Fishman began serving as our Chief Scientific Officer and later became our Chief Executive
Officer and is a member of our Board of Directors and continues to be retained through this agreement. F.D. Consulting&#8217;s current
gross monthly fee is NIS 124,614 or $35,412 (based on the exchange rate reported by the Bank of Israel on December 31, 2022) which is
linked to the Israeli CPI and fluctuates accordingly. Dr. Fishman, through F.D. Consulting, is also entitled to reimbursement for reasonable
out-of-pocket expenses and use of a company automobile and mobile phone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of F.D. Consulting&#8217;s
service management agreement is indefinite, unless earlier terminated for cause by us or without cause by either party, subject to three
months&#8217; advanced notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Fishman is also entitled
to receive options exercisable into our ordinary shares from time to time. As of the date of this Annual Report, Dr. Fishman has outstanding
options to purchase an aggregate of 8,600,000 ordinary shares, of which (i) 200,000 options to purchase 200,000 ordinary shares have
an exercise price of NIS 3.573 per ordinary share or $1.01 per ordinary share (based on the exchange rate reported by the Bank of Israel
on December 31, 2022), fully vested as of the date of this Annual Report, (ii) 400,000 options to purchase 400,000 ordinary shares have
an exercise price of NIS 2.344 per ordinary share or $0.66 per ordinary share (based on the exchange rate reported by the Bank of Israel
on December 31, 2022), vesting on a quarterly basis over three years commencing January 7, 2019, and expire on January 7, 2029, (iii)
2,500,000 options to purchase 2,500,000 ordinary shares have an exercise price of NIS 0.25 per ordinary share or $0.07 per ordinary share
(based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing
May 27, 2020, and expire on May 27, 2030, (iv) 2,500,000 options to purchase 2,500,000 ordinary shares have an exercise price of NIS
0.25 per ordinary share or $0.07 per ordinary share (based on the exchange rate reported by the Bank of Israel on December 31, 2022),
vesting on a quarterly basis over four years commencing April 13, 2021, and expire on April 13, 2031 and (v) 3,000,000 options to purchase
3,000,000 ordinary shares have an exercise price of NIS 0.25 per ordinary share or $0.07 per ordinary share (based on the exchange rate
reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing September 5, 2022, and
expire on September 4, 2032.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Employment and Non-Competition
Agreement with Motti Farbstein:</i>&#160;On September 1, 2003 we entered into an employment and non-competition agreement with Motti
Farbstein pursuant to which Mr. Farbstein began serving as our Director of Clinical Operations and Administrative Affairs on September
1, 2003 and is currently serving as our Chief Operating and Financial Officer. Mr. Farbstein&#8217;s current gross monthly salary is
NIS 59,800 or $19,228 (based on the exchange rate reported by the Bank of Israel on December 31, 2021). Mr. Farbstein is entitled to
an allocation to a manager&#8217;s insurance policy equivalent to an amount up to 13-1/3% of his gross monthly salary, up to 2-1/2% of
his gross monthly salary for disability insurance and 7-1/2% of his gross monthly salary for a study fund. The foregoing amounts are
paid by us. Five percent of his gross monthly salary is deducted for the manager&#8217;s insurance policy and 2-1/2% is deducted for
the study fund. Mr. Farbstein is also entitled to reimbursement for reasonable out-of-pocket expenses, including travel expenses, and
use of a company automobile and mobile phone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of Mr. Farbstein&#8217;s
employment and non-competition agreement is indefinite, unless earlier terminated for just cause by either party, upon the death, disability
or retirement age, or without cause by either party, subject to 60 days&#8217; advanced notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Farbstein is also entitled to receive options exercisable into
our ordinary shares from time to time. As of the date of this Annual Report , Mr. Farbstein has outstanding options to purchase an aggregate
of 4,974,000 ordinary shares, of which (i) 100,000 options are exercisable into 4,000 ordinary shares at an exercise price of NIS 8.15
per option or $2.31 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2022) are fully vested, and
expired on March 20, 2023, (iii) 10,000 options to purchase 10,000 ordinary shares at an exercise price of NIS 8.1205 per option or $2.31
per option (based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years
commencing March 19, 2015, and expire on March 18, 2025, (iv) 60,000 options to purchase 60,000 ordinary shares at an exercise price of
NIS 4.317 per option or $1.22 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on
a quarterly basis over four years commencing February 18, 2016 and expire on February 18, 2026, (v) 250,000 options to purchase 250,000
ordinary shares at an exercise price of NIS 2.513 per option or $0.71 per option (based on the exchange rate reported by the Bank of Israel
on December 31, 2022), vesting on a quarterly basis over four years commencing December 28, 2017 and expire on December 28, 2027, (vi)
150,000 options to purchase 150,000 ordinary shares at an exercise price of NIS 2.344 per option or $0.66 per option (based on the exchange
rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four years commencing January 7, 2019 and
expire on January 7, 2029, (vii) 1,000,000 options to purchase 1,000,000 ordinary shares at an exercise price of NIS 0.25 per option or
$0.07 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting on a quarterly basis over four
years commencing May 27, 2020 and expire on May 27, 2030, (viii) 1,500,000 options to purchase 1,500,000 ordinary shares at an exercise
price of NIS 0.25 per option or $0.07 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2022), vesting
on a quarterly basis over four years commencing April 13, 2021 and expire on April 14, 2031; and (x) 2,000,000 options to purchase 2,000,000
ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option (based on the exchange rate reported by the Bank of Israel
on December 31, 2022), vesting on a quarterly basis over four years commencing July 7, 2022 and expire on July 6, 2032.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Consulting Agreement with
BioStrategics:</i>&#160;On September 27, 2005, we entered into a consulting agreement with BioStrategics through its President, Michael
Silverman pursuant to which Dr. Silverman began serving as our Medical Director. Dr. Silverman has extensive experience in clinical development
acquired through his involvement in clinical development in large pharmaceutical and small biopharmaceutical companies. He was involved
in international clinical research, market-oriented strategic planning, and the challenges of managing research and development portfolios
in various capacities at Sterling Winthrop Research Institute and subsequently at Sandoz Research Institute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">BioStrategics&#8217; current
fee is $400 per hour with a maximum daily fee of $2,600. In addition, BioStrategics is entitled to reimbursement for reasonable pre-approved
expenses. The term of the consulting agreement is currently on a year-to-year basis, unless earlier terminated by either party upon 30
days&#8217; prior written notice or immediately by either party if such termination is for cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Master Services Agreement
with Accellient Partners:</i>&#160;On May 10, 2010, we entered into a Master Services Agreement with Accellient Partners, a company owned
by William Kerns, who currently serves as our current Vice President of Drug Development. Dr. Kerns has over 20 years of experience in
Pharmaceutical Research and Development at SmithKline Beecham and Eisai Pharmaceuticals. As a Senior Executive he has participated in
the development of drugs for over 100 Phase I studies and 13 NDA&#8217;s and/or Marketing Authorization Applications. Dr. Kerns has chaired
an FDA committee on biomarkers and he is an expert in preclinical development and regulatory strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the agreement,
consulting services are provided by Accellient Partners&#8217; personnel in accordance with individual work orders that are executed
from time to time. Each individual work order defines the scope of work to be provided and sets forth the fees to be paid to Accellient
Partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beginning on May 10, 2012,
the term of the master services agreement is on a month-to-month basis, unless terminated by us upon 30 days&#8217; prior written notice,
by us at any time if Accellient Partners commits a breach and fails to cure, or by Accellient Partners upon 30 days&#8217; prior written
notice if we commit a breach and fail to cure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Cohn, De Vries, Stadler&amp;
Co.:</i>&#160;Cohn, De Vriew, Stadler &amp; Co. of which Ilan Cohn, Ph.D. is a partner provides intellectual property services to us
in the ordinary course of business. Previously, Dr. Cohn was a partner with Reinhold Cohn and Partners that provided intellectual property
services to us in the ordinary course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Board Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Israeli
Companies Law, the management of our business is vested in our Board of Directors. Our Board of Directors may exercise all powers and
may take all actions that are not specifically granted to our shareholders. Our executive officers are responsible for our day-to-day
management and have individual responsibilities established by our Board of Directors. Executive officers are appointed by and serve
at the discretion of our Board of Directors, subject to any applicable employment agreements we have entered into with the executive
officers. See &#8220;Item 6. Directors, Senior Management and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Election of Directors and Terms of Office</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association provide that the maximum number of members of the Board of Directors is 13. The Board of Directors is presently
comprised of six members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, a special
general meeting of our shareholders approved an amendment to the our Amended and Restated Articles of Association, according to which
the Board of Directors, excluding the external directors, if any (who shall be elected and serve in office in strict accordance with
the provisions of the Companies Law, if so required by the Companies Law), shall consist of three classes of directors as nearly equal
in number as practicable, which are appointed for fixed terms of office in accordance with the Israeli Companies Law and our Amended
and Restated Articles of Association, as follows: (i) the term of office of the initial Class I directors expired at the first annual
general meeting of our shareholders held in 2020 and when their successors are elected and qualified, (ii) the term of office of the
initial Class II directors shall expire at the first annual general meeting of our shareholders following the annual general meeting
of our shareholders referred to in clause (i) above and when their successors are elected and qualified, and (iii) the term of office
of the initial Class III directors shall expire at the first annual general meeting of our shareholders following the annual general
meeting of our shareholders referred to in clause (ii) above and when their successors are elected and qualified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors (other than external
directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of our shareholders, commencing
with the annual general meeting of our shareholders held in 2021, each of the successors elected to replace the directors of a class
whose term shall have expired at such annual general meeting of our shareholders shall be elected to hold office until the third annual
general meeting of our shareholders next succeeding his or her election and until his or her respective successor shall have been elected
and qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and qualified
or until such earlier time as such director&#8217;s office is vacated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of directors
(excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving directors shall be re-designated
to other classes and/or any newly created directorships or decrease in directorships shall be apportioned by the Board of Directors among
the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors
constituting the Board of Directors shall shorten the term of any incumbent director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors so elected may
not be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of their term of
office. The directors do not receive any benefits upon the expiration of their term of office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The three classes of directors
are Class I Directors, Class II Directors and Class III Directors. Abraham Sartani serves as our Class I Director until the close of
the annual meeting to be held in 2023; and Ilan Cohn serves as our Class II Director until the close of the annual meeting to be held
in 2024; Dr. Pnina Fishman and Mr. Guy Regev serve as our Class III Directors until the close of the annual meeting to be held in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amendment, replacement
or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described above, require a
majority of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and voting thereon,
disregarding abstentions from the count of the voting power present and voting, provided that such majority constitutes more than 20%
of our then issued and outstanding share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A nominee for service as
a director in a public company may not be elected without submitting a declaration to the company, prior to election, specifying that
he or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable,
and the ability to devote the appropriate time to performing his or her duties as such.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director, who ceases to
meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 30, 2013, Ilan Cohn
was appointed as Chairman of the Board. On August 1, 2017, at an annual general meeting of our shareholders Yaacov Goldman was elected
to serve as one of our external directors for a three-year term ending July 31, 2020.&#160;On August 12, 2020 at an annual general meeting
of our shareholders, Yaacov Goldman was elected to serve for an additional three-year term ending July 24, 2023.&#160;On December 27,
2017, at a special meeting of our shareholders, Israel Shamay was elected to serve for a three-year term ending December 26, 2020 as
one of our external directors. On December 9, 2020, at an annual general meeting of our shareholders, Israel Shamay was elected to serve
for an additional three-year term ending December 30, 2023. On June 11, 2021, Israel Shamay passed away. On August 5, 2021, at a special
meeting of our shareholders Yoseph Bornstein was elected to serve as one of our external directors for a three-year term ending July
29, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our directors or
senior management has any family relationship with any other director or senior management except that Sari Fishman is the daughter of
Pnina Fishman. None of our directors have service contracts that provide for benefits upon termination of his or her directorship with
us, other than the payment of salary due, accrued and unpaid as of and through the date of termination. See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Chairman of the Board.
Un</i>der the Israeli Companies Law, without shareholder approval, a person cannot hold the role of both chairman of the Board of Directors
and chief executive officer of a company. Furthermore, a person who is directly or indirectly subordinate to a chief executive officer
of a company may not serve as the chairman of the Board of Directors of that company and the chairman of the Board of Directors may not
otherwise serve in any other capacity in a company or in a subsidiary of that company other than as the chairman of the Board of Directors
of such a subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an Israeli company may, under certain circumstances, exculpate an office holder from liability with respect to a breach
of his duty of care toward the company if appropriate provisions allowing such exculpation are included in its articles of association.
Our Amended and Restated Articles of Association permit us to maintain directors&#8217; and officers&#8217; liability insurance and to
indemnify our directors and officers for actions performed on behalf of us, subject to specified limitations. We maintain a directors
and officers insurance policy which covers the liability of our directors and officers as allowed under the Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term office holder is
defined in the Israeli Companies Law as a director, general manager, chief business manager, deputy general manager, vice general manager,
executive vice president, vice president, any other manager directly subordinate to the general manager, director, or any other person
assuming the responsibilities of any of the foregoing positions, without regard to such person&#8217;s title.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>External and Independent Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the boards of directors of companies whose shares are publicly traded, either within or outside of Israel, are required to include
at least two members who qualify as external directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors must be
elected by a majority vote of the shares present and voting at a shareholders meeting, provided that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the majority of the shares
    that are voted at the meeting, shall include at least a majority of the shares held by non-controlling shareholders and shareholders
    who do not have a personal interest in the election of the external director (other than a personal interest not deriving from a
    relationship with a controlling shareholder) who voted at the meeting, excluding abstentions, vote in favor of the election of the
    external director; Anyone with a personal interest will be subject to the provisions of section 276, mutatis mutandis; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares
    held by non-controlling, disinterested shareholders (as described in the preceding bullet point) that are voted against the election
    of the external director does not exceed 2% of the aggregate voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;controlling
shareholder&#8221; means a shareholder with the ability to direct the activities of the company, other than by virtue of being an office
holder. A shareholder is presumed to have &#8220;control&#8221; of the company and thus to be a controlling shareholder of the company
if the shareholder holds 50% or more of the &#8220;means of control&#8221; of the company. &#8220;Means of control&#8221; is defined
as (1) the right to vote at a general meeting of a company or a corresponding body of another corporation; or (2) the right to appoint
directors of the corporation or its general manager. For the purpose of approving related-party transactions, the term also includes
any shareholder that holds 25% or more of the voting rights of the company if the company has no shareholder that owns more than 50%
of its voting rights. For the purpose of determining the holding percentage stated above, two or more shareholders who have a personal
interest in a transaction that is brought for the company&#8217;s approval are deemed as joint holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person may not serve as
an external director of a company if (i) such person is a relative of a controlling shareholder of a company or (ii) at the date of such
person&#8217;s appointment or within the prior two years, such person, such person&#8217;s relative, partner, employer or any entity
under such person&#8217;s control or anyone to whom such person is subordinate, whether directly or indirectly, has or had any affiliation
with (a) the company, (b) the controlling shareholder or his relative, at the time of such person&#8217;s appointment or (c) any entity
that is either controlled by the company or by its controlling shareholder at the time of such appointment or during the prior two years.
If a company does not have a controlling shareholder or a group of shareholders who have a control block entitling them to vote at least
25% of the votes in a shareholders meeting, then a person may not serve as an external director if, such person or such person&#8217;s
relative, partner, employer or any entity under such person&#8217;s control, has or had, on or within the two years preceding the date
of the person&#8217;s appointment to serve as an external director, any affiliation with the chairman of our Board of Directors, chief
executive officer, a substantial shareholder who holds at least 5% of the issued and outstanding shares of the company or voting rights
which entitle him to vote at least 5% of the votes in a shareholders meeting, or the chief financial officer of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term affiliation includes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an employment relationship;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a business or professional
    relationship even if not maintained on a regular basis (excluding insignificant relationships);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">control; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">service as an office holder,
    excluding service as a director in a private company prior to the initial offering of its shares to the public if such director was
    appointed as a director of the private company in order to serve as an external director following the public offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term relative is defined
as a spouse, sibling, parent, grandparent or descendant; a spouse&#8217;s sibling, parent or descendant; and the spouse of each of the
foregoing persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, no person may
serve as an external director if that person&#8217;s professional activities create, or may create, a conflict of interest with that
person&#8217;s responsibilities as a director or otherwise interfere with that person&#8217;s ability to serve as an external director
or if the person is an employee of the Israel Securities Authority, or the ISA, or of the TASE. Furthermore, a person may not continue
to serve as an external director if he or she received direct or indirect compensation from the company for his or her role as a director.
This prohibition does not apply to compensation paid or given in accordance with regulations promulgated under the Israeli Companies
Law or amounts paid pursuant to indemnification and/or exculpation contracts or commitments and insurance coverage. If, at the time an
external director is appointed, all current members of the Board of Directors not otherwise affiliated with the company are of the same
gender, then that external director must be of the other gender. In addition, a director of a company may not be elected as an external
director of another company if, at that time, a director of the other company is acting as an external director of the first company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the termination
of an external director&#8217;s service on a Board of Directors, such former external director and his or her spouse and children may
not be provided with a direct or indirect benefit by the company, its controlling shareholder or any entity under its controlling shareholder&#8217;s
control. This includes engagement to serve as an executive officer or director of the company or a company controlled by its controlling
shareholder, or employment by, or providing services to, any such company for consideration, either directly or indirectly, including
through a corporation controlled by the former external director, for a period of two years (and for a period of one year with respect
to relatives of the former external director).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an external director must meet certain professional qualifications or have financial and accounting expertise and that
at least one external director must have financial and accounting expertise. However, if at least one of our other directors (i) meets
the independence requirements of the Securities Exchange Act of 1934, as amended, (ii) meets the standards of the NYSE American rules
for membership on the audit committee and (iii) has financial and accounting expertise as defined in the Israeli Companies Law and applicable
regulations, then neither of our external directors is required to possess financial and accounting expertise as long as both possess
other requisite professional qualifications. Our Board of Directors is required to determine whether a director possesses financial and
accounting expertise by examining whether, due to the director&#8217;s education, experience and qualifications, the director is highly
proficient and knowledgeable with regard to business-accounting issues and financial statements, to the extent that the director is able
to engage in a discussion concerning the presentation of financial information in our financial statements, among others. The regulations
define a director with the requisite professional qualifications as a director who satisfies one of the following requirements: (i) the
director holds an academic degree in either economics, business administration, accounting, law or public administration; (ii) the director
either holds an academic degree in any other field or has completed another form of higher education in our primary field of business
or in an area which is relevant to the office of an external director; or (iii) the director has at least five years of experience serving
in any one of the following, or at least five years of cumulative experience serving in two or more of the following capacities: (a)
a senior business management position in a corporation with a substantial scope of business; (b) a senior position in our primary field
of business; or (c) a senior position in public administration. Yaacov Goldman, who is one of our external directors, meets the required
qualifications and has financial and accounting expertise as required by the Israeli Companies Law, while Guy Regev, an independent director,
also meets the required qualifications and has financial and accounting expertise as required by the Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
defines an independent director as a director who complies with the following and was appointed as such in accordance with Chapter 1
of Part 56 of the Israeli Companies Law: (1) the director complies with the qualification to serve as an external director as set out
in Sections 240 (b)-(f) of the Israeli Companies Law and the audit committee has approved such compliance; and (2) the director has not
served as a director of the company for more than nine consecutive years (which, for such purpose, does not include breaks in such service
for periods of less than two year).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an external directorship
becomes vacant and there are less than two external directors on the Board of Directors at the time, then the Board of Directors is required
under the Israeli Companies Law to call a shareholders&#8217; meeting as soon as possible to appoint a replacement external director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each committee of the Board
of Directors that is authorized to exercise the powers of the Board of Directors must include at least one external director, except
that the audit committee and compensation committee must each include all external directors then serving on the Board of Directors.
Under the Israeli Companies Law, external directors of a company are prohibited from receiving, directly or indirectly, any compensation
for their services as external directors, other than compensation and reimbursement of expenses pursuant to applicable regulations promulgated
under the Israeli Companies Law. Compensation of an external director is determined prior to his or her appointment and may not be changed
during his or her term subject to certain exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yoseph Borenstein and Yaacov
Goldman serve as external directors on our Board of Directors pursuant to the provisions of the Israeli Companies Law. They both serve
on our audit committee and our compensation committee. Our Board of Directors has determined that Yaacov Goldman possesses accounting
and financial expertise, and that both of our external directors possess the requisite professional qualifications. In addition to our
external directors, Guy Regev and Abraham Sartani serve as independent directors on our Board of Directors. Guy Regev also serves on
our audit committee and our compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires public companies to appoint an audit committee. The responsibilities of the audit committee include identifying irregularities
in the management of our business and approving related party transactions as required by law. An audit committee must consist of at
least three directors, including all of its external directors and a majority of independent directors. The chairman of the Board of
Directors, any director employed by or otherwise providing services to the company, and a controlling shareholder or any relative of
a controlling shareholder, may not be a member of the audit committee. An audit committee may not approve an action or a transaction
with a controlling shareholder, or with an office holder, unless at the time of approval two external directors are serving as members
of the audit committee and at least one of the external directors was present at the meeting in which an approval was granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is currently
comprised of three independent non-executive directors. The audit committee is chaired by Yaacov Goldman, who serves as the audit committee
financial expert, with Yoseph Borenstein and Guy Regev as members. Our audit committee meets at least four times a year and monitors
the adequacy of our internal controls, accounting policies and financial reporting. It regularly reviews the results of the ongoing risk
self-assessment process, which we undertake, and our interim and annual reports prior to their submission for approval by the full Board
of Directors. The audit committee oversees the activities of the internal auditor, sets its annual tasks and goals and reviews its reports.
The audit committee reviews the objectivity and independence of the external auditors and also considers the scope of their work and
fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee provides
assistance to our Board of Directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing,
financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants
and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee
also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that
the accountants are independent of management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our audit committee is responsible for (i) determining whether there are deficiencies in the business management practices of our
company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the Board of Directors
to improve such practices and amend such deficiencies, (ii) determining whether certain related party transactions (including transactions
in which an office holder has a personal interest) should be deemed as material or extraordinary, and to approve such transactions (which
may be approved according to certain criteria set out by our audit committee on an annual basis) (see &#8220;&#8212;Approval of Related
Party Transactions under the Israeli Companies Law&#8221;); (iii) establishing procedures to be followed in respect of related party
transactions with a controlling shareholder (where such are not extraordinary transactions), which may include, where applicable, the
establishment of a competitive process for such transaction, under the supervision of the audit committee, or individual, or other committee
or body selected by the audit committee, in accordance with criteria determined by the audit committee; (iv) determining procedures for
approving certain related party transactions with a controlling shareholder, which having been determined by the audit committee not
to be extraordinary transactions, were also determined by the audit committee not to be negligible transactions; (v) approving the working
plan of the internal auditor, to examine such working plan before its submission to the Board and proposing amendments thereto, (vi)
examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources
and tools to dispose of its responsibilities, (vii) examining the scope of our auditor&#8217;s work and compensation and submitting a
recommendation with respect thereto to our Board of Directors or shareholders, depending on which of them is considering the appointment
of our auditor, and (viii) establishing procedures for the handling of employees&#8217; complaints as to the management of our business
and the protection to be provided to such employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
charter for our audit committee, setting forth its responsibilities as outlined by the regulations of the SEC. In addition, our audit
committee has adopted procedures for the receipt, retention and treatment of complaints we may receive regarding accounting, internal
accounting controls or auditing matters and the submission by our employees of concerns regarding questionable accounting or auditing
matters. In addition, SEC rules mandate that the audit committee of a listed issuer consist of at least three members, all of whom must
be independent, as such term is defined by rules and regulations promulgated by the SEC. We are in compliance with the independence requirements
of the SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person who is not eligible
to serve on the audit committee is further restricted from participating in its meetings and votes, unless the chairman of the audit
committee determines that such person&#8217;s presence is necessary in order to present a certain matter; provided, however, that company
employees who are not controlling shareholders or relatives of such shareholders may be present in the meetings, but not for actual voting,
and likewise, company counsel and secretary who are not controlling shareholders or relatives of such shareholders may be present in
the meetings and for actual voting if such presence is requested by the audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the above,
all such committee&#8217;s members must apply with the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All members shall be members
    of the Board of Directors of the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least one of the committee&#8217;s
    members shall have financial and accounting expertise and the rest of the committee&#8217;s members must have the ability to read
    and understand financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company, through our
audit committee, is in full compliance with the above requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial Statement Examination Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the Board of Directors of a public company must appoint a financial statement examination committee, which consists of members with
accounting and financial expertise or the ability to read and understand financial statements. According to a resolution of our Board
of Directors, the audit committee has been assigned the responsibilities and duties of a financial statements examination committee,
as permitted under relevant regulations promulgated under the Israeli Companies Law. From time to time as necessary and required to approve
our financial statements, the audit committee holds separate meetings, prior to the scheduled meetings of the entire Board of Directors
regarding financial statement approval. The function of a financial statements examination committee is to discuss and provide recommendations
to its Board of Directors (including the report of any deficiency found) with respect to the following issues: (i) estimations and assessments
made in connection with the preparation of financial statements; (ii) internal controls related to the financial statements; (iii) completeness
and propriety of the disclosure in the financial statements; (iv) the accounting policies adopted and the accounting treatments implemented
in material matters of the company; and (v) value evaluations, including the assumptions and assessments on which evaluations are based
and the supporting data in the financial statements. Our independent auditors and our internal auditors are invited to attend all meetings
of audit committee when it is acting in the role of the financial statements examination committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amendment no. 20 to the Israeli
Companies Law was published on November 12, 2012 and became effective on December 12, 2012, or Amendment no. 20. In general, Amendment
no. 20 requires public companies to appoint a compensation committee and to adopt a compensation policy with respect to its officers,
or the Compensation Policy. In addition, Amendment no. 20 addresses the corporate approval process required for a public company&#8217;s
engagement with its officers (with specific reference to a director, a non-director officer, a chief executive officer and controlling
shareholders and their relatives who are employed by the company).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
shall be nominated by the Board of Directors and be comprised of its members. The compensation committee must consist of at least three
members. All of the external directors must serve on the compensation committee and constitute a majority of its members. The remaining
members of the compensation committee must be directors who qualify to serve as members of the audit committee (including the fact that
they are independent) and their compensation should be identical to the compensation paid to the external directors of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to the rules that
apply to the audit committee, the compensation committee may not include the chairman of the board, or any director employed by the Company,
by a controlling shareholder or by any entity controlled by a controlling shareholder, or any director providing services to the company,
to a controlling shareholder or to any entity controlled by a controlling shareholder on a regular basis, or any director whose primary
income is dependent on a controlling shareholder, and may not include a controlling shareholder or any of its relatives. Individuals
who are not permitted to be compensation committee members may not participate in the committee&#8217;s meetings other than to present
a particular issue; provided, however, that an employee that is not a controlling shareholder or relative may participate in the committee&#8217;s
discussions, but not in any vote, and our legal counsel and corporate secretary may participate in the committee&#8217;s discussions
and votes if requested by the committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The roles of the compensation
committee are, among others, to: (i) recommend to the Board of Directors the Compensation Policy for office holders and recommend to
the board once every three years the extension of a Compensation Policy that had been approved for a period of more than three years;
(ii) recommend to the directors any update of the Compensation Policy, from time to time, and examine its implementation; (iii) decide
whether to approve the terms of office and of employment of office holders that require approval of the compensation committee; and (iv)
decide, in certain circumstances, whether to exempt the approval of terms of office of a chief executive officer from the requirement
of shareholder approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy requires
the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires a majority of the shareholders
of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the proposed resolution, or that
shareholders holding less than 2% of the voting power in the company voted against the proposed resolution at such meeting. However,
under special circumstances, the Board of Directors may approve the compensation policy without shareholder approval, if the compensation
committee and thereafter the Board of Directors decided, based on substantiated reasons after they have reviewed the Compensation Policy
again, that the Compensation Policy is in the best interest of the company. The Compensation Policy is required to be brought before
the shareholders of the Company once every three years for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our Compensation Policy must generally serve as the basis for corporate approvals with respect to the financial terms of employment
or engagement of office holders, including exemption, insurance, indemnification or any monetary payment or obligation of payment in
respect of employment or engagement. The Compensation Policy must relate to certain factors, including advancement of the company&#8217;s
objective, the company&#8217;s business plan and its long term strategy, and creation of appropriate incentives for office holders. It
must also consider, among other things, the company&#8217;s risk management, size and nature of its operations. The Compensation Policy
must furthermore consider the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The knowledge, skills,
    expertise, and accomplishments of the relevant office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The office holder&#8217;s
    roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The relationship between
    the terms offered and the average compensation of the other employees of the company, including those employed through manpower companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The impact of disparities
    in salary upon work relationships in the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The possibility of reducing
    variable compensation at the discretion of the Board of Directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The possibility of setting
    a limit on the exercise value of non-cash variable equity-based compensation; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As to severance compensation,
    the period of service of the office holder, the terms of his or her compensation during such service period, the company&#8217;s
    performance during that period of service, the person&#8217;s contributions towards the company&#8217;s achievement of its goals
    and the maximization of its profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also include the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the link between variable
    compensation and the long term performance and measurable criteria;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between
    variable and fixed compensation, and the ceiling for the value of variable compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which
    an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation
    was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or
    vesting period for variable, equity-based compensation; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance
    compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy was
approved by the general meeting of shareholders on January 19, 2017 after discussions and recommendation of the compensation committee
and approval by the Board of Directors. The Compensation Policy was amended by the general meeting of shareholders on June 7, 2021. Moreover,
the approval of the compensation committee is required in order to approve terms of office and/or employment of office holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yaacov Goldman is the chairman
of our compensation committee. Guy Regev and Yoseph Bornstein serve as the other members of our compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Amendment no. 27 to
the Israeli Companies Law, which became effective as of February 17, 2016, the audit committee of an Israeli public company which has
been established and conducts itself also in accordance with provisions governing the composition of the compensation committee as set
forth in the Israeli Companies Law, may act in lieu of a compensation committee with respect to the responsibilities of a compensation
committee which are set forth in the Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Approval of Related Party Transactions under the Israeli Companies
Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Fiduciary duties of the
office holders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
imposes a duty of care and a duty of loyalty on all office holders of a company. The duty of care of an office holder is based on the
duty of care set forth in connection with the tort of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty
of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in the same position would
have acted under the same circumstances. The duty of care includes a duty to use reasonable means, in light of the circumstances, to
obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the advisability
    of a given action brought for his or her approval or performed by virtue of his or her position; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">all other important information
pertaining to these actions.&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty requires
an office holder to act in good faith and for the benefit of the company, and includes the duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any act involving
    a conflict of interest between the performance of his or her duties in the company and his or her other duties or personal affairs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any activity
    that is competitive with the business of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting
    any business opportunity of the company for the purpose of gaining a personal advantage for himself or herself or others; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company
    any information or documents relating to our affairs which the office holder received as a result of his or her position as an office
    holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may approve an act performed
in breach of the duty of loyalty of an office holder provided that the office holder acted in good faith, the act or its approval does
not harm the company, and the office holder discloses his or her personal interest, as described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Disclosure of personal
interests of an office holder and approval of acts and transactions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy requires
the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires a majority of the shareholders
of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the proposed resolution, or that
shareholders holding less than 2% of the voting power in the company voted against the proposed resolution at such meeting. However,
under special circumstances, the Board of Directors may approve the compensation policy without shareholder approval, if the compensation
committee and thereafter the Board of Directors decided, based on substantiated reasons after they have reviewed the Compensation Policy
again, that the Compensation Policy is in the best interest of the company. The Compensation Policy is required to be brought before
the shareholders of the Company once every three years for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term personal interest
is defined under the Israeli Companies Law to include the personal interest of a person in an action or in the business of a company,
including the personal interest of such person&#8217;s relative or the interest of any corporation in which the person is an interested
party, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal interest furthermore
includes the personal interest of a person for whom the office holder holds a voting proxy or the interest of the office holder with
respect to his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder itself has no personal
interest in the approval of the matter. An office holder is not, however, obliged to disclose a personal interest if it derives solely
from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, an extraordinary transaction which requires approval is defined as any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction other than
    in the ordinary course of business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction that is not
    on market terms; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction that may
    have a material impact on our profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, once an office holder has complied with the disclosure requirement described above, a company may approve a transaction between
the company and the office holder or a third party in which the office holder has a personal interest, or approve an action by the office
holder that would otherwise be deemed a breach of duty of loyalty. However, a company may not approve a transaction or action that is
adverse to our interest or that is not performed by the office holder in good faith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, unless the articles of association of a company provide otherwise, a transaction with an office holder, a transaction with a third
party in which the office holder has a personal interest, and an action of an office holder that would otherwise be deemed a breach of
duty of loyalty requires approval by the Board of Directors. Our Amended and Restated Articles of Association do not provide otherwise.
If the transaction or action considered is (i) an extraordinary transaction, (ii) an action of an office holder that would otherwise
be deemed a breach of duty of loyalty and may have a material impact on a company&#8217;s profitability, assets or liabilities, (iii)
an undertaking to indemnify or insure an office holder who is not a director, or (iv) for matters considered an undertaking concerning
the terms of compensation of an office holder who is not a director, including, an undertaking to indemnify or insure such office holder,
then approval by the audit committee is required prior to approval by the Board of Directors. Arrangements regarding the compensation,
indemnification or insurance of a director require the approval of the audit committee, Board of Directors and shareholders, in that
order.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director who has a personal
interest in a matter that is considered at a meeting of the Board of Directors or the audit committee may generally not be present at
the meeting or vote on the matter, unless a majority of the directors or members of the audit committee have a personal interest in the
matter or the chairman of the audit committee or Board of Directors, as applicable, determines that he or she should be present to present
the transaction that is subject to approval. If a majority of the directors have a personal interest in the matter, such matter would
also require approval of the shareholders of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Disclosure of personal
interests of a controlling shareholder and approval of transactions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company. See &#8220;&#8212;
Audit Committee&#8221; for a definition of controlling shareholder. Extraordinary transactions with a controlling shareholder or in which
a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest,
as well as transactions for the provision of services whether directly or indirectly by a controlling shareholder or his or her relative,
or a company such controlling shareholder controls, and transactions concerning the terms of engagement of a controlling shareholder
or a controlling shareholder&#8217;s relative, whether as an office holder or an employee, require the approval of the audit committee,
the Board of Directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in
a shareholders&#8217; meeting. In addition, such shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of
    the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor
    of approving the transaction, excluding abstentions; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders
    who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights
    in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that any such
transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three years,
unless the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Duties of shareholders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in
exercising its rights and performing its obligations to the company and other shareholders, including, among other things, voting at
general meetings of shareholders on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an amendment to the articles
    of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in our authorized
    share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related
    party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder also has a
general duty to refrain from discriminating against other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remedies generally available
upon a breach of contract will also apply to a breach of the above mentioned duties, and in the event of discrimination against other
shareholders, additional remedies are available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power
with respect to a company, is under a duty to act with fairness towards the company. The Israeli Companies Law does not describe the
substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of
a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Exculpation, Insurance and Indemnification of Directors and
Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate
an office holder in advance from liability to us, in whole or in part, for damages caused to us as a result of a breach of duty of care
but only if a provision authorizing such exculpation is included in its articles of association. Our Amended and Restated Articles of
Association include such a provision. We may not exculpate in advance a director from liability arising out of a prohibited dividend
or distribution to shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law and the Israeli Securities Law, a company may indemnify, or undertake in advance to indemnify, an office holder, provided its articles
of association include a provision authorizing such indemnification, for the following liabilities and expenses imposed on an office
holder or incurred by office holder due to acts performed by him or her as an office holder:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liability incurred
    by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award
    approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance,
    then such an undertaking must be limited to events which, in the opinion of the Board of Directors, can be foreseen based on our
    activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the Board of Directors
    as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonable litigation expenses,
    including attorneys&#8217; fees, incurred by the office holder as a result of an investigation or proceeding instituted against him
    or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against
    such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as
    a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed,
    it was imposed with respect to an offense that does not require proof of criminal intent or as a monetary sanction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasonable litigation expenses,
    including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her
    by us, on our behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or
    as a result of a conviction for an offense that does not require proof of criminal intent; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses, including reasonable
    litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such
    office holder, or certain compensation payments required to be made to an injured party, pursuant to certain provisions of the Israeli
    Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder
if and to the extent provided in the Company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of
    loyalty to us, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm
    us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    to us or to a third party; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed
    on the office holder in favor of a third party.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Israeli Companies Law and the Israeli Securities Law, we may also enter into a contract to insure an office holder, in respect
of expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding
instituted against such office holder or payment required to be made to an injured party, pursuant to certain provisions of the Israeli
Securities Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevertheless, under the Israeli
Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of fiduciary duty,
    except for indemnification and insurance for a breach of the duty of loyalty to us in the event office holder acted in good faith
    and had a reasonable basis to believe that the act would not prejudice us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed
    with intent to derive unlawful personal benefit; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine, monetary sanction,
    penalty or forfeit levied against the office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, exculpation, indemnification and insurance of office holders require the approval of the compensation committee, Board of Directors
and, in certain circumstances, the shareholders. Our Amended and Restated Articles of Association permit us to exculpate, indemnify and
insure our office holders to the fullest extent permitted by the Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Approval of Compensation to Our Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
prescribes that compensation to officers must be approved by a company&#8217;s Board of Directors after obtaining the approval of the
compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As detailed above, our compensation
committee consists of three independent directors: Yoseph Borenstein, Yaacov Goldman and Guy Regev. The responsibilities of the compensation
committee are to set our overall policy on executive remuneration and to decide the specific remuneration, benefits and terms of employment
for directors, officers and the Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The objectives of the compensation
committee&#8217;s policies are that such individuals should receive compensation which is appropriate given their performance, level
of responsibility and experience. Compensation packages should also allow us to attract and retain executives of the necessary caliber
while, at the same time, motivating them to achieve the highest level of corporate performance in line with the best interests of shareholders.
In order to determine the elements and level of remuneration appropriate to each executive director, the compensation committee reviews
surveys on executive pay, obtains external professional advice and considers individual performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Internal Auditor</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the Board of Directors must appoint an internal auditor, nominated by the audit committee. The role of the internal auditor is to
examine, among other matters, whether our actions comply with the law and orderly business procedure. Under the Israeli Companies Law,
an internal auditor may not be:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative
    of a person) who holds more than 5% of our ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative
    of a person) who has the power to appoint a director or the general manager of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an executive officer or
    director of the company (or a relative thereof); or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a member of our independent
    accounting firm, or anyone on his or her behalf.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">We comply with the requirement
of the Israeli Companies Law relating to internal auditors. Our internal auditors examine whether our various activities comply with
the law and orderly business procedure. Our current internal auditor is Brightman Almagor Zohar &amp; Co. (A Firm in the Deloitte Global
Network).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Employees.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022,
we had eight employees, three of whom were employed in management and administration, four of whom were employed in research and development
and one of whom was employed in business development. All of these employees were located in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While none of our employees
are party to any collective bargaining agreements, certain provisions of the collective bargaining agreements between the Histadrut (General
Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the Industrialists&#8217; Associations)
are applicable to our employees by order of the Israel Ministry of Labor. These provisions primarily concern the length of the workday,
minimum daily wages for professional workers, pension fund benefits for all employees, insurance for work-related accidents, procedures
for dismissing employees, determination of severance pay and other conditions of employment. We generally provide our employees with
benefits and working conditions beyond the required minimums. We have never experienced any employment-related work stoppages and believe
our relationship with our employees is good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Share Ownership.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information regarding the beneficial ownership of our outstanding ordinary shares as of March 30, 2023 by the members of our senior
management and Board of Directors individually and as a group. The beneficial ownership of ordinary shares is based on the 1,224,837,393
ordinary shares outstanding as of March 30, 2023 and is determined in accordance with the rules of the SEC and generally includes any
ordinary shares over which a person exercises sole or shared voting or investment power. For purposes of the table below, we deem shares
subject to options or warrants that are currently exercisable or exercisable within 60 days of March 30, 2023, to be outstanding and
to be beneficially owned by the person holding the options or warrants for the purposes of computing the percentage ownership of that
person but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Ordinary Shares*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage<br/> of<br/> Class**</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Senior Management and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Ilan Cohn, Ph.D.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">594,067</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Pnina Fishman, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,363,433</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Motti Farbstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,346,133</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sari Fishman, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,181,250</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Guy Regev</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">494,740</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Abraham Sartani, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460,500</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yaacov Goldman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460,500</td><td style="text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Yoseph Borenstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,500</td><td style="text-align: left">(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Senior Management and Directors as a group (8 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,163,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
                                            dollar translations of NIS amounts presented in the footnotes to this table are translated
                                            using the exchange rate reported by the Bank of Israel on December 31, 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
                                            less than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            (i) 133,567 ordinary shares, (ii) 48,000 options to purchase 48,000 ordinary shares at an
                                            exercise price of NIS 2.926 per option or $0.83 per option and expire on November 8, 2027,
                                            and (iii) 412,500 options to purchase 412,500 ordinary shares at an exercise price of NIS
                                            0.25 per option or $0.07 per option and expire on June 14, 2030. Excludes 187,500 options
                                            to purchase 187,500 ordinary shares that vest in more than 60 days from March 30, 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            (i) 263,433 ordinary shares, (ii) 200,000 options to purchase 200,000 ordinary shares at
                                            an exercise price of NIS 3.573 per option or $1.01 per option and expire on October 22, 2025,
                                            (iii) 400,000 options to purchase 400,000 ordinary shares at an exercise price of NIS 2.344
                                            per option or $0.66 per option and expire on January 7, 2029, (iv) 1,875,000 options to purchase
                                            1,875,000 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option
                                            and expire on May 27, 2030; (v) 1,250,000 options to purchase 1,250,000 ordinary shares at
                                            an exercise price of NIS 0.25 per option or $0.07 per option and expire on April 13, 2031;
                                            and (vi) 375,000 options to purchase 375,000 ordinary shares at an exercise price of NIS
                                            0.25 per option or $0.07 per option and expire on September 5, 2032. Excludes 4,500,000 options
                                            to purchase 4,500,000 ordinary shares that vest in more than 60 days from March 30, 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            (i) 1,133 ordinary shares, (ii) 10,000 options to purchase 10,000 ordinary shares at an exercise
                                            price of NIS 8.1205 per option or $2.30 per option and expire on March 18, 2025, (iii) 60,000
                                            options to purchase 60,000 ordinary shares at an exercise price of NIS 4.317 per option or
                                            $1.22 per option and expire on February 18, 2026, (iv) 250,000 options to purchase 250,000
                                            ordinary shares at an exercise price of NIS 2.513 per option or $0.71 per option and expire
                                            on December 28, 2027, (v) 150,000 options to purchase 150,000 ordinary shares at an exercise
                                            price of NIS 2.344 per option or $0.66 per option and expire on January 7, 2029, and (vi)
                                            750,000 options to purchase 750,000 ordinary shares at an exercise price of NIS 0.25 per
                                            option or $0.07 per option and expire on May 27, 2030; (vii) 750,000 options to purchase
                                            750,000 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and
                                            expire on April 13, 2031; and (viii) 375,000 options to purchase 375,000 ordinary shares
                                            at an exercise price of NIS 0.25 per option or $0.07 per option and expire on July 16, 2032.
                                            Excludes 2,625,000 options to purchase 2,625,000 ordinary shares that vest in more than 60
                                            days from March 30, 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents
(i) 10,000 options to purchase 10,000 ordinary shares at an exercise price of NIS 8.1205 per option or $2.49 per option and expire on
March 18, 2025, (ii) 40,000 options to purchase 40,000 ordinary shares at an exercise price of NIS 4.317 per option or $1.22 per option
and expire on February 18, 2026, (iii) 80,000 options to purchase 80,000 ordinary shares at an exercise price of NIS 3.662 per option
or $1.04 per option and expire on March 30, 2027, (iv) 150,000 options to purchase 150,000 ordinary shares at an exercise price of NIS
2.513 per option or $0.71 per option and expire on December 30, 2027, (v) 120,000 options to purchase 120,000 ordinary shares at an exercise
price of NIS 2.344 per option or $0.66 per option and expire on January 7, 2029, (vi) 750,000 options to purchase 750,000 ordinary shares
at an exercise price of NIS 0.25 per option or $0.07 per option and expire on May 27, 2030 and (vii) 750,000 options to purchase 750,000
ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on April 13, 2031; and (viii) 281,250 options
to purchase 281,250 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and expire on July 16, 2032. Excludes
2,218,750 options to purchase 2,218,750 ordinary shares that vest in more than 60 days from March 30, 2023.&#160;</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            (i) 24,240 ordinary shares, (ii) 10,000 options to purchase 10,000 ordinary shares at an
                                            exercise price of NIS 15.0 per option or $4.26 per option and expire on May 2, 2023, (iii)
                                            48,000 options to purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per option
                                            or $0.83 per option and expire on December 28, 2027, and (iv) 412,500 options to purchase
                                            412,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and
                                            expire on June 14, 2030. Excludes 187,500 options to purchase 187,500 ordinary shares that
                                            vest in more than 60 days from March 30, 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            (i) 48,000 options to purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per
                                            option or $0.83 per option and expire on November 8, 2027, and (ii) 412,500 options are exercisable
                                            into 412,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option
                                            and expire on June 14, 2030. Excludes 187,500 options to purchase 187,500 ordinary shares
                                            that vest in more than 60 days from March 30, 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            (i) 48,000 options to purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per
                                            option or $0.83 per option and expire on November 8, 2027, (ii) 412,500 options to purchase
                                            412,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.07 per option and
                                            expire on June 14, 2030. Excludes 187,500 options to purchase 187,500 ordinary shares that
                                            vest in more than 60 days from March 30, 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            262,500 options to purchase 262,500 ordinary shares at an exercise price of NIS 0.25 per
                                            option or $0.07 per option and expire on June 22, 2031. Excludes 337,500 options to purchase
                                            337,500 ordinary shares that vest in more than 60 days from March 30, 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The
Bank of New York Mellon, or BNY, is the holder of record for our ADR program, pursuant to which each ADS represents 300 ordinary shares.
As of March 26, 2023, BNY held 836,144,820 ordinary shares representing approximately 68% of the outstanding ordinary shares at that
date. Certain of these ordinary shares were held by brokers or other nominees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, the number of
holders of record or registered holders in the United States is not representative of the number of beneficial holders or of the residence
of beneficial holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Share Option Plans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain the following
share option plans for our and our subsidiary&#8217;s employees, directors and consultants. In addition to the discussion below, see
Note 10 of our consolidated financial statements, included elsewhere in this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors administers
our share option plans and has the authority to designate all terms of the options granted under our plans including the grantees, exercise
prices, grant dates, vesting schedules and expiration dates, which may be no more than ten years after the grant date. Options may not
be granted with an exercise price of less than the fair market value of our ordinary shares on the date of grant, unless otherwise determined
by our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022,
options to purchase an aggregate of 27,002,200 ordinary shares, are outstanding pursuant to the 2003 and 2013 share option plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2003 Share Option Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2003 Plan we granted
options during the period between 2003 and 2013, at exercise prices between NIS 0.25 and NIS 31.175 per ordinary share, no par value.
There are no options to purchase ordinary shares available to be granted under the 2003 Plan. As of December 31, 2022, 25,200 options
to purchase 25,200 ordinary shares were outstanding. Options granted to Israeli employees were in accordance with section 102 of the
Income Tax Ordinance, 1961, or the Tax Ordinance, under the capital gains route set forth in section 102(b)(2) of the Tax Ordinance.
The options are non-transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The option term is for a
period of ten years from the grant date. The options were granted for no consideration. The options vest over a four or two year period.
As of March 30, 2023, 250,000 options to purchase 10,000 ordinary shares were fully vested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2013 Share Option Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2013 Plan we granted
options at exercise prices between NIS 0.25 and NIS 12 per ordinary share, no par value. As of December 31, 2022, options to purchase
up to 8,023,000 ordinary shares were available to be granted under the 2013 Plan. As of December 31, 2022, 26,977,000 options to purchase
26,977,000 ordinary shares were outstanding. Options granted to Israeli employees were in accordance with the Tax Ordinance under the
capital gains route set forth in section 102(b)(2) of the Tax Ordinance. The options are non-transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The option term is for a
period of ten years from the grant date. The options were granted for no consideration. The options vest over a four year period. As
of March 30, 2023, options to purchase 12,655,125 ordinary shares were fully vested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Disclosure of a Registrant&#8217;s Action to Recover Erroneously
Awarded Compensation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 7. </b></span><b>Major
Shareholders and Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Major Shareholders.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in &#8220;Item
6. Directors, Senior Management and Employees&#8212;E. Share Ownership,&#8221; to the best of our knowledge, no other person who we know
beneficially owns 5.0% or more of the Company&#8217;s ordinary shares outstanding as of March 30, 2023. None of our shareholders has
different voting rights from other shareholders. Other than as described herein, to the best of our knowledge, we are not owned or controlled,
directly or indirectly, by another corporation, by any foreign government or by any natural person or legal persons, severally or jointly,
and we are not aware of any arrangement that may, at a subsequent date, result in a change of control of our Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, other than
as disclosed in the table above, our other filings with the SEC and this Annual Report on Form 20-F, there has been no significant change
in the percentage ownership held by any major shareholder since January 1, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Related Party Transactions.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of the transactions with related parties to which we, or our subsidiary, are party, and which were in effect since January 1, 2022. The
descriptions provided below are summaries of the terms of such agreements, do not purport to be complete and are qualified in their entirety
by the complete agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we have executed
all of our transactions with related parties on terms no less favorable to us than those we could have obtained from unaffiliated third
parties. We are required by Israeli law to ensure that all future transactions between us and our officers, directors and principal shareholders
and their affiliates are approved by a majority of our Board of Directors, including a majority of the independent and disinterested
members of our Board of Directors, and that they are on terms no less favorable to us than those that we could obtain from unaffiliated
third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Employment and Consulting Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have or have had employment,
consulting or related agreements with each member of our senior management. See &#8220;Item 6. Directors, Senior Management and Employees&#8212;Compensation&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employ Zivit Harpaz as
Director of Regulatory and Clinical Operations. For fiscal years 2022, 2021 and 2020, Ms. Harpaz received salary, bonus and benefits
totaling approximately $278,000, $262,000 and $229,000, respectively. During fiscal years 2022, 2021 and 2020, we awarded to Ms. Harpaz
options to purchase 1,250,000, 1,000,000 and 750,000 ordinary shares, respectively. Ms. Harpaz is the daughter of Pnina Fishman.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Options</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have granted options to
purchase our ordinary shares to certain of our senior management and directors. See &#8220;Item 6. B.&#8212;Compensation&#8221; and &#8220;Item
6. Directors, Senior Management and Employees&#8212;Share Ownership&#8221;. We describe our option plans under &#8220;Item 6. Directors,
Senior Management and Employees&#8212;Share Ownership&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Indemnification Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association permit us to exculpate, indemnify and insure our directors and officeholders to the fullest extent permitted
by the Israeli Companies Law. We have obtained directors&#8217; and officers&#8217; insurance for each of our officers and directors
and have entered into indemnification agreements with all of our current officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Interests of Experts and Counsel.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;<span style="text-transform: uppercase">&#160;</span></b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 8. </b></span><b>Financial
Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Consolidated Financial Statements and Other Financial Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements&#8221; for a list of all financial statements filed as part of this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Legal Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not involved in any
legal or arbitration proceedings that may have or have had in the recent past, significant effects on our financial position or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends to our shareholders. Currently we do not intend to pay cash dividends. We intend to reinvest any earnings in developing
and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our Board of Directors
and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions,
capital requirements, business prospects, applicable Israeli Companies Law and other factors our Board of Directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Significant Changes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Note 16:&#8212;Subsequent Events&#8221; to our consolidated
financial statements included in this Annual Report beginning on page F-1 for a discussion of significant events that have occurred since
December 31, 2022.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 9. </b></span><b>The
Offer and Listing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Offer and Listing Details</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have
been trading on the TASE under the symbol &#8220;CFBI&#8221; since October 2005.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>ADSs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 2, 2012, our ADSs
began trading OTC in the United States under the symbol &#8220;CANFY&#8221; and on November 19, 2013, our ADSs began trading on the NYSE
American under the symbol &#8220;CANF.&#8221; One ADS represents three hundred (300) ordinary shares. See &#8220;Item 12. Description
of Securities Other Than Equity Securities&#8212;D. American Depositary Shares&#8221; for a description of the rights attaching to our
ADSs. See &#8220;Item 12. Description of Securities Other Than Equity Securities&#8212;D. American Depositary Shares&#8221; for a description
of the rights attaching to our ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Plan of Distribution.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Markets.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;&#8212;Offer and
Listing Details&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Selling Shareholders.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Dilution.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Expenses of the Issue.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 10. </b></span><b>Additional
Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Share Capital.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Memorandum and Articles of Association.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our number with the Israeli
Registrar of Companies is 512022153. Our purpose is set forth in Section 3 of our Articles of Association and includes every lawful purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 22, 2023, our
shareholders approved the cancellation of the par value of our ordinary shares such that our authorized share capital is equal to NIS
1,250,000,000 divided into 5,000,000,000 ordinary shares with no par value. Our ordinary shares that are fully paid for are issued in
registered form and may be freely transferred under our Amended and Restated Articles of Association, unless the transfer is restricted
or prohibited by applicable law or the rules of a stock exchange on which the shares are traded. The ownership or voting of our ordinary
shares by non-residents of Israel is not restricted in any way by our Amended and Restated Articles of Association or the laws of the
State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law and our Amended and Restated Articles of Association, our Board of Directors may exercise all powers and take all actions that are
not required under law or under our Amended and Restated Articles of Association to be exercised or taken by our shareholders, including
the power to borrow money for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli
Companies Law and must be approved by a resolution duly passed by our shareholders at a general or special meeting by voting on such
change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends
in the absence of sufficient retained earnings and profits and an issuance of shares for less than their nominal value, require a resolution
of our Board of Directors and court approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend
distributions are determined by the Board of Directors and do not require the approval of the shareholders of a company unless such company&#8217;s
articles of association provide otherwise. Our Amended and Restated Articles of Association do not require shareholder approval of a
dividend distribution and provide that dividend distributions may be determined by our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law, we may only distribute dividends from our profits accrued over the previous two years, as defined in the Israeli Companies Law,
according to our then last reviewed or audited financial reports, or we may distribute dividends with court approval. In each case, we
are only permitted to pay a dividend if there is no reasonable concern that payment of the dividend will prevent us from satisfying our
existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Election of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association provide that the maximum number of members of the Board of Directors is 13. The Board of Directors is presently
comprised of six members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, a special
general meeting of our shareholders approved an amendment to the our Amended and Restated Articles of Association, according to which
the Board of Directors, excluding the external directors, if any (who shall be elected and serve in office in strict accordance with
the provisions of the Companies Law, if so required by the Companies Law), shall consist of three classes of directors as nearly equal
in number as practicable, which are appointed for fixed terms of office in accordance with the Israeli Companies Law and our Amended
and Restated Articles of Association, as follows: (i) the term of office of the initial Class I directors shall expire at the first annual
general meeting of our shareholders held in 2020 and when their successors are elected and qualified, (ii) the term of office of the
initial Class II directors shall expire at the first annual general meeting of our shareholders following the annual general meeting
of our shareholders referred to in clause (i) above and when their successors are elected and qualified, and (iii) the term of office
of the initial Class III directors shall expire at the first annual general meeting of our shareholders following the annual general
meeting of our shareholders referred to in clause (ii) above and when their successors are elected and qualified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors (other than external
directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of our shareholders, commencing
with the annual general meeting of our shareholders held in 2020, each of the successors elected to replace the directors of a class
whose term shall have expired at such annual general meeting of our shareholders shall be elected to hold office until the third annual
general meeting of our shareholders next succeeding his or her election and until his or her respective successor shall have been elected
and qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and qualified
or until such earlier time as such director&#8217;s office is vacated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of directors
(excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving directors shall be re-designated
to other classes and/or any newly created directorships or decrease in directorships shall be apportioned by the Board of Directors among
the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors
constituting the Board of Directors shall shorten the term of any incumbent director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors so elected may
not be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of their term of
office. The directors do not receive any benefits upon the expiration of their term of office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The three classes of
directors are Class I Directors, Class II Directors and Class III Directors. Abraham Sartani serves as our Class I Director until
the close of the annual meeting to be held in 2023; Ilan Cohn serves as our Class II Director until the close of the annual
meeting to be held in 2024; and Dr. Pnina Fishman and Mr. Guy Regev serve as our Class III Directors until the close of the annual meeting to be held in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amendment, replacement
or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described above, require a
majority of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and voting thereon,
disregarding abstentions from the count of the voting power present and voting, provided that such majority constitutes more than 20%
of our then issued and outstanding share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A nominee for service as
a director in a public company may not be elected without submitting a declaration to the company, prior to election, specifying that
he or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable,
and the ability to devote the appropriate time to performing his or her duties as such.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director, who ceases to
meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;C. Board Practices&#8212;External Directors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shareholder Meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Israeli Companies Law,
we are required to hold an annual general meeting of our shareholders once every calendar year that must be no later than 15 months after
the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as
special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place, within or outside of
Israel, as it may determine. In addition, the Israeli Companies Law and our Amended and Restated Articles of Association provide that
our Board of Directors is required to convene a special meeting upon the written request of (i) any two of our directors or one quarter
of our Board of Directors or (ii) one or more shareholders holding, in the aggregate, either (1) 5% of our outstanding shares and 1%
of our outstanding voting power or (2) 5% of our outstanding voting power.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings
are the shareholders of record on a date to be decided by the Board of Directors, which may be between four and forty days prior to the
date of the meeting. Furthermore, the Israeli Companies Law and our Amended and Restated Articles of Association require that resolutions
regarding the following matters must be passed at a general meeting of our shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments to our Amended
    and Restated Articles of Association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment or termination
    of our auditors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment of directors
    and appointment and dismissal of external directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of acts and transactions
    requiring general meeting approval pursuant to the Israeli Companies Law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">director compensation,
    indemnification and change of the principal executive officer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions
    of our authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise of our Board
    of Director&#8217;s powers by a general meeting, if our Board of Directors is unable to exercise its powers and the exercise of any
    of its powers is required for our proper management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires that a notice of any annual or special shareholders meeting be provided at least 21 days prior to the meeting and if the agenda
of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related
parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
does not allow shareholders of publicly traded companies to approve corporate matters by written consent. Consequently, our Amended and
Restated Articles of Association does not allow shareholders to approve corporate matters by written consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Amended and
Restated Articles of Association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted
to a vote before the shareholders at a general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Quorum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The quorum required for our
general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold or represent
between them at least 25% of the total outstanding voting rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A meeting adjourned for lack
of a quorum is adjourned to the same day in the following week at the same time and place or on a later date if so specified in the summons
or notice of the meeting. At the reconvened meeting, any number of our shareholders present in person or by proxy shall constitute a
lawful quorum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Resolutions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by
applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law provides that
a shareholder of a public company may vote in a meeting and in a class meeting by means of a written ballot in which the shareholder indicates
how he or she votes on resolutions relating to the following matters:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
appointment or removal of directors;</span></td>
</tr></table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
approval of transactions with office holders or interested or related parties;</span></td>
</tr></table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
approval of a merger or any other matter in respect of which there is a provision in the articles of association providing that decisions
of the general meeting may also be passed by written ballot;</span></td>
</tr></table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
the chairman of the Board of Directors or his relative to act as our chief executive officer or act with such authority; or authorize
our chief executive officer or his relative to act as the chairman of the Board of Directors or act with such authority; and</span></td>
</tr></table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
matters which may be prescribed by Israel&#8217;s Minister of Justice.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision allowing the
vote by written ballot does not apply where the voting power of the controlling shareholder is sufficient to determine the vote. Our Amended
and Restated Articles of Association provide that our Board of Directors may prevent voting by means of a written ballot and this determination
is required to be stated in the notice convening the general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that a shareholder, in exercising his or her rights and performing his or her obligations toward the company and its other shareholders,
must act in good faith and in a customary manner, and avoid abusing his or her power. This is required when voting at general meetings
on matters such as changes to the articles of association, increasing our registered capital, mergers and approval of related party transactions.
A shareholder also has a general duty to refrain from depriving any other shareholder of its rights as a shareholder. In addition, any
controlling shareholder, any shareholder who knows that its vote can determine the outcome of a shareholder vote and any shareholder who,
under such company&#8217;s articles of association, can appoint or prevent the appointment of an office holder, is required to act with
fairness towards the company. The Israeli Companies Law does not describe the substance of this duty except to state that the remedies
generally available upon a breach of contract will also apply to a breach of the duty to act with fairness, and, to the best of our knowledge,
there is no binding case law that addresses this subject directly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, unless provided otherwise in a company&#8217;s articles of association, a resolution at a shareholders meeting requires approval
by a simple majority of the voting rights represented at the meeting, in person, by proxy or written ballot, and voting on the resolution.
A resolution for the voluntary winding up of the company requires the approval of holders of 75% of the voting rights represented at the
meeting, in person, by proxy or by written ballot and voting on the resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution
rights to the holders of a class of shares with preferential rights that may be authorized in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Access to Corporate Records</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, all shareholders of a company generally have the right to review minutes of our general meetings, its shareholders register and principal
shareholders register, articles of association, financial statements and any document it is required by law to file publicly with the
Israeli Companies Registrar and the Israel Securities Authority. Any of our shareholders may request access to review any document in
our possession that relates to any action or transaction with a related party, interested party or office holder that requires shareholder
approval under the Israeli Companies Law. We may deny a request to review a document if we determine that the request was not made in
good faith, that the document contains a commercial secret or a patent or that the document&#8217;s disclosure may otherwise prejudice
our interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Acquisitions under Israeli Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Full Tender Offer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of a public Israeli company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share
capital is required by the Israeli Companies Law to make a tender offer to all of our shareholders for the purchase of all of the issued
and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over
90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders
who hold shares of the same class for the purchase of all of the issued and outstanding shares of the same class. If the shareholders
who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, all
of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law (provided that a majority
of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer except that if the total
votes to reject the tender offer represent less than 2% of the company&#8217;s issued and outstanding share capital, in the aggregate,
approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender
offer). However, a shareholder that had its shares so transferred may petition the court within six months from the date of acceptance
of the full tender offer, whether or not such shareholder agreed to the tender or not, to determine whether the tender offer was for less
than fair value and whether the fair value should be paid as determined by the court unless the acquirer stipulated in the tender offer
that a shareholder that accepts the offer may not seek appraisal rights. If the shareholders who did not accept the tender offer hold
5% or more of the issued and outstanding share capital of the company or of the applicable class, the acquirer may not acquire shares
of the company that will increase its holdings to more than 90% of our issued and outstanding share capital or of the applicable class
from shareholders who accepted the tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Special Tender Offer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer if as a result of the
acquisition the purchaser would become a holder of 25% or more of the voting rights in the company, unless one of the exemptions in the
Israeli Companies Law is met. This rule does not apply if there is already another holder of at least 25% of the voting rights in the
company. Similarly, the Israeli Companies Law provides that an acquisition of shares in a public company must be made by means of a tender
offer if as a result of the acquisition the purchaser would become a holder of 45% or more of the voting rights in the company, if there
is no other shareholder of the company who holds 45% or more of the voting rights in the company, unless one of the exemptions in the
Israeli Companies Law is met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to our outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated
only if (i) at least 5% of the voting power attached to our outstanding shares will be acquired by the offeror and (ii) the number of
shares tendered in the offer exceeds the number of shares whose holders objected to the offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special tender offer
is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling
person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger
with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to
effect such an offer or merger in the initial special tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
permits merger transactions if approved by each party&#8217;s Board of Directors and, unless certain requirements described under the
Israeli Companies Law are met, a majority of each party&#8217;s shares voted on the proposed merger at a shareholders&#8217; meeting called
with at least 35 days&#8217; prior notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares represented at the shareholders
meeting that are held by parties other than the other party to the merger, or by any person who holds 25% or more of the outstanding shares
or the right to appoint 25% or more of the directors of the other party, vote against the merger. If the transaction would have been approved
but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still
approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is
fair and reasonable, taking into account the value of the parties to the merger and the consideration offered to the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger,
and may further give instructions to secure the rights of creditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed by each party
with the Israeli Registrar of Companies and 30 days have passed from the date the merger was approved by the shareholders of each party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Antitakeover Measures</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain
preferred rights, distributions or other matters and shares having preemptive rights. As of the date of this Annual Report on Form 20-F,
we do not have any authorized or issued shares other than our ordinary shares. In the future, if we do create and issue a class of shares
other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent
a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The
authorization of a new class of shares will require an amendment to our Amended and Restated Articles of Association which requires the
prior approval of the holders of a majority of our shares at a general meeting. In addition, the rules and regulations of the TASE also
limit the terms permitted with respect to a new class of shares and prohibit any such new class of shares from having voting rights. Shareholders
voting in such meeting will be subject to the restrictions provided in the Israeli Companies Law as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Borrowing Powers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law and our Amended and Restated Articles of Association, our Board of Directors may exercise all powers and take all actions that are
not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders or other
corporate bodies, including the power to borrow money for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Changes in Capital</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies
Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital.
In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of
sufficient retained earnings or profits and, in certain circumstances, an issuance of shares for less than their nominal value, require
the approval of both our Board of Directors and an Israeli court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Material Contracts.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain material agreements to which we are a party. The descriptions provided below do not purport to be complete and
are qualified in their entirety by the complete agreements, which may be attached as exhibits to this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>License Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Employment and Consulting Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Exchange Controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no Israeli government
laws, decrees or regulations that restrict or that affect our export or import of capital or the remittance of dividends, interest or
other payments to non-resident holders of our securities, including the availability of cash and cash equivalents for use by us and our
wholly-owned subsidiary, except or otherwise as set forth under &#8220;Item 10. Additional Information&#8212;E. Taxation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following description
is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our
ordinary shares, ADSs, Warrants or Pre-funded Warrants. You should consult your own tax advisor concerning the tax consequences of your
particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, or other taxing jurisdiction.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Certain Israeli Tax Considerations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the material Israeli tax laws applicable to us. This section also contains a discussion of material Israeli tax consequences concerning
the ownership and disposition of our ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant
to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment
under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities who are subject to special tax
regimes not covered in this discussion. Because certain parts of this discussion are based on new tax legislation that has not yet been
subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept
the views expressed in this discussion. The discussion does not cover all possible tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>You are urged to consult
your own tax advisor as to the Israeli and other tax consequences of the purchase, ownership and disposition of our ADSs, including, in
particular, the effect of any non-Israeli, state or local taxes.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli companies are generally
subject to corporate tax, which has decreased in recent years, from a rate of 26.5% in 2014 and 2015 to 25% in 2016 and to 24% in 2017
to 23% for 2018, 2019, 2020, 2021 and 2022. However, the effective corporate tax rate payable by a company that derives income from an
Approved Enterprise, a Privileged Enterprise or a Preferred Enterprise (as discussed below) may be considerably less. Capital gains generated
by an Israeli company are generally subject to tax at the corporate tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2006, transfer pricing
regulations came into force, following the introduction of Section 85A of the Israeli Tax Ordinance under Amendment 132. The transfer
pricing rules require that cross-border transactions between related parties (as defined in Section 85A of the Israeli Tax Ordinance)
be carried out implementing an arms&#8217; length principle based on a transfer pricing study and reported and taxed accordingly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Law for the Encouragement of Capital Investments, 1959:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for Encouragement
of Capital Investments, 1959 (the &#8220;Investment Law&#8221;) provides tax benefits for Israeli companies meeting certain requirements
and criteria. The Investment Law has undergone certain amendments and reforms in recent years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli parliament enacted
a reform to the Investment Law, effective January 2011 (which was amended in August 2013). According to the reform, a flat rate tax applies
to Preferred Income of companies eligible for the &#8220;Preferred Enterprise&#8221; status. In order to be eligible for Preferred Enterprise
status, a company must meet minimum requirements to establish that it contributes to the country&#8217;s economic growth and is a competitive
factor for the gross domestic product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Benefits granted to a Preferred
Enterprise include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets
for Budget Years 2017-2018), 5777-2016, the tax rate is&#160;16% for all areas other than Development Area A (which was&#160;7.5% from
2017 onward).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Pre-Ruling from the Israeli Income Tax Authorities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the spin-off,
we received a pre-ruling decision from the Israeli Income Tax Authority which confirms: (i) that the grant of the license to Eye-Fite
is not liable for tax pursuant to the provisions of section 104a to the Income Tax Ordinance (New Version), 1961, or the Ordinance; (ii)
that OphthaliX is considered the receiving company pursuant to section 103c(7)(b) to the Ordinance; (iii) that the sale of Eye-Fite shares
to OphthaliX as consideration for OphthaliX shares does not create liability for tax pursuant to the provisions of section 103t to the
Ordinance, or change in structure; and (iv) the date for the change in structure was determined. According to the tax pre-ruling, the
date of change in structure shall also be the date of exchange of shares with respect to the spin-off and notification to the tax assessor.
We and Eye-Fite presented to the tax assessor and the merger and spin-off department of the tax assessor the forms required by the Ordinance
and the regulations thereunder. The tax pre-ruling further provides that the grant of a license to Eye-Fite as consideration for the issuance
of Eye-Fite shares to us does not create liability for tax pursuant to the provisions of section 104a to the Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the pre-ruling,
we must not sell more than 10% of our common stock holdings in OphthaliX issued in connection with the change in structure for at least
two years from the date of the change (i.e., November 21, 2011), OphthaliX must not sell more than 10% of its ordinary share holdings
in Eye-Fite received in connection with the change in structure for at least two years from the date of the change and Eye-Fite must retain
the assets received from us in connection with the change in structure for at least two years from the date of the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of Eye-Fite which
were transferred to OphthaliX in connection with the change in structure will be held in escrow. The sale of these shares will be deemed
as a sale by an Israeli company and will be taxed accordingly. The trustee will withhold tax at the source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of OphthaliX which
were transferred to us in connection with the change in structure will be held in escrow. The sale of these shares will be deemed as a
sale by an Israeli company and will be taxed accordingly. The trustee will withhold tax at the source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any dividend distributed by
Eye-Fite to OphthaliX will be taxed in Israel in accordance with paragraph 125b(5) of the Israeli Tax Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A description of the terms
of the pre-ruling is also included in the notes to the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Tax Benefits and Grants for Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to section 20A of
the Israeli tax Ordinance, under certain conditions, a tax deduction for research and development expenditures, including capital expenditures,
for the year in which they are incurred. These expenses must relate to scientific research and development projects in the fields of industry,
agriculture, transportation or energy and must be approved by the Office of the Chief Scientist, or the OCS, of the relevant Israeli government
ministry, determined by the field of research. Furthermore, the research and development must be for the promotion of the company and
carried out by or on behalf of the company seeking such tax deduction. The amount of such deductible expenses is reduced by the sum of
any funds received through government grants for the funding of the scientific research and development projects. No deduction under these
research and development deduction rules is allowed if such deduction is related to an expense invested in an asset depreciable under
the general depreciation rules of the Tax Ordinance. Expenditures not so approved are deductible in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On a yearly basis, we evaluate
the applicability of the above tax deduction for research and development expenditures and, based on our evaluation, determine whether
to apply to the OCS for approval of a tax deduction. There can be no assurance that any application for a tax deduction will be accepted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Capital Gains Taxes Applicable
to Non-Israeli Resident Shareholders</i>. Shareholders that are not Israeli residents are generally exempt from Israeli capital gains
tax on any gains derived from the sale, exchange or disposition of our ordinary shares, provided that such shareholders did not acquire
their shares prior to our initial public offering on the TASE and such gains were not derived from a permanent establishment or business
activity of such shareholders in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemptions if they are
managed and controlled from Israel (then they are deemed as Israeli Resident).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the U.S.-Israel
Income Tax Treaty, 1995, or the U.S.-Israel Tax Treaty, the sale, exchange or disposition of our ordinary shares by a shareholder who
is a U.S. resident (for purposes of the U.S.-Israel Tax Treaty) holding the shares as a capital asset is exempt from Israeli capital gains
tax unless either (i) the shareholder holds, directly or indirectly, shares representing 10% or more of our voting capital during any
part of the 12-month period preceding such sale, exchange or disposition or (ii) the capital gains arising from such sale are attributable
to a &#8216;permanent establishment&#8217; of the shareholder located in Israel. In either case, the sale, exchange or disposition of
the shares would be subject to Israeli tax, at the applicable rate; however, under the U.S.-Israel Tax Treaty, the U.S. resident would
be permitted to claim tax credit IL tax paid with respect to the sale, exchange or disposition, subject to the limitations in U.S. laws
applicable to foreign tax credits. The U.S.-Israel Tax Treaty does not relate to U.S. state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders may be required
to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Taxation of Non-Israeli
Shareholders on Receipt of Dividends</i>. Non-residents of Israel are generally subject to Israeli income tax on the receipt of dividends
paid on our ordinary shares at the rate of 25%, which tax will be withheld at the source, unless a different rate is provided in a tax
treaty between Israel and the shareholder&#8217;s country of residence. With respect to a person who is a &#8220;substantial shareholder&#8221;
at the time receiving the dividend or on any date in the 12 months preceding such date, the applicable tax rate is 30%. A &#8220;substantial
shareholder&#8221; is generally a person who alone, or together with his relative or another person who collaborates with him on a permanent
basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of the corporation. &#8220;Means of control&#8221;
generally include the right to vote, receive profits, nominate a director or an officer, receive assets upon liquidation, or order someone
who holds any of the aforesaid rights how to act, and all regardless of the source of such right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the U.S.-Israel Tax
Treaty, the maximum rate of tax withheld in Israel on dividends paid to a holder of our ordinary shares who is a U.S. resident (for purposes
of the U.S.-Israel Tax Treaty) is 25%. However, generally, the maximum rate of withholding tax on dividends paid shall be 12.5% in the
event that the U.S. corporation holding 10% or more of our outstanding voting capital throughout the tax year in which the dividend is
distributed as well as the previous tax year, and no more than 25% of the gross income of our income in such prior taxable year (if any)
consists of interest or dividends (excluding interest derived from the conduct of a banking, insurance, or financing business or interest
received from subsidiary corporations, 50 percent or more of the outstanding shares of the voting stock of which is owned us at the time
such dividends or interest is received). Note that 12.5% tax on dividend shall not apply in the event the dividend derives from income
that is entitled to the reduced tax rate applicable to an approved enterprise under Israel&#8217;s Encouragement of Capital Investments
Law (1959) (In such case, 15% tax rate shall apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-resident of Israel who
receives dividends from which tax was withheld is generally exempt from the duty to file tax returns in Israel in respect of such income,
provided such income was not derived from a business conducted in Israel by the taxpayer, and the taxpayer has no other taxable sources
of income in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Taxation of Israeli Shareholders on Receipt of Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Residents of Israel are generally
subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, which tax will be withheld at
the source. With respect to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any date
within the 12 months preceding such date, the applicable tax rate is 30%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Additional taxation of high income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 121B of the Israeli
Tax ordnance applies additional tax at a rate of 3% on individuals who produced annual income (of all sources) surpasses 698,280 ILS (for
2023).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. Federal Income Tax Consequences</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a general summary of certain material U.S. federal
income tax consequences relating to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, and Pre-funded Warrants
by U.S. Holders (as defined below) that hold such ordinary shares, ADSs, Warrants, or Pre-funded Warrants as capital assets (generally,
property held for investment). This summary is based on the Internal Revenue Code of 1986, as amended, or the Code, the regulations of
the U.S. Department of the Treasury issued pursuant to the Code, or the Treasury Regulations, administrative and judicial interpretations
thereof, and the U.S.-Israel Income Tax Treaty, all as in effect on the date hereof and all of which are subject to change, possibly with
retroactive effect, or to different interpretation. No ruling has been sought from the IRS, with respect to any United States federal
income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This
summary does not address all of the tax considerations that may be relevant to specific U.S. Holders in light of their particular circumstances
or to U.S. Holders subject to special treatment under U.S. federal income tax law, including but not limited to, (1) a bank, insurance
company, regulated investment company, or other financial institution or &#8220;financial services entity&#8221;; (2) a broker or dealer
in securities or foreign currency; (3) a person who acquired our ordinary shares, ADSs, Warrants, or Pre-funded Warrants in connection
with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder
that holds our ordinary shares, ADSs, Warrants, or Pre-funded Warrants as a hedge or as part of a hedging, straddle, conversion or constructive
sale transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6) a retirement plan or tax-exempt entity;
(7) real estate investment trusts; (8) a U.S. Holder that expatriates out of the United States or a former long-term resident of the United
States; or (9) a U.S. Holder having a functional currency other than the U.S. dollar. This discussion does not address the U.S. federal
income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, ordinary shares or ADSs representing 10% or
more of our voting power or value (including by treating U.S. Holders of Warrants, Pre-funded Warrants, or other options to acquire our
ordinary shares or ADSs as owning such ordinary shares or ADSs). Additionally, this summary does not address any U.S. state or local or
non-U.S. tax considerations or any U.S. federal estate, gift or alternative minimum tax considerations or any U.S. federal tax consequences
other than U.S. federal income tax consequences. In addition, this discussion assumes that a U.S. Holder will not be entitled to a fractional
share upon the exercise of a Warrant or Pre-funded Warrant.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this summary, the
term &#8220;U.S. Holder&#8221; means a beneficial owner of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants that is, for U.S.
federal income tax purposes, (i) an individual citizen or resident of the United States, (ii) a corporation, or other entity taxable as
a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof,
or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of its source or (iv)
a trust with respect to which a court within the United States is able to exercise primary supervision over its administration and one
or more U.S. persons have the authority to control all of its substantial decisions, or that has a valid election in effect under applicable
Treasury Regulations to be treated as a &#8220;United States person.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an entity or arrangement
treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, the tax
treatment of such partnership and each person or entity treated as a partner thereof will generally depend upon the status and activities
of the partnership and such partner. A holder that is treated as a partnership for U.S. federal income tax purposes should consult its
own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners of the purchase, ownership and
disposition of its ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>This summary is not intended
to be, and should not be considered to be, legal or tax advice. Prospective investors should be aware that this summary does not address
the tax consequences to investors who are not U.S. Holders, except to the limited extent discussed below. Prospective investors should
consult their own tax advisors as to the particular tax considerations applicable to them relating to the purchase, ownership and disposition
of their ordinary shares, ADSs, Warrants, or Pre-funded Warrants, including the applicability of U.S. federal, state and local tax laws
and non-U.S. tax laws.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Taxation of U.S. Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussions under &#8220;&#8212;
Distributions&#8221; and under &#8220;&#8212; Sale, Exchange or Other Disposition of Ordinary Shares, ADSs, Warrants, and Pre-funded Warrants&#8221;
below assume that we will not be treated as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. Based
on our analysis of our income, assets, and operations, we believe that we were not a PFIC for 2022. Because the PFIC determination is
highly fact intensive, there can be no assurance that we will not be a PFIC for 2023 or for any other taxable year. For a discussion of
the rules that would apply if we are treated as a PFIC, see the discussion under &#8220;&#8212; Passive Foreign Investment Company.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Tax Characterization of
Pre-funded Warrants</i>. Although the appropriate characterization of Pre-funded Warrants under the tax law is unsettled, it is likely
that the Pre-funded Warrants will be treated as a class of our ordinary shares for U.S. federal income tax purposes. However, it is possible
that the IRS could treat the Pre-funded Warrants as warrants to acquire our ADSs. If the Pre-funded Warrants are not treated as a class
of our ordinary shares for U.S. federal income tax purposes and are instead treated as warrants to acquire our ADSs, then the U.S. federal
income tax treatment of Pre-Funded Warrants generally should be the same as the treatment of Warrants as described below and the holding
period of an ADS acquired pursuant to the exercise of a Pre-funded Warrant would not include the period during which the Pre-funded Warrant
was held. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of an investment in our
Pre-funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Allocation of Purchase
Price and Characterization of Units</i>. Each Unit and Pre-funded Unit should be treated for U.S. federal income tax purposes as an investment
unit consisting of one ADS (or Pre-funded Warrant, as the case may be), and one Warrant to purchase one ADS. For U.S. federal income tax
purposes, each U.S. Holder must allocate the purchase price of a Unit or Pre-funded Unit between that ADS (or Pre-funded Warrant, as applicable),
and the Warrant based on the relative fair market value of each at the time of issuance. The purchase price allocated to each ADS, Pre-funded
Warrant, and Warrant generally will be the U.S. Holder&#8217;s tax basis in such security, as the case may be. Each U.S. Holder should
consult its own tax advisor regarding the allocation of the purchase price for a Unit or Pre-funded Unit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Distributions.&#160;</i>We
have no current plans to pay dividends. To the extent we pay any dividends, a U.S. Holder will be required to include in gross income
as a taxable dividend the amount of any distributions made on the ordinary shares or ADSs, including the amount of any Israeli taxes withheld,
to the extent that those distributions are paid out of our current and/or accumulated earnings and profits as determined for U.S. federal
income tax purposes. Any distributions in excess of our earnings and profits will be applied against and will reduce the U.S. Holder&#8217;s
tax basis in its ordinary shares or ADSs and to the extent they exceed that tax basis, will be treated as gain from the sale or exchange
of those ordinary shares or ADSs. If we were to pay dividends, we expect to pay such dividends in NIS with respect to the ordinary shares
and in U.S. dollars with respect to ADSs. A dividend paid in NIS, including the amount of any Israeli taxes withheld, will be includible
in a U.S. Holder&#8217;s income as a U.S. dollar amount calculated by reference to the exchange rate in effect on the date such dividend
is received, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted to U.S. dollars on
the date of receipt, a U.S. Holder generally will not recognize a foreign currency gain or loss. However, if the U.S. Holder converts
the NIS into U.S. dollars on a later date, the U.S. Holder must include, in computing its income, any gain or loss resulting from any
exchange rate fluctuations. The gain or loss will be equal to the difference between (i) the U.S. dollar value of the amount included
in income when the dividend was received and (ii) the amount received on the conversion of the NIS into U.S. dollars. Such gain or loss
will generally be ordinary income or loss and United States source for U.S. foreign tax credit purposes. U.S. Holders should consult their
own tax advisors regarding the tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain significant
conditions and limitations, including potential limitations under the U.S.-Israel Tax Treaty, any Israeli taxes paid on or withheld from
distributions from us and not refundable to a U.S. Holder may be credited against the investor&#8217;s U.S. federal income tax liability
or, alternatively, may be deducted from the investor&#8217;s taxable income. The election to credit or deduct foreign taxes is made on
a year-by-year basis and applies to all foreign taxes paid by a U.S. Holder or withheld from a U.S. Holder that year. Dividends paid on
the ordinary shares generally will constitute income from sources outside the United States and be categorized as &#8220;passive category
income&#8221; or, in the case of some U.S. Holders, as &#8220;general category income&#8221; for U.S. foreign tax credit purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the rules governing
foreign tax credits are complex, U.S. Holders should consult their own tax advisor regarding the availability of foreign tax credits in
their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid on the ordinary
shares and ADSs will not be eligible for the &#8220;dividends-received&#8221; deduction generally allowed to corporate U.S. Holders with
respect to dividends received from U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain distributions treated
as dividends that are received by an individual U.S. Holder from &#8220;qualified foreign corporations&#8221; generally qualify for a
20% tax rate so long as certain holding period and other requirements are met. A non-U.S. corporation (other than a corporation that is
treated as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be
a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the
Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of
information program, or (ii) with respect to any dividend it pays on stock (or ADSs in respect of such stock) which is readily tradable
on an established securities market in the United States. Dividends paid by us in a taxable year in which we are not a PFIC and with respect
to which we were not a PFIC in the preceding taxable year are expected to be eligible for the 20% tax rate, although we can offer no assurances
in this regard. However, any dividend paid by us in a taxable year in which we are a PFIC or were a PFIC in the preceding taxable year
will be subject to tax at regular ordinary income rates. Because the PFIC determination is highly fact intensive, there can be no assurance
that we will not be a PFIC in 2023 or in any other taxable year. The additional 3.8% &#8220;net investment income tax&#8221; (described
below) may apply to dividends received by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Adjustments with respect
to Warrants and Pre-funded Warrants</i>. The terms of the Warrants and Pre-funded Warrants provide for an adjustment to the number of
ordinary shares for which the warrant may be exercised or to the exercise price of the warrant in certain events. An adjustment that has
the effect of preventing dilution generally is not taxable. However, the U.S. Holders of the Warrants or Pre-funded Warrants would be
treated as receiving a constructive distribution from us if, for example, the adjustment increases the warrant holders&#8217; proportionate
interest in our assets or earnings and profits (e.g., through a decrease in the exercise price of the Warrants or Pre-funded Warrants)
as a result of a distribution of cash to the holders of our ordinary shares or ADSs, which is taxable to the U.S. Holders of such ordinary
shares or ADSs as described under &#8220;&#8212;Distributions&#8221; above. Such constructive distribution would be subject to tax as
described under that section in the same manner as if the U.S. Holders of the Warrants or Pre-funded Warrants received a cash distribution
from us equal to the fair market value of such increased interest. U.S. Holders of Warrants and Pre-funded Warrants are urged to consult
their own tax advisors on these issues<b>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sale, Exchange or Other
Disposition of Ordinary Shares, ADSs, Warrants, and Pre-funded Warrants.&#160;</i>Subject to the discussion under &#8220;&#8212; Passive
Foreign Investment Company&#8221; below, a U.S. Holder generally will recognize capital gain or loss upon the sale, exchange or other
taxable disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants in an amount equal to the difference between the amount
realized on the sale, exchange or other disposition and the U.S. Holder&#8217;s adjusted tax basis in such securities. This capital gain
or loss will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period in our securities exceeds one year. Preferential
tax rates for long-term capital gain (currently, with a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility
of capital losses is subject to limitations. The gain or loss will generally be income or loss from sources within the United States for
U.S. foreign tax credit purposes, subject to certain exceptions in the U.S.-Israel Tax Treaty. The additional 3.8% &#8220;net investment
income tax&#8221; (described below) may apply to gains recognized upon the sale, exchange, or other taxable disposition of our securities
by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders should consult
their own tax advisors regarding the U.S. federal income tax consequences of receiving currency other than U.S. dollars upon the disposition
of their ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercise or Lapse of a
Warrant and Pre-funded Warrants</i>. Subject to the discussion under &#8220;&#8212;Passive Foreign Investment Company&#8221; below, a
U.S. Holder generally will not recognize gain or loss upon the exercise of a Warrant or Pre-funded Warrant for cash. An ADS acquired pursuant
to the exercise of a Warrant or Pre-funded Warrant for cash generally will have a tax basis equal to the U.S. Holder&#8217;s tax basis
in the Warrant or Pre-funded Warrant, increased by the amount paid to exercise the Warrant or Pre-funded Warrant. The holding period of
an ADS acquired pursuant to the exercise of a Warrant generally would begin on the day after the date of exercise of the Warrant. Subject
to the discussion above regarding the tax characterization of the Pre-funded Warrants, the holding period of a Pre-funded Warrant should
carry over to an ADS acquired pursuant to the exercise of a Pre-funded Warrant. If a Warrant or Pre-funded Warrant is allowed to lapse
unexercised, a U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences of a
cashless exercise of Warrants are unclear and could differ from the consequences described above. It is possible that a cashless exercise
could be a taxable event. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of the
cashless exercise of Warrants, including with respect to whether the exercise is a taxable event, and their holding period and tax basis
in the ADSs received.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Passive Foreign Investment Company</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a corporation
organized outside the United States will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either
(i) at least 75% of its gross income is &#8220;passive income&#8221; or (ii) on average at least 50% of its assets (by value) produce
passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things,
certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of
property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds,
including those raised in the public offering. Assets that produce or are held for the production of passive income may include cash,
even if held as working capital or raised in a public offering, as well as marketable securities and other assets that may produce passive
income. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in
which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the tests described
above, whether or not we are a PFIC will be determined annually based upon the composition of our income and the composition and valuation
of our assets, all of which are subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our analysis of our
income, assets, and operations, we believe that we were not a PFIC for 2022. Because the PFIC determination is highly fact intensive,
there can be no assurance that we will not be a PFIC in 2023 or in any other taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Default PFIC Rules</i>.
If we are a PFIC for any tax year, a U.S. Holder who does not make a timely QEF election or a mark-to-market election, referred to in
this disclosure as a &#8220;Non-Electing U.S. Holder,&#8221; will be subject to special rules with respect to (i) any &#8220;excess distribution&#8221;
(generally, the portion of any distributions received by the Non-Electing U.S. Holder on the ordinary shares or ADSs (or warrants, to
the extent applicable) in a taxable year in excess of 125% of the average annual distributions received by the Non-Electing U.S. Holder
in the three preceding taxable years, or, if shorter, the Non-Electing U.S. Holder&#8217;s holding period for the ordinary shares or ADSs),
and (ii) any gain realized on the sale or other disposition of ordinary shares, ADSs, Warrants, or Pre-funded Warrants. Under these rules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the excess distribution or gain would be allocated ratably over the Non-Electing U.S. Holder&#8217;s holding period for such ordinary shares, ADSs, Warrants, or Pre-funded Warrants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to the current taxable year and any year prior to us becoming a PFIC would be taxed as ordinary income; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a Non-Electing U.S. Holder
who is an individual dies while owning our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, the Non-Electing U.S. Holder&#8217;s
successor would be ineligible to receive a step-up in tax basis of such ordinary shares, ADSs, Warrants, or Pre-funded Warrants. Non-Electing
U.S. Holders should consult their tax advisors regarding the application of the &#8220;net investment income tax&#8221; (described below)
to their specific situation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent a distribution
on our ordinary shares or ADSs (or warrants, to the extent applicable) does not constitute an excess distribution to a Non-Electing U.S.
Holder, such Non-Electing U.S. Holder generally will be required to include the amount of such distribution in gross income as a dividend
to the extent of our current and/or accumulated earnings and profits (as determined for U.S. federal income tax purposes) that are not
allocated to excess distributions. The tax consequences of such distributions are discussed above under &#8220;&#8212; Taxation of U.S.
Holders &#8212; Distributions.&#8221; Each U.S. Holder is encouraged to consult its own tax advisor with respect to the appropriate U.S.
federal income tax treatment of any distribution on our ordinary shares or ADSs (or warrants, to the extent applicable).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are treated as a PFIC
for any taxable year during the holding period of a Non-Electing U.S. Holder, we will continue to be treated as a PFIC for all succeeding
years during which the Non-Electing U.S. Holder is treated as a direct or indirect Non-Electing U.S. Holder even if we are not a PFIC
for such years. A U.S. Holder is encouraged to consult its tax advisor with respect to any available elections that may be applicable
in such a situation, including the &#8220;deemed sale&#8221; election of Code Section 1298(b)(1) (which will be taxed under the adverse
tax rules described above).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may invest in the equity
of foreign corporations that are PFICs or may own subsidiaries that own PFICs. If we are classified as a PFIC, under attribution rules
U.S. Holders will be subject to the PFIC rules with respect to their indirect ownership interests in such PFICs, such that a disposition
of the shares of the PFIC or receipt by us of a distribution from the PFIC generally will be treated as a deemed disposition of such shares
or the deemed receipt of such distribution by the U.S. Holder, subject to taxation under the PFIC rules. There can be no assurance that
a U.S. Holder will be able to make a QEF election or a mark-to-market election with respect to PFICs in which we invest. Each U.S. Holder
is encouraged to consult its own tax advisor with respect to tax consequences of an investment by us in a corporation that is a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">QEF Election</span>. Certain
adverse consequences of PFIC status can be mitigated for holders of our ordinary shares, ADSs, and Pre-funded Warrants if a U.S. Holder
makes a QEF election. A U.S. Holder may not make a QEF election with respect to our Warrants. A U.S. Holder who makes a timely QEF election,
referred to in this disclosure as an &#8220;Electing U.S. Holder,&#8221; with respect to us must report for U.S. federal income tax purposes
his pro rata share of our ordinary earnings and net capital gain, if any, for our taxable year that ends with or within the taxable year
of the Electing U.S. Holder. The &#8220;net capital gain&#8221; of a PFIC is the excess, if any, of the PFIC&#8217;s net long-term capital
gains over its net short-term capital losses. The amount so included in income generally will be treated as ordinary income to the extent
of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s ordinary earnings and as long-term capital gain to the extent
of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s net capital gains. Such Electing U.S. Holder generally will be
required to translate such income into U.S. dollars based on the average exchange rate for the PFIC&#8217;s taxable year with respect
to the PFIC&#8217;s functional currency. Such income generally will be treated as income from sources outside the United States for U.S.
foreign tax credit purposes. Amounts previously included in income by such Electing U.S. Holder under the QEF rules generally will not
be subject to tax when they are distributed to such Electing U.S. Holder. The Electing U.S. Holder&#8217;s tax basis in our ordinary shares,
ADSs, or Pre-funded Warrants generally will increase by any amounts so included under the QEF rules and decrease by any amounts not included
in income when distributed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Electing U.S. Holder will
be subject to U.S. federal income tax on such amounts for each taxable year in which we are a PFIC, regardless of whether such amounts
are actually distributed to such Electing U.S. Holder. However, an Electing U.S. Holder may, subject to certain limitations, elect to
defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If an Electing U.S. Holder is an individual,
any such interest will be treated as non-deductible &#8220;personal interest.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any net operating losses or
net capital losses of a PFIC will not pass through to the Electing U.S. Holder and will not offset any ordinary earnings or net capital
gain of a PFIC recognized by Electing U.S. Holder in subsequent years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">So long as an Electing U.S.
Holder&#8217;s QEF election with respect to us is in effect with respect to the entire holding period for our ordinary shares, ADSs, or
Pre-funded Warrants, any gain or loss recognized by such Electing U.S. Holder on the sale, exchange or other disposition of such shares,
ADSs, or Pre-funded Warrants generally will be long-term capital gain or loss if such Electing U.S. Holder has held such shares, ADSs,
or Pre-funded Warrants for more than one year at the time of such sale, exchange or other disposition. Preferential tax rates for long-term
capital gain (currently, a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility of capital losses is subject
to limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a U.S. Holder
must make a QEF election on or before the due date for filing its income tax return for the first year to which the QEF election is to
apply. A U.S. Holder makes a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions
thereto. Upon request, we intend to annually furnish U.S. Holders with information needed in order to complete IRS Form 8621 (which form
would be required to be filed with the IRS on an annual basis by the U.S. Holder) and to make and maintain a valid QEF election for any
year in which we or any of our subsidiaries that we control is a PFIC. There is no assurance, however, that we will have timely knowledge
of our status as a PFIC, or that the information that we provide will be adequate to allow U.S. Holders to make a QEF election. A QEF
election will not apply to any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable
year in which we become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may not make
a QEF election with respect to our Warrants. As a result, if a U.S. Holder sells or otherwise disposes of such Warrants (other than upon
exercise thereof), any gain recognized generally will be subject to special tax and interest charge rules treating the gain as an excess
distribution, as described above, if we were a PFIC at any time during the period the U.S. Holder held the Warrants. If a U.S. Holder
that exercises such Warrants properly makes a QEF election with respect to the newly acquired ADSs (or has previously made a QEF election
with respect to our ADSs), the QEF election will apply to the newly acquired ADSs, but the adverse tax consequences attributable to the
period prior to exercise of the Warrants, adjusted to take into account the current income inclusions resulting from the QEF election,
will continue to apply with respect to such newly acquired ADSs, unless the U.S. Holder makes a &#8220;purging election&#8221; that creates
a deemed sale of such ADSs at their fair market value. The gain recognized by the purging election will be subject to the special tax
and interest charge rules treating the gain as an excess distribution, as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each U.S. Holder should consult
its own tax advisor with respect to the advisability of, the tax consequences of, and the procedures for making a QEF election with respect
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mark-to-Market Election.&#160;</i>Alternatively,
if our ordinary shares or ADSs are treated as &#8220;marketable stock,&#8221; a U.S. Holder would be allowed to make a &#8220;mark-to-market&#8221;
election with respect to our ordinary shares or ADSs, provided the U.S. Holder completes and files IRS Form 8621 in accordance with the
relevant instructions and related Treasury Regulations. A &#8220;mark-to-market&#8221; election will not be available with respect to
our Warrants and Pre-funded Warrants. If the election is made, the U.S. Holder generally would include as ordinary income in each taxable
year the excess, if any, of the fair market value of our ordinary shares or ADSs at the end of the taxable year over such holder&#8217;s
adjusted tax basis in such shares or ADSs. The U.S. Holder would also be permitted an ordinary loss in respect of the excess, if any,
of the U.S. Holder&#8217;s adjusted tax basis in our ordinary shares or ADSs over their fair market value at the end of the taxable year,
but only to the extent of the net amount previously included in income as a result of the mark-to-market election. A U.S. Holder&#8217;s
tax basis in our ordinary shares or ADSs would be adjusted to reflect any such income or loss amount. Gain realized on the sale, exchange
or other disposition of our ordinary shares or ADSs would be treated as ordinary income, and any loss realized on the sale, exchange or
other disposition of our ordinary shares or ADSs would be treated as ordinary loss to the extent that such loss does not exceed the net
mark-to-market gains previously included in income by the U.S. Holder, and any loss in excess of such amount will be treated as capital
loss. Amounts treated as ordinary income will not be eligible for the favorable tax rates applicable to qualified dividend income or long-term
capital gains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, stock will be considered
marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable Treasury
Regulations. A class of stock is regularly traded on an exchange during any calendar year during which such class of stock is traded,
other than in&#160;<i>de minimis&#160;</i>quantities, on at least 15 days during each calendar quarter. To be marketable stock, our ordinary
shares and ADSs must be regularly traded on a qualifying exchange (i) in the United States that is registered with the SEC or a national
market system established pursuant to the Exchange Act or (ii) outside the United States that is properly regulated and meets certain
trading, listing, financial disclosure and other requirements. Our ordinary shares should constitute &#8220;marketable stock&#8221; as
long as they remain listed on the TASE and are regularly traded. Our ADSs will be listed on the OTC and/or the NYSE American. While we
believe that our ordinary shares and ADSs may be treated as marketable stock for purposes of the PFIC rules so long as they are listed
on the TASE and the OTC and/or the NYSE American, as applicable, and are regularly traded, the IRS has not provided a list of the exchanges
that meet the foregoing requirements and thus no assurance can be provided that our ordinary shares and/or ADSs will be (or will remain)
treated as marketable stock for purposes of the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A mark-to-market election
will not apply to our ordinary shares or ADSs held by a U.S. Holder for any taxable year during which we are not a PFIC, but will remain
in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any PFIC subsidiary that
we own. Each U.S. Holder is encouraged to consult its own tax advisor with respect to the availability and tax consequences of a mark-to-market
election with respect to our ordinary shares and ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, U.S. Holders
should consult their tax advisors regarding the IRS information reporting and filing obligations that may arise as a result of the ownership
of ordinary shares in a PFIC, including IRS Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or
Qualified Electing Fund.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The U.S. federal income
tax rules relating to PFICs, QEF elections, and mark-to market elections are complex. U.S. Holders are urged to consult their own tax
advisors with respect to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, any elections
available with respect to such shares, ADSs, Warrants, or Pre-funded Warrants, and the IRS information reporting obligations with respect
to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Tax Consequences for Non-U.S. Holders of Ordinary Shares, ADSs,
Warrants, or Pre-funded Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided below,
an individual, corporation, estate or trust that is not a U.S. Holder, referred to below as a non-U.S. Holder, generally will not be subject
to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our ordinary shares,
ADSs, Warrants, or Pre-funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-U.S. Holder may be subject
to U.S. federal income tax on a dividend paid on our ordinary shares or ADSs (or warrants, to the extent applicable) or gain from the
disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants if: (1) such item is effectively connected with the conduct
by the non-U.S. Holder of a trade or business in the United States and, if required by an applicable income tax treaty is attributable
to a permanent establishment or fixed place of business in the United States; or (2) in the case of a disposition of our ordinary shares,
ADSs, Warrants, or Pre-funded Warrants, the individual non-U.S. Holder is present in the United States for 183 days or more in the taxable
year of the disposition and other specified conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, non-U.S. Holders
will not be subject to backup withholding with respect to the payment of dividends on our ordinary shares or ADSs (or warrants, to the
extent applicable) if payment is made through a paying agent, or office of a foreign broker outside the United States. However, if payment
is made in the United States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder
provides an applicable IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise establishes an exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any backup withholding
from a payment to a non-U.S. Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may
entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><b>Certain Reporting Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. Holders may be
required to file IRS Form 926, Return by U.S. Transferor of Property to a Foreign Corporation, and IRS Form 5471, Information Return of
U.S. Persons With Respect to Certain Foreign Corporations, reporting transfers of cash or other property to us and information relating
to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply. See also the discussion regarding
Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, certain U.S.
Holders must report information on IRS Form 8938, Statement of Specified Foreign Financial Assets, with respect to their investments in
certain &#8220;specified foreign financial assets,&#8221; which would include an investment in our securities, if the aggregate value
of all of those assets exceeds $50,000 on the last day of the taxable year (and in some circumstances, a higher threshold). This reporting
requirement applies to individuals and certain U.S. entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who fail to report
required information could become subject to substantial penalties. U.S. Holders should consult their tax advisors regarding the possible
implications of these reporting requirements arising from their investment in our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Backup Withholding Tax and Information Reporting Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, information reporting
requirements will apply to distributions on our ordinary shares or ADSs (or warrants, to the extent applicable) or proceeds on the disposition
of our securities paid within the United States (and, in certain) proceeds on the disposition of our securities paid within the United
States (and, in certain cases, outside the United States) to U.S. Holders other than certain exempt recipients, such as corporations.
Furthermore, backup withholding (currently at 24%) may apply to such amounts if the U.S. Holder fails to (i) provide a correct taxpayer
identification number, (ii) report interest and dividends required to be shown on its U.S. federal income tax return, or (iii) make other
appropriate certifications in the required manner. U.S. Holders who are required to establish their exempt status generally must provide
such certification on IRS Form W-9.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Amounts withheld as backup withholding from a payment may be credited against a U.S. Holder&#8217;s U.S. federal income
tax liability and such U.S. Holder may obtain a refund of any excess amounts withheld by filing the appropriate claim for refund with
the IRS and furnishing any required information in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><b>Tax on Net Investment Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. persons, including
individuals, estates and trusts are generally subject to an additional 3.8% Medicare tax. For individuals, the additional Medicare tax
applies to the lesser of (i) &#8220;net investment income&#8221; or (ii) the excess of &#8220;modified adjusted gross income&#8221; over
$200,000 ($250,000 if married and filing jointly or $125,000 if married and filing separately). &#8220;Net investment income&#8221; generally
equals the taxpayer&#8217;s gross investment income reduced by the deductions that are allocable to such income. Investment income generally
includes passive income such as interest, dividends, annuities, royalties, rents, and capital gains. U.S. Holders are urged to consult
their own tax advisors regarding the implications of the additional Medicare tax resulting from their ownership and disposition of our
securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>U.S. Holders should
consult their own tax advisors concerning the tax consequences relating to the purchase, ownership and disposition of our ordinary shares,
ADSs, Warrants or Pre-funded Warrants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Dividends and Paying Agents.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>G. Statements by Experts.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H. Documents on Display.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports with
the SEC. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically
with the SEC. You may read and copy this annual report, including the related exhibits and schedules, and any document we file with the
SEC at http://www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we file
with the SEC, within four months after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on
Form 20-F containing financial statements audited by an independent registered public accounting firm, and submit to the SEC, on a Form
6-K, unaudited quarterly financial information for the first three quarters of each fiscal year within 60 days after the end of each such
quarter, or such applicable time as required by the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, because our ordinary
shares are traded on the TASE, we have filed Hebrew language periodic and immediate reports with, and furnish information to, the TASE
and the ISA, as required under Chapter Six of the Israel Securities Law. Copies of our filings with the ISA can be retrieved electronically
through the MAGNA distribution site of the ISA (<i>www.magna.isa.gov.il</i>) and the TASE website (<i>www.maya.tase.co.il</i>).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at&#160;<i>www.canfite.com. In</i>formation contained on, or that can be accessed through, our website does not constitute a part of this
Annual Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>I. Subsidiary Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>J. Annual Report to Security Holders.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 11. </b></span><b>Quantitative
and Qualitative Disclosures About Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market risk is the risk of
loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely
impact our consolidated financial position, results of operations or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Interest Rate Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate undertaking
any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents. We may invest in investment-grade
marketable securities with maturities of up to three years, including commercial paper, money market funds, and government/non-government
debt securities. The primary objective of our investment activities is to preserve principal while maximizing the income that we receive
from our investments without significantly increasing risk and loss. Our investments are exposed to market risk due to fluctuation in
interest rates, which may affect our interest income and the fair market value of our investments, if any. We manage this exposure by
performing ongoing evaluations of our investments. Due to the short-term maturities, if any, of our investments to date, their carrying
value has always approximated their fair value. If we decide to invest in investments other than cash and cash equivalents, it will be
our policy to hold such investments to maturity in order to limit our exposure to interest rate fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Foreign Currency Exchange
Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our foreign currency exposures give rise to market risk associated
with exchange rate movements of the U.S. dollar, our functional and reporting currency, mainly against the NIS and the euro. Although
the U.S. dollar is our functional currency, a portion of our expenses are denominated in both NIS and euro and currently all of our revenues
are denominated in dollars. Our U.S. dollar and euro expenses consist principally of payments made to sub-contractors and consultants
for preclinical studies, clinical trials and other research and development activities, Our NIS expenses consist principally of salary
related payments. We anticipate that a sizable portion of our expenses will continue to be denominated in currencies other than the NIS.
If the U.S. dollar fluctuates significantly against either the NIS or the euro, it may have a negative impact on our results of operations.
To date, fluctuations in the exchange rates have not materially affected our results of operations or financial condition for the periods
under review.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">To
date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk
of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not
adequately protect us from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;<span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 12. </b></span><b>Description
of Securities Other Than Equity Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Debt Securities.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Warrants and Rights.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Other Securities.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. American Depositary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as Depositary, will register and deliver American Depositary Shares, or ADSs. Each ADS will represent three hundred (300) ordinary shares
(or a right to receive three hundred (300) ordinary shares) deposited with the principal Tel Aviv office of Bank Hapoalim, as custodian
for the Depositary. Each ADS will also represent any other securities, cash or other property which may be held by the Depositary. The
Depositary&#8217;s corporate trust office at which the ADSs will be administered is located at 101 Barclay Street, New York, New York
10286. The Bank of New York Mellon&#8217;s principal executive office is located at One Wall Street, New York, New York 10286.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The form of the deposit agreement
for our ADSs and the form of American Depositary Receipt that represents an ADS have been incorporated by reference as exhibits to this
Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fees and Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Persons depositing or withdrawing shares or ADS holders must pay:</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 43%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation of ADSs for the purpose of withdrawal, including if the Deposit Agreement terminates</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$.05 (or less) per ADS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any cash distribution to ADS holders</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution of securities distributed to holders of deposited securities which are distributed by the Depositary to ADS holders</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$.05 (or less) per ADSs per calendar year</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depositary services</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration or transfer fees</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer and registration of shares on our share register to or from the name of the Depositary or its agent when you deposit or withdraw shares</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Depositary</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cable, telex and facsimile transmissions (when expressly provided in the Deposit Agreement)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converting foreign currency to U.S. dollars</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes and other governmental charges the Depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any charges incurred by the Depositary or its agents for servicing the deposited securities</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Depositary collects its
fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or
from intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from the
amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect its annual fee for depositary
services by deduction from cash distributions, by directly billing investors or by charging the book-entry system accounts of participants
acting for them. The Depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Depositary
may make payments to us to reimburse us for expenses and/or share revenue with us from the fees collected from ADS holders, or waive fees
and expenses for services provided, generally relating to costs and expenses arising out of the establishment and maintenance of the ADS
program. In performing its duties under the Deposit Agreement, the Depositary may use brokers, dealers or other service providers that
are affiliates of the Depositary and that may earn or share fees or commissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PART
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 13. </b></span><b>Defaults,
Dividend Arrearages and Delinquencies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 14. </b></span><b>Material
Modifications to the Rights of Security Holders and Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 15. </b></span><b>Controls
and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Disclosure controls and procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our chief executive officer, or CEO, and our chief financial officer, or CFO, are responsible for establishing and maintaining our disclosure
controls and procedures (within the meaning of Rule 13a-15(e) of the Exchange Act). These controls and procedures were designed to ensure
that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated
to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. We evaluated these
disclosure controls and procedures under the supervision of our CEO and CFO as of December 31, 2022. Based upon that evaluation, our management,
including our CEO and CFO, concluded that our disclosure controls and procedures as of December 31, 2022 were effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Management&#8217;s annual report on internal control over financial
reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our CEO, and our CFO, is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined
in Rules 13a-15(f) and 15d-15(f) of the Exchange Act of 1934, as amended. Our internal control over financial reporting is a process designed
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes policies and
procedures that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and asset dispositions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that receipts and expenditures are made only in accordance with authorizations of our management and board of directors (as appropriate); and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to its inherent limitations,
internal controls over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision and
with the participation of our management, including our CEO, and our CFO, we assessed the effectiveness of our internal control over financial
reporting as of December 31, 2022 based on the framework for Internal Control-Integrated Framework set forth by The Committee of Sponsoring
Organizations of the Treadway Commission (COSO) (2013).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our assessment and
this framework, our management concluded that our internal control over financial reporting were effective as of December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Attestation Report of Registered Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in internal control over financial reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal control over financial reporting, other than as described above, that occurred during the year ended December 31, 2022 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16. </b></span><b>[RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16A. </b></span><b>Audit
Committee Financial Expert</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
determined that Guy Regev and Yaacov Goldman are audit committee financial experts, as defined by applicable SEC regulations. Messrs.
Regev and Goldman qualified as an &#8220;independent director,&#8221; as that term is defined under NYSE American rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16B. </b></span><b>Code
of Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a code of
ethics, referred to as a Code of Business Conduct, applicable to our directors, officers and all other employees. Our code of ethics is
publicly available on our website at&#160;<i>www.canfite.com</i>. If we make any amendment to the code of ethics or grant any waivers,
including any implicit waiver, from a provision of the code of ethics, which applies to our chief executive officer, chief financial officer,
chief accounting officer or controller, or persons performing similar functions, we will disclose the nature of such amendment or waiver
on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16C. </b></span><b>Principal
Accountant Fees and Services</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for each of the years indicated, the fees billed by our independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended<br/>
December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Services Rendered</b></span></td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(USD in thousands)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit (1)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit related services (2)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other fees</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">166</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including
services that generally only the independent accountant can reasonably provide.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
related services consist of services that were reasonably related to the performance of the audit or reviews of our financial statements
and not included under &#8220;Audit Fees&#8221; above, including, principally, providing consents for registration statement filings.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Audit Committee Pre-Approval Policies and Procedures</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee&#8217;s
specific responsibilities in carrying out its oversight of the quality and integrity of the accounting, auditing and reporting practices
of us include the approval of audit and non-audit services to be provided by the external auditor. The audit committee approves in advance
the particular services or categories of services to be provided to us during the following yearly period and also sets forth a specific
budget for such audit and non-audit services. Additional non-audit services may be pre-approved by the audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16D. </b></span><b>Exemptions
from the Listing Standards for Audit Committees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16E. </b></span><b>Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16F. </b></span><b>Change
in Registrant&#8217;s Certifying Accountant</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16G. </b></span><b>Corporate
Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
whose ordinary shares are listed on the NYSE American. As such, we are required to comply with U.S. federal securities laws, including
the Sarbanes-Oxley Act, and the NYSE American rules, including the NYSE American corporate governance requirements. The NYSE American
rules provide that foreign private issuers may follow home country practice in lieu of certain qualitative listing requirements subject
to certain exceptions and except to the extent that such exemptions would be contrary to U.S. federal securities laws, so long as the
foreign issuer discloses that it does not follow such listing requirement and describes the home country practice followed in its reports
filed with the SEC. Below is a concise summary of the significant ways in which our corporate governance practices differ from the corporate
governance requirements of NYSE American applicable to domestic U.S. listed companies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NYSE American rules recommend that an issuer have a quorum requirement for shareholders meetings of at least one-third of the outstanding shares of the issuer&#8217;s common voting stock. We have chosen to follow home country practice with respect to the quorum requirements of our shareholders meeting and our adjourned shareholders meeting. Our Amended and Restated Articles of Association, as permitted under the Israeli Companies Law and Israeli practice, provide that the quorum requirements for a shareholders meeting are the presence of at least two shareholders who represent at least 25% of the outstanding shares of the issuer&#8217;s common voting stock, and in the event of an adjourned meeting, the presence of a minimum of two shareholders present in person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have chosen to follow our home country practice in lieu of the requirements of the NYSE American rules relating to shareholder approval required prior to the issuance of securities (i) when a stock option or purchase plan is to be established or materially amended or other equity compensation arrangement made or materially amended, pursuant to which stock may be acquired by officers, directors, employees or consultants and (ii) in connection with a transaction, other than a public offering, involving the issuance or potential issuance by the Company of ordinary shares (or their equivalent) equal to 20% or more of the ordinary shares or 20% voting power outstanding before the issuance for or at a price less than the greater of book or market value of the shares. We follow the provisions of the Israeli Companies Law with regard to transactions with our affiliates, i.e., our controlling shareholder and our directors and officers, including private placement transactions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16H. </b></span><b>Mine
Safety Disclosure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16I. </b></span><b>Disclosure
Regarding Foreign Jurisdictions that Prevent Inspections</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PART
III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 17. </b></span><b>Financial
Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have responded to Item
18 in lieu of responding to this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 18. </b></span><b>Financial
Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please refer to the financial
statements beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 19. </b></span><b>Exhibits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Index to Exhibits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>




</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.1</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex1-1_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Association of Can-Fite BioPharma Ltd *</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.1</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020007682/f20f2019ex2-1_canfite.htm">Description of Securities Registered under Section 12 (2)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.2</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413062206/v359878_ex4-2.htm">Form of Amended and Restated Deposit Agreement, by and among Can-Fite BioPharma Ltd., The Bank of New York Mellon and the Owners and Holders of American Depositary Shares, dated September 11, 2013 (3)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.1</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-3.htm">Employment and Non-Competition Agreement with Motti Farbstein, dated June 10, 2003 (4)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.2</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-4.htm">Consulting Agreement with BioStrategics Consulting, Ltd, dated September 27, 2005 (4)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.3</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-5.htm">Service Management Agreement with F.D. Consulting International and Marketing Ltd., dated June 27, 2002 (4)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.4</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-6.htm">Master Services Agreement with Accellient Partners, dated May 10, 2010 (4)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.5</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-10.htm">License Agreement, by and between The University of Leiden and Can-Fite BioPharma Ltd., dated November 2, 2009 (5)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.6</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-15.htm">License Agreement, by and between Kwang Dong Pharmaceutical Co., Ltd. and Can-Fite BioPharma Ltd., dated December 14, 2008 (4)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.7</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-25.htm">Can-Fite BioPharma Ltd. 2003 Israeli Share Option Plan (4)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.8</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390015002133/f20f2014ex4xiii_canfitebio.htm">Can-Fite BioPharma Ltd. 2013 Israeli Share Option Plan (5)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.9</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390023002788/ea171604ex99-1_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Policy of Can-Fite BioPharma Ltd. (24)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.10</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390015002133/f20f2014ex4xxxiv_canfitebio.htm">Distribution and Supply Agreement between Can-Fite BioPharma Ltd. and Cipher Pharmaceuticals Inc. dated as of March 20, 2015 (5)&#8224;</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.11</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390016010259/ff32016ex4iv_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on September 21, 2015 (6)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.12</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390016010259/ff32016ex4v_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on October 15, 2015 (6)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.13</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390017003022/f20f2016ex4xxxi_canfitebio.htm">Distribution Agreement between Can-Fite BioPharma Ltd. and Chong Kun Dang Pharmaceutical Corp. dated as of October 25, 2016 (7)&#8224;</a></span></td></tr>

<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.14</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390017000539/f6k012017ex10ii_canfitebio.htm">Form of Securities Purchase Agreement dated as of January 18, 2017 between Can-Fite BioPharma Ltd. and the investors listed therein (8)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.15</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390018010490/ff12018ex4-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on March 13, 2018 (10)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.16</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390019002713/ff12019ex4-36_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on January 23, 2019 (11)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.17</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390019007796/ff12019ex4-6_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on April 4, 2019 (12)</a></span></td></tr>

<tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.18</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390019009378/f6k052219ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of May 20, 2019 between Can-Fite BioPharma Ltd. and the investors listed therein (13)</a></span></td></tr>
</table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.19</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390019009378/f6k052219ex10-2_canfitebio.htm">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on May 22, 2019 (13)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.20</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390019009654/ff12019a1ex4-8_canfitebio.htm">Form
    of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on May 22, 2019 (14)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.21</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390019020567/ff12019a3bex10-2_canfitebio.htm">Agreement
    between Can-Fite BioPharma Ltd. and Capital Point Ltd. dated as of October 7, 2019 (15)&#8224;</a></span>

</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.22</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020000768/f6k010920bex10-1_canfitebio.htm">Form
    of Warrant Exercise Agreement dated as of January 9, 2020 between Can-Fite BioPharma Ltd. and the investors listed therein (16)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.23</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020000768/f6k010920bex10-2_canfitebio.htm"><span style="font-size: 10pt">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on January 13, 2020 (16)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.24</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex10-1_canfitebio.htm">Form
    of Securities Purchase Agreement dated as of February 10, 2020, between Can-Fite BioPharma Ltd. and the investors listed therein
    (17)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.25</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-1_canfitebio.htm">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (17)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.26</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-2_canfitebio.htm">Form
    of Pre-funded Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (17)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.27</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-3_canfitebio.htm">Form
    of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (17)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.28</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-2_canfitebio.htm">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (18)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.29</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-2_canfitebio.htm">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (19)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.30</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-3_canfitebio.htm">Form
    of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (18)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.31</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-3_canfitebio.htm">Form
    of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (19)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.32</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-1_canfitebio.htm">Form
    of Securities Purchase Agreement dated as of June 10, 2020 by and between Can-Fite BioPharma Ltd. and the Purchasers signatory thereto
    (18)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.33</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-1_canfitebio.htm">Form
    of Securities Purchase Agreement dated as of July 5, 2020 by and between Can-Fite BioPharma Ltd. and the Purchasers signatory thereto
    (19)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.34</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-2_canfitebio.htm">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (18)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.35</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-2_canfitebio.htm">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (19)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.36</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-3_canfitebio.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (18)</span></a></span></td></tr>

<tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.37</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-3_canfitebio.htm">Form
    of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (19)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.38</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390021042704/ea145842ex10-1_canfitebio.htm">Form
    of Securities Purchase Agreement dated as of August 11, 2021 between Can-Fite BioPharma Ltd. and the investor listed therein (20)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.39</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390021042704/ea145842ex10-2_canfitebio.htm">Form
    of Pre-Funded Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (20)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.40</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390021042704/ea145842ex10-3_canfitebio.htm">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (20)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.41</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390021042704/ea145842ex10-4_canfitebio.htm">Form
    of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (20)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.42</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390021067180/ea152948ex10-1_canfitebio.htm">Form
    of Warrant Exercise Agreement issued by Can-Fite BioPharma Ltd. on December 23, 2021 (21)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.43</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390021067180/ea152948ex10-2_canfitebio.htm">Form
    of Private Placement Warrants issued by Can-Fite BioPharma Ltd. on December 23, 2021 (21)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.44</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-1_canfitebio.htm"><span style="font-size: 10pt">Form
    of Registered Direct Offering Securities Purchase Agreement dated January 11, 2023, between Can-Fite BioPharma Ltd. and the investor
    listed therein (23)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.45</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-2_canfitebio.htm"><span style="font-size: 10pt">Form
    of PIPE Securities Purchase Agreement dated January 11, 2023, between Can-Fite BioPharma Ltd. and the investor listed therein (23)</span></a></span></td></tr>
</table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.46</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-3_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registered Direct Pre-funded Warrant issued by Can-Fite BioPharma Ltd. on January 13, 2023 (23)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.47</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-4_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A and Series B Warrant issued by Can-Fite BioPharma Ltd. on January 13, 2023 (23)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.48</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-5_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Private Placement Pre-funded Warrant issued by Can-Fite BioPharma Ltd. on January 13, 2023 (23)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.49</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390023002651/ea171609ex10-6_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement dated January 11, 2023, between Can-Fite BioPharma Ltd. and the investor listed therein (23)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.1</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390022014672/f20f2021ex8-1_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of Subsidiaries of Can-Fite BioPharma Ltd. (22)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.1</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex12-1_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.2</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex12-2_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.1</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex13-1_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.2</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex13-2_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.1</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f20f2022ex15-1_canfitebio.htm">Consent of Independent Registered Public Accounting Firm*</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><b>&#160;</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">101.INS</span></td>
    <td style="width: 1%; text-align: left; direction: rtl; unicode-bidi: embed">&#160;</td>
    <td style="width: 90%; text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">Inline XBRL Instance Document </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">101.SCH</span></td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&#160;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">101.CAL</span></td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&#160;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">101.DEF</span></td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&#160;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&#160;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">101.PRE</span></td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&#160;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">104</span></td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed">&#160;</td>
    <td style="text-align: left; direction: rtl; unicode-bidi: embed"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed Herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain confidential information contained in this exhibit was omitted by means of redacting a portion of the text and replacing it with [...]. This exhibit has been filed separately with the Commission without the redaction pursuant to a Confidential Treatment Request under Rule 24b-2 of the Securities Exchange Act of 1934 and Rule 406 of the Securities Act.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on February 13, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Annual Report on Form 20-F filed with the SEC on March 27, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Registration Statement on Form 8-A filed with the SEC on November 15, 2013.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Amendment No. 1 to the Draft Registration Statement on Form 20-F filed with the SEC on September 10, 2013.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Annual Report on Form 20-F filed with the SEC on March 27, 2015.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Registration Statement on Form F-3 filed with the SEC on January 19, 2016.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Annual Report on Form 20- F filed with the SEC on March 30, 2017.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 20, 2017.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on May 30, 2017.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on August 8, 2018.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on February 15, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on May 3, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Current Report on Form 6-K filed with the SEC on May 22, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on May 28, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Registration Statement on Form F-1 filed with the SEC on October 18, 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 10, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on February 12, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on June 12, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on July 8, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on August 16, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on December 23, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Annual Report on Form 20- F filed with the SEC on March 24, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to the Current Report on Form 6-K filed with the SEC on January 13, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td>(24)</td>
    <td style="text-align: justify">Incorporated herein by reference to the Current Report on Form 6-K
filed with the SEC on January 13, 2023.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
Annual Report on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE BIOPHARMA LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 30, 2023</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pnina Fishman, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pnina Fishman, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS
OF DECEMBER 31, 2022</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">1281</ix:nonNumeric>)</b></span></a></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2 - F-3</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; "> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Balance Sheets</b></span></a></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4 - F-5</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; "> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Comprehensive Loss</b></span></a></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; "> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#a_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Changes in Shareholders&#8217; Equity</b></span></a></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-7 - F-8</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; "> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Cash Flows</b></span></a></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-9</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; "> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#a_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></span></a></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-10 - F-33</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- - - - - - - - - - -</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; text-align: left"><img alt="" src="image_004.jpg"/></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kost
    Forer Gabbay &amp; Kasierer</b><br/>
    144 Menachem Begin Road, Building A<br/>
    Tel-Aviv 6492102, Israel&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    +972-3-6232525<br/>
    Fax: +972-3-5622555<br/>
    ey.com</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>To
the Shareholders and the Board of Directors of</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE
BIOPHARMA LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying consolidated balance sheets of Can-Fite
Biopharma Ltd. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of
comprehensive loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022,
and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and
the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with
U.S. generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 104.45pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter
does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the
critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
    and Capital Resources</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description
    of the Matter</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    discussed in Note 1 to the consolidated financial statements, the Company has incurred operating losses and negative cash-flow from
    operations since inception. The Company&#8217;s operations are dependent on its ability to raise additional funds. This dependency will
    continue until the Company will be able to completely finance its operations by generating revenue from its product candidates. Management
    has concluded that, based on its current projections and plans, the Company will be able to satisfy its liquidity requirements for
    more than one year from the date these financial statements were issued.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    identified the assessment of liquidity and the Company&#8217;s ability to continue as a going concern as a critical audit matter
    due to the subjective judgments required of management to conclude the Company would have sufficient liquidity to sustain itself
    for at least a year beyond the date of the issuance of the consolidated financial statements. This in turn led to a high degree of
    auditor subjectivity and judgment to evaluate the audit evidence supporting the liquidity conclusions. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
    We Addressed the Matter in Our Audit</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addressing
    the matter involved performing procedures and evaluating audit evidence in connection with our overall opinion on the consolidated
    financial statements. Our audit procedures to evaluate the significant judgments made by management included, among others, testing
    the reasonableness of forecasted research and development costs, comparison of prior period forecasts to actual results, &#160;evaluating
    the fluctuations in forecasted clinical trial expenses and payments thereof as compared to historic amounts and the underlying management
    assumptions, evaluating the reasonableness of the amounts and timing of payments of forecasted general and administrative expenses
    and other income, net, and considering positive and negative evidence impacting management&#8217;s forecasts. In addition we assessed
    the adequacy of the company&#8217;s liquidity and capital resources disclosures included in note 1 to the consolidated financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<ix:nonNumeric contextRef="c0" name="dei:AuditorName">KOST FORER GABBAY&amp; KASIERER</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Member of Ernst &amp; Young Global</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since at least 2001, but we are unable to determine the specific year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv,
Israel</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
30, 2023</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_034"></a></div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(U.S.
dollars in thousands except for share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 66%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">2,978</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd">5,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd">14,512</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Prepaid expenses, and other current assets</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Short-term investment</td><td>&#160;</td>
    <td style="text-align: center">4</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-style: normal; font-weight: normal"><span style="text-decoration:underline">Total</span> current assets</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">9,157</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">20,068</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease right of use assets</td><td>&#160;</td>
    <td style="text-align: center">11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: center">5</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="text-decoration:underline">Total</span> non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">126</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">185</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="text-decoration:underline">Total</span> assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">9,283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">20,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(U.S.
dollars in thousands except for share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 66%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">896</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">954</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Current maturity of operating lease liability</td><td>&#160;</td>
    <td style="text-align: center">12</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">53</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: center">8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">818</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">6</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">2,502</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">2,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: center">12</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">71</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Deferred revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">2,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">3,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">2,309</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">3,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">CONTIGENT LIABILITIES AND COMMITMENTS</td><td>&#160;</td>
    <td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: center">10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Ordinary shares of <span style="-sec-ix-hidden: hidden-fact-5"><span style="-sec-ix-hidden: hidden-fact-6">no</span></span> par value - Authorized: <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">5,000,000,000</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021; Issued and outstanding: <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares as of December 31, 2022 and 2021</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">154,192</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">153,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">150,847</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> shareholders&#8217;
    equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">4,472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> liabilities and shareholders&#8217;
    equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">9,283</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">20,253</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF COMPREHENSIVE LOSS</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(U.S.
dollars in thousands except for share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">8</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">810</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">853</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">763</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">7,763</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">9,850</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">11,951</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,143</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,845</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">2,951</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">10,096</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">12,842</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">14,139</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total financial income (expense), net</td><td>&#160;</td>
    <td style="text-align: center">13</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">77</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">227</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">10,173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Taxes on income</td><td>&#160;</td>
    <td style="text-align: center">14</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">10,173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deemed dividend</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RedeemablePreferredStockDividends" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RedeemablePreferredStockDividends" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total comprehensive loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">10,173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">15,205</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">15,158</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><div style="-sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11">Basic and diluted net loss per share</div></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.01</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.03</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.04</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><div style="-sec-ix-hidden: hidden-fact-16; -sec-ix-hidden: hidden-fact-15; -sec-ix-hidden: hidden-fact-14">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</div></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">553,079,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">358,411,297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_036"></a></div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(U.S.
dollars in thousands except for share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional<br/> paid-in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated&#160;other <br/> comprehensive</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total shareholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 46%; text-align: left">Balance as of January 1, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">120,652,683</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">111,626</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">110,311</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,442</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deemed dividends related to the warrants exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" sign="-" unitRef="usd">715</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of share capital and warrants, net of issuance expenses of $ <ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:WarrantsNetOfIssuanceExpenses" scale="3" unitRef="usd">3,703</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" scale="0" unitRef="shares">341,766,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Balance as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">463,769,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">130,416</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">125,469</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of share capital due to warrants exercise, net of issuance expenses of $ <ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" unitRef="usd">980</ix:nonFraction> (Note 10b(9), 10b(11) &#160;and 10b(12))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" scale="0" unitRef="shares">293,926,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" scale="3" unitRef="usd">11,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" scale="3" unitRef="usd">11,767</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of share capital and warrants, net of issuance expenses of $ <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:WarrantsNetOfIssuanceExpenses" scale="3" unitRef="usd">1,307</ix:nonFraction> (Note 10b(11))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" scale="0" unitRef="shares">57,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">8,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">8,690</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of share capital in exchange for services (Note 10b(10))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">1,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;&#160;dividends related to the warrants exercise (Note 10b(12))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" sign="-" unitRef="usd">2,590</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Balance as of December 31, 2021</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">153,929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(U.S.
dollars in thousands except for share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional<br/> paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated&#160;other <br/> comprehensive</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balance as of January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">153,929</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">263</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">10,173</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">10,173</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">154,192</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">150,847</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">4,472</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="a_037"></a></div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(U.S.
dollars in thousands except for share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">10,173</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Depreciation of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reduction in the carrying amount of operating lease right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">54</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Changes in fair value of short-term investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" sign="-" unitRef="usd">229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" unitRef="usd">162</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Financial expenses (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd">113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" unitRef="usd">46</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd">23</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Change in prepaid expenses, and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">241</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd">128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd">4,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Decrease in operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">62</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">63</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Increase (decrease) in trade payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">58</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">1,595</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Increase (decrease) in deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" sign="-" unitRef="usd">810</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">1,398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" sign="-" unitRef="usd">401</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Increase (decrease) in other accounts payable</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd">130</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd">574</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd">279</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">10,801</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">9,858</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">12,063</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Withdrawal (investment) in short-term deposits, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:WithdrawalinvestmentInShorttermDepositsNet" scale="3" sign="-" unitRef="usd">9,511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:WithdrawalinvestmentInShorttermDepositsNet" scale="3" unitRef="usd">14,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd">9,502</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">14,511</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of share capital and warrants, net of issuance expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" unitRef="usd">20,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">20,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exchange differences on balances of cash and cash equivalents</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd">113</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd">23</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">1,412</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">3,878</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">5,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cash and cash equivalents at the beginning of the year</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">2,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cash and cash equivalents at the end of the year</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">2,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; text-align: left">Non-cash activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Lease liabilities arising from obtaining right-of-use-assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deemed Dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cash paid during the year for interest</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">23</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="a_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1:-&#160;GENERAL</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company description:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221; and the Company&#8217;s
American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;. Each ADS represents
<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">300</ix:nonFraction> ordinary shares of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company incurred net losses of $&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="canf:NetLosses" scale="0" unitRef="usd">10,173</ix:nonFraction> and it had negative cash flows from operating activities in the amount of $&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="canf:CashFlowsFromOperatingActivities" scale="0" sign="-" unitRef="usd">10,801</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development
of all of its products or may be required to implement a cost reduction measures and may be required to delay part of its development
programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During January 2023, subsequent to
the balance sheet date, the Company raised $ 6,808 net of direct issuance costs for the issuance of its ordinary shares, pre-funded warrants
and warrants exercisable into its ordinary shares. See also Note 15.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s management and
board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company&#8217;s
products for at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment Information</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Operating segments are identified as
components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the
Company&#8217;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#8217;s
drug candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The functional currency of the Company
is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars
in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) No. 830 &#8220;Foreign Currency Matters.&#8221; All transaction gains
and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial
income or expenses, as appropriate.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation id="_DebtPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2022 and 2021, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" scale="-2" unitRef="pure">5.79</ix:nonFraction>% and <ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" scale="-2" unitRef="pure">0.53</ix:nonFraction>%. Short-term bank deposits are presented at their cost, including accrued interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="padding-left: 6.25pt; text-indent: -6.25pt; width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly
from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate
to a clinical trial and no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:nonNumeric contextRef="c0" continuedAt="_OperatingLeaseLeaseIncomeTableTextBlock-c0_cont_1" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation continuedAt="_OperatingLeaseLeaseIncomeTableTextBlock-c0_cont_2" id="_OperatingLeaseLeaseIncomeTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
&#8220;Leases (Topic 842)&#8221;, the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation id="_OperatingLeaseLeaseIncomeTableTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at
amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The
lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over
the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental
Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments.
The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic
environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the
lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will
exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">10</ix:nonFraction></td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">6</ix:nonFraction> - <ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">33</ix:nonFraction></span></td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"></td><td style="width: 24px; text-align: left">i.</td><td style="text-align: justify">Impairment of long-lived assets:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2022, and 2021, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes revenue in accordance
with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition through the
following steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the contract, or contracts, with a customer;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the performance obligations in the contract;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of the transaction price;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_6" id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_7" id="_RevenueRecognitionPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_8" id="_RevenueRecognitionPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company generates revenues from
supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential
royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_9" id="_RevenueRecognitionPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price
is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf
of third parties (such as taxes).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in"></p><div>


</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_10" id="_RevenueRecognitionPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_11" id="_RevenueRecognitionPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_12" id="_RevenueRecognitionPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_13" id="_RevenueRecognitionPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2022, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_14" id="_RevenueRecognitionPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_15" id="_RevenueRecognitionPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_16" id="_RevenueRecognitionPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2022 and December
31, 2021 contract liabilities amounted to $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="canf:ContractLiabilities" scale="3" unitRef="usd">3,078</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:ContractLiabilities" scale="3" unitRef="usd">3,888</ix:nonFraction>, respectively and are presented under deferred revenues. During the year
ended December 31, 2022, the Company recognized revenues in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:Revenue" scale="3" unitRef="usd">810</ix:nonFraction> which have been included in the contract liabilities at
December&#160;31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_17" id="_RevenueRecognitionPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_18" id="_RevenueRecognitionPolicyTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_18"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Cipher Pharmaceuticals (Canada)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">11</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">12</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">20</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp. (South Korea)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">25</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">24</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">45</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmbH (Austria)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">18</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">23</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">35</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG (Switzerland)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">41</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified
within level 1 in the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of Credit Risk:&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially
subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents,
the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term
deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a
liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews
the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered
probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2022,
and 2021, the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial
position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:nonNumeric contextRef="c0" continuedAt="canf_SeverancePayPolicyTextBlock-c0_cont_1" escape="true" name="canf:SeverancePayPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation continuedAt="canf_SeverancePayPolicyTextBlock-c0_cont_2" id="canf_SeverancePayPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="canf:PercentageOfDepositsOnMonthlySalary" scale="-2" unitRef="pure">8.33</ix:nonFraction>% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation id="canf_SeverancePayPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2022, 2021 and 2020 amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">51</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">53</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">46</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value of share options granted using
the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected
stock price, volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical
volatility of the Company and early exercise factor was calculated based statistical studies in the U.S. market. The risk-free interest
rate is based on the yield from Israeli Government bonds with an equivalent term. The Company has historically not paid dividends and
has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022, and 2021, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfRealizationOnUltimateSettlement" scale="-2" unitRef="pure">50</ix:nonFraction>% likely to be realized upon ultimate settlement.
As of December 31, 2022, and 2021, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:nonNumeric contextRef="c0" continuedAt="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_1" escape="true" name="canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td><td style="text-align: justify">Ordinary share and warrants classification and measurement:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:continuation continuedAt="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_2" id="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:continuation id="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: right; text-indent: 0.25in"><b>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The potential shares of ordinary shares
that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented
because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="canf:Options" scale="0" unitRef="shares">27,002,200</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="canf:Options" scale="0" unitRef="shares">18,422,700</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="canf:Options" scale="0" unitRef="shares">11,923,400</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">375,197,640</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">377,947,640</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">228,192,286</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="canf:TotalinDollars" scale="0" unitRef="shares">402,199,840</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="canf:TotalinDollars" scale="0" unitRef="shares">396,370,340</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="canf:TotalinDollars" scale="0" unitRef="shares">240,115,686</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently adopted and recently issued accounting pronouncements</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective January 1, 2022. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The Company&#8217;s adopted the standard effective January 1, 2022. Adoption of the new standard did not have a material impact on the financial statements. &#160;</p></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OtherCurrentAssetsTextBlock-c0_cont_1" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3:-&#160; PREPAID EXPENSES AND OTHER
CURRENT ASSETS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_OtherCurrentAssetsTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="canf:GovernmentAuthorities" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:GovernmentAuthorities" scale="3" unitRef="usd">48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" unitRef="usd">1,123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" unitRef="usd">881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd">1,170</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd">929</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: right; text-indent: 0.25in"><b>CAN-FITE BIOPHARMA
LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4:-&#160;SHORT-TERM INVESTMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_InvestmentTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022 and 2021, the
Company holds <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">5,947</ix:nonFraction></ix:nonFraction> shares of Mawson Infrastructure Group Inc. a public traded company on the NASDAQ Capital Market, which as of such
dates represents less than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfOutstandingShares" scale="-2" unitRef="pure">5</ix:nonFraction> percent of Mawson Infrastructure Group Inc.&#8217;s outstanding shares, respectively. The investments in
marketable equity securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance
income (expenses), net. Refer to note 12 for financial expenses incurred in 2022.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5:-&#160;PROPERTY, PLANT AND
EQUIPMENT, NET </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Composition of assets, grouped by major classification,
is as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">35</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">234</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">42</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expenses for the year ended
December 31, 2022, 2021 and 2020 amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">14</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">14</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">12</ix:nonFraction>, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:-</b>&#160;<b>OTHER ACCOUNTS PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="canf:EmployeesAndPayrollAccruals" scale="0" unitRef="usd">492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="canf:EmployeesAndPayrollAccruals" scale="0" unitRef="usd">603</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">283</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">775</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">905</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7:- FAIR VALUE MEASUREMENTS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with ASC 820 &#8220;Fair
Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_3" id="_FairValueDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_4" id="_FairValueDisclosuresTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measurements</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold">Description</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
                                            value</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            1</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            2</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            3</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_4"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold; padding-bottom: 1.5pt">Description</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:- REVENUES&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Cipher Pharmaceuticals</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March 2015, the Company signed a
distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute
Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon
receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_4" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the terms of the agreement, Cipher
made an upfront payment of $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd">1,292</ix:nonFraction> (<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="3" unitRef="cad">1,650</ix:nonFraction> thousand Canadian Dollar) to the Company in March 2015. In addition, the agreement provides that
additional payments of up to <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalLiabilityLongDurationInsuranceBenefitPayment" scale="3" unitRef="cad">2,000</ix:nonFraction> thousand Canadian Dollar will be received by the Company upon the achievement of certain milestones
plus royalty payments of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" unitRef="pure">16.5</ix:nonFraction>% of net sales of Piclidenoson in Canada.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_5" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_6" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;REVENUES (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_7" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Chong Kun Dang Pharmaceuticals
Corp.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_8" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In October 2016, the Company signed
a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;). As part of the distribution agreement, CKD will
have exclusive rights to distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory
approvals. On February 25, 2019, distribution agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for
the treatment of NASH in addition to liver cancer in South Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_9" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the distribution agreement,
the Company is entitled to receive an amounts of up to $ <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmountOfRegulatoryAssistanceReceived1" scale="0" unitRef="usd">3,000</ix:nonFraction> in upfront and milestone payments payable with respect to the liver cancer
indication and additional $ <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLoansPayable" scale="0" unitRef="usd">6,000</ix:nonFraction> in upfront and milestone payments payable with respect to NASH indication. In addition, the Company
will also be entitled to a transfer price for delivering finished product to CKD following commercial launch at a cost plus <ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PercentageOfFIFOInventory" scale="-2" unitRef="pure">10</ix:nonFraction>% basis
or <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PercentageOfFIFOInventory" scale="-2" unitRef="pure">23</ix:nonFraction>% of net sales of Namodenoson following commercial launch in South Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_10" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_11" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
received an amount of $ <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesReceivedAsCollateral" scale="0" unitRef="usd">1,500</ix:nonFraction> for up-front payment and additional $ <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd">500</ix:nonFraction> for achieved milestone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_12" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
estimates that such services will be completed by December 31, 2025 and therefore revenues from such up-front payment are recognized over
such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_13" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Gebro Holding GmBH</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_14" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 8, 2018, the Company entered
into a Distribution and Supply Agreement with Gebro Holding GmBH (&#8220;Gebro&#8221;), granting Gebro the exclusive right to distribute
Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_15" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><ix:nonNumeric contextRef="c69" name="canf:DistributionAndSupplyAgreementDescription">Under the Distribution and Supply Agreement,
the Company is entitled to &#8364; 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone
payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#8364; 300 thousand upon initiation of the ACRobat
Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364; 300 thousand upon the initiation of the COMFORT Phase III
clinical trial for the treatment of psoriasis, (ii) between &#8364; 750 thousand and &#8364; 1,600 thousand following first delivery of
commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364; 300
thousand and up to &#8364;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall
be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.</ix:nonNumeric>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_16" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
received an amount of &#8364; <ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesReceivedAsCollateral" scale="3" unitRef="eur">1,500</ix:nonFraction> thousand (approximately $ <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesReceivedAsCollateral" scale="0" unitRef="usd">1,850</ix:nonFraction>) for up-front payment and additional &#8364; <ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="eur">600</ix:nonFraction> thousand (approximately
$ <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd">720</ix:nonFraction>) for achieved milestone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_17" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;REVENUES (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_18" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">CMS Medical Venture
Investment Limited </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_19" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 6, 2018, the Company entered
into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the
commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver
cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_20" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the License, Collaboration and
Distribution Agreement, the Company is entitled to receive an up-front amount of $ <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmountOfRegulatoryAssistanceReceived1" scale="0" unitRef="usd">2,000</ix:nonFraction> upon execution of the agreement. In addition,
the Company is also entitle to received an amount of up to $ <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLoansPayable" scale="0" unitRef="usd">14,000</ix:nonFraction> for milestone payments upon achieving certain regulatory milestones
and up to $ <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredSalesInducementsNet" scale="0" unitRef="usd">58,500</ix:nonFraction> for milestone payments upon achieving certain sales milestones. In addition, following regulatory approval, the Company
shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and
Namodenoson.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_21" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
received an amount of $ <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesReceivedAsCollateral" scale="0" unitRef="usd">2,000</ix:nonFraction> for up-front payment which was previously recognized in revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_22" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Kyongbo Pharm Co., Ltd.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_23" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On July 31, 2019, the Company signed
a distribution agreement with Kyongbo Pharm Co., Ltd. (&#8220;Kyongbo Pharm&#8221;), to distribute Piclidenoson, for the treatment of
psoriasis in South Korea, upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_24" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the terms of the distribution
agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea,
is required to make a total a payment of $ <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToSuppliers" scale="0" unitRef="usd">750</ix:nonFraction> for access to information and clinical study data. In addition, the Company will be also
entitle to additional payments of up to $ <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalCollateralAggregateFairValue" scale="0" unitRef="usd">3,250</ix:nonFraction> upon achievement of certain milestones. The Company will also be entitled to a transfer
price for delivering finished product to Kyongbo Pharm upon commercial launch.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_25" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In 2019, the Company received an amount
of $ <ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesReceivedAsCollateral" scale="0" unitRef="usd">750</ix:nonFraction> for up-front payment which recognized as revenues upon the Company providing access to information and clinical study data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_26" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Ewopharma</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_27" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 16, 2021, the Company signed
an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in
the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis
(NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $ <ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmountOfRegulatoryAssistanceReceived1" scale="0" unitRef="usd">2,250</ix:nonFraction>
and is entitled to up to an additional $ <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLoansPayable" scale="0" unitRef="usd">40,450</ix:nonFraction> payable upon the achievement of regulatory and sales milestones and <ix:nonFraction contextRef="c75" decimals="3" format="ixt:num-dot-decimal" name="canf:MilestonePercentage" scale="-2" unitRef="pure">17.5</ix:nonFraction>% royalties on
net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries
and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that
Can-Fite may identify for its drug candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_28" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
received an amount of $ <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesReceivedAsCollateral" scale="0" unitRef="usd">2,250</ix:nonFraction> for up-front payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_29" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;REVENUES (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_30" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Vetbiolix</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_31" id="_RevenueFromContractWithCustomerTextBlock-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 28, 2021, the Company announced
it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development
of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company
will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for <ix:nonNumeric contextRef="c77" format="ixt-sec:durwordsen" name="canf:SignatureDate">two years</ix:nonNumeric>
from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies
yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite
a non-refundable upfront payment in an amount of Euro <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmountOfRegulatoryAssistanceReceived1" scale="0" unitRef="eur">250</ix:nonFraction>, additional milestones payment equal to <ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="canf:MilestonePercentage" scale="-2" unitRef="pure">30</ix:nonFraction>% upon each upfront payment received
from sublicensee and <ix:nonNumeric contextRef="c77" name="canf:RoyalitiesDescription">15%-40% royalties on net sales upon regulatory approval for veterinary use.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RevenueFromContractWithCustomerTextBlock-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
did not received payment related to such agreement.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; padding-right: 0.9pt">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities to pay royalties:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is committed to pay royalties
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A one-time concession commission of &#8364;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpenseCommissionExpense" scale="3" unitRef="eur">25</ix:nonFraction> thousand;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual royalties of &#8364;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="3" unitRef="eur">10</ix:nonFraction> thousand until the clinical trials commence;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfNetSales" scale="-2" unitRef="pure">2</ix:nonFraction>%-<ix:nonFraction contextRef="c79" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfNetSales" scale="-2" sign="-" unitRef="pure">3</ix:nonFraction>% of net sales (as defined in the agreement) received by the Company;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" name="canf:PatentAgreementDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties in a total amount of up to &#8364;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdvanceRoyalties" scale="3" unitRef="eur">850</ix:nonFraction> thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.</span></ix:nonNumeric></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in">As of December
31 2022, no accrual has been recorded with respect to Leiden University.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10:-&#160;SHAREHOLDERS&#8217; EQUITY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2023, subsequent to the balance sheet date, the Company&#8217;s shareholders meeting approved to change the Company&#8217;s ordinary shares par value from NIS <ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction> per share to no par value. All par value data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the change.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to be invited and participate in all the Company&#8217;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#8217;s general meeting participated.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to participate in the distribution of the Company&#8217;s assets upon liquidation.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of shares and warrants and changes in equity:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, the Company entered into warrant exercise agreements (the &#8220;Exercise Agreements&#8221;) with several accredited investors who are the holders of certain warrants (the &#8220;Public Warrants&#8221;) to purchase the Company&#8217;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">22,278,540</ix:nonFraction> ordinary shares having exercise prices ranging from $<ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.43</ix:nonFraction> to $<ix:nonFraction contextRef="c83" decimals="3" format="ixt:num-dot-decimal" name="canf:AggregatePurchasePrice" scale="0" unitRef="usd">2.625</ix:nonFraction> per ordinary share issued by the Company, at a reduced exercise price of $<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">0.10</ix:nonFraction> per share, for gross proceeds to the Company of approximately $<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">2,400</ix:nonFraction>, prior to deducting placement agent fees and estimated offering expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">22,278,540</ix:nonFraction> ordinary shares for an exercise price of $ <ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.11</ix:nonFraction> per shares (the &#8220;Private Placement Warrants&#8221;). The placement agent in the offering also received compensation warrants exercisable for up to <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="canf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" scale="0" unitRef="shares">1,559,498</ix:nonFraction> Ordinary share The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of $ <ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.11</ix:nonFraction> per ordinary share, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="canf:DeemedDividend" scale="3" unitRef="usd">715</ix:nonFraction>.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2020, <ix:nonNumeric contextRef="c86" name="canf:SecuritiesPurchaseAgreementDescription">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 54,750,000 units, each unit consisting of one Ordinary share, and one warrant to purchase one Ordinary share, at a price of $ 0.05 per unit, and (ii) 45,250,020 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one Ordinary share and one warrant, at a price of $ 0.05 per pre-funded unit.</ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds from the offering were approximately $ <ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="3" unitRef="usd">5,000</ix:nonFraction>, prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent in the offering also received compensation warrants exercisable for up to <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="canf:CompensationWarrantsExercisable" scale="0" unitRef="shares">7,500,000</ix:nonFraction> Ordinary share at an exercise price of $ <ix:nonFraction contextRef="c87" decimals="4" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">0.0625</ix:nonFraction> per Ordinary share expiring on <ix:nonNumeric contextRef="c86" format="ixt:date-monthname-day-year-en" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">February 10, 2025</ix:nonNumeric>.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">20,250,000</ix:nonFraction> ordinary shares, at a price of $<ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">0.05</ix:nonFraction> per ordinary share for gross proceeds of $<ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">1,012</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#8217;s authorized share capital to <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="canf:IncreaseAuthorizedShareCapital" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction> ordinary shares of no par value each and on June 7, 2021, &#160;a special meeting of shareholders of the Company approved to increase Company&#8217;s authorized share capital to <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">5,000,000,000</ix:nonFraction> ordinary shares of no par value each.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">31,000,020</ix:nonFraction></ix:nonFraction> ordinary shares, at a price of $<ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePriceSubjectToAdjusment" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePriceSubjectToAdjusment" scale="0" unitRef="usdPershares">0.05</ix:nonFraction></ix:nonFraction> per Ordinary share for gross proceeds of $<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">1,550</ix:nonFraction></ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">117,073,200</ix:nonFraction> ordinary shares at a purchase price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">0.07</ix:nonFraction> per Ordinary share for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">8,000</ix:nonFraction> prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">58,536,600</ix:nonFraction> ordinary shares. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $<ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">0.08</ix:nonFraction> per ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ordinary shares sold in the offering (or warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">8,780,490</ix:nonFraction> Ordinary share), at an exercise price of $<ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.08</ix:nonFraction> per ordinary share and a term expiring four and a half years from the date of issuance.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of <ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">51,165,000</ix:nonFraction> Ordinary share at a purchase price of $<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.06</ix:nonFraction> per Ordinary share for aggregate gross proceeds of approximately $ <ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">3,400</ix:nonFraction> prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">25,582,500</ix:nonFraction> Ordinary share. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $<ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.08</ix:nonFraction> per Ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to <ix:nonFraction contextRef="c100" decimals="3" format="ixt:num-dot-decimal" name="canf:AggregateNumbersOfADS" scale="-2" unitRef="pure">7.5</ix:nonFraction>% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="canf:WarrantsToPurchaseAggregateShares" scale="0" unitRef="shares">3,837,390</ix:nonFraction> Ordinary shares), at an exercise price of $<ix:nonFraction contextRef="c101" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrice" scale="0" unitRef="usdPershares">0.08</ix:nonFraction> per Ordinary share and a term expiring.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company issued <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,350,000</ix:nonFraction> of its ordinary shares to a consultant in exchange for his services.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February and March 2021, the Company issued <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">50,926,830</ix:nonFraction></ix:nonFraction> ordinary shares in exchange for exercise of warrants. Total consideration received by the Company was $ <ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="canf:TotalConsiderationAmount" scale="3" unitRef="usd"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="canf:TotalConsiderationAmount" scale="3" unitRef="usd">2,744</ix:nonFraction></ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued <ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,050,000</ix:nonFraction> of its ordinary shares to certain consultants in exchange for their services with fair value of $ <ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent" scale="3" unitRef="usd">68</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) <ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">57,000,000</ix:nonFraction> ordinary shares, and (ii) a pre-funded warrant to purchase <ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">93,000,000</ix:nonFraction> ordinary shares at an offering price of $<ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">0.07</ix:nonFraction> per Ordinary share and $<ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="canf:PreFundedWarrant" scale="0" unitRef="usdPershares">0.06</ix:nonFraction> per pre-funded warrant, for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">10,000</ix:nonFraction> (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#8217;s fees and other estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">150,000,000</ix:nonFraction> Ordinary shares. The warrants have an exercise price of $ <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.07</ix:nonFraction> per Ordinary share and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the Company received a total of $ <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:AggregateNumberOfADS" scale="3" unitRef="usd">9,997</ix:nonFraction> and issued <ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">57,000,000</ix:nonFraction> ordinary shares and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">93,000,000</ix:nonFraction> ordinary shares following the exercise of the pre-funded warrants (issuance expenses were $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceExpenses" scale="3" unitRef="usd">1,307</ix:nonFraction>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also paid on aggregate of $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" unitRef="shares">700</ix:nonFraction> in placement agent fees and expenses and issued <ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">10,500,000</ix:nonFraction> placement agent warrants, at an initial exercise price equal to $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare" scale="0" unitRef="usdPershares">0.07</ix:nonFraction> per Ordinary share, on substantially the same terms as the investor warrants, except that the placement agent warrants expire on the earlier of (i) the third-year anniversary of the date on which an initial resale registration statement registering the ordinary shares (or the ADSs) issuable upon the exercise of the warrants becomes effective and (ii) August 11, 2026.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c114" name="canf:StockIssuanceAgreementDescription">On December 20, 2021, the Company entered into
a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing
warrants to purchase Company&#8217;s ordinary shares in a registered direct offering consummated in August 2021.</ix:nonNumeric> Pursuant to the Exercise
Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">150,000,000</ix:nonFraction> Ordinary Shares having an
exercise price of $<ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.07</ix:nonFraction> per Ordinary share, for gross proceeds to the Company of $<ix:nonFraction contextRef="c114" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">10,000</ix:nonFraction> prior to deducting placement agent fees and offering
expenses (which amounted to $<ix:nonFraction contextRef="c116" decimals="-4" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="6" unitRef="usdPershares">0.98</ix:nonFraction> million).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">180,000,000</ix:nonFraction> Ordinary Shares (the &#8220;Private Placement Warrants&#8221;). <ix:nonNumeric contextRef="c114" continuedAt="canf_ExerciseAgreementDescription-c114_cont_1" name="canf:ExerciseAgreementDescription">The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $0.07 per Ordinary share. The Company also paid $875 in placement agent fees and issued unregistered placement agent warrants to purchase 10,500,000 Ordinary shares on the same terms as the warrant.</ix:nonNumeric></p><ix:continuation id="canf_ExerciseAgreementDescription-c114_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</p></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to Purchase Common stock:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes information
regarding outstanding warrants to purchase the Company&#8217;s ordinary shares as of December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><ix:nonNumeric contextRef="c118" name="canf:IssuanceDate">March 2018</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">333,334</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c119" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">1.0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c120" name="canf:IssuanceDate">January 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">223,810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c122" name="canf:IssuanceDate">April 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">492,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c124" name="canf:IssuanceDate">May 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c125" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">47,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c126" name="canf:IssuanceDate">January 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">23,838,038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c128" name="canf:IssuanceDate">February 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c129" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">11,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.05</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c130" name="canf:IssuanceDate">June 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">61,390,260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c132" name="canf:IssuanceDate">July 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">29,419,890</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c134" name="canf:IssuanceDate">August 2021</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c135" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">10,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.07</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c136" name="canf:IssuanceDate">December 2021</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">190,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.07</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">375,197,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2022 and 2021, all
of the Company&#8217;s outstanding warrants are classified as equity instruments.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11:-&#160;SHARE-BASED PAYMENT TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options plan:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#8220;2013 Plan&#8221;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of <ix:nonNumeric contextRef="c138" format="ixt-sec:duryear" name="canf:GrantedExcessYears">10</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s 2013 Plan, in July
2022, the Company&#8217;s Board of Directors approved to increase number of ordinary shares reserved for issuance to <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">35,000,000</ix:nonFraction>. As of
December 31, 2022, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="canf:FutureShares" scale="0" unitRef="shares">8,023,000</ix:nonFraction> shares available for future grant under the 2013 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11:-&#160;SHARE-BASED PAYMENT TRANSACTIONS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses recognized in the financial statements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd">263</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd">466</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions granted by the Company:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c78" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.41</ix:nonFraction>%-<ix:nonFraction contextRef="c79" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.08</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.22</ix:nonFraction>-<ix:nonFraction contextRef="c141" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.28</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c142" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.93</ix:nonFraction>-<ix:nonFraction contextRef="c143" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.40</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c78" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">83.98</ix:nonFraction>%-<ix:nonFraction contextRef="c79" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">84.26</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">82.40</ix:nonFraction>-<ix:nonFraction contextRef="c141" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">82.43</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c142" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">65.63</ix:nonFraction>-<ix:nonFraction contextRef="c143" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">78.77</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contractual life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c142" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">9.83</ix:nonNumeric> - <ix:nonNumeric contextRef="c143" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Early Exercise Multiple (Suboptimal Factor)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c78" decimals="1" format="ixt:num-dot-decimal" name="canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" scale="0" unitRef="pure">2.5</ix:nonFraction>-<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" scale="0" unitRef="pure">3</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" scale="0" unitRef="pure">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c142" decimals="1" format="ixt:num-dot-decimal" name="canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" scale="0" unitRef="pure">2.5</ix:nonFraction> - <ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" scale="0" unitRef="pure">3</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise price (NIS)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction>-<ix:nonFraction contextRef="c141" decimals="3" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.253</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction> - <ix:nonFraction contextRef="c143" decimals="3" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">2.344</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the year ended December 31, 2022 and related information:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> exercise <br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> remaining<br/> contractual<br/> terms (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> intrinsic<br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding at December 31, 20221</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">18,422,700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.18</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.45</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">8,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" scale="0" unitRef="shares">170,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">27,002,200</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.13</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.14</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" scale="0" unitRef="shares">27,002,200</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.13</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">7.14</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">11,071,575</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.21</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.18</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11:-&#160;SHARE-BASED PAYMENT TRANSACTIONS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2022, 2021 and 2020 was <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">6.96</ix:nonNumeric> years, <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.45</ix:nonNumeric> years and <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">6.98</ix:nonNumeric> years, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value in 2022 was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">0.02</ix:nonFraction> and in 2021 was $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">0.18</ix:nonFraction> and the remaining compensation costs not yet recognized as of December 31, 2022 is $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" unitRef="usd">230</ix:nonFraction> with a weighted average period of <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.73</ix:nonNumeric> years to recognize these expenses.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12- LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of <ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">3</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_3" id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_4" id="_LesseeOperatingLeasesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.42</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.42</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">13</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">13</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_5" id="_LesseeOperatingLeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2022 and 2021 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_6" id="_LesseeOperatingLeasesTextBlock-c0_cont_5"><ix:continuation continuedAt="_LeaseCostTableTextBlock-c0_cont_2" id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">54</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">55</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_7" id="_LesseeOperatingLeasesTextBlock-c0_cont_6"><ix:continuation id="_LeaseCostTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" scale="3" unitRef="usd">54</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" scale="3" unitRef="usd">55</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_8" id="_LesseeOperatingLeasesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">Maturities
of lease liabilities as of December 31, 2022 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd">54</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">2024</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease payments</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="canf:LesseeOperatingLeaseLiabilityPaymentDue" scale="3" unitRef="usd">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: imputed interest</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="canf:ImputedInterestLessImputedInterest" scale="3" unitRef="usd">10</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liability</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InterestIncomeAndInterestExpenseDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13:-&#160;FINANCE INCOME (EXPENSE), NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_InterestIncomeAndInterestExpenseDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">16</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">18</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">23</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:NetLossFromExchangeRateFluctuations" scale="3" sign="-" unitRef="usd">54</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:OtherLossFromShorttermInvestmentRevaluation" scale="3" sign="-" unitRef="usd">229</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">363</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">299</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">386</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">44</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:ExchangeRateFluctuations" scale="3" unitRef="usd">63</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:ExchangeRateFluctuations" scale="3" unitRef="usd">27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd">162</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" sign="-" unitRef="usd">77</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">227</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14:-&#160;TAXES ON INCOME</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate tax rates:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Israeli taxation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Corporate tax rate in Israel in 2022,
2021 and 2020 was <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Law for the Encouragement of Capital
Investments, 1959:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Law for Encouragement of Capital
Investments, 1959 (the &#8220;Investment Law&#8221;) provides tax benefits for Israeli companies meeting certain requirements and criteria.
The Investment Law has undergone certain amendments and reforms in recent years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Israeli parliament enacted a reform
to the Investment Law, effective January 2011 (which was amended in August 2013). According to the reform, a flat rate tax applies to
Preferred Income of companies eligible for the &#8220;Preferred Enterprise&#8221; status. In order to be eligible for Preferred Enterprise
status, a company must meet minimum requirements to establish that it contributes to the country&#8217;s economic growth and is a competitive
factor for the gross domestic product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Benefits granted to a Preferred Enterprise
include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for
Budget Years 2017-2018), 5777-2016, the tax rate is&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">16</ix:nonFraction>% for all areas other than Development Area A (which was&#160;<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="canf:DevelopmentAreaAPercentage" scale="-2" unitRef="pure">7.5</ix:nonFraction>% from 2017
onward).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14:-&#160;TAXES ON INCOME (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final tax assessments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company received final tax assessments
through 2017.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating carryforward losses for tax purposes and other temporary differences:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2022, the Company
had carryforward losses amounting to approximately $&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" unitRef="usd">157,106</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_13" id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_14" id="_IncomeTaxDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_15" id="_IncomeTaxDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s
deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_16" id="_IncomeTaxDisclosureTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">25,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">26,348</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">1,376</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">2,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">26,513</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">28,633</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">26,513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">28,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_17" id="_IncomeTaxDisclosureTextBlock-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main reconciling item between the statutory tax rate of the Company
and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating
losses carried forward due to the uncertainty of the realization of such deferred taxes and the company&#8217;s preferred enterprise tax rate.<b>&#160;</b></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15:- TRANSACTIONS WITH RELATED PARTIES
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Chairman of the Company&#8217;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#8220;Service Provider&#8221;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">218</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">241</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">252</ix:nonFraction> in 2022, 2021 and 2020, respectively, which were recorded under research
and development expenses within Company&#8217;s consolidated statements of comprehensive loss.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS
SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16:- SUBSEQUENT EVENTS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On January 11, 2023, the Company entered into
a securities purchase agreement (the &#8220;RD Purchase Agreement&#8221;), pursuant to which the Company agreed to sell and issue in a
registered direct offering (the &#8220;Registered Direct Offering&#8221;) an aggregate of <ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">90,000,000</ix:nonFraction> ordinary shares for a purchase price
of $ <ix:nonFraction contextRef="c148" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.018</ix:nonFraction> per share (the &#8220;RD Shares&#8221;) and pre-funded warrants to purchase up to <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">210,000,000</ix:nonFraction> of the Company&#8217;s Ordinary
Shares at a purchase price of $ <ix:nonFraction contextRef="c150" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.018</ix:nonFraction> per share and at an immaterial exercise price (the &#8220;Pre-funded Warrants&#8221;), and, unregistered
Series A warrants to purchase up to <ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">300,000,000</ix:nonFraction> Ordinary Shares for an exercise price of $ <ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.02</ix:nonFraction> per shares (the &#8220;Series A Warrants&#8221;),
and unregistered Series B warrants to purchase up to <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">300,000,000</ix:nonFraction> Ordinary Shares for exercise price of $ <ix:nonFraction contextRef="c154" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.018</ix:nonFraction> per share (the &#8220;Series
B Warrants&#8221;).</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, the Company entered into
a securities purchase agreement (the &#8220;PIPE Purchase Agreement,&#8221; and together with the RD Purchase Agreement, the &#8220;Purchase
Agreements&#8221;) pursuant to which the Company agreed to sell and issue in a concurrent private placement (the &#8220;PIPE Offering,&#8221;
and together with the Registered Direct Offering, the &#8220;Offerings&#8221;) unregistered Pre-funded Warrants to purchase up to <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">109,091,100</ix:nonFraction>
of the Company&#8217; Ordinary Shares at purchase price of $ <ix:nonFraction contextRef="c156" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.018</ix:nonFraction> per share and additional immaterial exercise price per share, unregistered
Series A Warrants to purchase up to <ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">109,091,100</ix:nonFraction> of the Company&#8217;s Ordinary Shares for an exercise price of $ <ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.02</ix:nonFraction> per share and unregistered
Series B Warrants to purchase up to <ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">109,091,100</ix:nonFraction> of the Company&#8217;s Ordinary Shares for an exercise price of $ <ix:nonFraction contextRef="c160" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.018</ix:nonFraction> per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_4" id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Moreover, the Company has also issued a placement agent warrants (the
&#8220;Placement Agent Warrants&#8221;) on substantially the same terms as the Series A Warrants to purchase up to <ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">28,636,500</ix:nonFraction> of the Company&#8217;s
Ordinary Shares for an exercise price of $ <ix:nonFraction contextRef="c162" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.022</ix:nonFraction> per share. In addition, the Company paid an aggregate of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpenseTransferAgentAndCustodianFees" scale="0" unitRef="usd">675</ix:nonFraction> thousands in placement
agent fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_5" id="_SubsequentEventsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company received total consideration
of $ <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="canf:NetOfDirectIssuanceCosts" scale="0" unitRef="usd">6,808</ix:nonFraction> net of direct issuance costs from the above mentioned issuance of shares, prefunded warrants and Series A and B warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_6" id="_SubsequentEventsTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">The Company has also agreed to amend certain warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">180,000,000</ix:nonFraction> Ordinary
shares that were issued in December 2021 to the investor in this offering and private placement by reducing the exercise prices from $
<ix:nonFraction contextRef="c141" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.067</ix:nonFraction> per share to $ <ix:nonFraction contextRef="c140" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">0.018</ix:nonFraction> per share.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">3.</td><td style="text-align: justify">During January through March 2023, certain investors exercised prefunded warrants and purchased <ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">319,091,100</ix:nonFraction>
of the Company&#8217;s Ordinary shares for an exercise price at an immaterial amount.</td></tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-33</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-7" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-9" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-10" name="us-gaap:RedeemablePreferredStockDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.01</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.03</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-13" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.04</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="0" id="hidden-fact-14" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">358411297</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="0" id="hidden-fact-15" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">553079638</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-16" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">815746293</ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-17" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-21" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-22" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-23" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-30" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-31" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-32" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-33" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-34" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-35" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-36" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-37" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-43" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-44" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-45" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-46" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-49" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-50" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-51" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-52" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-53" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-54" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-55" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-56" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-57" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-58" name="canf:WithdrawalinvestmentInShorttermDepositsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-59" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-60" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-62" name="us-gaap:PaymentsOfDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-64" name="canf:RevenueContractWithCustomer" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-65" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-66" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-67" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-68" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-72" name="canf:WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-73" name="canf:AggregateIntrinsicValueForfeitedexpired" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-76" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-77" name="canf:NetLossFromExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-78" name="canf:NetLossFromExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-79" name="canf:OtherLossFromShorttermInvestmentRevaluation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-80" name="canf:OtherLossFromShorttermInvestmentRevaluation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-81" name="us-gaap:OtherExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-82" name="canf:ExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-83" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-84" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-85" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001536196</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="canf-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:LaboratoryEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-03-31</xbrli:startDate>
    <xbrli:endDate>2015-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-08</xbrli:startDate>
    <xbrli:endDate>2018-01-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CMSMedicalVentureInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CMSMedicalVentureInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:EwopharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-16</xbrli:startDate>
    <xbrli:endDate>2021-03-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:EwopharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-16</xbrli:startDate>
    <xbrli:endDate>2021-03-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:EwopharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-28</xbrli:startDate>
    <xbrli:endDate>2021-01-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmPO7kW86fCwO9BDdY5bf5b9H+vvjKwz2saovEzZ3dBRA5yWdSLppMepuvQwgTmpdXkG6aEqg3eKP65vjM+XithEfqz6791Pl3kR8GSmegnWDxXRqVGeC1a80eULcC/VdL] CSR-->
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-09</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-09</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-11-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-11-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">canf:RDPurchaseAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">canf:RDPurchaseAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesAWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesAWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesBWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesBWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:UnregisteredPrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:UnregisteredPrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesAWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesAWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesBWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesBWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PlacementAgentWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PlacementAgentWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>f20f2022ex1-1_canfitebio.htm
<DESCRIPTION>AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF CAN-FITE BIOPHARMA LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Articles of Association<BR>
Pursuant to the Companies Law, 1999, of a Company Limited by Shares<BR>
CAN FITE BIOPHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 9%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 80%; text-align: justify"><B>Clause</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center"><B>Page</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Interpretation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Company Name</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Company Purposes</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Company Intent</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Authorised Share Capital</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Shareholder Liability</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>7</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Public Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>8</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Shares</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>9</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Share Certificate; Share Warrant</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Call on Shares</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>11</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Share Forfeiture and Mortgage</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>12</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Share Transfer and Delivery</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>13</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Redeemable Shares</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>14</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Recapitalisation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>15</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">General Meetings</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>16</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">General Meeting Resolutions</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>17</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Shareholders&rsquo; Vote</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>18</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Voting Rights</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>19</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>20</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Board&rsquo;s Authority</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">20</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>21</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Board Meetings</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>22</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Board Committee</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">22</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>23</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Minutes</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>24</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">CEO</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>25</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Local Management</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>26</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Registry of Shareholders</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>27</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Company Officers</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>28</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Distribution</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>29</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">The Internal Auditor</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">The Auditing Accountant</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>31</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Transactions Requiring Special Authorisation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>32</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Merger</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>33</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Notices</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>34</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Liquidation of the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>35</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Exemption from Liability</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>36</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Liability Insurance</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>37</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Indemnity</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>38</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Binding the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>39</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Amendment of these Articles of Association</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD STYLE="text-align: justify"><B><U>Interpretation</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1.</TD><TD STYLE="text-align: justify">In these Articles, unless the wording demands a different interpretation, the following words and expressions
shall bear the following meanings:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Stock Exchange</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Tel Aviv Stock Exchange Ltd.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Board</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors duly elected pursuant to the provisions hereof.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Director</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A member of the Company&rsquo;s Board and any person who acts as a Director in actual fact, be his/her title what it may.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Securities Law</B>&rdquo; -</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Securities Law, 1968, as amended from time to time, and the regulations promulgated thereunder.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Companies Law</B>&rdquo; -</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Companies Law 1999, as amended from time to time, and the regulations promulgated thereunder.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Law</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Companies Law, the Securities Law and any other legislation in effect, pertaining to companies, applicable to the Company at that time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Company</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The abovementioned Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Ledger</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The members&rsquo; ledger that must be kept pursuant to Section 127 of the Companies Law, the Material Shareholders Ledger that must be kept pursuant to Section 128 of the Companies Law, and in the event that the Company maintains an additional Ledger outside of Israel, any other Ledger, as the case may be.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Office</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s Registered Office, at any particular time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Writing</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed matter, lithograph, photograph, telegram, telex, facsimile, email and any other form of imprint or formation of words in visible form.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities</B>&rdquo; &ndash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Including, Shares, Bonds, Capital Notes, other Certificates and Documents that bestow a right to sell, convert or sell any such.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Companies Ordinance</B>&rdquo; - </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Companies Ordinance [New Version], 1983, as periodically amended.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>The Articles</B>&rdquo; &ndash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s Articles of Association in its current version, or as shall be amended from time to time.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2.</TD><TD STYLE="text-align: justify">Sections 2, 3, 4, 5, 6, 7, 8, 10 of the Interpretation Law, 1981-5741, shall apply, <I>mutatis mutandis</I>,
to the interpretation hereof, in the absence of any other provision relating to the subject matter, and in the absence of anything in
the subject matter, or its context, that does not fit the said application.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.3.</TD><TD STYLE="text-align: justify">Except as provided for herein this article, every word and expression in these Articles, shall bear the
meaning ascribed to them in the Companies Law, unless such would contradict the subject matter or its contents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.4.</TD><TD STYLE="text-align: justify">Subject to this article, in these Articles &ndash; unless the wording demands a different interpretation,
the phrases defined in the Companies Law, shall bear the meanings ascribed to them therein; and words put forth in the singular shall
include the plural, and vice versa, and words in the masculine shall include the feminine, and words which mean individuals shall include
corporations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD STYLE="text-align: justify"><B><U>The Company Name</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&rsquo;s name is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In Hebrew: <B>&#1499;&#1503;-&#1508;&#1497;&#1497;&#1496;
&#1489;&#1497;&#1493;&#1508;&#1512;&#1502;&#1492; &#1489;&#1506;&#1497;&#1497;&#1502;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In English: <B>CAN FITE BIOPHARMA
LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD STYLE="text-align: justify"><B><U>The Company Purposes</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To carry out any lawful business</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD STYLE="text-align: justify"><B><U>The Company Intent</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&rsquo;s intent is to Law
pursuant to commercial considerations to maximise its profits, however, the Company is entitled to donate a reasonable sum for a worthy
goal, even if the donation is otherwise than in the framework of said commercial considerations, and pursuant to the discretion of the
Company Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD STYLE="text-align: justify"><B><U>The Authorised Share Capital</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s Authorised Share Capital is 5,000,000,000 ordinary shares of no par value each (hereinafter:
&ldquo;<B>Ordinary Shares</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.2.</TD><TD STYLE="text-align: justify">All Ordinary Shares shall be of equal rights vis-&agrave;-vis each other for all intents and purposes,
and each Ordinary Share shall bestow on its holder:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 28.35pt">(1)</TD><TD STYLE="text-align: justify">The right to be invited to and participate in all the Company&rsquo;s General Meetings, both annual and
regular, and a right to one vote on account of each Ordinary Share in his possession, at every ballot, in any General Meeting of the Company
in which he participated;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 28.35pt">(2)</TD><TD STYLE="text-align: justify">A right to receive Dividends, if and when such are distributed, and a right to receive Bonus Shares, if
distributed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 28.35pt">(3)</TD><TD STYLE="text-align: justify">A right to participate in the distribution of the Company&rsquo;s assets upon liquidation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.</B></TD><TD STYLE="text-align: justify"><B><U>Shareholder Liability</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The liability of holders of Ordinary
Shares shall be limited so that each Shareholder shall be liable to settle and pay exclusively the par value of his Shares. In the event
that the Company allocates Shares at a discount from the par value thereof, pursuant to Section 304 of the Companies Law(hereinafter:
&ldquo;<B>Reduced Consideration</B>&rdquo;), the liability of each Shareholder shall be limited to settlement of the sum of the Reduced
Consideration on account of each Share thus allocated to him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>7.</B></TD><TD STYLE="text-align: justify"><B><U>Public Company</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon the registration of the Shares
for trading on the Stock Exchange, the Company shall become a public company, and shall maintain a Ledger of Material Shareholders, as
defined in the Companies Law, in addition to the Ledger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD STYLE="text-align: justify"><B><U>Shares</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.1.</TD><TD STYLE="text-align: justify">Notwithstanding the previous privileges granted to shareholders of the Company , the Company is entitled
to issue Shares with preferential rights or Shares with deferred rights or to issue, from the unissued Capital, Redeemable Securities,
subject to Section 309a of the Companies Law, or to issue Shares with other special limited rights or upon limitations as to the distribution
of Dividends, voting rights, or other matters, as the Company may from time to time decide by resolution adopted at a General Meeting
by an ordinary majority of Shareholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.2.</TD><TD STYLE="text-align: justify">If at any time the Share Capital is divided into different classes of Shares, the Company is entitled,
by resolution adopted at a General Meeting by an ordinary majority of Shareholders, unless the terms and conditions of the issuance of
that Class of Shares stipulates otherwise, to convert, expand, add or otherwise change the rights, privileges, advantages, limitations
and provisions, related or unrelated at that time to one of the Classes, or as shall be resolved by resolution adopted at a General Meeting
by an ordinary majority of Shareholders of that Class.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.3.</TD><TD STYLE="text-align: justify">The special rights granted to shareholders or a Shares of different Class, including Shares with preference
rights or other special rights, shall not be deemed altered in any way by the creation or issue of additional Shares of equal ranking
thereto, unless the terms and conditions of the issue of those Shares stipulates otherwise.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The provisions hereof relating to General
Meetings shall apply, <I>mutatis mutandis</I>, to any and every meeting of a said Class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.4.</TD><TD STYLE="text-align: justify">The Company&rsquo;s unissued Shares shall be under the supervision of the Board, which may allocate them,
up to the limit of the Company&rsquo;s Authorised Share Capital, to such persons, in consideration of cash or non-cash consideration,
on such terms and conditions and limitations, whether above their par value, whether at their par value and whether (subject to the provisions
of the Companies Law) for consideration lower than their par value, and at such times and dates that the Board deems fit, and the Board
shall have the authority to present any person with a Call on the Share for whichever such Shares, at their par value or above their par
value or (subject to the provisions of the Companies Law) for consideration lower than their par value, for such times and for such consideration
and terms and conditions as the Board deems fit.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.5.</TD><TD STYLE="text-align: justify">Upon the allocation of Shares, the Board is entitled to differentiate as amongst Shareholders in relation
to the amounts of the Call on the Share and/or times of settlement thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.6.</TD><TD STYLE="text-align: justify">If, according to the terms and conditions of the issuance of any Shares, payment of the consideration
on account of such Shares, in whole or in part, is by instalments, then each instalment shall be paid to the Company at its time of settlement
by that person who is the registered a shareholder at that time or by his administrators.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.7.</TD><TD STYLE="text-align: justify">The Company is entitled to pay, at any time, a commission, to any person for his function as an underwriter
or his consent to serve as an underwriter, conditionally or unconditionally, for any Security, including Bond Stock in the Company or
his consent to underwrite, conditionally or unconditionally, any Security, Bond or Stock of Bonds in the Company. On each event the commission
may be paid or settled in cash or Securities or Bonds or Stock of Bonds in the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>9.</B></TD><TD STYLE="text-align: justify"><B><U>Share Certificate; Share Warrant</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.1.</TD><TD STYLE="text-align: justify">Subject to the provisions of the Companies Law and pursuant thereto, a Share Certificate shall bear the
seal or stamp or the Company, and the signatures of two Directors, or as the Board may determine.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.2.</TD><TD STYLE="text-align: justify">Any Shareholder registered in the Ledger of Members is entitled to receive one Share Certificate on account
of the Shares registered to his name, or, if the Board approves (following payment of the sum determined by the Board from time to time),
several Share Certificates, each for one or more such Shares; every Share Certificate shall mention the number of Shares on account of
which it was issued and the serial numbers thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A Share Certificate registered in the
name of two or more persons, shall be handed over to that person, from amongst the joint owners, whose name appears first in the Ledger
of Members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company is entitled to deliver a Share Certificate on account of Shares that the full consideration
of which was paid to the Company, which shall grant the holders thereof the rights to the Shares stipulated therein, and the right to
transfer the same by handing over the Share, and the provisions hereof relating to transfer of Shares shall not apply to the Shares set
forth in such Share Certificate.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">A Shareholder lawfully possessed of a Share Certificate is entitled to return it to the Company for cancellation
and to turn it into a Share Registered to a Name; and entitled, in consideration of a fee to be determined by the Board, to have his name
registered in the Ledger of Members on account of the Share mentioned in the Share Certificate, and that he be issued with a certificate
of a Share Registered to a Name.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">A holder of a Share Certificate is entitled to deposit the Share Certificate at the Office, and for as
long as it is so deposited, the depositor shall have the right to demand convening a meeting of the Company, subject and pursuant to the
provisions of the Companies Law and these Articles, to be present at such meeting, to vote therein, and to make use of the remaining rights
of a Shareholder at any Meeting convened upon his said demand within 30 days after said deposit, in the same manner as if his name was
registered in the Ledger of Members as the holder of the Shares included in the Share Certificate. Only one person shall be recognised
as the depositor of the Share, and the Company is obliged to return the Share Certificate to the depositor, should he request so in writing
30 days in advance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">In the event that a Share Certificate
was not so deposited, its holder shall not have the rights set forth in this sub-Article (c), and he shall have, subject to the provisions
of these Articles, all the remaining rights bestowed upon a Shareholder in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.4.</TD><TD STYLE="text-align: justify">In the event that a Share Certificate is lost or destroyed, the Board is entitled to issue a new certificate
or warrant instead, provided that the certificate or warrant was not rescinded by the Company, or it was proven, to the satisfaction of
the Board, that the certificate or warrant were lost or destroyed, and received satisfactory sureties against any possible damages, and
all in consideration of a payment, if the Board resolves to impose such.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.</B></TD><TD STYLE="text-align: justify"><B><U>Call on Shares</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.1.</TD><TD STYLE="text-align: justify">The Board may, from time to time, at its discretion, present the Shareholders with a Call on Shares to
pay any outstanding consideration on account of the Shares held by each Shareholder, and which according to the terms and conditions of
the allocation of the Shares they are not to be settled upon fixed times and dates, and each Shareholder is obliged to pay the Company
the sum of the Call presented to him, at the time and place as determined by the Board. A Call on Shares may divide the payment into instalments.
The date of the Call shall be the date of the Board&rsquo;s resolution pertaining to the Call.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.2.</TD><TD STYLE="text-align: justify">A prior notice of fourteen (14) days shall be provided regarding each Call on Shares, which shall mention
the rate of the payment, the place of payment, provided that prior to the time of settlement of such a Call on Shares the Board is entitled,
by written notice to the Shareholders, to cancel the Call or extend its time for settlement, and provided that such resolution was adopted
prior to the time of settlement of the Call.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.3.</TD><TD STYLE="text-align: justify">Joint owners of a Share shall be jointly liable for payment of any instalment and Call on a Share due
on account of such Share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.4.</TD><TD STYLE="text-align: justify">If, according to the terms and conditions of the allocation of any Share, or otherwise, any sum must be
settled on a fixed date or by instalments on fixed dates, then any such sum or instalment shall be settled as if it were a Call on a Share
duly presented by the Board, and for which notice was duly given, and to such sum or instalment all the provisions of these Articles pertaining
to Calls on Shares shall apply.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.5.</TD><TD STYLE="text-align: justify">In the event that the sum of a Call on Shares or instalment was not paid by or prior to its date of settlement,
the person who is at that time the owner of the Share on account of which the Call was presented or for which the instalment was due,
shall be obliged to pay interest on the said sum, at a rate to be determined by the Board from time to time, or at the rate permitted
at that time by law, from the day fixed for such payment until payment in fact, however the Board is entitled to waive the payment of
interest, in whole or in part.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.6.</TD><TD STYLE="text-align: justify">Should the Board see fit, it is entitled to receive from a Shareholder who wishes to advance monies not
yet Called or that the settlement of which is not yet due, and that have not yet been settled on account of his Shares, or any part thereof.
The Board is entitled to pay the Shareholder for the monies advanced in the abovementioned manner, or for any part thereof, interest to
the day the monies should have been settled had they not been so advanced, at a rate to be agreed upon between the Board and the Shareholder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>11.</B></TD><TD STYLE="text-align: justify"><B><U>Share Forfeiture and Mortgage</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.1.</TD><TD STYLE="text-align: justify">In the event that a Shareholder fails to pay the consideration he committed to, in whole or in part, at
the times and dates and on the terms and conditions determined, whether a Call on Share was issued or not, the Board may at any time provide
notice to that Shareholder and demand he pay the unsettled sum, plus interest accrued and any other expense the Company was made to suffer
on account of such non-settlement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.2.</TD><TD STYLE="text-align: justify">The notice shall set a date, at least fourteen (14) days after the date of the notice, and a place or
places, in which the Call or abovementioned instalment must be paid, plus interest and the abovementioned expenses. The notice shall stipulate,
that in the event of non-payment at the fixed time and date and the place set forth in the notice, the Company may forfeit the Shares
on account of which the Call was made or on account of which the instalments have become conclusively due.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3.</TD><TD STYLE="text-align: justify">In the event of failure to fulfil the requirements included in the abovementioned notice, then at any
time thereafter, prior to the payment of the Call on the Share or the instalment, interest and expenses due on account of those Shares,
the Board may resolve to forfeit the Shares on account of which the said notice was provided. Such forfeiture shall include all the dividends
declared in respect of the forfeit Shares which have not been distributed in fact prior to the forfeiture.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.4.</TD><TD STYLE="text-align: justify">Any Share thus forfeit shall be deemed the property of the Company, and the Board may, taking account
of the provisions hereof, sell it, reallocate it, or otherwise transfer it, as it deems fit.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.5.</TD><TD STYLE="text-align: justify">Forfeit Shares that have not yet been sold shall be treasury stock in accordance with the Companies Law,
and shall not grant any rights whatsoever for as long as they are the property of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.6.</TD><TD STYLE="text-align: justify">The Board may at any time prior to the sale, reallocation or other transfer of any Share forfeited as
abovementioned, rescind the forfeiture on such terms and conditions that the Board deems fit.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Any Shareholder whose Share have been forfeit shall cease to be the owner of the said forfeit Shares,
however he shall continue to be indebted to the Company for all Calls on Shares, payment instalments, interest and expenses due on account
of those Shares or for them, at the time of forfeiture, plus interest at the maximum rate permissible at law at that time, unless the
forfeit Shares have been sold and the Company has received the full consideration to which the Shareholder committed, plus the expenses
accompanying the sale.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">In the event that the consideration received on account of the forfeit Shares was greater than the consideration
to which the owner of the Shares thus forfeit was committed to, the Shareholder is entitled to recoup the partial consideration he gave
for them, if any, subject to the terms and conditions of the allocation, and provided that the consideration remaining in the hands of
the Company shall be no less than the full consideration committed to by the owner the Share thus forfeit, plus the expenses accompanying
the sale.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.7.</TD><TD STYLE="text-align: justify">The provisions hereof pertaining to forfeiture of Shares shall apply also to events of non-payment of
a fixed consideration the time of settlement of which, according to the terms and conditions of the allocation of the Share, is due, as
if it were a sum due for settlement by virtue of a Call on Shares presented and for which notice was given.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.8.</TD><TD STYLE="text-align: justify">The Company shall have the right to a first ranking mortgage over any and all Shares registered to the
name of any Shareholder, except for fully paid up Shares, and over the income from the sale of such Shares, for the settlement of the
debts and liabilities of that Shareholder to the Company, whether individually or jointly with any other person, whether the time for
settlement of such debts or fulfilment of such obligation is due or not, whatever the source of the debts may be, and no rights in Equity
shall be created in any Share. The abovementioned lien and mortgage shall apply to all Dividends declared from time to time for such Shares.
Unless resolved otherwise, registration by the Company of a transfer of Shares shall be deemed a waiver on behalf of the Company of such
lien or mortgage (if any) over the Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.9.</TD><TD STYLE="text-align: justify">To realise the abovementioned mortgage, the Board shall be entitled to sell the Mortgaged Shares in a
manner it deems fit, pursuant to it&rsquo;s discretion; however, no Share may be sold unless the period of time set forth in Article 11.2
above has passed, and the Shareholder (or such person entitled to be given notice following his death or insolvency or liquidation or
the receivership of his assets) was provided written notice stipulating that the Company intends to sell the Share, and the Shareholder
or person so entitled to the Share, has not paid the abovementioned debts or has not met the abovementioned obligations after the passing
of fourteen (14) days from the date the said notice was sent.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.10.</TD><TD STYLE="text-align: justify">The proceeds of any such sale, after the expenses of the sale have been settled, shall be used to settle
the debts and fulfil the obligations of the owner of such a Share (including the debts, obligations and liabilities and contracts the
time for settlement or fulfilment of which is not yet due) and the provisions of Article 11.6(b) shall apply, <I>mutatis mutandis</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.11.</TD><TD STYLE="text-align: justify">In the event of a sale following forfeiture or for the realisation of a mortgage under the powers and
authorities granted above, the Board shall be entitled to appoint a person to sign a deed of transfer for the sold Shares and to register
the purchaser in the Ledger of Members as the owner of the sold Shares, and the purchaser shall not be obliged to ensure these actions
were duly and properly taken, and it shall be none of his business what the proceeds of sale were used for, and following the registration
of his name in the Ledger of Members on account of those Shares, the validity of the sale shall not be called into question, and the only
remedy available to any person injured as a result of the sale, shall be suing the Company, and only the Company, for damages.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>12.</B></TD><TD STYLE="text-align: justify"><B><U>Share Transfer and Delivery</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1.</TD><TD STYLE="text-align: justify">A Share transfer shall not be registered unless the Company was provided with the appropriate deed of
transfer. A Company Share deed of transfer shall be signed by the transferor and transferee, and the transferor shall be deemed continuing
to be the Shareholder until such a time as the name of the transferee is recorded in the Ledger of Members on account of the transferred
Share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A Share deed of transfer shall be drafted
and filled out in the following form, or such similar form, or in the ordinary or customary way approved by the Board:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&ldquo;I, ____________, of __________
(&ldquo;The Transferor&rdquo;), in consideration of _______________ NIS paid to me by ____________, of __________ (&ldquo;The Transferee&rdquo;),
do hereby transfer to the Transferee _________ shares ___________ of _____________ par value each, marked numbers _________ to ______________
in _______________ Ltd., to be in the hands of the Transferee, his executors, guardians, and attorneys, under all the terms and conditions
on which I held them prior to the execution hereof, and I, the Transferee, do hereby agree to receive the said shares on the abovementioned
terms and conditions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>And in Witness hereof we have signed
our names this ____ Day of ________ in the year __________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>_________________</B></FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>_________________</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transferor</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transferee</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>_________________</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>_________________</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>Witness to Transferor&rsquo;s Signature Witness to Transferee&rsquo;s
Signature&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.</TD><TD STYLE="text-align: justify">The Company is entitled to seal the Ledger of Members for such a time that the Board sees fit, provided
that it is does not exceed thirty (30) days a year. The Company shall provide notice to the Shareholders of the sealing of the Ledger
of Members pursuant to the provision hereof, for the purposes of providing notices to the Shareholders. The Company is entitled to fix
a determining date for the purposes of the right to receive invitations to General Meetings, to participate and vote therein, and for
the purposes of the right to receive a Dividend, provided that such date won&rsquo;t be more than seven (7) days prior to the date fixed for
the convention of the General Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Any and every deed of transfer shall be handed in to the Office for recording. Deeds of transfer recorded
shall remain in the possession of the Company, but any deed of transfer which the Board refuses to register, shall be, upon demand, returned
to the person who delivered it, together with the Share Certificate (if handed in).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">The Company is entitled to demand payment of a fee for the registration of the transfer, which fee shall
be fixed by the Company Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.4.</TD><TD STYLE="text-align: justify">The administrators and executors of a deceased Shareholder, or, in the absence of administrators or executors,
the persons entitled as the heirs of the deceased Shareholder, shall be the only individuals the Company shall recognise as owners of
rights in the Share that was registered to the name of the deceased.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In the event that a Share is registered
in the name of two or more owners, the Company shall exclusively recognise the surviving partner or partners as those persons who own
the rights to the Share or any beneficial interest therein. In the event that a Share is registered in the name of several owners jointly
as mentioned, each one of them shall be entitled to transfer his right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.5.</TD><TD STYLE="text-align: justify">The Company may recognise the receiver or liquidator of a Shareholder which is a corporation in liquidation
or in the process of winding up or the trustee in bankruptcy or any receiver of a bankrupt Shareholder as owners of the rights in and
to the Shares registered to the name of such Shareholder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.6.</TD><TD STYLE="text-align: justify">Any person who gains an interest in Shares owing to the death of a Shareholder, shall be entitled, on
production of proof of probation of a will or the appointment of an administrator or the granting of an inheritance order, testifying
that he has the right to the Shares of the deceased Shareholder, to be registered as the Shareholder on account of those Shares, or may,
subject to the provisions hereof, transfer those Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.7.</TD><TD STYLE="text-align: justify">The receiver or liquidator of a Shareholder that is a corporation in liquidation or in the process of
winding up, or the trustee in bankruptcy or any receiver of a bankrupt Shareholder, may, having produced such evidence the Board demands
of him, testifying that he has the right to the Shares of the Shareholder in liquidation or winding up or bankruptcy, with the consent
of the Board (which consent the Board may withhold without giving any reasons for its refusal) be registered as the Shareholder on account
of those Shares, or he may, subject to the provisions hereof, transfer those Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.8.</TD><TD STYLE="text-align: justify">All the abovementioned pertaining to the transfer of Shares shall apply to the transfer of other Company
Securities, <I>mutatis mutandis</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>13.</B></TD><TD STYLE="text-align: justify"><B><U>Redeemable Shares</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.1.</TD><TD STYLE="text-align: justify">The right to redeem shall be limited to the eventuality of a winding up of the Company following the settlement
of all the Company&rsquo;s obligations to its creditors at the time of winding up.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.2.</TD><TD STYLE="text-align: justify">Redeemable Shares shall grant the holders thereof the following rights:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Voting rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">Rights to participate in Dividends.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>14.</B></TD><TD STYLE="text-align: justify"><B><U>Recapitalisation</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">14.1.</TD><TD STYLE="text-align: justify">The Company is entitled, from time to time, by resolution of the General Meeting, passed by an ordinary
majority of Shareholder votes, to increase the Company&rsquo;s Authorised Share Capital in Classes of Shares as it shall determine.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">14.2.</TD><TD STYLE="text-align: justify">Unless stated otherwise in the resolution approving the said Capital increase, the provisions hereof shall
apply to the New Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">14.3.</TD><TD STYLE="text-align: justify">By resolution of the General Meeting passed by an ordinary majority of Shareholder votes, the Company
is entitled:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">To consolidate and distribute its Share Capital into Shares of higher par value than those extant, and
in the event of no par value &ndash; to capital comprising a smaller number of Shares, provided that such will not alter the proportional
respective holdings of the Shareholders in the issued capital.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">For the purposes of carrying out any
such resolution, the Board is entitled to settle in a manner it deems fit any difficulty arising, and <I>inter alia</I>, to issue Certificates
for Share fractions or Certificates in the name of a number of Shareholders that shall include the fractions of Shares to which they are
entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Notwithstanding the foregoing authority
of the Board, in the event that as a result of consolidation there shall be Shareholders, the consolidation of whose Shares leaves fractions,
the Board is entitled, with the consent of the General Meeting passed by ordinary majority of Shareholder votes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">To sell the total number of fractions and for such purposes to appoint a trustee in whose name the Share
Certificates that include fractions shall be made, who shall sell them and the proceeds of sale, after deduction of commissions and expenses,
shall be distributed amongst those entitled; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">To allocate to each Shareholder who is left by the consolidation with fractions, Shares of the Class of
Shares prior to the consolidation, fully paid up, at such a number that their consolidation with the fraction shall be sufficient for
one complete Consolidated Share, and such allocation shall be deemed valid close in time prior to the consolidation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Determine that Shareholders shall not be entitled to receive a Consolidated Share on account of a Consolidated
Share fraction, arising from the consolidation of half or less of the number of Shares the consolidation of which created one Consolidated
Share, and shall be entitled to receive one Consolidated Share on account of a fraction of a Consolidated Share arising from the consolidation
of more than half the number of Shares the consolidation of which created one Consolidated Share;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">In the event that actions pursuant
to the foregoing paragraphs (2) or (3) shall necessitate issuing additional Shares, then the settlement of such shall be done in the same
way as settlement on account of Bonus Shares. Such consolidation and division shall not be deemed an alteration of the rights of the Shares
which are the subject matter of the consolidation and division.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">To distribute, by way of new distribution of existing Shares, all or part thereof, its Share Capital,
in whole or in part, to Shares of lower par value than the existing Shares, and in the event that its Shares had no par value, to Share
Capital comprising a larger number of Shares, provided that such will not alter the proportional respective holdings of the Shareholders
in the issued Capital.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify">To cancel any Authorised Share Capital which on the date of the resolution had yet to be allocated, provided
that the Company has no obligations, including no conditional obligations, to allocate the Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>15.</B></TD><TD STYLE="text-align: justify"><B><U>General Meetings</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.1.</TD><TD STYLE="text-align: justify">In addition to the resolutions the authority to adopt which is given to the General Meeting, and set forth
herein these Articles and/or in the Companies Law, the decisions of the Company on the following matters shall be taken at General Meetings
by ordinary majority of votes of participating Shareholders:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Amendment of these Articles pursuant to Article 39 hereinafter.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">Exercising the powers and authorities of the Board in the event that the Assembly has determined that
the Board is prevented from exercising its power and authorities, and that the exercise thereof is essential to the proper management
of the Company pursuant to Section 52(a) of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">Appointment of the Company&rsquo;s auditor, fixing his terms of employment and terminating his appointment
pursuant to the provisions of Sections 154 through 167 of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify">Approval of actions and transactions which require the General Meeting&rsquo;s approval pursuant to the
provisions of Sections 255, 270(1)-(3), 271 through 273 of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify">Increase the Share Capital and cancellation thereof, pursuant to the provisions of Section 286 &amp; 287
of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT></TD><TD STYLE="text-align: justify">A merger pursuant to Section 320(a) of the Companies Law, and subject to Section 320(A1) of the Companies
Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.2.</TD><TD STYLE="text-align: justify">The General Meeting is entitled to assume powers and authorities granted to another organ.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.3.</TD><TD STYLE="text-align: justify">The Company shall hold an annual General Meeting every year, and no later than after fifteen (15) months
following the preceding annual General Meeting (the &ldquo;<B>Annual General Meeting</B>&rdquo;). A General Meeting that is not an Annual
General Meeting shall be an Extraordinary Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.4.</TD><TD STYLE="text-align: justify">The agenda at the Annual General Meeting shall include the following subjects:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Discussion of the Companies audited financial statements, with the enclosed Board report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">Appointment of Directors pursuant to Article 19, and determining their remuneration as Directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">Appointment of a financial auditor;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify">Matters that one or more Shareholders, representing at least five (5) percent of the issued Capital and
at least one (1) percent of the voting rights in the Company, or one or more Shareholders, who have at least five (5) percent of the voting
rights in the Company, have asked the Board to include, provided that they are matters to be properly discussed at an Annual General Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.5.</TD><TD STYLE="text-align: justify">Any time the Board deems fit, it is entitled to convene an Extraordinary Meeting by resolving to do so,
and Extraordinary Meetings shall be convened pursuant to demands as set forth in the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.6.</TD><TD STYLE="text-align: justify">Notice of a General Meeting, on the agenda of which there are no matters for which voting may be by written
ballot under Section 87 of the Companies Law, shall be published up to at least fourteen (14) days prior to the Convention, and notice
on the agenda of which there are such matters, shall be published at least twenty one (21) days before the Convention. Notice shall be
published in no less than two daily newspapers, of wide circulation in Israel, published in Hebrew. In any event, no notice shall be sent
to each one of the Shareholders registered on the Company&rsquo;s Ledger of Members.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The notice shall specify the type of
meeting, the time and place of the meeting, a list of the items on the agenda, an extract of proposed resolutions, the required majority
to adopt the resolutions and the date for the determination of entitlement of Shareholders to vote in the General Meeting, as set forth
in Section 182 of the Companies Law. In the event that an adjourned Meeting is set for a date later than that stipulated for in Section
78(b) of the Companies Law, namely, more than seven (7) days, that date shall be specified in the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left">15A.</TD><TD STYLE="text-align: justify"><B><U>Shareholder Proposal Request</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">15A.1</TD><TD STYLE="text-align: justify">Any Shareholder or Shareholders of the Company holding at
least one percent (1%) or a higher percent, as may be required by the Companies Law from time to time, of the voting rights of the Company
(the &ldquo;<B>Proposing Shareholder(s)</B>&rdquo;) may request, subject to the Companies Law, that the Board of Directors include a
matter on the agenda of a General Meeting to be held in the future, provided that the Board determines that the matter is appropriate
to be considered in a General Meeting (a &ldquo;<B>Proposal Request</B>&rdquo;). In order for the Board of Directors to consider a Proposal
Request and whether to include the matter stated therein in the agenda of a General Meeting, notice of the Proposal Request must be timely
delivered in accordance with applicable laws, and the Proposal Request must comply with the requirement of these Articles (including
this Article 15A) and any applicable law and stock exchange rules and regulations. The Proposal Request must be in writing, signed by
all of the Proposing Shareholder(s) making such request, delivered, either in person or by certified mail, postage prepaid, and received
by the Secretary (or, in the absence thereof by the Chief Executive Officer of the Company). To be considered timely, a Proposal Request
must be received within the time periods prescribed by applicable law. The announcement of an adjournment or postponement of a General
Meeting shall not commence a new time period (or extend any time period) for the delivery of a Proposal Request as described above. In
addition to any information required to be included in accordance with applicable law, the Proposal Request must include the following:
(i) the name, address, telephone number, fax number and email address of the Proposing Shareholder (or each Proposing Shareholder, as
the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity; (ii) the number of Shares held
by the Proposing Shareholder(s), directly or indirectly (and, if any of such Shares are held indirectly, an explanation of how they are
held and by whom), which shall be in such number no less than as is required to qualify as a Proposing Shareholder, accompanied by evidence
satisfactory to the Company of the record holding of such Shares by the Proposing Shareholder(s) as of the date of the Proposal Request,
and a representation that the Proposing Shareholder(s) intends to appear in person or by proxy at the meeting; (iii) the matter requested
to be included on the agenda of a General Meeting, all information related to such matter, the reason that such matter is proposed to
be brought before the General Meeting, the complete text of the resolution that the Proposing Shareholder proposes to be voted upon at
the General Meeting and, if the Proposing Shareholder wishes to have a position statement in support of the Proposal Request, a copy
of such position statement that complies with the requirement of any applicable law (if any), (iv) a description of all arrangements
or understandings between the Proposing Shareholders and any other Person(s) (naming such Person or Persons) in connection with the matter
that is requested to be included on the agenda and a declaration signed by all Proposing Shareholder(s) of whether any of them has a
personal interest in the matter and, if so, a description in reasonable detail of such personal interest; (v) a description of all Derivative
Transactions (as defined below) by each Proposing Shareholder(s) during the previous twelve (12) month period, including the date of
the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions;
and (vi) a declaration that all of the information that is required under the Companies Law and any other applicable law and stock exchange
rules and regulations to be provided to the Company in connection with such matter, if any, has been provided to the Company. The Board
of Directors, may, in its discretion, to the extent it deems necessary, request that the Proposing Shareholder(s) provide additional
information necessary so as to include a matter in the agenda of a General Meeting, as the Board of Directors may reasonably require.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A &ldquo;<B>Derivative Transaction</B>&rdquo;
means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proposing Shareholder
or any of its affiliates or associates, whether of record or beneficial: (1) the value of which is derived in whole or in part from the
value of any class or series of shares or other securities of the Company, (2) which otherwise provides any direct or indirect opportunity
to gain or share in any gain derived from a change in the value of securities of the Company, (3) the effect or intent of which is to
mitigate loss, manage risk or benefit of security value or price changes, or (4) which provides the right to vote or increase or decrease
the voting power of, such Proposing Shareholder, or any of its affiliates or associates, with respect to any shares or other securities
of the Company, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position,
note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement,
performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion
in any such class or series), and any proportionate interest of such Proposing Shareholder in the securities of the Company held by any
general or limited partnership, or any limited liability company, of which such Proposing Shareholder is, directly or indirectly, a general
partner or managing member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">15A.2</TD><TD STYLE="text-align: justify">The information required pursuant to this Article shall be
updated as of (i) the record date of the General Meeting, (ii) five business days before the General Meeting, and (iii) as of the General
Meeting, and any adjournment or postponement thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">15A.3</TD><TD STYLE="text-align: justify">The provisions of Articles 15A.1 and 15A.2 shall apply,&nbsp;mutatis
mutandis, on any matter to be included on the agenda of an Extraordinary Meeting which is convened pursuant to a request of a Shareholder
duly delivered to the Company in accordance with the Companies Law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify"><B><U>General Meeting Resolutions</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.1.</TD><TD STYLE="text-align: justify">No discussion in General Meeting may be commenced unless a legal quorum is present within half an hour
of the time scheduled for the meeting. Unless otherwise provided for by Companies Law or by these regulations, legal quorum will be present
when at least two (2) shareholders holding together twenty five percent (25%) of company&rsquo;s votes are present in person or by their attorneys.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.2.</TD><TD STYLE="text-align: justify">If half an hour after the time scheduled for the meeting legal quorum is not present, meeting shall be
postponed to same day on following week, same time and place, or to a later date, if specified on notice as to meeting, and if the matters
for which first meeting was called will be covered on postponed meeting. If no legal quorum is present on second meeting half an hour
after the time scheduled for the meeting, then meeting shall take place with any number of attendees.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If a General Meeting was convened at
shareholders&rsquo; request as covered in Companies Law, postponed meeting will only be held if the minimum number of shareholders required
for holding a meeting was present, as covered in Section 63 of Companies Law, i.e., one or more shareholders holding at least five (5)
percent of issued capital and one (1) percent at least of the voting rights in the company, or one or more shareholders holding at least
five (5) percent of the company&rsquo;s voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.3.</TD><TD STYLE="text-align: justify">The chairman of the Board will chair every General Meeting. If there is no chairman or if he is not present
within fifteen (15) minutes of the time scheduled for the meeting, or if he does not wish to chair the assembly, the shareholders present
in the meeting will select one of them as chairman.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.4.</TD><TD STYLE="text-align: justify">The General Meeting&rsquo;s chairman shall be permitted, with the consent of the assembly where a legal quorum
is present, to postpone the meeting to another time and location, and must postpone it as above if the assembly instructs him to do so.
At the postponed meeting, only matters on the agenda which discussion was not completed or commenced at the meeting where the postponement
was resolved will be discussed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.5.</TD><TD STYLE="text-align: justify">Subject to the provisions of Companies Law and these Articles that require an extended majority of shareholders,
any proposed resolution brought before the assembly shall be decided upon by simple majority of the votes of shareholders present and
voting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.6.</TD><TD STYLE="text-align: justify">The General Meeting&rsquo;s chairman shall not have an additional or decisive vote.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.7.</TD><TD STYLE="text-align: justify">The Chairman&rsquo;s announcement that a resolution was made unanimously or by certain majority or was rejected,
and the meeting&rsquo;s minutes signed by the chairman, will serve as prima facie evidence of contents of minutes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify"><B><U>Shareholders&rsquo; Vote</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">17.1.</TD><TD STYLE="text-align: justify">Subject to any special provisions, privileges and limitations as to the voting of shareholders involved
at that time with any shares, when voting by counting votes or by secret ballot, every shareholder whether present himself or by attorney
or proxy, will have one vote for each share he owns granting him a voting right.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">17.2.</TD><TD STYLE="text-align: justify">A corporation constituting a company shareholder is permitted, by the decision of its Directors or another
managing body, to authorize any person it may deem fit to serve as its representative at any General Meeting. A person authorized as covered
above will be permitted to use &ndash; on behalf of the corporation he represents &ndash; the same voting rights the corporation itself
may have used were it an individual shareholder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">17.3.</TD><TD STYLE="text-align: justify">Subject to the provisions of Companies Law, General Meeting resolutions on issues listed below will also
be made by proxy:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify; padding-right: 56.25pt">Appointing and dismissing Directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Approving actions or transactions requiring General Meeting&rsquo;s approval as per
Sections 255 and 268 to 275 of Companies Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify; padding-right: 56.25pt">Approving merger as per Section 320 of Companies Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Issues covered by the Ministry of Justice in the regulations that were set forth
or will be set forth under Section 89 of Companies Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Subject to the provisions of Companies
Law, proxy will be deposited in Office or any other location designated for convening the General Meeting at least forty eight (48) hours
prior to the time scheduled for commencing the meeting where person specified in proxy is to vote. However, the General Meeting chairman
is permitted to waive this requirement and accept proxy when meeting commences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify"><B><U>Voting Rights</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.1.</TD><TD STYLE="text-align: justify">Minor shareholders and shareholders who were declared by court to be incompetent, may vote only through
their guardians, and each guardian as above may vote through an attorney.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.2.</TD><TD STYLE="text-align: justify">In the event of co-owners of a share, the opinion of one co-owner will be accepted, whether given personally
or by attorney &ndash; and the opinion of remaining co-owners will not be accepted. For this purpose, the co-owner whose opinion shall
be heard shall be determined by the order their names are listed in the book of shareholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.3.</TD><TD STYLE="text-align: justify">Shareholders can vote personally or by attorney, or in the case of a corporation, by representative as
covered in Article 18.4 below or by attorney with proper power of attorney as covered below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.4.</TD><TD STYLE="text-align: justify">Any document appointing an attorney for voting (hereinafter <B>&ldquo;Letter of Appointment&rdquo;</B>)
will be signed by the appointer or his attorney authorized in writing to do so, or if the appointer is a corporation, the appointment
will be done in writing, signed as legally required and stamped with the corporation seal or signed by its authorized attorney.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.5.</TD><TD STYLE="text-align: justify">Letter of appointment and power of attorney (if any) based on which letter of appointment was signed,
or its copy approved to board&rsquo;s satisfaction, will be deposited in office or any other location designated for convening the assembly
at least forty eight (48) hours prior to the time scheduled for commencing the meeting, in which the person specified in letter of appointment
is supposed to vote. However, the General Meeting chairman is permitted to waive this requirement for all attendees of certain meeting
and accept power of attorney when meeting commences.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.6.</TD><TD STYLE="text-align: justify">A Shareholder holding more than one share will be entitled to appointing more than one attorney, subject
to following provisions:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Letter of appointment specifies type and number of shares for which it is granted;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Should number of shares of any kind specified in letters of appointment granted by one shareholder exceed
number of shares of that kind held by him, all Letters of Appointment granted by that shareholder for excessive shares shall be canceled,
without detracting from the validity of the vote for shares held by him;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">in case that only an attorney is appointed by a shareholder, but the Letter of Appointment does not specify
the number and type of shares for which it was granted, than such Letter of Appointment shall be deemed as granted for all shares held
by the shareholder on date the letter of appointment was deposited with the company or handed to the General Meeting chairman, as the
case may be. If the Letter of Appointment was granted for a number of shares smaller than number of shares held by shareholder, shareholder
shall be deemed as refraining from voting for remaining shares he holds, and letter of appointment shall be valid only for the number
of shares specified on it.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.7.</TD><TD STYLE="text-align: justify">Any Letter of Appointment for an attorney, whether for a specifically named meeting or otherwise, will
be made as follows, as far as circumstances permit:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;I, ________________, of __________________
shareholder of _____________ Ltd. (hereinafter <B>&ldquo;The Company&rdquo;</B>) hereby appoint _________, whose ID is ____________, of
______________, or in his/her absence, ___________, whose ID is ____________, of ______________, or in his/her absence, ___________, whose
ID is ____________, of ______________, to vote for me and on my behalf for ___ shares of type ____________ held by me, at the company&rsquo;s
annual / extraordinary meeting / at a shareholder meeting of type _____________ to be held on day ____________ of month __________, year
_____________, and at any meeting postponed from that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In witness whereof I hereby sign on
this day of ____ month _________ year ________. Signature&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.8.</TD><TD STYLE="text-align: justify">Vote based on the provisions of a document appointing an attorney will be valid despite the appointer&rsquo;s
decease or cancellation of the power of attorney or transferring the share for which voting was done as covered above, unless notice in
writing of such decease, cancellation or transfer was received at the office or by the meeting&rsquo;s chairman prior to voting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify"><B><U>Board of Directors</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.1.</TD><TD STYLE="text-align: justify">The number of Board members for the Company shall be no more than thirteen (13) (hereinafter <B>&ldquo;Normal
Directors&rdquo;</B>), plus the number of external Directors which appointment is legally required (hereinafter <B>&ldquo;External Directors&rdquo;</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.2.</TD><TD STYLE="text-align: justify"><B><U>Election and Removal of Directors</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.1.</TD><TD STYLE="text-align: justify">The Directors, excluding the External Directors if any (who shall be elected and serve in office in strict
accordance with the provisions of the Companies Law, if so required by the Companies Law), shall be classified, with respect to the term
for which they each severally hold office, into three classes, as nearly equal in number as practicable, hereby designated as Class I,
Class II and Class III.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.1.1.</TD><TD STYLE="text-align: justify">The term of office of the initial Class I directors shall expire at the first Annual General Meeting to
be held in 2020 and when their successors are elected and qualified,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.1.2.</TD><TD STYLE="text-align: justify">The term of office of the initial Class II directors shall expire at the first Annual General Meeting
following the Annual General Meeting referred to in clause (i) above and when their successors are elected and qualified, and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.1.3.</TD><TD STYLE="text-align: justify">The term of office of the initial Class III directors shall expire at the first Annual General Meeting
following the Annual General Meeting referred to in clause (ii) above and when their successors are elected and qualified.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.2.</TD><TD STYLE="text-align: justify">Directors (other than External Directors), may be elected only in Annual General Meetings. At each Annual
General Meeting, commencing with the Annual General Meeting to be held in 2020, each of the successors elected to replace the Directors
of a Class whose term shall have expired at such Annual General Meeting shall be elected to hold office until the third Annual General
Meeting next succeeding his or her election and until his or her respective successor shall have been elected and qualified. Notwithstanding
anything to the contrary, each Director shall serve until his or her successor is elected and qualified or until such earlier time as
such Director&rsquo;s office is vacated.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.3.</TD><TD STYLE="text-align: justify">If the number of Directors (excluding External Directors) that constitutes the Board of Directors is hereafter
changed, the then-serving Directors shall be re-designated to other Classes and/or any newly created directorships or decrease in directorships
shall be apportioned by the Board of Directors among the classes so as to make all classes as nearly equal in number as is practicable,
provided that no decrease in the number of Directors constituting the Board of Directors shall shorten the term of any incumbent Director.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.4.</TD><TD STYLE="text-align: justify">Prior to every Annual General Meeting of the Company at which Directors are to be elected, and subject
to Articles 19.2.1 and 19.2.8 of this Article, the Board of Directors (or a Committee thereof) shall select, by a resolution adopted by
a majority of the Board of Directors (or such Committee), a number of Persons to be proposed to the Shareholders for election as Directors
at such Annual General Meeting (the &ldquo;<B>Nominees</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.5.</TD><TD STYLE="text-align: justify">Any Proposing Shareholder requesting to include on the agenda of an Annual General Meeting a nomination
of a Person to be proposed to the Shareholders for election as Director (such person, an &ldquo;<B>Alternate Nominee</B>&rdquo;), may
so request provided that it complies with this Article 19.2.5 and Article 15A&nbsp;and applicable law. Unless otherwise determined by
the Board, a Proposal Request relating to Alternate Nominee is deemed to be a matter that is appropriate to be considered only in an Annual
General Meeting. In addition to any information required to be included in accordance with applicable law, such a Proposal Request shall
include information required pursuant to Article 15A, and shall also set forth: (i) the name, address, telephone number, fax number and
email address of the Alternate Nominee and all citizenships and residencies of the Alternate Nominee; (ii) a description of all arrangements,
relations or understandings between the Proposing Shareholder(s) or any of its affiliates and each Alternate Nominee; (iii) a declaration
signed by the Alternate Nominee that he consents to be named in the Company&rsquo;s notices and proxy materials relating to the Annual
General Meeting, if provided or published, and, if elected, to serve on the Board of Directors and to be named in the Company&rsquo;s
disclosures and filings, (iv) a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable
law and stock exchange rules and regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information
that is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment
has been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable disclosure
requirements under Form 20-F or any other applicable form prescribed by the U.S. Securities and Exchange Commission or applicable Israeli
rules and regulations under the Company Law or Israeli Securities Laws); (v) a declaration made by the Alternate Nominee of whether he
or she meets the criteria for an independent director and/or External Director of the Company under the Companies Law and/or under any
applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi) any other information required
at the time of submission of the Proposal Request by applicable law, regulations or stock exchange rules. In addition, the Proposing Shareholder
shall promptly provide any other information reasonably requested by the Company. The Board of Directors may refuse to acknowledge the
nomination of any person not made in compliance with the foregoing. The Company shall be entitled to publish any information provided
by a Proposing Shareholder pursuant to this Article 19.2.5 and Article 15A, and the Proposing Shareholder shall be responsible for the
accuracy and completeness thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.6.</TD><TD STYLE="text-align: justify">The Nominees or Alternate Nominees shall be elected by a resolution adopted at the Annual General Meeting
at which they are subject to election.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.7.</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary herein, this Article 19.2 and Article 15A may only be amended,
replaced or suspended by a resolution adopted at a General Meeting by a majority of [65%] of the voting power represented at the General
Meeting in person or by proxy and voting thereon, disregarding abstentions from the count of the voting power present and voting, provided
that such majority constitutes more than [20%] of the Company&rsquo;s then issued and outstanding share capital.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.8.</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in these Articles, the election, qualification, removal or dismissal
of External Directors shall be only in accordance with the applicable provisions set forth in the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.9.</TD><TD STYLE="text-align: justify">Directors whose terms of office have expired or terminated may be re-elected. The aforesaid will not apply
to external directors, whose reappointment shall be in accordance with the provisions of the Companies Law and the regulations promulgated
thereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.10.</TD><TD STYLE="text-align: justify">Election of Board members as detailed above will be done by shareholders present at the Annual General
Meeting, personally or by attorney, or, subject to the provisions of Companies Law, by proxy, by simple majority of shareholder votes.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">19.2.11.</TD><TD STYLE="text-align: justify">A Director&rsquo;s tenure will commence on the date of his appointment by the Annual General Meeting in which
he was appointed as above. A Director appointed as above by the Annual General Meeting shall serve until the end of the next applicable
Annual General Meeting in which such Director&rsquo;s term expires in accordance with the relevant classification in Article 19.2.1 above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.2.12.</FONT></TD><TD STYLE="text-align: justify">Notwithstanding the aforesaid, Directors may not be dismissed from office by the Shareholders or by a
General Meeting prior to expiration of their term of office pursuant to Articles 19.2.1 and 19.2.2 above, and the provisions of Section
230(a) of the Companies Law in this regard shall not apply<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">At any time, a Director may appoint a person to serve as his substitute Director, subject to the provisions
of Companies Law (hereinafter <B>&ldquo;Alternative Director&rdquo;</B>). Any person disqualified to be appointed as Director, or serving
as Director or alternative Director shall not be appointed as alternative Director. So long as the alternative Director&rsquo;s appointment
is effective, he shall be entitled to be invited to all board meetings (without revoking the Director&rsquo;s right to be invited) and attend
and vote at any board meeting from which appointing Director is absent.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Alternative Director shall have, subject to the provisions of his Letter of Appointment, all rights held
by the Director he substitutes, and he shall be treated as Director.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Director appointing Alternative Director shall be permitted to cancel appointment at any time. Alternative
Director&rsquo;s tenure shall be terminated if the Director appointing him notifies the company in writing of his resignation or if his tenure
as Director was otherwise terminated.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Any appointment of an Alternative Director and cancellation of his appointment shall be done by notifying
the company in writing.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.4.</TD><TD STYLE="text-align: justify">A Director ceasing to serve in such position can be reappointed, but in the event of termination of his
tenure due to being convicted of an offense as specified in Article 19.6 (c) below, he can be reappointed only if five (5) years have
passed since the date of his conviction as covered in Section 226 of Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.5.</TD><TD STYLE="text-align: justify">A Director&rsquo;s position shall automatically become vacant under any one of the following conditions:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If he resigns from his position as covered in Section 229 of Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If he is convicted of an offense as covered in Section 232 of Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">If the court decides to direct his tenure to be terminated as covered in Section 233 of Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">If he declares bankruptcy, and if a corporation, if it has decided on voluntary liquidation or liquidation
order is issued on it.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">In event of his decease.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">If he becomes incompetent.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.6.</TD><TD STYLE="text-align: justify">Notwithstanding anything herein to the contrary, if a Director&rsquo;s office becomes vacant, then the remaining
Directors shall be permitted to take any action, so long as their number is minimally three. Additionally, the remaining Directors shall
be permitted to appoint a Director in place of the Director whose tenure was terminated, who will serve in his office until the next Annual
General Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.7.</TD><TD STYLE="text-align: justify">Directors shall not be paid wages with company funds, unless the company resolves as covered in Sections
270 (3) and 273 of Companies Law. A Director shall be entitled to have his reasonable transportation expenses reimbursed, as well as other
expenses connected to his attending board meetings and fulfilling his duties as board member. Reward and expenses for outside Directors
shall be paid according to Company Regulations (Rules for Reward and Expenses for Outside Director), 2000, or any other regulations replacing
these in the future.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify"><B><U>Board&rsquo;s Authority</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.1.</TD><TD STYLE="text-align: justify">In addition to the powers generated to the Board according to the Companies Law and these Articles, and
without detracting from such, the Board shall outline the Company&rsquo;s policy and shall supervise the execution of the CEO&rsquo;s duties and actions,
including:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Determining the Company&rsquo;s plans, principles for their funding, and priorities among them;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Reviewing the Company&rsquo;s financial condition and determining the limit for credit it may use;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Determining organizational structure and wage policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Being permitted to decide on issuing a series of bonds;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Responsibility for preparing financial statements and for their approval as per Section 171 of the Companies
Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Appointing and dismissing CEO as covered in Section 250 of the Companies Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Deciding on actions and transactions requiring his approval as per Sections 253 and 268 to 275 of the
Companies Law and the provisions of these Articles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">Being permitted to allocate shares and convertible securities up to the Company&rsquo;s registered share capital
as per Section 288 of the Companies Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Being permitted to distribute as covered in Sections 307 and 308 of the Companies Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">Voicing his opinion to the General Meeting as to a special acquisition offer as per Section 329 of the
Companies Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">Being permitted to determine, from time to time, who would be authorized to sign bills of exchange, promissory
notes, invoices, acceptance documents, endorsements, checks, contracts and any kind of other documents on behalf of the company, but such
authorized signatories would be obligated to sign with the company seal, or next to its printed or written name.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.2.</TD><TD STYLE="text-align: justify">The board will act, on any of the matters listed in Article 20.1 above, according to the Companies Law
and these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.3.</TD><TD STYLE="text-align: justify">The Board&rsquo;s powers according to Article 20.1 (a) to (j) above cannot be delegated to the CEO, except as
covered in Section 288 (b) (2) of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.4.</TD><TD STYLE="text-align: justify">Recommendations, reports and approvals to be given by the board as per regulation 20.1 above shall be
accompanied by the Board&rsquo;s explanations to the recommendation, report or approval, as the case may be.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.5.</TD><TD STYLE="text-align: justify">Chairman of the Board shall direct Board meetings. On first Board meeting after each Annual General Meeting,
the Board will elect one of its members to serve as chairman of the board. Appointment of chairman of the board shall remain in effect
until the first Annual General Meeting after his appointment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify"><B><U>Board Meetings</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.1.</TD><TD STYLE="text-align: justify">The Board shall convene for meetings as per Company&rsquo;s needs, and at least once every three (3) months.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.2.</TD><TD STYLE="text-align: justify">The Chairman of the Board shall be permitted to convene the Board at any time. Additionally, any two Directors
(and if number of board members does not exceed five (5) &ndash; any one Director) shall be permitted to demand a Board meeting on a specified
subject.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.3.</TD><TD STYLE="text-align: justify">Any notice of a board meeting can be communicated verbally, by telephone, in writing (including fax or
e-mail) or by telegram, so long as notice is given at least 12 hours prior to the time established for the meeting, unless all board members
or their replacements (if any) have agreed on shorter notice or on convening without notice. A Director travelling or staying outside
of Israel at any time, shall not be entitled to be provided with notice of a board meeting for the length of his trip, so long as if he
has appointed an alternative Director as per these regulations, such notice would be sent to that alternative Director.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.4.</TD><TD STYLE="text-align: justify">Notice of a Board meeting shall specify its date and place and contain reasonable details of all issues
on the agenda.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The agenda shall include all issues
established as per Article 21.2 above, and any issue a Director or the CEO requested the chairman to add to the agenda within a reasonable
period of the board meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.5.</TD><TD STYLE="text-align: justify">Until board resolves otherwise, most Board members for that time, who are not legally prevented from participating
and voting at the Board meeting, shall constitute a legal quorum for Board meetings and its decisions. Legal quorum shall be examined
when meeting commences and each time Board makes a resolution.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Notwithstanding the above, the legal
quorum for the Board&rsquo;s resolution to terminate internal auditor&rsquo;s tenure shall not in any event be less than most Board members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.6.</TD><TD STYLE="text-align: justify">Board resolutions will be based on simple majority of attending, voting Directors. Each Director shall
have one vote.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.7.</TD><TD STYLE="text-align: justify">The chairman of the Board shall chair each Board meeting. If the chairman of Board is absent, within fifteen
(15) minutes of time scheduled for meeting, or if he does not wish to chair the meeting, the Board members present at meeting shall elect
one of them to serve as chairman, direct meeting and sign meeting minutes. However, when board votes, the person elected shall not have
an additional or decisive vote.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.8.</TD><TD STYLE="text-align: justify">Each Board meeting where a legal quorum is present shall be permitted to fulfil every authority, power
of attorney and judgment that according to these regulations are given to board at that time or that are normally utilized by the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.9.</TD><TD STYLE="text-align: justify">The Board shall be permitted to make resolutions without actually convening, with the consent of all Directors
entitled to participating in the discussion and voting as to the resolution. In such an event, the chairman of board shall prepare minutes
and attach Directors&rsquo; signatures.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.10.</TD><TD STYLE="text-align: justify">Subject to the provisions of any law, all actions taken by board or under its decision, or by meeting
of a board committee or by person serving as board member, shall be valid even if it is later discovered that there has been some flaw
in electing these board members or the persons serving as above, or that all or one of them are invalid, just as though each of them were
legally elected and had the necessary qualifications for becoming a member of the board or of said committee.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.11.</TD><TD STYLE="text-align: justify">A resolution signed by all Directors (or their alternative Directors) or agreed to in writing (including
fax) by all Directors (or their alternative Directors) who are not legally prevented from participating in such resolution; and resolutions
made by using any means of communication that allow all Directors who are not legally prevented from participating in such resolution
to hear the other Directors simultaneously &ndash; shall be valid for all intents just as though they had been made at a properly convened
board meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">22.</TD><TD STYLE="text-align: justify"><B><U>Board Committee</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.1.</TD><TD STYLE="text-align: justify">Board shall be permitted, by a resolution of the majority of Directors constituting Board at that time,
to establish committees and appoint Board members as committee members. Subject to the provisions of Companies Law and these Articles,
Board may delegate its powers or any part thereof to above committees, and for a special matter, can cancel such delegation from time
to time. At least two (2) Directors shall serve on each committee. At least one (1) External Director shall serve on any committee permitted
to utilize any of the Board&rsquo;s powers.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.2.</TD><TD STYLE="text-align: justify">When using its powers, any committee established as covered in Article 22.1 above must fulfil all provisions
established by the Board. Meetings and actions of each committee shall be conducted according to the provisions contained in these articles
as far as Board&rsquo;s meetings and actions, so long as they are suitable and so long as no provisions by the Board have replaced them.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">A Resolution made or action taken by board committee according to a power delegated to it by the Board,
shall be the same as a board&rsquo;s resolution or action.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding this section, on the issues listed below a Board committee shall not be permitted to make
resolutions but recommendations only:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">Establishing general Company policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Distribution, with the exception of acquiring Company shares according to framework formerly outlined
by Board;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Establishing Board&rsquo;s position as to an action requiring General Meeting&rsquo;s approval, or as to providing
an opinion as per Section 329 of Companies Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">Appointing Directors, if the Board is permitted to do so;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">Allocating shares or securities convertible to shares or which can be realized as shares &ndash; or a
series of bonds &ndash; unless the share distribution is due to realizing or converting Company securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">Approving financial statements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">Approving transactions and actions requiring Board&rsquo;s approval as per Sections 255 and 268 to 275 of Companies
Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.4.</TD><TD STYLE="text-align: justify">A Board committee shall report to board on ongoing basis of its resolutions or recommendations as determined
by Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.5.</TD><TD STYLE="text-align: justify">The Board may cancel resolution of committee appointed by it, but such cancellation shall not detract
from the validity of a committee resolution acted upon by company towards another person not knowing of its cancellation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">However, all actions taken in good
faith at board meeting or by a Board committee or by any person serving as Director shall be valid even it is later discovered that there
has been some flaw in appointing such Director or person acting as above, or that all or one of them are invalid, just as though each
of them were legally appointed and had the necessary qualifications for becoming a Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.</TD><TD STYLE="text-align: justify"><B><U>Minutes</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">23.1.</TD><TD STYLE="text-align: justify">The Company shall document minutes of General Meetings, class meetings, Board meetings and Board committee
meetings, and shall keep them in its office for a period of seven (7) years of the General Meeting or meeting, as the case may be.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">23.2.</TD><TD STYLE="text-align: justify">Minutes will always contain the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Day and place where meeting or assembly took place;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Names of attendees, and if they are attorneys or alternative participants, names of those granting power
of attorney or appointing, and for a shareholders&rsquo; meeting, number and types of shares based on which voting is conducted;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Summary of discussions, course of discussions and resolutions made;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Instructions given by board to board committees or CEO;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Documents, reports, approvals, opinions, etc. presented, discussed and/or attached.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Such General Meeting minutes signed
by the General Meeting&rsquo;s chairman shall serve as prima facie proof of its contents, and such board or board committee meeting minutes
approved and signed by meeting chairman or board chairman shall serve as prima facie proof of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Above provisions shall also apply to
written resolutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">24.</TD><TD STYLE="text-align: justify"><B><U>CEO</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">24.1.</TD><TD STYLE="text-align: justify">The CEO shall be appointed, whether for a fixed or limited period, and dismissed by board through majority
of board members.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">24.2.</TD><TD STYLE="text-align: justify">The CEO shall be responsible for ongoing management of company&rsquo;s affairs as part of policy established
by board and subject to its directions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">24.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The CEO shall have all management and execution powers not granted by Companies Law or by these regulations
to any other company agency, and shall be supervised by board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The CEO may delegate some of his powers, with board&rsquo;s approval, to anyone under him. Approval can be general
and granted in advance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">24.4.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The CEO shall notify the chairman of Board immediately of any exceptional matter meaningful to the Company,
and shall submit to board reports on such matters, at such times and at such extent as the board sees fit. Should the Company not have
a chairman of the Board, or should he be prevented from fulfilling his duties, CEO shall notify all Board members of such circumstance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Chairman of Board shall be permitted, as his own initiative or at board&rsquo;s decision, to demand of CEO
to report on the Company&rsquo;s affairs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Should such notice or report require board&rsquo;s action, chairman of board shall immediately summon a board
meeting to discuss notice or resolve upon required action.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>25.</B></TD><TD STYLE="text-align: justify"><B><U>Local Management</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">25.1.</TD><TD STYLE="text-align: justify">The Board may arrange, from time to time, arrangements for the management of the Company&rsquo;s business in
any specific location; whether in Israel or abroad, as it sees fit, and the provisions set forth in Article 25.2, below, shall not derogate
from the general authorisations granted the Board under this Article.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">25.2.</TD><TD STYLE="text-align: justify">The Board may, at any time and from time to time, establish any local management or local agency to manage
the business of the Company in any specific location, in Israel or abroad and can appoint any person to be a member of said local management,
or any manager or agent and may determine their salary. The Board may, from time to time, grant any person so appointed any power, authority
and freedom of discretion that are granted at that time to the Board, and he may empower any person who is at that time serving as a local
member of management to continue in his position even though a position has been vacated there, and any such appointment or such authorisation
may be made under the same terms and conditions that the Board will see fit and the Board may at any time terminate the employment of
any person who was so appointed and to cancel or amend any such authorisation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>26.</B></TD><TD STYLE="text-align: justify"><B><U>Registry of Shareholders</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">26.1.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company shall administer a registry of shareholders (the &ldquo;<B>Primary Registry</B>&rdquo;) and
will record in it the following details:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">For registered share -</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Name, I.D. number and address of every shareholder, all as was provided to the Company; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Amount of shares and types of shares held by each shareholder, listing their par value, if existent, and
if any amount has yet to be paid in consideration for such shares - the amount yet to be paid; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Date of allocation of the shares or the date of transfer to the shareholders, whichever relevant; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">If the shares have been marked with serial numbers, the Company shall note, next to the name of each shareholder,
the serial numbers of the shares registered in the shareholder&rsquo;s name; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">All other details that, by the Companies Law or these Articles of Association, are required or permitted
to be registered in the Primary Registry.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Bearer Shares -</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Notification of the facts that bearer shares have been allocated, their date of allocation and the amount
of shares that have been allocated; and -</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The numbering of the bearer shares and of the share certificates.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify">If the share certificate is cancelled
by request of the shareholder, the name of the shareholder and the number of shares registered in his name will be registered in the Primary
Registry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Dormant Shares - Their numbers and the date they became dormant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company may, subject to and in accordance with the provisions of sections 138 and 139 of the Companies
Law, maintain an additional shareholders registry outside of Israel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>27.</B></TD><TD STYLE="text-align: justify"><B><U>Company Officers</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">27.1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s CEO may, from time to time, appoint officers (except for Directors and a CEO) to the Company
to permanent, temporary or special positions, as the CEO so decides from time to time, and similarly, the CEO may terminate the services
of one or more of the aforementioned from time to time and at any time, in his absolute discretion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">27.2.</TD><TD STYLE="text-align: justify">The CEO can determine, subject to the provisions of the Companies Law, the authority and the role of each
officer he so appoints, as well as the terms under which they will fulfil of their position and may demand collateral in the cases and
in the amounts he deems necessary.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>28.</B></TD><TD STYLE="text-align: justify"><B><U>Distribution</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.1.</TD><TD STYLE="text-align: justify">Subject to all special rights or restrictions granted to particular shares, dividends or share dividends
will be distributed and paid to the shareholders relative to the sum of capital paid-up against the par value of the shares held by them,
and this without taking into account the premium paid on them.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.2.</TD><TD STYLE="text-align: justify">Decisions on the distribution of dividends will be made by the Company Board. All profits made that are
worthy of being distributed as dividends, subject to accepted accounting principles and to the provisions of the Companies Law, will be
distributed by the Company to the shareholders, whether as a dividend or by means of the purchase of shares from all shareholders by the
Company or a corporation in its control, and this with their being actually received by the Company, and subject to all applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.3.</TD><TD STYLE="text-align: justify">The Board may delay any dividend, benefit, rights or sums about to be paid for shares in which the Company
has a lien and/or charge, and to use any such amount or to realise any benefit and any right and to use the consideration from such realisation
to pay off the debts for which the Company holds liens or charges.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.4.</TD><TD STYLE="text-align: justify">The transfer of a share shall not entitle the recipient of the share the right to a dividend or to any
other distribution that was decreed after the transfer but before the transfer was registered, however, if the transfer is subject to
the Board&rsquo;s approval, the date of approval shall be used instead of the date the transfer was registered.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.5.</TD><TD STYLE="text-align: justify">In the event of a dividend whose payment is not demanded within seven (7) years from the date of the decision
on its distribution, the person entitled to said payment will be deemed to have ceded same and it shall be returned to the Company&rsquo;s
ownership.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If not deemed otherwise, any dividend
may be paid by cheque or payment order to be sent by mail to the registered address of the Company or individual thereto entitled or,
in the event of registration of joint ownership, to that member whose name in the registry is registered first with respect the joint
ownership. Any such cheque will be written to the order of the person to whom it is sent. The receipt of the person whose name, on the
date of decree of dividend, is listed in the members&rsquo; registry as a shareholder or, in the event of joint ownership, as one of the joint
owners, will serve as release with respect to all the payments made in connection with that given share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.6.</TD><TD STYLE="text-align: justify">The Board is entitled to deduct from any dividend, grant or other distribution to be made in connection
with shares held by a shareholder, whether held solely or jointly with another shareholder, any sum of money due from him which he must
pay by himself or together with another to the Company, against demands for payment or similar.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.7.</TD><TD STYLE="text-align: justify">Subject to Article 28.2, the Board may, in its own discretion, set aside in special funds any sum from
the Company&rsquo;s profits, or the revaluation of its assets, or the relative portion of the assets of the companies connected with it,
and to determine the designation of these funds.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>29.</B></TD><TD STYLE="text-align: justify"><B><U>The Internal Auditor</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">29.1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s Board shall appoint an internal auditor, according to the recommendation of the auditing
committee.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">29.2.</TD><TD STYLE="text-align: justify">The organisational superior of the internal auditor shall be the Chairman of the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">29.3.</TD><TD STYLE="text-align: justify">The internal auditor shall submit, for the approval of the Board, a proposal for an annual, or periodic,
work plan and the Board shall approve same with the amendments it sees fit.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">29.4.</TD><TD STYLE="text-align: justify">The internal auditor shall operate in accordance with the provisions of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>30.</B></TD><TD STYLE="text-align: justify"><B><U>The financial Auditor</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">30.1.</TD><TD STYLE="text-align: justify">A financial auditor shall be appointed in every Annual General Meeting and shall serve in this position
until the end of the following Annual General Meeting. Notwithstanding the above, the General Meeting may, in a majority decision of the
shareholders, appoint a financial auditor for a longer period that shall not exceed the end of the third Annual General Meeting following
the meeting in which he was appointed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">30.2.</TD><TD STYLE="text-align: justify">The General Meeting may terminate the appointment of the financial auditor .The fee of the financial auditor
for auditing activity will be set by the General Meeting and in accordance with Section 165 of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">30.3.</TD><TD STYLE="text-align: justify">The fee of the accountant for additional services to the Company which are not auditing activities will
be set by the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>31.</B></TD><TD STYLE="text-align: justify"><B><U>Transactions Requiring Special Authorisation</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">31.1.</TD><TD STYLE="text-align: justify">A transaction of the Company with one of its officers and a transaction of the Company with another person
with whom a Company Officer has a personal interest, and which is not an irregular transaction, requires authorisation of the Board alone,
all subject to the fifth chapter of the sixth part of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">31.2.</TD><TD STYLE="text-align: justify">The Company is not allowed to enter into a transaction with related parties for a period of three years
commencing on the date said related party became a controlling holder in the Company, this unless as a result of the completion of the
transaction the related party becomes a controlling holder holding no less than 75% of the Company&rsquo;s share capital, and all subject
to the fifth chapter of the sixth part of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For this purpose, &ldquo;Control&rdquo;
as defined in the Securities Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>32.</B></TD><TD STYLE="text-align: justify"><B><U>Merger</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The authorisation of a merger requires
a regular majority of shareholder votes and subject to the provisions of Section 320(A1) of the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>33.</B></TD><TD STYLE="text-align: justify"><B><U>Notices</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.1.</TD><TD STYLE="text-align: justify">Subject to the provisions of Article 15.6 of these Articles, a notice on the General Meeting shall be
given only to shareholders registered in the primary registry and entitled to participate in the general assemblies, who have provided
addresses in Israel. Any other person shall not be entitled to receive notices about general assemblies.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.2.</TD><TD STYLE="text-align: justify">When the Company has grounds to assume that the address provided by a shareholder is no longer his address,
such a shareholder shall be deemed as not having provided an address to the Company, in each of the following cases:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">When the Company sent him to the address he provided a registered
letter in which he was requested to either confirm that the said address is still his address or to notify the Company of a new address,
and the Company did not receive a reply within thirty (30) days of the date the letter was posted by the Company at the post office.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">When the Company posted a registered letter to the address
he provided and the Postal Authority, whether with or without the return of the letter, notified the Company that the letter was not
delivered to the given address because he is unknown at that address or for any other reason.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company may deliver any notice and any document to a shareholder by hand delivery or by delivering
via mail to the address provided to the Company. If a notice was sent by mail, the notice shall be deemed fully performed if the letter
containing the notice bore the address provided to the Company and if it was sent with appropriate postage, and as long as the opposite
has not been proved, it shall be deemed delivered within seventy-two (72) hours of posting at the post office by the Company when the
address is in Israel, and when the address is abroad - within ten (10) days from posting at the post office by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Company may send notices to shareholders whether they are holders of registered shares and whether
they are holders of bearer shares, by publication of the notice at least once in two daily newspapers of broad circulation in the Hebrew
language as set forth in Article 15.6 above, and the date of publication in the newspaper shall be deemed the date the notice was received
by the shareholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Nothing in the above paragraphs (a) and (b) shall be deemed as imposing any obligation on the Company
to give a notice to whoever did not provide the Company with an address in Israel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.4.</TD><TD STYLE="text-align: justify">The Company may give notice to partners in a share by sending the notice to the partner whose name first
appears in the Shareholders Registry for that share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.5.</TD><TD STYLE="text-align: justify">Any and all documents or notices sent by the Company in accordance with the provisions of this article
shall be deemed properly sent despite the death, bankruptcy or liquidation of said shareholder (whether or not the Company knew), as long
as no other was registered as a shareholder in his place, and sending and delivery as set forth above shall for all purposes be deemed
sufficient for all parties interested in those shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.6.</TD><TD STYLE="text-align: justify">The unwitting failure to send notice to a shareholder, or the non-receipt of such a notice by a shareholder
shall not derogate from the validity of any resolution accepted in such an assembly.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>34.</B></TD><TD STYLE="text-align: justify"><B><U>Liquidation of the Company</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event of liquidation of the
Company, whether willingly or otherwise, the following provisions shall apply, unless specifically set forth otherwise in these Articles
or in the terms under which a given share was issued:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The liquidator shall first use all of the Company&rsquo;s
assets for the payment of its debts (the Company&rsquo;s remaining assets after the payment of its debts shall hereinafter be referred
to as the &ldquo;<B>Surplus Assets</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Subject to any special rights attached to shares, the liquidator
shall distribute the Surplus Assets amongst the shareholders <I>pari passu</I> their par value.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">With the Company&rsquo;s permission by a resolution that
was accepted in the General Meeting by a regular majority of shareholders&rsquo; votes, the liquidator may distribute the Surplus Assets
of the Company, or any portion thereof, in their original physical form amongst the shareholders, and may also transfer any asset of
the Surplus Assets to a trustee in a trust for the benefit of the shareholders, all as the liquidator deems fit.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>35.</B></TD><TD STYLE="text-align: justify"><B><U>Exemption from Liability</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may, by resolution reached
in the manner set forth in the Companies Law, exempt in advance any of its officers from all or part of their responsibilities due to
breach of their duty of care to it, however, in accordance with Sections 259(b) and 311 of the Companies Law, the Company may not exempt
in advance a Director from its responsibilities to it due to a breach of the duty of care in distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>36.</B></TD><TD STYLE="text-align: justify"><B><U>Liability Insurance</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the provisions of the Companies
Law, the Company may, by resolution reached in the manner set forth in the Companies Law, obtain liability insurance for an officer of
the Company due to liability he may incur as the result of an action performed in his position as an officer, entirely or partially, in
each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Breach of duty of care towards the Company or towards another
person;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Breach of his duty of trust to the Company, as long as the
officer acted in good faith and had a reasonable basis to presume that his action will not be detrimental to the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">A financial obligation that he will be subject to for the
benefit of another person.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>37.</B></TD><TD STYLE="text-align: justify"><B><U>Indemnity</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the provisions of the Companies
Law, the Company may, by resolution reached in the way set forth in the Companies Law, indemnify an officer for a financial obligation
or expense as set forth in paragraphs (a), (b) and (c) below, which the officer made or was subject to due to an action performed in his
position as an officer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">A financial obligation he was subjected to for the benefit
of another person by court ruling, including court rulings made following a compromise or an arbitrator&rsquo;s ruling authorized by
a court, as long as the commitment to indemnify be limited to events that, in the Board&rsquo;s opinion, are expected in light of the
Company&rsquo;s actual activities when the commitment to indemnify was given, and to a sum or to a degree that the Board deemed reasonable
under the circumstances, and that in the commitment to indemnify will be stated those events that in the Board&rsquo;s opinion are to
be expected in light of the Company&rsquo;s actual activities at the time the commitment was made and also the sum or the degree which
the Board deemed reasonable under the circumstances;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Reasonable litigation expenses including lawyer&rsquo;s fees,
which the officer incurred as a result of an investigation or a procedure held against him by an authority authorized to conduct such
investigation or procedure, and that were concluded without the filing of an indictment against him but with the imposition of a financial
liability instead of criminal procedures for offences that do not require proof of criminal intent;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In this article - the conclusion of
procedures without the filing of an indictment in a matter for which a criminal investigation was opened - means the closing of a case
in accordance with Section 62 of the Criminal Procedure Law (combined version), 1982 (hereinafter in this paragraph: the &ldquo;<B>Criminal
Procedure Law</B>&rdquo;) or stay of procedures by the Attorney General under Section 231 of the Criminal Procedure Law. &ldquo;A financial
liability instead of criminal proceedings&rdquo; - A financial liability imposed by law as an alternative to criminal proceedings, including
an administrative fine under the Administrative Offences Law, 1985, a fine for an offence deemed a finable offence under the provisions
of the Criminal Procedure Law, a financial sanction or a financial penalty;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Reasonable litigation expenses including lawyer&rsquo;s fees,
which the officer incurred or that a court ruled he must pay, in a procedure instigated against him by the Company or in its name or
by another person, or in a criminal charge from which he was found cleared, or in a criminal charge in which he was convicted for a crime
that does not require proof of criminal intent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>38.</B></TD><TD STYLE="text-align: justify"><B><U>Binding the Company</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">38.1.</TD><TD STYLE="text-align: justify">The signature of any person who has been appointed by the Board from time to time, either generally or
for a specific case, whether by himself or together with additional persons, together with the Company&rsquo;s seal or stamp will bind
the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">38.2.</TD><TD STYLE="text-align: justify">The Board may determine different signatory rights for different dealings of the Company and set the financial
limitations for which each signatory is authorised to sign.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>39.</B></TD><TD STYLE="text-align: justify"><B><U>Amendment of these Articles of Association</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">These Articles of Association may
be amended by resolution the shareholders in the General Meeting, by regular majority of votes of the participating shareholders, and
notwithstanding all of the above in these Articles of Association, the passing of a resolution that constitutes an amendment of a provision
of these Articles of Association, directly or indirectly, will require the resolution of the shareholders in the General Meeting, in a
regular majority of the votes of the participating shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">30</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>f20f2022ex12-1_canfitebio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 12.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION
302 OF THE SARBANES-OXLEY ACT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">I, Pnina Fishman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of Can-Fite
BioPharma Ltd;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 30, 2023</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pnina Fishman</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pnina Fishman, Ph.D. Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>f20f2022ex12-2_canfitebio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION
302 OF THE SARBANES-OXLEY ACT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">I, Motti Farbstein, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of Can-Fite
BioPharma Ltd;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 30, 2023</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mott Farbstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motti Farbstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating and Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.95pt"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>f20f2022ex13-1_canfitebio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION
906 OF THE SARBANES-OXLEY ACT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Pursuant to 18 U.S.C. Section
1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Can-Fite BioPharma Ltd. (the &ldquo;Company&rdquo;)
hereby certifies to such officer&rsquo;s knowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the accompanying Annual Report on Form 20-F of the Company
for the year ended December 31, 2022 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d),
as applicable, of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 30, 2023</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pnina Fishman</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pnina Fishman, Ph.D. Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The foregoing certification
is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether
made before or after the date hereof, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.45pt 0pt 13.95pt; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>f20f2022ex13-2_canfitebio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION
906 OF THE SARBANES-OXLEY ACT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Pursuant to 18 U.S.C. Section
1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Can-Fite BioPharma Ltd. (the &ldquo;Company&rdquo;)
hereby certifies to such officer&rsquo;s knowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the accompanying Annual Report on Form 20-F of the Company
for the year ended December 31, 2022 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d),
as applicable, of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 30, 2023</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mott Farbstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motti Farbstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating and Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The foregoing certification
is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether
made before or after the date hereof, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.45pt 0pt 13.95pt; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>f20f2022ex15-1_canfitebio.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We consent to the incorporation
by reference in the following Registration Statements: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
Statement (Form F-3 No. 333-236064) of Can-Fite Biopharma Ltd.,</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
Statement (Form F-3 No. 333-249063) of Can-Fite Biopharma Ltd.,</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
Statement (Form F-3 No. 333-262055) of Can-Fite Biopharma Ltd., and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
Statement (Form S-8 No. 333-227753) pertaining to the 2003 Israeli Share Option Plan and 2013 Global Incentive Option Scheme of Can-Fite
Biopharma Ltd.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">of our report dated March
30, 2023, with respect to the consolidated financial statements of Can-Fite Biopharma Ltd. included in this Annual Report (Form 20-F)
of Can-Fite Biopharma Ltd. for the year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="width: 19%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Kost Forer Gabbay &amp; Kasierer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2023</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Member of Ernst &amp; Young Global</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $; BL# 2(  A$! Q$!_\0
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M5]6T4R?[<S/_ *#_ ,SY2_X8;_96_P"B8#_PK_BA_P#-51_PPW^RM_T3 ?\
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M]Z+]Y7:2T>F[3>B;:.[VV>VO;2R=[='K??YGY3_\,-_LK?\ 1,!_X5_Q0_\
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MMFT]!UZ_$-!JUWK;17_SZ?>? _\ PPW^RM_T3 ?^%?\ %#_YJJ/^&&_V5O\
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M(_LG^Q?"WC4?VYP>,]N*K?%OX#^+?@OH_P )=;\3ZKX?U*'XM_#^P^(N@_\
M"/W6O7W]F^%]8M?MA_M;_A)_"O\ R'/]+X^AP.*R_M[ /'?4%)7O:W7F<>9:
M6WMKOMKN2\?G/U;ZU]??5=>]GT[Z;'YT_P###?[*W_1,!_X5_P 4/_FJH_X8
M;_96_P"B8#_PK_BA_P#-57U;17HG-2SC,[J^/OJK[]6KK]#^7GXPZ#I7A3XM
M?%'PWH<)TW1_#_Q%\?Z-HUG]J&J_8]/\.:]XD\.>'SGG\/\ ./T,_8A_9P^"
MWQ@^%GB+Q'\1?!__  DFL6WQ&O\ 1[6\_P"$C\9:2?[/_L'PYXD./[%\5_\
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M_P 4/_FJK[RL_A-\5[SPA-XXL_A?\1[GP)!I_P#:%UXSL_"6J?\ "$?V./\
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M1XV_\)011_X)U:[^P'\.?"?B[Q!^TM^U[_P3\\<^(_C)^TS\<+[X\?"R./\
M97\'?"6S_M@^)/ 6@6G@C2?&?P?U'XH?$#X/>(1I6D^(/";?\)/\+_"WA;P#
MXE!\8?VJ5\=_\)3_  WT4EP-)8=T%G<]5&^LNG9\]TFNB=KW=VVQ']>/A/\
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M:=\#?%C7OC3-#\(/AQK>L>._$6G7.C?%_P#L;4_#?B*ST_1M!\.>',_\(_\
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M0G"%?RT^//\ D?/'/_8V>)__ $^FOZEJ_EI\>?\ (^>.?^QL\3_^GTUT'W_
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M?^(FI_$+X+?'_P &^#?A)X'?P;_PJ7XCZP?$YQ_PNT^*+\Z__8@_M7_BD_\
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M'PY^ _@_P?8?:;^X^$'P_O[J\O/^059Z?_PAOAO_ (GWB'/Y#].,"OU=L_\
M@FG?S6MM]O\ C!;VUS_R]6<'@/\ M4'_ ,NK/XGKV/4USW\_Z_JY_.>?9YEF
M69A..)>KE+3>WO-:KM?R/RXHK]4/^'9__5:/_,<__C&H_P"'9_\ U6C_ ,QS
M_P#C&HL>'_K1E7_0=^"/ROHK]4/^'9__ %6C_P QS_\ C&H_X=G_ /5:/_,<
M_P#XQJ _UHRO_H/?W(_*^BOU0_X=G_\ 5:/_ #'/_P",:C_AV?\ ]5H_\QS_
M /C&H%_K/E7_ $'_ (1/ROHK]4/^'9__ %6C_P QS_\ C&H_X=G_ /5:/_,<
M_P#XQJ!_ZT97_P!![^Y'Y7T5^J'_  [/_P"JT?\ F.?_ ,8U'_#L_P#ZK1_Y
MCG_\8U!KAN*,G4DWF&B<7]TDW\K)G^?/7]'W[*'_ ";E\'_^Q-->TWG_  ;.
M6&FZ??ZKJO[<]OIMAI=M]ON=8O/V;O[*TJST_KSG]HP?CUZ5^AWP'_X):^&_
M#?PJ\'^%?"O[3^A^/]'\+6G]C?\ "6>'_ >E_P!E7GK_ ,@7XC>)/U(_I2YE
MWVWT>FE_/]7Y'W/$/&W#>:9?%87'MN*BK)-ZI)=$[:H^$J*_3_6/^"<^E>']
M+O\ 6];^/VGZ)H^F6NH:SK.LZQX#_LK2K/3]'/\ Q4.N^(?$'_"QOQ.>GMDF
MN>U+]@_P!H_A.Z\?ZK^T_P"$]-\ 6VC:?XHNO'&L>'-!TKPI_P (QK'/A[7O
M^$B_X6-_PCXT3L/&'7Z<FI]K2O:[OZO_ .1_JSV/A/[>P/GZV73K^I^<-%?J
MA_P[/_ZK1_YCG_\ &-1_P[/_ .JT?^8Y_P#QC59'^L^6+_F.?_@*2]+O[C\K
MZ*_2>T_8#\'7GB2;P?8?M,^&[GQAI9^WW7A.S\-Z8?$=GV&?#W_"QCW')) K
MJ?\ AV?_ -5H_P#,<_\ XQJ+I_(T_P!8<M[-^9^5]%?JA_P[/_ZK1_YCG_\
M&-7/>&OV /"OC#3_ .U?"O[2?AKQ)8?VSJ&C?VQH'@W0M5TO^T-'U[_A'/$&
M@_\ $E^(O&N>#?%/A_5M ..A(&?1.232>[O;1O;5[*R^;5^E[,/[>P/9_<C\
MT**_5#_AV?\ ]5H_\QS_ /C&KE8?V _!TGB2X\'P_M,^&[KQA!_I]UX4_P"$
M<T$^([//_4O?\+&/B ?X9Q3NEN"SW M[/[O^ ?FS7\M/CS_D?/'/_8V>)_\
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M /&-1_P[/_ZK1_YCG_\ &-0+_6?+'MCF_P#MW_@'Y7T5^J'_  [/_P"JT?\
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M-G_XF@/]3,P[?BO\C]T**_"__AO7]H?_ )__  ?_ .$V?_B:/^&]?VA_^?\
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MLF>&_ ?@GXH>(?&X_P"*@UG]G0>*O^$A\/\ BSX7C_A%_P#H;?KY[X'^%?\
MP4"_X9S^($'CGXG?M=VOQ7N+OX/_ -L^"++PYXR_TWX@:/KOCSQ)XW_X1[XL
M:-^VEXV\0?\ "N/&?_%/>'_%GB#]G?\ X4WX5\*Y\(_\*X^'N?\ A._"E>M?
M\-Z_M#_\_P#X/_\ ";/_ ,31_P -Z_M#_P#/_P"#_P#PFS_\33Y7I?=>6CTM
MJFG;6[TM]RL>@H9NDE_9N0:)+9=$EV\B76(?V]K(VVB?\*Z_:/TVY\>>&_\
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MQ9X/'@;/BH^',GX@@9QQ/_#>O[0__/\ ^#__  FS_P#$T?\ #>O[0_\ S_\
M@_\ \)L__$UE[%W;4K7MIRZ*SU^]::^JU1Q?4LV^LU\1AXQVUT5O-:K;=>GS
M.&\;? _]O73?@'^QU9Z3\3?VJ_M_B#X=>*-:_::U>S\1^,OB+\6_"OQVU?X7
M^!/#?@<_V3HO[1G[-_B'^Q/!G]D^-O\ B0#QSXG\ ?\ "5D^+?B1\/?%'_"1
MFKTVH?M>ZQ^VCX^TKP#JO[0_C_Q%\)_CO^R^-8Q\13X'_9F'PO/[&'@3Q)\>
M-!\<>"/^%C_V!HNM^,_%/B :_P"$\>!_%!\+>*O$>?"'7QYCJ_\ AO7]H?\
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MZ^*/B-X?^"'QNU[PW\3?%7@;_A5Y_P"%#^,O!'B#Q/\ $;P3_P 2,_$;5?\
MBK/^$-\2_P#%59\)_P#"QSXH\'^"N?K;]E?X5?M6S?&?POXJ_:8\<?%@?\()
M^RY^SE]IT>R\>:G9?#/Q5\=O["^+WASXK_\ "1>'M%/_  CVM:YX-'B'22<Y
M\+'Q3_PB?BX\^'/ F?GG_AO7]H?_ )__  ?_ .$V?_B:/^&]?VA_^?\ \'_^
M$V?_ (FAQ;5G:^JORZVNMKWMHG?7KY&\\OS>>%6&MERVO9*ZT6B=NG34]?\
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M*P_\1]_9L_\ G'TG_#^3_@JG_P!'-6/_ (C]^RM_\X^LGCL[Z9:G_P!Q$O\
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MG_AHO!__ ,RU#>;?RQ_\#7_R :=_P_X)\D45];_\-E_%'_H5?@I_X:+P?_\
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MI?-OY8KRYEIY?#T/S*R_I'R/17UO_P -D_$3_H0?@)_X9?PA_C1_PV3\1/\
MH0?@)_X9?PA_C1?-OY8_^!K_ .1"R\O_  %'R117UO\ \-D>/_\ HG7P$_\
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M%%% !1110:X7_>%ZQ_-'\F]?T??LH?\ )N7P?_[$TU_.#7]'W[*'_)N7P?\
M^Q--=!^D\7?\B[+O3]$?15%%%<Y^8O=^K_-A1110 4444 %%%% !1110 5_+
M3X\_Y'SQS_V-GB?_ -/IK^I:OY:?'G_(^>.?^QL\3_\ I]-=-WW?WO\ S/ON
M!'IF!^VO_!/?_DW.Q_[''Q1_(YK[AKX>_P"">_\ R;G8_P#8X^*/Y'-?<-<Q
M\UG/_(XS#^NK"BBB@\8**** "BBB@ HHHH ****#:ET_Q+\XG\R'Q_\ ^2Z?
M&G_LJOQ _P#4P\1U^KW_  33_P"2&>,/^RJW_P#ZAW@.ORA^/_\ R73XT_\
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MZ/\ M(?%KQ)#XD^-G@;X#VO@>P\.>'[?^WOAS_PGFH>//&7_  C?A[7O&_\
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M#_7C%?\ 0 OP_P S^;?_ (47\<O^B-_%#_PW7C+_ .96C_A1?QR_Z(W\4/\
MPW7C+_YE:_I(HH#_ %XQ7_0 OP_S/YM_^%%_'+_HC?Q0_P##=>,O_F5H_P"%
M%_'+_HC?Q0_\-UXR_P#F5K^DBB@/]>,5_P! "_#_ #/YM_\ A1?QR_Z(W\4/
M_#=>,O\ YE:/^%%_'+_HC?Q0_P##=>,O_F5K^DBB@:XXQ-_]P6_EW]3^;?\
MX47\<O\ HC?Q0_\ #=>,O_F5K^;;QM^PK^VQ>^,?&$T'['G[5ES:W'B/Q1?V
MMY9?L^_&3_30=>X_YE4_USUK_21K^<_X!?M3_MNZ[\ /#/QJ^*?BKXH>)/AO
MXO\ ^&.CI_C?Q9X=^#?PDU2]^*'CO]J#PYX;\;:#\)_^%?>%<ZU\'O\ A7/B
M  _\)GX&SVI.]U:UNNNORZ/2_;IYGVW"G'&8I9A4P^!R]:=9)?@Y+7Y'P]^P
MW^S'^TEX/^ =AI/BK]GKXV>&]8_X2/Q1?_V-X@^%7C+2M5[X/_$[\+>@Z_\
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MA\5/$.J3>,-0\1^'?"'QN_X*=_\ %)ZO=?\ $JU[PQ\"?A?X<\2?"CP:./\
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M\]/[<G_)T?Q/_P"Y'_\ 58^&Z#[/@S_?_G^A\FT445T'ZJ%%%% !117K-Y\
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MR*O_ "3D^*A_PB'_  F'_(K8]JZ/K&G9?YZ+KYJWR7D*7PR_PR_])D?U0?\
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MV:AH_P#R,.@^W_"&>OI3/B/]3,&]?>U_O/J?M-_PWO\ L]_]!#Q=_P"$J?\
M"C_AO?\ 9[_Z"'B[_P )4_X5^+,7@GQA=VMM?Q>%?$ES;7&CZAXHM+RST;7O
M],\,:.?^*AU[)_Y@?@P_\SAWSCK1-X)\86<=U--X5\26UM;Z-I_BBZO+S1M>
M_P!#\+ZQ_P B]KX_Z@8X&/?% _\ 4S!?WO\ P)_YG[3?\-\_L^?\_P#XP_\
M"7'^?3_)X7_AOG]GS_G_ /&/_A+CW_\ K?KZ\?BQ<> _'-G)?PS>#_&%M<Z7
MK.GZ-K-O>>'=>_T/4-9_Y%[0<?\ 0<\9_P"/I5G_ (5_X_\ M5M8#P-XL^TW
M'B/4/"]K9_\ ".:]_P C1H_'B'03C _MS_J3_?TH%_J;E'?\S]GO^&^?V?/^
M?_QC_P"$N/?_ .M^OKP?\-\_L^?\_P#XQ_\ "7'^?3_)X_%B'P?XPO([":'P
MKXDNK;5+74-0T:XL]%U[_3=/T?GQ#_PCW_8F?3\:/^$)\8?9?M__  BOB3[-
M_P (Y_PF?VS^QM>_Y%;^WO\ A&_^$RQT_L3O_P )AC]*/ZW'_J;E'?\ ,_:?
M_AOG]GS_ )__ !C_ .$P/\*3_AO3]GK_ )__ !9_X2PK\69O!/C"S^W^=X5\
M26W]E_V>=9^V>'->_P!#_M@?\4]_PD/_ &.?_,I_0^U3?\(!X_\ M'V3_A!O
M%GG?\)'_ ,(=]C_X1S7O^1H_Z$S_ +#O_4G]>U'];E_ZH93W?WL_:#_AO7]G
M?_H(>,/_  G?_K5^=VI?\%F/^"5.AZ##\)9_#>N6_@;P'K.GV&C>![/X#Z6/
M ^@ZAX#UX^)/#Y\/>'N- T;_ (0W7/#W_"0>%/7&17S5#X#\<WDEA#%X/\67
M-SJEWJ%AHWV/PYKQ^V:AHX_XJ'_A'O\ L3!GG^E?S#>-O@S\8[SQ9XPU6P^$
MOQ)N;"XM?B!\6K6\LO ?C(:5>?##1]>\2_\ "0_%#GPJ/^+<^#,?\59XP_Y%
M7''K63I)[O\ K[SZ_@_@+*<<LP^L2:>MFFUMMLUKH?W/_"_]O7]@/XV:#XY^
M(OA7P@=3MOBQG1OB-K&L?"'2['5?B/\ \()H1TCP_H/C;K_;7_"&:)_Q3^/&
M? KH(OCA_P $_8?"_ACP-#\'/ UKX)\":R/%'@[PI_PH;P=_PCGA7Q1G_D/:
M3X>_X14^']%US/3Q?X,'TK^?#]A7X9_$[PK^S?83>*OAUXX\-VUO=_\ "9?\
M5!X-UZR/_"+^.S_Q1'C$?VSR=#\9=/"GC#/_ !57UK[*F\!^.;.2YAE\'^++
M:YM]9T_1K^SO/#FO?\2WQ1K'_(OZ#QG_ (GG/<<?RCV=&RLY6Z6;_P"#Y_CL
M>7F/#E#!XK'X7"YA+1V6^FMO\NQ^F>G_ !=_X)T:/!KMCI7P0^&^FVWB?_D8
M[/1_V??!VE?V]_Q/O#GB3'B''A;'B?\ XG>E:3X@Y&/^*;!ZBO49OVR?V4;S
MQ18>,)M*N+CQAI6C:AX8T;Q9<> \>([/PQK'_"-_\)#H7A[Q!_R'_P"P_&7_
M  CVD_7_ (1OVK\@X?A[X_O);:&P\#>++BYN-9U#PO:V=GX<U[_3/%&C_P#(
MPZ#CC_B>_P#4G]?7-9L/@_QA>1V$UAX5\27%MJEKJ.LZ-]CT;7O],T_1_P#D
M8=>\.^_@OITX_2ATJ+[ZN^\NFG]='97O8\W_ %>6C>)U[W?Y\US]<9/VHOV)
M[R^FU6;P-I]S?W'C+_A8%U=WGPJT'^U;OQO_ &%_PC?_  F6>_BK_A%O^)!_
M;YSXJ_X18\9&#7F:?$#_ ()G0Z)?^%H?V<_A/;^&-4.G_:M _P"&;O!O_".7
MAT?7O$GB3P^#X>_X17!_X0S7/$/B'Z?\))XMK\X_^$/\8&.YF_X13Q)]FM_#
MG_"9?;/[&U[_ )%?I_;W_8#&?^1P^OX+>> _'5G]O_M#P?XLM?[+NM/L-9^V
M>'->_P!#_MC_ )%[_P +/CKZ\9INC>UWM;[36SNMK=?R7H]O]78?]#+Y7E]V
M_P C]3IOC[^P3/XH\(>.)OA7X3NO%_PWT>PT;P'XL_X4MX-_X2/P%I^D?\B_
MH7@CQ!C^W]%T//0>#21P!VK8U_\ :@_8M\2ZAK&J^(?!-AXDO_%'_"+V'B.\
MUCX5:#JNJZ\/ FO?\))X)'B'@_VU_P (=XJ_XG_A3_H5?%(XYYK\H?\ A7OQ
M %U]D/@GQ9]O_P"$C_X0[[)_PCFOX_X2C.?^$-Q_T'/^I/\ _P!55K/P'XYO
M/L!L/!_BRY_M3^T!HWV/PYKV+S_A&^?$/_"/=O\ BC!_R-G/3)SZKV5+O+;N
M_P +)/KW?^>?^KM/^;YW=_6]_F?L+H_[97[*/AJVUFP\-Z7<:)8>(=9\4>*-
M9M]'\!_V5I>O>*-8U[^U_$.O:OP?[:USQGK?_(UYSGOZU\U?$CQ)^P)XP^#'
MQ(^"W@;P9I_P3\/?%"_\,7WC*]^&?P1\&^'/MFH:1XR\.>._^)MX>T;_ )#6
M/^$?SQQU!/>O@;_A#_&$T?G0^%?$GV;_ (1S_A*/M9T;7O\ D5^G]O\ _8#_
M .IP_KTL3>"?&$,=_--X5\26UMI=I8:SK-Y>:-KW^AZ?XD_Y%[7O$([_ /"9
M=Q^8]7]571S_ !?6ZWOL]OSVM>'X<P^'_P!WS"5V]=7UZ;GZ<WGQ@_X)TZCX
M'M_AC?\ P0^&^I?#?2]8&L6OP_O/V??!NJ^![36?^@]_PA/_  BH\/\ ]MYZ
M\9SS73?\-.?L0_:C?#P!H_V__A(_"_C$S_\ "H=!.J_\)/X$T'_A'/!'C+/&
M-;\&>%M)\/>'_"?B_IX5P,8YK\JIO ?CFSNKFTF\'^++:_M_$>G^%[ZTO/#F
MO?VI9^)]8Y\/:#Q_S'/^I/Z'UZ9(? ?CF\NK"PL/ WBRYN=4UG4/"]K9V?AS
M7@+SQ/HX/_"0Z%R<#7/7VQS0Z5];]]5)[/7?MU['2N':;:3S!V;2:N^K2=M?
M-GU+X]_X++_\$O\ 3?&7Q"TKQAHNNZCXGO+3_A5_Q&O;OX#_ -JGQ3X7T?7?
M$?\ Q1OB#Q <C6M#_P"$J\0>(#_PCYX!\2#())KUG]GK]O3_ ()T>//!OA[6
MO@MX T_PWX8^%_B/Q/8>!++1_@CI?@?_ (0/Q3J^@_\ %0'P1I.B_P#(%_X3
M+PMXA)SX,_'/ K^+#XY_!/XTZA\8?BCK>E?"7XH:EHWB#Q'\=O'^C:Q;^ _&
M6JZ5KW@CP)XQ\1CQOXQ\/>(?^$5_XG>B>#/[)U8>+-?_ .15\*\=^OZD?\$Z
M_AC\1?#?P(\0S>)/ 'CC1+:X\1?\+!M;S6/!NO:5]L\ :QX.\"#P]XR_[ ?C
M,_\ (I^,"<]>^0)]E1UU?WOJ[_FGZZKR7T>9\!93A,G6+PTLPO9:W>[LV][V
MUOTT/Z3/&/[0G[!/Q#\7>&/'_C_X5^%/&WCCPA_9_P#PB7C?Q;\%M!\1^(O"
MITC7AXD\/?\ "/:MK7_%0:)_Q50_X2#CJ<U:F_:$_83O-/\ [*E^&/ANYL/L
MOQ L?[,O/@MH)TK[!\4S_P 77/\ W54<>+#_ ,S5Q_PL?L:_+&;P)XYADOX9
MO _BRVN=+NM/L=9^V>'->Q9ZAK!_XI[01_V.?_,IG@<^O%5_^$$\<_:OL'_"
M'^+/MX\1?\(2;/\ X1S7N/%'_0FX_P"@YCC_ (0_.,=^]7[)?S/O^-^^BUZ6
MWWU/C%D%!?\ ,?)>7O+Y.S7H?J]KW[2'[#'BK6O!_B3Q5\.?#7B3Q!\._P#D
MG.O^(?A!H&JZIX#]/^$(\0ZU_P @4_\ 8F=1GKQ5:;]H_P#88O)+F:]^&OAR
MYFU2Z\?7]U>WGPAT'_3-0^*6@_\ ".>-M>)_ZG/PKC_A+>_BKIZ5^5</@CQA
M>?8/L'@_Q+<_VI_:']C_ &/PYKW^F?V/G_A(O^$?X'_(F=NY_DG_  A_C#9Y
MW_"+>)?)/AW_ (3$7O\ 8VO<^&/^1;_X3''3^P_^I@Z_CS3=)/=_GY=FNU_7
MU92R6C_/+UO+[]_F?JM_PTA^PQT_X5UX;_YD#_FD.@X/_"K#GX4]N?\ A51'
M_%*9'_%+?\TXZ9K&3XV?\$][2Z\<7\7P6^']M?\ Q(NM/O\ XC7MG\!_!PU;
MQX-(U[_A(_#W_";D>%1_;7_$[_XG_P#Q6?3/0GI^84W@GQA9PW\U_P"%?$EM
M;:7:Z??ZS>7FC:]_H>GZQ_R+W_"0]\>,_P"O>I9/A_X_CNKFSF\#>+/M]OXB
M_P"$.^R?\(YJ?_(S_P#0G#_J.'@_\(>/PH=)/1NZ[>7HFM-?0V_U=A:_]I/T
MO+MMO\C]2?$G[0_["7B2QU.'Q)\)?#7BVVU7QC_PL_6='UCX+>#=5_M[XG#0
M?^$;'C$C6O\ FHO]A^'M*T#_ (2_G_D7.HKX:_:4_:*U7X_>*+"^%A_8GA?P
MO:ZA8^'-&O/^0KW_ .$AU[Q .WIQQUKQ:S\!^.KS[#]@\'>++C^U+J_L+7['
MX;U[_3=0\.?\C!H.?7P9QC%+%X)\8WD=M+#X5\27-M<:-J'B>UO+/1M>_P!,
M\,:/_P C#KW?_B1_]3AVQFFJ=%;>NKOJ]7:\NM_RZ)&^ RC#4']9;;<;I7WZ
MK3>W?2VYRU%=1>>#_&%I'<S7_A;Q);6UOHVGZS=7EWHVO?Z'X7U?_D7]>_[
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M'_PJ_/\ PE7_ "3D^*C_ ,)!_P (?_R*OTK1U'X\?&_7?^$A_MOXQ_$_6O\
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MOB#_ .$=J?\ C5?_ (57\3O^B=?$'_PCM3_QH#^T,O[K_P "C_F4O^%@>/\
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MSQ1H_P#R+VO?]ASU_'')K\_/^"?NCZK#^SGI\-SI6H6W_%9>*.+RU[].>_\
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M?M#V'QI\27'@G1O"_P"S[I^L^!/B!_;/]E>'/ ?Q0\>?M!? CX/^"/&7C?\
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MT,FN?^$;KW^-6O\ ANC]G+_H9-8_\(W5/\:->S^Y_P"0?V3G7_0 _P#P*?\
MF?7U%?'O_#<W[./_ $-6N?\ A&Z[3_\ ANG]FS_H<+__ ,)+7O\ "B_K]QHL
MISK2V G=VU3EOIU3[GU_17X^_P##]G_@FA_T6GQ)_P"&?^(O_P RU?47@_\
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M4_X2KQ%_PE_PX\*>&,X/M_P?\2?L>?!_X5^,/A+8?M">./%NC^,-&_X1>_\
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M0^(!UC6#:>#?$9\8^%_'GQB\2?'?Q#X.\0>'OB!\$/$GA_\ L+_A*O&VK?\
M")^,/!H\+^*SX6\1?\E"YKU:T\)?L,1>*+#Q5-\:O$ES<Z9\;OCK^T$=+O+H
M_P!E7?BC]H[X8>(_A7XWT$X^'0_XD?\ PBOB'Q#_ ,(GG/BG_J:S3:TO1YVU
MZW;O9].EEV223M9W?+6P.5:6P/$#U6[E:_G9[=_+0]AA_;O\*G]B"W_;;O\
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MOX$>)[_XE_$#Q)H.J>-QI_[.'C(>._!'@T?V+\.?!6@?\*Z_X2G(\6$^&?\
MA*O%7_"2'_BK#P0K2=WRM7:TL[Z[Z=%=NZ5V];-7N],-@,&_KWUFA.UM-9WZ
M>>LMK6TN>X:]_P %*_V9]#\)_P#"530_%"YN;8_$^_\ $?A.S^%6O?\ "<>
M[#X$>,?#?@3XK_\ ";^'O^8*?!OBCQ#X>\/_ /<Q\=<UT&K_ +=_P2AUCQ]X
M&TH^([;QAX0T;XGV&C:SXL\!^,M*^&6N_$#X6^#?^$[\:_##_A-_^$6(UG7/
M!OA;_D:QX-Z_\(YXL]#G\O\ ]I7X2> -9\?Z/XA^"/Q4\)ZW;V>M?M'?%KP=
MJ_BS6?A=JH\"?M$?';QCX;\=^(==\;^'OBW^SI\6O#^M?![P;_PCWA[_ (13
M_A#? Q^-(_XJS'BLGQL<_4-E\$_V*+OQ1X@\8^)/VCO%FI7/B?\ X6]XGN_
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M ,!/&'_S4U7U[&?\^I??#0_,VE=[;OIYOR/DBBOK?_AI7X??]&F? ;_R\O\
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M++XC_P#R[H_X:%^"O_1HOPN_\++XC_\ R[J_[0Q__0+^,!^73MT/D:BOK?\
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M7M4\$_\ !/+X4?"O1[?QWJ%A=:!X?^+_ ,8_$>E7NH'0?#8_M[_B<ZV <?\
MNN4UF&8MZY))+^9U*;^=HROY_P!(_3<__P"2=6O3S_DC^I<HKZW_ .%^_ '_
M *,^\"?^'*^(O_R[IO\ PO;X _\ 1H'@3_PXOQ'_ /FHK7Z[B/\ H"?_ (%3
M_P S\Q^?YGR517UK_P +V^ /_1H'@3_PXOQ'_P#FHI__  OC]GO_ *,]\%_^
M'5^(G^-)9C)[X2:_\!?Y ?(]%?7'_"^/V>_^C/?!?_AU?B)_C3?^%[_L^?\
M1F_@_P#\.A\1JU^N?]2]_P#@4?\ ,#Y)HKZU_P"%X?LX_P#1G'A3_P .M\3Z
M?_PN_P#9R_Z,W\*_^'>^)W_Q-'UQ_P#0N?\ X%'_ ##Y_@SY'HKZX_X7?^SE
M_P!&;^%?_#O?$[_XFH_^%Z?LV?\ 1FGA7_P[WQ._^)H^N/\ Z%S_ / H_P"8
M?/\ !GR77\]/[<G_ "='\3_^Y'_]5CX;K^LK_A>/[-G_ $9OX;_\._\ %"OQ
MS_:O_:__ ."?/AOXZ>/M$\8?\$H/!OC_ ,3V?_",_;_&EQ^U]^T5X;U74<^$
M/#IQ_P (]HNM= . >N!SDY)AYABE:V3N5VEI**LKK7WFD[+7373T/L^#/^1F
M_G^I^!]%6+V>&:[NIH8/LUK]J)%D#G[$,\<]?;/7O5>O5_#R[>7R/U9[OU?Y
ML****!!7UE\#/V$OVQ?VG/"FK^._V?OV<_BQ\5_!.@27.F:SXH\+^$Q?:4;^
MR_X_-,\.ZL3_ ,3O6QD ^'_!G )&>N*^3:_J.T/QAX9_:V_X)I_\$^_AU^S_
M /\ !1_X!_L,>,OV3/\ A<%I\<OAY\4_CQKWP)\5:]J&KZI_;'A_XC>"?^$8
M \0?$#7/[#/B'Q@,9R/B1J&2/&& /G.(LYS#+E'ZA%RYI*+?+.22=[-J,9/5
MI1N[13=VUH!^(L/_  3N_;:F^",W[27_  SA\0_^%'6_@W4/&]U\1_LV@_\
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M7):_&#QEX#^&?_"1_%#XN>-]!^%_P'\9?&#PWXW\8^(?$/PD^!_C;P_\0?\
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M_P#"4?\ "*_\))XNS7UA_P :$/\ K+U^?[''^'U_R>&9_P"""/\ ?_X*[_\
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M_D!\E45]:_\ "'_L8_\ 17_C/_X;'0O_ )=T?\(?^QC_ -%?^,__ (;'0O\
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M_P#]'$_$?_PR_P#]^Z/[1CVG_P" R ^3**^L_P#A ?V/_P#HXGXC_P#AE_\
M[]T?\(#^Q_\ ]'$_$?\ \,O_ /?NG]?_ +L__ 9?Y@?)E?ST_MR?\G1_$_\
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MU?3/^")_[>NM_!K1_CKHG@_X=ZWX/\4_L_Z1^TSX<TNV^)7A@^-_%7PX\1Z
M?$I_X1[P2!_;_P#;?ASPKX@\/CQ:<XW>)/":9W<5R_ZPY'_T,8KI:ZNM$[6M
MV:\O,#\F:*_6;3/^")_[>NM_!K1_CKHG@_X=ZWX/\4_L_P"D?M,^'-+MOB5X
M8/C?Q5\./$>@'Q*?^$>\$@?V_P#VWX<\*^(/#X\6G.-WB3PFF=W%>5Z#_P $
MOOVI?%G[,WB']K#P>/A!XV^'?@_X<_\ "VO&/A/PG\8_AUXD^+7A7X7@ _\
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MOXH?#GQ'X6U/6/CQ\4/ 7@(:%\3-)S_PD&B>*1_PG&/"H_X3CPQX6RRG/B<
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M/I\([O"/NXM_-IZ_?U/Y-Z_H^_90_P"3<O@__P!B::_G!K^C[]E#_DW+X/\
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MHH **** WT>ST?H]_P #Z7T']L?]I/PKH.C^&]$^(O\ 9ND>']&T_1M&L_\
MA#?!NJ_8]/T?_BF_#W_,J\],\GTK6_X;D_:I_P"BGG_PD/A?_P#,K7RE10<#
MRK)W=O Q;ZNZWUOT[GU;_P -R?M4_P#13S_X2'PO_P#F5H_X;D_:I_Z*>?\
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M#TZ.4X;+D_8*RDM5IUT_4]W^'O[3GQP^%?ANV\*^ /'/]B^'K>[U"_\ L?\
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D<?\ "/'^6?7D**#HH8?*\NUP^!BF^MUN_EYA1110>COJ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %[ 08# 2(  A$! Q$!_\0
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M'!"@_*">!F:3\?\ XAV_BG6_BCJM[H^IWL'P1AUS2/"^@W%^= L?[1UGS_\
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MUSNP""#C&,_F#U'-%8O@3_D3_"G_ &+&B?\ I#%10!D1_P#)4;S_ +$?2_\
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MHG;5TZE2VMKIN_O)W>J6]134^Z/Q_F:=7TQ\J%%%% !6)KW_ "!-7_[!5_\
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MEC-]C&TKRX(/)(HO/V;/^"D0%_\ 8TT6<Q6-AX=T@/HL-M]IN!_R&]:E /\
MQ+5;G&K)^\?MUK/_ %UR3_HG,T=N_#>+Z=_]CMZ_/H:?\0WS=?\ -X>#N_\
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MV5[;7Z_C<^G"L37O^0)J_P#V"K__ -):VZQ->_Y FK_]@J__ /26@#+\"?\
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MT;PHEC:ZAI?BKQEX9AT32==BF>2+R=,)OKFZ5R8I&6.^CA:159@N%./CF_\
M^"6]I>?&SP=\=M.^*-UHGB[0/V@OC#\6/$:66A&/3?'/@/XCZ7JUKHWP]\3V
MZ2[;Z_\ A_JEY;W>D>)I,W@%SK)0J;MJ]A^!W_!-SX$_"GX%?#_X/ZA8ZQ>:
MQX0GTG5M?\7>#_%'C/P<?%?BBQEDE35;M=/UN-I+)6U!_P#B4R%[4J'!C/(
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M8VMD6R2QC )XP/<?A!^SA\(O@9JWBO6?AGX8B\/WWCNW\(6_BB<7\]R^IQ>
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M9TW5I-TZKI>TA[LXW_J5_P"$BT/I_;&F_A=1$?@?,Z>_^!H_X2+0O^@QIO\
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M_1$YM_X68?\ ^3#_ (@WX(?])(Y-_P"(CQ'_ /*C^HP^(-%'_,:TP_2\@_\
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M8FO?\@35_P#L%7__ *2UMUB:]_R!-7_[!5__ .DM &7X$_Y$_P *?]BQH?\
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M6-*UG3['5=&U"SU72=119+/4K&\M[VUG20'8\%U;R20RHW8H[8(;//%:X92
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MP[JEKJ.OQJVD1W$HBFO$D8K7SM\4?^"A]GX*_9A_9^_:'TWX9Z1N_:)\?R^
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MKW_($U?_ +!5_P#^DM;=8FO?\@35_P#L%7__ *2T 9?@3_D3_"G_ &+&A_\
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M\I)S7Z L_P"%\KRB.52P<\9'-U>I35*I/$TY22DXRK1A*,8Q<K>]*-U&WI^
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MFO?\@35_^P5?_P#I+0!E^!/^1/\ "G_8L:'_ .D,5%'@3_D3_"G_ &+&A_\
MI#%10!D1_P#)4;S_ +$?2_\ T[ZS7HU><Q_\E1O/^Q'TO_T[ZS7HU !1110
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M6*>/S;>^U74+>]CD8Z>63[ KT3,**** "BBB@ HHHH *Q->_Y FK_P#8*O\
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MI6F7$RAO(T^\EAEEZI&W6O3M-_9L\<>.9#??'#QFT5@8EDA^%_POOM0T3P^
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M+% EL23B=U\^ZO=3WEKV]NMQ=BQ=RQ)/?4#H/Z]?QHH **** "BBB@ HHHH
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MO<\'T*Y^.WQB%_;:Y?Z-^S]HJ-&VJ^%/#NK6'BGXP0VMPF^"YU/Q!#--X?\
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M_3OK->C5YS'_ ,E1O/\ L1]+_P#3OK->C4 %-\Q 5!= 6)51N&68!B549R2
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M:'_Z0Q44>!/^1/\ "G_8L:'_ .D,5% &1'_R5&\_[$?2_P#T[ZS7HU><Q_\
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M_,4 +129'J/S%!*X/S >^1Q1Z[ 9>(GE<M*K!F(5=RDY'!4#)Y 5L@<Y#$\
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MG54\-^)8XQ8.-+#SGRR?+&M1;YEO%_O%:3>EG'3=VU/U)>Y18-QSGY@0>Q4
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M_OSJ?_QFN^\N/_GFG_?*_P"%'EQ_\\T_[Y7_  H X'_A9?@7_H88O^_.I_\
MQFC_ (67X%_Z&&+_ +\ZG_\ &:[[RX_^>:?]\K_A1Y<?_/-/^^5_PH X'_A9
M?@7_ *&&+_OSJ?\ \9I#\2_ G(/B*'Z&'4OU'DUW_EQ_\\T_[Y7_  IK11$$
M^6G /\(]/I0!\N^)/"O[.WC;6]0\3^)](\.:QKE]X<N?"%WJ.HZ=<7,K^&Y9
MC<3Z='%(K10V\DG1H$%X[=_3E;3X2?LKZ>(C;Z%H2B*Z\/7H<IK#R+>>%L?\
M(Q, T1)_LT=.T0X.:^P(+6W6-\0I]['W<]\=_:IC:VY3)AC_ .^1ZUY5;(LC
MQF(>(KY=1E)65W&-VWJW?EZM7/7I9YFN#BL)ALTS*GA[:0CBZD5[J5KJ,TK*
M^B27H?(6C_"[]F'P_KUEXGT;P]X<M?$%EXAU/Q1INLI%J*RZ?K^M6A74]:B@
ME;[.CW'W&M0HRPX7<<5O^.O#/[/'Q%U"/5O&%IHVM7\&AZEH"7%Q#J4JG0M6
M*_VM8>3%$@'VO',>"6ZKC@5]*31IY8^1>=V?E'H?:GPQ1@#$:=<?='HWM[#_
M #FL_P"R,E]I]1_LVC]7O?DM&U[7[=_+JS!9QFEUFG]IYA]:^%5'B9N:3:NE
M)RYDO21\E0_#3]E^.=;R+0]%%W#KFB:XDLL6J+C6_#%M]@T&_P F+#"TA V2
M#Y5 SR,FL#7/@9^R=XE"+K'AW1+K&H:SJ9+-J\8EO_$QW:\LQ1$/V>[P X?,
M;=,=:^U_LUOC'DQ_]\C^?6H_+C_YYI_WRO\ A7+7R7AQR]F\FPSLVKN$&M/+
MEM8[X<2Y]1K^VI9WFT96LVL954M5?XE4OKS.]_T/D:'X5?LL6\J3Q:-HBSPZ
MW::ZKK%JG.N6FD'0+._&8L$V^D9M?,QM5< C/6HOP6_9(6T^S+X7\.BUETRT
MTIX?LU]_R#K76?[9LK8J<'_1]4_TQE."OWSQQ7VC]F@_YXQ_]\C_ #V_SDT?
M9H/^>,?_ 'R/\]OY^IJ_[ R;_H4Y9_X2T_\ Y$?^L^?_ /0[S?>_^^UN]_\
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MO6]WVZ'&?\+,\!_]#%#_ -^M2_\ C-+_ ,++\"_]##%_WYU/_P",UWGD0_\
M/-/^^13O+C_YYI_WRO\ A6P+8X'_ (67X%_Z&&+_ +\ZG_\ &:/^%E^!?^AA
MB_[\ZG_\9KOO+C_YYI_WRO\ A1Y<?_/-/^^5_P * .!_X67X%_Z&&+_OSJ?_
M ,9K#USQO::K8W&D>$8[O7]6OK?[#;M;V5_#I5I(V<SWU^\'D0!0>"[C)'6O
M6O+C_P">:?\ ?*_X54MD14;8B1[I!N\I%BW<=3Y87)]^M &;HFG+I6C:;I2+
<*8=/LK.WC8AO,)2$A]W .%;CV) -%=!10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %: BT# 2(  A$! Q$!_\0
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M (0+P_\ \^@KIN3U/Y4O0=Z .7_X0+0/^?2C_A O#_\ SZ5T^1ZTOXT <O\
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M'.?2DW<XQ2XX]* #CTHS1D&C(/% " C%+U%)QTQ2T (.<CTI>E''-(.1WXH
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M"(Y<Q+_%(.V:[_1? D%GXCU'4[V-)VF?*$BK/BOPK_PD4VFE"%@LY0YBQP:
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M$9'!H 7MTI,\4<Y]J#UH 4=*.:.*08H ,THZ4"C&: $SD=*4$#BD)&:#ZXH
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MH 4#BD( %&,BCH,4  QFC@4' ZT#')% !C/>C.#[4F<C)XI<YH 7BD.<\=*
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M--N-,\-VMM<_+-&O-;P8=<YH <?NFD3I2<!<9S21XP<$GZT .S\M*1D#G%%
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M#Z4 97B:T2[T.XC.1D=JS_!^DI8Z<&2;>3VK6UL%-'G Y.*@\-IMTE<]3WH
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MO8H L@-GYNE*#DGUI,,.^:=@T  SCFDY'848_.@9H 7)]*.?:D.>*1L\8[4
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M ,M4_P"^J\9^T3Y/[Z3[O]XTBW,^QOWTG_?1H ]G\^(C_6I_WU1Y\7_/5/\
MOJO&!<S[?]?)U_OFE-Q-D_OI.O\ >- 'LIGA./WJ?]]4>=#M_P!:G_?5>._:
M)_E_?2=/[QH^TSX_UTG_ 'T: 9[&)HQUF3_OJ@SQ?\]D_P"^J\<^T3_\]I/^
M^C3HKB;G]])_WT:!'L GAS_K4S_O4OG19_UJ?]]5X\;B;'^ND_[Z--^T3_\
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&^\:0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L %T# 2(  A$! Q$!_\0
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1QQEOO%% S]:MT %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $' @X# 2(  A$! Q$!_\0
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M0O\ "C_AW'^PG_T:1\!/_#:Z%_A7V[10!\1?\.X_V$_^C2/@)_X;70O\*/\
MAW'^PG_T:1\!/_#:Z%_A7V[10!\1?\.X_P!A/_HTCX"?^&UT+_"C_AW'^PG_
M -&D? 3_ ,-KH7^%?;M% 'Q%_P .X_V$_P#HTCX"?^&UT+_"C_AW'^PG_P!&
MD? 3_P -KH7^%?;M% 'Q%_P[C_83_P"C2/@)_P"&UT+_  H_X=Q_L)_]&D?
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M K3IM3^*MLU]$GP\T&SRR^#_ !&PRO?D#O\ A7]"\D?3!]>WZ'_/KQ7Y(_\
M!8/_ )(?\,?^RK)_ZB'B.@#ZJ_X)_?\ )E'[*G_9#?A]_P"H^*^S*^,_^"?O
M_)D?[*G_ &0OX7_^F&TK[,H **** "BBB@ HHHH **** &[OFV_U]L]*H><?
M?\A5D_\ +?\ #^M?D_\ M:_\%6/@Y^R#\;+_ .!_B#X7?&_XB^(?#WP@_P"&
M@O'FL?"?P9_PDFE> _AA_;W_  C8U[Q#@CT&0>3VQC- 'ZP>9L_'],?B*K>=
M^\Z_J?Y_7]>>E?C?\5_^"Q7[-GA/6-/TKX8^"?CI^TSGX:>%_C1X]UCX#^ _
M^$XL?A+\+_'F?^$>U[QN0>"<Y'A_D@<$ \CU_P"/W_!3/]EC]FL_LG0_%'Q#
MXDTU?VP]?T_1?A3_ ,4VWVRS&L:8"->\;@D#1M$*ZL.<':<@$\Y /TQ\_P#>
M?],>N/;_ /5^';/>CSC[_D*^1/VA/VM/A?\ LP:I\$=)^(O]L9_: ^*NG_"7
MP)>:/8'5?^*GUG3#K']J:KSQHO&"PYZ' R,7_P#AL7]EN6^MM*A_:,^#$]_<
M>([#PO\ 8S\2_#_^F>*-7.!H7#'[XY7IQ]X*?E !]:[_ -WTY_\ K_7U_3WH
M\_V_3_Z]?.$/[2'P'N/B,/@W#\8/AA_PM;%_CX:_\);H7_"5G^Q\_P#"0#_A
M'RV[([D_WN#G('+7_P"V'^S!9^%+_P 9ZA^T-\(+?P59^*?^$'NO$'_">:!_
MPCEGXXZ?\(?_ ,)#NQ_;A'..H'! /% 'UQYDW_/'_P >%5M\V/.Q_A]/IV].
M_O7A,WQG^&EK>7\UQ\1? UK!H=_X8M=9G'B+0O\ B0MXE(;P]IFK$$ ?\)%D
MGPH!RQ.<C'-.']HWX ._Q"BA^-?PWNKKX3W0L/B,1XRT 'P'J&K'('B$Y_XD
MO.>IQSSU- 'T7!W_ !_I1Y_M^G_UZ^5_"7[5O[-GQ$UO1/#?@3X]_";Q;XK\
M46VHGPYH_A[QWH.JZKK T<_\5 -(&2>!@$Y )&< ' U--_:>^ .KZ#XO\36'
MQO\ A9J?ACP7J9T;Q;X@M_%NA'2O"M^,#^P=6;. >> QR0<_PL0 ?2GG^WZ?
M_7JQ7P!XC_;]_9&\,>(OV??!E[\:/!.L7_[4_BW4/!OP7.@:R-5TKQ5XFT<@
M^(<>(5/ #,$R0#D'J"K'[MM7S)C!Y]3Z]^] &E1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 -9MN.,YI-X]#^G^-12_ZD_C_ #-?(G[2'[9G[,O[
M*$?AG_AH;XT>#OA3)XS.L1>$HO$,I^W:Z=' /B#^R>,CC!^O(]* /KOS_;]/
M_KT>?[?I_P#7KY*UC]KS]FKPQ\-O!/QF\0?'+X<:9\*_B7K6C^'/ ?Q O/$8
M/AWQ5J'B(X\/:7I6K9(_MM_P.",X;IS7QX_;>_91_9C\3>#O ?QU^.OP_P#A
MOXR\9GRO#FE^)+HB>\_XF>!_R!3_ ,2@Y]< C!YP"0#[:\_V_3_Z]2[QZ']/
M\:\#\._'?X2>+KSXCZ5X5\<^'-;NOA/J&/BI_9=T"? F="_X2/\ XJ''KH8!
MXZ 9)&*Z+X;_ !(\#?%OP;X?\??#OQ7H?C7P-XH O_"?BOP_=?VKI6NZ>>A#
M8!['Z8'W3U /7:*SA)L'F_Z.EMZ_X8XI?M'_ $T_S^5 &A16<LVWI+]H_P _
MEW'X]?6CS/WGD^?_ "Z_X=_Z4 :-%9TTW^?\],?_ *\YJM>28XQ_K^/7IQ[>
MF: -+S_;]/\ Z]'F;_P_7/XFN1UC7],T'2;O7=;O],TBPTNV.IZS>:G=&SL;
M.P&<ZH2 P&-I&21S\N=Q&:WAO7=*\6:=8>(?#VH:?J6CZW:_VAHVOZ7=?;M*
MU[3SWY(..N3[$#D8H [^BBB@ HHHH **** "BBB@ HHHH *_(7_@L)YW_"CO
MAAT_Y*LOWNN/^$0\1X_#K7Z[R?<;Z5^1/_!8;_DA_P ,_P#LK*?^H?XCH ^J
M_P#@GW_R9/\ LJ?]D'^&'_IA6OLZOC/_ ()_?\F6?LK_ /9!_A?_ .F(5]F4
M %%5Y/D]_P#)_P *Y[^V+#/G^=<8QCW_ ,<]_P#Z] '4T5RTVO6?3_B89Q_S
MZ_C^G]:L_P!NV7_3Q^9_QH Z"BN6_MZQ_P"HG_X!_P#UJ/[;L?[M_P#Y_&@#
MJ:*Y9]<L.YU ^X&#]!_D4?V]8_\ 43_\ _\ ZU '02=#_K^W3IVK\*_VD/\
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MW\F83I5QWZ\#( [_ .>]'VS51]FBBLQ[D\8 ]3[_ (?SH _BN^/W@/\ :%^
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M]*_(G_@K]_R0WX9?\>__ "56#_U#O$E?KM)]QOI7Y&?\%@_^2'_#'_LJR?\
MJ(>(Z /JK_@G[_R9'^RI_P!D+^%__IAM*^S*^,/^"?WE?\,5?LJ^G_"A_A?C
MU_Y  Q[XSGI7V?0!G7/F_P"D8_Y]>/KD]/USCOUXJ#3O^/"U_P ^E3W$GEQS
M$_\ /KT/TXX_/]:@T_\ X\[#_/>@">3]WU^S_C^/;\/\]*/.AFZ0\^O'?/T_
M/_&C!_YXC]:_GF^+WCS_ (*=I^T%X_A^#EM\8+GX/^'_ -I#X7Z-:^%/%G@+
MP;_Q7O@?'_%;_P#"$>(?^8+\.>!U_#/& #^AF'R9ND/X<#_ _EC\N:L_NO\
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M?B7X \/ZQH_A76_&OACPYXGURU^T^'?#^OZSI=AJMWW)&E';D#(P5SU(ZYP
M>D_ZOU!!]B<G].G^<UPOC#Q9X;\':#K'BGQ5JMOX;\,>'Q]OUG5]8U#^RK&S
M (^H[^N3UP:V8=8L-<TLZAHM_!J6FW'_ !ZW>E_\34WGZD<=?SYQS7QQK'P
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MQWX[5^W7D>_Z_P#UJ3\OM&/\^V,?YVT ?G__ ,$\_P!F_P"(O[+_ .S'X/\
M@_\ %?Q5H_C/Q_I^L^*-9\1:QH']J?\ ".6A\2:]_;']A>'O[9Z@9 Y_3@U^
M@,'?\?Z5*G3\?\*?0 4444 %%%% !5>2/]W]/Q ZX_+^?>K%% 'YX_\ !1#]
MG/QM^UI^RK\0?@5\/M>L_#?BWQA+X7N;7Q!JD)(L[#1]=W=<?\AO.0#P,\ @
MD"OB?P__ ,$E]?\ A-X9\ >#/@A^TK\0--\&>%[3X@'QE\,_%E_JECX'U[XH
M^/-,_P"2GZ4/#'_(%USPZ#D>'QGPKU&!QG]WO*A]/T/^%5O)_P">V+GT_ICG
M_.* /YFO!_\ P3$_:Y\-_L;?&G]G:_TKX-W.H?$_XJZ?\2?^$4@\8Z\/AEJ6
MG^!=I_L#52?^)^?^%K<>(/%F,C((Z@UZI^RS_P $U?VCO@S^V%\'_CQXA\2>
M#SX9TO\ 9X'PT^(VO_\ "2:[XCOO[/SCP]\,/!/A[6C_ ,24>#,$_P#"8GG
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MP5>\.>(KG2O!_P"T/X3\"_#?3/@@/AI:>'M \6Z_G7M0_M[/3C_A&-<\9_\
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MP/K/C/PG;ZSI>DZ5_9YU[_BGO^$(SV)_Y&SWZYS7[*_MB?LA_"C]M#X?Z/\
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M_P"O^?T_3FK/E0^GZ'_"B;_4S?\  OYB@#Q_6(8?^%O>!_\ 1N?^$;UC$_\
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M_$&J:Q_PGD_@>_\ MW@C0K\'!T+P\.,@9&>W/(]>^\7_ +?G[*GP_P#&/_"
M>(?BI9VWC"W^*VC_  ,/A^"US_Q<_6/^05H(QCGJ <G'!P<8KY@_X(U^&;_P
MO^P9\*M*F\(_#KPGIOVG6K_1C\/_ !'_ ,)P;O3LKC7?&WB''/Q%('S'((P
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M^N"">Q!]*]%KC;7_ $._L+"$00_Z ?LMG9Y^PV8[\ >Q/'7MD8SV5 !1110
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MQ9^W9\4/V:]-'C3_ (0SX4?#R\\;S?%6X@_T[Q'=C5[3'A\>'L8-GK@.6'B
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MVS7L"&X N-&_Y;GCKSV[]_<^O%=A%_J1^'\Q0!8HHHH **** "BBB@ HHHH
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MS!=;'  ZXZDGFOZ6_P#CW^GVGV_^L!G\?Q%?SA>)/^"@=MIW[=FA?#J'Q_\
ML^>)/!/_  O@?#_61:?L_:]_PG'PW(QX;_XF_C?) _X3/Q4!X?\ "GC <'GK
MG)_3?_@H?\0/VN?AO\ FU7]BOX7Q_%'XS7/CSPOHU_IQNE^VZ%X(_MX'Q#K_
M #\V5T,$]<<DD$@%0#[])QJ%M#V'/Y?R/8UT%>4:%>:E<?\ ",S:KFSO[CP[
MH]W=69M?]._M# _X2'^U#GCCL,<[CC->KT %%%% !1110 57G[?A_6K%9MY-
M-%#,XQQTZ< ?CQS_ )[4 >6:K_R6;PY_V)VH?^GX5ZI--_G_ #TQ_P#KSFOB
M#XE_&RY\%_$2Z\26W@?7/%UMX8/_  K^ZM_"=T-5\17GBC6?^03_ ,4^.<''
M?.?7L(Y[#]K?XP1_Z7J.C_LU>!KO(&EZ/;?\)Q\6KO3]O?5@?^$?T7L!@$C(
M/0DT ?1?Q)^,'P^^$^G_ -J_$'Q5H_AG()M8)+_[=JEYP!C2M*R3SZX( !SC
M"[OGZ/\ : ^-_P 7KC[!\!_@[>^&_#LG3XK_ !@SX<TKG'.D^",'Q!K1XQU
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M;/XH>&/"NDV&G?\ "/:IHVH:QXBN+@_\30'.!T/KP1^ ->LUY1K'_)9?!/\
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M\9?AWX5U*ZTOQ1K?]A?9KJPL+G4]7Q8:5]OSD#^UB0N<8&21SGD#I9_X7?\
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M\$9R>IP1])58H KU8\CW_7_ZU6** *_E0^GZ'_"K%%% !1110 4444 %%%%
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MH.NY/C+^U_$__$_'I_PC_'UY%?K;##Y7^?\ /'?GI0!@6?VF/6+GK]F^R?\
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MCXB_M?M%K/Q%TWQ)\+OV8_M7_%.?#.X_T'QQ\9=.[:]\5_\ H6=#QS_PA_\
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MD/\ "OF>']F_38='_P"$;A\3:Y_8)N?M_P!L.H?\5OG_ +&(<X]\=^O:G_\
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MM!^.?CDUY%H/BNP_9\^&4]@?,U^0_P#"1_&_Q5IYQQX>T@#'AG[OWF!8$MC
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MJG_Q[/;\?T%=;9^'/!EG'_H&E>&[;C/^CVFE\<<X[>Y^E<]?^-?A[I/C;0O
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M'P]X.U72<'^QO^$RZCCJ,<9!KZ=L_)X\F;/^B^H/I^'OG_\ 50! _P#R&_\
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M1K'_ ""=!/@CD:SH8[D9]1FOTM_Y9?Y_NU0_T.0XF^S_ (_@?\?3]:3S8?\
MGX_\FS0!H55D]NG_ "]8STX_#_/TJ+,/_/8?^!8HFFA\S_7?E=$?EUY]?PH
M_.'X\?!/]K;QU^V=^RE\5OAM\7O#?A[]F#X3CQ3=?&7X87 U2Q\1^+]0U?2R
M-)U0G&W*G(VGG Y!Y-?I)#'^[_<_X>F?Q]JK>?;_ //S;_\ @4?\*?YT/E^?
MYW?_ )^QT]/S_P >M $WDGW_ #%5IO\ 52_C_P"S4>?;_P#/S;_^!1_PK\P/
M^"IGC;]JCX;_ +/.F_$3]D*S\1ZW\5_!_P 1?"^C7/@?P_:_VJ=?\,>._P#B
MF[S5-64C&/!?]KCQAG)_Y!'TR 3?M/\ [/?[5WQ!_:N_9(^+7PE^)EAIWP9^
M$^M:Q_PM_P ":CK&IZ58W@))'C#^R5 &MZVF=H&,X&268[C^H7G>9_GO_GZ?
MRK^2_P"&?[6G_!8;X#Z+K%M\0OA5XD^-GB?P/\:?"_[-U_X@\6>'-4L?"NOZ
M/HX_M?\ X6AI/]B<?\5F/$'_  C_ /PD&.*Z_P >?M\?\%??%%OJ?BKP9^QQ
MK&B>(?AG^TCH^C7_ ,)[+1M>_P")G\+\8\0GQ%XA&/\ A)]#_P"8_P#\4[QC
MCC% ']4.3_SV'ZTO[GR^V,>_7_#_ -EKA/"NL3:YX;\/:K+-_I.J:-I]_P#Z
M9:_V7JO.?^82>GMVP<"NQDFLO+\G[9T_'W]/\/KC% 'YA_M@?LW_ +37Q8_:
MH_8Q^(_P1\<_\(E\+O@WXHU&_P#B_H__  D1TH:]IV2!_P 4]@#6R.!QD^N>
MM?J+^YF_+Z?Y_E^?,,-Q9_OL3V_'_3UZ_P"1ZU+YEMGR?.[XS]J/KG.<X]\?
MIWH 7[&?;\S_ (T?ZF'M_P#K_P _EZ=H<P_\]A_X%BI?M$*=;NWQZ&ZZ?SQ_
M6@#\:OVV?V3_ -J_XN^+OB[XP^!'Q3U"VL/&'P@\,>$=/^'UWXS/AW2;/Q/X
M;\9G6-5.DDA3HI(P3K^,*> 6 S7Z=_!WP_XJ\,?#3X?>'O'/B$>*?&&B>$M/
MT;Q'XDSSJ>L8')]QPO?  [5Z9YUAYG_+O^7M^77]/:IOW/\ T[]O^/>Z[<?X
M?3F@"SY)]_S%$T?R>;W'/Y_CZG_'M4.8?^>P_P# L4?N?^6M_P#0?:OIZ=>A
MH _*/]N+]F/]H_XG^-/%GC_X(>*KCQ#IGBC]F[Q1\(!\*-8^(.O>#O#EG\0-
M9U[^U_#OQ/\ ^)*>OA[/\AWK[=^ ?A#Q5X"^#_P:\&>-+^_U;Q/X6^'6CZ-X
MBN+VY.JZK=^*!H/_ !-<ZL3R01D' [8'!)]^S8?\_-O_ .!7_P!>JT__ "%+
M#Z?T- &[_P L_P#/]ZLG1_\ 5W7_ %]'^=:4O^I/X_S-8^C_ .KN9L?\O)^F
M._3Z\=>WX@'05G70B$$W/DD <D#M[=OSZ_A5GS_;]/\ Z]% 'YS_ !D_8=\*
M_&7]J[X+?M4:CX[US0]3^$]@;6Y\$6=AG2M>S_R"2VK9SHW/7USUZFOT.$8\
MP$1?9QZ\<_EC'/MBE\N+_GB/L^/UQZ9Z8XQGK[\U9\_V_3_Z] %>H+S_ %8Z
M\XQ:<=O\Y].>,9-7_/\ ;]/_ *]'F_\ 3+_/_?- 'P#\:/V3[GXQ_M(_LY_'
MF_\ '%A;:!^S_<ZSK?\ PK>?P9H.J_V]XGUCIKO_  FO+:*<=@,9Z#)VG[UL
MSYGG9[G!S_G_ .O2_N>/.]./3/\ /UQFK'FP^OZG_&@ \CW_ %_^M3;O_5?G
M3O/]OT_^O2><?^>$_P"1_P#BJ /S]^*W[#?A7XP?M??L\?M@W_Q(^(.A>)OV
M=[7Q/8:-X'T:_/\ PA&O:?XC[ZMI.<\^W/TS7WU##_GO[^P[?TZT<^9YV?T]
MNG3T_P#U59\_V_3_ .O2LNR^Y?Y 5O0S0_R]^W2N5U76]*LQ':7]WI]C]H^W
MC_B9W8L?M@T@C)!)'R]SSD@< GKV<DG3 ]>_ZG_/KS7Y1_\ !5#]DSXQ?M9_
M 3PSX8_9S\2Z?X*^+OA?XG^%[\>(-4N_L.DCP1K!_P"$;^*^EGG^+PMP ?3C
MD@TP.[\>?L;>!OC#^VG\"?VR-,^*&H:3XK^#?A/6=&_X0G2+G3-5TKQ3X8\1
M_P#())!*G1E)  QG.1@@'=7WM/J.E:?>0PWE_96%UJ%U_HMO<?Z#>WAZ8 )/
M]LC\QGJ<U_++\-O^"5__  4T_9_T2QT'X'_M#Z5HD.E?'?3]&T>X'B?5-5\5
MC]F#PW@_"D>-]6UHC_A)O^$-US^UC_PA_ICCO70^*/\ @G__ ,%D?&UI;Z_X
MG_:BT.Y\;> _VB]/^*'@SQ!_PD7V'2[OPO@?\)#H/AY3SX8T3Q%TP1GV'2@#
M^J2.3KD?K^H_SZ<TDGE21#/^J/7_ /4?\C-<5X6_M!='TB'4+8:;?_V-I_\
M:EO]O_M7[)J(P#_Q4) &L\YXY&,'/.!VWFP^OZG_ !H _/#XP_L+>&_C)^V5
M^SQ^V#?^-M8TS7?V<[#6-'\.^%+?3/\ B57EAXCQU/&.?1?R.*_0:&'_ #W]
M_8=OZ=:L^?[?I_\ 7J/S/:X_/_ZU %RL[49)H8/W(^I[_G[U9\_V_3_Z]$DG
M3 ]>_P"I_P ^O- 'Y _M$_\ !+#X9?'CXH>,/BK9^.-=\ ZSX[\9?#[Q/XHM
M]'TL7OVP>!& )^8C_B>>(!R>^T?*"<"OU<T.SMK:SL[*'S_^)78Z?:#[1Z8_
MF<5L^2??\Q1'###)B&'_ #_G\.YH LU5O/-\N?R?OX]O_P!?Y5:\S9^/Z8_$
M4>?[?I_]>@#\G?V@O^";GAWXS^)?C!XA\(?$O_A6T_QW\=?!CQA\5/\ BC=!
M\2?VD/A8>-"_XG6,GQ$,<'@$XR0 3^G^AZ>-*TZUL(3_ *-96FGVMK_HV#@#
M!/X9'TSU&*VOW,/Y?7_/\ORXL_\ 77_/^>?N_A0!C_\ ,Q?]N?\ 2N@KGS_R
M&+G_ *]1_*N@H KR_P"I/X_S-?D3_P %@?\ DAGPS_[*TO\ ZB'B.OUVE_U)
M_'^9K\D?^"P?_)#_ (8_]E63_P!1#Q'0!]5?\$_?^3(_V5/^R%_"_P#],-I7
MV)/V_#^M?$'[">N:+8?L7?LMK<W@Q;_ ;X7W^>>^@C_ZX([_ (U]??\ "4:)
MY?[Z][?G_C_]?I0!L3?\\?\ EB/Q^@S[_I^-4/['L/\ GVM_\_\  :S_ /A*
M-%C!$-_;7/\ ]?TP?>I_^$NT3_H(6WYG_&@"S_8UA_SXZ?\ E1_9MA_SX:?^
M7_UZH?\ "8:)_P _X_,?X58_X2K2O^?D?D* )_[-L/\ GPM_R_\ KT?V-8?\
M^.G_ )5G_P#"6Z!_S_\ ^?SIO_"8:)]H\G[?_I/3['_G_P#5V]Z -+^Q[#_G
MVT__ #_P&C^Q[#_GVT__ #_P&J \8:)-C]]_GGCM[_YQ5K_A*M"_Y_Q^= $D
M.D6T/_+A8?7'3OG_ #Q2_P!C6'_/CI_Y5G_\)1X:_P"?ZII?%&AQ_OOM_;\/
MY?Y_D 6O[&L/^?'3_P J/[&L/^?'3_RJC_PF'A[S/^0A_G%2?\)AX?\ ^@A0
M!9?2+;R\?9K#\CUY[XP>:7^RK#_GVTO\JS_^$MT#_G__ ,_G4W_"8>'_ /H(
M4 6IM'L)A^^L-.SSUXZ^O;_/Y3&SAS--Y-O]I-KC_1QCUZ?TSP>WJ*7_  E6
ME?\ /R/R%5_^$JT3_G_M[;Z\]OZ?R_4 O_8^/^7;[-CWZY_/\?\ ]=6?L?[S
MM_GW^OO[^]8__"4:)')_Q_V]M_U\''//3G&/Y9X-'_"8:)_S_P!M^8_PH O_
M -DVWS_Z';_O\]><'_/TYZFC^Q[#R\0V&GG^GX@?IQT_.A_PE6E?\_(_(5,O
MC#1)/]3<B0_3']: %_L:P_Y\=/\ RI(='L,X^P:?W']?\]N?6H?^$PT3R_\
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M/Q#\.?\ "&W-YX?NOL/B33-/U@?\@$=^^.* /C#PI^WYKB)\"->^-'@#P/\
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MIY\9?\)Y_8/IK7_%59%?5'QK^$NB?M">$[;P-XYFU&V\'W&LZ?K/B/P_I?\
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M/"^G^(O[4_Y@.G:/H/\ PCGAW0?! X.B^%?^$5/OGZ\4 >7> OVH=;^)]OX
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MV)_GFK&L?M:?LV:/H-MXAO\ XJ6]MX8U31O[8M?$$&C:]JNE?\3?_F ^(?\
MJ.<9'@\X!].IKEO&'[%GPI\=^,/&WCSQ#>>-4\3^,-9U#6?M%Q=:"?[!U#6-
M!/AO^WO#WXG/([=:YSPE^Q)\'_!_A._\&SZUXS\2?#&Y\=V'Q)_X5_KYSI=G
MXV\"'IR ?[#.M@$CVZG&: /6[/\ :B_9[O)K#[!\1;?[3X@T87=KI=Y:_P!D
MZK9_]0'_ *@NN=?Z56L_VEO@/>:Q8:)8?$ZW_MBXNM0L+6S^R?\ 'G?Z/_R,
M.@^(1Z>_?BO*/$G[#?PE\2:Y\4=;F\7^.--O_BA\1?"_QGNA9?V6/^$5\?\
MAOG_ (E/_4$_ZE\=L#BL>;_@GQ\%]2T&Y\-ZWXD^)&I:/_Q7]_:ZQ_;7_%1V
M?BCQV/\ BH=>_P"$@SQQG_BCZ /2/'G[8WP0\*^ /'_C#PWXJM_&VL>#[7_D
M4[.USJNO>*/^9>X[Z'XR_4U\J?\ !3&[\2ZK^RE\%K_48-*T+7]5^)6D:YKW
MA^!OM@T"^UGX<ZQ=G3=W) 4$OTQP!7L<_P#P3V^$MY=:/+-XY^)&H_V7X<\
M>%_$=I9'0=)/BK_A!->'B3P__P )"?RX^F<\5Y__ ,%9IOLGP#^&SW\,'G7G
MQ?%Q\_)Y\'>(AZ_UH [?X1WGC"'_ ()=_"C_ (5CI6H:E\4?^&0?A]8>#?\
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MCA^V3X<\+^'K/XF^)/'/PV^T#3[6ZM[S1O\ BN/^%?GK\;M6_P"Q,US^R?\
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M_MV_ W6-8UOP?X/\67.@_%S6?[9^(UGH_P#8.J_\(K_PGFO?\(YX=\9>'O\
MH-:X=$TGT]J_9CPWXVT3QAX;\/>.?"NO6^I>'O&%J-8\)7EY_P 2K5=>]_\
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M>>G:.?T_[%"M+PWXDL/%7A_1O%6B7]Q<>'O$&B_VSHVL?\_FGZOH/_%/=/\
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M[9]J_P")J/Z9 _/F@"M-YTT9AF^SW/\ VZ^AY_SV_2B'[3#_ *X?Z3]J]/\
MF(?YS]/QQ5GR9II+F'R3<W/V7'/6][<9_P D]JY>7QWX4'Q$N?A7%?@?$<>'
M!XQNM+M_^7/PP< :[]2>,=^  : -_P []WC_ ,"O?]>._P#C1_I6[_IV_7_]
M?Z?A6E]DFFM/M_\ VX9L^1WY[_X9_*C['-]H_P!3;W/K[>WMST_#U- &;F:'
M]\.H[_KTX_R3WH^T30Q_OIK>Y^S_ /'K9CW[#^7;GWS5G_GVA^W_ .C7'^G_
M /'U_P 2K'3^OX?ABN8\'^//"OQ"M=8U7P-?_P!M^'O#^L_V-=:QS_95YJ/_
M %+WB$X_MO0_\/2@#>A\[_EB+?\ Y_\ [9>=L?YZ<?F*)_M//_/S@X_3'X],
M]_2M*&SF\SR?L%O]IM[7BSR?\^WY<^O*^)/$FE>"_"^L>.?%6J_V)X5\/VO]
ML^(]8L_^7/3_ -?\YZ\4 =#-YWF0]/T_7W_^O5;$_EVT,WV?[-_R]?8^_P#G
M'3\>>]71[[3_ !-I&E^*M ,]UH/B?1QK'AV\LCG2KNPU@ X/4@X(P.O(]16Y
M_9M_>26T/V/'VC_E\_Y\\'_D _Y_#TH S?\ EG^YFM\_YZ]SZY^OM1^^N(B9
MA]I_TK[?_GBO/_"OQ<\ _$+Q%K'A7PMJO]I:QX?\1ZAX-UG1_LQTK5;/Q1H_
M/B#0<X!_XHT8)&,9Z$]:] N(9H8[F:;_ $C[/_Q]7G_,*O.>A_Q_6@ S--)^
MY_TG[/\ Y]O\]AP:!UMO^/?[3_QX?YQ]./>H;S6-$TW4/"NB:J;?3;_Q1=?8
M-&M_^0J;P@^G^/U]:O\ DW\/V87\/_+T.WMU]_7GO^% %;S._G=_^/S]<?\
MUO7\ZLPS3?\ ;Q<8_P!#_P /\X_&N8L_'G@__A8 ^%<.MV^I>.3X-/BC^QM'
MM?[5TJS\+_\ (M_\C#[#M]/?'3G39O\ 1?)^SW/_ "X?8_M7_'YZ<>_;C.*
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M_D:N1CK7W1^S/\*_'_P?^!7B?1/$,.AZ;\;_ !YXC^*'Q!\>?V/_ ,372O\
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MR2>:^T/M'[SSL_Z1]E_Y<SG)_P#U'G'O1^XACMH9H;?[-_RZV?;'^?7_ /4
M?F_H_P"Q]\1;.UL-*U73_"ESH_BGXJ_!^_\ BKX3L]9_XE7A7X/_  'T#_A&
M_!'@WP]T_MK7/&?BK_BH/QKJ?VEOV9OVA/BUXD\,36WQ$TKQ_P"'?"]U\4/%
M'AS^U+7_ (0?5?AOXH\2Z#_PCG@G_A'O^$8Q_;?_  AAYX[GKD\_H!^_\S_4
MFYXZ_E_GWYHAA\GI_P >UN/]*!_S_7B@#\IO$G[&?[1N@ZC?^%?AUXYU"Y\
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M_P )#X@_P[_KC-^^CMOW(_'&E>W3I]<<U/YW[SSICG_E_P#]#_Y?-0'4^Y-
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MYN[%-0^&&G:C<?!S7OMMIH?;P\"/"N#HH[*.?;O4&E_MK?\ !.?PWI6J>%-
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MS_\ !.>+PG8:*/%5L? =O?\ VK1O#?\ PJ#QE_8=GXHR?^)G_97_  BO8_\
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MPX\9Y[^PX'X?3O21_P#!1?\ 8QDD(_X6MXPR.+?/PY\9#;D>P[^^WW/J45T
M0I_P44_8P\_SO^%H^+<_9?\ HG/C+G]/7/Y?G./^"C'[&ACN3+\4_%I^T=<?
M#GQECT[?3VHHH C/_!2?]BR[Q_Q>'Q..W_).O&(Y_P#"5]O2D_X>2_L4XN?^
M+P^*/7_DG/C+Z#_F5<?G110!<D_X*)_L:C_7?%+Q.>QQ\-/&/OC]?\:K_P##
MQ7]C QPS?\+3\6[;C_1?^2<>,\_B.F.?\]RB@!?^'B/[%V_RI?BGXM\WOCX<
M>,\<9[C/^1^:/_P44_8T2W^V2?%/Q9+"/^7<_#GQD!Z=3BBB@",?\%'_ -BO
M]Y_Q=?Q>?LO_ !^?\6U\9?Z7]<CH/0U.G_!1G]C.T,TS_%+Q1']GZ^1\-?&2
M_B..3T %%% $9_X*+?L72Q_NOBIXP'G\9/PY\9?D>!]#U_Q='_P45_8QYQ\4
M_%N)O^/?_BW'C/CZ^G;KCOUHHH $_P""C/[&A3]U\4_%@Z_\TX\9>_K_ (5-
M_P /%_V-#_K?BGXM,N.WPY\9D=SZ<C\J** (#_P4@_8P7B3XM>,)?^Z:^,AT
M_+V_STM?\/$_V-+3_CZ^*GBVX)Z?\6Y\9#\_SY_2BB@"#_AXQ^QMY6/^%I>)
M_P#PVOC+_=_S^?M5?_AY!^QJLA\GXM^+T^T=1_PK7QCQ_P#J^E%% &@/^"CG
M[&<_FX^*/BA/(_ZIIXR]N>X/7I[U1_X>.?L7&/R?^%K^*/\ 2,_9O^+7^,OW
M/3\\DXY(_*BB@!UQ_P %)/V)HA^Y^+?B0?:+G[#S\.O&0X/ /_(J]Z_.O_@I
MY^WC^RUXC_9\^'D.E?$/6=7MH?C MP#?> O&5FT6[P?XC3"KW^]CCBBBL<1_
%[<P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %+ G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_#S_ &_3
M_P"O1Y_M^G_UZ//]OT_^O5;SC[_D*YP+/G^WZ?\ UZ//]OT_^O5?S9O7]1_C
M119]G]S_ ,@+'G^WZ?\ UZ*KU8HL^S^Y_P"0!Y_M^G_UZ))/W?UZGU__ %_S
MQQ5:XZ?A_0U#-YW/_P!?\?P]/?I19]G]S_R O^;#Z_J?\:L5D?OH?M'DXNL?
M\N_UJ;[9#&>,>G/^?;J?_P!?0!9HJMYQ]_R%6?/]OT_^O0 0=_Q_I5:\N+:S
MA_?'C&/S_P ]A5GS_;]/_KU1FFF\O/\ H_K_ )]C[XKG _A<_P""G'PQT3]H
M3_@MIX_\ >,?@-XD_:TT?2_V;O\ BG/A/9ZR-*TKPIXH_L'_ )#V0/J:]6_8
M_P#VZ/C]\ _^": \#_#KXW_#^Y^/'A?XJZC\/M&\#?%#_D*?";PQX;*X^&'A
M[P]HO.1CCG SR"<5^Z/[5O\ P1S^ /[5'Q[UC]I*;Q]\4/A;\5_$'@/_ (0C
M6/%GPN\2?\(YJMYIW..<=QCM@9(]">)UO_@AA^QZ_P ._ /A#P+I_B3P#XP\
M!7VL:R/BOHU^!XEU_4=8S_:P\;$D#6BV0!G&.<G!X /RG\5?\%S/VPOB!^QW
M\*/BK\,?ACH>AZ]X@\>:Q\/OB-\0.-5_X176-'Y_Y%X^OY5Z/\9O^"W_ ,:;
M/X?_ +-7P[^"I^&^M_&[XRZ+K&L^(_'_ -J&JZ3H)\!Y/B+0CX>P#EB>3GT(
MP2Q/Z37'_!%']FS2_@C;_!;P-XA\6> --M]9UC6O[8\/WXS>:AK'_(5_M8'L
M1W.!G\:S/$G_  0O_8]O/@G\./A#X)A\0> -8^%^L_VUX<^*^CWY_P"$X^WD
MD:KSQG(Y(Q@'N1BNC0#\D]2_;,\8?M+?M0?LG?%KQSHG_" :A>? ?XP6'CWX
M?ZO_ ,@KQYJ&CZ#_ ,R\/S_+L:]?^&?[<W[3]I\._P!E?X%?L;>!O ^B^*OC
M9:_%'6=9O/$&/^)#_P ('ZC'3'7MU'%?K[HG_!*#]G#3[GX;ZK<S>)=8\5^
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M/C_1\_\ 'Q_7^M3:=>?:/.^O?]3VZ#U]_0URV?9_<QFU15?][_G=6/\ :O\
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MYO\ Q9GX6GCC:#\O7CD<9]L]#2?\1AG_  4!_P"B,_"[\C_\37\FO^NCN?\
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M/Z#]/YU#_P 1AO[?\4<.?A1\,L<];4\CVX/'H.F/>OY+[+R8;2YQ#_GT./\
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MP_Z/;6W'Z_7N?\,<US^W\OS_ ,P]AY_U]Q_839_\'<7[?DVE_;YO@Y\-N/\
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M?^NG[6R_\'#G_!6&-.?VCKW'M89/;U*_S]?6H(_^#B;_ (*Q/T_:1U3/J;#
M_P#'21V_.OQ)(A'_ #]?GG^568;/SOWT/X^G'^'I_C7S^(P_U;3H[K\['>?N
MUX<_X.$/^"KFH7G[[]H2X/M>Z?CG_/0XYQZ8%:&L?\%_O^"LOF?9H?VA+BVM
M_P#IS'Z_A]*_$[PK#80W=S-#_P"3G_U^GZ_TKH9M2G\RY_?6]S;7''^AY_\
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M&/\ KU_IQU/T'Z5^4$$L/^IA_+K[]<_K[=:H/=3V:8EQZ8_D.P_.C_5+!_\
M0OC;O9??\-O,V6?XON_O?^9^K,G_  <"?\%7_,\G_AH[4/-X_P"73G^?'KC)
MQQUJ?_A_Q_P5EF'DS?M&ZAW'VPZ?CTXZCGW]J_(>;_6>=Q_(?GS]?SJ;R?\
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M_P CG/?K\^\2F]^OZ_XCTS\[OBQ9V'@/PO\ VKK<UO\ VQJF?LMO>8_S_/\
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M^=-[_9^/K[^_]<'%;$$/DVOG>=SS@8^O;O\ YR<UWY9]K^NYXN(_]N9T\/\
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M1X?WP^T\X_P^F:V)IO\ )_S^0SZDFJVCPV%YH=MY,W_$P_7OQ[?Y^M$W[O\
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M\S^2WQ7'#_;VLVWG?R_S[>OL>M<]9V?VR[ Z?SY_#/&3^6>*V->FF_MC6/\
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MNULF?MO#7#=DF[;*6NG2Y[3H'AN'R[:+[';VW_7G:]_3U]QTKWC3=,AU2/\
MLJ&;[*,_YZ?U]>O<\-X#TV_FM;F::Y_T;^74<<_U^O7%?0_A7PWBU^W_ *XQ
M_P#J]<?G7YY]7>+UU[[O7\?G>Y[->O\ 5,5T=M.C6CMT_K[CP'XJ_ W2OB1X
M3O\ PW?_ &>Y_M2U^P8O+7_/J/UYK\%O"LWCG]B']H*Y^"VMS#4O WBC_CUU
MCG'&??\ .OZJ8;.&73[:'RA=7/\ RZ^G?\/\_A7X>_\ !3[X8Z5XDU[PK]@/
MV:__ .)>-9O+/']J_P"(X_SUKSZ]T_-/\F_\CU\-F&G_  .]_P#@?@?JS\!O
M"^E:/9VVJ^3;ZE;7&C?:O]#[^_Z^V/?FO>=-T.'4M4N9K^;[3_9?_+GZ]?IC
MO_D5\&_L6^/+^;P%H_P<\57]Q_;&J?\ (N7A_P"@?_G/XU^G.FP_V;'<PPP?
MZ-_S^'Z8/Y?_ *N@%>]EG^T6]/ZW?]=3PLPQ#>)N[]=_Z_KR,&;P_80Q?\>'
M?VQ^/^<=ZFO/"NE0_8)O^7;OSV]_J?J,_6NP^QF\M?)\[MQ^?_U_R]#5"&'_
M $7R9?P_P_SCKSUY]?$8?_+^MOZ_'SE7UVZK\_4_&?\ X*9?"OR=+MO%7D_Z
M+I=UVZ?7^O\ /V_CV^/'G:]\6K#SOL]T+?\ T#[/9W7M[_3K^-?WX?M@:/\
M\))\'_&'G0?\P;[?CK_G/OQT]\?P8>/(;"S\6>)]5FA-MJ5O=:AGO_/\>/7K
M6>'P_P#EI_7]?GZ_M[K;I^GJ9N@Z;#-I=_#9P_Z-^'IVX]14.I:'Y.EVT,/_
M !\ZIWL_PSG_ #FO3OA+X5.L:#<_;YKC[,/]/_[B&/7./H,US.L:EY.O6UAI
M7^DW^EW7^>?\BO6]@_Z_X8YSE_[!\F6PL+";_B36_P#Q]=3_ ,3#\N>O3O\
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M_K\=SPLQP_USFMKH^E^]C^+'_@MS_P $V[#]GWQ'8?M4_ NT/_"J?'7B,_\
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MJ&WR_2)Z^'PS6_3NGT]5_6NIG:E"89+;_0/3_P"M^'XYKL/A[H_G6M_YL/\
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M;]3R9=^5===D_P #\ZM]8Q5K;.VU^O\ 7WAYT/F?Z?-QW[?F>]>H_LT^#_\
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M?X5?#KPUJ%SXA\0:R+#6KS1\?R'Y_I7G8C#Z_/\ K3^MOO[\LVEZ/\I'T/\
M\$S?ACHL7BW]H']JCXJ_9M%M=3UC6+&U\0WO'., ?D.2>O\ +8TG2/$O_!2S
M]J/P_P"+M4TK^S?V9_@/K7V"UM+P\>*M0! YX^IYX//O5KPK\!_C?\3OA?X
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MU]\_ABNYL]2\G[3#W_K_ )],'D8KA]-EL(?^OG\^O\N?\]ZT89OW?^>,>_\
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M .KZ ]:\_P"L/M/[V=&Y^Z_[.OQ;T2\\+V'A76[#[-X_M[7[!=6=Y_R^Z?\
MKTZ?UK[_ +R&:'PO;?\ $JN/7G&?7'>OY\OV&]>TKXA:A_PKKX\>,/\ A /C
M!X#NO[&M;R\/_(>[]/IS^M?T7>"?"OBK0[6PL)M;_P"$DL+<?8/MF/KZ]_K[
MUZV6+%.U]4WUOM?2VYY.(P_R_K_@_P!=/D[QM\'];\;7MSJO@:;^S=8M[7[+
M]C[GK]/6M+X _L;S>#O$ESXP\<PV]SK'VK_E\]_Q_(^E??\ H^CPFZOQ#I7V
M;']G_P"F$?TY_K7?_9+"\^WV%M_I/V?^S_M7VS\O_P!?KU-?4_V6[7U[_J<O
MUCZI=7_I^?X6./T?P?86>H6U_-#_ *?;\@=3_P#J_P#K&NQFF\G[?^^_TG_C
M_P#MG\_Z_P#UZL6>FS32?^3V,]#[<?Y]A5::'SK7M]I_Y>K+MZ@?Y]^>U:X?
M#ZVVZ?I_7]6X'B&[[ZW_ !OYA9^3-'<X_P!&^T6O_'GS_P#J_D.?QKH;.X\F
MSMX8?L]STQ]H_P ?Q_SVLV>FZ?\ 9>O/7_3,?7IGWQU[56AA^Q^3U_P_#K^'
MZUTXBV$O;6_SW^\YM6<]Y/G2>=/^?^>GKWZYQ6Q#9V,Q_P"OC^T/]+_Y\_\
M/3\^U&HS?N_)_P"/;_)X_7]?6N8@U*&:UN?._P"H>+7^G^>_K7S^(>E_ZZGH
M'0S0^='_ *ZX_P!(X_R.?\^M9ODPPQ^1_P ?/K@__7Z=_2NJBF\G_7?]NO\
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M ,?G\O\ Z_\ 6OR._P""R7PK_P"%A?\ !/\ ^/&E30_\@O1O[9/VP'_F6_\
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M'^.?;Z#-?SGQ"F\3;=-V?7NO/N?H& LL/YZ^O^9@^/(?L>C^</\ /3TY.?\
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MO#09K^\MK#S?])/_ #^<?TZ_@>OXUY=J7_"*_$C_ (1[QSX;^SVUMJEJ+_\
MT/\ ^OQV_P \5ZOX)A$,=A;?_6[9YP1_D5Y-GV?W/_(ZL1?ZP[=I>G]=CU**
MSA_T;SOS//Y?EZ5WVFP3^7;6%A#]F]<=>/3^7UZ8[T-'TV#CWNO\]^/UKL(;
M/_3_ #S_ )Z]ORX^G/>O>PV'V^6GR77^NNIX^(>NKZ]7YR\SU'PW>>3)]@F[
M'O\ GT_#T'M6QK%YYTGD_P#+L?KV]O;OP*X:&\\F2YY_$?YZGW_"K,.L6$UU
M_P!.QZ_GCC_/X5[.'P_Z?U?_ (/?45O+\/\ @';:;_JQ#YWKR>,^WZY[?A6Q
M--Y$F?\ GW[^_P"G^>F*P=-\G[+_ -//&<?T_3^G>MB&;R8_.O\ _CY^OOS[
M^GYYKHK[_P!>9SV\OP_X!O3?OK6VFF@N/Z>WI_GZYK2O)O\ 3+:'SS_QZ]__
M -8&/RXST[\!#XDFL_\ EL+D?_7]_P"7ICKBMZ;7H8;6VFSZ=OK^/_Z_H*\\
MZ"_--Y,G^N^TW/O_ )QD\=<]>]>(?&S7H?#>@W_B2;_CYM[7[?=<_KGC_P"O
M70ZEK!AU3S_.Y]Q_7^O'85\3_MF>,)I/"?AWPW!]H_M#Q1K.+J\L^OO^7^17
MGYAB-&O*VGH>QE&'WNO-?T_Z\CY^^ ^C?\)YXH\0^/\ 5?\ B6_VI=?\2;[9
M_P OFG\?CZ8_IUK]0?!]GYUK;0^3]IYZ?CZ]_I_A7R+\)=-L+/0='L!]GN?[
M+M?^//G^?IU_#/:OLGP?-FT_<W/V;CW_ ,CIS[_G7-E>J=UTZ_/N=^:;?+]#
MV_P_Y,-C_J;?[3Q_7_ZWKWYKJO[3^Q_:?WUQW(_7_/KS]*X;39IH?^6W7CZ_
M_K_P[5I:_---:_;_ #LVW]?;\_?^5>QB-%IVZ?,\?#T'N[_U]ZZ_UTX_QOJ7
M[P8_Z_Q>8_#-?RS_ /!Q;K'D_ GX0P^3]IN;GQ&,VEYR<9]!C/7Z#WK^F[QC
M--<QVUAY/_3A]LL_UYZ?KW]Z_E$_X.2]<^QZ!\"=!E%Q;77]M<6?L,8_#K^/
M;M7ZEX6ZX^/77UZGQW&J?U1Z?9?_ *3(_E9A_<_ZG\.2?\X],5T,,ES<>G^>
MG'U_+OCO0AA\Z,30_7_]9/MG%7[.$R75M_R[6O\ ];M^OITQ7]N</Z45_A7Y
M(_G'$]?5_G(V?#D/VOQ7X8M!@&X\1Z=_I9]]<Y^HQ_/GK@_ZIG[,VFV&C_ '
MX/:)8#]SIG@/PN?],[_\2$_IW_"O\N+X<6<-Y\4_AA8><;FVN/&'AC'VP\8.
MO8Y^N?H?2O\ 4U^#OG0_#?P=;?Z/;6P\.>&/LOV.UX'_ !(NW;\.U?!<>;_,
MX&[_ -?U_7S/\?+7IICK.L=;D9/%YR3V]?3\_:N>FFA_T;]S_D^O;\R?QKH?
M%5Y#-KU_@<Y/L3@]>_3W^HK'N(89K6V_?^O^??/IZ'H:_ \;B']0:;UL]'?L
M_F?T/@_]]7;\-U\C]O\ _@B%IL,WQM\3W_G9N;?1A_/_ #_]:O[(?AO]O\SS
M_P#EV[C''K_A7\A'_!#?_D9/B1?_ /+S]EZ]_3/Z#].QK^P'X7_O-/T?]]<?
M\>I^U<YST_'\_J:_A7Q15\XG\_S/Z X>_P!P7HOR/=YIK^SM?.AL+>YMLXSZ
M>WOW_K7SK^U%\/=*^(7PO\0S3:5_RZF_T;[9WQ^/\\_EFOL#1YK:;2[F&>PM
MOLUL#_Q./Q]_\GG\>/\ B1H/]I:':PPCIHQ'^DCK^7MZU^.8C#[O^OZ_KU^P
MH=?G^A_/Q\$_$FJV?A>YTJYFN/[8\,77V#_]?Z<G\LU];_VEYVE_8)O])N>O
M_P"KN.?I7Q/K'G>"?C)K%A-8"UL-4UDX_P"@5SU_^MV_D/J+3=2FF^TGSO\
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M *\^F?IT%=--<?8[JVTK58?[;T^X(/VC//Y>WMGIDBN8\2^&]*\*VOV^YO\
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M%6;/Q)_RYS=O^7SOT_S]/3C->&V4,VI?8(<BV'^?_P!?3T]*OQS3:9)Y,/\
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M]JSZY]OPZ^U?:9AB/]D\^7UMI_7R^\K#[OOS+??_ #/Z;?\ @CI-##\'+_\
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MM_7_  ?ZZ<QYOY/]O:!;3W]A_I__ *1^_P#G'3&*S=2UZQTV.VT^;%M?V_\
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M06_^CZ-_I?K_ )^O;]>G#9?M]^_K_P  PQ-\(G:][/N^CU/K'P1#-9VOV_\
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M3YT_D^=_I/XYS_3/K^5?SCC=I>GZ,_IS#;_*/YH_;G_@C#J?V/QIXYMIH?\
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MZ#TZYZU6\'_"N;0<S2WUP?\ /O\ UZ5]!A\0OJW^=K_UH88C$:?*_P#7]?\
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M#K<L/V:Y_P"%=?C_ %_+)^AZU]\S3?O/.QVY_F/;U_#J:_%7_@MM\2(?!/\
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M?^7TQ7TAH]G8:]);&_\ [/\ L%OQ:_Z5]/3^0_'TKXPTW1["\M=/\[/VD?\
M+YS^.,<=?\/:OI#PWY.CQ^3YWVFVMO\ E[X^G4?_ *Q[BOGCS[/L_N?^1]#V
M0T2;[!80VW^DZ7Z>G/IZ8Y]_:O0H?L$,=M--]H]1_7CT_ISWKY.\-^*IKSQ(
M?.F^S6W3TZ''^?R'2OIC_A+-*O(Q#HDUOJ-_;\C[9C^6?;Z_C71KY_B>=B<,
M];I]>C\_+^M#UC39KF&UMI[#_2K;_/\ CVXKO_)FO-+UB'_1_LUQ_P OGO\
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M;_A*+K^V<YSQ_GZ5^B_@F[\F3)A_TGM_GIQ[U^>/[/<T.F_#/PQI4W^C6O\
M8VG_ /'X3],?YX^E?<_@^::;_KY_X\/\/_U8]/I7?@FN9:K\.XLU7N[?9_1G
MV!X5N+'4C#_+GUX_EW_ 5ZO;30V?V"PAS]IZ?8_UX^O'O7@/A6;R;4_\^W_+
MV/IC/?Z_7%>S:;#Y,?\ I_\ HUR,_EC_ *&'Z=<X_P /J$U9:K9?DC\YQ/\
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M;PM^K6_F_P#@GL'AKXG>9J']GPV%Q_H_^?KQ_@<5]/:;XDAO-/OX8?\ 1O\
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M:4,W_'__ *-VQ_G/X]P?6JUG-YUU_KOLO_7YCUY';(_3M]+,UGTFFA_R0?\
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MT/X;U+SH_P"?7_/?'^2*^2/!.L>3);>=";G_ $7_ #U.?I7T_P"&M2^V1_\
M3M_SY_YZ^OZ?7[?*VKO5;KJO/S/D,T5EIVZ'T/H_]GPVH\Z;_2;C]>?\]>AY
MKN;/YH_]=[_KQZ_C_.O-_"MGYUJ?^?;_ #W]C_05[!9PQ0Q_U.?IZ#VKZ![/
MT?Y,\#$;_/I\SX__ &BM'FU+1\^OZ'Z?Y]J_/?1[PV=]<^3_ *3;=?\ /;_Z
MYZ&OU9^/T,(\-^=_H_\ QZXZ?3\C^GYU^4T=F/M5_-#_ *-;?:CQW_S[U\QF
M>Z]?U9WY9]K^NY]@^%9H?] F\[_CX_Y<\_TYQTKW?38=/FZ_:._)_P ].?\
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MX\.I?"_P?I7_ #Y_E>?H/KQ^%?:<9X?_ (QW+W;["N_1-7;U_/IU.'A3$?\
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MNC[X_P C%>;7Z?+]3NP&8*SM;9]%V9[?X/O?#^I:786$U_\ 9O[+Q_H?^?\
MZ]?0_AOQA-X/N[#^U9K?[-JO_'IS[YS[_3]*^:?%7@_089+;7M*_T;_GZL_;
M]!U^F?Y^G>%?L'BJRMH=5_XEMS;_ /'KV^V?X>_;\*YSAQ/^UM_/\WW]=#ZZ
M_L'PK_:AOX=5^S7]Q_RY]_Q_+W]S7M^C_P!E:;I]M#?_ -GD?\_EYSZ^OZ]^
MWO7C_A7P38?9;;59O]*O_P#G\ZC..F.![9''YU?U[PWI7B2TO[#[?<?Z1S_H
M>/?K_G@]17H'B8C#_5'I^']/O\SV"\TW2M?_ .05-;W-MZ_Y_P#U?K7E&I>!
M_"UG)<W_ /97VF^M^N./Z_A_^JCP3X)F\*_N8=5N/LW?[9_C_+/'X4>)=-U6
M'0?$4-A]HN;F\'7]/\?IQFC$;]/E\S$^>/CEKW]D:1?^3_SZ^O\ Q*OQ_P#U
M]O6OYK?VEO$DVL?&?X/V'V#_ )F/[!=V9]_7G(Q_G-?N%\9KS^S='O\ 2O$E
M_P#Z?VLS=?X]/I^5?@M\3C_;'[0OPW\G[1_H_C+KQ_/T]^M<]#K\_P!#OH5_
MJ_G?_AKJ]S]W_ >CZ5_9]A^YN/\ 1[7'Z_G^'/<#FOK+P?IL-Q:_N?L_U/\
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M/KSUKPW#Y$GG0P\>V<8_S[]_2O?O!YF$?G<#_ISQG_Z_^<]Z\0\$P_8Y<?\
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M>A\[Q9AUB, ^MDWKZ/Y]C_/&AF^V6MA?Y^TW,]AZ\]N#_7Z<5I>3-#CTN/\
MCUY.>OX_R_I5+6M-O_#7B#Q1X4F^T6UAH?B36#;<8U7GD=3_ )S^-:FCS0S1
M^=-#]F^V=.F?Y]>HYY^M?Z1\,XEXS+XM/>,6M=](O1W\S^6<]PW+)K16;Z)=
M?ZON;4,.J6<=]#+FVZ9\C'UXQV/&/?.>M&AII\VHV'VR6XN;8_\ 'T/^G_\
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M^/GI_+\.W7_ZU?SD?MF?#T^%?&7AZ;[ +;^R]9_X_+/U_P#U^V<>E:4,/O\
M-:>C_K^M/1P^(^L/M:VA^CNF7$W]EW/_ "\VVEZ-_P >>3^' Y'Y_P"%>M?#
M'Q5#-=^3_P ?-M]E M;/V_7UX/X^F?+O!^FW_BKX7Z/?^3]J^TZ-_9_?^?\
M3^70\3YVMZ#KEM#86-Q;_P"B\\>_3]>O./QKKRU:RTZOIYL[L0O\OS/V)\$Z
MQ83WEMZV]KU'^>.G7\.._IVL:E_Q*[GR9ORSG/\ ^K^M?*_PKTW[9I=MJO\
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M^>??_P"O7Q_X),VL1CSN+;Z^_P!".X_^L*^TO@GIM_+)Y,/_ !X6_MCZ]O\
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M_P 2;_3>.W]![]J^0S=/#XFR5_ZU/T/*\P.A\!WFJ^%?^)K?S?:;;5+K_P
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M  CNC9]<X_ECIC\>*_Q;OV7HYH?VJ/V:YL_\U>\+<=L?\) .W2O]I'P-&/\
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M;\#[$^%>FW\,=M_:L/\ 7'^'^>]?HEX)TV&SCMO(_P!&-Q8?Y^G7H.E?GO\
M"6'[9):YA'^A_P#+Y>77?_'_ #UK]$?#>F^=:VUM-_HWZ?KV_2N#),O^^_\
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M  K^*/Q)^"&J_P#$MN=+\1ZAK-IV^V?]"]] .1UQQQQ7]0_B"$PQW,)O^?\
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MY[G_  K[ T'4IM-'[[I_/U^@_P \5P97N_5?J&:/7Y]/5GIVO:E#!I?DW_\
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MJOV^X^T7'^@6MYR?KW_I^=?FI]H_W]^VOY/TO>WW>9X/^U=XPAO-%\0ZK/\
M\22ZTNU^P6MG>$_AWS_G\OY;_P!EW]L8_ ']HCQ#/K<V='\7^(_['UD9_P")
M59\G_B??4=AS^F1^[_[6>I^)(? &L7^JS?VE<_9-0^U7G<]L_C_]>OY#M8@^
MV>)/&'[ZXU*VN/M_VJ\^R\V>H9'_ -;/O]*_8>!\GPN-PKNE)M:==>G1]>A^
M?9YB'@\5U2OW_P""O^ ?WX?!GXD>&_&WA>P\8>&[^W\2V%Q_I_\ H=U_Q-?Y
M]?\ /4U]U>%?[*U*.PGAOQ<W.J?\?7/_ !Y]O7MT]P/PK_.^_9C_ &ZOBU^R
MOK%A%HFJW&M^&#_Q]:/_ $YP/7MUXK^I']D#_@J+\"_C3;VV@GQ3;^"-2N/^
M/JRO<_\ (0XP><?YS7SO%? N+P^)EBE!N*;UC%V6]KV5E?I>U]4KO;MRC/,*
M]&U=JVK7;=7?]:']"UG###:BPR/LOIQT!X'\_P"HJ&'P3I5YJMM-#>7%M]GN
MOM_^B8_E^1]A^%?/WA7Q)K6I:?83PS6^MV%QQ:_8[K/MSTZ\_P ^HKVG3=8_
M=V]__I'V^W_Y=+/ISQ]?Q/\ ]:OSEX;%8-ZIVUT:>VM]U^![/UF+U3B_1I_E
M(]XT>8PXFAU6X_LW_EZ^V#Z9_P \>W:NAL[RP^U?OOPO!_+]./T["O!//UO3
M8_\ CP^S77_'_P#Z9=?VK]L]_IC\ZZ'3?&&E326WG?\ 'S_];WZC_/M2]OY?
MA_P0>(5GML^W;U/H'^WH9M/N?>ZZ^O'Z>OKZ^W:Z/J5A>6MM##I7^GV^?\_E
M_AQTKRG3IH;R/R1-;_\ /_P?P^GX^]=SIL4,W^G]/^O,9_GCK_2O8P^(_37[
MO/\ K70\A[OY_J;VI^*K#3?.\ZQ_T?C_ #V_SQ4,,?\ :%K;7\)M_P#B:8(L
M_P#/M]?I2_8_./DZA]GS_G_]7/0X_#H8;/R8_P!S!SG^7_ZOS-=&(:Q?5?>O
M\S#ZP[]?Z^9AS>%;";3[CSK#_CX_R/UY_P \^/\ B3X;V&CZ??ZM8?Z-^?'^
M?_KGW]XFU*'S+:'SNF?I^'X#O_\ KAO(;#4K7R9L#_/OW'X<8KF]@K/5=>J[
M>AM7Q#Z7Z=_+U_K\/G71M-FUCR;";I;_ /+YZ_YZ]\=^370Z;H]_H\MR;_\
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M&O%MK;_\?5G]J_XFOTX]_IT]Z^9Q&58E;)I:[)[:^7D=^'S'"OM=^??K^/\
M6I[?>:Q]C_<S?Z-;>_X_3^6?J*LZ;+#K$G?]?_K?3V_*N0\57$,UKY$T/]FV
MW_+K>=N_Y?CW'3UJZ/-?G[!]@F_M+K8?Z'C\\_Y_'K7DV?9_<_\ ([[I[-?>
M>M?OIOLT,/M_QY=/\/\ /O6QIEG?YML?:+G[,!]/J?I7/V?^LMH8;_\ T_C_
M $/VZ\C/;G_/7K]'FOYK7SKG[3]FTOU_SZ^_X#FE9]G]S_R.<V(>+7]\?]&N
M.G7^7?WQSSUHALYH;7R8?7^?^'/8_P S5_\ LV_FDMINWU_0_P \=JTH?/AN
MK:8>W^A_YY'3C^?ITT$]=']S\O(7UA>7]?,(;V::/R?L'X_GZ9_P'X5?AA\_
M_EPP/Z_EZ_Y%;']FSS_OH?LWT_3VY_/ KT?3=-L/,^QS0W'VGIU_K_3GU^OK
M^P?G^/\ \B8UWKOUZ/U\S@8=(FG'G>GN/3Z\_P!?TK8^Q^3'G_2+;KG_ #U[
MCO\ 2NYU+_A&[/[3#-?V]M<_\NMG[#_/)XQTXQ7&64WG?N9H?[2N?^G.U_SW
M^OUS72L-+L^G1_\ R)YU_/\ '_@G0Z#_ *'=?ZFXMO\ K\^O8GCIC_ZU>A6<
MW[L_\O/'T[CW/..@_GVXS-A#'_Q._P#B6GG_ (_+K\^?3&.G^%>;^,/VG/V<
MOA7:_;_'/QH^'^B:;_T^>(\?Y_3_ !]W#X=]G]WEZ>?]=,/K#\_Z^9],V<T,
M/2;Z?@/Y'\O2NALO)FNOM_\ R\VY_P"/RT_'Z>V??\Z_"7XX?\%YOV&/A)=7
M]AI6MZA\2+^W_P"A?_Y!1^G?K],=Z_'_ .,/_!S5\5-8D_LKX#_#JWT2PN/^
M7R\NOUZ__6KTJ&2?7-_ZW[G-_:&&H;W^;U_'K_PQ_95XJU+_ (1_3[_6[^_M
M[;_K\_T'T]1C_P"L*_)?]JC_ (**_LS? #2[G5?%7Q&T/6]3_P"A3L[LW_?]
M/Y^]?Q2_'C_@J!^W#\>/[0F\<_%JXTW1[RZ_Y _A.Z_LK(]/\]. >E?!/BC7
M?%6L:I8:KXJO]0\27YS]E^V7?^3^=;/*UA%LMG?;S'_:C\_Q/VP\8_\ !3__
M (:$_;1T_5-/L/[$\#7%H;#1C>=\GZ^@ _QZ5_1=\&=8AO-'\[[?S<#[?]>W
M^>.GK7^?OH]YJT/C/PQK?AO2KC4O$/A_6?[9NK/1\_Z'I_K^/?/Z5_;E^Q/X
MD/C?X7:-XJ.1<W&C#_0_3U'3K^&.E>'B,.K]%K^O_!_'[OILOQ%UUU]?\OU^
M\_8#PK-#>6MM8_I[8_0=!G]:[_3?)LXQUQZ?EQZ?_JKP?P=KWD_9LS?:;;H?
M\_R_7KBO49KR:;_4]_;Z?IW[BMO8>?X_\ Z<1M\OTD>KPZEY,?\ R[Y_S_C^
M';C%<!XJ\F:UL+_SK?\ X]>?H/7\^W3Z\5O6=[I7V6VAF_X_Q_GZ>OO]:XGQ
MO/Y-K;0P_P#/A_R^?Y _SFNS#4+8_+GTNMNNJ_K5?,^>EM+TE^4C^)C_ (+#
MWHO/VMI_._L__D#-T'N.WMS^?O7Y6U^E?_!6V\\[]K[5=/-S]IN=,\.'G[5[
MC'Z?7.?PK\WH?)FNOWTUQ]FY/U_SS]?H./[D\/O^11'T7_MI^!<2+_A8D[::
M_P#MY)!IL\UK<W__ "X?_K_7O_3I6GI,TNI:CI$,W_+OG_CWM??_ #T'],\]
MYWG?N?T_IWQC'X].V*Z&SO=*M]0AGAS;6WMQZ_T]<5^GK9>B_)'RSO=Z=>WJ
M?$_C2\/]O:Q#V^U<^N!Z_P#Z_P Q7/?\^W[[WZ_@<G_/OWKH?%,.-9UCR?M&
M1T&>W^>/Y^V/'^[CA_Z]?H?R_#.*_P W\3A[XEZZ._IU^7];']04-]/Z>C/O
M'_@G/K$6B?'S3+"YNC;?VIQ]LL_3.1CDXY)_'KU)K^O;X0>)/L]U<PV'0\?;
M/M1_TL?3K^7]:_B?_97\1_\ "-_'CX;W_DG \1Z?H_X<#C/U_EBO["?A[-]C
MNKGR8?M-M]K_ -%O?;\NIS^7>OYG\4\/[#%7[MV?H_TT^9^T\ 8A_5K;Z[/]
M?Z_X/U1J5[Y7BBVOX9N__'G_ "_4^GZ5VW_"27]YIXAFZ_:N/MG^'X\?X5XS
M-J1U+[-/--]I_P"G.X)ST_+J1BNV_MB:6,0_I_/IW]/\Y_&*^_3Y?,_3CY8_
M:8\*CQAJGA[X=:3,+FY\477V#6??^O-?@?\ \%)OV ];_97L?#WCGP3#J&HZ
M-JF+_P 27O7'O^7X^QQ7[\> M4_M[]HRYFU6;'_"/X_L8\XK[_\ C]^SKHG[
M77[._C_X5B'[3XAU2T%_X<O/Z'_/IZ&OON!^)/[+DD]N97OM:Z77YGP'%F =
M=-J^SMI_E\C_ #J='O-*UG[3/!-_9NH<W7^F9_LK/'?'^?P-:$$5_IL=K?Z6
M;C3;G_G[TC_D*]/48_SCGFN@^.7P/\<_ ;QQXP^&/C_1+C1/$/@_6?L!L[SU
M/O\ AG^F!D^7V^L>*M!^PS0S6]Q]GSBSZY]!_P#7';MV'](IX3.,*I>Z]$V_
M=?1/K=-=UJO+0_&W];P6*>K2N^_GZ:GZ@?LZ_P#!4K]JW]G632-$MO$EQXMT
M:WZ#6+KIGH!Q_G'/.:_HH_9=_P""^?[/?Q"DL/#_ ,8+#7/A=XYU3_0/^$@_
MYA7\_P#(%?Q;V?BKPWJ4EM_:O_$MN1_R^6?J/I[^W2NVL]&^V6_E7D/]MVW)
M^V6?_(5_G_2OD,XX2R;&)^ZDW?X8J-V[]E9*[M96TLK:(]W <28K#[M]M;O2
M_FW_ %N?Z<'@OXR_#'XG>%_[5\#>/_"?B2V_Y\[/63_:O\JLZ/>V%G=>=JO^
MC6V,?;/\]ORK_-8\!?%KXT?"76+:_P#A7\3?$GAO[/\ Z?;8NL?8_P# _3CI
M]:_5_P"!O_!<C]J[X8FPA^(NE:%\6K"VYM?MG^?S/<\5^99IX<=<*GWV?KV^
MX]W#<2IM-M:OOYJ_7U^:/[M[/6/L>C_Z[_3[C_CU^Q_\OG\^O/.?K78>&_%4
MUY]FL+;S_P"F.O\ 6OYP_@#_ ,%\/V0O&GVFS^($.N?"Z_O.?$?VS]?^$>_P
M-?JK\*_VNOV9OB1_Q4O@[XQ^&[;_ *_-9]?R[_A["OGGP7F4=&K6\CZ!9UA6
MMWJNZZ_\.?JA#J1FDMOWUN,#F\/^'^<UL6=Y-_:AF\ZW^P=_TX_PZ_CV^#[/
M]J#X.:;'_P E4^']S88_X]/[9_P_#G_Z]8^I?MR?LS6=U_IWQI\#VUL?^7.S
MNO\ CSX_IU/7UKF_U3Q7][_R;_(PYD];KONO7N?>%YX\T2SU"VA_<7-_<9SW
MZ#WX/;\/PJS-J4,P'[G[-_\ K_P&3QVK\IO&W_!0C]CS3M0_MS_A?&CW/V,?
M\N5USU_#_#WKP?7O^"WG[%O@FUOX;_Q_<>)+G)^R_P!C_P!.YXY_#MFO2P_"
M>*\WKUO^OJS?^T%A];I_=T^;WWZ=S]L-2AAO+4>3-]IMO3W_ ,_EQ7'S:/?W
M&)M*A^TVW^/M_GGOQ7\PWQF_X.7O"NEQ_P!E_!;X+7&MW_/V#Q9K'_$JTKO_
M /7SFOR@^/W_  7$_P""B/QFCN?L'CGPW\-[#5,V%UH_A_\ XE6?I[\_G7L8
M;@"5=]5=]G^.AX^)XD7==7T/[J-8\;:)X/C_ .*J\5>&_"5M_P O=GX@UG'_
M -;U[^O2OC;XG?\ !2W]C/X/W5_?^*OCQX;^WZ7Q]C\/W7]JY&3_ %_SV/\
MGL^-OC9\<OB==7.J_%3XU?$CQ)<_\>'_ ",1_LKC^5>#S3>=)=?VM#<:E]GZ
M6?']/K^'/OGZ;#^&%E=^5_ZM_P '3<\C_6SS_P#)C^WCXM?\'('[)'AO]SX&
M\-^+/']S;G_C\O+'_B5?T['CWK\OOC!_P<7?M)^-I+GPW\%OACH?@FVG_M#_
M (_.=5_S_G/6OYYK*WUN&/SH8=/TVP^RX^R<_P".?T[>]?3/[.O[,?Q4_:\^
M(VC_  Q^"&B:YXM\3SW6GV%UXLL]&_XE5G_D9]Q7M8?A#"Y7O:ZWOY>>M_\
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M6>O/^?SY^M?I3_P3'\;2Z'\3+_1)9\VVJ76?L9XZC\/7%?SIQ9A]7ZO]?/\
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MHZSX"\<>(.?[=T_G_B0\<D^N1GH>.M?U07GP#\ SVM]]O\*V^FW-O_I^L_\
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MWN=*^'7AOPWX)L+C_CZO/^8MU_S[?S/\\$WVGS/^G;CZ=_PQ]/YU-YT,/O\
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MXUC_ )"OX'KV_7/I7C/@GX2ZM\!_C)_PKJ&'[+H^J9O]&L_\>./Z]^*_H?\
M$FFZ5_QX9_<W'_3KQ[_X]:_,?]M[P'=:#H/ACXM6$-S_ ,)5X#NC8_;+,_\
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M!B2VB_Y97%KDG\2>HY_^N:Z+7/\ D-ZP>_S<]^U<_JWW[?\ Z]?ZU_GEB?\
M=EZ']%8??3OU[Z'7_#V\FT?QOX8,)^S?9]9T^_\ M??MS],'CG/'/&*_LX^#
M^L33:#X8\Z'_ (^/#NGZS88X_P#U]",?A7\6/AC_ )&+0O\ L,G_ -EK^OWX
M)WUW_P (/X0_TB3CPWI^/FK^;O%)>[%]T_S:/U?@AO37^4^Y]-L_.D_Y^O\
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MGIO_ #"O!VE:AK?B'5+K_D4[>U_XFMG^'Y8Z4GAV[N?L7B ><_[BZT_R>?\
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M&BX^ _P:DTS5=-?X:^$FL;L$W%J=)@\J4@'[RX]NQ%>WE;LON.#$_P#MS/\
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M9;6V1_IMYX<_XE7UYQUK_9DM?^";_P"P@&<C]E3X-9R?^92M/_BJZ&+]@_\
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HAP5S_P ]#WKZU>-N)=E_9S_\"A_\D<>)X;POU6[:ULM+]?DM.Z/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $X ?H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^M[]G7]F_
MX#^,/@=X&U6_\#6V/LO?J,=B,8QSCCH?SKW/_AD7X ?]"/!^G^-'[)F/^&</
MA_'YPS_8H&>^.OY5]+1^=YGX=^OX]L>OMCVH ^98?V-?V<H;@7/_  K'2[F;
MCF\Y]3[9_0YJ+_ACG]G.S^T>5X T^V-QC./4?3TYQ^7:OICSI?+\['[WI^&.
MGY<^M>"?M(?$CQ5\)_ =UX[\-^'K?Q(=#_X^K.X/('U!SG_Z^/8 PA^QS^SK
M-GSO &GW,W7K_3&.<]J3_AD7]G+S/W/@#3[:YG_Y\\_IU'O[#\#7QMXH_P""
MF'_".?#V_P#B7;?"O4-1T:SM?]*LLXU7^T.^?SXSP.WOZ'^S%^WG!^T'K.D>
M')O"I\-WYT;[?K5G>DG5!]!G Y]!R>: /H^;]D;]GN7_ $&?P!;7  )/H!U]
MOS[_ (57_P"&+?V;/^B=:7_G\:^A_.M--^TW]S/]F]/MEUZ'_.*TH9H9K?[?
MZYZ_YSU/Z?6@#YOC_8[_ &>P/)/PZTX  'Z#U[<_3U[4O_#&?[.?_1.=/_\
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M8M_9L_Z)UI?^?QJU_P ,9_LY_P#1.=/_ /'O\*^B_M@FE\KC[/TSW[]2.?\
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MGU%6?*A]/T/^% 'RZ?V._P!GN09_X0#3_P#2/KZ'KG\?<U!-^Q;^SE-()O\
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M?Z!GI].1Z9_PYQ7>!L>?[?I_]>O-OBB9C\/_ !%^YS_Q)\9SGGC@\]AG\Z]
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MC+<?\>P^U9S@'/'.>OISZ'() &^))\^'];E[BUO[7!_'!_GQ_P#7-<W\-_\
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MK^YL+C[?<_Z>;.\ST_3\^.>?IT,/,$,TT/V:X_EW_EVZ^N: ->BBB@ HHHH
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MP.:NMX?9RG%\LK)IOW7T:?\ +V3_ *2#ZXGU7W+_ #-C089_,MIIC_RZ^O\
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M5C?LF?LH>*OB?\9/&'[8=C\5/[$\8"U_X1CP'X@T?/\ 95WX7X_XD/B'P[^
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MS]>_3T&.GL/6O2$5_@S_ ,DP\'R^FC#/MSQZ^@]:]1\_V_3_ .O7DOP9N?\
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MX(Y_KZ?YZT'YY(L_OI1U],?Y_P X'%F:;R_^6/\ G_ZW3WH T:*** "BBB@
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MOP_K0 >=%)]R8?A_3(]_>CS8?7]3_C54>5Y5S]@QYV.V>OM^'^>E5YD\Z/\
M<S_\>_:W[=1ZX_\ K#TY(!9_<_:,[X,^G'\^GM4,P\Z3S_.Q;8['Z?U_STK'
MA\B'_GXN<=?MHYQ^&/7^OO7S+^U;^UA\$?V/_A%J_P 4_CQXOM]$\/6]H;^V
MTPG_ (J+Q3J Z:%X?TH@G)_'OR3C)['S_'_@ =O\=_C9\+/V>_AYXF^+/Q9\
M00>%O#'@^UU"Z-[J=U]A^UX&?^)4 <DGG!&>_M7\Y&E^$_V@_P#@O'\0+GQ!
M\0_^$U^"?_!-'POK-A_8_@C2+O\ LOQ)\;/[(.3_ ,)!DG_B1D\C/;G & 4^
M$W[.'[3W_!:#XTZ1^U!^VA#J'PA_8%\+W_\ ;/[.'[.'_(*\2>*SH_'_  F7
MC;L-#X &?SR./ZA_!_ACP]X'\-Z1X4\*Z)I_A[P[H%K_ &/HVCZ1;?\ $KLK
M %<  #.#@DY)&>Q#'&NE!=&_OT_&W^?D<YRWPQ^&?A7X2^!O#OPY^'7AK3M!
M\#>#]%&C^'/#V@6@TO2_L'3/'&[WR>>AKTR&SA\OR88?LWX_U_EZ=:EBXR?-
M^S^WK^9&..?SJU#^[_7Z]OP__7^%>;B,%A<0_K51)M:_"K[][;^AT7$M/]5^
M5:5%%:K38"O+_J3^/\S7FWQ7^W_\*]\3G3Q!<7XL,8P .HZ^GMG%>HUY-\5)
M_)^'_B*:;_1S_8__ !^=<<#T/T_/\*Z #X2XB^'/A@0C/_$FST]#ZY_#/K^O
MI/FS>OZC_&O-?@S'Y?PP\'_O?M _L8'/8G)XY[\?KQBO4OWO^=U 'S-^R+-Y
MW[._@ ^3]F_XDW3'Y\]B3SU].E?0\?\ Q_?Z[/Y<^GMCMG\N,U\\_LB_\F\?
M#W_L#C^5?0'F>7?7/_7I_P#6_P G_P#70!T%1-'NCV?Y[XZ_Y_G5/[9#M\WR
MNW7C/3ITJ;[6GJ/R_P#KT 0_8S[?F?\ &H;?K^/]5J_Y_M^G_P!>J'G=L?\
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MT2W5NRNM5^?<_GF_9U_X*]?M&^)-/_:0\5>/]*\)W'PW\!?\)1HW@WQQ9_\
M(*_X2C_F7M!./QKH?!W_  5T^.OQ _9F^%'Q4T^P\-V6KCXC?\(1\>+O[5_R
M)VC\8UX8]A^'ZU^N.H?\$\?V>YO@C=?L]_\ "'Z?;?#?5/$?_"9>(_[,M?\
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M?O\ @HS\5?#W[>/_  4PTG4=#\+V=U_;/P'_ &3[R_(\-^$-/!']@:]XBTH
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M#^N>U?=^N?L]_"75[/3=$F\ ^'/[(TO_ $^UTR"U%EI748SMP/Y<<G YKO\
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MN3]178^7^\SYP_7Z_P"??VXK1HH **** "BBB@ HHHH **** "BBB@ HHHH
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MB3]AC_@DO^SM^R/'<^/]5AN/C9^T#XPQK7C+XL?$O_BH]5.H#.1X>!!_L48
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MY--_I,-__H'VH"Z[?8QWY]._^37Q_P#MC?MZ? ']B'P)#XQ^-_B&VMKJX_Y
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M /7_ /6]1^%=("_!_P#Y)?X5]?['_P#B:]0KR_X/_P#)+_"OK_8__P 37J%
M'RG^R*9O^% ?"F[FFN+;[1HH_P!#O+;!YR!P.1['@G)QC!KY7_X*=>,?V;/!
M/PBL+S]I/X%>)?C-X5'V_6/[+\)VH_M72,=3Q@C/(YQR,X]?K7]E?[?>? /X
M;_VK?V^I75OHW_'Y9\_E_7'?Z5\-?\%6O $WBKX=>#_$,7[0_ASX"V&CW_V#
MQ'>^(,?\3[PN<_VL-)'4'IG@9'Y4 8W_  2=\5?L/_%#X;^(?'_['?PEU3P#
MX8^U8N]7\06I_M4DX']A ZSDC:,D#C/!R.37V=^U=#?^)/@EXA\-Z5X5N=;N
M?%'_ !)K6S_YBO\ V'N<>W49KX+_ .",WA7X4>"OAG\2/#GP$\2:AXM^#_\
MPD@UG1M8U>P%B-3\4'_D8=4TGOC)';.<=LU^SEGY/VK['-#_ *3;_P#+Y<=2
M.@'I_2@#\"++]B'XQWGAO1_@MXX\'_VEX>TNU-_:^(/M6<<D8^HQT_ <=/3?
M@;^RQ\;O@#\?/ WB3P?I7VGX;ZI_H'B/1\_\>?\ 3_/T)_;ZUFB\RYA'G_\
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M#G_B:9X)YS[5_&Y^UU^V-XJ^,W[9'QA^ _[)%A_;?A[QY=?V-\1OVA+G1O\
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M_")DG['DECKVK#@ #C')],#&3^E/[*=D)OV>? $/_+&XT;_2B?\ E[[?Y_\
MK5Y+^V]_P3]^!_[?GA:V\'_%J;7--@TO_CUO/#]W]AU7_P#5G\>A^@!YO_P2
MQ^"__"A/V;='\*:?X_\ #?Q(\$ZI_P 3GPOK'A__ )"FFZ=_T"]6Z#/'U /;
M.*_3*'_3(QYP^S<_Z*>,YZ_YX'&:^+/V./V*/AU^P7\)O^%8?"N^\2^+=!MK
MHW_VSQ;K#:IJOX' !R.XS]!BOM./SA<&;S;<VT__ #\=_;KWZ9/!/Z &PGE;
M..GOGKQ^&>G7O5.:"0W$4T,PA_Y^O<8SW/!R?IQFG&YF^S^;#".>WZ9Q]?\
M]7-1"::?K#_GI_+O_C0!B>(H81I6L3?9A<?\2_4.GZ_SY_'\,'X;_N?!5J8>
M3ST[>_\ ];K6]XDFO(?#>L2D_P"DV]KUX^O7GV_'J:S/A]#_ ,4E;0X^S]1G
MT^OY?AQ0!W=K_J+;_KF/_0:M56AB\N+R2>!R/H3ST_\ K&K- !1110 4444
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M_/'[(OG?\,[^ /.S_P @8>F>V??/7KQ7TLO_ "$1_P!>P_G0 39ACXSZ^_\
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MV=)]_?C_ ".E/$8BV*ZI?U\OZW+H8=V\_6W]*_3^G^I$VIS7EW<^1BVAM_\
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M6/\ CS\0W7_$J]N/PY&0>*_0#X>_"3X;_#VU,'@_X=^&_"6,YM](T;M_GO\
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M#!\23?\ $AUCTM[48Z_T_7ZUB> X?^*3MH9CT_Y\^Q_'/^3GUK:\2&:3PYK
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MIR..N/;\:J:?IO\ 9[?\?QN3_P!/&,_SX_R:T/WWF9[?A_G_ .RK$Z1)+?\
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ML?R__57ZM>&_"6C^#M!L/#WA72-$\/:/IG^CVNC:1:"QTL#T  R0.W4YR.<
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M=?M?^1LU>Z_M75;/^0_K_7>A0P*U<N[MINM7Y]-A?6<4].5_U\CX=^&_[?\
M^T'^W%X;MO@M\#=)MM$\?3W1L?B-\0.,:!I'/(]#C.X_7UQ7Z??LQ_L3_#'X
M 1_\)-?Y\>?$BX_Y#/C#Q 1JNK?V@?KG'''3C/6M;]D7]CGX=?LB^!_^$/\
M!]A;VVI7%U]OUGQ9G_B:Z]Z?VMQWZ\=?7@5]G_Z%_G-88C$8;I;Y>73\%L=.
M'P^*W=^^OGZ^OY$MI<[Y+G_GKT)XX_SQ_GH?OLX^7R?_ *W\OTS3OW,9]/\
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M_/Z?K7#[>]_.^WG?^]YGH)&C'Y,8/D@<]<=/\?3_ !JO)>?NR?S/\_3';GC
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M^%GAM_\ B5>!/!MK==";/103D_AC@?\ UL5PT/K?7SWOM_5OF=7$?^KV#=L
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M_L>!Z''T]^#O/VI/V;--_<W_ ,6O"=MU_P"8SC\.?Z=*?L?7^OD@/HCSIO\
M1N;?UNNW3'MU_J:JS3>=:VW[[[+SS^'U_/D^_K7X_P#[:'_!3SP#\)?"_@77
M/A-XJT/Q9;:IXST[1O$8LSG5!8=P#@<9[D#(R<#H*TW[>'QO_: AL/"'[)'P
MEUS[-JEK_HGQ8\06O_%.=/IT/OGKU'2NCZO*U[/_ "_ #]6?&WC;PKX(T.XU
M7QSXAT_PEH]O_P ONJ7?^'K_ )]*_-[QY_P4LMO$FJW/@;]E?X8^)/C'XAS]
M@_X2"SMC_P (W9G&.1GD>QXXZ< C(\'_ /!.OQ5\5->L/''[6_Q?UWX@7_\
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MWP5HD'V7_C[\/W7_ !YG]/\ /XY_$G]LSP?K>@_&CQ##JOC"X^+5A<VNG_\
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M_P#$/G1#C1O^7CMST/OQ^/3'J 0_!?\ Y)?X0_[ W_LU>KUY+\%?^25^$O\
ML'C^M>M4 ?,W[(]O"/V?? $(A_<_V-W^O_Z\9[^U?1L<S-=7(\K_ (]Q@'/7
M/I^'I]:^;/V18_M'[.?@#U.C8Z_CG^?IQ7TM#'_I5ST_J?3M^?XT 69?]2?Q
M_F:S'LY/,BFAF_Z^>G(QSQVYSZGT[UL/T_'_ !JEY/[SS^_IST^O3./T[9H
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M]CT!Z=O;/4_UK\I?&'_!0O4M!_:T/[,X\-"UL;BZL+#1_%EX/^)5>$]>GK@
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M":;P!H?^C_\ +O\ \_?U&0>^./3MBOR _;$_X),_%3X\_%"ZUOX<>*]*\ ^
M+*VQX=T>SXZ@=L\=B,]L<GO_ $+>=9N_DRCIZVQQ[<X)Q^!]Z^$M,_:$\?ZQ
M^UGK'P0O]*&F^&+3PWJ%_:WMY_H/VS/X]OQY]*OZSBNU_DC?#YEB^\N^[]>C
M[]>QP7[,'[!_AGX8?!K0? WQ?\-Z%XN\1>'Q_I7BP_Z;JFIG/0X!/^>F.1].
M0_LE_L[22^=_PKGPV;GIG[+W]>>3ZUPW[,?QK\9_%34?B1X6\5>&X+:P\'ZQ
MJ&GVOB"W)Q>=3]W[HY[X!]3C KZ^M-EY<?:X3<?9_LHM1GO@CU[CC]*IXB3Z
MM>G_  =##$9AB<1?]?\ /K?^NYX5_P ,A_L]_P#1.-#_ / 4U6N/V/\ ]GB3
M_FFFACG_ )]<?EV_SZ#%?3-5O./O^0KG\^OZG!]8?:7WGS!-^Q_^SETE^'>A
MXZG_ $7T_P ]<'M[5\._MO?\$\;#X\?#[1_ WP6TK0_ $/VK-UJEG:]O\.O^
M37Z[W AMY/MC^_;GI_,?X8[U\4?M=_M$>/OV>]3^&^J:'X4'B/POXH\1Z?HW
MB.X'_+EGKC&""3_^JNBAB,3?;TOV77\/EH;T&]=>_5^1\'?L(?\ !,3Q#\ ]
M4\3Z+\>SX:^*/AZYT<#1KR\Y^QG(]._K_=')XK]2K/\ 9-_9ULY$FB^%'A-"
M.<?V.#_^KUZ=,]:^6/AC^VA8?$#XZZQ\-?.M]$\'V]UCPY>WG_(6U*_]^_N0
M.*_2_P#UD<WD]?S_ ,Y]?K[FIKXAXCR:Z;:K_@G1B*_Y?UO_ %I]_C\'P#^"
MT./)^%?A2W_[@PSU]O\ Z_TK8B^#?PE@SCX=>$\_]@;2^.G^>>M>FM)##'^^
M(QS^/L.1ZGTJ3S_;]/\ Z]97?=_>_P#,Y[ON_O?^9P&G_#'P#I<GG:;X,\/6
M<O\ ST@T>U YQ^8'\L8KE?'GPK\ >-M+N?"NO>%;?4K"XM?]*L[>UZ^GKU_7
ML:]6DDFN'V0_Z-,.F1SWZXQZ$]>O6O+OC)K&M^'_  'KVM^&]0@T?6-+L#K'
M^F8Q=X!SI?..<XS]!@#DG18AKJO_  )[_>(^0_AO_P $T_V5_A[XRT_QSX:\
M*W'_  D^E\6MY]J'^A__ *^WX5]O0^'/#7GFT_LK3[B4=S_IV![YZ?C@CV[?
MDO9_M^_%GQ5I?A[7+#P=;^&[#2S_ ,5E9WAS@G5,<>F1Z#')]3G]9_!?B2T\
M2>&]"\5:79_9K;Q!:F_NO/[<#KVSUP??&"1DY8C$.OU8[ON_O?\ F7[GP'X6
MO+@S2Z5;$\_:0?TR?3^G:GQ^ _"L/[G^P=/^S ?\^H_S]>O?'6NYJO/V_#^M
M CAI/AOX/\SSH=*M[:;_ *8=?Z?YZ&JUYX/\+3)+#JNGV^I"X_TZVM/LO;!Q
M@ '^+KR/7FNYN.GX?T-<]>3G['=6UG-]FO\ ^QOM7VS_ )\^G^2/_KT <3-\
M*_"MYKUMK<UA;BV^R?8+6SQQ^7'Y=>G&*Z?_ (0_PW;R6QL-$TL7 Z_3OGIP
M.N/3WK\Q]9_;PUOX9^%_CQ#XDL(-2UCX;VO_ !1NL7'_ ""M?_S[8SZU]P?L
MQ_%35?C!\$? 'Q.\2:5;VVL>(=&!NOL9X]\?4=>W?J: /5_^$/\ !\S^2-!M
M[;CO:GV_^MS_ #K0_P"$#\*B(PQ:5;(/8'T__5TZ?SV(9)O,\[SC<VUP?_ 3
M(_R/UZ8K2\_V_3_Z] '*?\(/X;\O9<Z59W/_ &ZY[>QP?\^G$5YX+\*^7SHF
MG?Y^HSCU_3O7<5G7GD^7^^SGWZY[>^,>OX5S@>6ZW\-_"VJ6<?DZ?I]M#I__
M "\?91_I9_ @=^@SSD\ YJUIO@_PK9V/DSZ)I_\ H]U]@M;C_G\_R!WZ_AS\
M?_&3]I3QS\'_ (N)X)AT2W\3^&-<T74-0^SZ?F^OM!(S_P A;G('X].M<Q^P
MU^W)JO[7^O>.81X6@\):/X#UG4-&^Q7A)U6\QZ#I]0,>I- 'Z#P_#WP?Y?&B
M6V/0C.<=NW(_R?1?^%>>#O\ H"6?YG_"NOMI?-C![C_/Z'\:LUT <8G@3PK#
M(9DT6VR.V/P]>F.V?QJ+_A"?!^^;_B2Z?V_#\#VZ'KQ[\UW%8GF0QR7W[G[/
MC@W!Z'^HY&<=OI0!S$G@/P>8S_Q)+?\ ?VV">PXR!C)Z'\#P*PM'\$^%='T^
MY_XDG_'Q=?\ +Y:^_K^'X=>O->"?M@?M!^(/V=O ]AXVTO1I];TVXUK3]&NK
MC_GR.L'^? /X8R.*X#_AHCQK;?''X9>!K#[-XL\._$CPC8:WJ&C]-5T#/)].
M^3^)- 'W!H_A7PWH]UYVE6%O;$VW^?KC\:[9.GX_X5@PW!_M3[ +;_1K>T_X
M^?\ /_U\<FMF+_4C\/YB@"5^GX_XUYE\2_._X5_XBQG_ ) VH=/I[]_UQGMB
MO2)?]2?Q_F:\N^)TQ_X0/Q#_ ,?'_'KJ'UQV]NO0?4=#0!!\$O\ DF/A#_KU
M7^M>L5Y/\$O^28^$/^O5?ZUZQ0!\S?LEP_\ &/\ X&A[?V-SUY/\^]?1XQ]N
M]?L]J!T]>V?\_E7S5^R5>9^ ?@";('GVOM_G_/-?2$,/^D7,W8_Y'?W[T :]
M%4^OE2F;(/';!R/\Y%29_P"F_P"G_P!>@"Q60(8;R3]]#[\=/;\.OTJ_Y<W_
M #V_\=%5KR&:;R?)FV<_@>.O^>AQZ"@#Q[XV?"6T^,7@D^%9KS^S9?M0O[2\
MQDV?4_U'0=CQ7/? KX!:!\"-*U#3]+U6XUO6-<P;^]U0\WF""!QSVQCN..<U
M[RB032?ZFX_<<9S_ )Z=NYP*L^7_ ,\8O?/;K_/KT_\ U $EE#Y,9],?R_&I
M?^6G^M[8QQZ]/7KWZ8[YJK';A)/.,Q\[D8['/;D'.>.U6?+$<AE^HQ^?7WQG
MI0!9JO1Y_M^G_P!>JWG?\MO^6/IWQZ^O7OZ?G0!CWMG]H\^&;_CPN+7[+=6_
MOTS[>_3K7RG\)_V*O@M\$_B9KWQ*\#6MQHFL^*+K[5=VXN\B[/'7H>O3&#].
MWV(]J'D\^+ ^O&>F?\GUJL8YII,RPV_^C]_P_P _RYH U8X_+[_S]<]ZEJOG
M_IO^G_UZ* +%5Y?]2?Q_F://]OT_^O4<GDS1F+SNWX_C_G/6@"G^YLXNWDC_
M (^OSZ\<\=/>OA;4/V&_AUK'QXMOC??ZI<7.LV]U_;.C65YTTTX]\#\1C]:^
M[[>SAA_R?\_RJ(QI(/W4/[ZS_P"/;/3ZD_U/7]: ([.%X;C]]PYY_/\ SZ]A
M6W6+&?WA_P">T^>I]N>>.WH16EY<W_/;_P =% %BJS_?@^HI?.A_Y[?^/'_"
MDD\J0<_GTS^9!_3N?6@#.FF\G[---_KN0?Z9]OSKXG^('[*FI>,/B_?_ !9F
M^(NHZ=_Q);_1["SLP?MMF"3T;H>G0<@8) !&?N&:/_EM-_\ JQV^GY<50^QP
M^7<PS?:/LUQP,X_#U_3^M 'SQ^S?^SWI7[/?A.Z\-P:WJ&MW.J77V^ZO+SCV
M]O;_ #Q7T3>S&/[/9^1FVN,_:I\\6AX/M@]1GMR>AJ[Y1_Y8CZ_:!^@]?\]:
MH7X^Q0S3#[1<S7&+7CWZ=QQV_3Z@&)<'RYK#4@]Q]DTO_1>O_'YGOP<>O_ZL
MUM_OIOWTW_'O_GT_D/KVK\)?&'[>'[3_ ,'_ -J[XWZ)\6O#?AO4O@/\&[#1
MK^PO/#__ ",=Y_;'?W]Q].PKTKPW_P %L/V8]8^)/A7X8W]AXDTWQ#XP\.?V
MS86]Y:X_LW3QWU?_  Y^M '[+>9Y*3>=C[#C .!GG'&?RKY-_:1_9R@_:/LO
M!=M-XON=%T?POXBL-:NK?_G\QCC)Q@\\9//.#D&OS1U[_@N9\*YO$EMX5^'7
M@?4/&^H6_B,:+K/]E_\ +GI_)[_AGTX]#G8L_P#@N9^SE-XX'@^_\(>+;:PN
M+K^QO[8^R_\ $JLQ[\=SSQW_ !H ^XO#_P"Q'\._#_Q,T?XJ:5?W%S#I=UI]
M_:V=SWQUZ^Y_'T&"1]X0_P#+Q^%?BG'_ ,%L_P!D(^)/B3X8\-_VYK1^%^C+
M<^19:>/[+U._!R!I/'3DCL1D@$'FLKPA_P %E_"OQ*^)GP'^'7@#P!KES-\6
M-8/]LWEYR-!T_CKU!_+^= '[8_N>!#-_VY@G\OY?SHF\V&.VGF_X^?P]1]/\
MFOP'_:L_X+):W^RG\5/$_P +/$/P[_M/6-+\1?Z!9_\ ,4_X1<GKC.#G&>?P
MX.*U[3_@MI\'/ \&FZW\5(;BYMO'&LZ/_P (Y_8^3]CT?6.AS_GF@#]X-]^D
ME]^Y@%L+;-KCOP>#V(_KUQBOG;]H_P"#,/Q^^'O_  @&K:WK'A+G[?\ VQH]
MSTXP/\<XR.?7C\P/C!_P7 _9LM-+\<Z!\*[S4-;\:^$-%_MBVST(QC]>>#WQ
MZU]T?L%?M@:/^VK\"_#WQ/TNPU"//V_3_$6;#&E7NH]?J>!G'L?J #'U/]A7
MPKK%QX&_XJJX^S>&+73[#6;:R_YCVGGN:^YM'TNPT'3[#1-+L,:7HEJ+72QU
MY(SC/?GCH,\FM..'R[KSO)M_)_X]<_3GO^OM6E####_J?\XXX[^Q_K0!>HJL
M'"_ZV4 ^@X_+''I^M+YT/_/;_P >/^% !+_J3^/\S7$>)-*AUC3]7T7SO[.N
M-<TLZ/\ VI9@9L^#QS@#KT..!BNWW_N^G/\ ]?Z^OZ>]9OES31S":+_ _P">
MOM0!^>_A3_@G_P"!H_A?XY^&WQ%U7_A-K#Q?=?;[;6;S/]JVA/OWX_(_0U]5
M_!KX2^%?@;X3L/!_@_\ M"YT>W_T7-X.1Z<<X].GJ*]EAAB\N+]U_P >X./K
MW_+J??-*@F(Q%!]F!ZY'7TXZ#&?TZ4 )^YWCRINGX_D>/\Y/:M*LZ.WF,GG&
M;MS[\<Y^G_UO6K.?^F_Z?_7H L57E_U)_'^9HS_TW_3_ .O5:8PW?[D3?ACG
M)_+_ #UZ4 ?!]Y^Q/I5Y\5/'/Q.U7Q_KF/&%K]@^Q_\ /GU[_P"/XUT_[-_[
M'_PZ_9KU34];T*_N-2UCQ!G[5>=C^7;@?X8K[#%G"9+GC_/0^G;V_P :9-"Y
MN(9O/_T/C_1^G/;IV'7V]>* +\<F?^6/7C_/'OZ8]ZMU3C!CDEZ>3Z_E_P#7
MJ3/_ $W_ $_^O0!8K$$,,KS3$YBN +0P=/KT]?R^O!K3S_TW_3_Z]5O+AFD[
M_3W]/QX_^MQ0!\Z_'+X!V?QRTO3=!O\ Q/JFB:/I=U]N-G9_\O?!_KT_#WKR
M+X5_LC6'P[^-%S\88?'^H:W8?V-_8UI9WG_+D.O(^G?\*^X8?/FDN?.$'V8_
M\>O^>!^@ZT00^3)-^Y^SVQ[_ *?7'T[?6@":%/WDLQF\Z$_S[]^V0>>._I5F
M#O\ C_2J\,/E?Y_SQWYZ4D-OY,?[G_//]/8=<T 69?\ 4G\?YFO-/BOYW_"!
M^(9H?(XTL\GZG\O8]NE>A2?;/^>UOCZ=#^([^_KUYKS'XOPPR_#[Q,/^/?\
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MX?\ PW^)P/AZWNO[9.F?:CP0,CC'.3UY''>BB@#ZVA_:[_9_BCMWB\;6WDW
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'/^-%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>canf-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 11:16:39 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.confite.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:canf="http://www.confite.com/20221231" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20221231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20221231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20221231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20221231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet" id="canf_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals" id="canf_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome" id="canf_r_ConsolidatedComprehensiveIncome">
        <link:definition>003 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals" id="canf_r_ConsolidatedComprehensiveIncome_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityType2or3" id="canf_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals" id="canf_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>006 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedCashFlow" id="canf_r_ConsolidatedCashFlow">
        <link:definition>007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/General" id="canf_r_General">
        <link:definition>008 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPolicies" id="canf_r_SignificantAccountingPolicies">
        <link:definition>009 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets" id="canf_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>010 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShortTermInvestment" id="canf_r_ShortTermInvestment">
        <link:definition>011 - Disclosure - Short-Term Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet" id="canf_r_PropertyPlantandEquipmentNet">
        <link:definition>012 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsPayable" id="canf_r_OtherAccountsPayable">
        <link:definition>013 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FairValueMeasurements" id="canf_r_FairValueMeasurements">
        <link:definition>014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/Revenues" id="canf_r_Revenues">
        <link:definition>015 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments" id="canf_r_ContingentLiabilitiesandCommitments">
        <link:definition>016 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquity" id="canf_r_ShareholdersEquity">
        <link:definition>017 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions" id="canf_r_ShareBasedPaymentTransactions">
        <link:definition>018 - Disclosure - Share-Based Payment Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/Leases" id="canf_r_Leases">
        <link:definition>019 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FinanceIncomeExpenseNet" id="canf_r_FinanceIncomeExpenseNet">
        <link:definition>020 - Disclosure - Finance Income (Expense), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncome" id="canf_r_TaxesonIncome">
        <link:definition>021 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TransactionswithRelatedParties" id="canf_r_TransactionswithRelatedParties">
        <link:definition>022 - Disclosure - Transactions with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SubsequentEvents" id="canf_r_SubsequentEvents">
        <link:definition>023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy" id="canf_r_AccountingPoliciesByPolicy">
        <link:definition>024 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables" id="canf_r_SignificantAccountingPoliciesTables">
        <link:definition>025 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="canf_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>026 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables" id="canf_r_PropertyPlantandEquipmentNetTables">
        <link:definition>027 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsPayableTables" id="canf_r_OtherAccountsPayableTables">
        <link:definition>028 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FairValueMeasurementsTables" id="canf_r_FairValueMeasurementsTables">
        <link:definition>029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityTables" id="canf_r_ShareholdersEquityTables">
        <link:definition>030 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables" id="canf_r_ShareBasedPaymentTransactionsTables">
        <link:definition>031 - Disclosure - Share-Based Payment Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/LeasesTables" id="canf_r_LeasesTables">
        <link:definition>032 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FinanceIncomeExpenseNetTables" id="canf_r_FinanceIncomeExpenseNetTables">
        <link:definition>033 - Disclosure - Finance Income (Expense), Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncomeTables" id="canf_r_TaxesonIncomeTables">
        <link:definition>034 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/GeneralDetails" id="canf_r_GeneralDetails">
        <link:definition>035 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails" id="canf_r_SignificantAccountingPoliciesDetails">
        <link:definition>036 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable" id="canf_r_ScheduleofpropertyplantandequipmentTable">
        <link:definition>037 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" id="canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
        <link:definition>038 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable" id="canf_r_ScheduleofoutstandingshareoptionsandwarrantsTable">
        <link:definition>039 - Disclosure - Significant Accounting Policies (Details) - Schedule of outstanding share options and warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" id="canf_r_ScheduleofprepaidexpensesandothercurrentassetsTable">
        <link:definition>040 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShortTermInvestmentDetails" id="canf_r_ShortTermInvestmentDetails">
        <link:definition>041 - Disclosure - Short-Term Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails" id="canf_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>042 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable" id="canf_r_ScheduleofpropertyplantandequipmentnetTable">
        <link:definition>043 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable" id="canf_r_ScheduleofotheraccountspayableTable">
        <link:definition>044 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" id="canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
        <link:definition>045 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/RevenuesDetails" id="canf_r_RevenuesDetails">
        <link:definition>046 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails" id="canf_r_ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>047 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityDetails" id="canf_r_ShareholdersEquityDetails">
        <link:definition>048 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" id="canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
        <link:definition>049 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmPO7kW86fCwO9BDdY5bf5b9H+vvjKwz2saovEzZ3dBRA5yWdSLppMepuvQwgTmpdXkG6aEqg3eKP65vjM+XithEfqz6791Pl3kR8GSmegnWB3UGcE2qeH1T1eSBhGyt0q] CSR-->
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails" id="canf_r_ShareBasedPaymentTransactionsDetails">
        <link:definition>050 - Disclosure - Share-Based Payment Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofexpensesTable" id="canf_r_ScheduleofexpensesTable">
        <link:definition>051 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable" id="canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
        <link:definition>052 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable" id="canf_r_ScheduleofshareoptionstheirweightedaverageexercisepriceTable">
        <link:definition>053 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of share options, their weighted average exercise price</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/LeasesDetails" id="canf_r_LeasesDetails">
        <link:definition>054 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" id="canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
        <link:definition>055 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable" id="canf_r_ScheduleofmaturitiesofleaseliabilitiesTable">
        <link:definition>056 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable" id="canf_r_ScheduleofcomponentsoffinanceincomeTable">
        <link:definition>057 - Disclosure - Finance Income (Expense), Net (Details) - Schedule of components of finance (income)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncomeDetails" id="canf_r_TaxesonIncomeDetails">
        <link:definition>058 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>059 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails" id="canf_r_TransactionswithRelatedPartiesDetails">
        <link:definition>060 - Disclosure - Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SubsequentEventsDetails" id="canf_r_SubsequentEventsDetails">
        <link:definition>061 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
  <xs:element name="ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
  <xs:element name="ScheduleOfExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfExpensesAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract"/>
  <xs:element name="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfFinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract43"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract44"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract49"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract50"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract51"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract52"/>
  <xs:element name="UnlabeledAbstract53" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract53"/>
  <xs:element name="UnlabeledAbstract54" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract54"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CostAbstract"/>
  <xs:element name="UnlabeledAbstract55" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract55"/>
  <xs:element name="UnlabeledAbstract56" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract56"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AccumulatedDepreciationAbstract"/>
  <xs:element name="UnlabeledAbstract57" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract57"/>
  <xs:element name="UnlabeledAbstract58" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract58"/>
  <xs:element name="UnlabeledAbstract59" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract59"/>
  <xs:element name="UnlabeledAbstract60" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract60"/>
  <xs:element name="UnlabeledAbstract61" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract61"/>
  <xs:element name="UnlabeledAbstract62" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract62"/>
  <xs:element name="UnlabeledAbstract63" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract63"/>
  <xs:element name="UnlabeledAbstract64" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract64"/>
  <xs:element name="ComponentsOfLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ComponentsOfLeaseExpenseAbstract"/>
  <xs:element name="UnlabeledAbstract65" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract65"/>
  <xs:element name="UnlabeledAbstract66" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract66"/>
  <xs:element name="FinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract67" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract67"/>
  <xs:element name="FinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceIncomeAbstract"/>
  <xs:element name="UnlabeledAbstract68" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract68"/>
  <xs:element name="UnlabeledAbstract69" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract69"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_DeferredTaxAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract70" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnlabeledAbstract70"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
  <xs:element name="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses"/>
  <xs:element name="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares"/>
  <xs:element name="WarrantsNetOfIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_WarrantsNetOfIssuanceExpenses"/>
  <xs:element name="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
  <xs:element name="WithdrawalinvestmentInShorttermDepositsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_WithdrawalinvestmentInShorttermDepositsNet"/>
  <xs:element name="ShortTermInvestmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShortTermInvestmentTable"/>
  <xs:element name="OtherAccountsPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_OtherAccountsPayableTable"/>
  <xs:element name="OtherAccountsPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsPayableLineItems"/>
  <xs:element name="SeverancePayPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SeverancePayPolicyTextBlock"/>
  <xs:element name="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
  <xs:element name="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
  <xs:element name="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
  <xs:element name="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
  <xs:element name="ScheduleOfExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
  <xs:element name="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
  <xs:element name="RevenueContractWithCustomer" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RevenueContractWithCustomer"/>
  <xs:element name="Options" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_Options"/>
  <xs:element name="TotalinDollars" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_TotalinDollars"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_GovernmentAuthorities"/>
  <xs:element name="EmployeesAndPayrollAccruals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_EmployeesAndPayrollAccruals"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
  <xs:element name="IssuanceDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceDate"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice"/>
  <xs:element name="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
  <xs:element name="WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired"/>
  <xs:element name="AggregateIntrinsicValueForfeitedexpired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregateIntrinsicValueForfeitedexpired"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
  <xs:element name="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
  <xs:element name="ImputedInterestLessImputedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_ImputedInterestLessImputedInterest"/>
  <xs:element name="BanksCommissions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_BanksCommissions"/>
  <xs:element name="NetLossFromExchangeRateFluctuations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_NetLossFromExchangeRateFluctuations"/>
  <xs:element name="OtherLossFromShorttermInvestmentRevaluation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherLossFromShorttermInvestmentRevaluation"/>
  <xs:element name="FinanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceExpenses"/>
  <xs:element name="ExchangeRateFluctuations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_ExchangeRateFluctuations"/>
  <xs:element name="FinanceIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceIncome"/>
  <xs:element name="NetLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_NetLosses"/>
  <xs:element name="CashFlowsFromOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_CashFlowsFromOperatingActivities"/>
  <xs:element name="ContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_ContractLiabilities"/>
  <xs:element name="Revenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_Revenue"/>
  <xs:element name="PercentageOfDepositsOnMonthlySalary" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfDepositsOnMonthlySalary"/>
  <xs:element name="PercentageOfRealizationOnUltimateSettlement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfRealizationOnUltimateSettlement"/>
  <xs:element name="PercentageOfOutstandingShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfOutstandingShares"/>
  <xs:element name="RevenuesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_RevenuesDetailsTable"/>
  <xs:element name="RevenuesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RevenuesDetailsLineItems"/>
  <xs:element name="DistributionAndSupplyAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_DistributionAndSupplyAgreementDescription"/>
  <xs:element name="MilestonePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_MilestonePercentage"/>
  <xs:element name="SignatureDate" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SignatureDate"/>
  <xs:element name="RoyalitiesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RoyalitiesDescription"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
  <xs:element name="PercentageOfNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfNetSales"/>
  <xs:element name="RoyaltyPaymentsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RoyaltyPaymentsPercentage"/>
  <xs:element name="PatentAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PatentAgreementDescription"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregatePurchasePrice"/>
  <xs:element name="IssueOfNewUnregisteredWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssueOfNewUnregisteredWarrants"/>
  <xs:element name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights"/>
  <xs:element name="DeemedDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_DeemedDividend"/>
  <xs:element name="SecuritiesPurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SecuritiesPurchaseAgreementDescription"/>
  <xs:element name="CompensationWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CompensationWarrantsExercisable"/>
  <xs:element name="ExercisePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePrices"/>
  <xs:element name="IncreaseAuthorizedShareCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IncreaseAuthorizedShareCapital"/>
  <xs:element name="AggregateWarrantPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregateWarrantPurchased"/>
  <xs:element name="ExercisePriceSubjectToAdjusment" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceSubjectToAdjusment"/>
  <xs:element name="AggregateNumbersOfADS" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregateNumbersOfADS"/>
  <xs:element name="WarrantsToPurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_WarrantsToPurchaseAggregateShares"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePrice"/>
  <xs:element name="TotalConsiderationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_TotalConsiderationAmount"/>
  <xs:element name="PreFundedWarrant" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_PreFundedWarrant"/>
  <xs:element name="AggregateNumberOfADS" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregateNumberOfADS"/>
  <xs:element name="IssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceExpenses"/>
  <xs:element name="StockIssuanceAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuanceAgreementDescription"/>
  <xs:element name="ExerciseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExerciseAgreementDescription"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareBasedPaymentTransactionsDetailsTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
  <xs:element name="GrantedExcessYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_GrantedExcessYears"/>
  <xs:element name="FutureShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_FutureShares"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="DevelopmentAreaAPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_DevelopmentAreaAPercentage"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SubsequentEventsDetailsLineItems"/>
  <xs:element name="NetOfDirectIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_NetOfDirectIssuanceCosts"/>
  <xs:element name="ADSMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ADSMember"/>
  <xs:element name="April2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_April2019Member"/>
  <xs:element name="August2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_August2021Member"/>
  <xs:element name="CMSMedicalVentureInvestmentLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CMSMedicalVentureInvestmentLimitedMember"/>
  <xs:element name="ChongKunDangPharmaceuticalsCorpMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ChongKunDangPharmaceuticalsCorpMember"/>
  <xs:element name="CipherPharmaceuticalsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CipherPharmaceuticalsMember"/>
  <xs:element name="ComputersOfficeFurnitureAndEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ComputersOfficeFurnitureAndEquipmentMember"/>
  <xs:element name="December2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_December2021Member"/>
  <xs:element name="EwopharmaAGMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_EwopharmaAGMember"/>
  <xs:element name="EwopharmaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_EwopharmaMember"/>
  <xs:element name="February2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_February2020Member"/>
  <xs:element name="GebroHoldingGmBHMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_GebroHoldingGmBHMember"/>
  <xs:element name="January2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_January2019Member"/>
  <xs:element name="January2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_January2020Member"/>
  <xs:element name="July2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_July2020Member"/>
  <xs:element name="June2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_June2020Member"/>
  <xs:element name="LaboratoryEquipmentAndLeaseholdImprovementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_LaboratoryEquipmentMember"/>
  <xs:element name="March2018Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_March2018Member"/>
  <xs:element name="May2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_May2019Member"/>
  <xs:element name="PlacementAgentWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PlacementAgentWarrantMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PrefundedWarrantsMember"/>
  <xs:element name="RDPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RDPurchaseAgreementMember"/>
  <xs:element name="SeriesAWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SeriesAWarrantMember"/>
  <xs:element name="SeriesBWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SeriesBWarrantMember"/>
  <xs:element name="UnregisteredPrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnregisteredPrefundedWarrantsMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>canf-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 11:16:39 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofexpensesTable" roleURI="http://www.confite.com/role/ScheduleofexpensesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmPO7kW86fCwO9BDdY5bf5b9H+vvjKwz2saovEzZ3dBRA5yWdSLppMepuvQwgTmpdXkG6aEqg3eKP65vjM+XithEfqz6791Pl3kR8GSmegnWDv8/jxCmEOLM5uE9IE/c5K] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20221231.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="canf_WithdrawalinvestmentInShorttermDepositsNet" xlink:href="canf-20221231.xsd#canf_WithdrawalinvestmentInShorttermDepositsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="canf_WithdrawalinvestmentInShorttermDepositsNet" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20221231.xsd#canf_GovernmentAuthorities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="canf_GovernmentAuthorities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20221231.xsd#canf_EmployeesAndPayrollAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="canf_EmployeesAndPayrollAccruals" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>canf-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 11:16:39 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquityType2or3" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_General" roleURI="http://www.confite.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SignificantAccountingPolicies" roleURI="http://www.confite.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShortTermInvestment" roleURI="http://www.confite.com/role/ShortTermInvestment"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PropertyPlantandEquipmentNet" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_OtherAccountsPayable" roleURI="http://www.confite.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_FairValueMeasurements" roleURI="http://www.confite.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_Revenues" roleURI="http://www.confite.com/role/Revenues"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ContingentLiabilitiesandCommitments" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquity" roleURI="http://www.confite.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareBasedPaymentTransactions" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_Leases" roleURI="http://www.confite.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_FinanceIncomeExpenseNet" roleURI="http://www.confite.com/role/FinanceIncomeExpenseNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TaxesonIncome" roleURI="http://www.confite.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TransactionswithRelatedParties" roleURI="http://www.confite.com/role/TransactionswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SubsequentEvents" roleURI="http://www.confite.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_AccountingPoliciesByPolicy" roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SignificantAccountingPoliciesTables" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_OtherAccountsPayableTables" roleURI="http://www.confite.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_FairValueMeasurementsTables" roleURI="http://www.confite.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquityTables" roleURI="http://www.confite.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareBasedPaymentTransactionsTables" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_LeasesTables" roleURI="http://www.confite.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_FinanceIncomeExpenseNetTables" roleURI="http://www.confite.com/role/FinanceIncomeExpenseNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TaxesonIncomeTables" roleURI="http://www.confite.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofoutstandingshareoptionsandwarrantsTable" roleURI="http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofpropertyplantandequipmentnetTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofexpensesTable" roleURI="http://www.confite.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable" roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofshareoptionstheirweightedaverageexercisepriceTable" roleURI="http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofcomponentsoffinanceincomeTable" roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_GeneralDetails" roleURI="http://www.confite.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SignificantAccountingPoliciesDetails" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShortTermInvestmentDetails" roleURI="http://www.confite.com/role/ShortTermInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_RevenuesDetails" roleURI="http://www.confite.com/role/RevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquityDetails" roleURI="http://www.confite.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareBasedPaymentTransactionsDetails" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_LeasesDetails" roleURI="http://www.confite.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TaxesonIncomeDetails" roleURI="http://www.confite.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TransactionswithRelatedPartiesDetails" roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SubsequentEventsDetails" roleURI="http://www.confite.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.confite.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:href="canf-20221231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:href="canf-20221231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20221231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20221231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsNetOfIssuanceExpenses" xlink:href="canf-20221231.xsd#canf_WarrantsNetOfIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="canf_WarrantsNetOfIssuanceExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20221231.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WithdrawalinvestmentInShorttermDepositsNet" xlink:href="canf-20221231.xsd#canf_WithdrawalinvestmentInShorttermDepositsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="canf_WithdrawalinvestmentInShorttermDepositsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestment">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShortTermInvestmentTable" xlink:href="canf-20221231.xsd#canf_ShortTermInvestmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="canf_ShortTermInvestmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableLineItems" xlink:href="canf-20221231.xsd#canf_OtherAccountsPayableLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTable" xlink:href="canf-20221231.xsd#canf_OtherAccountsPayableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="canf_OtherAccountsPayableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/Revenues">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseNet">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SeverancePayPolicyTextBlock" xlink:href="canf-20221231.xsd#canf_SeverancePayPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_SeverancePayPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20221231.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="canf_ScheduleOfExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20221231.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20221231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20221231.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="srt_MajorCustomersAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CipherPharmaceuticalsMember" xlink:href="canf-20221231.xsd#canf_CipherPharmaceuticalsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_CipherPharmaceuticalsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20221231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_GebroHoldingGmBHMember" xlink:href="canf-20221231.xsd#canf_GebroHoldingGmBHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_GebroHoldingGmBHMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_EwopharmaAGMember" xlink:href="canf-20221231.xsd#canf_EwopharmaAGMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_EwopharmaAGMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RevenueContractWithCustomer" xlink:href="canf-20221231.xsd#canf_RevenueContractWithCustomer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_RevenueContractWithCustomer" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_Options" xlink:href="canf-20221231.xsd#canf_Options"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:to="canf_Options" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_TotalinDollars" xlink:href="canf-20221231.xsd#canf_TotalinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:to="canf_TotalinDollars" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20221231.xsd#canf_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="canf_GovernmentAuthorities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentMember" xlink:href="canf-20221231.xsd#canf_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="canf_LaboratoryEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20221231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CostAbstract" xlink:href="canf-20221231.xsd#canf_CostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="canf_CostAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_CostAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AccumulatedDepreciationAbstract" xlink:href="canf-20221231.xsd#canf_AccumulatedDepreciationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="canf_AccumulatedDepreciationAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20221231.xsd#canf_EmployeesAndPayrollAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="canf_EmployeesAndPayrollAccruals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20221231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20221231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="us-gaap_AwardDateAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_March2018Member" xlink:href="canf-20221231.xsd#canf_March2018Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_March2018Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_January2019Member" xlink:href="canf-20221231.xsd#canf_January2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_January2019Member" order="1" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmPO7kW86fCwO9BDdY5bf5b9H+vvjKwz2saovEzZ3dBRA5yWdSLppMepuvQwgTmpdXkG6aEqg3eKP65vjM+XithEfqz6791Pl3kR8GSmegnWABO5zI1nJVbye0a4v55eSO] CSR-->
    <loc xlink:type="locator" xlink:label="canf_April2019Member" xlink:href="canf-20221231.xsd#canf_April2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_April2019Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_May2019Member" xlink:href="canf-20221231.xsd#canf_May2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_May2019Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_January2020Member" xlink:href="canf-20221231.xsd#canf_January2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_January2020Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_February2020Member" xlink:href="canf-20221231.xsd#canf_February2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_February2020Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_June2020Member" xlink:href="canf-20221231.xsd#canf_June2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_June2020Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_July2020Member" xlink:href="canf-20221231.xsd#canf_July2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_July2020Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_August2021Member" xlink:href="canf-20221231.xsd#canf_August2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_August2021Member" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_December2021Member" xlink:href="canf-20221231.xsd#canf_December2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_December2021Member" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceDate" xlink:href="canf-20221231.xsd#canf_IssuanceDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_IssuanceDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:href="canf-20221231.xsd#canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" xlink:href="canf-20221231.xsd#canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateIntrinsicValueForfeitedexpired" xlink:href="canf-20221231.xsd#canf_AggregateIntrinsicValueForfeitedexpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="canf_AggregateIntrinsicValueForfeitedexpired" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20221231.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20221231.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20221231.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20221231.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ImputedInterestLessImputedInterest" xlink:href="canf-20221231.xsd#canf_ImputedInterestLessImputedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="canf_ImputedInterestLessImputedInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_BanksCommissions" xlink:href="canf-20221231.xsd#canf_BanksCommissions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_BanksCommissions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NetLossFromExchangeRateFluctuations" xlink:href="canf-20221231.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_NetLossFromExchangeRateFluctuations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20221231.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="us-gaap_OtherExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpenses" xlink:href="canf-20221231.xsd#canf_FinanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_FinanceExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExchangeRateFluctuations" xlink:href="canf-20221231.xsd#canf_ExchangeRateFluctuations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_ExchangeRateFluctuations" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncome" xlink:href="canf-20221231.xsd#canf_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_FinanceIncome" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_DeferredTaxAssetsAbstract" xlink:href="canf-20221231.xsd#canf_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="canf_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NetLosses" xlink:href="canf-20221231.xsd#canf_NetLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_NetLosses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CashFlowsFromOperatingActivities" xlink:href="canf-20221231.xsd#canf_CashFlowsFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_CashFlowsFromOperatingActivities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ContractLiabilities" xlink:href="canf-20221231.xsd#canf_ContractLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ContractLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_Revenue" xlink:href="canf-20221231.xsd#canf_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_Revenue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20221231.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_PercentageOfDepositsOnMonthlySalary" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20221231.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfOutstandingShares" xlink:href="canf-20221231.xsd#canf_PercentageOfOutstandingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="canf_PercentageOfOutstandingShares" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/RevenuesDetails">
    <loc xlink:type="locator" xlink:label="canf_RevenuesDetailsLineItems" xlink:href="canf-20221231.xsd#canf_RevenuesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_RevenuesDetailsTable" xlink:href="canf-20221231.xsd#canf_RevenuesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="canf_RevenuesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_RevenuesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_RevenuesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_GebroHoldingGmBHMember" xlink:href="canf-20221231.xsd#canf_GebroHoldingGmBHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_GebroHoldingGmBHMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CMSMedicalVentureInvestmentLimitedMember" xlink:href="canf-20221231.xsd#canf_CMSMedicalVentureInvestmentLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_CMSMedicalVentureInvestmentLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_EwopharmaMember" xlink:href="canf-20221231.xsd#canf_EwopharmaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_EwopharmaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_PaymentsForFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfRegulatoryAssistanceReceived1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_AmountOfRegulatoryAssistanceReceived1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_OtherLoansPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfFIFOInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfFIFOInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_PercentageOfFIFOInventory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesReceivedAsCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_SecuritiesReceivedAsCollateral" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_DistributionAndSupplyAgreementDescription" xlink:href="canf-20221231.xsd#canf_DistributionAndSupplyAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="canf_DistributionAndSupplyAgreementDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredSalesInducementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredSalesInducementsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_DeferredSalesInducementsNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_PaymentsToSuppliers" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCollateralAggregateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_MilestonePercentage" xlink:href="canf-20221231.xsd#canf_MilestonePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="canf_MilestonePercentage" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SignatureDate" xlink:href="canf-20221231.xsd#canf_SignatureDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="canf_SignatureDate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RoyalitiesDescription" xlink:href="canf-20221231.xsd#canf_RoyalitiesDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="canf_RoyalitiesDescription" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20221231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseCommissionExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfNetSales" xlink:href="canf-20221231.xsd#canf_PercentageOfNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_PercentageOfNetSales" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_AdvanceRoyalties" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyPaymentsPercentage" xlink:href="canf-20221231.xsd#canf_RoyaltyPaymentsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_RoyaltyPaymentsPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PatentAgreementDescription" xlink:href="canf-20221231.xsd#canf_PatentAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_PatentAgreementDescription" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsTable" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ADSMember" xlink:href="canf-20221231.xsd#canf_ADSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="canf_ADSMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregatePurchasePrice" xlink:href="canf-20221231.xsd#canf_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregatePurchasePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssueOfNewUnregisteredWarrants" xlink:href="canf-20221231.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IssueOfNewUnregisteredWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" xlink:href="canf-20221231.xsd#canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_DeemedDividend" xlink:href="canf-20221231.xsd#canf_DeemedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_DeemedDividend" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SecuritiesPurchaseAgreementDescription" xlink:href="canf-20221231.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_SecuritiesPurchaseAgreementDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CompensationWarrantsExercisable" xlink:href="canf-20221231.xsd#canf_CompensationWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_CompensationWarrantsExercisable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrices" xlink:href="canf-20221231.xsd#canf_ExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePrices" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseAuthorizedShareCapital" xlink:href="canf-20221231.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IncreaseAuthorizedShareCapital" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateWarrantPurchased" xlink:href="canf-20221231.xsd#canf_AggregateWarrantPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregateWarrantPurchased" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceSubjectToAdjusment" xlink:href="canf-20221231.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePriceSubjectToAdjusment" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateNumbersOfADS" xlink:href="canf-20221231.xsd#canf_AggregateNumbersOfADS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregateNumbersOfADS" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAggregateShares" xlink:href="canf-20221231.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_WarrantsToPurchaseAggregateShares" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrice" xlink:href="canf-20221231.xsd#canf_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePrice" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_TotalConsiderationAmount" xlink:href="canf-20221231.xsd#canf_TotalConsiderationAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_TotalConsiderationAmount" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PreFundedWarrant" xlink:href="canf-20221231.xsd#canf_PreFundedWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_PreFundedWarrant" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateNumberOfADS" xlink:href="canf-20221231.xsd#canf_AggregateNumberOfADS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregateNumberOfADS" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceExpenses" xlink:href="canf-20221231.xsd#canf_IssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IssuanceExpenses" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuanceAgreementDescription" xlink:href="canf-20221231.xsd#canf_StockIssuanceAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_StockIssuanceAgreementDescription" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExerciseAgreementDescription" xlink:href="canf-20221231.xsd#canf_ExerciseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExerciseAgreementDescription" order="35" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_GrantedExcessYears" xlink:href="canf-20221231.xsd#canf_GrantedExcessYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_GrantedExcessYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FutureShares" xlink:href="canf-20221231.xsd#canf_FutureShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_FutureShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsLineItems" xlink:href="canf-20221231.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsTable" xlink:href="canf-20221231.xsd#canf_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="canf_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_TaxesonIncomeDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_DevelopmentAreaAPercentage" xlink:href="canf-20221231.xsd#canf_DevelopmentAreaAPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="canf_DevelopmentAreaAPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="canf_SubsequentEventsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_SubsequentEventsDetailsTable" xlink:href="canf-20221231.xsd#canf_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="canf_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SeriesAWarrantMember" xlink:href="canf-20221231.xsd#canf_SeriesAWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="canf_SeriesAWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SeriesBWarrantMember" xlink:href="canf-20221231.xsd#canf_SeriesBWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="canf_SeriesBWarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PrefundedWarrantsMember" xlink:href="canf-20221231.xsd#canf_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="canf_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_UnregisteredPrefundedWarrantsMember" xlink:href="canf-20221231.xsd#canf_UnregisteredPrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="canf_UnregisteredPrefundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PlacementAgentWarrantMember" xlink:href="canf-20221231.xsd#canf_PlacementAgentWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="canf_PlacementAgentWarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RDPurchaseAgreementMember" xlink:href="canf-20221231.xsd#canf_RDPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="canf_RDPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseTransferAgentAndCustodianFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NetOfDirectIssuanceCosts" xlink:href="canf-20221231.xsd#canf_NetOfDirectIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="canf_NetOfDirectIssuanceCosts" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelFaxNumber" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="41" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>canf-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 11:16:39 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Cash and cash equivalents at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Accounts Receivable and Prepaid Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding, at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of options, Outstanding, at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate intrinsic value end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelFaxNumber_lbl" xml:lang="en-US">Contact Personnel Fax Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelFaxNumber" xlink:to="dei_ContactPersonnelFaxNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract" xlink:to="canf_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses, and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract0" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract0" xlink:to="canf_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract1" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract1" xlink:to="canf_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract2" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract2" xlink:to="canf_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract3" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract3" xlink:to="canf_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract4" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract4" xlink:to="canf_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturity of operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract5" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract5" xlink:to="canf_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract6" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract6" xlink:to="canf_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract7" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract7" xlink:to="canf_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract8" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract8" xlink:to="canf_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">CONTIGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract9" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract9" xlink:to="canf_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares of no par value - Authorized: 5,000,000,000 shares at December 31, 2022 and 2021; Issued and outstanding: 815,746,293 shares as of December 31, 2022 and 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract10" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract10" xlink:to="canf_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract11" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract11" xlink:to="canf_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract12" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract12" xlink:to="canf_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract13" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract13" xlink:to="canf_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract14" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract14" xlink:to="canf_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total financial income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract15" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract15" xlink:to="canf_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract16" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract16" xlink:to="canf_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract17" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract17" xlink:to="canf_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract18" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract18" xlink:to="canf_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract19" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract19" xlink:to="canf_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract20" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract20" xlink:to="canf_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl" xml:lang="en-US">Deemed dividends related to the warrants exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract21" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract21" xlink:to="canf_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20221231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20221231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsNetOfIssuanceExpenses" xlink:href="canf-20221231.xsd#canf_WarrantsNetOfIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WarrantsNetOfIssuanceExpenses_lbl" xml:lang="en-US">Warrants, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssuanceExpenses" xlink:to="canf_WarrantsNetOfIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract22" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract22" xlink:to="canf_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of share capital (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract23" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract23" xlink:to="canf_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract24" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract24" xlink:to="canf_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract25" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract25" xlink:to="canf_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract26" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract26" xlink:to="canf_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:href="canf-20221231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl" xml:lang="en-US">Issuance of share capital due to warrants exercise, net of issuance expenses of $ 980 (Note 10b(9), 10b(11) and 10b(12))</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:href="canf-20221231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl" xml:lang="en-US">Issuance of share capital due to warrants exercise, net of issuance expenses of $ 980 (Note 10b(9), 10b(11) and 10b(12)) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Warrants exercise, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract27" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract27" xlink:to="canf_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract28" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract28" xlink:to="canf_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of share capital in exchange for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of share capital in exchange for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract29" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract29" xlink:to="canf_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">dividends related to the warrants exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract30" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract30" xlink:to="canf_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract31" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract31" xlink:to="canf_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract32" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract32" xlink:to="canf_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract33" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract33" xlink:to="canf_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract34" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract34" xlink:to="canf_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract35" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract35" xlink:to="canf_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract36" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract36" xlink:to="canf_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Decrease in operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in trade payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (decrease) in deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Increase (decrease) in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract37" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract37" xlink:to="canf_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract38" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract38" xlink:to="canf_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract39" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract39" xlink:to="canf_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract40" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract40" xlink:to="canf_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract41" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract41" xlink:to="canf_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract42" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract42" xlink:to="canf_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract43" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract43" xlink:to="canf_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract44" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract44" xlink:to="canf_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Exchange differences on balances of cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract45" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract45" xlink:to="canf_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract46" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract46" xlink:to="canf_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract47" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract47" xlink:to="canf_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract48" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract48" xlink:to="canf_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liabilities arising from obtaining right-of-use-assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract49" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract49" xlink:to="canf_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US">Deemed Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract50" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract50" xlink:to="canf_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the year for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl" xml:lang="en-US">Deemed dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Reduction in the carrying amount of operating lease right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20221231.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl" xml:lang="en-US">Changes in fair value of short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Financial expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Change in prepaid expenses, and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WithdrawalinvestmentInShorttermDepositsNet" xlink:href="canf-20221231.xsd#canf_WithdrawalinvestmentInShorttermDepositsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="canf_WithdrawalinvestmentInShorttermDepositsNet_lbl" xml:lang="en-US">Withdrawal (investment) in short-term deposits, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WithdrawalinvestmentInShorttermDepositsNet" xlink:to="canf_WithdrawalinvestmentInShorttermDepositsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20221231.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl" xml:lang="en-US">Depreciation rates property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract51" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract51" xlink:to="canf_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of major customer data as a percentage of total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RevenueContractWithCustomer" xlink:href="canf-20221231.xsd#canf_RevenueContractWithCustomer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RevenueContractWithCustomer_lbl" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract52" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract52" xlink:to="canf_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">schedule of outstanding share options and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_Options" xlink:href="canf-20221231.xsd#canf_Options"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_Options_lbl" xml:lang="en-US">Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Options" xlink:to="canf_Options_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Purchase aggregate warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract53" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract53"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract53_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract53" xlink:to="canf_UnlabeledAbstract53_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TotalinDollars" xlink:href="canf-20221231.xsd#canf_TotalinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_TotalinDollars_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalinDollars" xlink:to="canf_TotalinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20221231.xsd#canf_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract54" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract54"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract54_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract54" xlink:to="canf_UnlabeledAbstract54_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">SHORT-TERM INVESTMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CostAbstract" xlink:href="canf-20221231.xsd#canf_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CostAbstract" xlink:to="canf_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract55" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract55"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract55_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract55" xlink:to="canf_UnlabeledAbstract55_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract56" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract56"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract56_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract56" xlink:to="canf_UnlabeledAbstract56_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AccumulatedDepreciationAbstract" xlink:href="canf-20221231.xsd#canf_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="canf_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract57" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract57"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract57_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract57" xlink:to="canf_UnlabeledAbstract57_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract58" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract58"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract58_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract58" xlink:to="canf_UnlabeledAbstract58_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract59" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract59"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract59_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract59" xlink:to="canf_UnlabeledAbstract59_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20221231.xsd#canf_EmployeesAndPayrollAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_EmployeesAndPayrollAccruals_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract60" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract60"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract60_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract60" xlink:to="canf_UnlabeledAbstract60_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of financial assets and liabilities measured at fair value on a recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl" xml:lang="en-US">Schedule of information regarding outstanding warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceDate" xlink:href="canf-20221231.xsd#canf_IssuanceDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceDate_lbl" xml:lang="en-US">Issuance date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceDate" xlink:to="canf_IssuanceDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of outstanding warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract61" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract61"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract61_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract61" xlink:to="canf_UnlabeledAbstract61_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED PAYMENT TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesTableTextBlock" xlink:to="canf_ScheduleOfExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated using the binomial option pricing model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:href="canf-20221231.xsd#canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xml:lang="en-US">Early Exercise Multiple (Suboptimal Factor)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:to="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (NIS) (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of share options, their weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual terms (in years) beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual terms (in years), Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" xlink:href="canf-20221231.xsd#canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired_lbl" xml:lang="en-US">Weighted average remaining contractual terms (in years), Forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" xlink:to="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateIntrinsicValueForfeitedexpired" xlink:href="canf-20221231.xsd#canf_AggregateIntrinsicValueForfeitedexpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregateIntrinsicValueForfeitedexpired_lbl" xml:lang="en-US">Aggregate intrinsic value, Forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateIntrinsicValueForfeitedexpired" xlink:to="canf_AggregateIntrinsicValueForfeitedexpired_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract62" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract62"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract62_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract62" xlink:to="canf_UnlabeledAbstract62_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual terms (in years) end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract63" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract63"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract63_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract63" xlink:to="canf_UnlabeledAbstract63_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_lbl" xml:lang="en-US">Number of options, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual terms (in years), Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract64" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract64"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract64_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract64" xlink:to="canf_UnlabeledAbstract64_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual terms (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms and discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">weighted average remaining lease term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20221231.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ComponentsOfLeaseExpenseAbstract_lbl" xml:lang="en-US">Components of lease expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract65" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract65"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract65_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract65" xlink:to="canf_UnlabeledAbstract65_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20221231.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract66" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract66"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract66_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract66" xlink:to="canf_UnlabeledAbstract66_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20221231.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl" xml:lang="en-US">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20221231.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl" xml:lang="en-US">Total operating lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl" xml:lang="en-US">FINANCE INCOME (EXPENSE), NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of components of finance (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpensesAbstract" xlink:href="canf-20221231.xsd#canf_FinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceExpensesAbstract_lbl" xml:lang="en-US">Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_FinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_BanksCommissions" xlink:href="canf-20221231.xsd#canf_BanksCommissions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_BanksCommissions_lbl" xml:lang="en-US">Bank commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NetLossFromExchangeRateFluctuations" xlink:href="canf-20221231.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl" xml:lang="en-US">Net loss from exchange rate fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20221231.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl" xml:lang="en-US">Other loss from short-term investment revaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract67" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract67"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract67_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract67" xlink:to="canf_UnlabeledAbstract67_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpenses" xlink:href="canf-20221231.xsd#canf_FinanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceExpenses_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeAbstract" xlink:href="canf-20221231.xsd#canf_FinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceIncomeAbstract_lbl" xml:lang="en-US">Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_FinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US">Interest income on bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExchangeRateFluctuations" xlink:href="canf-20221231.xsd#canf_ExchangeRateFluctuations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExchangeRateFluctuations_lbl" xml:lang="en-US">Exchange rate fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Other gain from short-term investment remeasurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract68" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract68"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract68_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract68" xlink:to="canf_UnlabeledAbstract68_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncome" xlink:href="canf-20221231.xsd#canf_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract69" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract69"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract69_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract69" xlink:to="canf_UnlabeledAbstract69_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Total financial income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_DeferredTaxAssetsAbstract" xlink:href="canf-20221231.xsd#canf_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="canf_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Temporary differences mainly relating to Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnlabeledAbstract70" xlink:href="canf-20221231.xsd#canf_UnlabeledAbstract70"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnlabeledAbstract70_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract70" xlink:to="canf_UnlabeledAbstract70_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax asset before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">TRANSACTIONS WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of options, Forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ImputedInterestLessImputedInterest" xlink:href="canf-20221231.xsd#canf_ImputedInterestLessImputedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="canf_ImputedInterestLessImputedInterest_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other financial expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20221231.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Laboratory equipment and Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20221231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl" xml:lang="en-US">Computers, office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CipherPharmaceuticalsMember" xlink:href="canf-20221231.xsd#canf_CipherPharmaceuticalsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CipherPharmaceuticalsMember_lbl" xml:lang="en-US">Cipher Pharmaceuticals [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherPharmaceuticalsMember" xlink:to="canf_CipherPharmaceuticalsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20221231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl" xml:lang="en-US">Chong Kun Dang Pharmaceuticals Corp [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GebroHoldingGmBHMember" xlink:href="canf-20221231.xsd#canf_GebroHoldingGmBHMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GebroHoldingGmBHMember_lbl" xml:lang="en-US">Gebro Holding GmBH [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GebroHoldingGmBHMember" xlink:to="canf_GebroHoldingGmBHMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_EwopharmaAGMember" xlink:href="canf-20221231.xsd#canf_EwopharmaAGMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_EwopharmaAGMember_lbl" xml:lang="en-US">Ewopharma AG [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaAGMember" xlink:to="canf_EwopharmaAGMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentMember" xlink:href="canf-20221231.xsd#canf_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentMember" xlink:to="canf_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_March2018Member" xlink:href="canf-20221231.xsd#canf_March2018Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_March2018Member_lbl" xml:lang="en-US">March 2018 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_March2018Member" xlink:to="canf_March2018Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_January2019Member" xlink:href="canf-20221231.xsd#canf_January2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_January2019Member_lbl" xml:lang="en-US">January 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2019Member" xlink:to="canf_January2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_April2019Member" xlink:href="canf-20221231.xsd#canf_April2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_April2019Member_lbl" xml:lang="en-US">April 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_April2019Member" xlink:to="canf_April2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_May2019Member" xlink:href="canf-20221231.xsd#canf_May2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_May2019Member_lbl" xml:lang="en-US">May 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_May2019Member" xlink:to="canf_May2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_January2020Member" xlink:href="canf-20221231.xsd#canf_January2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_January2020Member_lbl" xml:lang="en-US">January 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2020Member" xlink:to="canf_January2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_February2020Member" xlink:href="canf-20221231.xsd#canf_February2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_February2020Member_lbl" xml:lang="en-US">February 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_February2020Member" xlink:to="canf_February2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_June2020Member" xlink:href="canf-20221231.xsd#canf_June2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_June2020Member_lbl" xml:lang="en-US">June 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_June2020Member" xlink:to="canf_June2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_July2020Member" xlink:href="canf-20221231.xsd#canf_July2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_July2020Member_lbl" xml:lang="en-US">July 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_July2020Member" xlink:to="canf_July2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_August2021Member" xlink:href="canf-20221231.xsd#canf_August2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_August2021Member_lbl" xml:lang="en-US">August 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_August2021Member" xlink:to="canf_August2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_December2021Member" xlink:href="canf-20221231.xsd#canf_December2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_December2021Member_lbl" xml:lang="en-US">December 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_December2021Member" xlink:to="canf_December2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number of ordinary shares represent by each ADS (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="canf_NetLosses" xlink:href="canf-20221231.xsd#canf_NetLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NetLosses_lbl" xml:lang="en-US">Net losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLosses" xlink:to="canf_NetLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CashFlowsFromOperatingActivities" xlink:href="canf-20221231.xsd#canf_CashFlowsFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CashFlowsFromOperatingActivities_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_lbl" xml:lang="en-US">Weighted average rates percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContractLiabilities" xlink:href="canf-20221231.xsd#canf_ContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ContractLiabilities_lbl" xml:lang="en-US">Contract liabilities under deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_Revenue" xlink:href="canf-20221231.xsd#canf_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_Revenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20221231.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl" xml:lang="en-US">Percentage of deposits on monthly salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance pay expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20221231.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl" xml:lang="en-US">Maximum percentage of realization on ultimate settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares hold by company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sold an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfOutstandingShares" xlink:href="canf-20221231.xsd#canf_PercentageOfOutstandingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfOutstandingShares_lbl" xml:lang="en-US">Percentage of outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment_lbl" xml:lang="en-US">Additional payments (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment" xlink:to="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Payments percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfRegulatoryAssistanceReceived1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1_lbl" xml:lang="en-US">Up-front amount receive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:to="us-gaap_AmountOfRegulatoryAssistanceReceived1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLoansPayable_lbl" xml:lang="en-US">Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayable" xlink:to="us-gaap_OtherLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfFIFOInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfFIFOInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PercentageOfFIFOInventory_lbl" xml:lang="en-US">Cost plus percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfFIFOInventory" xlink:to="us-gaap_PercentageOfFIFOInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesReceivedAsCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuritiesReceivedAsCollateral_lbl" xml:lang="en-US">Amount received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesReceivedAsCollateral" xlink:to="us-gaap_SecuritiesReceivedAsCollateral_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional and payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_DistributionAndSupplyAgreementDescription" xlink:href="canf-20221231.xsd#canf_DistributionAndSupplyAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_DistributionAndSupplyAgreementDescription_lbl" xml:lang="en-US">Distribution and supply agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DistributionAndSupplyAgreementDescription" xlink:to="canf_DistributionAndSupplyAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredSalesInducementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredSalesInducementsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredSalesInducementsNet_lbl" xml:lang="en-US">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredSalesInducementsNet" xlink:to="us-gaap_DeferredSalesInducementsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToSuppliers_lbl" xml:lang="en-US">Total payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliers" xlink:to="us-gaap_PaymentsToSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCollateralAggregateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue_lbl" xml:lang="en-US">Additional payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCollateralAggregateFairValue" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_MilestonePercentage" xlink:href="canf-20221231.xsd#canf_MilestonePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_MilestonePercentage_lbl" xml:lang="en-US">Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_MilestonePercentage" xlink:to="canf_MilestonePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignatureDate" xlink:href="canf-20221231.xsd#canf_SignatureDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SignatureDate_lbl" xml:lang="en-US">Signature date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignatureDate" xlink:to="canf_SignatureDate_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RoyalitiesDescription" xlink:href="canf-20221231.xsd#canf_RoyalitiesDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RoyalitiesDescription_lbl" xml:lang="en-US">Royalities, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyalitiesDescription" xlink:to="canf_RoyalitiesDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_lbl" xml:lang="en-US">Commission Income Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseCommissionExpense" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Annual royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfNetSales" xlink:href="canf-20221231.xsd#canf_PercentageOfNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfNetSales_lbl" xml:lang="en-US">Percentage of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvanceRoyalties_lbl" xml:lang="en-US">Royalties in a total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRoyalties" xlink:to="us-gaap_AdvanceRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyPaymentsPercentage" xlink:href="canf-20221231.xsd#canf_RoyaltyPaymentsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RoyaltyPaymentsPercentage_lbl" xml:lang="en-US">Royalty payments, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PatentAgreementDescription" xlink:href="canf-20221231.xsd#canf_PatentAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PatentAgreementDescription_lbl" xml:lang="en-US">Patent agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_AggregatePurchasePrice" xlink:href="canf-20221231.xsd#canf_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregatePurchasePrice_lbl" xml:lang="en-US">Ordinary share issued per share (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssueOfNewUnregisteredWarrants" xlink:href="canf-20221231.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl" xml:lang="en-US">Issue of new unregistered warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" xlink:href="canf-20221231.xsd#canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights_lbl" xml:lang="en-US">Warrants exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" xlink:to="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_DeemedDividend" xlink:href="canf-20221231.xsd#canf_DeemedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SecuritiesPurchaseAgreementDescription" xlink:href="canf-20221231.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl" xml:lang="en-US">Securities purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Gross proceeds from offering (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CompensationWarrantsExercisable" xlink:href="canf-20221231.xsd#canf_CompensationWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CompensationWarrantsExercisable_lbl" xml:lang="en-US">Compensation warrant exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrices" xlink:href="canf-20221231.xsd#canf_ExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePrices_lbl" xml:lang="en-US">Exercise prices (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Expiring date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Ordinary per share issued (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseAuthorizedShareCapital" xlink:href="canf-20221231.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl" xml:lang="en-US">Increase authorized capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateWarrantPurchased" xlink:href="canf-20221231.xsd#canf_AggregateWarrantPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregateWarrantPurchased_lbl" xml:lang="en-US">Aggregate warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceSubjectToAdjusment" xlink:href="canf-20221231.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl" xml:lang="en-US">Exercise price subject to adjustment (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateNumbersOfADS" xlink:href="canf-20221231.xsd#canf_AggregateNumbersOfADS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregateNumbersOfADS_lbl" xml:lang="en-US">Aggregate number of ADS percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumbersOfADS" xlink:to="canf_AggregateNumbersOfADS_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAggregateShares" xlink:href="canf-20221231.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl" xml:lang="en-US">Warrants to purchase aggregate ADS shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrice" xlink:href="canf-20221231.xsd#canf_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TotalConsiderationAmount" xlink:href="canf-20221231.xsd#canf_TotalConsiderationAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_TotalConsiderationAmount_lbl" xml:lang="en-US">Total consideration amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent_lbl" xml:lang="en-US">Exchange services (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:to="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PreFundedWarrant" xlink:href="canf-20221231.xsd#canf_PreFundedWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PreFundedWarrant_lbl" xml:lang="en-US">Pre-funded warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PreFundedWarrant" xlink:to="canf_PreFundedWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateNumberOfADS" xlink:href="canf-20221231.xsd#canf_AggregateNumberOfADS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregateNumberOfADS_lbl" xml:lang="en-US">Aggregate number of ADS percentage (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceExpenses" xlink:href="canf-20221231.xsd#canf_IssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceExpenses_lbl" xml:lang="en-US">Issuance expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpenses" xlink:to="canf_IssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl" xml:lang="en-US">Initial exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuanceAgreementDescription" xlink:href="canf-20221231.xsd#canf_StockIssuanceAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuanceAgreementDescription_lbl" xml:lang="en-US">Stock issuance agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExerciseAgreementDescription" xlink:href="canf-20221231.xsd#canf_ExerciseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExerciseAgreementDescription_lbl" xml:lang="en-US">Exercise agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExerciseAgreementDescription" xlink:to="canf_ExerciseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GrantedExcessYears" xlink:href="canf-20221231.xsd#canf_GrantedExcessYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GrantedExcessYears_lbl" xml:lang="en-US">Granted excess years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GrantedExcessYears" xlink:to="canf_GrantedExcessYears_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FutureShares" xlink:href="canf-20221231.xsd#canf_FutureShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FutureShares_lbl" xml:lang="en-US">Future shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Compensation costs not yet recognized (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_DevelopmentAreaAPercentage" xlink:href="canf-20221231.xsd#canf_DevelopmentAreaAPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_DevelopmentAreaAPercentage_lbl" xml:lang="en-US">Development area percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DevelopmentAreaAPercentage" xlink:to="canf_DevelopmentAreaAPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Carryforward losses amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Aggregate amount of research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseTransferAgentAndCustodianFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees_lbl" xml:lang="en-US">Aggregate amount paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees" xlink:to="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NetOfDirectIssuanceCosts" xlink:href="canf-20221231.xsd#canf_NetOfDirectIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NetOfDirectIssuanceCosts_lbl" xml:lang="en-US">Net of direct issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetOfDirectIssuanceCosts" xlink:to="canf_NetOfDirectIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmPO7kW86fCwO9BDdY5bf5b9H+vvjKwz2saovEzZ3dBRA5yWdSLppMepuvQwgTmpdXkG6aEqg3eKP65vjM+XithEfqz6791Pl3kR8GSmegnWDwHi4saeWspssaWBbo7hPE] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency, reporting currency and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Prepaid expenses, and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Legal and other contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SeverancePayPolicyTextBlock" xlink:href="canf-20221231.xsd#canf_SeverancePayPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20221231.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl" xml:lang="en-US">Ordinary share and warrants classification and measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted and recently issued accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CMSMedicalVentureInvestmentLimitedMember" xlink:href="canf-20221231.xsd#canf_CMSMedicalVentureInvestmentLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CMSMedicalVentureInvestmentLimitedMember_lbl" xml:lang="en-US">CMS Medical Venture Investment Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CMSMedicalVentureInvestmentLimitedMember" xlink:to="canf_CMSMedicalVentureInvestmentLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_EwopharmaMember" xlink:href="canf-20221231.xsd#canf_EwopharmaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_EwopharmaMember_lbl" xml:lang="en-US">Ewopharma [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaMember" xlink:to="canf_EwopharmaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ADSMember" xlink:href="canf-20221231.xsd#canf_ADSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ADSMember_lbl" xml:lang="en-US">ADS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl0" xml:lang="en-US">Israel Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_RDPurchaseAgreementMember" xlink:href="canf-20221231.xsd#canf_RDPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RDPurchaseAgreementMember_lbl" xml:lang="en-US">RD Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RDPurchaseAgreementMember" xlink:to="canf_RDPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PrefundedWarrantsMember" xlink:href="canf-20221231.xsd#canf_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PrefundedWarrantsMember" xlink:to="canf_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SeriesAWarrantMember" xlink:href="canf-20221231.xsd#canf_SeriesAWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SeriesAWarrantMember_lbl" xml:lang="en-US">Series A Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeriesAWarrantMember" xlink:to="canf_SeriesAWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SeriesBWarrantMember" xlink:href="canf-20221231.xsd#canf_SeriesBWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SeriesBWarrantMember_lbl" xml:lang="en-US">Series B warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeriesBWarrantMember" xlink:to="canf_SeriesBWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnregisteredPrefundedWarrantsMember" xlink:href="canf-20221231.xsd#canf_UnregisteredPrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnregisteredPrefundedWarrantsMember_lbl" xml:lang="en-US">Unregistered Pre-funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnregisteredPrefundedWarrantsMember" xlink:to="canf_UnregisteredPrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PlacementAgentWarrantMember" xlink:href="canf-20221231.xsd#canf_PlacementAgentWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PlacementAgentWarrantMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PlacementAgentWarrantMember" xlink:to="canf_PlacementAgentWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShortTermInvestmentTable" xlink:href="canf-20221231.xsd#canf_ShortTermInvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShortTermInvestmentTable_lbl" xml:lang="en-US">Short-Term Investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShortTermInvestmentTable" xlink:to="canf_ShortTermInvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTable" xlink:href="canf-20221231.xsd#canf_OtherAccountsPayableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsPayableTable_lbl" xml:lang="en-US">Other Accounts Payable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableTable" xlink:to="canf_OtherAccountsPayableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableLineItems" xlink:href="canf-20221231.xsd#canf_OtherAccountsPayableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsPayableLineItems_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="canf_OtherAccountsPayableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20221231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20221231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable_lbl" xml:lang="en-US">Schedule of Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems_lbl" xml:lang="en-US">Schedule of Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RevenuesDetailsTable" xlink:href="canf-20221231.xsd#canf_RevenuesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RevenuesDetailsTable_lbl" xml:lang="en-US">Revenues (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenuesDetailsTable" xlink:to="canf_RevenuesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RevenuesDetailsLineItems" xlink:href="canf-20221231.xsd#canf_RevenuesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RevenuesDetailsLineItems_lbl" xml:lang="en-US">Revenues (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenuesDetailsLineItems" xlink:to="canf_RevenuesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20221231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsTable" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="canf_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:to="canf_ShareBasedPaymentTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsTable" xlink:href="canf-20221231.xsd#canf_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TaxesonIncomeDetailsTable" xlink:to="canf_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsLineItems" xlink:href="canf-20221231.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Taxes on Income (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="canf_TaxesonIncomeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SubsequentEventsDetailsTable" xlink:href="canf-20221231.xsd#canf_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="canf_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SubsequentEventsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SubsequentEventsDetailsLineItems" xlink:to="canf_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregateIntrinsicValueForfeitedexpired_lbl0" xml:lang="en-US">Amount of aggregate intrinsic value, Forfeited/expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateIntrinsicValueForfeitedexpired" xlink:to="canf_AggregateIntrinsicValueForfeitedexpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregateNumberOfADS_lbl0" xml:lang="en-US">aggregate number of ADS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregateNumbersOfADS_lbl0" xml:lang="en-US">Percentage of aggregate number of ADS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumbersOfADS" xlink:to="canf_AggregateNumbersOfADS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregateWarrantPurchased_lbl0" xml:lang="en-US">Aggregate warrant purchased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_BanksCommissions_lbl0" xml:lang="en-US">Bank commissions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CashFlowsFromOperatingActivities_lbl0" xml:lang="en-US">Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl0" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights_lbl0" xml:lang="en-US">Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" xlink:to="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CompensationWarrantsExercisable_lbl0" xml:lang="en-US">compensation warrants exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ContractLiabilities_lbl0" xml:lang="en-US">Amouunt of contract liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_DeemedDividend_lbl0" xml:lang="en-US">Deemed dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_DevelopmentAreaAPercentage_lbl0" xml:lang="en-US">Development area percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DevelopmentAreaAPercentage" xlink:to="canf_DevelopmentAreaAPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_DistributionAndSupplyAgreementDescription_lbl0" xml:lang="en-US">The description of distribution and supply agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DistributionAndSupplyAgreementDescription" xlink:to="canf_DistributionAndSupplyAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_EmployeesAndPayrollAccruals_lbl0" xml:lang="en-US">Amount of employees and payroll accruals.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExchangeRateFluctuations_lbl0" xml:lang="en-US">Exchange rate fluctuations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePrice_lbl0" xml:lang="en-US">Exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl0" xml:lang="en-US">Exercise price Subject to adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePrices_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FinanceExpenses_lbl0" xml:lang="en-US">The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FinanceIncome_lbl0" xml:lang="en-US">The aggregate amount of income from finance income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FutureShares_lbl0" xml:lang="en-US">Future shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_GovernmentAuthorities_lbl0" xml:lang="en-US">Amount of government authorities for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ImputedInterestLessImputedInterest_lbl0" xml:lang="en-US">imputed interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl0" xml:lang="en-US">Increase authorized Share Capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl0" xml:lang="en-US">Amount of changes in fair value of short-term investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceExpenses_lbl0" xml:lang="en-US">Issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpenses" xlink:to="canf_IssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl0" xml:lang="en-US">Issuance of share capital due to warrants exercise, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl0" xml:lang="en-US">Issuance of share capital due to warrants exercise, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl0" xml:lang="en-US">Issue of New Unregistered Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_MilestonePercentage_lbl0" xml:lang="en-US">The percentage of milestone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_MilestonePercentage" xlink:to="canf_MilestonePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl0" xml:lang="en-US">Net loss from exchange rate fluctuations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NetLosses_lbl0" xml:lang="en-US">The amount of net losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLosses" xlink:to="canf_NetLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NetOfDirectIssuanceCosts_lbl0" xml:lang="en-US">Amount of net of direct issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetOfDirectIssuanceCosts" xlink:to="canf_NetOfDirectIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_Options_lbl0" xml:lang="en-US">The number of options shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Options" xlink:to="canf_Options_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for ordinary share warrants classification and measurement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl0" xml:lang="en-US">Other loss from short-term investment revaluation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PatentAgreementDescription_lbl0" xml:lang="en-US">The description of patent agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl0" xml:lang="en-US">Percentage of deposits on monthly salary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfNetSales_lbl0" xml:lang="en-US">The percentage of net sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfOutstandingShares_lbl0" xml:lang="en-US">Percentage of outstanding shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl0" xml:lang="en-US">Percentage of realization on ultimate settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PreFundedWarrant_lbl0" xml:lang="en-US">Per share amount of pre-funded warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PreFundedWarrant" xlink:to="canf_PreFundedWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_Revenue_lbl0" xml:lang="en-US">Revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RevenueContractWithCustomer_lbl0" xml:lang="en-US">Revenue contract with customer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RoyalitiesDescription_lbl0" xml:lang="en-US">The description of royalities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyalitiesDescription" xlink:to="canf_RoyalitiesDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RoyaltyPaymentsPercentage_lbl0" xml:lang="en-US">The royalty payment in percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of major customer data as a percentage of total revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl0" xml:lang="en-US">Useful lives of the assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl0" xml:lang="en-US">Securities Purchase Agreement, Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SeverancePayPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl0" xml:lang="en-US">Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:to="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SignatureDate_lbl0" xml:lang="en-US">The signature date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignatureDate" xlink:to="canf_SignatureDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuanceAgreementDescription_lbl0" xml:lang="en-US">Stock issuance agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl0" xml:lang="en-US">Number of issuance of share capital and warrants, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl0" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl0" xml:lang="en-US">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_TotalConsiderationAmount_lbl0" xml:lang="en-US">Total consideration amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_TotalinDollars_lbl0" xml:lang="en-US">The number of total shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalinDollars" xlink:to="canf_TotalinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl0" xml:lang="en-US">Depreciation rates property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WarrantsNetOfIssuanceExpenses_lbl0" xml:lang="en-US">Warrants, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssuanceExpenses" xlink:to="canf_WarrantsNetOfIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl0" xml:lang="en-US">Warrants to purchase aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WithdrawalinvestmentInShorttermDepositsNet_lbl0" xml:lang="en-US">Amount of withdrawal (investment) in short-term deposits, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WithdrawalinvestmentInShorttermDepositsNet" xlink:to="canf_WithdrawalinvestmentInShorttermDepositsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ADSMember_lbl0" xml:lang="en-US">American Depository Receipt (or American Depository Share, ADS).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_April2019Member_lbl0" xml:lang="en-US">April2019 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_April2019Member" xlink:to="canf_April2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl1"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="canf_ScheduleOfExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract61_lbl0" xml:lang="en-US">Unlabeled Abstract61</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract61" xlink:to="canf_UnlabeledAbstract61_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl0" xml:lang="en-US">Chong Kun Dang Pharmaceuticals Corp Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract62_lbl0" xml:lang="en-US">Unlabeled Abstract62</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract62" xlink:to="canf_UnlabeledAbstract62_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract60_lbl0" xml:lang="en-US">Unlabeled Abstract60</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract60" xlink:to="canf_UnlabeledAbstract60_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract65_lbl0" xml:lang="en-US">Unlabeled Abstract65</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract65" xlink:to="canf_UnlabeledAbstract65_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract66_lbl0" xml:lang="en-US">Unlabeled Abstract66</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract66" xlink:to="canf_UnlabeledAbstract66_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract63_lbl0" xml:lang="en-US">Unlabeled Abstract63</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract63" xlink:to="canf_UnlabeledAbstract63_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract64_lbl0" xml:lang="en-US">Unlabeled Abstract64</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract64" xlink:to="canf_UnlabeledAbstract64_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract69_lbl0" xml:lang="en-US">Unlabeled Abstract69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract69" xlink:to="canf_UnlabeledAbstract69_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FutureShares_lbl1" xml:lang="en-US">Future Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl0" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract67_lbl0" xml:lang="en-US">Unlabeled Abstract67</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract67" xlink:to="canf_UnlabeledAbstract67_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract68_lbl0" xml:lang="en-US">Unlabeled Abstract68</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract68" xlink:to="canf_UnlabeledAbstract68_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0" xml:lang="en-US">Interest Income, Deposits with Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BankingAndThriftInterestAbstract_lbl" xml:lang="en-US">Banking and Thrift, Interest [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_BankingAndThriftInterestAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl1" xml:lang="en-US">Warrants To Purchase Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract70_lbl0" xml:lang="en-US">Unlabeled Abstract70</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract70" xlink:to="canf_UnlabeledAbstract70_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SeriesBWarrantMember_lbl0" xml:lang="en-US">Series BWarrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeriesBWarrantMember" xlink:to="canf_SeriesBWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract38" xlink:to="canf_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract39" xlink:to="canf_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_August2021Member_lbl0" xml:lang="en-US">August2021 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_August2021Member" xlink:to="canf_August2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract40" xlink:to="canf_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract43" xlink:to="canf_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract44" xlink:to="canf_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract41" xlink:to="canf_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract42" xlink:to="canf_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract47" xlink:to="canf_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract48" xlink:to="canf_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract45" xlink:to="canf_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract46" xlink:to="canf_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract49" xlink:to="canf_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RoyalitiesDescription_lbl1" xml:lang="en-US">Royalities Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyalitiesDescription" xlink:to="canf_RoyalitiesDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceDate_lbl0" xml:lang="en-US">Issuance Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceDate" xlink:to="canf_IssuanceDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Share Capital And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract50" xlink:to="canf_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract51" xlink:to="canf_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract54_lbl0" xml:lang="en-US">Unlabeled Abstract54</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract54" xlink:to="canf_UnlabeledAbstract54_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract55_lbl0" xml:lang="en-US">Unlabeled Abstract55</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract55" xlink:to="canf_UnlabeledAbstract55_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract52" xlink:to="canf_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract53_lbl0" xml:lang="en-US">Unlabeled Abstract53</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract53" xlink:to="canf_UnlabeledAbstract53_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract58_lbl0" xml:lang="en-US">Unlabeled Abstract58</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract58" xlink:to="canf_UnlabeledAbstract58_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract59_lbl0" xml:lang="en-US">Unlabeled Abstract59</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract59" xlink:to="canf_UnlabeledAbstract59_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract56_lbl0" xml:lang="en-US">Unlabeled Abstract56</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract56" xlink:to="canf_UnlabeledAbstract56_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract57_lbl0" xml:lang="en-US">Unlabeled Abstract57</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract57" xlink:to="canf_UnlabeledAbstract57_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract18" xlink:to="canf_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract19" xlink:to="canf_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SeriesAWarrantMember_lbl0" xml:lang="en-US">Series AWarrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeriesAWarrantMember" xlink:to="canf_SeriesAWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract16" xlink:to="canf_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract17" xlink:to="canf_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:to="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLoansPayable_lbl0" xml:lang="en-US">Other Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayable" xlink:to="us-gaap_OtherLoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_lbl0" xml:lang="en-US">Noninterest Expense Commission Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseCommissionExpense" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract21" xlink:to="canf_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract22" xlink:to="canf_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract20" xlink:to="canf_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Share Issuance Of Share Capital And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract25" xlink:to="canf_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract26" xlink:to="canf_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_EmployeesAndPayrollAccruals_lbl1" xml:lang="en-US">Employees And Payroll Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract23" xlink:to="canf_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PatentAgreementDescription_lbl1" xml:lang="en-US">Patent Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees_lbl0" xml:lang="en-US">Noninterest Expense Transfer Agent and Custodian Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees" xlink:to="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SeverancePayPolicyTextBlock_lbl1" xml:lang="en-US">Severance Pay Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract24" xlink:to="canf_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract29" xlink:to="canf_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_lbl0" xml:lang="en-US">Investment [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract27" xlink:to="canf_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract28" xlink:to="canf_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CashFlowsFromOperatingActivities_lbl1" xml:lang="en-US">Cash Flows From Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl1" xml:lang="en-US">Israel Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesReceivedAsCollateral_lbl0" xml:lang="en-US">Securities Received as Collateral</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesReceivedAsCollateral" xlink:to="us-gaap_SecuritiesReceivedAsCollateral_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract32" xlink:to="canf_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract33" xlink:to="canf_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract30" xlink:to="canf_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract31" xlink:to="canf_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract36" xlink:to="canf_UnlabeledAbstract36_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract37" xlink:to="canf_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceExpensesAbstract_lbl0" xml:lang="en-US">Finance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_FinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract34" xlink:to="canf_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract35" xlink:to="canf_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Useful Lives Of The Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_January2020Member_lbl0" xml:lang="en-US">January2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2020Member" xlink:to="canf_January2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_Revenue_lbl1" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl1" xml:lang="en-US">Securities Purchase Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl2" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract10" xlink:to="canf_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract11" xlink:to="canf_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl1" xml:lang="en-US">Useful Lives Or Depreciation Rates Property Plant And Equipments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract14" xlink:to="canf_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TotalConsiderationAmount_lbl1" xml:lang="en-US">Total Consideration Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract15" xlink:to="canf_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract12" xlink:to="canf_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract13" xlink:to="canf_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl0" xml:lang="en-US">Payments of Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GebroHoldingGmBHMember_lbl0" xml:lang="en-US">Gebro Holding Gm BHMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GebroHoldingGmBHMember" xlink:to="canf_GebroHoldingGmBHMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl1" xml:lang="en-US">Percentage Of Deposits On Monthly Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl1" xml:lang="en-US">Issue Of New Unregistered Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePrices_lbl1" xml:lang="en-US">Exercise Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfExpensesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesTableTextBlock" xlink:to="canf_ScheduleOfExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl1" xml:lang="en-US">Supplemental Noncash Information Related To Lease Liabilities Arising From Obtaining ROUAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl1" xml:lang="en-US">Increase Authorized Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract2" xlink:to="canf_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract1" xlink:to="canf_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract4" xlink:to="canf_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract3" xlink:to="canf_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregateWarrantPurchased_lbl1" xml:lang="en-US">Aggregate Warrant Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract0" xlink:to="canf_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelFaxNumber_lbl0" xml:lang="en-US">Contact Personnel Fax Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelFaxNumber" xlink:to="dei_ContactPersonnelFaxNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract9" xlink:to="canf_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract6" xlink:to="canf_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract5" xlink:to="canf_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract8" xlink:to="canf_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract7" xlink:to="canf_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_February2020Member_lbl0" xml:lang="en-US">February2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_February2020Member" xlink:to="canf_February2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RDPurchaseAgreementMember_lbl0" xml:lang="en-US">RDPurchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RDPurchaseAgreementMember" xlink:to="canf_RDPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContractLiabilities_lbl1" xml:lang="en-US">Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnlabeledAbstract" xlink:to="canf_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregateNumberOfADS_lbl1" xml:lang="en-US">Aggregate Number Of ADS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1_lbl0" xml:lang="en-US">Amount of Regulatory Assistance Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:to="us-gaap_AmountOfRegulatoryAssistanceReceived1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl1" xml:lang="en-US">Net Loss From Exchange Rate Fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl0" xml:lang="en-US">Laboratory Equipment And Leasehold Improvements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract_lbl" xml:lang="en-US">Schedule Of Lease Expense And Supplemental Cash Flow Information Related To Leases And Weighted Average Remaining Lease Terms And Discount Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_BanksCommissions_lbl1" xml:lang="en-US">Banks Commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RoyaltyPaymentsPercentage_lbl1" xml:lang="en-US">Royalty Payments Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_lbl" xml:lang="en-US">Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl1" xml:lang="en-US">Percentage Of Realization On Ultimate Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired_lbl0" xml:lang="en-US">Weighted Average Remaining Contractual Termsin Years Forfeitedexpired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" xlink:to="canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_January2019Member_lbl0" xml:lang="en-US">January2019 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2019Member" xlink:to="canf_January2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_July2020Member_lbl0" xml:lang="en-US">July2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_July2020Member" xlink:to="canf_July2020Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl0" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="canf_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Major Customer Data As APercentage Of Total Revenues Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Using The Binomial Option Pricing Model Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignatureDate_lbl1" xml:lang="en-US">Signature Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignatureDate" xlink:to="canf_SignatureDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuanceAgreementDescription_lbl1" xml:lang="en-US">Stock Issuance Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceExpenses_lbl1" xml:lang="en-US">Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpenses" xlink:to="canf_IssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CMSMedicalVentureInvestmentLimitedMember_lbl0" xml:lang="en-US">CMSMedical Venture Investment Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CMSMedicalVentureInvestmentLimitedMember" xlink:to="canf_CMSMedicalVentureInvestmentLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NetLosses_lbl1" xml:lang="en-US">Net Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLosses" xlink:to="canf_NetLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl0" xml:lang="en-US">Depreciation Expense on Reclassified Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_Options_lbl1" xml:lang="en-US">Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Options" xlink:to="canf_Options_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnregisteredPrefundedWarrantsMember_lbl0" xml:lang="en-US">Unregistered Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnregisteredPrefundedWarrantsMember" xlink:to="canf_UnregisteredPrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">Laboratory Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentMember" xlink:to="canf_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl1" xml:lang="en-US">Issuance Of Share Capital Due To Warrants Exercise Net Of Issuance Expensesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="canf_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_DistributionAndSupplyAgreementDescription_lbl1" xml:lang="en-US">Distribution And Supply Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DistributionAndSupplyAgreementDescription" xlink:to="canf_DistributionAndSupplyAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PercentageOfFIFOInventory_lbl0" xml:lang="en-US">Percentage of FIFO Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfFIFOInventory" xlink:to="us-gaap_PercentageOfFIFOInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GovernmentAuthorities_lbl1" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl1" xml:lang="en-US">Increase Decrease In Changes In Fair Value Of Shortterm Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CostAbstract" xlink:to="canf_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RevenueContractWithCustomer_lbl1" xml:lang="en-US">Revenue Contract With Customer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TotalinDollars_lbl1" xml:lang="en-US">Totalin Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalinDollars" xlink:to="canf_TotalinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl1" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl1" xml:lang="en-US">Share Based Payment Award Fair Value Assumptions Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl0" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding Share Options And Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:to="canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ImputedInterestLessImputedInterest_lbl1" xml:lang="en-US">Imputed Interest Less Imputed Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CipherPharmaceuticalsMember_lbl0" xml:lang="en-US">Cipher Pharmaceuticals Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherPharmaceuticalsMember" xlink:to="canf_CipherPharmaceuticalsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_DevelopmentAreaAPercentage_lbl1" xml:lang="en-US">Development Area APercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DevelopmentAreaAPercentage" xlink:to="canf_DevelopmentAreaAPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GrantedExcessYears_lbl0" xml:lang="en-US">Granted Excess Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GrantedExcessYears" xlink:to="canf_GrantedExcessYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_June2020Member_lbl0" xml:lang="en-US">June2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_June2020Member" xlink:to="canf_June2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncome_lbl1" xml:lang="en-US">Finance Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ComponentsOfLeaseExpenseAbstract_lbl0" xml:lang="en-US">Components Of Lease Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Exchange Fee Rebate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:to="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Receivables and Portions of Securitizations that can be Prepaid at Potential Loss, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment_lbl0" xml:lang="en-US">Additional Liability, Long-Duration Insurance, Benefit Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment" xlink:to="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NetOfDirectIssuanceCosts_lbl1" xml:lang="en-US">Net Of Direct Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetOfDirectIssuanceCosts" xlink:to="canf_NetOfDirectIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregateIntrinsicValueForfeitedexpired_lbl1" xml:lang="en-US">Aggregate Intrinsic Value Forfeitedexpired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateIntrinsicValueForfeitedexpired" xlink:to="canf_AggregateIntrinsicValueForfeitedexpired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Financial Assets And Liabilities Measured At Fair Value On ARecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl0" xml:lang="en-US">Computers Office Furniture And Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PlacementAgentWarrantMember_lbl0" xml:lang="en-US">Placement Agent Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PlacementAgentWarrantMember" xlink:to="canf_PlacementAgentWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl1" xml:lang="en-US">Issuance Of Share Capital Due To Warrants Exercise Net Of Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Proceeds from Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncomeAbstract_lbl0" xml:lang="en-US">Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_FinanceIncomeAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WithdrawalinvestmentInShorttermDepositsNet_lbl1" xml:lang="en-US">Withdrawalinvestment In Shortterm Deposits Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WithdrawalinvestmentInShorttermDepositsNet" xlink:to="canf_WithdrawalinvestmentInShorttermDepositsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToSuppliers_lbl0" xml:lang="en-US">Payments to Suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliers" xlink:to="us-gaap_PaymentsToSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl0" xml:lang="en-US">Accelerated Share Repurchases, Initial Price Paid Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:to="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl1" xml:lang="en-US">Exercise Price Subject To Adjusment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue_lbl0" xml:lang="en-US">Additional Collateral, Aggregate Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCollateralAggregateFairValue" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl1" xml:lang="en-US">Lessee Operating Lease Liability Payment Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PrefundedWarrantsMember" xlink:to="canf_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="canf_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregateNumbersOfADS_lbl1" xml:lang="en-US">Aggregate Numbers Of ADS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumbersOfADS" xlink:to="canf_AggregateNumbersOfADS_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PreFundedWarrant_lbl1" xml:lang="en-US">Pre Funded Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PreFundedWarrant" xlink:to="canf_PreFundedWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl1" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract_lbl" xml:lang="en-US">Schedule Of Major Customer Data As APercentage Of Total Revenues Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Schedule Of Share Options Their Weighted Average Exercise Price Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Estimated Using The Binomial Option Pricing Model Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl0" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExchangeRateFluctuations_lbl1" xml:lang="en-US">Exchange Rate Fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl1" xml:lang="en-US">Other Loss From Shortterm Investment Revaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_ScheduleOfComponentsOfFinanceIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ADSMember_lbl1" xml:lang="en-US">ADSMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredSalesInducementsNet_lbl0" xml:lang="en-US">Deferred Sale Inducement Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredSalesInducementsNet" xlink:to="us-gaap_DeferredSalesInducementsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights_lbl1" xml:lang="en-US">Class Of Warrant Or Right Number Of Securities Called By Warrant Or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" xlink:to="canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_EwopharmaAGMember_lbl0" xml:lang="en-US">Ewopharma AGMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaAGMember" xlink:to="canf_EwopharmaAGMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_March2018Member_lbl0" xml:lang="en-US">March2018 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_March2018Member" xlink:to="canf_March2018Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceExpenses_lbl1" xml:lang="en-US">Finance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExerciseAgreementDescription_lbl0" xml:lang="en-US">Exercise Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExerciseAgreementDescription" xlink:to="canf_ExerciseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_MilestonePercentage_lbl1" xml:lang="en-US">Milestone Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_MilestonePercentage" xlink:to="canf_MilestonePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems_lbl0" xml:lang="en-US">Share Based Payment Transactions Details Scheduleofexpenses Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_December2021Member_lbl0" xml:lang="en-US">December2021 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_December2021Member" xlink:to="canf_December2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_DeemedDividend_lbl1" xml:lang="en-US">Deemed Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_May2019Member_lbl0" xml:lang="en-US">May2019 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_May2019Member" xlink:to="canf_May2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl1" xml:lang="en-US">Ordinary Share Warrants Classification And Measurement Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfOutstandingShares_lbl1" xml:lang="en-US">Percentage Of Outstanding Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_EwopharmaMember_lbl0" xml:lang="en-US">Ewopharma Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaMember" xlink:to="canf_EwopharmaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl0" xml:lang="en-US">Redeemable Preferred Stock Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule Of Other Accounts Payable Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="canf_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_lbl0" xml:lang="en-US">Short-Term Debt, Weighted Average Interest Rate, over Time</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvanceRoyalties_lbl0" xml:lang="en-US">Advance Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRoyalties" xlink:to="us-gaap_AdvanceRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePrice_lbl1" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfNetSales_lbl1" xml:lang="en-US">Percentage Of Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WarrantsNetOfIssuanceExpenses_lbl1" xml:lang="en-US">Warrants Net Of Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssuanceExpenses" xlink:to="canf_WarrantsNetOfIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CompensationWarrantsExercisable_lbl1" xml:lang="en-US">Compensation Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>canf-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 30 11:16:39 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquityType2or3" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_General" roleURI="http://www.confite.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SignificantAccountingPolicies" roleURI="http://www.confite.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShortTermInvestment" roleURI="http://www.confite.com/role/ShortTermInvestment"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PropertyPlantandEquipmentNet" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_OtherAccountsPayable" roleURI="http://www.confite.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_FairValueMeasurements" roleURI="http://www.confite.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_Revenues" roleURI="http://www.confite.com/role/Revenues"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ContingentLiabilitiesandCommitments" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquity" roleURI="http://www.confite.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareBasedPaymentTransactions" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_Leases" roleURI="http://www.confite.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_FinanceIncomeExpenseNet" roleURI="http://www.confite.com/role/FinanceIncomeExpenseNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TaxesonIncome" roleURI="http://www.confite.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TransactionswithRelatedParties" roleURI="http://www.confite.com/role/TransactionswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SubsequentEvents" roleURI="http://www.confite.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_AccountingPoliciesByPolicy" roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SignificantAccountingPoliciesTables" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_OtherAccountsPayableTables" roleURI="http://www.confite.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_FairValueMeasurementsTables" roleURI="http://www.confite.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquityTables" roleURI="http://www.confite.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareBasedPaymentTransactionsTables" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_LeasesTables" roleURI="http://www.confite.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_FinanceIncomeExpenseNetTables" roleURI="http://www.confite.com/role/FinanceIncomeExpenseNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TaxesonIncomeTables" roleURI="http://www.confite.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofoutstandingshareoptionsandwarrantsTable" roleURI="http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofpropertyplantandequipmentnetTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofexpensesTable" roleURI="http://www.confite.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable" roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofshareoptionstheirweightedaverageexercisepriceTable" roleURI="http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofcomponentsoffinanceincomeTable" roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_GeneralDetails" roleURI="http://www.confite.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SignificantAccountingPoliciesDetails" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShortTermInvestmentDetails" roleURI="http://www.confite.com/role/ShortTermInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_RevenuesDetails" roleURI="http://www.confite.com/role/RevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareholdersEquityDetails" roleURI="http://www.confite.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_ShareBasedPaymentTransactionsDetails" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_LeasesDetails" roleURI="http://www.confite.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TaxesonIncomeDetails" roleURI="http://www.confite.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_TransactionswithRelatedPartiesDetails" roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#canf_r_SubsequentEventsDetails" roleURI="http://www.confite.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.confite.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:href="canf-20221231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:href="canf-20221231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20221231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20221231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsNetOfIssuanceExpenses" xlink:href="canf-20221231.xsd#canf_WarrantsNetOfIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="WarrantsNetOfIssuanceExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20221231.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="WithdrawalinvestmentInShorttermDepositsNet" xlink:href="canf-20221231.xsd#canf_WithdrawalinvestmentInShorttermDepositsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="WithdrawalinvestmentInShorttermDepositsNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestment">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="ShortTermInvestmentTable" xlink:href="canf-20221231.xsd#canf_ShortTermInvestmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="ShortTermInvestmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermInvestmentTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableTable" xlink:href="canf-20221231.xsd#canf_OtherAccountsPayableTable"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableLineItems" xlink:href="canf-20221231.xsd#canf_OtherAccountsPayableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="OtherAccountsPayableTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableTable" xlink:to="OtherAccountsPayableLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/Revenues">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseNet">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayPolicyTextBlock" xlink:href="canf-20221231.xsd#canf_SeverancePayPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePayPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20221231.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20221231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20221231.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="LaboratoryEquipmentAndLeaseholdImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20221231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="ComputersOfficeFurnitureAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20221231.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20221231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="srt_MajorCustomersAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CipherPharmaceuticalsMember" xlink:href="canf-20221231.xsd#canf_CipherPharmaceuticalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CipherPharmaceuticalsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20221231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ChongKunDangPharmaceuticalsCorpMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GebroHoldingGmBHMember" xlink:href="canf-20221231.xsd#canf_GebroHoldingGmBHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="GebroHoldingGmBHMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EwopharmaAGMember" xlink:href="canf-20221231.xsd#canf_EwopharmaAGMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="EwopharmaAGMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RevenueContractWithCustomer" xlink:href="canf-20221231.xsd#canf_RevenueContractWithCustomer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="RevenueContractWithCustomer" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="Options" xlink:href="canf-20221231.xsd#canf_Options"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:to="Options" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalinDollars" xlink:href="canf-20221231.xsd#canf_TotalinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingShareOptionsAndWarrantsAbstract" xlink:to="TotalinDollars" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="canf-20221231.xsd#canf_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="GovernmentAuthorities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="canf-20221231.xsd#canf_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20221231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ComputersOfficeFurnitureAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="canf-20221231.xsd#canf_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="canf-20221231.xsd#canf_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndPayrollAccruals" xlink:href="canf-20221231.xsd#canf_EmployeesAndPayrollAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="EmployeesAndPayrollAccruals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20221231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20221231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:to="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="us-gaap_AwardDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="March2018Member" xlink:href="canf-20221231.xsd#canf_March2018Member"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmPO7kW86fCwO9BDdY5bf5b9H+vvjKwz2saovEzZ3dBRA5yWdSLppMepuvQwgTmpdXkG6aEqg3eKP65vjM+XithEfqz6791Pl3kR8GSmegnWDLfr6e5Y/epmc1OuxTfkwZ] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="March2018Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2019Member" xlink:href="canf-20221231.xsd#canf_January2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="January2019Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April2019Member" xlink:href="canf-20221231.xsd#canf_April2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="April2019Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="May2019Member" xlink:href="canf-20221231.xsd#canf_May2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="May2019Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2020Member" xlink:href="canf-20221231.xsd#canf_January2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="January2020Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="February2020Member" xlink:href="canf-20221231.xsd#canf_February2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="February2020Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2020Member" xlink:href="canf-20221231.xsd#canf_June2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="June2020Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July2020Member" xlink:href="canf-20221231.xsd#canf_July2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="July2020Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2021Member" xlink:href="canf-20221231.xsd#canf_August2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="August2021Member" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December2021Member" xlink:href="canf-20221231.xsd#canf_December2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="December2021Member" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IssuanceDate" xlink:href="canf-20221231.xsd#canf_IssuanceDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="IssuanceDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable" xlink:to="ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:href="canf-20221231.xsd#canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" xlink:href="canf-20221231.xsd#canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageRemainingContractualTermsinYearsForfeitedexpired" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueForfeitedexpired" xlink:href="canf-20221231.xsd#canf_AggregateIntrinsicValueForfeitedexpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="AggregateIntrinsicValueForfeitedexpired" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20221231.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="ComponentsOfLeaseExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20221231.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20221231.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20221231.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="LesseeOperatingLeaseLiabilityPaymentDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImputedInterestLessImputedInterest" xlink:href="canf-20221231.xsd#canf_ImputedInterestLessImputedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="ImputedInterestLessImputedInterest" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="BanksCommissions" xlink:href="canf-20221231.xsd#canf_BanksCommissions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="BanksCommissions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossFromExchangeRateFluctuations" xlink:href="canf-20221231.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="NetLossFromExchangeRateFluctuations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20221231.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="OtherLossFromShorttermInvestmentRevaluation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="us-gaap_OtherExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenses" xlink:href="canf-20221231.xsd#canf_FinanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="FinanceExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateFluctuations" xlink:href="canf-20221231.xsd#canf_ExchangeRateFluctuations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="ExchangeRateFluctuations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncome" xlink:href="canf-20221231.xsd#canf_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="FinanceIncome" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20221231.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="canf-20221231.xsd#canf_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLosses" xlink:href="canf-20221231.xsd#canf_NetLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NetLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivities" xlink:href="canf-20221231.xsd#canf_CashFlowsFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CashFlowsFromOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractLiabilities" xlink:href="canf-20221231.xsd#canf_ContractLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContractLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Revenue" xlink:href="canf-20221231.xsd#canf_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="Revenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20221231.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PercentageOfDepositsOnMonthlySalary" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20221231.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PercentageOfRealizationOnUltimateSettlement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOutstandingShares" xlink:href="canf-20221231.xsd#canf_PercentageOfOutstandingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="PercentageOfOutstandingShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/RevenuesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenuesDetailsTable" xlink:href="canf-20221231.xsd#canf_RevenuesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RevenuesDetailsLineItems" xlink:href="canf-20221231.xsd#canf_RevenuesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="RevenuesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GebroHoldingGmBHMember" xlink:href="canf-20221231.xsd#canf_GebroHoldingGmBHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GebroHoldingGmBHMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CMSMedicalVentureInvestmentLimitedMember" xlink:href="canf-20221231.xsd#canf_CMSMedicalVentureInvestmentLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CMSMedicalVentureInvestmentLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EwopharmaMember" xlink:href="canf-20221231.xsd#canf_EwopharmaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EwopharmaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsTable" xlink:to="RevenuesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_PaymentsForFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfRegulatoryAssistanceReceived1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_AmountOfRegulatoryAssistanceReceived1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_OtherLoansPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfFIFOInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfFIFOInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_PercentageOfFIFOInventory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesReceivedAsCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_SecuritiesReceivedAsCollateral" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DistributionAndSupplyAgreementDescription" xlink:href="canf-20221231.xsd#canf_DistributionAndSupplyAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="DistributionAndSupplyAgreementDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredSalesInducementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredSalesInducementsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_DeferredSalesInducementsNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_PaymentsToSuppliers" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCollateralAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCollateralAggregateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="us-gaap_AdditionalCollateralAggregateFairValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePercentage" xlink:href="canf-20221231.xsd#canf_MilestonePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="MilestonePercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SignatureDate" xlink:href="canf-20221231.xsd#canf_SignatureDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="SignatureDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyalitiesDescription" xlink:href="canf-20221231.xsd#canf_RoyalitiesDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesDetailsLineItems" xlink:to="RoyalitiesDescription" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20221231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContingentLiabilitiesandCommitmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="ContingentLiabilitiesandCommitmentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseCommissionExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfNetSales" xlink:href="canf-20221231.xsd#canf_PercentageOfNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="PercentageOfNetSales" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_AdvanceRoyalties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPaymentsPercentage" xlink:href="canf-20221231.xsd#canf_RoyaltyPaymentsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="RoyaltyPaymentsPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentAgreementDescription" xlink:href="canf-20221231.xsd#canf_PatentAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="PatentAgreementDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ADSMember" xlink:href="canf-20221231.xsd#canf_ADSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="ADSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="canf-20221231.xsd#canf_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregatePurchasePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfNewUnregisteredWarrants" xlink:href="canf-20221231.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IssueOfNewUnregisteredWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" xlink:href="canf-20221231.xsd#canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividend" xlink:href="canf-20221231.xsd#canf_DeemedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="DeemedDividend" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementDescription" xlink:href="canf-20221231.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="SecuritiesPurchaseAgreementDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationWarrantsExercisable" xlink:href="canf-20221231.xsd#canf_CompensationWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CompensationWarrantsExercisable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrices" xlink:href="canf-20221231.xsd#canf_ExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePrices" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseAuthorizedShareCapital" xlink:href="canf-20221231.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IncreaseAuthorizedShareCapital" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateWarrantPurchased" xlink:href="canf-20221231.xsd#canf_AggregateWarrantPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregateWarrantPurchased" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceSubjectToAdjusment" xlink:href="canf-20221231.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePriceSubjectToAdjusment" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNumbersOfADS" xlink:href="canf-20221231.xsd#canf_AggregateNumbersOfADS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregateNumbersOfADS" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseAggregateShares" xlink:href="canf-20221231.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseAggregateShares" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="canf-20221231.xsd#canf_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePrice" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalConsiderationAmount" xlink:href="canf-20221231.xsd#canf_TotalConsiderationAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="TotalConsiderationAmount" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrant" xlink:href="canf-20221231.xsd#canf_PreFundedWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PreFundedWarrant" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNumberOfADS" xlink:href="canf-20221231.xsd#canf_AggregateNumberOfADS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregateNumberOfADS" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpenses" xlink:href="canf-20221231.xsd#canf_IssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IssuanceExpenses" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuanceAgreementDescription" xlink:href="canf-20221231.xsd#canf_StockIssuanceAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockIssuanceAgreementDescription" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseAgreementDescription" xlink:href="canf-20221231.xsd#canf_ExerciseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExerciseAgreementDescription" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ShareBasedPaymentTransactionsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GrantedExcessYears" xlink:href="canf-20221231.xsd#canf_GrantedExcessYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="GrantedExcessYears" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="FutureShares" xlink:href="canf-20221231.xsd#canf_FutureShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FutureShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="canf-20221231.xsd#canf_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="canf-20221231.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentAreaAPercentage" xlink:href="canf-20221231.xsd#canf_DevelopmentAreaAPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="DevelopmentAreaAPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="canf-20221231.xsd#canf_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="canf-20221231.xsd#canf_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantMember" xlink:href="canf-20221231.xsd#canf_SeriesAWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SeriesAWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBWarrantMember" xlink:href="canf-20221231.xsd#canf_SeriesBWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SeriesBWarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RDPurchaseAgreementMember" xlink:href="canf-20221231.xsd#canf_RDPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="RDPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="canf-20221231.xsd#canf_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnregisteredPrefundedWarrantsMember" xlink:href="canf-20221231.xsd#canf_UnregisteredPrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="UnregisteredPrefundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantMember" xlink:href="canf-20221231.xsd#canf_PlacementAgentWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PlacementAgentWarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseTransferAgentAndCustodianFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseTransferAgentAndCustodianFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOfDirectIssuanceCosts" xlink:href="canf-20221231.xsd#canf_NetOfDirectIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NetOfDirectIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="canf-20221231.xsd#canf_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelFaxNumber" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543837956496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Can-Fite
BioPharma Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CANF<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">815,746,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001536196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10
Bareket Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Kiryat Matalon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">P.O. Box 7537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Petah-Tikva<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4951778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 300 Ordinary Shares, no par value *<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY& KASIERER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv,
Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10
Bareket Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Kiryat Matalon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">P.O. Box 7537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Petah-Tikva<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4951778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Motti
Farbstein<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(3) 924-1114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">972 (3) 924-9378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">motti@canfite.co.il<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543836403008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,978<span></span>
</td>
<td class="nump">$ 4,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term deposits</a></td>
<td class="nump">5,001<span></span>
</td>
<td class="nump">14,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses, and other current assets</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,157<span></span>
</td>
<td class="nump">20,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,283<span></span>
</td>
<td class="nump">20,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other accounts payable</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,502<span></span>
</td>
<td class="nump">2,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">3,070<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">3,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">CONTIGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of no par value - Authorized: 5,000,000,000 shares at December 31, 2022 and 2021; Issued and outstanding: 815,746,293 shares as of December 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">154,192<span></span>
</td>
<td class="nump">153,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(150,847)<span></span>
</td>
<td class="num">(140,674)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">4,472<span></span>
</td>
<td class="nump">14,382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 9,283<span></span>
</td>
<td class="nump">$ 20,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543836390304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | (per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">815,746,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">815,746,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839598048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(7,763)<span></span>
</td>
<td class="num">(9,850)<span></span>
</td>
<td class="num">(11,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(3,143)<span></span>
</td>
<td class="num">(3,845)<span></span>
</td>
<td class="num">(2,951)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(10,096)<span></span>
</td>
<td class="num">(12,842)<span></span>
</td>
<td class="num">(14,139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financial income (expense), net</a></td>
<td class="num">(77)<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">(10,173)<span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Taxes on income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,173)<span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Deemed dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
<td class="num">(715)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="num">$ (10,173)<span></span>
</td>
<td class="num">$ (15,205)<span></span>
</td>
<td class="num">$ (15,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in Shares)</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">553,079,638<span></span>
</td>
<td class="nump">358,411,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemablePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839490192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">553,079,638<span></span>
</td>
<td class="nump">358,411,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543836449696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive Income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 111,626<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="num">$ (110,311)<span></span>
</td>
<td class="nump">$ 2,442<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">120,652,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockDividend', window );">Deemed dividends related to the warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,683<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses (in Shares)</a></td>
<td class="nump">341,766,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of share capital</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of share capital (in Shares)</a></td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">130,416<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(125,469)<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">463,769,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses', window );">Issuance of share capital due to warrants exercise, net of issuance expenses of $ 980 (Note 10b(9), 10b(11) and 10b(12))</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,767<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares', window );">Issuance of share capital due to warrants exercise, net of issuance expenses of $ 980 (Note 10b(9), 10b(11) and 10b(12)) (in Shares)</a></td>
<td class="nump">293,926,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of share capital in exchange for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of share capital in exchange for services (in Shares)</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">dividends related to the warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,590<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,690<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses (in Shares)</a></td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">153,929<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(140,674)<span></span>
</td>
<td class="nump">14,382<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,173)<span></span>
</td>
<td class="num">(10,173)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 154,192<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="num">$ (150,847)<span></span>
</td>
<td class="nump">$ 4,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital due to warrants exercise, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital due to warrants exercise, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued to shareholders as a dividend during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543844075760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WarrantsNetOfIssuanceExpenses', window );">Warrants, net of issuance expenses</a></td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="nump">$ 3,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Warrants exercise, net of issuance expenses</a></td>
<td class="nump">$ 980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsNetOfIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsNetOfIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839431600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,173)<span></span>
</td>
<td class="num">$ (12,615)<span></span>
</td>
<td class="num">$ (14,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of property, plant and equipment</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Reduction in the carrying amount of operating lease right of use asset</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based payment</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment', window );">Changes in fair value of short-term investment</a></td>
<td class="nump">229<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Financial expenses (income), net</a></td>
<td class="nump">113<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Change in prepaid expenses, and other current assets</a></td>
<td class="num">(241)<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payable</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenues</a></td>
<td class="num">(810)<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Increase (decrease) in other accounts payable</a></td>
<td class="num">(130)<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,801)<span></span>
</td>
<td class="num">(9,858)<span></span>
</td>
<td class="num">(12,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WithdrawalinvestmentInShorttermDepositsNet', window );">Withdrawal (investment) in short-term deposits, net</a></td>
<td class="nump">9,511<span></span>
</td>
<td class="num">(14,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">9,502<span></span>
</td>
<td class="num">(14,511)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,457<span></span>
</td>
<td class="nump">17,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,457<span></span>
</td>
<td class="nump">17,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Exchange differences on balances of cash and cash equivalents</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,412)<span></span>
</td>
<td class="num">(3,878)<span></span>
</td>
<td class="nump">5,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">4,390<span></span>
</td>
<td class="nump">8,268<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the end of the year</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">4,390<span></span>
</td>
<td class="nump">8,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease liabilities arising from obtaining right-of-use-assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Deemed Dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of changes in fair value of short-term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WithdrawalinvestmentInShorttermDepositsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of withdrawal (investment) in short-term deposits, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WithdrawalinvestmentInShorttermDepositsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839500688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1:-&#160;GENERAL</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company description:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221; and the Company&#8217;s
American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;. Each ADS represents
300 ordinary shares of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company incurred net losses of $&#160;10,173 and it had negative cash flows from operating activities in the amount of $&#160;10,801.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development
of all of its products or may be required to implement a cost reduction measures and may be required to delay part of its development
programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During January 2023, subsequent to
the balance sheet date, the Company raised $ 6,808 net of direct issuance costs for the issuance of its ordinary shares, pre-funded warrants
and warrants exercisable into its ordinary shares. See also Note 15.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s management and
board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company&#8217;s
products for at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543921965056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment Information</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Operating segments are identified as
components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the
Company&#8217;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#8217;s
drug candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The functional currency of the Company
is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars
in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) No. 830 &#8220;Foreign Currency Matters.&#8221; All transaction gains
and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial
income or expenses, as appropriate.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2022 and 2021, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 5.79% and 0.53%. Short-term bank deposits are presented at their cost, including accrued interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="padding-left: 6.25pt; text-indent: -6.25pt; width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly
from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate
to a clinical trial and no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
&#8220;Leases (Topic 842)&#8221;, the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at
amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The
lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over
the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental
Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments.
The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic
environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the
lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will
exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left">i.</td><td style="text-align: justify">Impairment of long-lived assets:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2022, and 2021, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes revenue in accordance
with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition through the
following steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the contract, or contracts, with a customer;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the performance obligations in the contract;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of the transaction price;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company generates revenues from
supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential
royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price
is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf
of third parties (such as taxes).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2022, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2022 and December
31, 2021 contract liabilities amounted to $3,078&#160;and $3,888, respectively and are presented under deferred revenues. During the year
ended December 31, 2022, the Company recognized revenues in the amount of $810 which have been included in the contract liabilities at
December&#160;31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Cipher Pharmaceuticals (Canada)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp. (South Korea)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmbH (Austria)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG (Switzerland)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified
within level 1 in the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of Credit Risk:&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially
subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents,
the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term
deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a
liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews
the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered
probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2022,
and 2021, the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial
position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2022, 2021 and 2020 amounted to $51, $53 and $46, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value of share options granted using
the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected
stock price, volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical
volatility of the Company and early exercise factor was calculated based statistical studies in the U.S. market. The risk-free interest
rate is based on the yield from Israeli Government bonds with an equivalent term. The Company has historically not paid dividends and
has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022, and 2021, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2022, and 2021, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td><td style="text-align: justify">Ordinary share and warrants classification and measurement:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The potential shares of ordinary shares
that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented
because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,002,200</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,422,700</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,923,400</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">375,197,640</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,947,640</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">228,192,286</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">402,199,840</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">396,370,340</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,115,686</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently adopted and recently issued accounting pronouncements</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective January 1, 2022. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The Company&#8217;s adopted the standard effective January 1, 2022. Adoption of the new standard did not have a material impact on the financial statements. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543922054816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3:-&#160; PREPAID EXPENSES AND OTHER
CURRENT ASSETS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,123</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">881</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,170</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">929</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543949863152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">SHORT-TERM INVESTMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4:-&#160;SHORT-TERM INVESTMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022 and 2021, the
Company holds 5,947 shares of Mawson Infrastructure Group Inc. a public traded company on the NASDAQ Capital Market, which as of such
dates represents less than 5 percent of Mawson Infrastructure Group Inc.&#8217;s outstanding shares, respectively. The investments in
marketable equity securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance
income (expenses), net. Refer to note 12 for financial expenses incurred in 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543930269472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5:-&#160;PROPERTY, PLANT AND
EQUIPMENT, NET </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Composition of assets, grouped by major classification,
is as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expenses for the year ended
December 31, 2022, 2021 and 2020 amounted to $14, $14 and $12, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543949863152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherAccountsPayableLineItems', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:-</b>&#160;<b>OTHER ACCOUNTS PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">492</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">283</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">775</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843739024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7:- FAIR VALUE MEASUREMENTS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with ASC 820 &#8220;Fair
Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measurements</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold">Description</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
                                            value</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            1</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            2</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            3</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold; padding-bottom: 1.5pt">Description</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543922054816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:- REVENUES&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Cipher Pharmaceuticals</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March 2015, the Company signed a
distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute
Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon
receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the terms of the agreement, Cipher
made an upfront payment of $1,292 (1,650 thousand Canadian Dollar) to the Company in March 2015. In addition, the agreement provides that
additional payments of up to 2,000 thousand Canadian Dollar will be received by the Company upon the achievement of certain milestones
plus royalty payments of 16.5% of net sales of Piclidenoson in Canada.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Chong Kun Dang Pharmaceuticals
Corp.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In October 2016, the Company signed
a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;). As part of the distribution agreement, CKD will
have exclusive rights to distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory
approvals. On February 25, 2019, distribution agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for
the treatment of NASH in addition to liver cancer in South Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the distribution agreement,
the Company is entitled to receive an amounts of up to $ 3,000 in upfront and milestone payments payable with respect to the liver cancer
indication and additional $ 6,000 in upfront and milestone payments payable with respect to NASH indication. In addition, the Company
will also be entitled to a transfer price for delivering finished product to CKD following commercial launch at a cost plus 10% basis
or 23% of net sales of Namodenoson following commercial launch in South Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
received an amount of $ 1,500 for up-front payment and additional $ 500 for achieved milestone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
estimates that such services will be completed by December 31, 2025 and therefore revenues from such up-front payment are recognized over
such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Gebro Holding GmBH</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 8, 2018, the Company entered
into a Distribution and Supply Agreement with Gebro Holding GmBH (&#8220;Gebro&#8221;), granting Gebro the exclusive right to distribute
Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the Distribution and Supply Agreement,
the Company is entitled to &#8364; 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone
payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#8364; 300 thousand upon initiation of the ACRobat
Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364; 300 thousand upon the initiation of the COMFORT Phase III
clinical trial for the treatment of psoriasis, (ii) between &#8364; 750 thousand and &#8364; 1,600 thousand following first delivery of
commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364; 300
thousand and up to &#8364;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall
be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
received an amount of &#8364; 1,500 thousand (approximately $ 1,850) for up-front payment and additional &#8364; 600 thousand (approximately
$ 720) for achieved milestone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">CMS Medical Venture
Investment Limited </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 6, 2018, the Company entered
into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the
commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver
cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the License, Collaboration and
Distribution Agreement, the Company is entitled to receive an up-front amount of $ 2,000 upon execution of the agreement. In addition,
the Company is also entitle to received an amount of up to $ 14,000 for milestone payments upon achieving certain regulatory milestones
and up to $ 58,500 for milestone payments upon achieving certain sales milestones. In addition, following regulatory approval, the Company
shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and
Namodenoson.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
received an amount of $ 2,000 for up-front payment which was previously recognized in revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Kyongbo Pharm Co., Ltd.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On July 31, 2019, the Company signed
a distribution agreement with Kyongbo Pharm Co., Ltd. (&#8220;Kyongbo Pharm&#8221;), to distribute Piclidenoson, for the treatment of
psoriasis in South Korea, upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the terms of the distribution
agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea,
is required to make a total a payment of $ 750 for access to information and clinical study data. In addition, the Company will be also
entitle to additional payments of up to $ 3,250 upon achievement of certain milestones. The Company will also be entitled to a transfer
price for delivering finished product to Kyongbo Pharm upon commercial launch.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In 2019, the Company received an amount
of $ 750 for up-front payment which recognized as revenues upon the Company providing access to information and clinical study data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Ewopharma</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 16, 2021, the Company signed
an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in
the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis
(NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $ 2,250
and is entitled to up to an additional $ 40,450 payable upon the achievement of regulatory and sales milestones and 17.5% royalties on
net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries
and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that
Can-Fite may identify for its drug candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
received an amount of $ 2,250 for up-front payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Vetbiolix</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 28, 2021, the Company announced
it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development
of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company
will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years
from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies
yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite
a non-refundable upfront payment in an amount of Euro 250, additional milestones payment equal to 30% upon each upfront payment received
from sublicensee and 15%-40% royalties on net sales upon regulatory approval for veterinary use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2022, the Company
did not received payment related to such agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843523536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; padding-right: 0.9pt">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities to pay royalties:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is committed to pay royalties
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A one-time concession commission of &#8364;25 thousand;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual royalties of &#8364;10 thousand until the clinical trials commence;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2%-3% of net sales (as defined in the agreement) received by the Company;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties in a total amount of up to &#8364;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in">As of December
31 2022, no accrual has been recorded with respect to Leiden University.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843739024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10:-&#160;SHAREHOLDERS&#8217; EQUITY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2023, subsequent to the balance sheet date, the Company&#8217;s shareholders meeting approved to change the Company&#8217;s ordinary shares par value from NIS 0.25 per share to no par value. All par value data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the change.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to be invited and participate in all the Company&#8217;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#8217;s general meeting participated.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to participate in the distribution of the Company&#8217;s assets upon liquidation.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of shares and warrants and changes in equity:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, the Company entered into warrant exercise agreements (the &#8220;Exercise Agreements&#8221;) with several accredited investors who are the holders of certain warrants (the &#8220;Public Warrants&#8221;) to purchase the Company&#8217;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of 22,278,540 ordinary shares having exercise prices ranging from $0.43 to $2.625 per ordinary share issued by the Company, at a reduced exercise price of $0.10 per share, for gross proceeds to the Company of approximately $2,400, prior to deducting placement agent fees and estimated offering expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to 22,278,540 ordinary shares for an exercise price of $ 0.11 per shares (the &#8220;Private Placement Warrants&#8221;). The placement agent in the offering also received compensation warrants exercisable for up to 1,559,498 Ordinary share The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of $ 0.11 per ordinary share, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $715.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2020, the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 54,750,000 units, each unit consisting of one Ordinary share, and one warrant to purchase one Ordinary share, at a price of $ 0.05 per unit, and (ii) 45,250,020 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one Ordinary share and one warrant, at a price of $ 0.05 per pre-funded unit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds from the offering were approximately $ 5,000, prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent in the offering also received compensation warrants exercisable for up to 7,500,000 Ordinary share at an exercise price of $ 0.0625 per Ordinary share expiring on February 10, 2025.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 20,250,000 ordinary shares, at a price of $0.05 per ordinary share for gross proceeds of $1,012.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#8217;s authorized share capital to 1,000,000,000 ordinary shares of no par value each and on June 7, 2021, &#160;a special meeting of shareholders of the Company approved to increase Company&#8217;s authorized share capital to 5,000,000,000 ordinary shares of no par value each.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 31,000,020 ordinary shares, at a price of $0.05 per Ordinary share for gross proceeds of $1,550.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold 117,073,200 ordinary shares at a purchase price of $0.07 per Ordinary share for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of 58,536,600 ordinary shares. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $0.08 per ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ordinary shares sold in the offering (or warrants to purchase up to an aggregate of 8,780,490 Ordinary share), at an exercise price of $0.08 per ordinary share and a term expiring four and a half years from the date of issuance.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 51,165,000 Ordinary share at a purchase price of $0.06 per Ordinary share for aggregate gross proceeds of approximately $ 3,400 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of 25,582,500 Ordinary share. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $0.08 per Ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 3,837,390 Ordinary shares), at an exercise price of $0.08 per Ordinary share and a term expiring.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company issued 1,350,000 of its ordinary shares to a consultant in exchange for his services.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February and March 2021, the Company issued 50,926,830 ordinary shares in exchange for exercise of warrants. Total consideration received by the Company was $ 2,744.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued 1,050,000 of its ordinary shares to certain consultants in exchange for their services with fair value of $ 68.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares at an offering price of $0.07 per Ordinary share and $0.06 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#8217;s fees and other estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 150,000,000 Ordinary shares. The warrants have an exercise price of $ 0.07 per Ordinary share and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares and 93,000,000 ordinary shares following the exercise of the pre-funded warrants (issuance expenses were $1,307).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also paid on aggregate of $700 in placement agent fees and expenses and issued 10,500,000 placement agent warrants, at an initial exercise price equal to $0.07 per Ordinary share, on substantially the same terms as the investor warrants, except that the placement agent warrants expire on the earlier of (i) the third-year anniversary of the date on which an initial resale registration statement registering the ordinary shares (or the ADSs) issuable upon the exercise of the warrants becomes effective and (ii) August 11, 2026.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2021, the Company entered into
a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing
warrants to purchase Company&#8217;s ordinary shares in a registered direct offering consummated in August 2021. Pursuant to the Exercise
Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares having an
exercise price of $0.07 per Ordinary share, for gross proceeds to the Company of $10,000 prior to deducting placement agent fees and offering
expenses (which amounted to $0.98 million).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $0.07 per Ordinary share. The Company also paid $875 in placement agent fees and issued unregistered placement agent warrants to purchase 10,500,000 Ordinary shares on the same terms as the warrant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes information
regarding outstanding warrants to purchase the Company&#8217;s ordinary shares as of December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">March 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">333,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">January 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">April 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">May 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">January 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,838,038</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">February 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,390,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,419,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">December 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">190,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">375,197,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2022 and 2021, all
of the Company&#8217;s outstanding warrants are classified as equity instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843666720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED PAYMENT TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11:-&#160;SHARE-BASED PAYMENT TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options plan:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#8220;2013 Plan&#8221;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of 10 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s 2013 Plan, in July
2022, the Company&#8217;s Board of Directors approved to increase number of ordinary shares reserved for issuance to 35,000,000. As of
December 31, 2022, 8,023,000 shares available for future grant under the 2013 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses recognized in the financial statements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">159</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">126</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">266</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">263</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">466</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">317</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions granted by the Company:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41%-3.08%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22-1.28%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93-2.40%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.98%-84.26%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;82.40-82.43%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65.63-78.77%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contractual life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.83 - 10</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Early Exercise Multiple (Suboptimal Factor)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5-3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 - 3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise price (NIS)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25-0.253</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25 - 2.344</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the year ended December 31, 2022 and related information:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> exercise <br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> remaining<br/> contractual<br/> terms (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> intrinsic<br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding at December 31, 20221</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,422,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,750,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(170,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">27,002,200</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">27,002,200</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,071,575</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2022, 2021 and 2020 was 6.96 years, 8.45 years and 6.98 years, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value in 2022 was $0.02 and in 2021 was $0.18 and the remaining compensation costs not yet recognized as of December 31, 2022 is $230 with a weighted average period of 2.73 years to recognize these expenses.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839550928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12- LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of 3 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.42</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2022 and 2021 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;54</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;54</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">Maturities
of lease liabilities as of December 31, 2022 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">54</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">2024</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease payments</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: imputed interest</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(10</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liability</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">62</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843604816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BankingAndThriftInterestAbstract', window );"><strong>Banking and Thrift, Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock', window );">FINANCE INCOME (EXPENSE), NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13:-&#160;FINANCE INCOME (EXPENSE), NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(23</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(54</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(229</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(299</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(22</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(386</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(77</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(304</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankingAndThriftInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankingAndThriftInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843620176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14:-&#160;TAXES ON INCOME</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate tax rates:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Israeli taxation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Corporate tax rate in Israel in 2022,
2021 and 2020 was 23%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Law for the Encouragement of Capital
Investments, 1959:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Law for Encouragement of Capital
Investments, 1959 (the &#8220;Investment Law&#8221;) provides tax benefits for Israeli companies meeting certain requirements and criteria.
The Investment Law has undergone certain amendments and reforms in recent years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Israeli parliament enacted a reform
to the Investment Law, effective January 2011 (which was amended in August 2013). According to the reform, a flat rate tax applies to
Preferred Income of companies eligible for the &#8220;Preferred Enterprise&#8221; status. In order to be eligible for Preferred Enterprise
status, a company must meet minimum requirements to establish that it contributes to the country&#8217;s economic growth and is a competitive
factor for the gross domestic product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Benefits granted to a Preferred Enterprise
include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for
Budget Years 2017-2018), 5777-2016, the tax rate is&#160;16% for all areas other than Development Area A (which was&#160;7.5% from 2017
onward).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final tax assessments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company received final tax assessments
through 2017.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating carryforward losses for tax purposes and other temporary differences:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2022, the Company
had carryforward losses amounting to approximately $&#160;157,106.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s
deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,348</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,376</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,633</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,513</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,633</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main reconciling item between the statutory tax rate of the Company
and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating
losses carried forward due to the uncertainty of the realization of such deferred taxes and the company&#8217;s preferred enterprise tax rate.<b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543838615168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">TRANSACTIONS WITH RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15:- TRANSACTIONS WITH RELATED PARTIES
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Chairman of the Company&#8217;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#8220;Service Provider&#8221;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $218, $241 and $252 in 2022, 2021 and 2020, respectively, which were recorded under research
and development expenses within Company&#8217;s consolidated statements of comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843499824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16:- SUBSEQUENT EVENTS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.25in">1.</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On January 11, 2023, the Company entered into
a securities purchase agreement (the &#8220;RD Purchase Agreement&#8221;), pursuant to which the Company agreed to sell and issue in a
registered direct offering (the &#8220;Registered Direct Offering&#8221;) an aggregate of 90,000,000 ordinary shares for a purchase price
of $ 0.018 per share (the &#8220;RD Shares&#8221;) and pre-funded warrants to purchase up to 210,000,000 of the Company&#8217;s Ordinary
Shares at a purchase price of $ 0.018 per share and at an immaterial exercise price (the &#8220;Pre-funded Warrants&#8221;), and, unregistered
Series A warrants to purchase up to 300,000,000 Ordinary Shares for an exercise price of $ 0.02 per shares (the &#8220;Series A Warrants&#8221;),
and unregistered Series B warrants to purchase up to 300,000,000 Ordinary Shares for exercise price of $ 0.018 per share (the &#8220;Series
B Warrants&#8221;).</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, the Company entered into
a securities purchase agreement (the &#8220;PIPE Purchase Agreement,&#8221; and together with the RD Purchase Agreement, the &#8220;Purchase
Agreements&#8221;) pursuant to which the Company agreed to sell and issue in a concurrent private placement (the &#8220;PIPE Offering,&#8221;
and together with the Registered Direct Offering, the &#8220;Offerings&#8221;) unregistered Pre-funded Warrants to purchase up to 109,091,100
of the Company&#8217; Ordinary Shares at purchase price of $ 0.018 per share and additional immaterial exercise price per share, unregistered
Series A Warrants to purchase up to 109,091,100 of the Company&#8217;s Ordinary Shares for an exercise price of $ 0.02 per share and unregistered
Series B Warrants to purchase up to 109,091,100 of the Company&#8217;s Ordinary Shares for an exercise price of $ 0.018 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Moreover, the Company has also issued a placement agent warrants (the
&#8220;Placement Agent Warrants&#8221;) on substantially the same terms as the Series A Warrants to purchase up to 28,636,500 of the Company&#8217;s
Ordinary Shares for an exercise price of $ 0.022 per share. In addition, the Company paid an aggregate of $675 thousands in placement
agent fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company received total consideration
of $ 6,808 net of direct issuance costs from the above mentioned issuance of shares, prefunded warrants and Series A and B warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">The Company has also agreed to amend certain warrants to purchase up to an aggregate of 180,000,000 Ordinary
shares that were issued in December 2021 to the investor in this offering and private placement by reducing the exercise prices from $
0.067 per share to $ 0.018 per share.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">During January through March 2023, certain investors exercised prefunded warrants and purchased 319,091,100
of the Company&#8217;s Ordinary shares for an exercise price at an immaterial amount.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543836430416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment Information</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Operating segments are identified as
components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the
Company&#8217;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#8217;s
drug candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency, reporting currency and foreign currency</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The functional currency of the Company
is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars
in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) No. 830 &#8220;Foreign Currency Matters.&#8221; All transaction gains
and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial
income or expenses, as appropriate.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Short-term bank deposits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2022 and 2021, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 5.79% and 0.53%. Short-term bank deposits are presented at their cost, including accrued interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock', window );">Prepaid expenses, and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="padding-left: 6.25pt; text-indent: -6.25pt; width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly
from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate
to a clinical trial and no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Operating lease</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
&#8220;Leases (Topic 842)&#8221;, the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at
amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The
lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over
the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental
Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments.
The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic
environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the
lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will
exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left">i.</td><td style="text-align: justify">Impairment of long-lived assets:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2022, and 2021, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes revenue in accordance
with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition through the
following steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the contract, or contracts, with a customer;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the performance obligations in the contract;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of the transaction price;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company generates revenues from
supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential
royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price
is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf
of third parties (such as taxes).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2022, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2022 and December
31, 2021 contract liabilities amounted to $3,078&#160;and $3,888, respectively and are presented under deferred revenues. During the year
ended December 31, 2022, the Company recognized revenues in the amount of $810 which have been included in the contract liabilities at
December&#160;31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Cipher Pharmaceuticals (Canada)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp. (South Korea)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmbH (Austria)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG (Switzerland)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenditures</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified
within level 1 in the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of Credit Risk:&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially
subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents,
the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term
deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Legal and other contingencies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a
liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews
the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered
probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2022,
and 2021, the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial
position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2022, 2021 and 2020 amounted to $51, $53 and $46, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value of share options granted using
the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected
stock price, volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical
volatility of the Company and early exercise factor was calculated based statistical studies in the U.S. market. The risk-free interest
rate is based on the yield from Israeli Government bonds with an equivalent term. The Company has historically not paid dividends and
has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxes on income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022, and 2021, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2022, and 2021, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock', window );">Ordinary share and warrants classification and measurement</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td><td style="text-align: justify">Ordinary share and warrants classification and measurement:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The potential shares of ordinary shares
that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented
because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,002,200</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,422,700</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,923,400</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">375,197,640</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,947,640</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">228,192,286</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">402,199,840</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">396,370,340</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,115,686</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted and recently issued accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently adopted and recently issued accounting pronouncements</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective January 1, 2022. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The Company&#8217;s adopted the standard effective January 1, 2022. Adoption of the new standard did not have a material impact on the financial statements. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ordinary share warrants classification and measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for classification and method of accounting for interest-only strips, loans, other receivables, or retained interests in securitizations that can be contractually prepaid or otherwise settled in a way that the holder would not recover substantially all of its recorded investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543840236256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of major customer data as a percentage of total revenues</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Cipher Pharmaceuticals (Canada)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp. (South Korea)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmbH (Austria)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG (Switzerland)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">schedule of outstanding share options and warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,002,200</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,422,700</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,923,400</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">375,197,640</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,947,640</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">228,192,286</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">402,199,840</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">396,370,340</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,115,686</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of major customer data as a percentage of total revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543844034080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,123</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">881</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,170</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">929</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843570416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843563216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other accounts payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">492</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">283</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">775</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843464784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measurements</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold">Description</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
                                            value</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            1</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            2</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level
                                            3</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold; padding-bottom: 1.5pt">Description</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843575136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock', window );">Schedule of information regarding outstanding warrants to purchase shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">March 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">333,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">January 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">April 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">May 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">January 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,838,038</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">February 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,390,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,419,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">December 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">190,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.07</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">375,197,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543837734448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfExpensesTableTextBlock', window );">Schedule of expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">159</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">126</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">266</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">263</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">466</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">317</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock', window );">Schedule of estimated using the binomial option pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41%-3.08%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22-1.28%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93-2.40%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.98%-84.26%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;82.40-82.43%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65.63-78.77%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contractual life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.83 - 10</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Early Exercise Multiple (Suboptimal Factor)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5-3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 - 3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise price (NIS)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25-0.253</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25 - 2.344</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of share options, their weighted average exercise price</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> exercise <br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> remaining<br/> contractual<br/> terms (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> intrinsic<br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Outstanding at December 31, 20221</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,422,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,750,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(170,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">27,002,200</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">27,002,200</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.13</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,071,575</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543837775904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of weighted average remaining lease terms and discount rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.42</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;54</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/> December&#160;31,<br/>
 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;54</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">54</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">2024</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease payments</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: imputed interest</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(10</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liability</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">62</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843555920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BankingAndThriftInterestAbstract', window );"><strong>Banking and Thrift, Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of components of finance (income)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(23</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(54</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(229</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(299</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(22</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(386</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(77</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(304</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankingAndThriftInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankingAndThriftInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843570416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,348</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,376</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,633</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,513</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,633</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543838708800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of ordinary shares represent by each ADS (in Shares) | shares</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NetLosses', window );">Net losses</a></td>
<td class="nump">$ 10,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CashFlowsFromOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="num">$ (10,801)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CashFlowsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CashFlowsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543834158960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average rates percentage</a></td>
<td class="nump">5.79%<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContractLiabilities', window );">Contract liabilities under deferred revenues</a></td>
<td class="nump">$ 3,078<span></span>
</td>
<td class="nump">$ 3,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_Revenue', window );">Revenues</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfDepositsOnMonthlySalary', window );">Percentage of deposits on monthly salary</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay expense</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfRealizationOnUltimateSettlement', window );">Maximum percentage of realization on ultimate settlement</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amouunt of contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfDepositsOnMonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of deposits on monthly salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfDepositsOnMonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfRealizationOnUltimateSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of realization on ultimate settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfRealizationOnUltimateSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543832827136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember', window );">Laboratory equipment and Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember', window );">Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation rates property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839322528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember', window );">Cipher Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember', window );">Chong Kun Dang Pharmaceuticals Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember', window );">Gebro Holding GmBH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_EwopharmaAGMember', window );">Ewopharma AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RevenueContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RevenueContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_EwopharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_EwopharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543842853632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of outstanding share options and warrants - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract', window );"><strong>Schedule Of Outstanding Share Options And Warrants Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_Options', window );">Options</a></td>
<td class="nump">27,002,200<span></span>
</td>
<td class="nump">18,422,700<span></span>
</td>
<td class="nump">11,923,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants</a></td>
<td class="nump">375,197,640<span></span>
</td>
<td class="nump">377,947,640<span></span>
</td>
<td class="nump">228,192,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TotalinDollars', window );">Total</a></td>
<td class="nump">402,199,840<span></span>
</td>
<td class="nump">396,370,340<span></span>
</td>
<td class="nump">240,115,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_Options">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_Options</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TotalinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of total shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TotalinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543836477088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Other Accounts Receivable and Prepaid Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and others</a></td>
<td class="nump">1,123<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total</a></td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="nump">$ 929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government authorities for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543842739952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investment (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares hold by company</a></td>
<td class="nump">5,947<span></span>
</td>
<td class="nump">5,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543840494352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExpenseOnReclassifiedAssets', window );">Depreciation expenses</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExpenseOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=29634951&amp;loc=d3e1756-110224<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2459-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExpenseOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839259072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember', window );">Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839391568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable (Details) - Schedule of other accounts payable - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfOtherAccountsPayableAbstract', window );"><strong>Schedule Of Other Accounts Payable Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_EmployeesAndPayrollAccruals', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable</a></td>
<td class="nump">$ 775<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_EmployeesAndPayrollAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of employees and payroll accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_EmployeesAndPayrollAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543836433024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543833920256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 28, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenuesDetailsLineItems', window );"><strong>Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment', window );">Additional payments (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountOfRegulatoryAssistanceReceived1', window );">Up-front amount receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLoansPayable', window );">Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional and payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_DistributionAndSupplyAgreementDescription', window );">Distribution and supply agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the Distribution and Supply Agreement,
the Company is entitled to &#8364; 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone
payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#8364; 300 thousand upon initiation of the ACRobat
Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364; 300 thousand upon the initiation of the COMFORT Phase III
clinical trial for the treatment of psoriasis, (ii) between &#8364; 750 thousand and &#8364; 1,600 thousand following first delivery of
commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364; 300
thousand and up to &#8364;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall
be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliers', window );">Total payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCollateralAggregateFairValue', window );">Additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_MilestonePercentage', window );">Royalties</a></td>
<td class="nump">17.50%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SignatureDate', window );">Signature date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyalitiesDescription', window );">Royalities, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15%-40% royalties on net sales upon regulatory approval for veterinary use.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenuesDetailsLineItems', window );"><strong>Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PercentageOfFIFOInventory', window );">Cost plus percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenuesDetailsLineItems', window );"><strong>Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PercentageOfFIFOInventory', window );">Cost plus percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_GebroHoldingGmBHMember', window );">Gebro Holding GmBH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenuesDetailsLineItems', window );"><strong>Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional and payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalVentureInvestmentLimitedMember', window );">CMS Medical Venture Investment Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenuesDetailsLineItems', window );"><strong>Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountOfRegulatoryAssistanceReceived1', window );">Up-front amount receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLoansPayable', window );">Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredSalesInducementsNet', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_EwopharmaMember', window );">Ewopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RevenuesDetailsLineItems', window );"><strong>Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountOfRegulatoryAssistanceReceived1', window );">Up-front amount receive</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLoansPayable', window );">Payables</a></td>
<td class="nump">$ 40,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_DistributionAndSupplyAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of distribution and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_DistributionAndSupplyAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_MilestonePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_MilestonePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RevenuesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RevenuesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RoyalitiesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of royalities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RoyalitiesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SignatureDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The signature date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SignatureDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCollateralAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCollateralAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to policyholder related to benefit payment for present value of total expected payment to policyholder in excess of present value of total expected assessment. Excludes benefit classified as market risk benefit or under provisions of Topic 815 on derivative and hedging.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 55<br> -Paragraph 13I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126561865&amp;loc=SL117783724-158441<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountOfRegulatoryAssistanceReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory assistance received from a federal regulatory agency in conjunction with either an acquisition of a troubled financial institution, transfer of nonperforming assets to a newly-formed entity, or other reorganization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 11.N)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897409&amp;loc=d3e533348-122875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountOfRegulatoryAssistanceReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredSalesInducementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred sale inducement cost capitalized on contract remaining in force.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124505477&amp;loc=SL117422543-158416<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6481654&amp;loc=d3e11214-158414<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124505477&amp;loc=d3e11332-158416<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredSalesInducementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term loans payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to suppliers for goods and services during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PercentageOfFIFOInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of FIFO (first in first out) inventory to total inventory as of the balance sheet date if other than 100 percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PercentageOfFIFOInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesReceivedAsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesReceivedAsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_GebroHoldingGmBHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_GebroHoldingGmBHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalVentureInvestmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalVentureInvestmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_EwopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_EwopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543838754576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseCommissionExpense', window );">Commission Income Expense</a></td>
<td class="nump">&#8364; 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalties</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyalties', window );">Royalties in a total amount</a></td>
<td class="nump">&#8364; 850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PatentAgreementDescription', window );">Patent agreement, description</a></td>
<td class="text">Royalties in a total amount of up to &#8364;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ContingentLiabilitiesandCommitmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PatentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of patent agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PatentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The royalty payment in percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid to music publishers, record producers, songwriters, or other artists in advance of their earning royalties from record or music sales. Such an amount is based on contractual terms and is generally nonrefundable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473541&amp;loc=d3e61799-108003<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fees incurred for commissions on mutual funds and insurance products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543829537328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 08, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 12, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2020 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Nov. 28, 2013 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in New Shekels per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 5,000,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase aggregate warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,192,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,197,640<span></span>
</td>
<td class="nump">377,947,640<span></span>
</td>
<td class="nump">228,192,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregatePurchasePrice', window );">Ordinary share issued per share (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.625<span></span>
</td>
<td class="nump">$ 2.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 1,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,550,000<span></span>
</td>
<td class="nump">$ 1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssueOfNewUnregisteredWarrants', window );">Issue of new unregistered warrants</a></td>
<td class="nump">25,582,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_DeemedDividend', window );">Deemed dividend (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SecuritiesPurchaseAgreementDescription', window );">Securities purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 54,750,000 units, each unit consisting of one Ordinary share, and one warrant to purchase one Ordinary share, at a price of $ 0.05 per unit, and (ii) 45,250,020 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one Ordinary share and one warrant, at a price of $ 0.05 per pre-funded unit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Gross proceeds from offering (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Expiring date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IncreaseAuthorizedShareCapital', window );">Increase authorized capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregateWarrantPurchased', window );">Aggregate warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000,020<span></span>
</td>
<td class="nump">31,000,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,947<span></span>
</td>
<td class="nump">5,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregateNumbersOfADS', window );">Aggregate number of ADS percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WarrantsToPurchaseAggregateShares', window );">Warrants to purchase aggregate ADS shares</a></td>
<td class="nump">3,837,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePrice', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TotalConsiderationAmount', window );">Total consideration amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,744,000<span></span>
</td>
<td class="nump">$ 2,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent', window );">Exchange services (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PreFundedWarrant', window );">Pre-funded warrant (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregateNumberOfADS', window );">Aggregate number of ADS percentage (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceExpenses', window );">Issuance expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare', window );">Initial exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuanceAgreementDescription', window );">Stock issuance agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On December 20, 2021, the Company entered into
a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing
warrants to purchase Company&#8217;s ordinary shares in a registered direct offering consummated in August 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExerciseAgreementDescription', window );">Exercise agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $0.07 per Ordinary share. The Company also paid $875 in placement agent fees and issued unregistered placement agent warrants to purchase 10,500,000 Ordinary shares on the same terms as the warrant. &#160; Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=canf_ADSMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase aggregate warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278,540<span></span>
</td>
<td class="nump">22,278,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssueOfNewUnregisteredWarrants', window );">Issue of new unregistered warrants</a></td>
<td class="nump">51,165,000<span></span>
</td>
<td class="nump">58,536,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,559,498<span></span>
</td>
<td class="nump">1,559,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CompensationWarrantsExercisable', window );">Compensation warrant exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePrices', window );">Exercise prices (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary per share issued (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregateWarrantPurchased', window );">Aggregate warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,780,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePriceSubjectToAdjusment', window );">Exercise price subject to adjustment (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,073,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary per share issued (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,926,830<span></span>
</td>
<td class="nump">50,926,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExercisePrices', window );">Exercise prices (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregateNumberOfADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>aggregate number of ADS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregateNumberOfADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregateNumbersOfADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate number of ADS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregateNumbersOfADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregateWarrantPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate warrant purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregateWarrantPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CompensationWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>compensation warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CompensationWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExerciseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExerciseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePriceSubjectToAdjusment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price Subject to adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePriceSubjectToAdjusment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant, Exercise Price, Decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IncreaseAuthorizedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase authorized Share Capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IncreaseAuthorizedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssueOfNewUnregisteredWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of New Unregistered Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssueOfNewUnregisteredWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PreFundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of pre-funded warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PreFundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SecuritiesPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Purchase Agreement, Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SecuritiesPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuanceAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuance agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuanceAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TotalConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total consideration amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TotalConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsToPurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsToPurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=canf_ADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=canf_ADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543837987632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">375,197,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_March2018Member', window );">March 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">March 2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">333,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2019Member', window );">January 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">223,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_April2019Member', window );">April 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">April 2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">492,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_May2019Member', window );">May 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">May 2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">47,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2020Member', window );">January 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">23,838,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_February2020Member', window );">February 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">February 2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">11,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_June2020Member', window );">June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">June 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">61,390,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_July2020Member', window );">July 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">July 2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">29,419,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_August2021Member', window );">August 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">August 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_December2021Member', window );">December 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">December 2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">190,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_March2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_March2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_April2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_April2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_May2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_May2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_February2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_February2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_June2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_June2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_July2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_July2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_August2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_August2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_December2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_December2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543829419296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 28, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_GrantedExcessYears', window );">Granted excess years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FutureShares', window );">Future shares (in Shares)</a></td>
<td class="nump">8,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 11 months 15 days<span></span>
</td>
<td class="text">8 years 5 months 12 days<span></span>
</td>
<td class="text">6 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in Dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation costs not yet recognized (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">2 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FutureShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FutureShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GrantedExcessYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GrantedExcessYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543834177952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems', window );"><strong>Schedule of Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total Expenses</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543839464320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model - &#8362; / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (NIS) (in New Shekels per share)</a></td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">1.22%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.98%<span></span>
</td>
<td class="nump">82.40%<span></span>
</td>
<td class="nump">65.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor)</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (NIS) (in New Shekels per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.08%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.26%<span></span>
</td>
<td class="nump">82.43%<span></span>
</td>
<td class="nump">78.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (NIS) (in New Shekels per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.253<span></span>
</td>
<td class="nump">&#8362; 2.344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543833877888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of share options, their weighted average exercise price - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract', window );"><strong>Schedule Of Share Options Their Weighted Average Exercise Price Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding, at beginning of year</a></td>
<td class="nump">18,422,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price beginning of year</a></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual terms (in years) beginning of year</a></td>
<td class="text">8 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther', window );">Number of options, Vested and expected to vest</a></td>
<td class="nump">27,002,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual terms (in years), Vested and expected to vest</a></td>
<td class="text">7 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable</a></td>
<td class="nump">11,071,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual terms (in years), Exercisable</a></td>
<td class="text">7 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Grants</a></td>
<td class="nump">8,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Grants</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual terms (in years), Grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">2 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, Grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of options, Forfeited/expired</a></td>
<td class="num">(170,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/expired</a></td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired', window );">Weighted average remaining contractual terms (in years), Forfeited/expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AggregateIntrinsicValueForfeitedexpired', window );">Aggregate intrinsic value, Forfeited/expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding, at end of year</a></td>
<td class="nump">27,002,200<span></span>
</td>
<td class="nump">18,422,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price end of year</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual terms (in years) end of year</a></td>
<td class="text">7 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregateIntrinsicValueForfeitedexpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate intrinsic value, Forfeited/expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregateIntrinsicValueForfeitedexpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843705824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543842706192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract', window );"><strong>Schedule Of Lease Expense And Supplemental Cash Flow Information Related To Leases And Weighted Average Remaining Lease Terms And Discount Rate Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">weighted average remaining lease term (years)</a></td>
<td class="text">1 year 5 months 1 day<span></span>
</td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">weighted average discount rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ComponentsOfLeaseExpenseAbstract', window );"><strong>Components of lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets', window );">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ComponentsOfLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ComponentsOfLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543844075072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract', window );"><strong>Schedule Of Maturities Of Lease Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_LesseeOperatingLeaseLiabilityPaymentDue', window );">Total operating lease payments</a></td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ImputedInterestLessImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ImputedInterestLessImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ImputedInterestLessImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_LesseeOperatingLeaseLiabilityPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_LesseeOperatingLeaseLiabilityPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543833794288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net (Details) - Schedule of components of finance (income) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfComponentsOfFinanceIncomeAbstract', window );"><strong>Schedule Of Components Of Finance Income Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_BanksCommissions', window );">Bank commissions</a></td>
<td class="num">$ (16)<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NetLossFromExchangeRateFluctuations', window );">Net loss from exchange rate fluctuations</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherLossFromShorttermInvestmentRevaluation', window );">Other loss from short-term investment revaluation</a></td>
<td class="num">(229)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other financial expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FinanceExpenses', window );">Finance expenses</a></td>
<td class="num">(299)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income on bank deposits</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExchangeRateFluctuations', window );">Exchange rate fluctuations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Other gain from short-term investment remeasurement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_FinanceIncome', window );">Finance income</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Total financial income (expenses), net</a></td>
<td class="num">$ (77)<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="num">$ (304)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_BanksCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_BanksCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExchangeRateFluctuations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate fluctuations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExchangeRateFluctuations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from finance income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetLossFromExchangeRateFluctuations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net loss from exchange rate fluctuations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetLossFromExchangeRateFluctuations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherLossFromShorttermInvestmentRevaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other loss from short-term investment revaluation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherLossFromShorttermInvestmentRevaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfComponentsOfFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfComponentsOfFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543834159792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax rate percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_DevelopmentAreaAPercentage', window );">Development area percentage.</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Carryforward losses amount (in Dollars)</a></td>
<td class="nump">$ 157,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_DevelopmentAreaAPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development area percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_DevelopmentAreaAPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543840460192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 25,137<span></span>
</td>
<td class="nump">$ 26,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Temporary differences mainly relating to Research and Development</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset before valuation allowance</a></td>
<td class="nump">26,513<span></span>
</td>
<td class="nump">28,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(26,513)<span></span>
</td>
<td class="num">(28,633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543843459952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Aggregate amount of research and development expenses</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140543838869856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>Jun. 12, 2020</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Aug. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseTransferAgentAndCustodianFees', window );">Aggregate amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=canf_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NetOfDirectIssuanceCosts', window );">Net of direct issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=canf_UnregisteredPrefundedWarrantsMember', window );">Unregistered Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,091,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=canf_PlacementAgentWarrantMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,636,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="nump">210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,091,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="nump">$ 0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=canf_RDPurchaseAgreementMember', window );">RD Purchase Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="nump">$ 0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_SeriesAWarrantMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,091,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_SeriesAWarrantMember', window );">Series A Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_SeriesBWarrantMember', window );">Series B warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,091,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_SeriesBWarrantMember', window );">Series B warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share</a></td>
<td class="nump">$ 0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetOfDirectIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net of direct issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetOfDirectIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseTransferAgentAndCustodianFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees paid to an agent employed by a corporation or mutual fund to maintain shareholder records, including purchases, sales, and account balances. Also includes custodian fees incurred during an accounting period from an agent, bank, trust company, or other organization that holds and safeguards an individual's, mutual fund's, or investment company's assets for them. These fees will be billed back to the client and are a component of noninterest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseTransferAgentAndCustodianFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=canf_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=canf_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=canf_UnregisteredPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=canf_UnregisteredPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=canf_PlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=canf_PlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=canf_RDPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=canf_RDPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=canf_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=canf_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=canf_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=canf_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>f20f2022_canfitebio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:canf="http://www.confite.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="canf-20221231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:LaboratoryEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2015-03-31</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2018-01-08</startDate>
            <endDate>2018-01-08</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CMSMedicalVentureInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CMSMedicalVentureInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:EwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:EwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:EwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-01-28</startDate>
            <endDate>2021-01-28</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-01-09</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-09</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-12</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-12</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-12</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-12</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-12</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-07-08</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2013-11-28</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-28</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">canf:RDPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">canf:RDPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesAWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesAWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:UnregisteredPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:UnregisteredPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PlacementAgentWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PlacementAgentWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="c0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0">001-36203</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">Can-Fite BioPharma Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0">10 Bareket Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Kiryat Matalon</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c0">P.O. Box 7537</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c0">Petah-Tikva</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0">4951778</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1">Motti Farbstein</dei:ContactPersonnelName>
    <dei:CityAreaCode contextRef="c1">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1">(3) 924-1114</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber contextRef="c1">972 (3) 924-9378</dei:ContactPersonnelFaxNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c1">motti@canfite.co.il</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="c1">10 Bareket Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1">Kiryat Matalon</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c1">P.O. Box 7537</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c1">Petah-Tikva</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1">4951778</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="c0">American Depositary Shares, each representing 300 Ordinary Shares, no par value *</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">CANF</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">815746293</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c0">1281</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0">KOST FORER GABBAY&amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">2978000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">4390000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">5001000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">14512000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">1170000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">929000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="-3" unitRef="usd">8000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="-3" unitRef="usd">237000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">9157000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">20068000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">84000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">138000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">42000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">126000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">185000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">9283000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">20253000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c2" decimals="-3" unitRef="usd">896000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="-3" unitRef="usd">954000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">53000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c2" decimals="-3" unitRef="usd">783000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c3" decimals="-3" unitRef="usd">818000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">775000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">905000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">2502000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">2730000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">14000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">71000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c2" decimals="-3" unitRef="usd">2295000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c3" decimals="-3" unitRef="usd">3070000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">2309000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">3141000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">5000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">5000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">815746293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">815746293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">815746293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">815746293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">154192000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">153929000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="-3" unitRef="usd">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" unitRef="usd">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-150847000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-140674000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">4472000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">9283000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">20253000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">810000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="-3" unitRef="usd">853000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" unitRef="usd">763000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">7763000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">9850000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">11951000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">3143000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">3845000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">2951000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-10096000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-12842000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-14139000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-77000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">227000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">-304000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" unitRef="usd">-10173000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="-3" unitRef="usd">-12615000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="-3" unitRef="usd">-14443000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-10173000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:RedeemablePreferredStockDividends contextRef="c4" decimals="-3" unitRef="usd">2590000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:RedeemablePreferredStockDividends contextRef="c5" decimals="-3" unitRef="usd">715000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="-3" unitRef="usd">-10173000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="-3" unitRef="usd">-15205000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="-3" unitRef="usd">-15158000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">815746293</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="0" unitRef="shares">553079638</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">358411297</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="INF" unitRef="shares">120652683</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" unitRef="usd">111626000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">-110311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" unitRef="usd">2442000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c12" decimals="-3" unitRef="usd">715000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c14" decimals="-3" unitRef="usd">-715000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <canf:WarrantsNetOfIssuanceExpenses contextRef="c5" decimals="-3" unitRef="usd">3703000</canf:WarrantsNetOfIssuanceExpenses>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants contextRef="c11" decimals="INF" unitRef="shares">341766780</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c12" decimals="-3" unitRef="usd">17683000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c5" decimals="-3" unitRef="usd">17683000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c11" decimals="INF" unitRef="shares">1350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c12" decimals="-3" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="-3" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c12" decimals="-3" unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c15" decimals="INF" unitRef="shares">463769463</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" unitRef="usd">130416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" unitRef="usd">-125469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" unitRef="usd">6074000</us-gaap:StockholdersEquity>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c3" decimals="-3" unitRef="usd">980000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares contextRef="c20" decimals="INF" unitRef="shares">293926830</canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses contextRef="c21" decimals="-3" unitRef="usd">11767000</canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses contextRef="c4" decimals="-3" unitRef="usd">11767000</canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses>
    <canf:WarrantsNetOfIssuanceExpenses contextRef="c4" decimals="-3" unitRef="usd">1307000</canf:WarrantsNetOfIssuanceExpenses>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants contextRef="c20" decimals="INF" unitRef="shares">57000000</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c21" decimals="-3" unitRef="usd">8690000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c4" decimals="-3" unitRef="usd">8690000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c20" decimals="INF" unitRef="shares">1050000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c21" decimals="-3" unitRef="usd">68000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c4" decimals="-3" unitRef="usd">68000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c21" decimals="-3" unitRef="usd">2590000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c23" decimals="-3" unitRef="usd">-2590000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c23" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c21" decimals="-3" unitRef="usd">398000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">398000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding contextRef="c24" decimals="INF" unitRef="shares">815746293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" unitRef="usd">153929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" unitRef="usd">-140674000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c24" decimals="INF" unitRef="shares">815746293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" unitRef="usd">153929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" unitRef="usd">-140674000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c29" decimals="-3" unitRef="usd">263000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">263000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" unitRef="usd">-10173000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-10173000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c32" decimals="INF" unitRef="shares">815746293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" unitRef="usd">154192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" unitRef="usd">-150847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">4472000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-10173000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="-3" unitRef="usd">14000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c4" decimals="-3" unitRef="usd">14000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="-3" unitRef="usd">12000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="-3" unitRef="usd">-54000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c4" decimals="-3" unitRef="usd">-55000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c5" decimals="-3" unitRef="usd">-9000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">263000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">466000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">355000</us-gaap:ShareBasedCompensation>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c0" decimals="-3" unitRef="usd">-229000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c4" decimals="-3" unitRef="usd">162000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c5" decimals="-3" unitRef="usd">11000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-113000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">46000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">-23000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">241000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="-3" unitRef="usd">-128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="-3" unitRef="usd">-4275000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">-62000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c4" decimals="-3" unitRef="usd">-63000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c5" decimals="-3" unitRef="usd">-8000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" unitRef="usd">-58000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c4" decimals="-3" unitRef="usd">393000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c5" decimals="-3" unitRef="usd">-1595000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="-3" unitRef="usd">-810000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c4" decimals="-3" unitRef="usd">1398000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c5" decimals="-3" unitRef="usd">-401000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" unitRef="usd">-130000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c4" decimals="-3" unitRef="usd">574000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c5" decimals="-3" unitRef="usd">-279000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-10801000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">-9858000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" unitRef="usd">-12063000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">11000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" unitRef="usd">26000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <canf:WithdrawalinvestmentInShorttermDepositsNet contextRef="c0" decimals="-3" unitRef="usd">-9511000</canf:WithdrawalinvestmentInShorttermDepositsNet>
    <canf:WithdrawalinvestmentInShorttermDepositsNet contextRef="c4" decimals="-3" unitRef="usd">14500000</canf:WithdrawalinvestmentInShorttermDepositsNet>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">9502000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="-3" unitRef="usd">-14511000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" unitRef="usd">-26000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c4" decimals="-3" unitRef="usd">20457000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c5" decimals="-3" unitRef="usd">17683000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">20457000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">17683000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="-3" unitRef="usd">-113000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">34000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" unitRef="usd">-23000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-1412000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="-3" unitRef="usd">-3878000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="-3" unitRef="usd">5571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">4390000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c19" decimals="-3" unitRef="usd">8268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c10" decimals="-3" unitRef="usd">2697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c2" decimals="-3" unitRef="usd">2978000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">4390000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c19" decimals="-3" unitRef="usd">8268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c4" decimals="-3" unitRef="usd">120000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c5" decimals="-3" unitRef="usd">29000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:PaymentsOfDividends contextRef="c4" decimals="-3" unitRef="usd">2590000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c5" decimals="-3" unitRef="usd">715000</us-gaap:PaymentsOfDividends>
    <us-gaap:InterestPaidNet contextRef="c4" decimals="-3" unitRef="usd">18000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="-3" unitRef="usd">23000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1:-&#160;GENERAL&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company description:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Can-Fite Biopharma Ltd. (the &#x201c;Company&#x201d;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#x2019;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#x201c;CFBI&#x201d; and the Company&#x2019;s
American Depositary Shares (&#x201c;ADSs&#x201d;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#x2019;s ADSs have been publicly traded on the NYSE American under the symbol &#x201c;CANF&#x201d;. Each ADS represents
300 ordinary shares of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2022, the Company incurred net losses of $&#160;10,173 and it had negative cash flows from operating activities in the amount of $&#160;10,801.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development
of all of its products or may be required to implement a cost reduction measures and may be required to delay part of its development
programs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During January 2023, subsequent to
the balance sheet date, the Company raised $ 6,808 net of direct issuance costs for the issuance of its ordinary shares, pre-funded warrants
and warrants exercisable into its ordinary shares. See also Note 15.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s management and
board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company&#x2019;s
products for at least the next twelve months beyond the date of the filing date of the consolidated financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SharesIssued contextRef="c2" decimals="0" unitRef="shares">300</us-gaap:SharesIssued>
    <canf:NetLosses contextRef="c0" decimals="0" unitRef="usd">10173</canf:NetLosses>
    <canf:CashFlowsFromOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-10801</canf:CashFlowsFromOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles of consolidation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment Information&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Operating segments are identified as
components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the
Company&#x2019;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#x2019;s
drug candidates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency, reporting currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and reporting currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The functional currency of the Company
is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars
in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) No. 830 &#x201c;Foreign Currency Matters.&#x201d; All transaction gains
and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial
income or expenses, as appropriate.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions, assets and liabilities in foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term bank deposits:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2022 and 2021, the Company&#x2019;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 5.79% and 0.53%. Short-term bank deposits are presented at their cost, including accrued interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="padding-left: 6.25pt; text-indent: -6.25pt; width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses, and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Prepaid expenses are composed mainly
from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate
to a clinical trial and no longer have an alternative future use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In accordance with ASU No. 2016-02,
&#x201c;Leases (Topic 842)&#x201d;, the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets are initially measured at
amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The
lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over
the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental
Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments.
The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic
environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the
lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will
exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 48px"/&gt;&lt;td style="width: 24px; text-align: left"&gt;i.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Impairment of long-lived assets:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are reviewed
for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment,&#x201d; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2022, and 2021, no impairment indicators have been identified.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes revenue in accordance
with ASC Topic&#160;606, Revenue from contracts with customers (&#x201c;ASC 606&#x201d;) and determines revenue recognition through the
following steps:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification of the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determination of the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition of revenue when, or as, the performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company generates revenues from
supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential
royalty payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution
agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price
is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf
of third parties (such as taxes).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2022, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The prepayments terms from the Company&#x2019;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &#x2013; Contract
Balances &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2022 and December
31, 2021 contract liabilities amounted to $3,078&#160;and $3,888, respectively and are presented under deferred revenues. During the year
ended December 31, 2022, the Company recognized revenues in the amount of $810 which have been included in the contract liabilities at
December&#160;31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage
of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Cipher Pharmaceuticals (Canada)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp. (South Korea)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmbH (Austria)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG (Switzerland)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies ASC 820, &#x201c;Fair
Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market
participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified
within level 1 in the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concentration of Credit Risk:&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Financial instruments that potentially
subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents,
the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term
deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal and other contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a
liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews
the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered
probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2022,
and 2021, the Company is not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial
position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severance pay&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s liability for severance
pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant to which all the Company&#x2019;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Severance pay expense for the year
ended December 31, 2022, 2021 and 2020 amounted to $51, $53 and $46, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for share-based
compensation in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s
consolidated statement of comprehensive loss, based on acceleration method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company estimates the fair value of share options granted using
the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected
stock price, volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical
volatility of the Company and early exercise factor was calculated based statistical studies in the U.S. market. The risk-free interest
rate is based on the yield from Israeli Government bonds with an equivalent term. The Company has historically not paid dividends and
has no foreseeable plans to pay dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for income taxes
in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022, and 2021, a full valuation allowance
was provided by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2022, and 2021, no liability for unrecognized tax benefits was recorded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Ordinary share and warrants classification and measurement:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#x201c;Earnings per Share&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants
for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The potential shares of ordinary shares
that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented
because including them would have been anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,002,200&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,422,700&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,923,400&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;375,197,640&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;377,947,640&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;228,192,286&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;402,199,840&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;396,370,340&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,115,686&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recently adopted and recently issued accounting pronouncements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective January 1, 2022. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The Company&#x2019;s adopted the standard effective January 1, 2022. Adoption of the new standard did not have a material impact on the financial statements. &#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles of consolidation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment Information&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Operating segments are identified as
components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the
Company&#x2019;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#x2019;s
drug candidates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency, reporting currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and reporting currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The functional currency of the Company
is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars
in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) No. 830 &#x201c;Foreign Currency Matters.&#x201d; All transaction gains
and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial
income or expenses, as appropriate.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions, assets and liabilities in foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term bank deposits:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2022 and 2021, the Company&#x2019;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 5.79% and 0.53%. Short-term bank deposits are presented at their cost, including accrued interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime contextRef="c0" decimals="4" unitRef="pure">0.0579</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime contextRef="c4" decimals="4" unitRef="pure">0.0053</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="padding-left: 6.25pt; text-indent: -6.25pt; width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses, and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Prepaid expenses are composed mainly
from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate
to a clinical trial and no longer have an alternative future use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In accordance with ASU No. 2016-02,
&#x201c;Leases (Topic 842)&#x201d;, the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets are initially measured at
amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The
lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over
the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental
Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments.
The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic
environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the
lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will
exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c36" decimals="2" unitRef="pure">0.10</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c36" decimals="2" unitRef="pure">0.10</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c37" decimals="2" unitRef="pure">0.06</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c38" decimals="2" unitRef="pure">0.33</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c39" decimals="2" unitRef="pure">0.33</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 48px"/&gt;&lt;td style="width: 24px; text-align: left"&gt;i.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Impairment of long-lived assets:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are reviewed
for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment,&#x201d; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2022, and 2021, no impairment indicators have been identified.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes revenue in accordance
with ASC Topic&#160;606, Revenue from contracts with customers (&#x201c;ASC 606&#x201d;) and determines revenue recognition through the
following steps:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification of the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determination of the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition of revenue when, or as, the performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company generates revenues from
supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential
royalty payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution
agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price
is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf
of third parties (such as taxes).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2022, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The prepayments terms from the Company&#x2019;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &#x2013; Contract
Balances &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2022 and December
31, 2021 contract liabilities amounted to $3,078&#160;and $3,888, respectively and are presented under deferred revenues. During the year
ended December 31, 2022, the Company recognized revenues in the amount of $810 which have been included in the contract liabilities at
December&#160;31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage
of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Cipher Pharmaceuticals (Canada)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp. (South Korea)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmbH (Austria)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG (Switzerland)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <canf:ContractLiabilities contextRef="c2" decimals="-3" unitRef="usd">3078000</canf:ContractLiabilities>
    <canf:ContractLiabilities contextRef="c3" decimals="-3" unitRef="usd">3888000</canf:ContractLiabilities>
    <canf:Revenue contextRef="c0" decimals="-3" unitRef="usd">810000</canf:Revenue>
    <canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Cipher Pharmaceuticals (Canada)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp. (South Korea)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmbH (Austria)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG (Switzerland)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock>
    <canf:RevenueContractWithCustomer contextRef="c40" decimals="2" unitRef="pure">0.11</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c41" decimals="2" unitRef="pure">0.12</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c42" decimals="2" unitRef="pure">0.20</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c43" decimals="2" unitRef="pure">0.25</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c44" decimals="2" unitRef="pure">0.24</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c45" decimals="2" unitRef="pure">0.45</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c46" decimals="2" unitRef="pure">0.18</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c47" decimals="2" unitRef="pure">0.23</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c48" decimals="2" unitRef="pure">0.35</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c49" decimals="2" unitRef="pure">0.46</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c50" decimals="2" unitRef="pure">0.41</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c0" decimals="2" unitRef="pure">1</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c4" decimals="2" unitRef="pure">1</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c5" decimals="2" unitRef="pure">1</canf:RevenueContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies ASC 820, &#x201c;Fair
Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market
participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified
within level 1 in the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concentration of Credit Risk:&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Financial instruments that potentially
subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents,
the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term
deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal and other contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a
liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews
the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered
probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2022,
and 2021, the Company is not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial
position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <canf:SeverancePayPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severance pay&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s liability for severance
pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant to which all the Company&#x2019;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Severance pay expense for the year
ended December 31, 2022, 2021 and 2020 amounted to $51, $53 and $46, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</canf:SeverancePayPolicyTextBlock>
    <canf:PercentageOfDepositsOnMonthlySalary contextRef="c0" decimals="4" unitRef="pure">0.0833</canf:PercentageOfDepositsOnMonthlySalary>
    <us-gaap:SeveranceCosts1 contextRef="c0" decimals="-3" unitRef="usd">51000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c4" decimals="-3" unitRef="usd">53000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c5" decimals="-3" unitRef="usd">46000</us-gaap:SeveranceCosts1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for share-based
compensation in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s
consolidated statement of comprehensive loss, based on acceleration method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company estimates the fair value of share options granted using
the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected
stock price, volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical
volatility of the Company and early exercise factor was calculated based statistical studies in the U.S. market. The risk-free interest
rate is based on the yield from Israeli Government bonds with an equivalent term. The Company has historically not paid dividends and
has no foreseeable plans to pay dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for income taxes
in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022, and 2021, a full valuation allowance
was provided by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2022, and 2021, no liability for unrecognized tax benefits was recorded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <canf:PercentageOfRealizationOnUltimateSettlement contextRef="c0" decimals="2" unitRef="pure">0.50</canf:PercentageOfRealizationOnUltimateSettlement>
    <canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Ordinary share and warrants classification and measurement:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;</canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#x201c;Earnings per Share&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants
for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The potential shares of ordinary shares
that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented
because including them would have been anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,002,200&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,422,700&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,923,400&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;375,197,640&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;377,947,640&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;228,192,286&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;402,199,840&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;396,370,340&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,115,686&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,002,200&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,422,700&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,923,400&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;375,197,640&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;377,947,640&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;228,192,286&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;402,199,840&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;396,370,340&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,115,686&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <canf:Options contextRef="c0" decimals="INF" unitRef="shares">27002200</canf:Options>
    <canf:Options contextRef="c4" decimals="INF" unitRef="shares">18422700</canf:Options>
    <canf:Options contextRef="c5" decimals="INF" unitRef="shares">11923400</canf:Options>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c2" decimals="INF" unitRef="shares">375197640</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c3" decimals="INF" unitRef="shares">377947640</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c19" decimals="INF" unitRef="shares">228192286</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <canf:TotalinDollars contextRef="c0" decimals="INF" unitRef="shares">402199840</canf:TotalinDollars>
    <canf:TotalinDollars contextRef="c4" decimals="INF" unitRef="shares">396370340</canf:TotalinDollars>
    <canf:TotalinDollars contextRef="c5" decimals="INF" unitRef="shares">240115686</canf:TotalinDollars>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recently adopted and recently issued accounting pronouncements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The ASU addresses the previous lack of specific guidance in the accounting standards codification related to modifications or exchanges of freestanding equity-classified written call options (such as warrants) by specifying the accounting for various modification scenarios. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for any periods after issuance to be applied as of the beginning of the fiscal year that includes the interim period. The Company adopted this standard effective January 1, 2022. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The Company&#x2019;s adopted the standard effective January 1, 2022. Adoption of the new standard did not have a material impact on the financial statements. &#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3:-&#160; PREPAID EXPENSES AND OTHER
CURRENT ASSETS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepaid expenses and others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,123&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;881&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,170&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;929&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepaid expenses and others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,123&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;881&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,170&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;929&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <canf:GovernmentAuthorities contextRef="c2" decimals="-3" unitRef="usd">47000</canf:GovernmentAuthorities>
    <canf:GovernmentAuthorities contextRef="c3" decimals="-3" unitRef="usd">48000</canf:GovernmentAuthorities>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c2" decimals="-3" unitRef="usd">1123000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c3" decimals="-3" unitRef="usd">881000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c2" decimals="-3" unitRef="usd">1170000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="-3" unitRef="usd">929000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InvestmentTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4:-&#160;SHORT-TERM INVESTMENT&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022 and 2021, the
Company holds 5,947 shares of Mawson Infrastructure Group Inc. a public traded company on the NASDAQ Capital Market, which as of such
dates represents less than 5 percent of Mawson Infrastructure Group Inc.&#x2019;s outstanding shares, respectively. The investments in
marketable equity securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance
income (expenses), net. Refer to note 12 for financial expenses incurred in 2022.&lt;/p&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c0" decimals="0" unitRef="shares">5947</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c4" decimals="0" unitRef="shares">5947</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <canf:PercentageOfOutstandingShares contextRef="c0" decimals="2" unitRef="pure">0.05</canf:PercentageOfOutstandingShares>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5:-&#160;PROPERTY, PLANT AND
EQUIPMENT, NET &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Composition of assets, grouped by major classification,
is as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Depreciation expenses for the year ended
December 31, 2022, 2021 and 2020 amounted to $14, $14 and $12, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c52" decimals="-3" unitRef="usd">62000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c53" decimals="-3" unitRef="usd">62000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c54" decimals="-3" unitRef="usd">215000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c55" decimals="-3" unitRef="usd">206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c56" decimals="-3" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c57" decimals="-3" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" unitRef="usd">290000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c52" decimals="-3" unitRef="usd">42000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c53" decimals="-3" unitRef="usd">35000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c54" decimals="-3" unitRef="usd">196000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c55" decimals="-3" unitRef="usd">190000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c56" decimals="-3" unitRef="usd">10000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c57" decimals="-3" unitRef="usd">9000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">248000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">234000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">42000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c0" decimals="0" unitRef="usd">14</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c4" decimals="0" unitRef="usd">14</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c5" decimals="0" unitRef="usd">12</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6:-&lt;/b&gt;&#160;&lt;b&gt;OTHER ACCOUNTS PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;775&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;775&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <canf:EmployeesAndPayrollAccruals contextRef="c2" decimals="0" unitRef="usd">492</canf:EmployeesAndPayrollAccruals>
    <canf:EmployeesAndPayrollAccruals contextRef="c3" decimals="0" unitRef="usd">603</canf:EmployeesAndPayrollAccruals>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c2" decimals="0" unitRef="usd">283</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">302</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c2" decimals="0" unitRef="usd">775</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c3" decimals="0" unitRef="usd">905</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7:- FAIR VALUE MEASUREMENTS &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In accordance with ASC 820 &#x201c;Fair
Value Measurements and Disclosures&#x201d;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company&#x2019;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
                                            value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
                                            1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
                                            2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
                                            3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold; padding-bottom: 1.5pt"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
                                            value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
                                            1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
                                            2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level
                                            3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; width: 52%; font-weight: bold; padding-bottom: 1.5pt"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c58" decimals="-3" unitRef="usd">8000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c59" decimals="-3" unitRef="usd">8000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c62" decimals="-3" unitRef="usd">237000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c63" decimals="-3" unitRef="usd">237000</us-gaap:ShortTermInvestments>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8:- REVENUES&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Cipher Pharmaceuticals&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In March 2015, the Company signed a
distribution agreement with Cipher Pharmaceuticals (&#x201c;Cipher&#x201d;). As part of the distribution agreement, Cipher will distribute
Can-Fite&#x2019;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon
receipt of regulatory approvals.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Under the terms of the agreement, Cipher
made an upfront payment of $1,292 (1,650 thousand Canadian Dollar) to the Company in March 2015. In addition, the agreement provides that
additional payments of up to 2,000 thousand Canadian Dollar will be received by the Company upon the achievement of certain milestones
plus royalty payments of 16.5% of net sales of Piclidenoson in Canada.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Chong Kun Dang Pharmaceuticals
Corp.&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In October 2016, the Company signed
a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#x201c;CKD&#x201d;). As part of the distribution agreement, CKD will
have exclusive rights to distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory
approvals. On February 25, 2019, distribution agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for
the treatment of NASH in addition to liver cancer in South Korea.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;According to the distribution agreement,
the Company is entitled to receive an amounts of up to $ 3,000 in upfront and milestone payments payable with respect to the liver cancer
indication and additional $ 6,000 in upfront and milestone payments payable with respect to NASH indication. In addition, the Company
will also be entitled to a transfer price for delivering finished product to CKD following commercial launch at a cost plus 10% basis
or 23% of net sales of Namodenoson following commercial launch in South Korea.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
received an amount of $ 1,500 for up-front payment and additional $ 500 for achieved milestone.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
estimates that such services will be completed by December 31, 2025 and therefore revenues from such up-front payment are recognized over
such period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Gebro Holding GmBH&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On January 8, 2018, the Company entered
into a Distribution and Supply Agreement with Gebro Holding GmBH (&#x201c;Gebro&#x201d;), granting Gebro the exclusive right to distribute
Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Under the Distribution and Supply Agreement,
the Company is entitled to &#x20ac; 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone
payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#x20ac; 300 thousand upon initiation of the ACRobat
Phase III clinical trial for the treatment of rheumatoid arthritis and &#x20ac; 300 thousand upon the initiation of the COMFORT Phase III
clinical trial for the treatment of psoriasis, (ii) between &#x20ac; 750 thousand and &#x20ac; 1,600 thousand following first delivery of
commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#x20ac; 300
thousand and up to &#x20ac;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall
be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
received an amount of &#x20ac; 1,500 thousand (approximately $ 1,850) for up-front payment and additional &#x20ac; 600 thousand (approximately
$ 720) for achieved milestone.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;CMS Medical Venture
Investment Limited &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On August 6, 2018, the Company entered
into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#x201c;CMS Medical&#x201d;) for the
commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver
cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Under the License, Collaboration and
Distribution Agreement, the Company is entitled to receive an up-front amount of $ 2,000 upon execution of the agreement. In addition,
the Company is also entitle to received an amount of up to $ 14,000 for milestone payments upon achieving certain regulatory milestones
and up to $ 58,500 for milestone payments upon achieving certain sales milestones. In addition, following regulatory approval, the Company
shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and
Namodenoson.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
received an amount of $ 2,000 for up-front payment which was previously recognized in revenues.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Kyongbo Pharm Co., Ltd.&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On July 31, 2019, the Company signed
a distribution agreement with Kyongbo Pharm Co., Ltd. (&#x201c;Kyongbo Pharm&#x201d;), to distribute Piclidenoson, for the treatment of
psoriasis in South Korea, upon receipt of regulatory approvals.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Under the terms of the distribution
agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea,
is required to make a total a payment of $ 750 for access to information and clinical study data. In addition, the Company will be also
entitle to additional payments of up to $ 3,250 upon achievement of certain milestones. The Company will also be entitled to a transfer
price for delivering finished product to Kyongbo Pharm upon commercial launch.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In 2019, the Company received an amount
of $ 750 for up-front payment which recognized as revenues upon the Company providing access to information and clinical study data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Ewopharma&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On March 16, 2021, the Company signed
an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in
the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis
(NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $ 2,250
and is entitled to up to an additional $ 40,450 payable upon the achievement of regulatory and sales milestones and 17.5% royalties on
net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries
and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that
Can-Fite may identify for its drug candidates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
received an amount of $ 2,250 for up-front payment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
estimates that such services will be completed by March 31, 2027 and therefore revenues from such up-front payment are recognized over
such period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Vetbiolix&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On June 28, 2021, the Company announced
it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development
of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company
will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years
from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies
yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite
a non-refundable upfront payment in an amount of Euro 250, additional milestones payment equal to 30% upon each upfront payment received
from sublicensee and 15%-40% royalties on net sales upon regulatory approval for veterinary use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2022, the Company
did not received payment related to such agreement.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:PaymentsForFees contextRef="c66" decimals="0" unitRef="usd">1292</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees contextRef="c66" decimals="-3" unitRef="cad">1650000</us-gaap:PaymentsForFees>
    <us-gaap:AdditionalLiabilityLongDurationInsuranceBenefitPayment contextRef="c0" decimals="-3" unitRef="cad">2000000</us-gaap:AdditionalLiabilityLongDurationInsuranceBenefitPayment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c0" decimals="3" unitRef="pure">0.165</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AmountOfRegulatoryAssistanceReceived1 contextRef="c0" decimals="0" unitRef="usd">3000</us-gaap:AmountOfRegulatoryAssistanceReceived1>
    <us-gaap:OtherLoansPayable contextRef="c2" decimals="0" unitRef="usd">6000</us-gaap:OtherLoansPayable>
    <us-gaap:PercentageOfFIFOInventory contextRef="c67" decimals="2" unitRef="pure">0.10</us-gaap:PercentageOfFIFOInventory>
    <us-gaap:PercentageOfFIFOInventory contextRef="c68" decimals="2" unitRef="pure">0.23</us-gaap:PercentageOfFIFOInventory>
    <us-gaap:SecuritiesReceivedAsCollateral contextRef="c2" decimals="0" unitRef="usd">1500</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="0" unitRef="usd">500</us-gaap:AdditionalPaidInCapitalCommonStock>
    <canf:DistributionAndSupplyAgreementDescription contextRef="c69">Under the Distribution and Supply Agreement,
the Company is entitled to &#x20ac; 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone
payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#x20ac; 300 thousand upon initiation of the ACRobat
Phase III clinical trial for the treatment of rheumatoid arthritis and &#x20ac; 300 thousand upon the initiation of the COMFORT Phase III
clinical trial for the treatment of psoriasis, (ii) between &#x20ac; 750 thousand and &#x20ac; 1,600 thousand following first delivery of
commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#x20ac; 300
thousand and up to &#x20ac;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall
be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.</canf:DistributionAndSupplyAgreementDescription>
    <us-gaap:SecuritiesReceivedAsCollateral contextRef="c70" decimals="-3" unitRef="eur">1500000</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:SecuritiesReceivedAsCollateral contextRef="c70" decimals="0" unitRef="usd">1850</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c70" decimals="-3" unitRef="eur">600000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c70" decimals="0" unitRef="usd">720</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AmountOfRegulatoryAssistanceReceived1 contextRef="c71" decimals="0" unitRef="usd">2000</us-gaap:AmountOfRegulatoryAssistanceReceived1>
    <us-gaap:OtherLoansPayable contextRef="c72" decimals="0" unitRef="usd">14000</us-gaap:OtherLoansPayable>
    <us-gaap:DeferredSalesInducementsNet contextRef="c72" decimals="0" unitRef="usd">58500</us-gaap:DeferredSalesInducementsNet>
    <us-gaap:SecuritiesReceivedAsCollateral contextRef="c72" decimals="0" unitRef="usd">2000</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:PaymentsToSuppliers contextRef="c0" decimals="0" unitRef="usd">750</us-gaap:PaymentsToSuppliers>
    <us-gaap:AdditionalCollateralAggregateFairValue contextRef="c2" decimals="0" unitRef="usd">3250</us-gaap:AdditionalCollateralAggregateFairValue>
    <us-gaap:SecuritiesReceivedAsCollateral contextRef="c10" decimals="0" unitRef="usd">750</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:AmountOfRegulatoryAssistanceReceived1 contextRef="c73" decimals="0" unitRef="usd">2250</us-gaap:AmountOfRegulatoryAssistanceReceived1>
    <us-gaap:OtherLoansPayable contextRef="c74" decimals="0" unitRef="usd">40450</us-gaap:OtherLoansPayable>
    <canf:MilestonePercentage contextRef="c75" decimals="3" unitRef="pure">0.175</canf:MilestonePercentage>
    <us-gaap:SecuritiesReceivedAsCollateral contextRef="c76" decimals="0" unitRef="usd">2250</us-gaap:SecuritiesReceivedAsCollateral>
    <canf:SignatureDate contextRef="c77">P2Y</canf:SignatureDate>
    <us-gaap:AmountOfRegulatoryAssistanceReceived1 contextRef="c77" decimals="0" unitRef="eur">250</us-gaap:AmountOfRegulatoryAssistanceReceived1>
    <canf:MilestonePercentage contextRef="c77" decimals="2" unitRef="pure">0.30</canf:MilestonePercentage>
    <canf:RoyalitiesDescription contextRef="c77">15%-40% royalties on net sales upon regulatory approval for veterinary use.</canf:RoyalitiesDescription>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 9:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; padding-right: 0.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a. &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities to pay royalties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company is committed to pay royalties
as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A one-time concession commission of &#x20ac;25 thousand;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual royalties of &#x20ac;10 thousand until the clinical trials commence;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2%-3% of net sales (as defined in the agreement) received by the Company;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalties in a total amount of up to &#x20ac;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#x20ac;50 thousand upon initiation of Phase I studies; (ii) &#x20ac;100 thousand upon initiation of Phase II studies; (iii) &#x20ac;200 thousand upon initiation of Phase III studies; and (iv) &#x20ac;500 thousand upon marketing approval by any regulatory authority.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"&gt;As of December
31 2022, no accrual has been recorded with respect to Leiden University.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:NoninterestExpenseCommissionExpense contextRef="c0" decimals="-3" unitRef="eur">25000</us-gaap:NoninterestExpenseCommissionExpense>
    <us-gaap:RoyaltyExpense contextRef="c0" decimals="-3" unitRef="eur">10000</us-gaap:RoyaltyExpense>
    <canf:PercentageOfNetSales contextRef="c78" decimals="2" unitRef="pure">0.02</canf:PercentageOfNetSales>
    <canf:PercentageOfNetSales contextRef="c79" decimals="2" unitRef="pure">-0.03</canf:PercentageOfNetSales>
    <canf:PatentAgreementDescription contextRef="c0">Royalties in a total amount of up to &#x20ac;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#x20ac;50 thousand upon initiation of Phase I studies; (ii) &#x20ac;100 thousand upon initiation of Phase II studies; (iii) &#x20ac;200 thousand upon initiation of Phase III studies; and (iv) &#x20ac;500 thousand upon marketing approval by any regulatory authority.</canf:PatentAgreementDescription>
    <us-gaap:AdvanceRoyalties contextRef="c2" decimals="-3" unitRef="eur">850000</us-gaap:AdvanceRoyalties>
    <canf:RoyaltyPaymentsPercentage contextRef="c0" decimals="2" unitRef="pure">0.10</canf:RoyaltyPaymentsPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10:-&#160;SHAREHOLDERS&#x2019; EQUITY &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 22, 2023, subsequent to the balance sheet date, the Company&#x2019;s shareholders meeting approved to change the Company&#x2019;s ordinary shares par value from NIS 0.25 per share to no par value. All par value data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the change.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to be invited and participate in all the Company&#x2019;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#x2019;s general meeting participated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to participate in the distribution of the Company&#x2019;s assets upon liquidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of shares and warrants and changes in equity:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 9, 2020, the Company entered into warrant exercise agreements (the &#x201c;Exercise Agreements&#x201d;) with several accredited investors who are the holders of certain warrants (the &#x201c;Public Warrants&#x201d;) to purchase the Company&#x2019;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of 22,278,540 ordinary shares having exercise prices ranging from $0.43 to $2.625 per ordinary share issued by the Company, at a reduced exercise price of $0.10 per share, for gross proceeds to the Company of approximately $2,400, prior to deducting placement agent fees and estimated offering expenses.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to 22,278,540 ordinary shares for an exercise price of $ 0.11 per shares (the &#x201c;Private Placement Warrants&#x201d;). The placement agent in the offering also received compensation warrants exercisable for up to 1,559,498 Ordinary share The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of $ 0.11 per ordinary share, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $715.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 12, 2020, the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 54,750,000 units, each unit consisting of one Ordinary share, and one warrant to purchase one Ordinary share, at a price of $ 0.05 per unit, and (ii) 45,250,020 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one Ordinary share and one warrant, at a price of $ 0.05 per pre-funded unit.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The gross proceeds from the offering were approximately $ 5,000, prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The placement agent in the offering also received compensation warrants exercisable for up to 7,500,000 Ordinary share at an exercise price of $ 0.0625 per Ordinary share expiring on February 10, 2025.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 20,250,000 ordinary shares, at a price of $0.05 per ordinary share for gross proceeds of $1,012.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#x2019;s authorized share capital to 1,000,000,000 ordinary shares of no par value each and on June 7, 2021, &#160;a special meeting of shareholders of the Company approved to increase Company&#x2019;s authorized share capital to 5,000,000,000 ordinary shares of no par value each.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 31,000,020 ordinary shares, at a price of $0.05 per Ordinary share for gross proceeds of $1,550.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold 117,073,200 ordinary shares at a purchase price of $0.07 per Ordinary share for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of 58,536,600 ordinary shares. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $0.08 per ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ordinary shares sold in the offering (or warrants to purchase up to an aggregate of 8,780,490 Ordinary share), at an exercise price of $0.08 per ordinary share and a term expiring four and a half years from the date of issuance.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 51,165,000 Ordinary share at a purchase price of $0.06 per Ordinary share for aggregate gross proceeds of approximately $ 3,400 prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of 25,582,500 Ordinary share. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $0.08 per Ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 3,837,390 Ordinary shares), at an exercise price of $0.08 per Ordinary share and a term expiring.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2020, the Company issued 1,350,000 of its ordinary shares to a consultant in exchange for his services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In February and March 2021, the Company issued 50,926,830 ordinary shares in exchange for exercise of warrants. Total consideration received by the Company was $ 2,744.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In March 2021, the Company issued 1,050,000 of its ordinary shares to certain consultants in exchange for their services with fair value of $ 68.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares at an offering price of $0.07 per Ordinary share and $0.06 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#x2019;s fees and other estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 150,000,000 Ordinary shares. The warrants have an exercise price of $ 0.07 per Ordinary share and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2021, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares and 93,000,000 ordinary shares following the exercise of the pre-funded warrants (issuance expenses were $1,307).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company also paid on aggregate of $700 in placement agent fees and expenses and issued 10,500,000 placement agent warrants, at an initial exercise price equal to $0.07 per Ordinary share, on substantially the same terms as the investor warrants, except that the placement agent warrants expire on the earlier of (i) the third-year anniversary of the date on which an initial resale registration statement registering the ordinary shares (or the ADSs) issuable upon the exercise of the warrants becomes effective and (ii) August 11, 2026.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 20, 2021, the Company entered into
a warrant exercise agreement (the &#x201c;Exercise Agreement&#x201d;) with an institutional investor who is the holder of certain existing
warrants to purchase Company&#x2019;s ordinary shares in a registered direct offering consummated in August 2021. Pursuant to the Exercise
Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares having an
exercise price of $0.07 per Ordinary share, for gross proceeds to the Company of $10,000 prior to deducting placement agent fees and offering
expenses (which amounted to $0.98 million).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares (the &#x201c;Private Placement Warrants&#x201d;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $0.07 per Ordinary share. The Company also paid $875 in placement agent fees and issued unregistered placement agent warrants to purchase 10,500,000 Ordinary shares on the same terms as the warrant.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table summarizes information
regarding outstanding warrants to purchase the Company&#x2019;s ordinary shares as of December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Issuance date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; outstanding &lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;br/&gt; price per&lt;br/&gt; warrant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;March 2018&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;333,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;January 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;April 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;May 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;January 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,838,038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;February 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;June 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,390,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,419,890&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;December 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;190,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;375,197,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2022 and 2021, all
of the Company&#x2019;s outstanding warrants are classified as equity instruments.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c80" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c81" decimals="0" unitRef="shares">22278540</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c82" decimals="2" unitRef="usdPershares">0.43</us-gaap:StockOptionExercisePriceIncrease>
    <canf:AggregatePurchasePrice contextRef="c83" decimals="3" unitRef="usd">2.625</canf:AggregatePurchasePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c84" decimals="2" unitRef="usd">0.1</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c84" decimals="-3" unitRef="usd">2400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c84" decimals="0" unitRef="shares">22278540</canf:IssueOfNewUnregisteredWarrants>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c85" decimals="2" unitRef="usdPershares">0.11</us-gaap:StockOptionExercisePriceIncrease>
    <canf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights contextRef="c81" decimals="0" unitRef="shares">1559498</canf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c84" decimals="2" unitRef="usdPershares">0.11</us-gaap:StockOptionExercisePriceIncrease>
    <canf:DeemedDividend contextRef="c84" decimals="-3" unitRef="usd">715000</canf:DeemedDividend>
    <canf:SecuritiesPurchaseAgreementDescription contextRef="c86">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 54,750,000 units, each unit consisting of one Ordinary share, and one warrant to purchase one Ordinary share, at a price of $ 0.05 per unit, and (ii) 45,250,020 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one Ordinary share and one warrant, at a price of $ 0.05 per pre-funded unit.</canf:SecuritiesPurchaseAgreementDescription>
    <us-gaap:ProceedsFromOtherEquity contextRef="c86" decimals="-3" unitRef="usd">5000000</us-gaap:ProceedsFromOtherEquity>
    <canf:CompensationWarrantsExercisable contextRef="c87" decimals="0" unitRef="shares">7500000</canf:CompensationWarrantsExercisable>
    <canf:ExercisePrices contextRef="c87" decimals="4" unitRef="usdPershares">0.0625</canf:ExercisePrices>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="c86">2025-02-10</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c88" decimals="0" unitRef="shares">20250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="c89" decimals="2" unitRef="usdPershares">0.05</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c88" decimals="-3" unitRef="usd">1012000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IncreaseAuthorizedShareCapital contextRef="c90" decimals="0" unitRef="shares">1000000000</canf:IncreaseAuthorizedShareCapital>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c91" decimals="0" unitRef="ilsPershares">5000000000</us-gaap:CommonStockParOrStatedValuePerShare>
    <canf:AggregateWarrantPurchased contextRef="c92" decimals="0" unitRef="shares">31000020</canf:AggregateWarrantPurchased>
    <canf:AggregateWarrantPurchased contextRef="c93" decimals="0" unitRef="shares">31000020</canf:AggregateWarrantPurchased>
    <canf:ExercisePriceSubjectToAdjusment contextRef="c94" decimals="2" unitRef="usdPershares">0.05</canf:ExercisePriceSubjectToAdjusment>
    <canf:ExercisePriceSubjectToAdjusment contextRef="c95" decimals="2" unitRef="usdPershares">0.05</canf:ExercisePriceSubjectToAdjusment>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c92" decimals="-3" unitRef="usd">1550000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c93" decimals="-3" unitRef="usd">1550000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c96" decimals="0" unitRef="shares">117073200</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice contextRef="c97" decimals="2" unitRef="usdPershares">0.07</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c98" decimals="-3" unitRef="usd">8000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c96" decimals="0" unitRef="shares">58536600</canf:IssueOfNewUnregisteredWarrants>
    <canf:ExercisePrices contextRef="c96" decimals="2" unitRef="usdPershares">0.08</canf:ExercisePrices>
    <canf:AggregateWarrantPurchased contextRef="c96" decimals="0" unitRef="shares">8780490</canf:AggregateWarrantPurchased>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c98" decimals="2" unitRef="usdPershares">0.08</us-gaap:StockOptionExercisePriceIncrease>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c99" decimals="0" unitRef="shares">51165000</canf:IssueOfNewUnregisteredWarrants>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c99" decimals="2" unitRef="usdPershares">0.06</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c100" decimals="-3" unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c100" decimals="0" unitRef="shares">25582500</canf:IssueOfNewUnregisteredWarrants>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c100" decimals="2" unitRef="usdPershares">0.08</us-gaap:StockOptionExercisePriceIncrease>
    <canf:AggregateNumbersOfADS contextRef="c100" decimals="3" unitRef="pure">0.075</canf:AggregateNumbersOfADS>
    <canf:WarrantsToPurchaseAggregateShares contextRef="c101" decimals="0" unitRef="shares">3837390</canf:WarrantsToPurchaseAggregateShares>
    <canf:ExercisePrice contextRef="c101" decimals="2" unitRef="usdPershares">0.08</canf:ExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c102" decimals="0" unitRef="shares">1350000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c103" decimals="0" unitRef="shares">50926830</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c104" decimals="0" unitRef="shares">50926830</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:TotalConsiderationAmount contextRef="c105" decimals="-3" unitRef="usd">2744000</canf:TotalConsiderationAmount>
    <canf:TotalConsiderationAmount contextRef="c106" decimals="-3" unitRef="usd">2744000</canf:TotalConsiderationAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c107" decimals="0" unitRef="shares">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent contextRef="c106" decimals="-3" unitRef="usd">68000</us-gaap:AccruedExchangeFeeRebateCurrentAndNoncurrent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c108" decimals="0" unitRef="shares">57000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c109" decimals="0" unitRef="shares">93000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare contextRef="c110" decimals="2" unitRef="usdPershares">0.07</us-gaap:SaleOfStockPricePerShare>
    <canf:PreFundedWarrant contextRef="c110" decimals="2" unitRef="usdPershares">0.06</canf:PreFundedWarrant>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c111" decimals="-3" unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:AggregateWarrantPurchased contextRef="c108" decimals="0" unitRef="shares">150000000</canf:AggregateWarrantPurchased>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c111" decimals="2" unitRef="usdPershares">0.07</us-gaap:StockOptionExercisePriceIncrease>
    <canf:AggregateNumberOfADS contextRef="c4" decimals="-3" unitRef="usd">9997000</canf:AggregateNumberOfADS>
    <canf:AggregateWarrantPurchased contextRef="c112" decimals="0" unitRef="shares">57000000</canf:AggregateWarrantPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c4" decimals="0" unitRef="shares">93000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:IssuanceExpenses contextRef="c4" decimals="-3" unitRef="usd">1307000</canf:IssuanceExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c113" decimals="-3" unitRef="shares">700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c32" decimals="0" unitRef="shares">10500000</us-gaap:SharesIssued>
    <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare contextRef="c0" decimals="2" unitRef="usdPershares">0.07</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare>
    <canf:StockIssuanceAgreementDescription contextRef="c114">On December 20, 2021, the Company entered into
a warrant exercise agreement (the &#x201c;Exercise Agreement&#x201d;) with an institutional investor who is the holder of certain existing
warrants to purchase Company&#x2019;s ordinary shares in a registered direct offering consummated in August 2021.</canf:StockIssuanceAgreementDescription>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c114" decimals="0" unitRef="shares">150000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c115" decimals="2" unitRef="usdPershares">0.07</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c114" decimals="-3" unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:ExercisePrices contextRef="c116" decimals="-4" unitRef="usdPershares">980000</canf:ExercisePrices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c117" decimals="0" unitRef="shares">180000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:ExerciseAgreementDescription contextRef="c114">The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $0.07 per Ordinary share. The Company also paid $875 in placement agent fees and issued unregistered placement agent warrants to purchase 10,500,000 Ordinary shares on the same terms as the warrant. &#160; Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</canf:ExerciseAgreementDescription>
    <canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Issuance date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; outstanding &lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;br/&gt; price per&lt;br/&gt; warrant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;March 2018&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;333,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;January 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;April 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;May 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;January 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,838,038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;February 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;June 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,390,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,419,890&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;December 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;190,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;375,197,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"&gt;&#160;&lt;/p&gt;</canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock>
    <canf:IssuanceDate contextRef="c118">March 2018</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c119" decimals="INF" unitRef="shares">333334</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c119" decimals="1" unitRef="usdPershares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c120">January 2019</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c121" decimals="INF" unitRef="shares">223810</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c121" decimals="2" unitRef="usdPershares">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c122">April 2019</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c123" decimals="INF" unitRef="shares">492308</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c123" decimals="2" unitRef="usdPershares">0.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c124">May 2019</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c125" decimals="INF" unitRef="shares">47250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c125" decimals="2" unitRef="usdPershares">0.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c126">January 2020</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c127" decimals="INF" unitRef="shares">23838038</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c127" decimals="2" unitRef="usdPershares">0.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c128">February 2020</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c129" decimals="INF" unitRef="shares">11250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c129" decimals="2" unitRef="usdPershares">0.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c130">June 2020</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c131" decimals="INF" unitRef="shares">61390260</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c131" decimals="2" unitRef="usdPershares">0.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c132">July 2020</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c133" decimals="INF" unitRef="shares">29419890</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c133" decimals="2" unitRef="usdPershares">0.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c134">August 2021</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c135" decimals="INF" unitRef="shares">10500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c135" decimals="2" unitRef="usdPershares">0.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c136">December 2021</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c137" decimals="INF" unitRef="shares">190500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c137" decimals="2" unitRef="usdPershares">0.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c2" decimals="INF" unitRef="shares">375197640</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 11:-&#160;SHARE-BASED PAYMENT TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share options plan:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#x201c;2013 Plan&#x201d;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of 10 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Under the Company&#x2019;s 2013 Plan, in July
2022, the Company&#x2019;s Board of Directors approved to increase number of ordinary shares reserved for issuance to 35,000,000. As of
December 31, 2022, 8,023,000 shares available for future grant under the 2013 Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;126&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;266&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;466&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;317&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions granted by the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The fair value of the Company&#x2019;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.41%-3.08%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22-1.28%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.93-2.40%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83.98%-84.26%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;82.40-82.43%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;65.63-78.77%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.83 - 10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5-3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5 - 3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise price (NIS)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.253&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25 - 2.344&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movement during the year:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the year ended December 31, 2022 and related information:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; terms (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding at December 31, 20221&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,750,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(170,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,002,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Vested and expected to vest at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,002,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,071,575&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2022, 2021 and 2020 was 6.96 years, 8.45 years and 6.98 years, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average grant date fair value in 2022 was $0.02 and in 2021 was $0.18 and the remaining compensation costs not yet recognized as of December 31, 2022 is $230 with a weighted average period of 2.73 years to recognize these expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <canf:GrantedExcessYears contextRef="c138">P10Y</canf:GrantedExcessYears>
    <us-gaap:SharesIssued contextRef="c139" decimals="0" unitRef="shares">35000000</us-gaap:SharesIssued>
    <canf:FutureShares contextRef="c2" decimals="0" unitRef="shares">8023000</canf:FutureShares>
    <canf:ScheduleOfExpensesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;126&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;266&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;466&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;317&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</canf:ScheduleOfExpensesTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c0" decimals="-3" unitRef="usd">137000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c4" decimals="-3" unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c5" decimals="-3" unitRef="usd">159000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">126000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">266000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">158000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">263000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">466000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">317000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.41%-3.08%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22-1.28%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.93-2.40%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83.98%-84.26%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;82.40-82.43%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;65.63-78.77%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.83 - 10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5-3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5 - 3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise price (NIS)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.253&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25 - 2.344&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c78" decimals="4" unitRef="pure">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c79" decimals="4" unitRef="pure">0.0308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c140" decimals="4" unitRef="pure">0.0122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c141" decimals="4" unitRef="pure">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c142" decimals="4" unitRef="pure">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c143" decimals="4" unitRef="pure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c78" decimals="4" unitRef="pure">0.8398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c79" decimals="4" unitRef="pure">0.8426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c140" decimals="4" unitRef="pure">0.824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c141" decimals="4" unitRef="pure">0.8243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c142" decimals="4" unitRef="pure">0.6563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c143" decimals="4" unitRef="pure">0.7877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c4" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c142" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c143" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c142">P9Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c143">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice contextRef="c78" decimals="1" unitRef="pure">2.5</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice contextRef="c79" decimals="0" unitRef="pure">3</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice contextRef="c4" decimals="0" unitRef="pure">3</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice contextRef="c142" decimals="1" unitRef="pure">2.5</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice contextRef="c143" decimals="0" unitRef="pure">3</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c0" decimals="2" unitRef="ilsPershares">0.25</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c140" decimals="2" unitRef="ilsPershares">0.25</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c141" decimals="3" unitRef="ilsPershares">0.253</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c142" decimals="2" unitRef="ilsPershares">0.25</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c143" decimals="3" unitRef="ilsPershares">2.344</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; terms (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify"&gt;Outstanding at December 31, 20221&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,750,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(170,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,002,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Vested and expected to vest at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,002,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,071,575&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">18422700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">0.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0">P8Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="INF" unitRef="shares">8750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations contextRef="c0" decimals="INF" unitRef="shares">170500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="INF" unitRef="shares">27002200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">0.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c0">P7Y1M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther contextRef="c0" decimals="INF" unitRef="shares">27002200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">0.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0">P7Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c2" decimals="INF" unitRef="shares">11071575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">0.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0">P7Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c0">P6Y11M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c4">P8Y5M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c5">P6Y11M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c0" decimals="2" unitRef="usdPershares">0.02</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c4" decimals="2" unitRef="usdPershares">0.18</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c3" decimals="0" unitRef="usd">230</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c4">P2Y8M23D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 12- LEASES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of 3 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2022 and 2021 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Components of lease expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;54&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Supplemental cash flow information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;54&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;Maturities
of lease liabilities as of December 31, 2022 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(10&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c2">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Components of lease expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;54&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Supplemental cash flow information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;54&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P1Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P2Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="2" unitRef="pure">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="2" unitRef="pure">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">54000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="-3" unitRef="usd">55000</us-gaap:OperatingLeaseCost>
    <canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities contextRef="c0" decimals="-3" unitRef="usd">54000</canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities contextRef="c4" decimals="-3" unitRef="usd">55000</canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets contextRef="c4" decimals="-3" unitRef="usd">120000</canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(10&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="-3" unitRef="usd">54000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c2" decimals="-3" unitRef="usd">18000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <canf:LesseeOperatingLeaseLiabilityPaymentDue contextRef="c2" decimals="-3" unitRef="usd">72000</canf:LesseeOperatingLeaseLiabilityPaymentDue>
    <canf:ImputedInterestLessImputedInterest contextRef="c2" decimals="-3" unitRef="usd">10000</canf:ImputedInterestLessImputedInterest>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="-3" unitRef="usd">62000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13:-&#160;FINANCE INCOME (EXPENSE), NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Bank commissions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Net loss from exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(54&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other loss from short-term investment revaluation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(229&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other financial expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(363&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(299&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(386&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Interest income on bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other gain from short-term investment remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;249&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total financial income (expenses), net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(77&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(304&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Bank commissions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Net loss from exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(54&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other loss from short-term investment revaluation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(229&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other financial expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(363&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(299&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(386&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Interest income on bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other gain from short-term investment remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;249&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total financial income (expenses), net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(77&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(304&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <canf:BanksCommissions contextRef="c0" decimals="-3" unitRef="usd">-16000</canf:BanksCommissions>
    <canf:BanksCommissions contextRef="c4" decimals="-3" unitRef="usd">-18000</canf:BanksCommissions>
    <canf:BanksCommissions contextRef="c5" decimals="-3" unitRef="usd">-23000</canf:BanksCommissions>
    <canf:NetLossFromExchangeRateFluctuations contextRef="c0" decimals="-3" unitRef="usd">-54000</canf:NetLossFromExchangeRateFluctuations>
    <canf:OtherLossFromShorttermInvestmentRevaluation contextRef="c0" decimals="-3" unitRef="usd">-229000</canf:OtherLossFromShorttermInvestmentRevaluation>
    <us-gaap:OtherExpenses contextRef="c4" decimals="-3" unitRef="usd">4000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c5" decimals="-3" unitRef="usd">363000</us-gaap:OtherExpenses>
    <canf:FinanceExpenses contextRef="c0" decimals="-3" unitRef="usd">-299000</canf:FinanceExpenses>
    <canf:FinanceExpenses contextRef="c4" decimals="-3" unitRef="usd">-22000</canf:FinanceExpenses>
    <canf:FinanceExpenses contextRef="c5" decimals="-3" unitRef="usd">-386000</canf:FinanceExpenses>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c0" decimals="-3" unitRef="usd">222000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c4" decimals="-3" unitRef="usd">24000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c5" decimals="-3" unitRef="usd">44000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <canf:ExchangeRateFluctuations contextRef="c4" decimals="-3" unitRef="usd">63000</canf:ExchangeRateFluctuations>
    <canf:ExchangeRateFluctuations contextRef="c5" decimals="-3" unitRef="usd">27000</canf:ExchangeRateFluctuations>
    <us-gaap:GainLossOnInvestments contextRef="c4" decimals="-3" unitRef="usd">162000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c5" decimals="-3" unitRef="usd">11000</us-gaap:GainLossOnInvestments>
    <canf:FinanceIncome contextRef="c0" decimals="-3" unitRef="usd">222000</canf:FinanceIncome>
    <canf:FinanceIncome contextRef="c4" decimals="-3" unitRef="usd">249000</canf:FinanceIncome>
    <canf:FinanceIncome contextRef="c5" decimals="-3" unitRef="usd">82000</canf:FinanceIncome>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="-3" unitRef="usd">-77000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c4" decimals="-3" unitRef="usd">227000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c5" decimals="-3" unitRef="usd">-304000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 14:-&#160;TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate tax rates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Israeli taxation:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Corporate tax rate in Israel in 2022,
2021 and 2020 was 23%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Law for the Encouragement of Capital
Investments, 1959:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Law for Encouragement of Capital
Investments, 1959 (the &#x201c;Investment Law&#x201d;) provides tax benefits for Israeli companies meeting certain requirements and criteria.
The Investment Law has undergone certain amendments and reforms in recent years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Israeli parliament enacted a reform
to the Investment Law, effective January 2011 (which was amended in August 2013). According to the reform, a flat rate tax applies to
Preferred Income of companies eligible for the &#x201c;Preferred Enterprise&#x201d; status. In order to be eligible for Preferred Enterprise
status, a company must meet minimum requirements to establish that it contributes to the country&#x2019;s economic growth and is a competitive
factor for the gross domestic product.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Benefits granted to a Preferred Enterprise
include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for
Budget Years 2017-2018), 5777-2016, the tax rate is&#160;16% for all areas other than Development Area A (which was&#160;7.5% from 2017
onward).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Final tax assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company received final tax assessments
through 2017.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating carryforward losses for tax purposes and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2022, the Company
had carryforward losses amounting to approximately $&#160;157,106.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,348&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences mainly relating to Research and Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,376&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26,513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation of the theoretical tax expense to the actual tax expense:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The main reconciling item between the statutory tax rate of the Company
and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating
losses carried forward due to the uncertainty of the realization of such deferred taxes and the company&#x2019;s preferred enterprise tax rate.&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c144" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c145" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c146" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" unitRef="pure">0.16</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <canf:DevelopmentAreaAPercentage contextRef="c0" decimals="3" unitRef="pure">0.075</canf:DevelopmentAreaAPercentage>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c2" decimals="0" unitRef="usd">157106</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,348&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences mainly relating to Research and Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,376&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26,513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="-3" unitRef="usd">25137000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" unitRef="usd">26348000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c2" decimals="-3" unitRef="usd">1376000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="-3" unitRef="usd">2285000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" unitRef="usd">26513000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" unitRef="usd">28633000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" unitRef="usd">26513000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" unitRef="usd">28633000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 15:- TRANSACTIONS WITH RELATED PARTIES
&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Chairman of the Company&#x2019;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#x201c;Service Provider&#x201d;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $218, $241 and $252 in 2022, 2021 and 2020, respectively, which were recorded under research
and development expenses within Company&#x2019;s consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c0" decimals="-3" unitRef="usd">218000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c4" decimals="-3" unitRef="usd">241000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c5" decimals="-3" unitRef="usd">252000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 16:- SUBSEQUENT EVENTS &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"/&gt;&lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On January 11, 2023, the Company entered into
a securities purchase agreement (the &#x201c;RD Purchase Agreement&#x201d;), pursuant to which the Company agreed to sell and issue in a
registered direct offering (the &#x201c;Registered Direct Offering&#x201d;) an aggregate of 90,000,000 ordinary shares for a purchase price
of $ 0.018 per share (the &#x201c;RD Shares&#x201d;) and pre-funded warrants to purchase up to 210,000,000 of the Company&#x2019;s Ordinary
Shares at a purchase price of $ 0.018 per share and at an immaterial exercise price (the &#x201c;Pre-funded Warrants&#x201d;), and, unregistered
Series A warrants to purchase up to 300,000,000 Ordinary Shares for an exercise price of $ 0.02 per shares (the &#x201c;Series A Warrants&#x201d;),
and unregistered Series B warrants to purchase up to 300,000,000 Ordinary Shares for exercise price of $ 0.018 per share (the &#x201c;Series
B Warrants&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition, the Company entered into
a securities purchase agreement (the &#x201c;PIPE Purchase Agreement,&#x201d; and together with the RD Purchase Agreement, the &#x201c;Purchase
Agreements&#x201d;) pursuant to which the Company agreed to sell and issue in a concurrent private placement (the &#x201c;PIPE Offering,&#x201d;
and together with the Registered Direct Offering, the &#x201c;Offerings&#x201d;) unregistered Pre-funded Warrants to purchase up to 109,091,100
of the Company&#x2019; Ordinary Shares at purchase price of $ 0.018 per share and additional immaterial exercise price per share, unregistered
Series A Warrants to purchase up to 109,091,100 of the Company&#x2019;s Ordinary Shares for an exercise price of $ 0.02 per share and unregistered
Series B Warrants to purchase up to 109,091,100 of the Company&#x2019;s Ordinary Shares for an exercise price of $ 0.018 per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Moreover, the Company has also issued a placement agent warrants (the
&#x201c;Placement Agent Warrants&#x201d;) on substantially the same terms as the Series A Warrants to purchase up to 28,636,500 of the Company&#x2019;s
Ordinary Shares for an exercise price of $ 0.022 per share. In addition, the Company paid an aggregate of $675 thousands in placement
agent fees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company received total consideration
of $ 6,808 net of direct issuance costs from the above mentioned issuance of shares, prefunded warrants and Series A and B warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"/&gt;&lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company has also agreed to amend certain warrants to purchase up to an aggregate of 180,000,000 Ordinary
shares that were issued in December 2021 to the investor in this offering and private placement by reducing the exercise prices from $
0.067 per share to $ 0.018 per share.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1in"/&gt;&lt;td style="width: 0.25in"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;During January through March 2023, certain investors exercised prefunded warrants and purchased 319,091,100
of the Company&#x2019;s Ordinary shares for an exercise price at an immaterial amount.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c147" decimals="0" unitRef="shares">90000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c148" decimals="3" unitRef="usdPershares">0.018</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c149" decimals="0" unitRef="shares">210000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c150" decimals="3" unitRef="usdPershares">0.018</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c151" decimals="0" unitRef="shares">300000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c152" decimals="2" unitRef="usdPershares">0.02</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c153" decimals="0" unitRef="shares">300000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c154" decimals="3" unitRef="usdPershares">0.018</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c155" decimals="0" unitRef="shares">109091100</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c156" decimals="3" unitRef="usdPershares">0.018</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c157" decimals="0" unitRef="shares">109091100</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c158" decimals="2" unitRef="usdPershares">0.02</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c159" decimals="0" unitRef="shares">109091100</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c160" decimals="3" unitRef="usdPershares">0.018</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c161" decimals="0" unitRef="shares">28636500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c162" decimals="3" unitRef="usdPershares">0.022</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:NoninterestExpenseTransferAgentAndCustodianFees contextRef="c0" decimals="0" unitRef="usd">675</us-gaap:NoninterestExpenseTransferAgentAndCustodianFees>
    <canf:NetOfDirectIssuanceCosts contextRef="c163" decimals="0" unitRef="usd">6808</canf:NetOfDirectIssuanceCosts>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c3" decimals="0" unitRef="shares">180000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c141" decimals="3" unitRef="usdPershares">0.067</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c140" decimals="3" unitRef="usdPershares">0.018</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c164" decimals="0" unitRef="shares">319091100</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <dei:DocumentAccountingStandard contextRef="c0" id="hidden-fact-0">U.S. GAAP</dei:DocumentAccountingStandard>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c0"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c5"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="c0"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-13"
      unitRef="usdPershares">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="hidden-fact-14"
      unitRef="shares">358411297</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="hidden-fact-15"
      unitRef="shares">553079638</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-16"
      unitRef="shares">815746293</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c6"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c11"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c13"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c5"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c11"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c13"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c14"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c11"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c13"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c14"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c11"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c13"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c14"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c15"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses
      contextRef="c22"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses
      contextRef="c23"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c22"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c20"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c22"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c23"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c22"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c4"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c20"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c21"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c20"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c22"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c23"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c24"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c24"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c28"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c30"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c31"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c30"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c32"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:WithdrawalinvestmentInShorttermDepositsNet
      contextRef="c5"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="c0"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="c0"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:RevenueContractWithCustomer
      contextRef="c51"
      id="hidden-fact-64"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c60"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c61"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c64"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c65"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c3"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c0" id="hidden-fact-70" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:WeightedAverageRemainingContractualTermsinYearsForfeitedexpired contextRef="c0" id="hidden-fact-72" xsi:nil="true"/>
    <canf:AggregateIntrinsicValueForfeitedexpired
      contextRef="c0"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c2"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="c2"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c2"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:NetLossFromExchangeRateFluctuations
      contextRef="c4"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:NetLossFromExchangeRateFluctuations
      contextRef="c5"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:OtherLossFromShorttermInvestmentRevaluation
      contextRef="c4"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:OtherLossFromShorttermInvestmentRevaluation
      contextRef="c5"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherExpenses
      contextRef="c0"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:ExchangeRateFluctuations
      contextRef="c0"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c0"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c2"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001536196</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7HAO4S&.S^]HSFB6)IB3!-QS\2(>&\X 78*[%<X?"0-I#NY7N" KFB6D8'^
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MIP]*V&P@-"GKF+)G$F6NFR1Q5G/:O%%*OI:EM(\H->93Z\?;"@7%?68(:#[
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M@CISQCG-3NJQ>;!$?E'UN(W49RIB4#&^NB)>TEIV*6OG+NP4)0LKRM_/-C#
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MFX!XJ\BQ4!BX EFP!#,<+@(*V FTO*)'4H!:KE< ]Q"2![<<M##AA_F,=,$
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M)^(C(+)$*<Z+M*($Y68G0+%2?]0&26NUIGHMADJFA4_]4\14"3" ^%%X))P
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M?IH\>YG=I5%R^-"Z16QOM#0,1F&L5U=7#8D/W4_J+ SMC2[].5Y.W<4F;O+
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M\R_S"NOZ]QM:C"S0- I YW*-E;XDWH%[4V$/X8J8]YH6(P[\5P8[!FLA]E6
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M!U)1#GC SGZ0666_FL%V$$I\3,,%- 5V; V.$^'*3B!P81#^W@LSX54@.T^
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MS_W/F>"H!V@!GD\TX**Z( ;-IWX7_P502P,$%     @ S#Y^5BA,A(3B!
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MRND^0!<D&Z;QENE5_";B-2<=&O3;%/?B^ V\06/Y(. -?FIY8][&W(TG$N^
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M0UT".%V!<QMV "*X:?SYI!=[NQ(V3GC[V!CIM($[._2TPP+6)"&3/8V7GC\
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MPY@3/C/,E6S\!9S/M7;;A5?03*K#_P!02P,$%     @ S#Y^5D=&,%\<#0
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MH#)VB(6=$EZWU7:7EOM__.UJ,;]\;I,(V%(71M_!!,TF;0CCAX!5K=7PH-:
M8&JK,ET6FF0]5^T.%F]*5G^D1NY24]  F0# :_RP3Q# -LTU86D?.'66 LS5
M"I0400.25W6#V&R1-2T2'H9K>;,PZ=(4ID%.Q>^YL5E1V;:F_0/"(S/#/,FQ
M=W@6W#_K]G1H&R?TYC&$:B!QV6H:HS^#@;  +6]K%*3P#GQ+=KHV53Y5-UG3
MP@2P]: M8=%56R#RL.Y:K>IJ"Z]5,<6F:D1@SKW G(\*S'M *#.[@I<:6!?H
M/B0[H\".R,YRJD9F83&*96:0V D *-J<N C,5.;IW 1F)UH;>&S;I36Y 0LZ
M56_*1M>9&^!>I)VKT]*F&;/8)KT#=M:Z5" =8$,0D5$"7W@"7XP2^*,FI@8\
MO'P,$784R!'"@J(?@*[> 4.EI+"M=@(%O&]R^&A6!MG4)DB1JM1.>F#92*==
M;8##TB6X)NI^8[(-@"#UIDF*:MW$HA"+O+&1U,-CI>_2HN7?P%227MP8O5*5
MQR[7F4''Y0156PT;C#HN_L&"+*S3.L=GL.JJK3- KBBJ3-0,JPEM+8X N(1.
MF>F."O1<,3Z_ND/W"/!,>JK3O8'X("C6I 1QV<+,,#TJ="!F!%LH+T0T5D3>
MZK2&[Z250#\4U8Y&==G8Z^R\;M>H^W*2BW%YO_3L>#G*CM^W)7$\;%_6UK4N
ML_TDZ"+_C% $<H+#5OJ'0WP[.MMQOOTK:%PG\T$ -/@0!BN8U<#X+MD3V26R
MQ'E5%&F-.CFKB $+P&\+>]R 4@EJ!%WZ!OX/,F4\@FA#*H!4HX$M^S#%A)YL
MP8J"2<(7P;I' U#5T0QUCKS,[D'DA7UL8)T@%8 W& <CLO 8N68Q>W[S\98^
MS9\_4?]53=75Z4S)3]\+'6_=^M^F#<B\G<H+ZJ8H8J6HUK RFY!YK%#,',%B
M[#U-EFE!Z'*<9$!M6UGJ"J,+IE#?/8J=(C(,6V"3#<8SH(UQ4I#OH'#0!E3@
M2*!V$8LZP0'I;E=7H+H U#19@/!'BGURS#, ; X8J_,FO2&K LNMRTK, NY/
MO%^T3&+ODGP <A],#6B:M4&&$Z]@BJY^CX$BL.,<-,P\"3&/PV.(;S[>.C:8
M?(D/A VFPWR@(CX0;R1&!?<P@2W\3_'# ]A!#;-#$K/#F,J\\BKS:E1EWJ:6
M57:&'] [!].&+#ND#T=!'=&'X&@<G>.:?XJ>$!7M!K3<">S:=J(V$%07^Z0P
M, :I"JY]PR)%#KZX[+DI]DCK.PWJ$8TT, Y-1GR2@BIKP#EM1"O66N-68F *
MY"W0QD5N,;D,&4QG#3+(!&$M-8%+(DQ'J?_,4__9N/_D5PHL57X"B=E5,.T@
M\4<A'2$^\,BQ*:Z/_D)$]5^(@D(_PVIR"S+FA#>B)<D0$I-^0I=AK\G,T$L0
MNNOM$J3>A>\T'C[ UP'_8!"EH$[0-L&6'R@KU&H:/^'4- #6!RR#&WQ/"1I4
M8L FZ.74+@@ZGUX^^X9>GDW/3[\Y3K1CVC"K;#-1[,6C&0--5;=L_FCZ46:9
MST*J9O:%> 8<5I/'&@%P9F7*VK41BS"8K!D%?H2#5AC?/'36ZX.Q1#!RQZW?
MM80T+.46]B+*%40UNQU$[K*'-(+S=6JW2<'QS73;@#N >G$-ML'X4#J#== /
M38UJ$]W*DRS=09@)L[.'BC@(0CD\@C HUQ:,!&Q_ E.G?1@(MJQ )T,D77/P
MA#%Z 7L)[R!.J[;!B+NUXTIX'B7AYJ,[&\*: DR.'MR^40A'MF\]53W0UQ!.
M#5C27\B2+F;SBY/98I*(-?T)W[#J\<_5SF3JZFSQ1.QH1V:!G"@J&"TH0_%6
M6H.%E8P,!D\\M4\I9 7P2W#O2"F#+,F@!@5)4W8DX1P,!M*/YT]P[\1Q(,M*
M63JT"57!&1_:$=+?&-'!FO'G.#($)IVHQXLN)+>*:MF0+T"V'U4%\^42S#9
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MQ'U#UIS84USOJJOW+.*\!G&M"6?D-J>V,*U#"@W<=W9M O>V]"8@\*;,.!"
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M(@7KFVW*QFFIR7_#4!6,!?@+[@NKH% 5Y/3$1A<YX4J53&!>;Y27>XQP4#.
M)P(NM2ODCN" NF@3HIPRLM>455D!WUKRWIR["1BP;6UX1N^@@C/X9@5>-(9A
MP=L)RBWAEWF/=,YQ1;1C_+/W9 ^61A/Q"I9[<9..+"_@!*AG6N?L1:U@JJ3C
M-SG$CR0N)E'F L+$#GO13E=U7'(+ <BXZ@U= //Q-H /4GP5HAPKNHU#.:)P
M?T=&.P!_W7'H_6987P?NR%7BY8K#QHO9Q<1#)3?8Q6X23G"7"\;^4:(?7PMA
M"-64?)!9'Z+HPBS2LT&SVD;O+-54WL@V9/UV!L)D0A+LT)JX,,=A]APS[\,0
MHLI<%!78* %,,)\GIVA@G(F/ ,3)Z%T-JOQY<D9IZBH;'^?$]*$8(!63<]8D
MCFI1+1]5&I$AM9-1N&1;X;-EGHY9P^D OT4<&">4W=F[AH6F-LN6G>%UK;E"
M,O65<M0+O' *UA 5C-W\2,Z<&RG9M#N8 $1OI3$Q!?XI6&!,/78\TUW5: KA
MD[K:IP6H3^\\=QGS")Y)-'N/8\DC\\J)'$-/]*H(CL&ZJG(R$RAI)N-PA+9T
MI3',<IOI(#,]#O;<U?&Z6JU+-C(SYD _ YJ:[&<G-/%I%'+J)Z@970Y3VCTP
M)F X6.W6F[18L0TQ-08 -47'CT7#JR;]K.V3OTQ6-N*>KDQ&[+-);<?3=7QH
MQSBVRZ.M;2D"!(6E=YA#0,\"5Y\X7A+F8-RIN.[P@D#%T2O.#7 2 ?M7>B .
M%I(&Y>77--C3%.E('[1&;2*8=O=;%RWU6CTV3QP=0C?.D=*\YT6G/&N]1H<7
M/4X*%L$L/@>( #+7Z'S5Z'@DV%"!;,*5*P!0LG=<A=W5$KE6>4O*%7?$1[ZD
MB28(%W%%#LK,3KSN4OU>&42MT9K:B3!$-@U\Z^XBILB  $2/W$= "7C,=\11
M  R]%4]$_(2Q4JH0U^(8KP3%%N\/;+H%!Q/ %E3)CUB;M5.81_1!#5@E'4&3
MC-G#-N1++($Y-<\-,0"O &U7 XHK9U/X^83Q8E5H<+)77X+0DT8LO8B^HE"[
M8=>6 U38]"7E-[A IS#33E:S;(ATM:4L?D^-24R&'-6S[J1774!;0?!6!S7;
MEA(#8Q1@;87!&Q">E D+9+0<P[U3;B.IZZ:X0Q-V8]E#)?*H'GD&5^\Q"!#I
M;4:0?,=DV'?LYWEQ57O=!/7,#$)MDOF00(;LIX@7[W /EE<XY3XYLNL_NPY/
M5X6AM([/4_8;=HXZ;3GG;AT[=G=<"MHLR)R^=3H<#!KV@:M=6V-Y2(0C3OH9
M7A*PFE G@$L\GI%R=D8G]G (?XC8G.).7KJNAR%5/E%YZQTK4>:)PV<2UBBV
MT6\:N[6>)+A#+F7+*,7;0V%!V*/Q"JE[FLC3>=#[G;[.K01H@/O?3R>SRRMZ
M&SY>75VASK+H# "N8H>[A4SVM'(MOHASWD SA)Y.K*@F&ANYO\36$?MY-_!
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M\+ MOU-0"JOMV,F$:HMW*5B8UJK044Z.7IIMD$N%G%A7 )_:V W:/[4QP)W
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MF0*TV0V4FUCLB #EY\CFITW2P X4)5[E=++)&;61%&M#Y2:HM-:L9!F[@B"
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MH-JWK%T8637OQTX:JK%FFM/SC\H*T/E>2O.RL ;Z/Q3+?P!02P,$%     @
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M241,&%?!<+KI1L16.QPXW;+ "0_&.R"^T]@@O>$##/\9Z]]02P,$%     @
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M='TM4- 1 7694'34692'XY36K?!I0LC_.Q)83H1LS/H38\C]R.(^49E:T:B
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M54+);:$;Y< PAWTY[8S:GQ/5'N4<3:C_]B)Z$C'8OT-F[ %DA\,<<AK^]WM
M&[(!/ ]#](,\ ;V&8#.-SK2LM4+EK*].&PEOJ259'$=?:X)T&PJ%M@[V8#3T
MP^@1Q,NFK@527W%,0,%L!0OJ3,!5V^&H541G?K=FO 3: R8]74L6A6@\&%?@
M*@1),1L3D#;<!&=S+KCCI+@-DP<QE5:O0MRMD%1-P7R5G.X!8H9;G^7": EZ
M[M9UO_AZ#<Q:=#[4*_IE>0H[]#CJ]#AZLAZ)7F-:%GTY]LEN)WB_[.BF#T*Y
M(IKYFF7'T97VQ=+_'''-[F10PQZ\SJ//:.T8N*P;%\Z%-(A! OM9"@?1N0]
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M&PH=75Q./-"-UC0+J\IZOA-E22UJ,R=Y1NT<Z'RCE#TL7().\.,_4$L#!!0
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MZJ$)9J,MW2>ERONC8/(MD7HB>B2[DFQ)@DN!;I.$UJ4@Y0ZM:4X2 AS]$(/
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M$I#OMY2*IX%:H._[1E\ 4$L#!!0    ( ,P^?E99Z;;XXP(  &((   9
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MM NP\TNE<-MQ"W0/3_8+4$L#!!0    ( ,P^?E8QUITX90(  (L&   9
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MXF?R1#&Y4M)6AES($LK'!!2+[BN/=Y5/XQ<9<RB.R2@Z(G$8QP,%G;\>'@W
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M';Y%T^%;-1VVV-K*&]/AVS,=%=7A^RKNOM(:8L:=ZK@'VS-Z;^PCX6N:"93
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M(S&=Q P2,TG,(C&;Q!P2<TG,VV#BYBI-=47[\=.P]_S?Q\O'W53PCH:%MBP
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MF-*:Z:"NVQ6["W>;5U'R[56FUKR 5NVBFBRVE/KUI)8G6!2T7175-%334<U
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MW\#ZMNXB?6K>@GV^2]D:[UO>)BR*H^%!ZOW2MN1XV!^-]I>4NSMZ<CQ'YPE
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M31W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M9C2FHFA+@@>=!<$:]DR+W-
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MJ<FHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL64UDP@4IU
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MELOB^8>J@:=E]MMZ,S_]+U!+ P04    " #,/GY6S?*QL5 %    *   &0
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M>1 Z /?GG*O-1!_0_G&(_@%02P,$%     @ S#Y^5F9JE\\$!0  @QP  !D
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M>=6.50/)MF6#LF92M3OE:Z):6.#:0/T?,R8/ SU!TQ3/_P=02P,$%     @
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M8\RY9W%N/%&WOGTZOW_^0K+4(/OS%&'$]RCQ_2'$O<YA"[!W!5!RW[H$&PN
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M:[G*!   %RD   \   !X;"]W;W)K8F]O:RYX;6S%FEUOVCH8@/^*E9O#I/9
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M4]9G:Y=_'#\\\];4W2&?#7\RFKT!4$L! A0#%     @ S#Y^5@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #,/GY6(\'GX^\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #,/GY6F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,P^
M?E9IOA ?,0<   8B   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #,/GY6;2GX8L8%  !4&   &
M        @(%U#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ S#Y^5BY+U:R8 @  P <  !@              ("!<14  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,P^?E8U4"^=:P0  (X0   8
M              " @3\8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " #,/GY6[ H;D-$"  #*!P  &               @('@'   >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ S#Y^5GNO,1:S!@
M/2\  !@              ("!YQ\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( ,P^?E9IQX>-GP(  ,T&   8              " @= F
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #,/GY6]Z?$
M,50'  !C(@  &               @(&E*0  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ S#Y^5E(<BIK6!@  R@X  !@
M ("!+S$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ,P^
M?E:C8S)1<1\  *I<   9              " @3LX  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ S#Y^5BS,ZB6/ @  A 4  !D
M         ("!XU<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " #,/GY6TA3;V$ #  #"!@  &0              @(&I6@  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,P^?E9T@R$O* ,  .<&
M   9              " @2!>  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ S#Y^5B%FER-D @  . 4  !D              ("!?V$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #,/GY6ET7/
MK%,#  "N!P  &0              @($:9   >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( ,P^?E:AM^%=Y@L  /8G   9
M  " @:1G  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MS#Y^5BA,A(3B!   M0H  !D              ("!P7,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " #,/GY61T8P7QP-   K,0  &0
M            @(':>   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( ,P^?E9'!2T%M08  ,D.   9              " @2V&  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ S#Y^5@!+E5&S P
MNP@  !D              ("!&8T  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " #,/GY6N1F[9"4#  #'!@  &0              @($#
MD0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,P^?E9$
M;SQC= 8  +D.   9              " @5^4  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ S#Y^5HUXAMU3 P  _ 8  !D
M     ("!"IL  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,P^?E9)&HY*KP(  "D&   9              "
M@8[+  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ S#Y^
M5@HR-LQ> @  + 4  !D              ("!=,X  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " #,/GY6&@0[UH\"  #_!0  &0
M        @($)T0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( ,P^?E:#-&&TZP(  #\&   9              " @<_3  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ S#Y^5G,SVH<A!   >0D
M !D              ("!\=8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " #,/GY65@SDTS0#  "\!P  &0              @(%)VP
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,P^?E8;85LS
M( ,  +4&   9              " @;3>  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ S#Y^5@_I)G/# @  _ 4  !D
M ("!"^(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #,
M/GY6^K1N?7\"  #$!0  &0              @($%Y0  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,P^?E9:OK0S;P,    ,   9
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M970T,2YX;6Q02P$"% ,4    " #,/GY6NSD5I(@"  "$!@  &0
M    @(&!^   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M ,P^?E8QUITX90(  (L&   9              " @4#[  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ S#Y^5MND<]'* P   !0  !D
M             ("!W/T  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " #,/GY6=U!X'VH"  !I!@  &0              @('= 0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,P^?E9C//3D%0,
M %P/   9              " @7X$ 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ S#Y^5B,,%[;!"@  KG(  !D              ("!
MR@<! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #,/GY6
M/NTH;>,#  #(#   &0              @('"$@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( ,P^?E9"S-VQ1!D  (J3 0 9
M      " @=P6 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ S#Y^5LWRL;%0!0   "@  !D              ("!5S ! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #,/GY6&4E6\S4$  "!%0
M&0              @('>-0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( ,P^?E;K,BOIV0(  $0(   9              " @4HZ 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ S#Y^5F9JE\\$
M!0  @QP  !D              ("!6CT! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " #,/GY6HN2<VQ4%  #7'   &0
M@(&50@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ,P^
M?E84\4?8T $  /0#   9              " @>%' 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ S#Y^5EC6F&>< P  )0L  !D
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M=#8P+GAM;%!+ 0(4 Q0    ( ,P^?E;X9Q 6BP(  +D&   9
M  " @?]: 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
MS#Y^5L^MI#5!"0  ,X(  !D              ("!P5T! 'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    " #,/GY6AL7Q'8$#   S&   #0
M            @ $Y9P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,P^?E:7
MBKL<P    !,"   +              "  >5J 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( ,P^?E9E96NYR@0  !<I   /              "  <YK 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #,/GY6=TMQA08"  #Q)   &@
M        @ '%< $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #,/GY6_R>G=>,!  !L)   $P              @ $#<P$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     1@!& "$3   7=0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>165</ContextCount>
  <ElementCount>317</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Short-Term Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShortTermInvestment</Role>
      <ShortName>Short-Term Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Share-Based Payment Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactions</Role>
      <ShortName>Share-Based Payment Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Finance Income (Expense), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FinanceIncomeExpenseNet</Role>
      <ShortName>Finance Income (Expense), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Transactions with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TransactionswithRelatedParties</Role>
      <ShortName>Transactions with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsPayable</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Share-Based Payment Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</Role>
      <ShortName>Share-Based Payment Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Finance Income (Expense), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FinanceIncomeExpenseNetTables</Role>
      <ShortName>Finance Income (Expense), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/FinanceIncomeExpenseNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncome</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/General</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of property, plant and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Significant Accounting Policies (Details) - Schedule of outstanding share options and warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of outstanding share options and warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Short-Term Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShortTermInvestmentDetails</Role>
      <ShortName>Short-Term Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShortTermInvestment</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable</Role>
      <ShortName>Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofotheraccountspayableTable</Role>
      <ShortName>Other Accounts Payable (Details) - Schedule of other accounts payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsPayableTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/Revenues</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Share-Based Payment Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactionsDetails</Role>
      <ShortName>Share-Based Payment Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofexpensesTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of share options, their weighted average exercise price</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of share options, their weighted average exercise price</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable</Role>
      <ShortName>Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Finance Income (Expense), Net (Details) - Schedule of components of finance (income)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable</Role>
      <ShortName>Finance Income (Expense), Net (Details) - Schedule of components of finance (income)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/FinanceIncomeExpenseNetTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncomeTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncomeTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TransactionswithRelatedPartiesDetails</Role>
      <ShortName>Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TransactionswithRelatedParties</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f20f2022_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SubsequentEvents</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f20f2022_canfitebio.htm 20493</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentAccountingStandard, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f20f2022_canfitebio.htm 20585, 20596, 20597, 20598, 20599, 20600, 20601</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="f20f2022_canfitebio.htm">f20f2022_canfitebio.htm</File>
    <File>canf-20221231.xsd</File>
    <File>canf-20221231_cal.xml</File>
    <File>canf-20221231_def.xml</File>
    <File>canf-20221231_lab.xml</File>
    <File>canf-20221231_pre.xml</File>
    <File>f20f2022ex1-1_canfitebio.htm</File>
    <File>f20f2022ex12-1_canfitebio.htm</File>
    <File>f20f2022ex12-2_canfitebio.htm</File>
    <File>f20f2022ex13-1_canfitebio.htm</File>
    <File>f20f2022ex13-2_canfitebio.htm</File>
    <File>f20f2022ex15-1_canfitebio.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="549">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f20f2022_canfitebio.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 549,
    "http://xbrl.sec.gov/dei/2022": 47
   },
   "contextCount": 165,
   "dts": {
    "calculationLink": {
     "local": [
      "canf-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "canf-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f20f2022_canfitebio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "canf-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "canf-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "canf-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 470,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 70,
    "http://www.confite.com/20221231": 15,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 89
   },
   "keyCustom": 72,
   "keyStandard": 245,
   "memberCustom": 26,
   "memberStandard": 15,
   "nsprefix": "canf",
   "nsuri": "http://www.confite.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.confite.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.confite.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Short-Term Investment",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.confite.com/role/ShortTermInvestment",
     "shortName": "Short-Term Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Property, Plant and Equipment, Net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Other Accounts Payable",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.confite.com/role/OtherAccountsPayable",
     "shortName": "Other Accounts Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.confite.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Revenues",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.confite.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Contingent Liabilities and Commitments",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.confite.com/role/ContingentLiabilitiesandCommitments",
     "shortName": "Contingent Liabilities and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.confite.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Share-Based Payment Transactions",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactions",
     "shortName": "Share-Based Payment Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.confite.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.confite.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Finance Income (Expense), Net",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.confite.com/role/FinanceIncomeExpenseNet",
     "shortName": "Finance Income (Expense), Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Taxes on Income",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.confite.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Transactions with Related Parties",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.confite.com/role/TransactionswithRelatedParties",
     "shortName": "Transactions with Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.confite.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://www.confite.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.confite.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Other Accounts Payable (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.confite.com/role/OtherAccountsPayableTables",
     "shortName": "Other Accounts Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.confite.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Shareholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.confite.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Share-Based Payment Transactions (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactionsTables",
     "shortName": "Share-Based Payment Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.confite.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Finance Income (Expense), Net (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.confite.com/role/FinanceIncomeExpenseNetTables",
     "shortName": "Finance Income (Expense), Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Taxes on Income (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.confite.com/role/TaxesonIncomeTables",
     "shortName": "Taxes on Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - General (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.confite.com/role/GeneralDetails",
     "shortName": "General (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "canf:NetLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.confite.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c36",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c36",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:RevenueContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:RevenueContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.confite.com/role/ConsolidatedComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "canf:Options",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Significant Accounting Policies (Details) - Schedule of outstanding share options and warrants",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of outstanding share options and warrants",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "canf:Options",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:GovernmentAuthorities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable",
     "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:GovernmentAuthorities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Short-Term Investment (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.confite.com/role/ShortTermInvestmentDetails",
     "shortName": "Short-Term Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "lang": null,
      "name": "canf:PercentageOfOutstandingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNetDetails",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable",
     "shortName": "Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "canf:EmployeesAndPayrollAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.confite.com/role/ScheduleofotheraccountspayableTable",
     "shortName": "Other Accounts Payable (Details) - Schedule of other accounts payable",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "canf:EmployeesAndPayrollAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c58",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
     "shortName": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c58",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c66",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Revenues (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.confite.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c66",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NoninterestExpenseCommissionExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NoninterestExpenseCommissionExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c91",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "ilsPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.confite.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c91",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "ilsPershares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
     "shortName": "Consolidated Statements of Comprehensive Loss (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c138",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:GrantedExcessYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Share-Based Payment Transactions (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
     "shortName": "Share-Based Payment Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c138",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:GrantedExcessYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.confite.com/role/ScheduleofexpensesTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of share options, their weighted average exercise price",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of share options, their weighted average exercise price",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.confite.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable",
     "shortName": "Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:BanksCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Finance Income (Expense), Net (Details) - Schedule of components of finance (income)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable",
     "shortName": "Finance Income (Expense), Net (Details) - Schedule of components of finance (income)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:BanksCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Taxes on Income (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.confite.com/role/TaxesonIncomeDetails",
     "shortName": "Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.confite.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Taxes on Income (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Transactions with Related Parties (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.confite.com/role/TransactionswithRelatedPartiesDetails",
     "shortName": "Transactions with Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.confite.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:WarrantsNetOfIssuanceExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parentheticals)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:WarrantsNetOfIssuanceExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.confite.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - General",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.confite.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "canf_ADSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Receipt (or American Depository Share, ADS).",
        "label": "ADSMember",
        "terseLabel": "ADS [Member]"
       }
      }
     },
     "localname": "ADSMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_AccumulatedDepreciationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation Abstract",
        "terseLabel": "Accumulated depreciation:"
       }
      }
     },
     "localname": "AccumulatedDepreciationAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_AggregateIntrinsicValueForfeitedexpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate intrinsic value, Forfeited/expired.",
        "label": "Aggregate Intrinsic Value Forfeitedexpired",
        "terseLabel": "Aggregate intrinsic value, Forfeited/expired"
       }
      }
     },
     "localname": "AggregateIntrinsicValueForfeitedexpired",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_AggregateNumberOfADS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "aggregate number of ADS.",
        "label": "Aggregate Number Of ADS",
        "terseLabel": "Aggregate number of ADS percentage (in Dollars)"
       }
      }
     },
     "localname": "AggregateNumberOfADS",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_AggregateNumbersOfADS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate number of ADS.",
        "label": "Aggregate Numbers Of ADS",
        "terseLabel": "Aggregate number of ADS percentage"
       }
      }
     },
     "localname": "AggregateNumbersOfADS",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_AggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate purchase price.",
        "label": "Aggregate Purchase Price",
        "terseLabel": "Ordinary share issued per share (in Dollars)"
       }
      }
     },
     "localname": "AggregatePurchasePrice",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_AggregateWarrantPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate warrant purchased.",
        "label": "Aggregate Warrant Purchased",
        "terseLabel": "Aggregate warrant"
       }
      }
     },
     "localname": "AggregateWarrantPurchased",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_April2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April2019 Member",
        "terseLabel": "April 2019 [Member]"
       }
      }
     },
     "localname": "April2019Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_August2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August2021 Member",
        "terseLabel": "August 2021 [Member]"
       }
      }
     },
     "localname": "August2021Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_BanksCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank commissions.",
        "label": "Banks Commissions",
        "terseLabel": "Bank commissions"
       }
      }
     },
     "localname": "BanksCommissions",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CMSMedicalVentureInvestmentLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CMSMedical Venture Investment Limited Member",
        "terseLabel": "CMS Medical Venture Investment Limited [Member]"
       }
      }
     },
     "localname": "CMSMedicalVentureInvestmentLimitedMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CashFlowsFromOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Flows From Operating Activities",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromOperatingActivities",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_ChongKunDangPharmaceuticalsCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chong Kun Dang Pharmaceuticals Corp Member",
        "terseLabel": "Chong Kun Dang Pharmaceuticals Corp [Member]"
       }
      }
     },
     "localname": "ChongKunDangPharmaceuticalsCorpMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CipherPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cipher Pharmaceuticals Member",
        "terseLabel": "Cipher Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "CipherPharmaceuticalsMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrant Or Rights",
        "terseLabel": "Warrants exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantOrRights",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_CompensationWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "compensation warrants exercisable.",
        "label": "Compensation Warrants Exercisable",
        "terseLabel": "Compensation warrant exercisable"
       }
      }
     },
     "localname": "CompensationWarrantsExercisable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_ComponentsOfLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Lease Expense Abstract",
        "terseLabel": "Components of lease expense:"
       }
      }
     },
     "localname": "ComponentsOfLeaseExpenseAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ComputersOfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers Office Furniture And Equipment Member",
        "terseLabel": "Computers, office furniture and equipment [Member]"
       }
      }
     },
     "localname": "ComputersOfficeFurnitureAndEquipmentMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ContingentLiabilitiesandCommitmentsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Line Items]"
       }
      }
     },
     "localname": "ContingentLiabilitiesandCommitmentsDetailsLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ContingentLiabilitiesandCommitmentsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Table]"
       }
      }
     },
     "localname": "ContingentLiabilitiesandCommitmentsDetailsTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amouunt of contract liabilities.",
        "label": "Contract Liabilities",
        "terseLabel": "Contract liabilities under deferred revenues"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Abstract",
        "terseLabel": "Cost:"
       }
      }
     },
     "localname": "CostAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_December2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December2021 Member",
        "terseLabel": "December 2021 [Member]"
       }
      }
     },
     "localname": "December2021Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_DeemedDividend": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend.",
        "label": "Deemed Dividend",
        "terseLabel": "Deemed dividend (in Dollars)"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Abstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_DevelopmentAreaAPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development area percentage.",
        "label": "Development Area APercentage",
        "terseLabel": "Development area percentage."
       }
      }
     },
     "localname": "DevelopmentAreaAPercentage",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_DistributionAndSupplyAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of distribution and supply agreements.",
        "label": "Distribution And Supply Agreement Description",
        "terseLabel": "Distribution and supply agreement, description"
       }
      }
     },
     "localname": "DistributionAndSupplyAgreementDescription",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_EmployeesAndPayrollAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of employees and payroll accruals.",
        "label": "Employees And Payroll Accruals",
        "terseLabel": "Employees and payroll accruals"
       }
      }
     },
     "localname": "EmployeesAndPayrollAccruals",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_EwopharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ewopharma AGMember",
        "terseLabel": "Ewopharma AG [Member]"
       }
      }
     },
     "localname": "EwopharmaAGMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_EwopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ewopharma Member",
        "terseLabel": "Ewopharma [Member]"
       }
      }
     },
     "localname": "EwopharmaMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExchangeRateFluctuations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate fluctuations.",
        "label": "Exchange Rate Fluctuations",
        "terseLabel": "Exchange rate fluctuations"
       }
      }
     },
     "localname": "ExchangeRateFluctuations",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_ExerciseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Agreement Description",
        "terseLabel": "Exercise agreement description"
       }
      }
     },
     "localname": "ExerciseAgreementDescription",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price.",
        "label": "Exercise Price",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ExercisePriceSubjectToAdjusment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price Subject to adjustment.",
        "label": "Exercise Price Subject To Adjusment",
        "terseLabel": "Exercise price subject to adjustment (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePriceSubjectToAdjusment",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant, Exercise Price, Decrease.",
        "label": "Exercise Prices",
        "terseLabel": "Exercise prices (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrices",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_February2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "February2020 Member",
        "terseLabel": "February 2020 [Member]"
       }
      }
     },
     "localname": "February2020Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_FinanceExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Finance Expenses",
        "terseLabel": "Finance expenses"
       }
      }
     },
     "localname": "FinanceExpenses",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_FinanceIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from finance income.",
        "label": "Finance Income",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_FutureShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future shares.",
        "label": "Future Shares",
        "terseLabel": "Future shares (in Shares)"
       }
      }
     },
     "localname": "FutureShares",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_GebroHoldingGmBHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gebro Holding Gm BHMember",
        "terseLabel": "Gebro Holding GmBH [Member]"
       }
      }
     },
     "localname": "GebroHoldingGmBHMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails",
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_GovernmentAuthorities": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government authorities for the period.",
        "label": "Government Authorities",
        "terseLabel": "Government authorities"
       }
      }
     },
     "localname": "GovernmentAuthorities",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_GrantedExcessYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted Excess Years",
        "terseLabel": "Granted excess years"
       }
      }
     },
     "localname": "GrantedExcessYears",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "canf_ImputedInterestLessImputedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "imputed interest.",
        "label": "Imputed Interest Less Imputed Interest",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "ImputedInterestLessImputedInterest",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IncreaseAuthorizedShareCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase authorized Share Capital.",
        "label": "Increase Authorized Share Capital",
        "terseLabel": "Increase authorized capital"
       }
      }
     },
     "localname": "IncreaseAuthorizedShareCapital",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of changes in fair value of short-term investment.",
        "label": "Increase Decrease In Changes In Fair Value Of Shortterm Investment",
        "negatedLabel": "Changes in fair value of short-term investment"
       }
      }
     },
     "localname": "IncreaseDecreaseInChangesInFairValueOfShorttermInvestment",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Date",
        "terseLabel": "Issuance date"
       }
      }
     },
     "localname": "IssuanceDate",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_IssuanceExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance expenses.",
        "label": "Issuance Expenses",
        "terseLabel": "Issuance expenses (in Dollars)"
       }
      }
     },
     "localname": "IssuanceExpenses",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of share capital due to warrants exercise, net of issuance expenses.",
        "label": "Issuance Of Share Capital Due To Warrants Exercise Net Of Issuance Expenses",
        "terseLabel": "Issuance of share capital due to warrants exercise, net of issuance expenses of $ 980 (Note 10b(9), 10b(11) and 10b(12))"
       }
      }
     },
     "localname": "IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of share capital due to warrants exercise, net of issuance expenses.",
        "label": "Issuance Of Share Capital Due To Warrants Exercise Net Of Issuance Expensesin Shares",
        "terseLabel": "Issuance of share capital due to warrants exercise, net of issuance expenses of $ 980 (Note 10b(9), 10b(11) and 10b(12)) (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_IssueOfNewUnregisteredWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue of New Unregistered Warrants.",
        "label": "Issue Of New Unregistered Warrants",
        "terseLabel": "Issue of new unregistered warrants"
       }
      }
     },
     "localname": "IssueOfNewUnregisteredWarrants",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_January2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2019 Member",
        "terseLabel": "January 2019 [Member]"
       }
      }
     },
     "localname": "January2019Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_January2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2020 Member",
        "terseLabel": "January 2020 [Member]"
       }
      }
     },
     "localname": "January2020Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_July2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "July2020 Member",
        "terseLabel": "July 2020 [Member]"
       }
      }
     },
     "localname": "July2020Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_June2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "June2020 Member",
        "terseLabel": "June 2020 [Member]"
       }
      }
     },
     "localname": "June2020Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LaboratoryEquipmentAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment And Leasehold Improvements Member",
        "terseLabel": "Laboratory equipment and Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndLeaseholdImprovementsMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment Member",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LesseeOperatingLeaseLiabilityPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payment Due",
        "terseLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentDue",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_March2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March2018 Member",
        "terseLabel": "March 2018 [Member]"
       }
      }
     },
     "localname": "March2018Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_May2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "May2019 Member",
        "terseLabel": "May 2019 [Member]"
       }
      }
     },
     "localname": "May2019Member",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_MilestonePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of milestone.",
        "label": "Milestone Percentage",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "MilestonePercentage",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_NetLossFromExchangeRateFluctuations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss from exchange rate fluctuations.",
        "label": "Net Loss From Exchange Rate Fluctuations",
        "terseLabel": "Net loss from exchange rate fluctuations"
       }
      }
     },
     "localname": "NetLossFromExchangeRateFluctuations",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_NetLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net losses.",
        "label": "Net Losses",
        "terseLabel": "Net losses"
       }
      }
     },
     "localname": "NetLosses",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_NetOfDirectIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net of direct issuance costs.",
        "label": "Net Of Direct Issuance Costs",
        "terseLabel": "Net of direct issuance costs"
       }
      }
     },
     "localname": "NetOfDirectIssuanceCosts",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_Options": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of options shares.",
        "label": "Options",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "Options",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ordinary share warrants classification and measurement.",
        "label": "Ordinary Share Warrants Classification And Measurement Policy Text Block",
        "terseLabel": "Ordinary share and warrants classification and measurement"
       }
      }
     },
     "localname": "OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_OtherAccountsPayableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "localname": "OtherAccountsPayableLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsPayableTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Table]"
       }
      }
     },
     "localname": "OtherAccountsPayableTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherLossFromShorttermInvestmentRevaluation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other loss from short-term investment revaluation.",
        "label": "Other Loss From Shortterm Investment Revaluation",
        "terseLabel": "Other loss from short-term investment revaluation"
       }
      }
     },
     "localname": "OtherLossFromShorttermInvestmentRevaluation",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_PatentAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of patent agreement.",
        "label": "Patent Agreement Description",
        "terseLabel": "Patent agreement, description"
       }
      }
     },
     "localname": "PatentAgreementDescription",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_PercentageOfDepositsOnMonthlySalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of deposits on monthly salary.",
        "label": "Percentage Of Deposits On Monthly Salary",
        "terseLabel": "Percentage of deposits on monthly salary"
       }
      }
     },
     "localname": "PercentageOfDepositsOnMonthlySalary",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales.",
        "label": "Percentage Of Net Sales",
        "terseLabel": "Percentage of net sales"
       }
      }
     },
     "localname": "PercentageOfNetSales",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding shares.",
        "label": "Percentage Of Outstanding Shares",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "localname": "PercentageOfOutstandingShares",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestmentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfRealizationOnUltimateSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of realization on ultimate settlement.",
        "label": "Percentage Of Realization On Ultimate Settlement",
        "terseLabel": "Maximum percentage of realization on ultimate settlement"
       }
      }
     },
     "localname": "PercentageOfRealizationOnUltimateSettlement",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PlacementAgentWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrant Member",
        "terseLabel": "Placement Agent Warrants [Member]"
       }
      }
     },
     "localname": "PlacementAgentWarrantMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_PreFundedWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of pre-funded warrant.",
        "label": "Pre Funded Warrant",
        "terseLabel": "Pre-funded warrant (in Dollars per share)"
       }
      }
     },
     "localname": "PreFundedWarrant",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_PrefundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants Member",
        "terseLabel": "Pre-funded Warrants [Member]"
       }
      }
     },
     "localname": "PrefundedWarrantsMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_RDPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RDPurchase Agreement Member",
        "terseLabel": "RD Purchase Agreement [Member]"
       }
      }
     },
     "localname": "RDPurchaseAgreementMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_Revenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues.",
        "label": "Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_RevenueContractWithCustomer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue contract with customer.",
        "label": "Revenue Contract With Customer",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueContractWithCustomer",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_RevenuesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues (Details) [Line Items]"
       }
      }
     },
     "localname": "RevenuesDetailsLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_RevenuesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues (Details) [Table]"
       }
      }
     },
     "localname": "RevenuesDetailsTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_RoyalitiesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of royalities.",
        "label": "Royalities Description",
        "terseLabel": "Royalities, description"
       }
      }
     },
     "localname": "RoyalitiesDescription",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_RoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The royalty payment in percentage.",
        "label": "Royalty Payments Percentage",
        "terseLabel": "Royalty payments, percentage"
       }
      }
     },
     "localname": "RoyaltyPaymentsPercentage",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_ScheduleOfComponentsOfFinanceIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Finance Income Abstract"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfFinanceIncomeAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Using The Binomial Option Pricing Model Abstract"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Using The Binomial Option Pricing Model Table Text Block",
        "terseLabel": "Schedule of estimated using the binomial option pricing model"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Expenses Abstract"
       }
      }
     },
     "localname": "ScheduleOfExpensesAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Expenses Table Text Block",
        "terseLabel": "Schedule of expenses"
       }
      }
     },
     "localname": "ScheduleOfExpensesTableTextBlock",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets And Liabilities Measured At Fair Value On ARecurring Basis Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Abstract"
       }
      }
     },
     "localname": "ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Table Text Block",
        "terseLabel": "Schedule of information regarding outstanding warrants to purchase shares"
       }
      }
     },
     "localname": "ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Expense And Supplemental Cash Flow Information Related To Leases And Weighted Average Remaining Lease Terms And Discount Rate Abstract"
       }
      }
     },
     "localname": "ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Major Customer Data As APercentage Of Total Revenues Abstract"
       }
      }
     },
     "localname": "ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of major customer data as a percentage of total revenues.",
        "label": "Schedule Of Major Customer Data As APercentage Of Total Revenues Table Text Block",
        "terseLabel": "Schedule of major customer data as a percentage of total revenues"
       }
      }
     },
     "localname": "ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Lease Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOtherAccountsPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Accounts Payable Abstract"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOutstandingShareOptionsAndWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding Share Options And Warrants Abstract"
       }
      }
     },
     "localname": "ScheduleOfOutstandingShareOptionsAndWarrantsAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable and Prepaid Expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Net Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Options Their Weighted Average Exercise Price Abstract"
       }
      }
     },
     "localname": "ScheduleOfShareOptionsTheirWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.confite.com/20221231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful lives of the assets.",
        "label": "Schedule Of Useful Lives Of The Assets Table Text Block",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      }
     },
     "localname": "ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_SecuritiesPurchaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement, Description.",
        "label": "Securities Purchase Agreement Description",
        "terseLabel": "Securities purchase agreement, description"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementDescription",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SeriesAWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series AWarrant Member",
        "terseLabel": "Series A Warrants [Member]"
       }
      }
     },
     "localname": "SeriesAWarrantMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_SeriesBWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series BWarrant Member",
        "terseLabel": "Series B warrants [Member]"
       }
      }
     },
     "localname": "SeriesBWarrantMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_SeverancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for severance pay.",
        "label": "Severance Pay Policy Text Block",
        "terseLabel": "Severance pay"
       }
      }
     },
     "localname": "SeverancePayPolicyTextBlock",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price",
        "terseLabel": "Early Exercise Multiple (Suboptimal Factor)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "pureItemType"
    },
    "canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.",
        "label": "Share Based Payment Award Fair Value Assumptions Exercise Price",
        "terseLabel": "Exercise price (NIS) (in New Shekels per share)"
       }
      }
     },
     "localname": "ShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Transactions Details Scheduleofexpenses Line Items",
        "terseLabel": "Schedule of Expenses [Abstract]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsScheduleofexpensesLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Expenses [Abstract]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsScheduleofexpensesTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShortTermInvestmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investment [Table]"
       }
      }
     },
     "localname": "ShortTermInvestmentTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignatureDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The signature date.",
        "label": "Signature Date",
        "terseLabel": "Signature date"
       }
      }
     },
     "localname": "SignatureDate",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_StockIssuanceAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance agreement description.",
        "label": "Stock Issuance Agreement Description",
        "terseLabel": "Stock issuance agreement, description"
       }
      }
     },
     "localname": "StockIssuanceAgreementDescription",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of issuance of share capital and warrants, net of issuance expenses.",
        "label": "Stock Issued During Period Share Issuance Of Share Capital And Warrants",
        "terseLabel": "Issuance of share capital and warrants, net of issuance expenses (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of share capital and warrants, net of issuance expenses.",
        "label": "Stock Issued During Period Value Issuance Of Share Capital And Warrants",
        "terseLabel": "Issuance of share capital and warrants, net of issuance expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.",
        "label": "Supplemental Noncash Information Related To Lease Liabilities Arising From Obtaining ROUAssets",
        "terseLabel": "Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets"
       }
      }
     },
     "localname": "SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_TaxesonIncomeDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Line Items]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsLineItems",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_TaxesonIncomeDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsTable",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_TotalConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total consideration amount.",
        "label": "Total Consideration Amount",
        "terseLabel": "Total consideration amount (in Dollars)"
       }
      }
     },
     "localname": "TotalConsiderationAmount",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_TotalinDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of total shares.",
        "label": "Totalin Dollars",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "TotalinDollars",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_UnregisteredPrefundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unregistered Prefunded Warrants Member",
        "terseLabel": "Unregistered Pre-funded Warrants [Member]"
       }
      }
     },
     "localname": "UnregisteredPrefundedWarrantsMember",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation rates property, plant and equipment.",
        "label": "Useful Lives Or Depreciation Rates Property Plant And Equipments",
        "terseLabel": "Depreciation rates property, plant and equipment"
       }
      }
     },
     "localname": "UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_WarrantsNetOfIssuanceExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, net of issue expenses.",
        "label": "Warrants Net Of Issuance Expenses",
        "terseLabel": "Warrants, net of issuance expenses"
       }
      }
     },
     "localname": "WarrantsNetOfIssuanceExpenses",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_WarrantsToPurchaseAggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase aggregate shares.",
        "label": "Warrants To Purchase Aggregate Shares",
        "terseLabel": "Warrants to purchase aggregate ADS shares"
       }
      }
     },
     "localname": "WarrantsToPurchaseAggregateShares",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_WeightedAverageRemainingContractualTermsinYearsForfeitedexpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Termsin Years Forfeitedexpired",
        "terseLabel": "Weighted average remaining contractual terms (in years), Forfeited/expired"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermsinYearsForfeitedexpired",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "durationItemType"
    },
    "canf_WithdrawalinvestmentInShorttermDepositsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of withdrawal (investment) in short-term deposits, net.",
        "label": "Withdrawalinvestment In Shortterm Deposits Net",
        "negatedLabel": "Withdrawal (investment) in short-term deposits, net"
       }
      }
     },
     "localname": "WithdrawalinvestmentInShorttermDepositsNet",
     "nsuri": "http://www.confite.com/20221231",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address",
        "terseLabel": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number",
        "terseLabel": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r199",
      "r424",
      "r474",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r264",
      "r383",
      "r396",
      "r409",
      "r410",
      "r423",
      "r428",
      "r433",
      "r473",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/RevenuesDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r264",
      "r383",
      "r396",
      "r409",
      "r410",
      "r423",
      "r428",
      "r433",
      "r473",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/RevenuesDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r199",
      "r424",
      "r474",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r257",
      "r264",
      "r277",
      "r278",
      "r279",
      "r359",
      "r383",
      "r396",
      "r409",
      "r410",
      "r423",
      "r428",
      "r433",
      "r469",
      "r473",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/RevenuesDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r257",
      "r264",
      "r277",
      "r278",
      "r279",
      "r359",
      "r383",
      "r396",
      "r409",
      "r410",
      "r423",
      "r428",
      "r433",
      "r469",
      "r473",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/RevenuesDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r163",
      "r265",
      "r445",
      "r460"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r163",
      "r265",
      "r445",
      "r446",
      "r460"
     ],
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Initial Price Paid Per Share",
        "terseLabel": "Initial exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "OTHER ACCOUNTS PAYABLE"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Other accounts payable"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r1",
      "r14"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent": {
     "auth_ref": [
      "r99",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group.",
        "label": "Accrued Exchange Fee Rebate",
        "terseLabel": "Exchange services (in Dollars)"
       }
      }
     },
     "localname": "AccruedExchangeFeeRebateCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r99",
      "r115"
     ],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r57",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r129",
      "r390",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r20",
      "r23",
      "r82",
      "r343",
      "r397",
      "r398",
      "r451",
      "r452",
      "r453",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCollateralAggregateFairValue": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period.",
        "label": "Additional Collateral, Aggregate Fair Value",
        "terseLabel": "Additional payments"
       }
      }
     },
     "localname": "AdditionalCollateralAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalLiabilityLongDurationInsuranceBenefitPayment": {
     "auth_ref": [
      "r432",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to policyholder related to benefit payment for present value of total expected payment to policyholder in excess of present value of total expected assessment. Excludes benefit classified as market risk benefit or under provisions of Topic 815 on derivative and hedging.",
        "label": "Additional Liability, Long-Duration Insurance, Benefit Payment",
        "terseLabel": "Additional payments (in Dollars)"
       }
      }
     },
     "localname": "AdditionalLiabilityLongDurationInsuranceBenefitPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r431"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional and payments"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r457",
      "r458",
      "r459",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRoyalties": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid to music publishers, record producers, songwriters, or other artists in advance of their earning royalties from record or music sales. Such an amount is based on contractual terms and is generally nonrefundable.",
        "label": "Advance Royalties",
        "terseLabel": "Royalties in a total amount"
       }
      }
     },
     "localname": "AdvanceRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountOfRegulatoryAssistanceReceived1": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of regulatory assistance received from a federal regulatory agency in conjunction with either an acquisition of a troubled financial institution, transfer of nonperforming assets to a newly-formed entity, or other reorganization.",
        "label": "Amount of Regulatory Assistance Received",
        "terseLabel": "Up-front amount receive"
       }
      }
     },
     "localname": "AmountOfRegulatoryAssistanceReceived1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r109",
      "r128",
      "r148",
      "r182",
      "r191",
      "r195",
      "r203",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r309",
      "r311",
      "r324",
      "r431",
      "r471",
      "r472",
      "r509"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r123",
      "r130",
      "r148",
      "r203",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r309",
      "r311",
      "r324",
      "r431",
      "r471",
      "r472",
      "r509"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r148",
      "r203",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r309",
      "r311",
      "r324",
      "r471",
      "r472",
      "r509"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankingAndThriftInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Banking and Thrift, Interest [Abstract]"
       }
      }
     },
     "localname": "BankingAndThriftInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r125",
      "r413"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r35",
      "r41",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at the end of the year",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r88"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Expiring date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per warrant (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants",
        "verboseLabel": "Purchase aggregate warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoutstandingshareoptionsandwarrantsTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of outstanding warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r100",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "CONTIGENT LIABILITIES AND COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r213",
      "r214",
      "r404",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Legal and other contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Aggregate ordinary shares"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r457",
      "r458",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Par value (in New Shekels per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r431"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares of no par value - Authorized: 5,000,000,000 shares at December 31, 2022 and 2021; Issued and outstanding: 815,746,293 shares as of December 31, 2022 and 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r83",
      "r132",
      "r134",
      "r140",
      "r386",
      "r391"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r107",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r89",
      "r228",
      "r231",
      "r421",
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Warrants exercise, net of issuance expenses"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredSalesInducementsNet": {
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred sale inducement cost capitalized on contract remaining in force.",
        "label": "Deferred Sale Inducement Cost",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "DeferredSalesInducementsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r79",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Carryforward losses amount (in Dollars)"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax asset before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r79",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Temporary differences mainly relating to Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax asset, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r79",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r39",
      "r181"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation of property, plant and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationExpenseOnReclassifiedAssets": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).",
        "label": "Depreciation Expense on Reclassified Assets",
        "terseLabel": "Depreciation expenses"
       }
      }
     },
     "localname": "DepreciationExpenseOnReclassifiedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r266",
      "r281",
      "r282",
      "r284",
      "r289",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED PAYMENT TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r141",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r164",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r316",
      "r317",
      "r387",
      "r392",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic and diluted net loss per share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r141",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r316",
      "r317",
      "r387",
      "r392",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Exchange differences on balances of cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r149",
      "r292",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax rate percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation costs not yet recognized (in Dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r64",
      "r121",
      "r136",
      "r137",
      "r138",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r173",
      "r204",
      "r246",
      "r285",
      "r286",
      "r287",
      "r301",
      "r302",
      "r315",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r343",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r229",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r319",
      "r356",
      "r357",
      "r358",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r229",
      "r258",
      "r263",
      "r319",
      "r356",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r229",
      "r258",
      "r263",
      "r319",
      "r357",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r229",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r319",
      "r358",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r229",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r356",
      "r357",
      "r358",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r230",
      "r243",
      "r313",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r420",
      "r462",
      "r463",
      "r464",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional currency, reporting currency and foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r29",
      "r52",
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Other gain from short-term investment remeasurement"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r24",
      "r92",
      "r101",
      "r117",
      "r182",
      "r190",
      "r194",
      "r196",
      "r388",
      "r419"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r148",
      "r153",
      "r182",
      "r190",
      "r194",
      "r196",
      "r203",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r317",
      "r324",
      "r419",
      "r471"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r293",
      "r294",
      "r299",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r290",
      "r291",
      "r294",
      "r295",
      "r298",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Increase (decrease) in trade payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Increase (decrease) in deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "terseLabel": "Increase (decrease) in other accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Reduction in the carrying amount of operating lease right of use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Decrease in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Change in prepaid expenses, and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of components of finance (income)"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Text Block]",
        "terseLabel": "FINANCE INCOME (EXPENSE), NET"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "auth_ref": [
      "r106",
      "r411",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.",
        "label": "Interest Income, Deposits with Financial Institutions",
        "terseLabel": "Interest income on bank deposits"
       }
      }
     },
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Total financial income (expenses), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r142",
      "r144",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the year for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r461",
      "r465",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "SHORT-TERM INVESTMENT"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Israel.",
        "label": "Israel Tax Authority [Member]",
        "terseLabel": "Israel [Member]",
        "verboseLabel": "Israel Tax Authority [Member]"
       }
      }
     },
     "localname": "IsraelTaxAuthorityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of weighted average remaining lease terms and discount rate"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r96",
      "r112",
      "r431",
      "r456",
      "r466",
      "r504"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r124",
      "r148",
      "r203",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r310",
      "r311",
      "r312",
      "r324",
      "r431",
      "r471",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r148",
      "r203",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r310",
      "r311",
      "r312",
      "r324",
      "r471",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r40",
      "r102",
      "r116",
      "r122",
      "r131",
      "r133",
      "r138",
      "r148",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r167",
      "r182",
      "r190",
      "r194",
      "r196",
      "r203",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r317",
      "r324",
      "r419",
      "r471"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow",
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted and recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoninterestExpenseCommissionExpense": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees incurred for commissions on mutual funds and insurance products.",
        "label": "Noninterest Expense Commission Expense",
        "terseLabel": "Commission Income Expense"
       }
      }
     },
     "localname": "NoninterestExpenseCommissionExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoninterestExpenseTransferAgentAndCustodianFees": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fees paid to an agent employed by a corporation or mutual fund to maintain shareholder records, including purchases, sales, and account balances. Also includes custodian fees incurred during an accounting period from an agent, bank, trust company, or other organization that holds and safeguards an individual's, mutual fund's, or investment company's assets for them. These fees will be billed back to the client and are a component of noninterest expense.",
        "label": "Noninterest Expense Transfer Agent and Custodian Fees",
        "terseLabel": "Aggregate amount paid"
       }
      }
     },
     "localname": "NoninterestExpenseTransferAgentAndCustodianFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Total financial income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r182",
      "r190",
      "r194",
      "r196",
      "r419"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r336",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r172",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Operating lease"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturity of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r339",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r338",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "totalLabel": "Other accounts payable"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r28",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "negatedLabel": "Other financial expense"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.confite.com/role/ScheduleofexpensesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLoansPayable": {
     "auth_ref": [
      "r5",
      "r95",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term loans payable classified as other.",
        "label": "Other Loans Payable",
        "terseLabel": "Payables"
       }
      }
     },
     "localname": "OtherLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Financial expenses (income), net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Payments"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "terseLabel": "Deemed Dividend"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance cost (in Dollars)"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToSuppliers": {
     "auth_ref": [
      "r454",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of cash to suppliers for goods and services during the current period.",
        "label": "Payments to Suppliers",
        "terseLabel": "Total payments"
       }
      }
     },
     "localname": "PaymentsToSuppliers",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PercentageOfFIFOInventory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of FIFO (first in first out) inventory to total inventory as of the balance sheet date if other than 100 percent.",
        "label": "Percentage of FIFO Inventory",
        "terseLabel": "Cost plus percentage"
       }
      }
     },
     "localname": "PercentageOfFIFOInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and others"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses, and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement Warrants [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r32",
      "r75"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Issuance of share capital and warrants, net of issuance expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Gross proceeds from offering (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r406",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r56",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r58",
      "r113",
      "r389",
      "r431"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for classification and method of accounting for interest-only strips, loans, other receivables, or retained interests in securitizations that can be contractually prepaid or otherwise settled in a way that the holder would not recover substantially all of its recorded investment.",
        "label": "Receivables and Portions of Securitizations that can be Prepaid at Potential Loss, Policy [Policy Text Block]",
        "terseLabel": "Prepaid expenses, and other current assets"
       }
      }
     },
     "localname": "ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemablePreferredStockDividends": {
     "auth_ref": [
      "r45",
      "r64",
      "r65"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.",
        "label": "Redeemable Preferred Stock Dividends",
        "negatedLabel": "Deemed dividend"
       }
      }
     },
     "localname": "RedeemablePreferredStockDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r120",
      "r346",
      "r347",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Aggregate amount of research and development expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TransactionswithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r347",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "TRANSACTIONS WITH RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TransactionswithRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r76",
      "r119",
      "r517"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.confite.com/role/ScheduleofexpensesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenditures"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r65",
      "r111",
      "r401",
      "r403",
      "r431"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r121",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r204",
      "r285",
      "r286",
      "r287",
      "r301",
      "r302",
      "r315",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r139",
      "r148",
      "r179",
      "r180",
      "r189",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r203",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r324",
      "r388",
      "r471"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r337",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Lease liabilities arising from obtaining right-of-use-assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Annual royalties"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares hold by company",
        "verboseLabel": "Sold an aggregate shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShortTermInvestmentDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other accounts payable"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "schedule of outstanding share options and warrants"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of share options, their weighted average exercise price"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesReceivedAsCollateral": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.",
        "label": "Securities Received as Collateral",
        "terseLabel": "Amount received"
       }
      }
     },
     "localname": "SecuritiesReceivedAsCollateral",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.confite.com/role/ScheduleofexpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "totalLabel": "Total Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance pay expense"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based payment"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual terms (in years), Grants",
        "verboseLabel": "Weighted average period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable",
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedLabel": "Number of options, Forfeited/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other",
        "terseLabel": "Number of options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, Grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value end of year",
        "periodStartLabel": "Aggregate intrinsic value beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, Outstanding, at end of year",
        "periodStartLabel": "Number of options, Outstanding, at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price end of year",
        "periodStartLabel": "Weighted average exercise price beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r267",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based payment transactions"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Ordinary per share issued (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Payments percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/RevenuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual terms (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual terms (in years) beginning of year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual terms (in years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual terms (in years) end of year"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ScheduleofshareoptionstheirweightedaverageexercisepriceTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "netLabel": "Shares issued (in Shares)",
        "terseLabel": "Number of ordinary shares represent by each ADS (in Shares)",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/GeneralDetails",
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Investment [Abstract]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated over time.",
        "label": "Short-Term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted average rates percentage"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r97",
      "r98",
      "r108",
      "r449"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investment"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r44",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r64",
      "r121",
      "r136",
      "r137",
      "r138",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r173",
      "r204",
      "r246",
      "r285",
      "r286",
      "r287",
      "r301",
      "r302",
      "r315",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r343",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r173",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of share capital (in Shares)",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of share capital in exchange for services (in Shares)",
        "verboseLabel": "Aggregate shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of share capital",
        "verboseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of share capital in exchange for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r65",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockDividend": {
     "auth_ref": [
      "r19",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued to shareholders as a dividend during the period.",
        "label": "Stock Issued During Period, Value, Stock Dividend",
        "terseLabel": "Deemed dividends related to the warrants exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "dividends related to the warrants exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Increase",
        "terseLabel": "Exercise price (in Dollars per share)",
        "verboseLabel": "Exercise price per share"
       }
      }
     },
     "localname": "StockOptionExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r51",
      "r431",
      "r456",
      "r466",
      "r504"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r147",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r246",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r332",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r332",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r332",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "verboseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r230",
      "r243",
      "r313",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r462",
      "r463",
      "r464",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r174",
      "r175",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r165",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r164",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-12)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473541&loc=d3e61799-108003",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6481654&loc=d3e11214-158414",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=d3e11332-158416",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783724-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r437": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r438": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r439": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r441": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r442": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r443": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2459-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 11.N)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897409&loc=d3e533348-122875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001213900-23-024298-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-024298-xbrl.zip
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M>B&T?B:;N\831:CYPEQ'81,1@+SZF;('#(K>@%S$#QC 8(J)+0DQQ\8#.'[
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MR?G/5@0O?GCAH&!!N1T>OCE,>?T?]I/?R>_'81"%ON<R)1TAGXWY=H5Q_.*
MD?YX<U8:K1,&"R_&3,VOV.]?M7[^*K4!DR+^?HT(#N(5CCT'^5%/B:O4# V
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M:53EQNBI:>G3&X444;C0+3OUG>,8>=*'[)6/("-D41)034@I4D;/8!7E;2<
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MB;IUP<TZOF[V=N/G7OY0 MONF ,FY# >:DQ*3P)- *=S"IR,YW3$O":8V.D
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MUY829(:ZYG$9LBP+=*EMF?;TE-2"D<R#IFIS)Y.D60TM\Z/ZS30=5FWD$L\
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MR(S+:X6K.P.KHQT>N]%-5#0+W+1BAV6B%@U21'>47-3\*R/^$50TJ_>,.J9
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MP+I9&WZ.<E?7MI:^*=^_8N3O4839V/\74$L#!!0    ( ,P^?E:+468T%+
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M^L.V56<"/_SW/5:+>-D#3<BQ!OI7QA;%M22_=M#H7]B006OLX[6#T#8-!WQ
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M?6BA1[.EN?-G1\M&?YV%(0Q"$A5\XQC=;.2:915KJ&Q(6+V<KV_N03P#Y*8
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MAA\.-.((!QJ)A@,5\FJCV/[YT<<^/^C;7I1_1/XVMY]M"[JRE3_^?;5D6/-
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M1VE*0,H)Q"VP*'(GRAR*WU+ZBH"HV4F]350##2MSY7ZQGBWG8/&/]>)NL]B
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M$4*NCZ P0;%W/+\W@_^2(;@,*]0B0YEHS;I\EX\ANQ98CH-D:XY-VVGHO]<
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MDCF;:TO5/FP>H%B5XJ)9A%.-PKPJL^HJ<LE)X4JU2QZ,='9>+X+0WF,MX&.
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M8@S2HMZ]Z4RUF^K(1^ #C?\E82"J$P]QZ>I3(QK$D@Q2,<URZ[.*#%/FJ8W
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M$&/%<^+2R+L=]'%]E0'((DXZ%K3L&@2(EI3-$F63ZWV1W>Y\FE'#&DI]O W
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M);E1V@K,M*9F4>7D.;QP0--]'#V&9'$NU#5^YH]VDLYCS3MJN+ YP&*R65T
MGF7C,!Z]#J<61"ZR'A]*1._I-/'U U),$9(R/:!GIS[WOJH-?6[(6"[[+(=[
MGZV@]^YM3>6"][T50CJT6<3GP(47L("]MX//USY$7R[^27ZP 7,G#<YU-C3,
M%+C<#*SJ13, GC* 2(,F*I8"#6H/+_IXX^WW-FF\A)U$43+=(W1-W'RZYS@6
M[HUU<!HO<,S$WT?#R;LA\TOH?$5O3^]R)' +O(C$56X@KCCAXN*6]3<KL]D]
M>[[B0F,UH#!#+N(9X&#H>9;FI4&N67W](;O6(:L418C*E"#V6Q*!B$Q94L:H
M%_5?! +E+6[:P\A\/T0KG9.Z,)C_B%D0YD((!E!]2XP;*N5Q!- EKJZE.;D]
M>_%8VRA_SV!!PL[GQH&@+K#)/,T.XR9J%3QL=0<5;1R1=)LBC)JTA"-]KNV=
M;1HQGU9,C':W9.=-U"8J= 67J[$74=>^)'T%S<+JY&]T*U7Y[2R+0=(K7 IV
MQ>7CPO!Q,9D@J63>KYALVDWU]=T #X-ST05FFY$/SW:.N$B>"T.22)[5P-/J
MQ>,D:J'B!0<FQ+GL#GZ9F2;.<\,AP+[GHA]-PLU*(GQ:;Z_C[:(MD$P?,]:A
MG!,P+.] "C@B/O637]JDQR PTHW H;"3;K^,**,4DA!%$"G6?.CZP^8#M)"8
M=GY&R^,D7%(S#N]U:R-C'2+!C9O;<*D%W(NI;E+$"QC+#_AA ^+Y(%X 9"N
M> GP:[3(OW3>[FWIF=[BK5 DU,3^BW= <GEOM&"H\AS5?%/:G]7 (1E%Y0#U
M31OHB,[Z-% .)>C^W1P? OC[$;^4/:/_HU&VNQ.%NH=R-PD-"I8C)!T+R. J
M6^CP?]21JN#A8)Y4L#W0;+YI\<EGH]7:B.F^K'('\PWM\U;]<5>0F76C*QQ
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M)E;QL=Q,,- KH07E4M;AQ8B0LI#8C:0H8GL!4C=?<91=#2@LM2&U_LF4@?@
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M9)T!P_KM&'69QO]P+8#8UGV$>'A<H,SU0F#!'=)%+=QNP29MJ4EI##\I>E8
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M<=HFQQYY'($<DL##">3')?VLR,YG .\-R.8@MWLY)U;GA2&&LAIN$D"]>AO
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M2X:!:)S63Z8(<O7#H1U)1>?XI%]OWLA.6O[DK.S90T!"_3!@ETT^#M)(!R\
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MR#]$U]@07X]4MM=]4 F8EDK?7+W-U=<H\:$>>$C_\@%.KF:;DMVC5U?R2^?
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MV#?U4*B32R52L)O'9M_'-J8R;7D0MKF1)=>(? 1ASX!B]\V!WV3/@"N%M38
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M>A;RU=,N$^K5L9VG2H082,C2>C3%Y6=3*\4MCO7>." \M@W;O$]K9E;OTNP
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M)$$OO>M=C[DY>UYSY^N-DX=EBRJ+?+O-OBUD=IED&=U]>.^V<V=B\0C\IHW
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M/K(IRJV,_8;] Q"XL%K_'U!+ P04    " #,/GY6C\*CXBI"  #)& 0 %0
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MO9.RYY2O:FM&G#W(+%_2Y43:QSC 2X1B^#-%F3V^FXI_-B*9TM9LXQ-8I S
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M+8,_DH.U2U];,M)R!MG. VZIO#,BOVY<X]ASHJ+LX9O5+&"!TCHS\A7&.XI
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MF\22@96A/VUMT."Z0L(P<,=L9KE8)S.Z?)-MEMOQ6+Z%#F4J.ABMD S6K@1
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MBLZ$I\ I6^_6:6D0!7&YH%J,3A,2X)A=< O>J(0T)<"-)!6O2XXRS($^^IZ
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MOCU$&%_R (9G?Z,RE?A=47:E2  #=NX\XG6R!N->&9XE8][)OLJ*[5F+<QS
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M%5&N8< VA\$0Y%J]=N@O*B)1VI:DFZ*!S>E$EP ?(&# "_C9'[7,$U0H&O0
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M";LMJOX2EG"09=$E-4*BJ@HUKBOKBJFY\!LT--*WDLJ &M(9RYG()@BL*3[
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M)<$4&5G!HN!3+,'P./8Y#&QDH:PI>3Z5F5A2#**L2WH7O,&TL#3!9SLI@X=
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MW/0]:'"/#?!M3^6"Q](BP[T&E^&83*@!P;*/=WF]V8T [4J*]9G1-*8MFW!
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M?.-9(*<VS#\&[GE^G/*$"/S,T8J<Z6<.EV4;MY]GJ-(@D]%.S9A7^3RTE=,
MR:OBFNM_UKV43 G^T/N;0I?A&T/5\R\[HN>"NY)P@;$^VOH8[I5SU%-PD>G&
M+5%YTYD,FQ!IOWESPK=$Z9N-@?\@BDX*)V,OK=YLV.WN"@1ZJ&J+&0V.*<M&
MD,.6B61IKH?>1R+,S$W04\'&^QO#@RC'%MC$&X(;YU]IH:0+;4/EU(R%$=D*
M2JF1#2VV 4-;EAM8J2"+C:.TRDV$K28+(F2\2;MZ@#=C4G=_)3X40K2%\L^6
MS#)U4K CH#,X;)GBEB\1F<./X=Q15!Q^43<56BS25)4W72'P,7!FT&,%%[X
M]%GV/GZ@&9VX^</I*.;\RO&Z*IP,]7R+,-?3C(07'6KZ_ASR">8$'3$62%2S
M2>_!R;"2IX<GY!_^N!.$/0=+"?)=I.H^)3'>_-H#9[[1\D))++1->#U Z6,J
M^_&-"10G_&J!#(5O*^E%YHQ+,3_[Z1H2D6&_._"F6C&+KW0*+&^D*HM2!;^"
M:W]E5]R*U%I+$B<'M<6);XV4J5^[7Z<D0RE+^( <0A4#OXXB=C/%L$"OG4&L
M)RS6[+TV)VTP.F,NSUIDD3<E]N:M+@@_?PNW$FS*1:3\SJSJ&H=]VXF?Q@S:
M-Y0()ZJ!ADJ^33PK?-[G-O>=FRJ9CR7LPB'A#6FG9$W"2^\XGM-I/-*NP6](
MM:K6>00OT5_P)W_\1-"]]D'UJB^$(3&+I]0-5]Z2)-:(,^AUW=[Z?ZW3;6M;
M\-H6_.L7]MPQ)SO$CU8D6OIM5<(?:4IFE=)52N^7E/Y8= %G+=A(UX!A&77'
MV@%0[8\DA:O\K?)W7^3O2753U2I]VZZ2EA[G_Y?=]AVE43G=UORDA-^K-*[2
MN$KC^Y=&*6AA,;VK?E'$A=*AX+-*WBIYJ^1]$,E[>J DOAI"*I!WP^:J8'*Y
MSH22JP"N K@*X%*KH%0$W^=J_X/F76*2%L'T/RHYMZP9^LY1!42[Q'G<BG'2
MT+]B4MFKY*Z2NTKN^S>=+]#^0#R$*J5I^6MIP'^5Q5465UE\_[+XLAV*D,Y!
M2PU8X%5 4>EGP^G_M8(2K8*X"N)'=&>?N]W8BWP.8;J=LJVE=#=25P5W6>W:
M;J'QD028QL LA$T_^M])M\9@9N;MY>XQOM'O9W[K\<-U?FL^O_7G=7[K#P'R
MQ>UALVY) K;!B$O=WO(L:9C.*(NC(%L0@[-T^0LLU=EVLL[_KCWJN KILCN^
M>FPICG>]F2>)W<.[]NP(ES0>$BH'ZEJ8:.:&3 :WIV?(I9N/E@L4,W1\ JP)
M?:#<H><UO>N'MJ%%Z)W0(TXM75U[TCJ9C%J_ 0'Y1@C([^%TUSV=,?B1@-?\
M/J)'<%_\4G1E._:9[J],3OGK)%V-KKFINA;\S-0LNW<T;B_C2.BGI!$NR1OA
M!#+>M304>Y-_Y>(0D Z/( ^\V7M9 -I<F#-96_\-?AH!V=S$F3:>I6^97V/8
M5UWY@$*3T[0!B\7BRNV+>N<E\J:M;YPVGQ-K!.!%M,-^%.:'LNJ/;<^>43@:
M0?22-LMMVW4M)KJHI[MNPWME. S$" +28]N9XU7I=+5C4_+ FHY_ID_!XX"A
M313ML3M7TE 9S0=@FH%^6;?^-CE@^I[V7>'JRMQ2X0Z73JC0CFO?J-^'I)/-
M#"%XM5S6VF9O]XF'7Q9VZR(+@"ZW!"M0$P\(]VGSH"OD!HUQ)6J3.PS(SFXC
M?=1\GRBFTYYC0$CX-?34&=QON^HJL';T+CLCG@$C,9"<</\R#1T#1 EX$@,/
MTPX%O@)KTZ&#P5L9[;RV:YOB1\ 8"E!?5DPZ XD,@]++=\QUTMQ#/^VS3C12
M\DZ!R[C096R>+'N+)]-6](573*8N/;6FUW&=+18(OQN!="N:<*#RC 4/76FF
MLYWG7T8:=*^QL[+WT\//+33^7]UX')(916O^TV-H>\]K#(^0Q-&8Y&9+C3N;
MLC@4Y'I!1'7^D2T8+8N&+AUKJ3AC'OE7=.!8\&G 3=,=DK49B"?Z6%55F-^D
M#OOKKCCP'*<7<9GX'ZF%SV&FHQ]+OW_DR]5C%.*RQ=0'37$Q1(!?A;<*),YQ
M.!3^'T,GQ?G^"#8#N!QRH#+,*4\':W3A]!N9ZS7#JCU#!NF\1%WM!#68=D9N
M?/:A<GVJ1*2SJN]'.(KZK#HF_>^FHL+4BX$)EOR^/RD:[T#3M(Y_20RR%*27
M[X['24YCJC]H2&$/=J*V2S5")NBC>G+-,/">8"CC4<*V1C=8CA-;*/J3F>W%
M.30'*ARC^9GE>V7)#)I>Y\R0NU634XC;]+%A%E1WDNJ:H!^&+M*#*S$G%'(E
MBL\9+_?)ZSOVK[]-/67@%=498PQTQQ9"R<H/4OG9MR_^_J>-GG4[QM)BZC9@
M7FZ]A<;L% )$F?;K293D-/"P-X=+S7*8E+TC3 9[(SC/<ER/(\]K?7A7_?Z]
MYPC1TIC11J\!MJ.@*JJ.\WXWQ;L$E^7_-K0'(&<1IMO(_^F\H+8GYZR+[-_I
M*[=OZQ+:DK&EZ/K^H&R$$=L;$E$1!?!NA<L,%I& 0 F8H7;754]B34E1(MD>
MN^0\R6\"=BJ ;+_\&K<Y$A)<1;J;5&%%\?L  +);3+[1$4B_IH-P!^>&<SF(
M#*X5;TC<C[@=<3?,&*+71[H7ND!'L0Q4&7"XS F-+O".&XV.A("'4"2(GG<U
MJU]\&+JOCH3U5]#;,V*7JL=^<+=T/?_E'*EA:F2B:R/@P%"=$ ?FF[^U_ILD
M-M]4A%G<\H!H>*12^.?\VP(F(_F]U8 9X\:+U0%.4?CV/+X.>QTS)X#>IPLB
M:7TBS4# 8O%ZRQH'4:1W"7KO(7@#?<HG(IUG5QV;++/\3ILFU=[,QH-IO$^C
MN'#814U1\MQU(94T-C1V+D/B]H29' "L5S:N7O231<41-$MF%(<1%L&74>4$
MR,SMR+'DQ-%:,#ZIK?&"Z?T]H9&\Q0@T N5C7?2$SW=+M)UV'8E9"O!XA.^-
M_P(RX=2>,924#@2+UR(/X A:Z%J&B\]E./WQ8=).TC.$4GD-]Q=GL]?PS[HK
MFR=T9SRN;+$@ ?$FD]+<$3S/-AEB=^=7D#Q"%K]?.NJTDN9'\WU_'<(H)+>+
M=U(P514;83GQPEB5#S1E0]0'7M^<M@RHH^]$_;0LN6(>Z.8.7C7J2+*=<%;H
MCJJ;'A+& &B;F=>1[,WR5NH1H%=S9&!X*.W/;O>.9Z )5*Q@,@=_:?G7G\P6
MX>WI_/E.TP,(+RB*8! EM;N3AV)D^?I$UX%:X7#RW'NQ&+T6-:<(-G>*;"&>
M$@E73*$GC)^4P?CD5=G;%0@?K07">8'PB[5 ^#L7 BX-2L8FE/V$J:0^92%J
M3S*U*;[!BV^?B#?<LQ_?[QD-@Y$2NK'6--:M(&U O5D:9:#TW1#F2._73-Q.
M!=@ &![%E9G8YP<:,E"&I&Y[9*HY^*^@S*NV]/;&X/;$C)G>-H$>BW>S"G6:
MXD6"#\ /QI B@01P[M8_\W418'@D!RM^+]-=JSM>BCO>PU(E@4J()&)8$CBQ
MVR002V(-">8%]#>:* J)HB\E_IEL!)G"JF2P%+]OZOSSUQ03F!Y#&$=,ZF=+
M0)DF_1/G"7DAB:\=7$3.I.Y;05[VWSGZH])Y;ZM7S,P4U40[71AH:(*&F$(#
M34JRV;F2;(@H3':V6\H\K)8QP+^%G8(_'3(PF81.2U"H 5,O).4TQTG"-)*_
MWI]Z(KFATZ]C<+W;$B@[06PZ FI?JZZZA&\('U\J8=5!VL$D%[R+^W;P2HDV
M,Q<0QH$"['JZY[VBX;4":#1R?AE8^X'D)J%JAZ)Z\OP'^2F[["CU*K,T@21)
MCP1R.J<<\=[-6%-B7EI*)%_'"2E=E'?I1\!OC8V478C.H  .I0\P3U?>02J&
M@4%UFL([N)P<IQ"O0]J0JJ)4>/$_[0]Y=EL(T=) N.N<$.$^.4X@ (P=>%QZ
M^)!"8HZ"1K'Y*:%&5A!XQ//B3I2#G%"YIO!11>A>H*72KTPM J!?"4L8%UG\
M.KY#8KR@5\S ;\2, KE)P),9*PK[J)"+Y.;71=-0Q),"+6?3Q97>?IY"I7 )
MB\ZK36\[)5>2&&,U?7)J>@US44KAN(65.!]66N?%YB5"W0P0?H/0\#6G9&=F
MTA_2OB@>Z3;0L"P?(N'FP4:T7=(-F8>O^S--[@2U_@P2,N,9CQTA]F?1@6#5
MU.P89;^H)6H*?,Q5).*RGH\@M_H]E_1890F[.B&@U/=%)9Z076760V_30HJ-
MA NG7I\MO$?Z-40P/4N,+K90YS65179QTOH,0VMW$&)S##-[/&=(RE>.SXTK
M YPO<,JNID*>2"R5^_?^/P2!1RHW1;WS9XAB9>+%(ZH6X<7@5Z\+P96B<BN8
M*M$?^BJ</_/&[-8+15]:&)U\86:M)D7;+C-H<,CU8'<=O7B25-[ 7 K!Z5K5
M@$GWP*ZNH%K5^_#70B5V//JEC.(7I^FFT*Z6"83F#06>K,"\?#E-E@]>>?[&
M=2[;578?>\OFR--9 NA-103>6 0:D_KX=VPC!#Q4RTWT&^KX4"1YU#;K^@U;
M T/-*SM?VUKV2>_!OMX#=V@93MR^U&SR4L%_I,C6J0>E5CE(/IE11:'E:-$$
M<O[+_.X3,Z" W?X8@+)6B@RA7RC3WXB+Q!</SD(3S:KXR[4#M\LNEHQ8??/8
M0%A-(#CF-"UA3%*GA3=[5:.'C6L[C&V*$"\SI?V7X53/3S2L")8Z*^;'^DC8
M2XV/,?)@/"1I'(O'69Q0#5FI\Z]G@-\CL+YY\=Q'$.0M5'VN"B*S0A>B;$DJ
MF!,I6I!3>1*!Q\_LPZ =M 2I.R^IV:,^E5R82NCQ:>(Z):O*#Y3'](,^L-!.
MA=XZ6.)VH_367$B8(LHSL"O[,N"Y3EBM!?,SA:7OMX3&/Q[UA<CKD5<3*A/!
MZV_#*Z$: 3G X>X$#NP%MD8K9T/&CEPHW),HWHAXB3P(_OJVFO2(V^>.^^)/
M=Q,.UD2"#\4K%Z'X,POGEQS *7WR!-H^HO\GZEMV>O,..\UXY^HSJ7P%X4I;
MKL3Q.AQ=F1B+MC,R;UE(^.\7FTA/*IY=J)HNRDSDR_378]EG9H$K$R2Z,E&5
M)7&7#=P;A(!'%5/ 1Q_<T9\/_R(:NA3(UE,MXV5&Q9QIOQ9>\^: G)C<->[R
M\HF]TZXBO%JRK6=R/+&?Y&UMZV_NJ]P[YVGA967">A%.4NCFRR?N=FSB"0'$
M&^2'?*Q.%V1D<G\MN4TMW!\.^/ZHVG$<.+,%J:K?=F.52#PZ%,"BUM*AU"1E
M2,G*8C6T65HQZ[\ Y>VC2+J2/VH01-X?F#W=HG!Q[1>!ERFWU\\62$Y6?^].
M?X]W.INTDY(5(BA8,*T4E,<H]0=C4H&8':W4"Q1K[=\R1<W"=<)G3O,+G3+3
M7IVR)!FF&8^-9#PF@66\+M-)]9P-T>9,)L--+I_FVBQA#^V)8%E3R&H>2C^]
M.KV)C+Y),G?-B;]5M?CQ6BV>5XO_LE:+?^="\.,"\Y2V^6>+9%A@;TJ:.T\<
M1E+*>$;S?:"4K2I<1%Z+AIH-OR6:HEPT?,10GLUVR)F^F_5EGSBVUML A+.J
M(1XP@T&F[TB3XV%SF/+D #==*>:5'XL^NX)?ON5;4"KX.$@#61F_YUT,0XLX
M\Z6- 7#1JMDMS$SY^7;1L(JKA'B%':C7>DW1B_^M^R/OJ2M-AY4&V_PQ:XCU
MKJ(F7;2K9L3HT@0JS28&;"?2.I:;2B,:1/:]K<#;'@;;#(BYF7NQ#?=#<X']
M@TL>W"#?';2CA:H.\H9ZVXZH3(.1*QDM'*#11L(CD"R%%GQX7C^CQ5T2C)>?
M7[XS4LOSB^S'?56[=&:3[B;#J$'YF(DS2CY)(SA3TTN+C%_@CHZ5,M/+('33
M$I&UJ-(P$&H&?2D"SZXL%6;.W%%2RPMU8^@%4]L4/QK]A\H+I>7%21XT(5.B
M(7SN'PT](7*_+++J\!5$588&^Y+XJ"J) 275%1LODVDF;@U''H57&J@794!9
M&V'T9&CS429[<Y)!/.H+DJXBVQAL*CXRP_:"<B;X;TD@NY419L5D6C&9/A F
MT_<\)4C-Z5AET/#,,.B%L&9Y'<$9;>?Y:10Q)$8[1!PT?0^$"$MAX=6[^85M
MOY,1Q0U:X_7.6 :G(.KJ%:>I5 -RVTY2V6#^Q"8@HJ[8BJOZ6-7'QU(?WWUS
MB=7M?0R+[NB OA8ABVSOT;*W*,U.W#?5Q:S;*LJK**^B_)%$^0G#F&&%%6/O
MY#.0ENNQ*GV(19PX=M!=G8:T1^OLX,#!ZP.3E)+XBX9T0>I)8^^T"F/GN4#I
M[,383Z./$LJ5EF#5%*NF^,B:@B40*[PJFE=];%:15$/ID&$0EE^NZ&%RB1M<
MZ4>$NG,#)((ACI C882\0LE8*$&SD/))@H]#VSC"L$-<HA1ZB"_0)4-5[?!=
M(O;B!J;F6G/$H<:'P?J"U8C<78>VI*&5QU=IIH?R85R%]W>B5CG-<JQ8TJL.
M6G701]1!+ZG@C_5)T9_UQ>W>ZYL4FA)."4;8*P7S\[)]0G*8\Y(E%W4FN4@N
MRXDWHQWWDRQGN G[*RGN(]V7@*4.4FZBN1HHR078#"X+K1C52V@:"1# (B9D
MAM>AZ"2QBM0#7TPT>LZ.I_M9VYX9V30/[PIX+X/I*PP#NP3ATUB\)>EF9.O&
M< @]39OVV:19>M(?+V!OQ@/&,Z%/<!'L,G6H[2@2H[?A.+_-B.>[MO]M7GI[
M^,VWE_G&A_PR:CM0'5H:6QE'S[T28#XS\=H1ZKO436E(NG%4("D Q7$M#/(Z
M0B=5/V='2?B7-^TK%Q"VS,]0K]"08%MUV_$@*!/YYJ9J=1^Q15GM"HY7 M&G
MF5BY!T70^SLCHEF;9*01XSE!XSKTADLSP$)?X-5I/IVH@T@R'>:.WD<\5-L^
MXA(%+2E]Z#JCI9?0T;I31F,)?:@-FSJ_#*%1B F!+13P,5QDK0#+$OXU>T&L
M6WI'%=OZE,F W=(HP5N.]BSKG_,H=_XMLHJEOHZLF)TE0IV\I1%+;\6!_IL>
M*<.NS:VT6Y0U2]:@1V">TRG50\+ 2T6-2<<B265@;@%EZRSVCE@08IGIH(-=
M%U<;<HP=.OL+[9 L207!4Z7IM\X_0#<J?#'&;/N%X47_7Y0/00,G6QD#)IV%
M">4$CSF7J>0P*NFC,EZ+$>0P(SMQ8/KMWI4 IM!*-G;PEL8+Y2"X<C+IJU/O
MH>EWPQ@-44<7&&8&4@0CO4GZQP[.H"(->08PA.J ';\+4]%G- L,)7@!^.0;
M,)]2WLZ;S\</'WWE=:C7A#0FQ?,8Y)H\^>$_3[]Y@+]1 _>KIKUMZ+!MV\[[
MO9@TSPD<3*9SN/_\QW%/*WRR]Y+)[\-=DQ?OA:8HQ>FZ*5BCTHGJ=?;VMNWJ
M\F+SK6IUG.T,9YM:2"+D94"DF[<8\[';30YLXNM+4,\R<\)U&0DJ3@/W1JXZ
MKZ?JC+A-<^K;ZN@D-0KZ&H;8H=:DS:SOI611J0!%D#S!\$O1-J+'%J?<>::<
MAT .<1:;P6.H+T,ZE01;=KE91 ?A^3KI&#OZW6+?"S?!D3I$2RA>BKY^?@$I
M^%EA9"F\ 3-/S8,( F$F/B\C,>+-*4))U.\I_HWK*9"I^KW6?%1?C>C;$C]M
M7QUE1QAFA1!CJ'W.-81_CZ$I[ND*T_F33<@#8+[X"FA:ZIPFH"*^.C4R#M4P
MAC>-[D.]^JW+X,TB9T3W-BAK)BVM ).*0?. 1N. -Z<OD&+(@P.1+E8B755R
M*;U? (0,P-E\S !]U@]C>;+(<CJ+Q"O3#0UK-RLM]PR')V$&+F2!TSYYA?EV
M'>N?KQWK\X[U+]>.]=^Y$%!H/XNGT J]%'VQ7W;KM)=<1BN19</48YQ*FTVO
MS4,OV^N-KP7TC!FI1,8Y&[*^:68. ^%4.?2:%V%!@.U9?*K%F!)/=2=FECHK
MV7) <W_R!Q\KF&75@GL_1[_F\U@1IG;NI_[/-24]R<0_DY&NWSS*OJ?][R\Q
M#7>LNA/+R;&@E&/&\WATO+=T] U)PK\T5_U4_!@<^G\@ZD4N[5]/_Q%=!0*9
M@V8>(F(2M7#WE4(\,$XYLS'TW+FK-]\77A.<"(AJ&(7;P[N/LB1)G1Z\&];O
MM94XX +I'=8,BRSA<JZZ^+43M/G_C UBMR_L&= ,A?BORZ]-<ESXD*:&GE7>
M,?8W;GM)GWBSW<J_\\T=I\H?FNP6_>YUVUS3@6A^:D_G[LH+M&?&9N+O6L2%
MWUI*M^]=C6CARG',9G^337[#K>2$?4491B!N*F'5AO+S FW\KR??YM['KNOV
M=LH=ZD/#?WUS27,]RG%$L0'PGJJN'[13K1GB_"S]()#NY9K?Q.UJUG4[JBN=
MO+\/L0*2E=V110J4:=2'Z-0OG'@"O%"WU["1="FN3E K76:OBO/02^)\1_$W
M2B3ER+F8L-" %D'K^'8D+6PB."7:2GIIF-V+\@.P@!U!%?32_TNM.2GC"/A^
M@*%9RGF8/]U=!P'_#A=/O[H(WJ5W\><4QEI;"Q8.(ZU#XD0,=3!!ELPEC/X5
MUIQFJ\H'&$P@\-3'#Q\_I"V83Y2PS.B^RBR8"!XR@:GN[$"^@Q=+6R3+HW#1
MG\VJE10"/4"(N\T%!-V.XH&SNEHO&60_F^GBI%4Z4 TM:>C )TDI$ 2Q8\^9
MQN25D'Q9*8Z8'(&9C,9@--NGNZ8P.7>+FA=/JBXE%)?4&^IUJ/:/WKT>'4E\
M_4*L 'NYLUL_)_2!'! 8GN0G2^T.(4 S75:QX5HV2,:%TEBL>,)LS&?]I[8B
ME_BV\2[EOCJBJ81#=Z^"Z4@H2H)D)H15Z_+SR^>;XKKU+_C<Z-5XX_S*=9(&
MIV%4),QSYOENC_>M4OCW'T#DWOE^/P9+S(;XGXZ.=^8MAA"00":#*ZWH"!JM
MB/Q'GJ[^0'6+0^M_@.R]#. 15Q9Z'W"*<IZ4Q80N@SCM-.T^H,TIH@0Q:G&
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M3S.>;?SA)R]D3X?0$A[@(2/P9(_Y=ID5GPB# 4(6,,\ Y1EI$ZM?9M81 W8
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MK"L=.YY$F.:-6[,3.COMT.I\4/+.0Q#?E(_,L@DT1]%$@\X8&'#@>02K6(B
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MTT&X2&E:.5/CC+VL]Q/AZ5U/U7*;U.^X:4:'N;.S?('JZ"EZ/6=\O:'95\<
M-_YF['07]VG+[D';YX_G:1JYA7O>>ILR (>)YW2NE'N6FP@5(9;4PJO<01]"
M_GX3WG,&X_M _SF'T@B#R,G)"+CSC#DOPU/-KJ8Q(4H?&K9KYC<(0Q(!V9QF
M8Q-@)D(;$7TT(08W_1(7FW\F5)J;*96FC$,K_X4,.86CNW#N[9/1W G!J!.
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M<^B9%KX7WVV#\4U[GSZ!6X*Z<NY5Q% 0JCYGI[ E?6<O.UT^P!<-17;E%:;
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MU@N(X;J^I]?[@%>.\PS+C;'P)1[PF5O2B5K#LV_") ^7L *'%FFFT.)O<CN
M<0J8XV=\<:_,CI6_C1<BJ1%"3=*)D!?ME\DXY^F"(QI<?$8F"8 \]GOB"?.7
M.S"2K9J%L]N.Y,5 .RJMB!:NKG?#5;%]U2OV.B/2SI?T@OE%ZQ,GWQ0[WF_(
MDB3P3IY=S:*%,FX#N,>6O,,/X0H^FUM!\0GG1C"<8#&!K#0S59I@95<F5FM=
MC1(Q)E)@V:8W801D:TK'\^:47%D&F,G K> #FD:(GI  36&>*\&'3W&C*-J
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M9(SI53FMRNF/JYS.-7X4,H% ;1_$ #4.#]K=@V.[I4D#1=.\ZI4<]LTTEO_
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M2!6@5;)6R5HEZWT8-9/.$" #= M3^T6EQ5Y.[%#B0O,ZL<\2#?&-@Q>Z6\&
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MI8;GB,T+M0^Z6S@J_*F/<#JP+_GUW< ]%6+7W> :P5N<B!@]$5IO3Q;W/8O
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MK3FW*D74!8HUXHR4,),#2\[\RF*!7)EI(CB9\WW\_T7;!L,8C&DP3)SAN:G
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ML4=;JI-TTKEH"D,@Z?30;X5$"!(RJ1]IDU@M)Y\V7X4D%G<PX57U<@!\>/A
M4!J[3.G>%=MP-[?3_1FCX8](G#8*"=W>#"'K(0,8HS7(FV IJY(R;9EX$%JX
M3U:%3W[<MWY[")OI<NN?1JK<3[S=@'-:5[U$2#FGQBEC2J;=_VW!W/F=K[!6
M1]DP'N;:7./(4I+(2])_??Z%H$IXZ1[V-/] 8/B0G;$?4:DF6XB[T0\Y ?7L
MC3=O$ZCF_3/?^+^'7"Z.0^K@:)=AZ"$@1T#*3GAV[UU@"IG;'R2/)V&-V,Z
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MI?)7KS6F_S0H-5D]&2[V'PJ/1U)@Z)7-@Y-_*!W<5<80U_7BHTGN[PQ7X:W
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MD53"ZB."6WBPP .(!U"L6Y8K0CP5.5.R^4S!CW/#O+EM&Y9C[4.5G4Y2Z!-
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MJ86N;-D]$& -KI0A'7^NJZY_P]ZYI/")*U)3436 RB$:VS6.6DW":A)^*Y/
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M)K$'$=S2&T^)_'I=*$Z[B 9HXH;IO(7)L,O:KKQX$,EA8>X'DP6)0[#-CDS
M=='6Y"VQX.'Y"<^=W[X@)^EB+LZ9MBPFHA=Z?&@QOV8EH8>12[(39G8B]\%:
MD:V[72<JW76B? :BOVBM%]N063)^A? \^#DGUO\]\/"'4=D=FT;J6FI+_63L
MD[X5@N"&MX5P$"_AFJ\AP4I85Q2KG#A>)B^V7N%[9+O?OG?GVY,CM*_@%A:
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M*VX1QMY*$ED*T>(X@\*T_,2X^AX6/$,SHQ-J*N.-DN^TC,:/*'AP1Y*E5$;
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M+D5&"S3P8-Y5I$3Q"6-@IJN4#$CUT9^*:[#9QGGD$%RL?6TZMW4Z(U-@=.1
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M?_[OL\>'QP]E&NN>*XD/LG3:;&9-SPP"<R'L$9X;FG>GM :!C=.W:!>WBUO
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MMDLA/V<.,SQP.^FWVRTXI'<59&=F[=JF0L0+Q0/.U/^N&VF@TB6^P)W;#)C
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MU5'QXS&\>6;;!%$ &E*(D1'@G_AD=ZMU?4A'4B(N4B7ABF>:U45_D5?HP+"
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M+7!Z\J@5?NUGGW+A;:'60 0AC=IN90*@7&FRT,I];>%P7'6W)30A P-%<P6
M802Z4V7&YN#!X?O=;6=]J6T9[>P"'3&FL<)8+'IB< =3^@L2Z8>(N@LHS*RH
ML" *C_1YS@%-H#):;F#0+=4%#;S"HHB/EW7!#2FX/UJN,9.)L\WJO+W]?40K
MA*@#DP0F!I8]_V8_' [7_M%5)B2XLP./G*]\LOU]U'/ED^WA#;A10]IE(4 B
M)@5)UEH&)L42D:H=LK&42[FHNE6!PU4\GZLXIS,@<K0S\2#JI^[I0+GZV'E
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MN%#HK&R&> 0V1M*0236:*S21%])[&DU@G%9-DNFR-V0 U^,JFTDWHV0L_#3
M HRTE)YN\;^QM_@V'<X&\G6QI10WB+Q%;/5.TA"8^>\Y'$L!D2<\^CEPP/B
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M.G?OR7#_>^0S=_90$V!X=[VJK%9=BR_@PCJCK'!%OW]L7'(R(S<PO'!O?\G
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MOBC"_@!G5R_2'YT:'/CZ+,0WF?J9LG O-\U8[<,"KSI0L!%;1VP-695ZP+2
MEB"89DKV/^8LZ\UV=,*O[9H/F$KH35A_A$QO2Y;A?TR.9XC1+NVGEQKGIH'B
M,A=!*I',AD&,H+PF"Z%Q^!NN4/([=O!K=61 \P0?'V9+QBS!VMS#;*F5#!BO
MXIR.B\A9AQHO+(3Q28R\+6OD#4Q)K9PHM0.-X6]D""QT]1ND(K)E<J)1#[HH
MYM+WVXJ]871"?T$9C-XW@7-Z,>@Y0=(I78J\45Z2+.&0/)_G.=?X<NW=\KA%
M4Y8?108!RP@9&((GDGA_>SNFK_]TY_D/'X5R8&VVWOLYT=8VK=H[?;* 1F#
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M;["^$E.%UWSP"O5.39+V* /-5&GBX%IP*V>!4^^MWV#/=C0S9U2RJFZB2<I
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M1,,H\,2'4I^,2T@W+G>?E77&->7*1&OYZF95"D^H2)@E"H!"8Y2^?75TQG3
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M"W1SI]B>KLWN8,>/\(E>N36ZNI;*]WY.BH)1)SA?W("'D8_^&7 8%Z1\^?9
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M!;;X%#!!-#9)CT9##*SB-&TN#?,GEDSQHUWI!7DD('+ZG SO2PK;/V.DG,?
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MKWD9[QH:-YDK!T5".Q7]\OA1TK^5>YA[3XULN)A.%1H&T3;DO-S<?$NS&E<
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M,C\ #8M3L\A;H0P67B#98$P89*2N^)6>">TW*M1 >XT=\69@;*@5&;<@\"O
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MTYJW9M*:[7'.=N)^ZWR)P(%W=877;*\H6>5R+PMQ#2J.H]G8+&30)E:08GY
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M,&CJ'4<:L &4)(#;YO2S(+13*J?5OG2/J-6-;42TSP"8MI6U1*F.@&MU)GY
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MHT*64-EI$LAWZK,.VSW?P?NT%^=,&D(WY=9.WL;2N^&@BAOMH3/V593P52'
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M 4UQ&_?8C?0^X>T1@(%>=#ORW]N"+1>++PNZ:RIR#H6D&MJMV/J_$6/4VA)
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MN,HE$M,^)3LX8'$/\*!5@GP.M(JRYG60O'U!N10(5L%H6N\9C[&FMHOM2=K
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MLI/P(A>4\E-X1(.S^EN'(00"&UYK-(RA/6FUI.%FMA5L61\FXH;4QE\+KSD
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M45XL'").WG#YT.226R?'',$%6);4P..5-VZGB>;5"&0+;9.53DMXNF]7BBU
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M6J6H]QRM74&#L%!(GG-Q);Q?S%>:EL%RB5^PYMQ1/#@!O=,\\H*0_ZZEBI!
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M&UCG]FK@@A<29FC\BH6$VN)5 Y))>6[EV\K31!&!V%:. @?WY %Z1=:1(?!
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M=ZO]+V&JL? )7)6(=4WZ'-4/EVYM@WN_)Q*N"<T7.'VC\M*)/,SK%M5ZI.'
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MRULLX2^)++J\PQT2!G2G(^/%-CF=@4G"X#B6YLRA+(-30.CK\66<9I+4-F.
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MZ4S7I8QZ99B1EB-R#=FG@(&1_^T=.C^9#:V(]^P^P[\TX Q:OK^]H_G[33(
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MXS^C++WK:43^[-KQ\+PF B-ID@1\<>P9L6>C[6.OXNL*J5LJ@6S*9"S%'OJ
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M-"1A3]^ZR5@:'(I.P#HBH]9KZA,GO!@FY=FEI+1S5*V1M1+8?!:!A 2&7-O
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M2&3:CJX0<ZU4C\A7/@*7Z>%2A@?M*%\[4>-CDS1<CD:PE*.!>)")>6W@9_E
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MOG'*OJ5(5=7F3IDC<2D\^"C*\G;,?X;@@^%@OZ_\3.L:I)$V39HO="/3E#4
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M$WQ2^R )ZO-+D(15_'>T]N81/J<[U6##H/B\+F8?XA_3\@.L\N>F9H0;?69
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M>!-IV6\#>QGW[B5&'_NW\N T\%UTUR)]FZU<(#-H[V1$C?9XGP[:VVB_.SS
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M<1&DLI%=%@CM>T$)_*-D_Q'?TF)^P^XCB684Y;K@5$[4M.*]26LHR4J)YGZ
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M79RQPO]+)8#J'R=L>K-:!P_!QL2<WY/789I6"*ML'/]K28#"3C_IIKW@#*E
MPDGE)U7Z"8.TOU>9G!NNF%((32- <H:W;^XU%I-FM0/@*?,B/%D#VKGM5;IW
M->-+*1M>#>B@6;2]ISH0'^?%*)X<:$8A,BCR:^(I6;ZA6"]WWO@)) Q5&8PG
M"?QZ/"&RGJI9"N))+1:4+DN^U]<@J+PG*3>D/3R%O:339&*_C61RVU7$]-5E
MZP0F9$#MIX@]W728>49Z#D$L5DDDZHM'4;_0#UOANLZNPE<E%W4RUV+,'643
MHW4*CI'@@E'HZ6[&1G20(6G&[C3C/?H(EX#5G/!&1.669-G4J7!/*?_>0=0P
M[<&XK5879)+3%8)PD28LFKD^6.VU=>MC'+8]H&6\E\WH4FMD_%2(WY6[8=00
M @;=NMBKM^!HA90N] \4*+9R0\21><49AXA[ZFCH+5ZD9<,MQ-'JK&YJU2[*
M:L\9C-Z4,FJB%I3WIL5,E5O@ S3(I<T^\GSK?6UQVM("%^FL-HG%-^ULXGV'
M^KV)V11+KJ^;83E"T5T 8:D[B'A=, ??"?FT;\UYMLJPVY-L&.<?,,RG1L,/
M)A1NHALI?=/ED*%8WA3O7:)+\H+%?UH\H-\G@K\W%O;A]Q8NV,>WW5Q:YXU_
M>XUA1)Q_PTSP^YUG$NB\U9W<->7P"RH<:/(( ,3I(R81/]^T6!=NPZ"IW%8M
M:;+T1 ZA=-8IJ=B)TH82K97.261]U*%]IC(3&QDVEE#(T:I-X]I@H=C8;93*
M6VCWR$SLC]ZZS2\T$@X5:F[:"5,SBK/>9L:1Q=9T K<":(BA;EL)IDM:;*C6
MZC0V:+OMP ZH)UN>TO]ST0VS#@'63TS_.1G2?[KI/Y.#(?WGD5^#]^+A""J&
M3N)-2KU^''Q?3&EGOYQQ#?97^O39?9PXZY;;Z$1(^\K(Z XQIH1B'TM,\J?\
M2P8FU%I?7AF?9V@LXOS8$YV]U[J^IHUF;W$0G3%>1N0@["S514BXB9NU[CW?
ML]Y$NA<Y7F@6"KHV('-]=ZE!#:9ZIQF(ML@DX]M*(AP+LZ*XR(LWDP3-PFU
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MR0%IUGF(>8\V84K;"SI=P#T8\M4'"K]C"L^NM$ZFT>IF3KMI8]R8"OP6FO=
MC@,YW@DYJH_K99'9V@F@3DMS!.+>Y ZNCV:?6B58-Z7N^GPA^EGJ,$]$H*@Q
MI93-BQ6Y79GEZG\RU-A@.0Q$_5DSD,8+J@7L:HC:LXY!TA>SAHO4.<F-[0KJ
MM\P"WZDE\+5D:96,;1&XQTJSK'O,87I$:]DT$W['$)J^D_J#YT/]0:#^8#+4
M'SSR:_";\C#?4O+562\<-GO!0P+NI)O.M$,$ 6^_QDVV:8K^]^SI]FQ_"<#.
M")H*$VZ,4W!>J"I"^+[+M%QU?0'=MVON7'EL4JL)VJ"C%NIS5<W*;(K>1K4L
M[B, ^5A#;:]M;R$,=LCN17KWJN"Y>[DT^ #&O^F0G+#G5U_= [AU YSF *<Y
MP&D.<)H/B1_I2B]?3$;4'&*1Y;>W1*0&34ZQ8N=='!'4U=*Y*!MB)&DB<7Q0
M)LD@B?SN+\$W<T]XOU;<]%P0#X(W$VINSSB?&4\H5-*-:8"&=47$NK@9@_IH
ML"\#$X*GX9(B0RR6:GECT:87 KFCV1B1;MMC/(K/ N]TP"(C+P2R>:<7W/=C
M%5"5N+UD:OAF67R\">U5]Y?48M1)#G-4+62TR&2FZC)%MTM'JM@97=+)5)?*
MS(2GH#!HG,F9NK^49#KL&9H77;5$;V-;='*;0MC50%X*B#*GOP?AJ#*K,59^
MZ'RY+ =>05"C?,B1.>3@@3A;9.@2;X&K'<5N.Q$-"$H9A8A(7Z;4<A43H)S?
M/'GN=2L8\*;=Z^A#FG0<QI=6NH^-5X0]A!P'9^'M,_#OMVT^I('6B+=JPIP5
M3<D>;BT(A^C+0'MW1'N.;.$$+6SD6WY0-=>*O 0R'(AM(+8[)#:P?SD40?FM
MMFVT1I[,*0K"<$N2.IA0"^B:5*5EENI"@R&,\:F-$!BTHZWXIYP#L,RP)MQD
M-UNGG],4Q_&2IM,"X?N-8>;[CKWSUQ .[3R8KBE!_9+JRZP4SY!OB77G'5#'
MN=&AY\.F.=PXKXATYAD2)A?DDS"^1K@^;%&*2-*8!&_]W2U?MW4&M7: >O\%
M=Z$H8Y_Y1NG\"N/1.@)H#832T_V]/-CN/GB^\\$ N.T2-+EX"['Q&+!RZ4\&
MG*:89:GI(V$.50(8ED"2UKFRK[5UJ\(/,6E'GT[:Y%6WKI* WWU[DH[Z,C2W
MJH']N9$R/*EQ^U7#1)PYFWKF;.J\8&)N;^<H>L>V5/BN.(8O7 ?L";?)@DMB
MZJ6V^Q9%6]UZT_.T7X@9PC&.IVU$6L*=V# WECQK=?I!4@-TWY<;=HP10^YB
MBEP6MN^H;2,.O\!^:N1C8;='U7(DN(/-4#Q0S2$Q:E,SW(8PWW9TXZ=+VB/U
M+(L\//XMPIGD'7ILUV:Z?F'N#&!JGS<3\5D)I'.A=$+&15H:OZ*/EQGHOF-Z
M\S"[,&UU==>[D.^IT_:XIU^XZ\-.V#!,L8<0YW \;09_YG4P;K%*S_N7"M$[
MF8Z6]I%6G>A93[A$_)]M@D,68!M'(>%/E>X>'',C<OMRZP6U[D<CAKHAM[D[
M^"V=T(4-!5R27%HGZY=5M)MF=TJ<R\ 64&P<>W<#Z1/,REPA9T!_!.^K]=O:
MCNIZ*YR>RFT.K\^D:J@5E'MC1_&[Q<:-N6799H\Y>L=[P,5U5'G=UY<R%#FR
MR*U/^];MF"+U8DB1"J1('0XI4D\K*:8W':*='3,DQ>QHQ?6[*$0LH<BB$NAN
M9A+* /MU?\H*Q4T]H(\1K$OI+!92\"<OHS,2HZ^T&-7)+-S[F<)&!KBC9ZA1
M_*;/H#&I/!L2:[0A&?4_U6M0.ET;476^0B# -3!7)3TC32G[KF^.X/-KM5P2
MR(V['I/!K\%.')#WRC1V9F&_%// _ 6Z_,:M",15DZ@H'7->0!'#;Y#/-=J[
M.VUK'<6>=>1W]>R=G)Y$\,M.CH)M<)T&@ @XETKWCTIVLCBB'D67,1^"Z5^5
MI$N)';5!2R*?73;+UIS8CN^4; )/^<56I*GW'MD FVGU+C>]+I-NY-\L4OIF
M+A<9EO'FIGN!Q<9V&<,0HQU"%UN$+FILW5#5_G4P'3/D2ERJ)=T(/^N2[-$K
MY>:C=(P3UPBB6U>:7$5)G=.6(U'W5,GUHUZ[5P*$J3O=F@X3G@_,24>:5C7V
MP 4.-H3TAGOQN;"L;7G@I0<3N/"N-P!_0.X1-QG7?:!4VID KZ3>R.$\WQ(!
M;2HWD6)HNK(YSY/KU> ;\M20SBSZ412(7/2I3-(E/=68O/0^XCU3=5-0D,\D
MVB9>1I5QV8:S<C'+VD9J6JZJMA.*JU%*XZ-N4Q$-9V"0&(BF;B,?27=S2:.N
MBZ$$Q%J[!F/-O?)??68/X!K=GG 8,)<T/)=?H$]I7A?<=2I4M4 V21]6BLZA
MGJDU2U!88\ZZMC2BT^]F3LEME#FRK+^AA-=4-]/JC,WY:NW8A WRK+!)B$YJ
M@X_@:Z/81*V*E0XM:1/!JNX2L1JT]D$[V4)KSQEY>25A!S>\;S1F&XT>,BD'
M6OL<6@.VA_H$)>U3\7Y37X*I^+N:TUR(L<6S=)W5Z7*@M8'6/B.1<J7*"XQ+
M#3@E R%]IOGN.H?%UJ%9<#Z:Y^XFS]2L=IL&:$6-#"[M<PZY90>+NR]SQ=LM
M#$.1.6!TXZ!90%W-,]#1Q:DN?I*N,O[D<Q2P<A5=_7,T56UZ3GJ59DMJ;TB]
ML=ST/G)J,*@S1JI:@4$?[(+RG>,5>U/57##[- @E^U*N) SDGAD.Z9Y9Y!M0
M.LP!QV_F3B#<>M9:F\WR?S?H+7'CAD_]Q+TP$1?Q&B^5N\_\I7O[B(E]R(MK
MX6=H_I(?<@;\UGB7.#6WJ<$*EC0_]QWLMZ2,W.[+$\YXC+KYH#U9QPDQ XJ,
MDO'/"5%%EE,^^+IDXA(VCA^;F&,G];@0/T/.3(+>%[5;.-B*:O2.<3VW]4P8
MI',$I:(B[$!W;:[4#Q> (U0+9<;IB@%*2!.P =UG7,#7,6"AUC0K2B*V/KU-
MUSG>_CJW[F?4OMN]JTYBG;+J1SYM<J^&W&KY:N!\"NKOT>3UO?>RN-<N%CLE
M?AT>#(E?@<2OHR'QZVN2,(WSYN.L6:Z%U;XSR=O(O]^UL[M;F1'1S\1?M</[
M*[=A>0!R=PNG=[LF2LGV!ZH72,W5Q1 W$D[:B#1&Z UZ:'<D,TH791P=Y @+
M"I^T!J0^&0DG.Q5+)2E5:!0E-)EYNH(;4(%JT%0,!]%4;13&4-$(-N6($!ZD
MR%$&+1C20I*>M,>(XFF8X*(L?3)0#H%ZD&Y)&&AAK6&[0IS(+<31N"PTJC.E
M42P </YQ.?OF5#FTMC M.;Z X$6%+/0RFV8X#R#.#*AGCBE0H!C7H PPOA**
M^\%^V?I6F9))_>VYFC4EM]X*7#I384/ZH"Z_\<[3K<-) GJDP>YS"3!J%<MI
M<MI(W*WZF<1D =IPCU,-12M5'['^!N%P5HS,1?DRK0).NJJP"R7G([3 _QHE
M2EWEUU Z+94#^75#P&GPI]T^@[>F[;7E@IH4:2I3SEVUQ.LV\I9<+C;?Q$IC
MA*9U4U9-FHN)]N]F?H%VGI^H6ZFZ7DK.*9!P"7RV3($K6Q,3336&('8ZJZ8$
M*5([I<O98F-I7K?2KV5#TMUVUE\Y+,.PF43GSN4B<OP1=98;-==E\4IVFB A
M)P8799WE3G9'J%();?<I87ZK"OLS&(P[6#;O!N/?9YQHS._M73VLAA)%$A-X
MQQ@C&G1<GCHKI%JPB,' I4)0ZSF8]Y<=\DR\A!2+IM;"$J1B0-PT=Y8@-,&\
MA:' $+:N*>N9,NN7?207A9FXGNL0EAJXWR?/X%=+NRBR.6G$B.Q$TO ,QP*+
MM,S5C<GS7BC%N2-&<G=KX-L*-FH:U/]=!B.G6#%3BH9 _VI6-RZL)_!;COPS
MSYT2/Q/-!%56$[*E&\PM6K6VTCM0T@(TQH+TG+A&-F./'#:!7F1+.Q&."'=J
MF]L+O&UDB@!R>3L,N B('QQ9RQORC7EZCC2T(0\<[931P<15O73W<\?)Q05+
M$WKNEKD)==3>?#O>21(]2$V\S\:=J -/,#:%INSL,<U4>#/5U0(OK+&:IH+)
M##D? \-[Z S/T1:MLD:>"'/-JAX^)[=<ZYWHS1 \)0;>)!.07NI@ZR3BZ&AW
M60VP@VH36 EUO9_!K:QK!!:6"H6.?P2&N<IXF 57,'W:!1\R(8:K_%DS>*,O
MK7-AK2Y.DPE<<9*^2W4!=-B]S"%G(]?RL9L+%8\Y$#%ZOU(">]VLNE 2/F<M
MM@-[,VY(V8(/3V\TAHD'C[U*YTK&U^%CN?JNF:E?Z;2?%R-+/$TT%=_;-.1X
MW(EGO _0QZV&";O(#/DM&"MI)Q=71(;_7*<62 V(:[O7%C7]ML#UX"\;N.XV
MB8S!B ZS6T'7DD#,)[2,X;::Z=SON3Y-JZQB5KC,U)635T"!?D*KT=UD:"+-
M +$[T/C=T+@7!"0'*(4-!9O,U<,'A78@N\\DNY#'16Q)C>X<Q VU00B7( ?=
M+CR%<PM5Y@&8F,Y(X4RXV\*VU])V#=/5*!5)DL=L.AN%)8**8L*6!KG-<!9J
MHVWS1>V:J,>NZ7H]Q'JY+^.E8[@\[2R#'1/ZQD-"7R"A[WA(Z'ODU^ GC( #
MFUA2EF^GG57D\?!00IN3.6.3I39@]&H>.'2/&?2\SS<O%MF\ 86OO"%#@^,/
MDD6_8,@T+Z.5BU1TSNL6&99BKK02YV^QPMGQ_SF6^+I4_P:M!4893/'AKMR7
M*:YQ9.824J+R*\8:+-7L XJ$Y8T'HZ7?ULIS10+.U06VB<MKDT,0:I(W$/-
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M(KS$$#CE^'#L,(3#PUZ&L--$S'N&?,;[1[O<,87Q:$AA#*0P/A]2&.^6!A\
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MWQ<:!VE5)UY8F -L%%!!;=M2^;JH,HV1 T,MLAK$[S*KOW*D_T'1\.L,HXW
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M=@L8&[P_FG>!+8;1Z_51Y7G!F4D9A#8C$\R@S26C:H;G6X219Q%F#:/0-!G
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M,3B&DH#Z4A]I$%Y4U("J-@ZDP=.%QZ'=\9F;P[ ID?59!S^OCI]NDU7:0&W
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MUPEI!%AOA>L-X?CH"DQL:?]J[G3^5%VB/D1@6#:A#D7\,G,<T&1P.-G;/OH
M7"QG;L+5'91J9PUY2^&D58XRD3XT%1;E:;E*LLH$FH*Z"97Y1 ^YH9R\68%K
M%6@FIJK>DH;RYD0^Q3^;5.-Q. ^HH82R",53HH-X8IB62'PNH9.XT= [QZI0
M@%OS2/,7T$'W&V!^H$;O.1-N]';O%V )<MH@Y'$Y9M,Z&TX8/3!XX\-%A 3%
M/S^FGJ%'>T*Y[W4-J))MPU&*Z>8DLCGP85N'^)F>+'=WMRV7S,WUZ:=TOB#O
MDBX.1 3!RLX@HU9+=F Y2YM('[($&#,\TZIC L8MI>Z=BJI H7EHR,K8U^?9
M/)M!#]9U#.<;+F*PU5CWXKGG>'C1HL]8M*/;+IK,K**T=! -X>IPL=&KV[_J
MB^7CJ>N9L_".!R%3T,SN4TW5TNQB=6<B1DO'J2F"-J?Q*%BZC76-V'IS2C<W
MFB((7E+7R?B2GA3N>!%S]T@2"4@M7P-ZR:03L34"?B799(W&\1TS07DYX 98
MSN=8+$Y]Z;D5B.B'CD:3-X_:^%=LZ!AS4682;!1L%H) /*$XD.B'^2#>&M;E
M21DC8UD1Y(787MZL(N)!K-G\ .R5![ OWG0=AJ#4Q,Q##=_4HURP8EDFL(W'
MRL..9ICIH.@H)$2*7/YL$EW^$QE^99Z@6H\7<YGC(X!O(N8G7YQ#T0X_EN''
MP%#ZY-D8MP=?LS#U.<J,MW'?E-(Z>A4*A*R"BL;62BW7SPA=[/I&[<]O?3+.
M7UT4'P$:P,T("468\]?"64)E1+P[LCS#S'MH97L;/3"@MSA]#V) #T KK+'*
MP=>O*Q$WKRP3+#$)3FG=CN _3/.:R%$ V(W8/]X/$AKU^GW:#L@F\=MAZL"Y
MIVV=N!%<"HR#-0'$Q2:"DD($3H54._AI+>0:WVT ;-!<3)^2E.EN4 7*M<08
MV#?Y_!R>DV&?\0UD?$_ZC.\CWP:O 2F^+$'9V,2* W3Q")02CJ:"9^_0*9'/
MS9H*#6ONRCU) <!M]7 V#83:FWZ)1=%ZV1Q1=.2["[$BH$^II+[9U)%^Y&*#
MPAEAS$A5QUZTOG @5M)V'A2;<P;T):C[P-U.F\)I<UPQ%P%< $JG=H9H8L8>
MB E#!9B#& $EG\RJ B=0+,PJ722(]G/1OGCF<(:O9']]/%M*ZV=VGVC]Y=3S
M.2@=('8RTB^-C2B E:K%:S930DSJR()IZ>BT<G3]V!O#/*ZS*R$.?C&METFF
MB<598<D"&M 0F"YRZJI=)Q^)_1?SKOH)7!A!>01^MTB2)RX&WX:DBQ.;;C,Y
MNZ:H/H2C]0%HEK\'%C\Q:&5(*7!/36^/-@R?V%EQ@M'-DE6SND76'LI]8)D,
MPS/)1@GRCG29B2,3>&%:YICGB4-1.W<$U;*\HE(C$S_C (+E(2><-H<1G"*Q
M@CBOUPE9K,3CFU*SQN@"@-.@%DKN D&MYL?+T@&<THX5_/=#D+O[QM,[]5PB
M%GI6%9]'DG^=F /-!)(.B%0;U2NS3/@^,Z<#23ZU7D57V^6$<8Y 2&=FLZ;C
M8;UV\1@LB%8_P+H/( N'&PS(>Z'K[+32C9[CT;O<@0&=070C^9@B..FME@F]
MT:H',;X'L+&Z/7 L]JZBI52B2*=<S/0Z1-G.F3[)IE2,(?(,<=%6Q-8O2HF9
MM]\)X%H:&399U,(TYZ8WQ5[1"/6)KBVA#>TS?XCZ$9C(N$I-]O[,6&XV=)95
MT1EU,'B?0J$,>.W:D)Y'PX.]U]@FW4.,0$#/5I@4)@\N(4!KN 8^'<M4"9H!
M)2FQH,0#T]VJ?E'NHYLS2M%-_X88:FI3LG7Y]&;"X'&P;L99-7WM/ Z>T2J)
MS,Z2-1 $.94^M:!W(!CZZV;(I ):MZBY>D??,\^6<P(1H@I,RH]I[1ER66 2
M/T#NE!?! *:2*-=;I5TRA)2S3"FKSQ3I)AM@D;^93X#X)MQ*/$5QF.;AX25X
M7"?)3$\'&7R[Q3OY9V0#V_;7_)X/9^>OL#I6S;)Y)KB3<EY%%$Z#C\&32MB>
M,/ <FBBJ5"DNLU%64QDSB%3H2EQ0WF,^/WAT[CIY_#?!4XG/)[96Y?<"!^Q5
MF8U-<V]R4#CHW!&5<T-XZ,KTIV%@0+\494DD'G]@EYP',;0'<!#>4#CV63W4
MXW4L(Z9_$>2!W=Y&F'""FDOQ#C@LHKS\+P6I 1=J,E]8(^H,KY3A=?&U$3.)
M# 3/+WA[CO#3IN86_:YL>Y)1,<G\$QS=($S4PK-1U "BF%+^2APLB4KU&S0P
MH!?,UZ&5W0O"S3V(P3V +=K%-F^VGVH<T"DY\&3"&CRC=&!,K8P+0I&J&<E\
MXF6 OS8.)T.(9 [>;I4AZ"+7A_.("R;+V<HA/VQMNY!= !?:TGMGN ;/PY^C
M?/O!3:(Q^IBC>ISM12X7/364=F* M1#)H*&<ZO.?XV1H(R0KVZ":2\$-(GM4
MI40(HAPRIS(%BUY_;)J4.;5 P:YLTZSF)!W4+$CM0E:.EW,B%D'^#C2'A69$
M+!"&%YL <0:9,*!BFI'M&(O65 P]-<;9J ""U[".ILI:!^NW++<!;_HZ560O
M]J.WT"\$[.P73*8"ZK=7*N  6]9TVNUS(&I29$TNC(4M0CF7B41X/"6/M68@
M;^ ZQ6<D'(]!'AWO0<:8':70 XR]23P1RYI/9%-, ,VLX''_T@ZIV]HE(\R&
MWDLK"X:7>\RH8I\1S[AT>B^GG]"TYUCE6J=W6S+_%<[>6Z>"#_M4<" 5_*Q/
M!=^G".-[?LOT0FOCY<SL[MXJI"&<IVD$,)CAP4]OZG0>'4'4!,C]T$I1'.MZ
MX=26#7_Z93_Z!3CWP&IX=Y660-? ?WJWK/=HLJ6SQTLGU.C,/[YS\-/C5H_X
MGE?ZY"C(CH/OA2:7RQE:E[VTW21M)_O69(S5>9I#_.^MZ2Z,$TKSFZ:5E3X0
M1RUB**+\VTU68<LRMW4S].5^].H3NRHO"'W;LQ:1$5J2X9@7QN.X@$!X#NL.
MS?,P@#_&PE5T8&WPEZEL*&!J&%\2]NB6 %XGHZZ,LCG]:^J6Y%&\%<+#XEA-
M+*N7*82%O#[G]%?&YLV+?$__%2ZNF^1CE6$+:@:(F.@1B,Y6-):*F%+Q'^"J
M:?<,7P&NW;+"LIQE)2$XJ/Z>S59[Q36XD0#,SB:9-MAC*4SV,A':V*U21-%H
M5X_B9.[^'1QHGY\]9#T=SLDAVU+;\,DG_,T^;[_'NON<3[GW3=<XWNYW)+X/
MZ+AKBJMN8!=(V8[;U=+UU)+9JLHJ83NHDT_4JIF,Y7:G+J=P+(Y E,OJ,EN@
MC$^R:E'8VC40^5:*[^SEN?[OGTD)]'JH$OXHT[WI$D<IO]Z/_E$LI91Z3 =*
MM,),Y'6.0TPF5UF%D5E$S,@.;8U>#P/NHS[G8ZUZ]/[6<\!1;H<E$&N(FW>;
MQ&)2PI:TQ%J@UP1$@[&\.)H58P@Z@:^@URZVJ5W]5!C>/[52J2:4&MK?CO!\
MI9 ,AQ-$W>NMB8>^ :+U)V,K/(/M:"0^(\@<"<?(1(+XH6 Y1>9ZTRV%VE(?
M3!2_!!IAATD-Z-"6E4 G@X_UI-KN&8PKWK2'0XEKY _&KW%HE6D8I$5 46"J
M%K=)XPN]A+W6+^F5WO34=]S9IUE^I<]O;%L5S1#6"E!-AVK<<E[ A<0OY\9=
MT48HH@KJ6.O5@K2!/+5R@^.F"@C@"VBX^(15T(15&X )Z,S*X"T^9OG$?21;
M"Y@$1LO"^7:F_T,[ U+)EI$0Z0+\6+T93O)) ;_BG&=X#(:5Q-*RREEX[1:F
MXP0L#@GVP43:H3HB N\:)175=4!B'!<%4%\S3JY1@)U>N4IKA/8J9WA(L9>1
M#99,YMB2 G8^H@.U\"T@5$X*]AKYQ['6ND*^/JV,+4 6(]H++:PU:6YIU9*E
M!A6,T6O&/U"U'<HL^+T0#%P@HW5X1C"":;_;R"G.(B<O]9]PES6VR+WG][:I
MQ&\W$CB(0626Y84U(_1QK(+'<6) I+)UT/:5<[!U-KL%?C=;$VP\&*,<_NF<
M['$C(X2=P+6AST.)F<H=LBYP5L. TFWE$KYV*.173K19;ETXEL\1J@O[SIS7
M?3S$;Z8[MA#7,K4TNJZ^L[@!+3&2F[A$V YE9B?4B XBVEC:JD>'Z*(D*AF?
M-SS9/_X>KAH>#(Y0NO4_CN'A0_/[$T)1Z%\=R:^>P:$X//P>_4G]\_,8_GL*
M_QT>X'\'_+#AT*%KLML =+(W?!J1=H71NL"<KL>@HP\H?0^<44C_0)^1JS/)
M K\B!8\5-HDVW;7#K<\.[P_$X_J'03XZ?]E)C(J61-*N6UB/)N1HML*TZ+[
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MSF\2M].[X\QJ(U@CD'UMI6I)D-/IE^7D(L7V7!^0HJE2<!W]-OH'J"KT.??
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M'(45;#3NB0$]K[&Q&#22 D9@;"#A=L6V&\DX/WCODS_X_MYE)2G72IHGGZ@
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M1\*$[C_AVPCF*(ETGE/CASBEX,[UC:OUZ)09G931+.JF@FH<?<07-"XN %1
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M!UQ,0>&"BAHIF4;9^IS'$D_\<'W?19G,8T/^':IXM@M2@Z>,$1?BL=N1,&6
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M)\U8 L?',!(@FA.?GT@+B[2JO#YFL4]6S77>F6U8*]T>R$U%>\(!@[ UU]!
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MZ;XEP<FROBRT]YIX7/#6.L5'C@IM7A%LA#M@1CN^R[C[$US82WDOY5N1<M_
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M@.9J\NGTR::L0-@2(8.F?X"8(D\$#B'P83AR*4BECI_A.:/G4&8!O%:FK%9
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M%TQ+^9C$TGW_USL4MAQ<N?>^<2=_;36.R_)4G2?35.L(V\^J#Z\\_DC>O;>
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M4LZ3Z#?]3?^/^?KD=LOF+HJO=+YD&F]7X7_/\C.\2_FYNX&))%[6]>+''WX
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MKH^\8^G:E"S/EBS.3!Q7T:\WXKXNS?D,4&FBZK;Q*N.N5,, 2@(YC(_"G^<
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M<531G/#P54C)U@A'PS9LICJ6282H.HYGTZO5$<YB?9DR^(:]9*$L"9<)V@P
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M5I+#P.&#UZV %KL FD=FU.A;/"D\EI>I#G:K[OKG6I@-M8T9Z]RNM%D\L;V
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M-,Q,-UX_;5N<GG7T?S,.2[@57! V,_<W4!7X'Z>LH8['X(RJYBN8(Y)IN;
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M]%KR:3>WP]GJUI7U7#9?>NZ)3[IR]Z00P7685BYOKJ*W]/"_@9XQ2\Y!!QV
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MQ&\2J KUXU[!77?"W%*Y]6:PU'BEKBQ(0QJ D?3/._M)-?5_4PSD/-!Y\,O
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MB:'.9JIKV:^B,@2WPY^2Z9,IO1HO:\3:R%JPN(E1'L-_TO&>GL30"7<JJDD
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M_1'RE4<],WS8?^OH532<XC7+/K^ A2O%/,PXE-0!*^@!>2S=+3_90&M5?$F
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M2!)+&-L063<,:V?0EGF9Z@9;!=[R7!^W[]P.R9BU?A+7=#Q_$;.?B(,/H9@
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MK"3@\JHMPCM6@9'@/QM6H+#>LK(&Q6535 :=9PH]FCMEE1KAE:?/M"@#Z\U
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MA^Q'VY+!/O4)#5?@;Z?^Z)*YW/UUB7E!?A<([W?R*(.RW+[?=T/Z64/YAS"
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M9$_L;V(7;UX]5WJL#3+CNU^]*CND]C82ERRM&ET\K; 8_=X_[>D!HVTO"BN
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M!*.?)][VEK@<KF'B-A=DZM]17X7SMGZ4?? 4<H\JY&%8[I840JE9X9?8RVR
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M>/UXYEMD>TO6..WE3#-,@]:0?\0Q?C?RE@(@BF^17[[NB*8#7Y,#+?D:JL1
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MV(=U [LXG.8']K(J(7\B*M'!2Z.+9)?/BFJOC'@A.Z7><95)'B(TZ;XF&X)
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M? 4/-,\OXG>XK;#_@R4:+NUA\CQ,#0RT <J+??'/?=PWR")TX$O"4K,>UN1
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MFJ)B)AW&KS15L9>8VO48M!0#[%5*QS-U>0;\HBT56;TD)&9.W&@<;;KT)<G
M!G?YJ,/XZ)'D.@VICB)OF%CDY38%*18,W&FL)EV4C=4K6!5&+YHDO#W*$(BA
MBQFNB'G]R-PE1XR<:8891UO=28^C.&E]K5-_1^4UK=5=X,/8R@9:D/T 0EY
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MLFGY[OW!!#[(0N"#?&.\T_*][ ,)QP^ / BG?.^U*L+I]_(DG 9X@F&X#;/
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M>F=1N@=I36&C(M]]JJXLT'C3;8DX9.TR12+7&V#T>[;V$"'0L& VKW!ZML\
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M*Z8Q!3=,*S4(G3N'<,.I(S%MY1)%!D@KI_;&^R/E)$:TF?M-J[9BA4/^X]H
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MSIIG*960=O 2^>1D*V&7=9A=T <^XI++PI.59 ?Q-[9A6EGJY22E#K#81XB
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M3_BY"S)7:U<\P;'+PO&S+$R=G)%,?DS,VR'1H;3;3>6)[?]O[]IVV[:RZ+L
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MM=:=#><^KI(Z[!>I[*^%Y6,ZX?:Z[_]/W,.7,"\&9@?<O(!AT+G!$45/'2+
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MC&4/=)I\V_X630H0G(L+.D2$3Y\;V: XGK@L%ME&P*$Z:=]A]@TP&VQ9N3-
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MKC-:]XR5O&K^'](+1MD;1_1BTO]02P,$%     @ S#Y^5JZD4)0?!P  HR4
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M3L*03 *5AC *Z*U H K82J/F; +@$.@I&Y1:HCK'DWTP-S(GE&2X2CU2A0Z
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M\(2/_/'(5^Z,GT4\47HN<'LVUADC\WL9 ,!^2X9LCNR]]T#2*G(>(NO9DZZ
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M#YYRC8H[O0DH7@W0&X2_ %!+ P04    " #,/GY6:4<N\K,#  "E%   '0
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M/.1=V%6IQFE&)_O(6Y<HFI1OCT]&U5F#,]$+G2@F11\6Z\U& ;O0:CH5F-W
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MX5D=L78V?0$:D^#8SDW\[M*QVEK7B:N+SH<G)F[?V+?Y\ZT+@<W.3ZF,LEU
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MV11,;!+<7)^;(WD[[V:"]E6@#U(E62%Z(9 !#K](9(7V9)$_&*"WTJJPX2>
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M,I8ZQ95#O 5XBSB%L5K%(3R8KGPY&W>VG8W5%*N1'A].U<A]-H$.X@+-6;G
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M\XG!UK')+<2Y&_N =X<=0+.!B0/J;I:D!%PJA6D3P+?#/F?>!:!+VO-!PTY
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M"8PXBE#Z)0&OM$,Z-N%N?[]2[S=P^+XX]].8?CPP]WD$OWDD(R B&B?=L"+
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MJP-;7 M09:]"BE1XM8YFU^JH[''X3G?9QU3:-(1>&/L$&'(5M%,(4/54MN
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MPG7Q()8_P$*>@\$E1>K?UH^2Y3P;&^"$'[2U;VN(IMLT-3;B4:%C!RJ-JV
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M).?*L?/Y?TG.#O5 TP\!5PO-#",3?@5HDI"S'W3=52<UV@N N9R*WR'&_01
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M?&W9TH.A\U%K$0&9V 3@RV?R#)J9!T)GD4_,-ZC"!Y6(M8QE?3;Z#A]AVX*
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M7$,!\Z]U.,!)^$WT"KKKT^5]353'(.VP4O=ME(TIDW8G$_4.1_9*DG)TY41
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M*"&@V@V3&EH-8 B85/2&$3.__<ERGD==GXK\$.GJR*,<:^EE;5EL,C:/A*O
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MV!Y@D[-D9>EV>I\#M .?K'CY-1E2AHSA.FB: 5KJ<WGA+;$$K>ES_@:I9#(
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MULZMS)^_Z!ZA?L/^F[7A_]F?]E\T5(KK.\@T"[JTZ#^'[^'_B*#9-IS-9#I
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MO>T-M7SKU,IM\Z*W;FV0S:\9NC6$$)NTH9T#/DG4CCQJENDBQP%T1:112N\
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M%FV/7QSAFC5ZMZXK-_EVM$$1"^'I46DQ\)1LI/B__.G 1>8SV\\G],4L$FA
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M&=#U9(VR>?M.^TF7<X:&78Q/Y5N1+]K/TC'X+NPV81[3$-)MP;.NZ5;:%$J
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ML[J(.+N$<YY7._)-#$=@4=PP'0L^HLH>ZV[':<*556M9Q5LF1WZ_UF1KUK?
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M^J^9Q?^AY=07NV!]PU][H-=[?3M,$=#29JLJ-?;($:E3[A6[9 ^NKI$FY&#
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M-(&L6TY0-OKFGK!L3HQID2S$C=1CO^OTQ227IE8XR,05#16Y%&<.@G+$SAR
MZQ0V0Q<QLWUF[026+@0CV7*T[7RF:DM,%@XE GTHP6<R??_-S\3^<=;VYA;;
M<Q=$7-M3!%_>>2W/O[240Z__[*>2Y=X1%ECP>/OY'Q[Y\M_ '@I)8$%MPTP'
MGM2;A)&G5*G5L(::9/Q!]_ZJ_!P]WX\]*OGU:>$ESE,)>GSXPZV*5J]]4"0&
M?W,D$GP2?AP&)H++[=:%LON>RXP%^2!Z%K@(1DED<9@M+E'D08:*8\/XWL=9
ML[,^>C0 9WTZW*JP(VD;$%O%6*#UFRDHF#])LVD#2[!!)%?[+:%C5.&@9@MA
M(J(KU17ES>=H5*6'G<BY\>%]\\ZT=>W4KP_/UM9'V-P">%)^O4V[$G6((_[=
M%NBG/-_[)(:3Z6M%QH,DSQ$C\+&]JG!A J(#Q$UT&#$A_$ E;)W%DQVXGDU;
M-J8MD8+7;^?<&;O_:J:ZXT?%('_) ][C%)DQ\&(ZDB\0% NNIP&=IPE;-Z;;
MA$@W7-8E3R>:$D!1-5O55$GBNW6< Y$Z:('?G&SXZI"'C@SR!I1I /^J__QY
M]&1_F]O#P\IX2AZ<<567C5*L#)[IW.EM%YAP'6]7N4FZ1;;$RT362]AVN0#X
MWVC\08>F42P<!/7NK"4F6D[L53]A^^'E#98D%I'HW36F(B$I!%;]"@U-L<YP
M)6@$RTA$/R]&-G^=G$=!2T+/;>#R$TQD?WBCUN"2Q%2<.^LO)Z,,:$2>NTBP
MK2@ODM>Z<]CNXPB;\,?;?1-)JQ,IS(+O"N6"9,QKWCOUE]?MRBYN;?J35&NJ
M2\@@_*LL7=9QF! 6*=F'=JF/ZEP0P!>#F<GW"F'RTV0M?YWNHL!,JO2DW.XG
M36%6->_MN5AIVQ2R*:55FY4P8DZL(ZG!..N)&85D=X) 4X]?+)(#=C,4.XCD
M7($K$J/P(R;VL- "HEEW)PX7H67W?HS]A6=8>Z&/#\><9G55S0]8;"\$;[QI
MU(/D(7,0', I0IHA"7!QL@FQCN#>(:CH81&*U=KB(QL1Q]T(+F(6DBMUQCXP
MZT6*[J Y]6NL*9KWT91[7>OUH78C-[P?E?4-#A,+;LC(VN2K(!O@K\S,P&X3
M4003!%88']/L1F#KIE?28VN%9XEKT!HR]&,OBZZ/F=]_LIK]0/3M4VZGFJNH
M@/Y+<M5N/KP?YFX*I'Z5G>Z^3U#JO>\VHF$:D//D2?JKD@LF_?V-\[FY.6%-
M,L%SNG*45#@O6:^>4D@&X2" E^2EVHDJN,R:;0#TM+90#31X$*OP^7>B;52W
M [B72Q!B9X]*U+9'U;<$9<4H9R"=T[J<+3;!]6\YEHX")5A<\HZHNGNW?Z8-
M#-"54XW10E<!Z=T3Q=17BZY'#E_V0,MTE %KLG<F7-$Q.J0!>ZG#2:F65 3%
M=:?@V+\]]X_]+OJ%W^?K-JC+5#WW&<H(.?IMNM0$_'[R@.9[4%S!\;?__?XB
M*7K"30/LR"O OSM7L NV*!&1+/J;P/0MFR"OZ:#+=D!Y %P%=I?RB>R'/]@?
MG(#SSL\1%3K1C%0)V#6B$I8KKOT2X2'RW<W]0]T+1+9>W?-U-X7LZU\N< FK
M%A9ZBAK%U$<WJ<Z6O2DO+BS.,PC3;?Z[8D.\()-,YEM$1.DR$E$D/0O<#R;B
M2'=+7Q>8[6LCA!,FVJXP#N-<4"3<1,;_'/6=Z@B*<+@\E7G9Y+1B2]QD7<H&
MM0/,I6U$LB([4XKAYP:T@[B2VZSQ_XVX]PYKJNOV1:.H* A(EQH4$)'V2I>2
MJ"@(B"!(+Q$1*1&1'B D M*;@H+2(AVEA-XATJ5)"45J2!#ID B$)81P>;]]
MOWWV_O8^][GWN><YYX^9/V:R5N::<XPY?K\QYAA+I<ON--EQ7<5WRBF8YD!6
M;T_M"G8JF;/LEON!O*6Y0"@MR>X+9#X,=W2T49!BTP:&#R[0OQ/ J$L +\F]
MP_#TW. "-,)LR9!,_TS$L</M6'C5+,?7FW2.J3D=YT1L+%)%WLW*>-:CE.12
M^*<\*,NPI[[R)C@5)H";KT6S(4]X41I;"2STTT@MX"U%@"@^]U$V+=?PR[*O
M,)A2$^-/4;D%.))L_>Z/?6KP+JLATXM*WB=._=*UX\-YKPE^L%JR_SOO"=4'
M.]<"1=J0,9$:2@<W;6#(BWB:O9IS16Y 1%B3Q *!#="&"M!NDY]]M#]/]ZDI
M<,]S13O9.EBV8.Y_?U)UTSJA/N?X/@]1;<F\,$YW>^"Z\%;,/JJZ /$5P[[V
M 0[E %JZNP/6 P3=_(] '&?2.AMLPYLE?IRR;'A=.\<G?(EH.)E$/]=# 2_@
M.K'G$(&M>U,3'8?PMBG,:XB4RX357B2Z;#=&((8%VJZV^=D#3JUTDXOQ*1$7
MK:VC\"P@OPH-=DUM4W[</_W\@1U%V:VV-RUN46XS'Y]<,W7@+<?RWL'KKH89
MK^R[G'==IA*JM[UB)5TS+'NT1U<VWQ$:\AQ1!;S'XSH=2PY:HHD*7VX$T!1F
M8OQ'XJ @\O8P2I*F0D&'5<TZ=)L'&(9#6+HI,>U[#=+C_*_*1QS'=OAV9F\;
M*EMF/*O[_>%,N[).-.HR&+BV]:I)#\*&D.@&GZ=?0K+4J4$CZ8(T6WTPJZL:
MX=41R-DPC&QK00"\;*I3Z=WM*+%1I,R7*5<UI;D\+L*3Q#FJ!&B@GKX_CIM/
M)Y13ZV5+?(IIXF6XI$>CST;E!KK*BZ_"F_6_^D)9W&?87S*C.SD=X$^MQ<IC
M3R*^[H%?@RLCVN2"4VNC=S'AJ(O'PYU3KR6'X:(E>+=G6@IX7^U(R9U#0%&T
M31X[<&7\3,T#4+N#JG!8247%I$M>,B$L<G?+'>,.DZ$EO(?:;TVJ6P G/@.U
MG:D38=Z8"+.IP? =-A"@0ZQ)(%DVN4!B/CGSQQ<4VZVU7*>XWCUEM1=%LRQ>
M\W*])TT,;[^%/U%5<U?\U2'/!/J84:+_;T()?_$O;C=0W[^ZU7+^A7&^DA?]
M]^#5Q[^#5PY_EP#X#R4,!@_5U\"'KG\[VR1 23^<?F=_E+A><P:A$3 DG+:S
MNP)D@BFX!5APRTFD/,6P$QVI5K$"N4B._PCY'.3]2%_J#D::ATJ1G)6N;!D-
MN=K>HQC+(?Y,!+RP1'2G<3-\G6*C<2ET$*KEHC3.^3B1NSNZE@P"EZNL<8#>
MSC3\0%.XRP"U[_-N:K! 6N\IXI3T<&>#-E/A/7K",?$J0)]%NE&<J!9CTDTG
MLO1)@QP 6Y?=62"!+91'BP-!ZFL3OE([7BUWUE;PB;5UR0W^J_A?;"),G][
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MY^,%?"G_ZL_2^<])Z*"G.O],35#X.S6A^PADU<S?].N?!Y0P^W[CT/VQ?ZM
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M?;Y5:*O/TAR>XZ3>[:-!;G472^SCK^TA5&W1N R/\0L!BW#2K2-_QU%NRUU
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MH$$1L!0:483"HWB4?^,BD$(4<-?9V%LI='9KPOGER-43':E;L?$)!=J=9:#
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MXR!6^5)9J0-?>K6_C='.X<.UNH4ZKH[3M,J=8-EV8\A=2[!MZNU&=$?[Z$8
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M7,X$]/K\MQ=54P=3&<_*Z=L8O&DVD+9C15U&=+W0!E(<(UB8@/<Q*M2=2B:
MG&M$5OGR+HH@'Q$C8;$G:1G*^,\N_L;G3A_Z?@%U&1B^.;&]%:^O0-6#S3A/
MZ%L1PJ6PN;W-X?C!0G:7-=V4_, @!4J 8_(QA /-D.<UM\U'BV[ B OCF6B*
M.55AE2 %?>]S\U(+:>_/DUQL?U.!8!]-BA\PRH>H-[T]RL/CO\&N!,%I=5\^
MJ#T(6I"@?_3P#["3%68"MM+67>\^2I3J=9>\U.%B8FL/#DR>>=X4X8J\M[?J
MG5/-H\ 1,Z1^!1;FRTY8,PZK=%I3OSEP))W]?ELPE=2Z_X#$:/<BA(MAY\4;
MR"S9<2&@\[XM \85GUHB,$@G@8F]BJ+,CN'4P /1"?E!'J' 'BAE'0NJ[^MV
M^<? N5<P5[,!P1I;Z<,1&,A3>B6?TUZ!CGSPJX?OQ'Y;D"1'0%4*2_CE:[[+
MJ6G/Y@K?/ ?ZP55- -V^D\#@YUI--4R SB<FH$[-S7</N#$- K<?*HFY3A(7
M!JNN.O;ZAN0B?%> 3I2[IO%YN995I7+*GNW2\$Q>K-54A YN6XG76.CQ>J[L
MY_1!P8K/.)HJ9)^;E0F05;R*CN9.Y\V\/B(E6Z,Q\K*P+C3^'^5:_!S?NFA,
M?67Z4%6O#(:L.H=2[#G'.[5).A7[#3(NX4]$U#LO2=Y"'/0SPOU _X'4D\FO
ML,#!J;8\KHWIUFC1\<$LG!Z^NWE/E#&=%9IG8E_O+W+7XBXB_DY'V_ !G3?M
M_;&25'0>R.@I]DG4UYTK:ZFN]7NWGI5[X[OB5J][I^:1"03^#7+WBY2!GTHG
M=.HBQ/!;AQ#I3T/V+?18 ;#>#=&O.^G(F*IKO/(8,;IGM=MK%XF!DWO"B_=]
M0+^3CH_'!!A@ABV!#Z,8L#XF )ZZ,W-XE(O9X,ICO-+Q9O"-,P&_3!GUOX^=
M5F_H $,E!APP 87Y(W$-J2\P=<"XIL9:/)3'M:VEL8H@<B#[GJ-Y8L_9>WS/
M\?>5+^C0US.7J?Q\=2JO.]4&_$WM*#I4.;\ZEZ$*"O3ZVWG*32#KO:Q(4NGD
MJUULZ^WQ\J:F"P+C#H4;^U[4Y^GP#X"E#4R],Q,P\E^H)#).IOY?=[5, %@-
M<22PC MC NJ-CJ/.SK$K.NX0@?OSD%(B8\;98IH)V-[Q]@K!]?49"E-LJ*JP
MJS!7*VZ?%L%\Q"(5:7N ;:J9<6O_\8K1\.C1GL)N<_/LSNR('[Q1RVOP!'IG
M4FPQ&^L6 V)KV$HHD,ON'2) S]+ 9!VR;%.ERVIB^;-SGV<$<Z"2!>FLD0)Z
MCN!4:U;C\(K1O@Z5-!T1ZG$JO>D2OW+A9SLO*74S:G7=A5/ZZU5*TLG2K-'4
M&EMKM(<_>OSILL7#HY"-0*S!,-FZ#WLN!UQ1RVUB.6"YW1O873+[+H^^G%^=
M^>/ C#(_N%BXD7T??@?G*D3ZY;NDY]RNU8TC"E8H:NB)M:*(G#][<B!9701W
MLZM7!"-8K02:*^':])R]:-S2Q#45[N$.N=%@!+N_I*>0*=7TW]'N)=/Q4FE$
ML9&[''07)U_!IJS=AZODNL=8,USXTL&82#TM)9Q@R 1\Z9C_T734C*6E *>"
M%6?"E.:.GAQB+F&:@D8>?60"( ]S%63V/F:/2F.6?]]VH ^L[E$>;NW#Z&DH
MN$HYQ80)P.9J]$:5^H&/Y@O+T4=?8!HBR*'DW26;&+N(2^V)FU/QC;< "B*N
M"AZ.Q^A06,]P=5EK$4Q4&J["$]6[#NI-68NYLB6!H[>#VS6#?"^]5F("(NV9
M #/75S4*&UUQ)[KD%PM;0%TOXJX/7%X$'H^RCYJPQV!5.+XLJAZ#5S=8 WZC
MNRF(,=/3K.R-\+4]6MO;SX=4YQX"]6E:310%4N$--TX*'T3OQG>IYM86"T[M
M/4VU-2';9P>3ZN;2GDQ R56@WE4>\\XE@54V@MO+DQE,  >7M"3O9HBDS@;7
M/42!]E!H%9<#=*Y<*6H[I?#J[N[)M^ZI@VYSY?.@+@Q^RS5?WT!<4&(,VY>N
M&N8+N3MFKJ28*M@H6ZW,*^!TVR&Q=2* V-K:.(]LAX;.O.]%='TC >E<UDS
M M*""4@:8P*Z!DDJ="Y5Q$*^U?'$Y+-?QVC7'V<<GO\_<M4C3H__L=SFSWN/
MW%Y6Y1%8 C/1:T?8=S11N5N=I]RPI4YF4]\.)K?8T@#6,.4EZ1"4T_82$U#@
M>QPY4)2[%I[&)C_C)5=9MRX+*LV&&#K<*XQ G\C[X#M8ZC,=\";Q<JQ577U3
M<ASTZIOHV+DOVO9+/U]S"WRWN0YD3OTO4$L#!!0    ( ,P^?E:BVHE4ADX
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MXOOOXM!_A;Q_"L2;N!7E2_']);#=W6-&"KEC#)]"",Z2P\KD=;#&=M%\MDS
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MU":Z;!BP@02$RZNYHTOY"&!^ CL&*=A'KSZ'HL%"#)$^T$;!_DP!X(83&SH
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MYHF]!"*5)]%)8C+-9VGP@1MA2"96D: 8*#]QA<JA%;KU1(]G!G/D7.$,D^7
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MGBW=](LM!US:CT/0YT)AH.&BYJ0LTNCS:@M#>J7*1$;X!))M8QC/N$LMGWB
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M"*)!#NN&%!$U,$C&1@0:TXY6B#.FY>KK PQ$!>PQ!L,X^ X!3!2BX]O);U=
M,N,O![NLN[3KPPET8AF9!^3#B$0]B2 40 _M@;8)J5.+XRX,"!0JDHHW5/@S
MJ]%'XT//#FN +DG3 5"2]=7+0?V)F>93',-$0#!NFW5D35MP <N&H<IM>P14
M2,UL%'MF$5$,[X7]?IA43* 3C"$+JVUI'T7*!?2Z BY37M*A @[SQOR(  (=
M?$T;'.^JG3F3"04Q[A+7]*]@D-T [>)H'+:_#X.<0]$$69V?B0EUD1)?M[(/
M *@W[Z@24>]D'KB]V9)>?^X<C9-+7R)NX3X%\@*VIKF*PBO7Q+S2((2XK!(W
M7W[:4^2B27UPK5QD1KG5P#/P!;$A4+S.^1%)9,(5V'9@=34M7O*R-XF)F\BH
M>(2%?#/!W#XYQZ42P3Z:^V>$O5;&EO,;GY>I(Y*=Y*K#W-%V<1-A?%Z5KPVX
M6EDY$ZI\STSJ[\=N/=ZL!ZR#:9?'=).J)KW@RDX/0I+KYQ:PTB3B2(OO,-J=
M+ZOVR\41UIR,X1@4&-S#0-0.&P]V 6=6BE"L3+=+QU+'/&4X^BQYBO[Y/#*;
M,UU:JB?9_$@8VP=1<,I?Y>@P <T-.R0FQ;%Z]TW^;/%W_.)+>[RR:G[SM7\N
M7;!>D#O$0LJAZ_::1<\Z9AG5&C*Z.[31;P47DND-@09DGP(WZN,F6;_%>"<>
ME93M!6,0Z\^3;*4G UE<U;+8&'473FH\!4<OM%Y_<"O($I'ZPE,K*L\FX)F/
M+J.Y^M#Z.]NEOQ>LLAK>LK//H<TBPMDU@@YNI?^RN-*,SZTMQY.]S&=X+^KY
M7)R,2*ZKLX2<^XQOHESW%Z#[CE][M<&WG\?S+>#*S(5NTG/[T35(BD+'O=$,
MV-R7PL_R4A%MM%OM"I/%E7DLQA7I=\NT=]Z2;"MTH;=><O7=5-*T4;)1/?>Y
M#?/E8F64$=_<Y9*/7E<$:H[+9JY^=<+P";GU/G6FT/-)X;ZW(JWFS!_HGG4N
MN'.-Q?*C;N+S3<(:CSL]&7-[4G@P;W"[Y$GDW*>[AY8_&Q=>.9EHO%,BU1
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M<8!V$]^&T2I.+80J,6>13/!5[6,H&':7FD;>!@G0)41QP"J2,>88K2]A?E=
M"0G1UN-VA+D3Z);4+ S$(4)!9*Q>D$)"( ',)TAFN:*9G/\0RQ8,J0#XN^5I
M$E#4M ,U-6T8#6\2.V#I?PF 4_]OEW87_C9 G(W.^T2:M/LLD#1>1I77I(#W
M)U<Y3@$J:]2 220U]N]?>Q3+Y;M3IBAKV/]4'E-@ZG$*C+*>9QJ#2];ET ON
M&0YW=:H_&7I<-1,+T?_!.^IV\TE9#7@=#_S<K#][)L"'+-W>B5P*EG$IN^V,
M+RF8O'#\S)\Q]IUJVQV+:N\V0'TR(9-E"V^[NVJ0&;. Y9N;.S-RZ_!GF<]
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M(<F19KKS^4/N?'\,CUW]!F7S5>\D6UHE*IWGM [7\[X9<U;,-+7[XZIV5N(
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MUFI6A$UY02(?48Y'EP!X 2AJ-?/0O%@=;:)G" 6QS^N'>$1S-S2@0>H^>C"
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MR?P;H;U2XB_0BS64Q]%#<T%&&0>&[/+[DF-DPK];> 41[\X,EJXR7SR5RA$
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M[=[[GG/NOG?=]=WU_7=PE0LJ-;S#\_R&YWVC:]-)@!F;-VS: .CIZ0&'B7^
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M%?NPX9 S.N XS8!)>J84U#ZG36$>0-V4U^NA::,#?"2>U9)IUQI_FLZV6R'
MYMF9H5Q)9V3BV1BH6/@DB#]B,)%9Q&!:'W.]SAV9UD*,RRM1Z3 >K3VACZ2J
MYFHS=, )WI0^"-GM>4 .UER"IJ&U\A)>[&=DX#H;17@))1PT8+ _FK89V;;"
M)-[CYVTQJQN\K 9I'!99&Z,#Z,'0V;395PE"R!V8*R'/P!:@9,1A ^HK(<>S
M/"ASD*\W91D!<D?L$#%84\>BPW!3/T/)D)N .L#H%+_\<]O54#%/WYZP7HH*
M\.1[GP^W$EY'I38 HQ1B!H>SR++G\C'B-2=HQ'\S*+/P-URSA]!)HD/8;*7/
M0(#&!ZYY@ 8@.;*"^P^PK6@*4H4YZ8 $)GG&L)8(MZGT!'6DO-!#:XIH5!X$
M+-]$"YS,&'D-E 5HQRTL!#U" !?^Z)'VQGI!W<],T[M80&LX80?EZY25>G@[
M>HG@_D'<=' JB/Z$ZJ?'O>3ULH9KK:<\+PBD.+9ZS*&'%Z!T?/T;7]^2=PUY
M65TV!(VD!]Q_8=]EES[:B[\GYL[K)A>SG !:5(,>TD!P]8\AN#4S LW3N#,"
M5/=0_R/(SBWH6J6W1%!-YG2N$O'*=RMK5=??&4)S5MHP_N2BI11G(+%KRI&4
MQ+.[\%6LO[C(SGQ' M4>3[D*RZCM/@>>*'UJ*QP:?/:B\$-;7WR6:."(7'BQ
M5I"YBB"3%DG .B0@;B.",XG.SKK[6^X7 W*_]T#:=?6'XIO)[D?[SHZ?'K&=
M#(:\A[O-B<P_*R DRKBMTK%_LB886X^FNE["X =X:RI<$Z'9RFIJ=ZWKXQ@R
M_5HP5^ES88P8R2/(HZ6OTP[Y"C3Y)%9^-U*E2 _S.R05$G.&[(E !1I;;R45
MMX:V/7N'VS*7EZ"P3$S^Q#$MK87-4'J#.Q^;3USYO!&6$N"7\*HF?;I</S4!
M?XV+_LYS1;\.&!EM'L'/8/<TOXQK1PC(4?MH/2,&.3]I9#$0AZ2-A>C\F:C3
MOA:/+7=83=;B2_B: RQQYU14*=WJ+WMR_P'Z*\/7%U0FGT'&]->_+0\08A?9
MF27:23J@>D&Y\0/F*FT,=-P)",8-E(J:@> JFM%ISO1@.Q)Z';\IRR?1FJJL
M'ZUVA'K&/8NJ!%90MA\1)3=T@'T>!S.B_$EH9^[FFP/6UZ]_.V5IQZ7U]0CW
M QV)OP^'?20T*/?DX9;*HS!CSZR(ZQ=UP+*\<U!?'\;0 0[O.$]HX]RA:1.9
MRC^5 ;\83 ,^#9MI:FY],RC^VJ()+-TMP VX2,Y 9*EV$G\H6P=\V#Y%\+?3
M^X?!]1]OOZ[5+X"0U4VJB@/X6=KX=D+ZWM/W_X\^XZ'3?P';6,ZCF5$=-U-2
MT>D3.7@/Z%Y0$"G<_L>G5P$>D]KT!$]\#FK46DK)V[?Z\S1)([P77'31&'99
M'$]3$IC[_1ZRUKM\$ZW@772#VK<K )M-QC?"M:!F0L;<8U_HUN_E_;NR"%J+
M&VH_P[7FK+\JN4@V;B$7X5[Z=FACI.^'$;V,L"\ZX+8_'LU0=XUHPY*UC'LK
M!U&D1 =0KGK691X,,R-^JR W)T-0:U:S#I WUF)C689=6C&M"(<X]%IL)*<Q
M_M3EX3X!4PM!RAP2SN"T\C/IESHG(" C=V"R'&69'& >?H9"4AW0[BUE)05+
MJ;,91M5\I1\*@LH#A*4WE8'CYS W23CFW ! V7\R;Y1YH[]"5?A>[%D>5$;H
M/1C[_5G?EI=W6U[O/&.S/T#?JEBP6B%*#!BN/WEFS3Q!<Z8"4GA6U /[AHC,
MRX10@AJM4X_"0N@S[@+^Q[D#['SX?3J@->?%F!96MPA+O/D!=C>J&N%:3+,3
M(U"6Z"7/BY0RJ)YP$D,$L]'PDBWED6 S%C@"O(EMP;G2'6?LB(L(\7"GTY/<
M@Z]4 [RBL6BX$19TW+'4 7?!B<\>[O R5^J GR#B_G^\,V_6]LFP@Y@@B;X=
M75$X7QM4N!YP/CP*Y:*[G P;CE9YC,D1Z$_\^,,F+W., XL(=>;SK24/ZF?I
MT<"1VK_OY:B/_.O<MVZ<B2*)U+]W+ZSWO:[=A,$WLO3_/O^>;?GA3(@0>TY3
MX)/6JN'4/E]6TW3HV<UF[JN1@7W\8=-WQ//:"1F3!A ONR9&G'#^\ -W4,T9
M_?"5)!)YL,P)7[68+QP+SFR2UK'$07(,%O)#O6S)7_F-[=DNBNL<2G 4G"_R
M<R:"Z#[/>=YQ,W,!_X.R9[2G)X66 #WA869]<K8 M&'N1B\AL3*B!VPAIY]B
MN?^5)!JN3]-RV%.R)9Y$!@7UE6TTR)@UX.#9EM1F-0V @K/+ARLJ,V !A@>H
MNZ-@-5_XN4_<R'3-[3R1!L5BK@^"BGI=U33VZ0'KOEU5]5^R;W?O"V$<'CUJ
M..:?FG9?1K8+]",\Y@:E8T*Q=N;)HZTOTGM+)R#DE5N/EUW.%R<U0<H5(R_4
M_LV6 ]OQ+W2Q"9N/)K.XW"!EA:N,'7>\8O9,]$&GZ.?T.2G2@8/^=?X]MU4#
MS>9*J%:,+J3WARF=ZS(=D6NQ2B=:LPO5J,^=$X?Y/&3P:KD?]N])9[JEYBEV
MZ]N-S^L:_NJ=I5TW7,X?%F.C?5BO\":9UPLW5*ZZI'JAO6;VD_5'<3&U]JRT
MOT<UNTR(S3O<XPMWD"A$H%TLA91K'&S=J@<:.YVJ^*7L_EQYA5WM 80G@ V%
M=_LR%Q/4LV9+Z7N7Z4%\Y ]CZB./I!GIG %,8A*6/LE&(:[\IA3SS%_XV&+B
MXZ3=.N"KT,]S*)+<6! X=ATZP8\?!H^?ZYM=2N*+6HXI1??'LDR2\]XG+)C$
M_U?T;==;_^\.<[] @^7$)?%A;UF[] XT$EKB\BVZ6OZ"&&214AO\5TG>J^=P
M@IU9D29<\*%@98B7-DTLBG$6/*I66&*+WD?J@.:):R\Z8,,MDSA7X">$;A+P
M2E$UGA[5V@6'LJ[&D;&XI416Y]*$N3:XE:(POPV7:1=,^@%NX0K&T[ D FBJ
MX9<FZ!'A31U@L8]U"N[>KK08[QGHHQ40>'X?X@R[3-0G)L/?XR3F<GOXS1ZJ
M]D</'R&T'U#GX(1WU0'S?29JS%/00T3Z&KEK*']7*E@ZX&4*_A=7M>[O2D7\
MN\J7+"X'?3MY$6_4%QKM#8;6ZP".+8B7PW>VNJKOPZ VK9*L+2TG6CN57<VX
M"]GB]BRAM<<8?*258L^$D"^Q,JKIA]"S63J@K@_W8M\CIB[FM$(T2V],2(3B
MXN.#9QL](9 GWW/,MOQCA .D$+NYC <2RJE&R:VC782+6O@SRZ/EM$N5BYNP
MM;(E&YIKKXFMEIPNE <O6>.CCSORD<LGV-:M;-EB9JX-0>YN6O-+#79SEG2]
MDH'DCJWT<)71<W@@8\$<3^^LMYQM;2^J&I8G+_-R@5OZ+!Q:10X$Y#1CN/G;
M?Q@/C_DW-7[TC^.T;CY'--(SB/IZ_Z,,Z&4SA2?+,P9?XJVM(]I5"LZ(,T'4
M(IR;>[ #LNR)&'YER[ZP\M(90I==_.7+8GJ,9<-O8>,_@#^)/&6\J9A[J\-6
M>D,[*YE.V(UQYONEE;71/=QA0>07#U<)[[SU"!^Y$NCMK72\X*.*XV'S7 F^
M5^[H4B17^#S]NCPY-%?C.NI_%SUP:K"7(3@+2;*YCRWJA#-[6;.0" '5^"-Z
M<TNKB[%UGT_+ *NJE5V;'M36DS0CF6T_XA'.RSI%6<E<5*1M$5M6VAR(3NNM
MJ>FS<W@+=<U]Z(^;2E_:PB;IET-IERL]M(3>EEPM&ZLEH4L"E)3:ZE5ECAR/
M'5*Z:1].4EH^4O(3F*'RQ[!T;K/'6MD,U^!?'J\PK +\TZ\I\F$)8>.0GPY$
MP0#3N0P5>XZQ,5NEI1@UJH&1DL>+,:K$<QG'NIO6W@9V_)@X<TT D'[L2QA8
MP#+0WL6-L'7OBODS4$C&JWVSIZ/.[CL^4D&(D?-)OS)WW%X.MNFG?_::_!AH
MKPT\.A7TAG/'N03=Y&HIK_ HY8@\GV7V@5!<[K D#;=XBFY1?D>_E!9WE9M$
M<8!/,-V4!I4>&C+;(^0>3/BKFBVWN]VWK3 TL.F3%L9>/E//DG%G!&[OU,9J
MZ#[6UZ!WIXL>!,(A18\4]UYX1*F1WY8!KHOGR_H:$\1:$&<29K6.!6I##TT.
M+?-HC4BAB=MH';U[+*PT2SY5B#KX^LF0T]V-]>%*;;UZNW[WO]9H\H0="%X,
MG,'%N3K [Q_.4V0AH\U$X1JUWYU\-'5_\\@A<,L337AKX<-#28LV%_6\?)^\
MVNIE;VCS??,#WDIV?#DMNP=W0.Y6Y*"<M>])U@2]E&0X[7[W:(WQKLC0Y!6K
M+8&WI"C^6,9JXN'1T1 MR.,?+.^W*5#I6-7.CB^!K#H8\IKK?M/>.FN+Y&L@
MTYZ S<W;DIT?)!W8TZ@WT#(]<]NVGUJY,\K-(GC=G7/8#7:SW,<NK Q[V-T^
MF7M!H"K((3KPEKI9CCMZ?S1Q3TV\HM=W0)"MA1IN/>@\UC2&4=V(E[,L>:M$
MK.]1_5IU T=ZB-Y0:8DH+HZ^HA6C$;5JO.A.6U!I]$OK'1V75RSS]=S8EPY$
M4M7\[6M5CHXC/7C80:=$CWU2/NF$NR"!N?M!!TJOM0-!>FMXM/]V_*_"(H!S
M;[ O533ER9'6Q2YO%O=:+\&LK]TDO*!=:20-V[I5T>MC"U-"WS!#'S*!%@)$
M0J@R:,!1ED]@=I4=^;VQ#JCEQOT>R6ZKM&7 &H=YP;CKIY3\X!O=9-N8&EG,
M,J:K#+3%FZT;BN1+2-6^=K/1GY<\7$EG^RU1KF]][B_;>EH'!'8Q!)O?;0#>
M(KZ W#Y6N%_S] PWZ)W'8.='[76M(\\AEOLZG?-Z!ZCF?ZSQR"PG0O9< 20,
M7:O]FGM[:T<_5R$N@)9J8]S!\5]P^/E>-1V+!-4XX0W;N*52;7!FO%5EE<$*
M[<W^,<<GGL[BMYJ(D2QCSAK<DR_T'!;GTOP^G6"[@I6>D!-O'*^ TF'.-=:\
MMT02%U2:(+^BUY5#'=6@J0Z0TC O/H+GR3_!6]!?HK0$BRP#S^-@4UE*<WTF
MVO6%3Z=XXN_ *?!Q\K1]!.#):8G]Y8;2I(BZ2-?8D/ DGQ0=8$@I2KD3R'C1
MZQS;3+D5XWEE^"5[UQ.H6[YZM2,18&JM\1E^$J=VSIH?"O#OWDBW! <?P1/"
M)] _"!X5-M]=$T!Z6OJ4LZO\46:[K/.+[3K1P!Z1/DY;B;N!W%&>DU)1Q2'<
MP\SC\70;%*J-_-1*H.!W7PK/I#PXX697KC\8$ZWTFE7N]( YNV7I<;SN9NWL
MSKFE8 ^M/25P%<75X'<">\5N#HCDUS7X#N9Z1(C-]&\ C9?@TQCGHJ+75+7#
M]0/>5:K4[MEE7Z\^"!;/8OY.5O&P/=)-2DH_]L'1\J#3XN#1S>"'7.G/Z#E%
M@WOI^96#LQE?Y#BE?*V,C*;U\B\.B"K)_K1%:!ANF(MX^[1Z@*LJ\M%F0:8E
M2I,+T?W@M$H0C=TG9'N09+!Z,AK%&=<C $,=#J!\W K&IS;=Z2Z#:@8'^)/;
M&$>%,I[*B>WA EX8I:(^S"5*;ZG?M2GY6>=\CJ07F&QJD(IO7U+M)(+F1Q1:
MA_HJD]M5+]  &;M^+1$B?;+)E44\6N!^5;:V$I(EXZV$-[IH*M*K<NMKK2Q6
MLC&SG:HH96Y=-"@84[E_SG_#K3_D+8LODFI!C0'#UZ_%)54'F$\Y*[-=H ->
MFWGX?SQLI\Z<1[PN&G-]SR0C9E(.FWE$3C5 YZA.HP]9B]$(KR8=\+CA*B_(
MZ#Z7B*O#:)N_=LV/I#T-JP6.'H 7I9PK@VLJ7 _=K$DE9F#*35[@M=N'&*S!
M^O89[XL[Q4-.O\LSL_#=3:AS?::E,OY/]5CL: 58[VYR/^SF(:K7^RGY_A&C
M[\^Z"9C@P1DFP<.@G(W-W*(ZB0IE] 1PYO&;=6F.]?2+[HW9O#>R%R[7#!A<
MDN6AVQEF]L:YMHV; %<^JPI\_/L=C3G>B%NB<WD,O$-&NG 26_^0D>.K_+Z2
MH[UZIS/(6KA#.N!H<_K@C$V.CJ"3/9C]G]<"=W_6 3_#X)<3P#<?M9>WM,4C
M_-:)RN5OR\U6])H%X8XE?/Z[S[/;WCURJZ;<D+<=2Q7:)=ET'I4/+0O#QKL7
M3/HT:_>9;YH-*%P?<$9<WJ?F*D:U9WHVCOWD+%"[1G&R5&-6.F U83!3[7Y]
M(8D\+4!9E:/4Q@E+%_!"X?&[@.8G5O!>03/X0<+X2O/6G35IQ@W92A\!O*P$
M<:PE(%[J\+XHI53CNQM(LC3-W+)HNHG))AOG$W )K2'W3_327@+XCW,-/G)'
MMCK5P,J?F0?*'Q'R[T6U;!(L!9M6&T@CA[:=6:G7ZZY('GG*6L6 -A\(UG#[
M-2'>M67""XNET(<]D?R+  5\2ZU<ZR:9GFQ(@M9[K^STS7\YJAY3IZMA=W2X
M!M;#;;%52G[L::KQ&UG4O7#J &=64' ^RMGU_I3+@+<E_NG]Q=70LGEFQ:=M
M_!W[&7 $SB"LMO8,=F)2+B: !D3J/=B$^CW/';*X.79[.N!C U*W.3<R\B_P
M6SBUXPG ]]\F)'C(!S<BZ8!YD)28R6,ZH,6[+ES]Z9^+M2GB?[,ZEP=+N/RA
M8_#$VAP_CLC&(\7_^WT5V:[JU!'P+SX$AW#/ZP ]?#%S&>+"$_24[PR1<J82
M0=U0(7WC5(M/^)#?Q@XIO0@/L.W< <O6T]XIM3:7#;=[^=.RS. '-WNT$XV=
MEBK1 <9]8D/65$9J';>(5L]IY^$SH$NX15D)&H!P]\UVYV';G'-TP"F4C6>Q
M*I]*T@"-DPI6.IYS<E *XS$2TKP7#9$.3F*\Z"Y=%6'MJMISG1=D0Q[XY(AG
M'9Z>DAR;AF6A1#<,2E&E<J?J#S1%F8O/]CWK89;5R[5F+I%Q2 RZ5YGRL@Y(
M 'V C*@Z]XWCL-1?-2\T<W2,CIG1)2?%DZ  "%U/]S!7.DLK\.=*BWJ[%<\0
MUWK(#JYI4-K%$OB_M(+;7YT7EF&63-*_[U;%:SI92\RB#A!B"_33"TO3EOB\
MU/Q2]_1=OY[BT6IM),<_]M!!?B]5CKWQYXY//TCHY7OX[D(+=0H*+_<"ES(W
M:F]B>LJ('>]<^#;=I1;NJJM:KO9&7@_K.U%Q:H;]N>5W?@4:&-6.]EW^2U)(
M_7RDDVIYD)AGO^9P\@RT8Q<Q\NP+)H18HXV2Y)L4//@G)6VO<GIG+6'1N$>$
M=QPQPLZ?A4?Y5P'69@:,&X9+C**#I1N5; ZV1>ZDSR2A^?>8FU%71 =H+-8B
M7ZYF]9+NWI##,Z:CL;))BL3TW\BG@HUH!")NQ<Q$K(5P#6QQT45HW#T&FGGL
M4'K7P=,'1D)(FD5^% \K=]->$K9-L#-18;O17//]MT)"T)-!]5%*$^<4E[9-
MZZYY2_HRY3DQ44A3 5-/LX2Y",FM6R0V9)!5_FBF1Y1%W%>F:S9Z:3.:JH*>
MI&0QV [XO/;YIP97N">S2QCT!B$ZSR?6XXS,Z1*!W-CW2IIL T<9(4B++Y1Y
M+B9RCKVY.=S8'U_K3M;&#*<(6&M\!T3?3.U]R*G8']/X@XH0@ 436IG0A<=U
MP 7^8R)3!$2,QDX\<7<.*A2H646RI("Z_0UGM4103?V<K9Q?H2W4QDD'!S*S
MCIG VXQ9,=5B)7YUX6D,KN%Z39ZUX]OA>P7ZI(5FN,N'\.C>^EEZXW+"AL[0
MIF,AFOVLO_@S6).9%-%#S%4FMMPBC;I)FQ%T^<KB_I71$1$'X1=T-P!QKK*_
MO$@&DXGF?3]*Y%>G%4**I4QEO>//6"F>PO!KENDIK]="LVF]UR@D4>4"=/@G
M'7"%>X<\'7YA<1#I=K,#K1#>CK,-<$3YO6C(&S<_0'!B9MNS$?Q/!2:+@6[P
M".RH7@X%<XWQ!K$U'!"L723YU)BMA&0%7*4C;KK1PY]'CM]_C2LYE*O1W^V(
M.RKPV:5V]LKC*U9,[36.S.TO(J;OO3:G<CK>1B/A'@QV72:98O5.!P2<19IE
MJ_A$GLQ_+ELSV(_):\73/<RD R<(^_L'P]F <!Y'SU1YS);QL\'YX C]HQ9:
MRJI ![G;@JR@,-6-(GJR,QY)A&XD@(=2EK*JN<CN$'^I,'$QTU-S  XD('.+
M]G8Q,?7G0>4.K@GC5]8;-81MU0&/F'0=L#;C5[N*-2-6>3J@)*"?FH4W<4MS
M:VU]9;G)X9^.#@DE4!QF"TOXL6.*7<KY-Y4^/M!)O%/)O[ -EM*8J_O.Z@ '
MWX2S@&^/X!)K%;8>E<K63&Q<*_+\5/&$>^N0$?6"&/RZ9!.BB/O-"Z]&-NCA
M[<IM5,<LFW2]-#5)(JR&IC+-WBTMYAOM/_@I"+<OL\ 7*X\7GG:AS4$'=W3!
M= ;;M^_:IV3)81/R8CU4_X@&@*M]R]UDBS(65>N 8N@\9H2(?T+M*=;[&5%>
MRE/\C*CM>*=P&R2U%'D$Z !O]L'PO$I/(ATCX.K-%(=7<N/O%/(,?CQNC.:H
M3D%DIAN2.4S,@6SKHK6MO_E@<S/GOF=C\2\@Y7:X1FBC2#S.O\LG)K 9&AYO
M4L'J !QV!_ @C*290H3%CO+E(<B&=R+YP).;MQEF=9%KFXJ#A1?:N1<X51KC
M.8?T]Q CS]Y#T&[<LUL,H?<TTGE#0=RO;@V+U"[Q_MK[1WI"@ZA8I!RZ@ V/
MMXZDU(*4K?Q1G*OH71A#0-43+J&7E-H%^D>?];EY5*PB=!W5AW-?."08[SJ]
MXA^5F\::&MO%6SX':!?8L#Q#>]X L!OTY/L_*B=4V6MBNK?%*M?(-EP,RV*$
M5:F%B9@C_6%/Y+:KVLSP0327+YTJ/ IWG1SK2Q?U\P8N:N9B"[3%%+";X$/6
MDJT/O:4\,EJZ 25F>I96![2=,BG,,=.F7CECKTCVC-X @812%QJC'3CH@)!W
M(R1B4JP9I0-VQ@@?<\RT1[@)*POO!$6R.#P];84\VA$_7.88R\#@A7@R'(:+
M^KQLKB7=Z2GSP1RN7>.?V%BL-=)8=P@'C^3$N'EN:B"])?\DHG^K!#?<_ L7
M/>KA%H$T%C?>6>P9G)TU*6]\&<$E($88JZ2]MV(6C6]7L]C8@O]0XYXH(+^B
M?DVX]!>[>022[ODOFW>^.>PM?]=RWD<"0R&ARY415=!(;6WF MPK4DT6-N='
MUOW:01Y=IH:Y2%_ST%!2)!U][C>%FU^*.50N('&VC:MAVN92N?BBG3YZZ/:K
M?()NZM30^9$C@O9P(O,*YSPT@1^/W-KDZ$"R412<T'_/?,/E]'#J?-<\#-[3
M[AG7D ,_Z%&'G+=R]4VK$+:MYU)/A@F>*:P N3Q FTU9B.V_TMNL^A7=!ZG<
M!)@?E*#B(DFHC?\]@H/8?^_1.*#(GE8>FMC23N\G_(^AB[;T A3H=*'R>[2#
MYQ.&7\SR U$?EO4^8@(=JZVAG8*=+:."PZ1.5FL:[:++(AU PO00UC-E<YW*
MIU\TC,(46S0\FR;'CX-S^O;J%7$&?R6%-9Q YRKS9"V9$0-FRI]E'=Y/G[N*
MD5Q\AOYM]#<AH1'KV'64543>!,/+] UB?.9RK#20#X*G2M]0.M8CJJOTG)X]
MAR\=<MY<@K]ZW+]1GMH!K3TT/73\5*C%#E'!&KO(2-8LO<^@"6[.($E__W,E
M%6!0-R.-F=N6Y[0=50_&*W:_]YIW)?3R@;,OW!JCM[S4B@@+.:Z%M@4)KY)S
MN^&:B_R6-SI@$GXTQ@/>&P^B!SH)Z-Z@P$TK_,UT ('[Z1K?A[X)?>WU<=P&
M.A"XT^^ ME)1FU954M338<-*UP$I XX/Q=3>!?H>\(M3?7CYG/'\TRZ$NGX=
MAG^"[] %8Q8]7J;?HD74Q?FO2TQ]HXW4I^+-V$4B\VKAEV24 *!??H%&R4I;
M('JW9A+\\LK?^[K642S@GOC&2B$O<6(7V/\B-!?HN]-'=T9#^:QP7,RU9'EB
M9.TUC*JT4(6_PVS#Y*^B#NB3+V*A,D^GS0@44]40/K 7?AV\SLJ*B(BG/9<7
MC?P<6&@K1.%,F+H94Q"M20V,++BCF8R_F_V[W9RWY9M4'#8T9-0*=9EK.=SQ
M:9H^%O_/K E <\&=F#3T@V8!8X[,MX'@=P;8 ,_&UCX(!I%,JB1*!Y0R'-;Q
M2:1U""*W/Q90ZL'QT]039Q7]]XF7-T!(#(,MNY-1FK@$7T2PF#Z9+2D18@>U
MA,+8/[7!K5?OI8!$LN3]"4F26%9\A-]OA>1MOED#F90[WM7F[N<W<0B!2-C$
MFE]/C?07N(CG,-@VV'I[IL ^$=BE6#0(S^9+,N B<0-DUHLO5,9?+3A ."LT
M20HGV#G@52W08WYI^58)(55J/#8ILK["=L^RR&5S(>7J(;ZB4Z0FI%U^N,M?
M[=Y=O? 8R2_C<16!J?M[[P&W$A;\^R-O_#^5W]X://^[<)5]96.HYB/KZ>C
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M(43KK3[^&G7,=\181IV,N:/-TNB%D#7JNU%Y/8[07(78^CO=F<O>O5'&[G#
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MB($/V4QW-B$UBQ07/0@%9"1A0JWK<_NU/+@F%/F82"36?-SUI3YN!IGK277
M-$;5KV?ZTKG-,+H KB.W*PC*F_\>/LJ/4V([T#=A<J%1MT@=6D9[TNTW%>\D
MU;GK &B5K[?!J&#>Y8V3O2A:1^NX8D\V='W(,^FT^6=K\R]W)C;1OFXO.#GX
MU6--SJ=/^V[21@8'II/1C7")"4/^2+ FV=F/]Q\J?1/+DT'UQSNWKMS^6FYS
MNJ<*Y-@0-KU%[W,:#[M&-X';,N[!/:CO@ZVNXSK DP"POL9@&?DB/&<ITT(Y
MLZ_N6B=)Y'$H1!I+] ?O%==$>.]6FBL27+CC!H3HHKA5"Y@*T:/D*'*[6&X
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MR"UAWHI&PTLUZT]4=&7HIHXBT5R"H[4;GNLZ6_3N<+/(42@NWND2RUM39QC
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MT(A3E*[(F$IW=XD_5H8GLH-#%0B>]NY@9T#[J*Y4A^P1J<F8:%@ZJY7CK;N
MKU=)IW&BQ#QK//$.7EK-^*H1+>&NSS[8+=>.Y:C(Z3O,Z^9>S\@!:%U!P>\;
M;)$J6IBB/TB,S"[:'A04_7.0M^\ZO" L4SE48[_U/'<MW4%)H_P"*W:!@5L
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M?Y0^:EIVTOTW(%=(+^DILVV.V+C0SBB!>N ](-K_$@\KE$3=MD\[SZ[[2UC
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MK191_3SL?86%2SU!KB+O#TA+D&<-C(D-2X3],CH<89; %CLC1FSSL_G1<>D
ML.R,\Z(SMYI?-] %(6V<AE1ZA9TQ:!H,OF!#%_W9T=A0X=>'#0P52TPM&[]
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M-G4_]HG[  XP63*%4<2+KFB)G;&;=PP=$8QY[U[2R2 W=\'D6F&"SA\;0Q9
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M<]LKXR7R:05#+1A7OW7OE'X7,F_A+75_?/Z<RZ6UB/%?IOWU_P)02P,$%
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MO#GUZV9]/MGUT]\O;TF")O(4KP%TG9AA1,[B;1Q0(V.6\R>!C8LH3-OFH.!
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MTH*OL@AK*&_+R@2].0L;_6S_/L4RK'J8C+*]6(-:G,OYD_#>R_K0F2R-'/Y
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M"LR/T9-8JPFFUL-/8POBNO.HOP%L/:Z_#AM6?%QKT7 1-1'$:4(?4X8;]:Y
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MS'XW>I50)3T0^J^BAC_VZ[JT=1,!?J*VAK-3Q^QJFS91K5"^2,,R%6E/TL$
M_WZ]:*H$UI;;;/H7IL%9"OYX?6-A(FKECW6GR&V$[9& .<R;-Z(T>!A58!HF
M;3(MKU@0,V)3MAIY,FU.<7NVA_'UH[1CBI+]6]+H5LT]X0?DO*[6=S-W ,65
MX6'$-]+=]>[7@M8@\AM4%G:?/[M=@_:)[#\T.M=4/@L.FI590K/2+Z0\!EHV
MC+X56YL7PQZ WH\Y (@!*T>D)+W(Z=7#;&=<:68^UX3U,?LQ(#:YP45MX0C
MW!\![6+L%H6%,\,GQ;QYEQ,\C%DM8)"%/I/R>_PYNOVL:PT5HZK)/<KEH0-X
MI]M-M_8YQENTD9W#W?7;KV#C;HZ=1S82-B(.=RTR\:>B-6VNYE=+R!7FW93,
M_OBFA_'.&,#I7Q&77,,K#SL*]]>\D,Z%)M06I_ R7 "4Q:^+C-^BAL566H(H
M=SUXMG[>2+)1B>B)F76'3-3)]4"3($>%L-9_,E$^6_=/Z@>^ZYA1SD=N$N>H
MQ&KWLN;ZF=SI%T*$0MHZ>_X:Z]T1^RT)2TD-QLJRF9<B,W0#C4.;HY3)%18;
MO P\6QEO-GEMK>H1ET.L+4A7E2M!I,-\C4HCNX;E[J^VM,K3_GR1(X]/-QBM
M>J?2,>S^!CAFT\^YD%ETS8>\WZJ^@&O99)I#9HK5/#GZ(;EO1+#G<&1#*3_]
M1CQN(3-M^GW#P ^-E=LHH1"7-*G*=9.')L*.;DC(,/5+Z?/.[&.:[J_#?A&-
MZHYU>BU66'D.+ 5,MQG;X=P^O.OVX5"87ZB9DE(P/;+4UL$^$?Q,O[P@'XO>
MF\#3A1(Q2I>6/&-K.4'CPQ=2"^C[,]]65U<7T>_V>AAF6S<@4^F,%@-1="EU
MH"#_M_WM2"@1*1^C!8T>QFP;,N7G^FTFL[&(C@CE@5@)JLHV7U5^[Y3N%>WL
M#C[K8012?H#4#R!7"[4Y,#J9%G#1Y/.@-E/U".+G0=8B0?Q4P H6@ =@GFP'
M\0:D?\E](NH^?+(UH NS8K4'J ).;_(IU)]BUSOG>1BO)%&%L<Z;YD^DT47;
MW)P3UF;U2Z0O@F2+T =X->K\R+HI*?D@WLG)YQ_)05#.S+RL10X7_?NLF1/T
M;'^S9'AMS1 K@+]E2DEP:\O58EHBX681RF(RDVH.CO&Q@U\U"4^G)"%)P^WP
M5.M;NA=:2$LH$7=F)O,!;CKO/"C]AZFROKWCYFT+?59/(SM6_P$G,$6IS-=)
MR!E5FA#B"&6'T_+E[07]R'C4!.*%/C+J/*^\S<;*#KN9_IS^G-Z1FS6$OI&I
M&HFE>]V? LXZAXS<J ^GV6IM\26J3O@ _UU\2AA =PB9/>EXK4LJ156AO*,R
MS)G"$SN@VDK10\CYOK>"X40QH^M4Q\6A2#^..U*;",^98;6\OHRT\)[[&&1F
MZ 'Z.SYU?\1_?T!R.L<7 0^0CB+.+^X3XG)%\>J^^X!\)>?\:I/MZLJ[!-1>
M/B4QA4 #0?2<92.1AR-2/(R_BHX'G\+=6\-YCO"T%<*81'>LZ&-PRQC9?/Y]
MP8D)]M5L))]W'@3T/] ^R2/>7]E+G6<UO$<5<RYJQ&>7]7XZ-BSOWTC%WURJ
M(Y]8L<'*D(ZE2;G&0-A"PY-OHY;'[*M6'99#$KGRP 4_*L=QV DI>>]UU^G_
M^B_\S.$DNMU^("!;JV)32"7BM]PH76_:0L^Y-/2%]4;5FMOA'Z>?33QGHY6;
M[,!_LN"Z\W%/3V8I$%D#^WXW\J-57TC'XPGH*^TCF'-UQI3;]W1L2DKJK]%(
M4LR\(-6LI9OH*X8#;9%U5@4IWL7\L6F02%."-.-3_HGS72G(34DCB'&QAV&9
M0'ROZ%3BWHW(!DYC7M)J3G>=@$._1[07UW@8;V$(YTO+D_$6Y&'AW'4QS,!
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MF[V<<TLB?0EWN'=4(,R!9$1#[M.6SVC\VU/"?A&'E-X^[&$<<7\JJ;P"Z#>
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M/\X,VV#H=WF(R-[TC?+QTJE%]:<]Y6RM8@SJ2:^5)#B)<SU%,XZD%/<L%JR
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M'4_6RI]YW0;MHYN7JIV-OG.2P=7UF7]/NUA$F$:LQ5EH,0*/BI825NH);S'
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M#!UG?T>%2W9[4VF^C10TB*JT,"Z\9T ,VF6(X@$U3X<T/K^Z?G\1O5HJ)]'
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M>0HK8@MU6SI%A0D/(J-USH]]9\7:6\R$'CGFD==7*[I<1QT;X*,H!AN732Q
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M$K'_?XSL22'?.5FJHF*ZVYMA:7,.+M[#[FOQ711*W:&B6J.-Z:="QJ=[?RU
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MMFJ%*\E*8<Z8OKPRI"-%98'=["5^UL\!;'&ZVSKK.I@P^HXBG1>E;X-VC&Y
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M[O0Z9&F[H+=47I2 OD_=]Y.@=MW/^,?=N<L>/QN$-().L=QOP$L\+OL5+O6
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M0$"2ZR1E0!J>^X&*H;L-KD5K ]]D#DW6+43?5V+<2#H,$1Y=HC?2EJ\HLRO
M)#C"4A%DD$9-0CNRNW>E9>4+%_Z-&\P$G[T7Y#[]-KE>KC.SF\WHLK;)G:I@
MIOMP!R3!X,^L.I<;IP4G%U$%!H3"[)(, _/E-HM?(L ./PD>;<7I3=M1!'_E
M>(MO-VG.B;I!;H=499&RLE,M32;=9)8E[IZ)7*L;99YN\[SB>]SB1]3(&]AU
M("P*=$]U>)+=!'TVWNRQ=(O:TA/JB^_?KC1#@ 0_FZ\@$"\,7!N;4*TADBZ9
MK0<@LH[:;5_]P SG!R+*(_FJM# 5U0)+N">&E7D$EKWF^'S57[8.2G0!*E>L
M*,WC,!5.AJ1A.#.VP<DH_PV?E$VYG O4!-&>8[D(O-=.N2,7TPZ*=%)"PGW?
MP94E#1 >OO*WK1:"OQ6'<>JR7D&DM8&4P>T)[Z06+91NC#L"I@!L[(&+7L3/
M"E]_QMO\_D:O1&2*XF<(5DIR:".U P7#I0K/'LLR=Y8_&SO"!@/'$QL?)T,Q
MI()GU)HL%DL%?RE\DP*RE\#-A+_@JO3Q)(@.0VJ2[P!9R"QKKK<+<EX2OIHL
MI<K4,@*1!+UW 8IK!M./<Y8LF\,,]FXH*E,?7YW-"OB<M)ZX3YNNHM$1F/[B
MHV^,I03&,EYP-1K6G!0T_561)"A@D[Z:!79<<SZU,7=+F^](A@ 6*B^00>62
MK!T33'_9T^IZ$$G VKCDA][$QIE]M2^^IMU--ZI(CS*.I,J?0CZ;2@%<\06%
MKP',Q6YV@ Q=WM$>K4 D^ +5Y%A#=\* -T'ZSR]^-FVT:&RL9>..+4\=GK+U
M21)LK=4D?H%#0V\Y. 3@L%M*T@LW=OMU94$@T_GUFCFO4W+NRX%)OL3YAM6Q
MGX"H\;%:D-*3)C[!Y% M?$6ZHQ)R[*= 6H9Z/A"J*$@F<^=4U_SOY9%E9TT4
MM]@4WO8B6'OY %Q&TCO6%U1F(L,@O:3,PQ^TZKNF([M 1L1]8*5D!D(:RO:.
M8H%9+FFQ3?4+X);N;  I ?"(Q* FX^>%KQS[7"Y.L" F1(T8[07A:$X&3XK]
M:@PL$"\K3YU53%B"1N,E&P/R[9AR4.D(]A./4_SMZ+O]=6K4>PDO@#I,>IDE
M+! 4RXN0]MQK*XXZ&8T4)JR'D 4[\D7_QIPOC<VZ6J%]P4R%2-GVBJ2EP61
M^OK[?!%WDA]<*M2^^WX@8K,T0#PG8[?U?QVQEH8KQ<2J%6.%.1?@;[G_%Q\5
MBLF)K=_#/2ADC5(_M)K5?=C>9H^)4(\]4FTQZZ@;U&,SCV4(@H(>I\-:MS$'
M\ZR3\;)HPTP-_&QO:U,._1+-(.8^S)1)TQ+RFFO.WJKZ];\)Y1%/>7<.9[ "
M'E]/.?N071^JF:'X0F-'-J_^T!!7I?7U&LHPRD^1@H+]N5>V;3?]90H:ED%!
MG?B^S?&AF%YV-O"+\9VBWH3H8MN5 S[/8_:I+@/J*J"\;]_J6MIKEP9;>/7)
M:D0E^T.%5,*_9WF=2WLFVARD7%6G^+3%C9!,%5B7=6ZLW<^[>1@NGT\(7GX[
MULWTX;2\-.L"/TT<TQ%D+*H]&E?6]<<0_U[$^?P8$(N":1\=B4QXK"N[^^@W
MC=4^4%RC566'BZ[VS/C QYM 'OE/=2!9?44AHQ]X6]$JBSLL)!9-,T\'[F02
M8>8?%TOVTD^8U9(UU+Z+2]DP?@,,%BJ9P@T1H_]T,GZY5&."GNT/NK%P @,0
MDH-)685PWE#>LF@OMZBN2B[/MF[3PG.J_$]S/-K<;+E+KJ%:?;Y38_<JSP ,
M:WZ>)J0@/Z!FH+)*_KB>U?'&C.!#0'/A$8Y0"1$&*Y^!:6R6<"JS;M'-1*6B
M7L>'MAAPW^-.45EVE<&L) S</3/4ROYW#)>QOF)':#>L-!*)_<NO$MR)5YR,
M^B+=:"['"X\_O=H!3I<Y(QQAG:*V4%W2JB/5U?T?;!;U9YI5!,P\'CX<M<Y0
MZW5(SA>MN^@SZ9C\'NK^$.K /$2OSD;Y+<S#$_&\;KB'!/=58[*H6OB;F4+V
M/X<UK*_R_T/U]4H(>MW?)<3]TR+8LXWN] *"TGUKXAH0N)@DS,V=65G4$KWM
MI-?:2GHW&3U8=EVD[^,#6<@RQ:S[2=P;PUU@GM@M( F7"6WACP_MFZQ7Q%;?
MKV\<^ #,R5C";"JG @QO0T/^+4!O1\2E-H$QE'M"4T:D#<=9P7,507>/:2O#
M(SP.IS01DB5OYC3%-]6ADX,C D1%_ UN#3.EUPGE7NV'!%<934V-E/AAC41P
MG]UV^PFYE5N!W%T]IY@HA\Z,KJ$&JAT@*)SU=#*4W4:ZCU1NDGC<Y/ZF'AT#
MQ]0F.E*)3VWG[X ,\'\Y/Q AOZ9;W"G53$B5!_Z5ONR'\5[3.M[=Q[P$RWG4
M%"' 8DQ*)Z,2_XY==M[KF<?3Z!]"?=>\4UJ?<+B\U"+M+$MZ\N<6UM['?@?G
MY0[%WD?;6#_!0_[\VM'0KJ[N:_Y1,%Y#\<M[M8$KX%A6H052P)U5&12F:CAF
MU?@1^=Q-3QV[1QN0ZV"8IPYQ9U:\"4  D+E=$N5A..:(6W RGE;BK,^,(0TM
M-@1*XST4O#WH+0R(N+O:G]]*0+EV*UIIWORJD^%X5?Z9_L49S*?L;\^,.C,!
ME[@&%6P!,5,Q@ZDTPBF;K,1V8NUXD[%8/ F3D;%N9Y( _J MKF-)RQ0H9Z_O
MN.X''=49O;R2NFBY5 0DO>U"^ !KB'O4X7-UJ9,QL]XTQ\% *EGN.FIL2X6/
M>"5]#[&BL$FJ3NUZO&<T)'HI%%L'5NV4+9-9PA>XSGN<G$?_W.2SX4USCCP<
M+Y_)*C;L;;6X)C18]M&K!S[*M2CE8'4*2[+>3"\="JZ(5.]_PV35#650[@4R
M@#=B#XG_@OQIOG;#+@)WT*8^6SR,X@[7CO+8BN>TMSG/>.KYV*5A:E_K]6@$
M 5!U[\$+'19A+SR2_UO;Q"Y.-;CWM^";X)?&3.Z *=OT5>(=^JR>0_)U-D%7
MP@E(N2 IL^$"/TF&DEB!'CAV*&=M?2-MV2W5$&3YK'#9Z)).[J9]IY_+8W[\
M]O%WF2XO*&@RX2S>1<%G)!_I1^^6!(\[CO[G!:S4D>\NA]P+!I_YL\]M@WGZ
M%[;5UO6DL $SZ:(BMHU\*0OW?]M_GX04'%3AJLL/=1&N;.%$Z =>S&RZ&N@!
MB!1%(0T]D[*[.6&DDU'2V'I8BRIG,SY&?LKZ,F5)A".?6*XL*V.I6MS_(:T[
MH&S,6XOU)3@94\\29<*H445))B=[3C=G6L?4'JRL2KF 9)EO&G<8*Q.:=35D
MF=!F=#*"(/?FZ:(-8#6'Z\CD!:C.5;K7@%A^T8?6M_RQQ XFPSDQZ??71AHJ
M!QL_V:Y]-<%7B?S(TX'#*-JY!EULBDZQYB_%4"Z\P%IZW!/JRT)L=C6!+7\!
MXP/$I& 887+.9'T[KA8]W$R_\K(1-6;:/3O6_6K)4K:3X5UVB\(J@]:S-VB8
M=97%>$!I9"B9FT0;'8Y$700"*!W*67393GO^RMI8*X.]%7^5C2N^_=N@1&XV
MCU'L&PLZ%W4#]9Z->TMAAXXYPBZ2"-VNC3/58V"G-ORFN=8S=.!YA)-QTRC&
M.#)T.Q&/;C[4&8:6Y0?<74)@7I9-K?Z/3UNOC=9;6D+LRC)NVR6JL.(8U^#1
MN'"$J"D <1"KS$+U:*CC2&["'2<C 9!';H_@OI9PR)H/SOB/EL1/MEHRB_@9
M< &%7.2_NHD<SF!!Y]IT,"1#S=*][=Z>?^>JB]YO)*V[4+2,APZ*.FP\)<_W
MR][Q;)Z)=V^6!03I>@&_*6_,&SGE'YY+ML!,/%0$/PFJ"2?>4L6M7NWU&MP#
MI, &D<<ICX18OZ0'^R=Y^^L3,V:Q%1W/-K_OT78R5,"4&>N$1H!*/XT0OF#(
M0,I\Y9\VE"Y^/6+XN JI -.O2B "J!$^[:VZXMUPA8G[T%"Y2:$(TN @/)[Z
M3>3^>!P;B1AS,MKG(N6L%;:D.=9Q%>FE%@YB^0Z_YJ) G8FW\!TD:8%+HE9,
ML!NN;,YX)]/RLWD._D?:C[G-&[]7%"E\[:Z?MTV*I6:@@==G).Z+7L@2D4%T
M\W W$W&L7\J_^84-WJ A!5B$ZW^AO][,JFFV@EW)Q+_JY'YLAU=!GCTFWO!@
M'#9^&SJR]@'\:(#>GE'J/5[$OJ$Q>U,]@N7GG^KA,_Q:MW_ 4Y[K\840CL!,
MO>]DU$3G4ZY7+,= #.V-TM=#>@&3]</L5N01-A+3NB>FU9WIUY'E=XMJ^ESE
M;C,I?Z9X!HCZ9(F,D,BV[R4',KS*\LF== NS*PI]9)P/D(=T*ZKA%H'KL37B
M:C',,6KQFFVCN_DPAV,0HROM--P^<3+^>U@PR+6\Y4N=X5[_"AJ]I6$]PWUE
M,G.L;628FAZ4![$')$85;M*<^EE\7VV#@R-2]?;40GA* T51BL&[&YV,2,$M
MNVQFN>+SS!..5#_A/2RZZZ,%Z41[CYQ_ZT\?$#\*UE,A/_8[9":.GA6:G? !
M!>"=Y?AW/%!C=I61^A[^6O@V$0/T=ZV <"^TQTC6=H=Y/?\JW*31CRY9MB&D
M,9L%3IE^#GQ*,MF\(QZRN<<J]-/_['SJV8,'MV4\IG(L3(C<)(-4YK5NAD'1
MD"W&U](>LR]O/?]6:0+'KJ+W:7)9MK>[*CX)G-\L M/IHP A58W6BA:K&Q:>
M3M*%:*NH(9Q^J$MYCTUE8OOL-</M$WM$+S)0"-*$,LL(UG@$\P-Y0Y!_+!'/
M$O^BQ@/SNIR,0O!-RRW2Z[(6:.-R<)BA@UVP#S+9YBV"6$8B1Y!)*!Q?I"VP
M7(AW;)>5:['>D!S"Y0^NB65B@*!R*>#K%N/TUI6#6X<C,GTJFIM8;;#V*<JE
M^ED-T#E3)5/K>ID: 3@6R<],QI,UEQ\+",&?T*+W!>XV9HB^ZFHT+X',C7<R
M5N1+?J,W$%9!KQ-@=?R41BS+%\-O!$8;E.V_3*N^'$PY[^!JSW-QH0#*K8,_
M=E_<$YTM^SR?97.A8-:31(7D6:+O?DY)K8X\VER1V2A@S<Y2X?(2+$KNWCI&
M;NB45C8CIJ,\2&J4LI070*2G6DO;+)WE/*HA3%!$#1&2W*/^EH9EZ%!@/OR$
MBBJ[:S%[S[DOKC'>6L'9/@])%DB/)[?XW'+B@F'->:Z.:JZEFO"P4^,5AV,!
MIWE%&7YK6Y7/PN<+W%^ #Z.;:JX_A&4P AO6XM8J^8[FO*/SL%)!*8(:08 O
MZY&AN]Z4=YH62';LQ;/M_G@6AGK->+X^FN[+U3PPBNT6W(3NIQLA/:=80MEO
MVS4(+T//6A[U\73$XA8,0L?5VL>96;Z_M%IXBN6PA#=%AO*KPL]*=QW#.)+Y
M0%VTRN9D//2#SX9T]YS(NH$A;!5JAPX1F.$=I+ BDMZZ?EMKZA(4I"GVY#B@
MIPL)=A;Y/]OJ'P)WKO\PWC5G7M0,8GHG,<;R]!W (!LTG3&4%20ZW *AFA/A
M.XH2?.<&WS#=!P1-(;0ALW_N%<MUH*JFQ@0(.A8B+9"=G[%\-_HIE,1+2*(=
M8)%?R*US&;+:M!-KP-"(&XC[S/H8 J%?6L3FM+_O/Z.;L5+8L\XW<W#QGV0
M]^0"^R?]\]'4?^2\*C<^P8T:&]^C?]L+WVYZYWW9^E1-3^K*\29FH=M <T];
MH@4<@FN2]"2OU+FR2WA,XNZ<H(B +Y/\0)#JW/;AQQQ%GVQ@\G+-)+Q_*"=T
MX1O:\9(K402!F:R9:,H,@/R]5'#1ATGVC-0[;W1-9U*(2D'\W).]8EL4)X+7
M=@DKFU*4G)SPL0LN&%,^>;6$RF'A^?!Q58-4(S%701T P=3_:Z^Q$P",T,DP
M2HNP,ZE]!^T]U+1[2PO=,C%(P]JS() D.9![5)"76&U6%6LBF4QSRZ$Z$?='
M=;1A71;F3<*'8$^6_J#"9=1M]4/NJNA3<U8VTW"I$+9(BA<)_]@4"!_2$"[I
MON?8ZVV9[5>.K;+ZR%P]Y>#V;8WH"D91C1HG?P01\D.Z/&=)@(5O>.;_)2N.
MZJQS5ZB$XDOQ1H7%;]#3+/Q1X&X425+HV_-WGFDT -ZA&Q$%^W*8Y^Z%4W50
M\)_&1<5ZM^GR<:XM3]%ER4_80UN#BL<5EV6B^'G8Q5;>?6GD*-1?U))39B;B
MGR5#R]3A=S6N^P@?*S0,@^$X3A4!J@$C;&$QD^$Y5BW9_)R?K]"HB9R@UI*/
M*'C@XM;M0IY@Y(5<9F#_TDLIT(C(KF4  7Q)-@QQI=(R[RB62QM91BM1=X71
MKJ!;Q^_=.1:4\6C9)]2:I"3+*05A94GUEOP@WV[';LBD 8'0^"/"D[0D3VRQ
MY0%Q* [NLF@2(/3&U CO3&CA0.V@6R-!89&"E)[90X%><4Z&6D^6NH5_XGAE
M4&A3 24;7Y\M>>K8-LH9KDJ2!4&Y*IVMUU=76IW'LUD<GCR9].U8<]7S_.7Z
MX6QNYJ@Z2&?8#,) 1Q=W\)]Z.0#GC5:H6V>9M@FR7!P'B!/ZTUN6Q"^J6'9L
ML%M"1=K5]AADA^(/.QJ:/Y<J^O0T+%?YJ8B,F(8ZP660_&)JU]9ZRMTM(^N^
M2"!OY\\9J!L_,;1:*711D'K4(DB]-9FNH'N[YU9A4H.&.R/.&4)LGW36S:!6
M3\U^R728Y_['M4WLHK 72[:,1O"O3:^S5[WRD/;>>,"1E=D&NX6W@WGH4>N5
M8-[ME^*[D/$._@)35G"R@EG+%P*U_E7.*K&,782-J\,)#U_BRRCWZUT\WOG?
MV,/I3]BJ?N./]FELCT7-^U931CT77KAK"#\'3?I5?,U[_E,2+D@3CX_<*Q6/
M))22XJN):I)OPT]:RZ,V@'!RK@-E%EI^"/,:BEFKEJWE/HL9;%0+=9MS2/_;
M!$:F4,<FXK&YU*9:'9_%S8=NWVN8<^4T$;)1>#]7OWO[D7Q+=#7&6M#]P3^%
M:!"C>1K;0:VA%]T>;A<3#\'#N4_@(M& _040^TC_D6;R6N#'RQJ(+/5)DA,U
M"K*=I%+P7QNT.S]X$.I_#K=+W0+&Z%*YJ_ [B9?<[:>+\)9?YPG$;$7Z C>?
M=3*^%=X<R/#0WK6X_)3E"Y?.KK;F\0M;&IP,0+<R/+P/>S4+"*D53$4<]X@C
MA*"2M;88A+=WI'E#*P4(1GCTR$_*.1GKWR$<B;I?<%7'&K[F^M]K*XY^/29/
MMF@*8#.>D4F(:GT(@(R+/K:Z4V_9R5P9M=C4?:K4%KZG?ZDT;C^X.@_(8!?R
MDF:@IVJC6%M2<> H]!(1?4?-C86.ZJ>!>G&G"F')8$O^CO[B/F7U73'.&8:5
M1CL)XW:T6VA[=_4%:.)B+^%A,2;"$^?1.9[1I)'LEN4+V[\^&:: !L'5W!B/
M-W?7R[ ;1M\Y#_TU5C9[$36 98]. .F6XX@EE_?#4VT]0JKA$.G:$Y/_;$L;
M$R"#&5]^=4JQN-:6Y:%W,D+TULN)"7#)2)QE-1>Q:\2J*&FIYHTN"Z_ZZQ$5
M%>BBT0*UB6JB5KTSD3=07SF@X.0?F6:?6@J-Y/JX<T9.P"H)!I ,QUEE 3TS
M4;M/>H52YYV,L'2E276;J,X,7S$1R@)C?_JW8TU?^JZ202:5+L\*Y @F]P^J
M':F U$'I2CF+S)A:="X[+=KA<H4Y7%E#\HVVZ0<D:\\;3XYHCB]681KA(6RY
M<"FT(-;^@\4)4P621VOT*&')GY/YNI]"6:KZ?XVO=NR5[JHJ.KI\@K6L;>+3
M.4^=.>(\MQ:6($HJ+:C\HP06]8:C? D9'J'4?M0F;S J\<$.X:WIP4=K0#2=
M".6II6;E J%A3?R?%&XO8E7#(,JT@T%P.%)PEK&++SAHP:K&DMS?[TFNW/6E
M@W_:NMH7,JKLM#G>H.A3V^7QN-*!#V ^!0+9$,G/5!:]I%)KK8'LL)82NS]*
M?&J&[:<.#ELVH"(^Q&QK9[^5MI_BU7!O- EM1/-3\L,D*DU[2+6$DT]R8&9#
MIRFDLXF=_58N^&HFT]@/&,AC!GM9W> %QK-=1,@C,F(;N'OM)XG0]/J[R\M+
M1^3,C1,J?/G62XDF DR6FJRMS=D)$,G!/R5(3*(>%7%0B7G5AC<QNF#+\R-I
MEL>=UC\BN&09Z:IT1[BTE76O27%W6!@PYV2 BS<GFW24G[KMH+K:R;BU)*X%
MEB@UDLCPZ-MQ#4:ZDOCMKBX[_=!3P:7NHZ6M<RVL2>&-]@E?.]7B2<85W[T=
M5[\B1)6N..* 5#/,THQ3AY<5^(=;@B1#4!^']#/CL2Q2<#5^1T_*P5K8=ILM
MH<V6V/NS8,2H/KS-?SE2.D)-LVHBX!P5Y3WC8$*:^<"D=L&FN!KX6_N6M@2+
MX9@G59!AIHJN$CC<^A';O2M]'+;]]]$'/*J3K+%T2NQ)4$YP3ZJRH<S4A@KP
MCD%6-;^,PK9343> *E_$_=7)J'=I4VB%RVQ%<KJ,YGSDBZB#CF358/7)8CA$
MU01[R/'&.8 >.@\9(;P.?<-=%^S[B.M2&,R*Z[-!92Y2._,+A7RZIMJP_S9\
M,[0D,@X;08QK.K93"");@W;JACTZ5L3A[+MCB\&ZWZD7U?QQX'!4%+A$D/1W
MC!5^S=/2!GN<81#K6*KU2?+U0UD?8:%XA*@)/IS,+O\[-IPJ"\LS!VT8GV/_
M2Q_60E[USAE)$.*O5#Y6D8OLU'63Y)BC'-"<Y<1M"WV,?]]72NWAOZJQ87\+
MDK!-8=C<Z/ ,HY3RAI4S_LL*"5GJ&P="0<:D1(7Q0TY&&J"0'ZW6!7:XE^@:
M)5+.WBA>2$X4FI#:5*T"M:OL]AEIUG4"V;1*85)U0 @Z+O,>BMNK:"MKM2!&
M*C/)K/[BV*%VKUU)T98E<"U93O[-2%PZ9=K4=\&'1;:PNZ!?,X:1K>?:H?(@
M$R;(78"N*FS^4*LOR/.MV$_ND,.%^,F,S/'J$\4HI+I@197BSR\-A40G+%6H
MUU#(,X03%N\ +''J<JV<3+(P>W6Z\8;ZQCXBO<S)^)JZ03]JM(?KT9>!3.X3
M:DR0!/H,:#[]AP^HCG#1-6[N#4(R >D,U@9)O%PVS<T!]WFG<7H]3&^SA=D_
M5<"=.KOICL7R=7SY#5$O=3'1R9B5H"KM?M[[U&.J@8I:#DD @5]^#/^GYP6]
MSV+A0HAAPP+)W$D60'S'/D'7=X_@:32->ZG%VR O4]G"'3O2O%CZLVD\%MV+
M[+7YBTBDTAY3"KE[$!'8MS/3.98_R+QI"3&@6Y(H9^E_6?["@_P]:QF8DJ>#
MV[9TRMN:V)G&'_C\K>)CU'%#,!7B28T21>)9XE^4=@$N[K,CS2R30>SV@"E9
MT,C+IE83JUV .LPY+!AH\0('7!$C_4.B+(BM#RHW'XO;F ,U.L+\!7R<"NG#
M_@6/-3*%MG<P;8Q.+_V<=#).\%W<,BCV@#V56_4O)^-G*)]=X&2L>[<C 2"2
MAF ]4>%?LCF%[SRA]TO9_?[OH/W#"#L;H42)8GN7^^Y-["]T-@O!=_$SX8+3
M>MULWHLX%?\!_'"[DS&] 9_G7W2\=I"L4:94G@ZR.V)/+ ]Z-=W- ]]9@SA\
M N*7>9 ;57*]CMPJ#LM@J4*HQ89M6X@3KOQGBB/7)OJI-6+W%QD9)U7"&>6.
M['C)'(RG.1F;")/V"?KG_2O+YTDNQT=P[DK$K(;WT+%B/"H?7IJJ& $!*Q+.
ML>NX-Z,62Z-K+LG!N7_BNXJE4LM^4W,!X2Z.=GQSK?$T#-9+Y]24##8 U(\W
MA;1E\ KC$Q)\<5\U;B$]3KW=23GH]X9[\[T%&MF<2,1Y9IK96"T5=/D2#^CR
MV,QD]$\GP_:NZMS+T*MFX<O!"4D6Y VX/9^@=VA@T,"R/6X><Y@(A!:>44?Q
M^? :.$'[M5MF1Y2[G@, QQ.6^W++L._AJ/C!9UNHUH#4S)34V#.GG PY,BUY
MA[Q.K6D=@Q;9H,\<+M"0PN"GHKX&43/ML>"L;?^**2#!'5L=FTPZFX%*,S"S
M<>C*IBO1M)658B%)?B'#C!:;AE(.)+P?>#W!R>C;QEL W&K5&K2S9MI5E0_^
M^3X**1XZJ!9Q\.NP4FE6V_&3A$??-CEDR[5#:I\7F'N2YA)Y5]9WG[=L%)8<
M=S(*^%OQ\*32KFU]H0Z'<#=.L0 +,S?\Y1MFU*)[J_6C^9-@E:T F<K$J_(#
MIX/\V5(6NO!U3;W4R>C5@M&&"AV7:$.SJ,._J;%F^@$R=%N+&//FMF5NCVEJ
MS#LH&C#3%?M42%UR)@L24R])OAWF/S'Q?8[^!VF\#B/'YHOSNW^6>PE884D:
M"0S_)LZ-JSEP\ 5_*^VI>TPW_JS7B'!AH_2">5%EYIJLD&K-5)-TUTG1^%R@
MD\&RO9I[SMMSH^*)A< D=A-ZI7EO+'.$WL[R*?A+\<ET</_">W"S*I=%$ 8A
MCVH(S*12)ES_"S32I6E60 /Q .9\H2F*SW_S7(N9PMP!DX6=R@:7KCK&$N5H
MV>#FTN]\WA;LTQR*6SABQ%2*AD#8<\H6ONS6:+KOZBWG1 /+@S#)I$>C_OF6
MKK+G -Q:P"H&ZL6+XGO\1,%"8D6!99GO0>-F>$HY-UJF)FK,UL<9]?GIU/EH
M52BUWJ+Z$:BPE5/^2]FA*&30DM#3296AJBTT;RUMX,3/E1-;%7;AGRT7%CD9
M1Q6A&6KL>=*$OU:6(.K5N?+P&A<[!8<I#72O:=RF,EI5A*I,VEF[3N*O(1,;
M57Y4BP/F9.C&\[N;ZL?(,H50TPT_F8V?8>9F8N'V>^N>%N=0A=AR/Y.%"$G*
MZ^K'>K59N@"CV";D=J(ER5X'NWQ'LM1863WL*96M?'8,#Y3R\Y]"1^;?=S*Z
M \SFJA\K97>(WG'LC6:7DOB1Y7=++GIH?=S?[:U;P@Q#E#:5]&?JA.CUN :Z
MB/9=8J?MK3L ?NI5NPSNQ14CJ0!SERC^[>>6*%X?;F9.O+9[Z_-'/!I)EGPA
M%!-&RIO6TZ^LM(5'CX& 9ENDM)P#?$FW$YWCO3EZ$.Z<+DB;SS102<BE[G!'
MV(N =)S%N_J .QD\9A,,GTSR+J =)S\&.DAB-UN"TJQH2>U0,GI/'KR-?7HT
M^:]R"2/W_:P@6<7&58JONKK./$;Q?>-C4<<V0=0MD$;0>]O2?\N3 0;;HJ$K
M>259UU/*.@DA=TO[P:RF] W%/5D>T99RGCW5O(G R;1 67-<$R_7PJNU:N72
M OQ-*NGG!=VRJ'398;A7-$#!;VKMLAY\Z4@6'G[%EX!QNNF!C$C7<8.SV[0+
M:K4,U]P&"7TD?M^WLH:\N>]67UES J/;%#D9*GNB I=MG0B>5*>^H"0$">V5
M+52-)/@D?+;K1DY$%IE!-2KM&>$O5:0KCK&3AW14CLFT1@/DS@QJ"\_.WR[G
M;+>[9Y6_V-6UR[#'"%V ;!^LAXZ3582G=UW.85:!8+O8%JY$"KV+WLHA3":0
M^08GL*^<C+&&&B>C8__(CJ6RU;X^N-\#MQ9!BQ<5&*Z<9)^$<C@:A491 J>F
M\>"Y)SI].6_X..QO\"0NN#FH>QZAOH5!$E$Z6$E1-_"3E9[+1OG"+WNGZ0+,
M_$S,3M<Q# A[#%=&:Z_ 8LD\Q$4;9&;+G9'CW[7]$<&R6702.Y'$+9EXUY^D
MPF7<#=.U"P3SURS.>H^*8TY&2X&Q1RG_"5Y^W?SXJZ@01R?/GL[ZUD5S"<D]
M-!>8P"+VY8G) ,7L6@+;H"",D=](TZW[1\4(D&.C6/><X>A<;8U<.@^5OLLS
MDE_#NR']SM"]<_#?"$X)W8K*_9]LHLC?R>!T8T?>:LYFS9$>W8Y0<Q=JMI@7
ME0A6  )ZB[<16I[% 1\.IO[.1L9UDD'LR#OY^_2*"^A4/O35P';'$4@IL5N=
M#%<J0BFT9&7R,PE'%IA[V5#:>.#'^O([]TPMN68RSBQNDS^]2?<,-.7S(B^U
M0!P#*LIB!9WVJ5=\E:V8>PZ+BZ RVG[V$;99L$ZC&&[B/^L9BHQ/9<FW.]QT
MQ)GO8,EMM!?-:7I\>I1539^P(EXB-K"$:NYK!B8=S=@Y;[PP8\KIC$]*MOE\
M#Q_KRL^/SXPTV&"SC0R"UU+OI?VJFI!IWXH&YV<J7/<PQA$[EWI#K$8^(U?;
M#(9_NKFTBMXREC;48SZ8025EJ1K0:0\#9(DSU.5>%&W.VI/-LMTX6=?,&D<Z
M94+Q^5G=VM0KJ0^&33+33%*TX74=+Z+<;L9@<;#E?$@^%5263[&K(*E!@L=*
M9411W8A:;Q>3'*(%+E*"0.!OA%V&VTBDE')H?9V,;VEA!E8A^G9X\U%]VW0$
MW-E@G($]T9(LR\8'85WQPZ7UJ;-7U&3*C$*"+X @=5R= >E0<5F9C*!>'FP?
M]7F66A.7NGJU#X!AH0IG1=OV=Q>/V<T>4?5.!KVYRAS;8->%UZ[K^KMD;F33
M%5Y2DMR@!,"Q]]#X@(P?E)GQXQ%)E%'41?TH8QGL8IFL)-F2E-XK#P;,,;(9
M4X'C7+>8JQX9Q]_WXN=1CW@FU&Y\2((<ROZI>##0UWL2_NIIO<,;M;L8E9>\
M^IKVL\B2 /A0.O4/+E!O_E##N4IM18!)^;EUTG!IZZ7A.ZXFK]"-P@F.";;A
M$@#\&\@0^\J8'?K1AMCXI&A?/+1A.$FFH5A(W5'FZYJ3R%_N5KQ.C?J2"&3M
MN7_6OY4J70 IL^)M_"C1!.TM,GR9ZOK?U,$5G(0$&&12,$A.QF\\2%7$+,L8
MK]/ 7IS&['6.S"LGMM<TDW 8S#EF_D.PKNMV"-F0)>BRP/8DJXY\+[MD#+FK
M=C*^ZBM>#9GL:7 1M#NV[%"%@6>44R_UU83<E#5P@R</[PK-WS/P%F;$:A(J
M#?9D/ 99B._/\EB>&VOA50?SDL2$("J3W#H?PM/TQU/K3H7VM4N'(F$9PB9)
MB.1[7-+#.I&4>06L,&ZNX!0.[^!N,*='63(5L9HAA69SY6@YED)Y>O5MI.2#
MF[,*/3ZOKV]4J:DD&V APG=5PV_BLJZ)RG#254%E&:@,8:E_INLW/F^()T&^
MKG,RB*;1%*O9A%L)_H:YJ'79LNX!06^213A%<=27H^99WZKQ_QCE"A5>*#F3
MHEFVBPK<>!\0!IY$!D&'9IN1C1Q%<&)*/QSHP$].-&I9(7VU\HB$_8]8-D)G
MVH!$%09!Z\.CF;H<P!,?*#H)<DO2T->B;-KT^KL@VOOU7#IO<N0Y-3TQ+4<;
MC+A[2_P$>BF*F;^GCNS*AGO3'+$H1&&\#A&5]ZR-N@]?%DL7T-6VRV..9;LX
MV,/[CD_K'"Y#5.$GD&2P\>YB>=6+9N2R-'=B\\^<A/#I9B<#];*_UMQ,FU(Z
M#D0.A48C2].D="&JF>I14RRN!+K)7M1?6M,/CZ^C2[Y-O :RAK"P.E_^WF.:
M)Y>//1M]75;!_J=Z/^O(X#;T3?P2UDFH!ENPAX*W'4>$MVR_A%J0VD-.1DF&
MQ23FS*:C-]JYKYE$J!$>%(_*-6_:^7B6 [E)K1R$>N>@)+*$.M]5J")$RS&5
MVZN".JW_\KO;/HQ(]V$-8[&$ .&BF\K6>"^$_!2X$\#"L0/PM\'4#U"-,38M
MPZRTIYC0BNB\^*#@;DCMZ^L&EC@2-DPGT:?6A;E0'+7!EXU#%6R0V2F^%H\P
M@OEBV'\5C1-P"C;3!N:>IPBS1.0/6%T=?N^HE<T9$=Q7HFJ[+&?&/W=H'I-%
M/"=O(7=IB_V]MF1U5^:RJ^IL&7ER!+[G9/1 8?Y)<LV(Z-;+=><;PM$N("%^
MRLK>%#OC9%B4]BE:Y)H]Y^"A(VU>L%@L9+?&QXJK7(*,="G?>-ZNMF65M3W#
M3L:M9-I]FHV4P,<@?9+H;G2L8QWQ 9T3>5K.SZ5.!LDD(&84(3-L+IV-"JW,
M9O>J%01,QFJXST<7]P"9F7*B<X%+"V/V];)9XD'A\GQ55.AD&W4Q@1;%JGJX
M.RG<[.%7H;#V/"=_SX"Y .WKX]ZZQOIPY"C<6P5+9(J%DOXZCO_T=%RIN"R:
MP'#2 W\OQVQC_?(7TJE9-8@..L89+EW/SZ<^0,_831TM($<$9;J"0 DTZC=I
MNUI'C[=D!=TT(/B/59S^Y8*;V.-.2]RU/M[(%<MWI(ZE;VC^8">N(?A0%'81
MKD5^PB9WZ87D>=R7RMN#%01^#D1YFYW*F7WN0; <R<-@CNZ'^;R$^4S!!A.5
M8N<"^&NBWQO]=)@:]'O[,8!(%?B.,"M960WX2NZ-U_G\YWO[%D=&+*["&L:Y
M_\7T$8C]D]7:$QO%Q)6@71O4PBG=*.;5.1/!<AE-UAKC\5GAG4P,&1NF? #4
M:SGS&2P-"7$'_XC<Y9 \1VI@9,KTMX;CXPO)N@#J %E.KE8K,"ZL_O)(C9F"
M?W$Q/J5EQ:R-@!RN=2+W\_<."]]S,K0!%%M0)H7NGBA.<C*6&-O>^$C0E91(
M_7#"A<<)NU6Z6/DS50BH/(#32\RD.<*'MO'JUR=2\!-TRL.2VE_<(]AF U.6
M"BIN:**^H3:A0<Q*>#_&C,[?TZ?%:M^ZWTAUTA KASSMJW/<)#)UER"D:#,5
M.SJ9=G&S+8.0U+-7!I<$;UHUJ#".\:!%L@9TI55R)F95HCQ&N]KOKWKDL'0R
M?ER8[9]:_@XZ'WW?%P(JCKH!4CB8BJ\[%NWH+Y6&Z)I@B/N;DQ$8_FKX S/W
MCR-"+L+9GY':<COXU=Q)!9BY!R(/\$_UF]546I=@4=8APQGD9RQ>@[BT0;B
M?K/L#G-Y!HNF#SO:''T;CCOJJP=?DD< )5EVOK.5$-41640:>;/8%@YN[FO]
M@3'1Y9&1MLPO'U =!K>I&ZTU[B]:H+*&EG-M3@;@(J1*,H +0H0_H,?#2_-A
M;NXH_!D8E^PU\U]A.7,*DUVRH%RP*NOX*\=W20+F%"+)R&;V ,4/X76+/K9!
MRF70XZAU]0/)MRO-F]TGI%H+%J,#02JL!?+'-:U>H=[%&'2T$>1^X=*H0P#@
MYQ.Y-[[^3J>)"#ALBB\W44VL@]P563Y6P"*M@-CFA)_6]$0;-S>K,:4"9:DP
MC596?1Z@XC6%09N@NT)ENO,SC/LJQA82$BJ;YYR,W3';P> /W+4(\3@*?F_P
MC!;E+01B%6P=&/W)2[="J9Z:NL:%:-\-%))FF>&8*F^CGD1K]+(S(A<<EK]&
M!/"W>^?'IEL"N K:(0)F"+!#E=-KOC'J=&"PZ>W2))S1',(Q;%V5I>7M <-\
M D$XG9!J97!H?W/TT@+RKQ;9T%GZID:7MEF$9A":.F!W $AX7LMDH0_O.04=
MMZKMF?QC)QP8H,L;V.#JW''JR']D><][*4=5HDE+P4^K,NC.QV:OB/R"R=',
M AAINQ3?(QK>/ G/PGT9U"G"JC95?=D&>\MT8$*AD)B@"E[W959X>K81S_B[
M0C#C9E$7M$@J-$JQNI1#0<@0UM]EX8F+^-@'6 FWII=00WSJRG%H2D+O]-#\
MQ^>D)98,Q31/E09<J-YGAOWX'9YO.##-0"'YW]'D:Z,<W >22*7"]DRKSW=M
MVZZ-[M#*62KYSPL7:;>37 +(!SUQ7PP;-8=)!%]_3=QMH34-@9O0X%?XOK;F
M[O##![4R,V70NK)O3(K/TMNG 5_A<-@KJ3Y1,%'?'< ':P?*K4M/%58<F967
MV?C^!AOSSY9/W'9I+U,.PF"VL,KZ1#>.MZR>%+Y$M^_L.IOE9'A9AZCK2IE>
MW?%>?<GZ&GX9O=D;*&9!&:+9?WPZIQ.,$,*K@KLA-&J:9^ZU;V'6RF.IB1:,
MV9_1JR4PIFW31WSA6EGMVE*6*%N%XS@9)+B!"D$^1'(P_3WV$AO2EA@'TZ^8
M^Z$>X\5PF8)PA"NLO]@W=>=#1P#(YM+K6W,2+0H,\;V24K%6U)MP:[8PJ4B!
MJC1]S1<^2JN?0U[(I^SN'>M6Q,?7->'I=D$&2P+/C4_<-BU[5?X9EJ]UV47U
M]%;-Z5PXL_[\S/ 9^$R*I]9S(P]%X1@J@X(*J"V]3L;X/JJWR$>?)84?!]W1
M<.4^I9+;5A46!+LZVAXF!?L@"9;%\VPI3V.G$%+PK\]#N2$#@I"[9F%E.?=;
MNR?GLOG2*>]:WZCD+60^Z<GZACJ@UFJCNDI'%RO)9Y Z""*Y%-KVLY[OTETC
MU?YP^OF+%.IZ$) !@RTANP<#Y]_ZW\O_"[*><7J=7AZKFUL'EAGT:\,+8X"-
MEY4?<1U6CDR/P9VJ69BCN1!^W7;%FLM=,"0DB.WTD^$?T+":O+6UCKV>Q ,G
MXW,OFR!2=IWX*/\I:<X)UEZ B]H1S>'K\?!1<8*,-WUN^O]+^M* )J[U[_3:
M2JUH;K7N0MJJ<"M%]"*B")G;\J^T*J1J-2I"BE10(U *R)9D;%$0M]1:04%(
M$0$5(2H"LHZ"F%H*4:($$B% A!"3D(1LD\R2]Z3O![X(SG+.\_R6,^<\3V,Y
M+YQT)S^&1NJ"?I<)=.>#@V"'0,NF,E@2&A'SG#E^;*V9L-T2JP7J<UFT_02(
MJE\Z.]^0 Z8>$$Z>R^^27(C*>(JL8=UTP (-:X@$_O[/@F6<?UMD;B;QPH,T
M:^<V=IMP"%@V5B;/(_#;HLU71_-T&Q"5J2;*D^;W;0,6+UNO<(!8LR0#('C;
M\WTG]G -1VB&'R2;/07BGW5G!IXGK8FXE[ 6@V2PH+'*1.YVQ)@0_S'%LE G
M9<&%5@A.22'J+/I2;J9>;JJ%B%0!2'Y^*3)*>HC@H]K@[SBZV+TF\D6/=-S.
MHU\6]9S^H6&:(5F"T]M\\)&>A",)TNEXRTQ:) >Q2FQ5Y/LF8:=[*61XK5!#
MDX(C^(EWK8X+;6S'NJ*$U0GOOI4:Y!A)VPX'D;N=E)'?2E>0?Z,U8VSJ9JTT
MJ/9, U*YJ3=S\1NF)<E0(&9(6_U2*HXB:M9DFZOXI[$+7IGQ>U%7?8W>[ZG>
M AT?06RL0E)VH7S4MS3?3986^7[B&E@  1_.')7H/#Q-Y,K #8M!&H0M'R01
M<6T8ZR@*(-S^PC);.,<.Q34_7+[,Y:3%YMK.G7F1AEI!RFVB7:E;1)M<V'A-
M((2!(IRHDD$*10-RR=RFLV664C%F1L>RGD5/@NZXOITU]^EX0-YE,$85D&J:
M! 1W2"%?C+]#7 \.I3=N2(47H7R,MF\)X.W= F_26[%C(,7Q T]/]F<)\C\Q
MS+P'W^XA*E*LX:$Z9HGX& D1661H_6GZX!AC,<^AW-GP$(-E0GIW3VG918!:
M8J0/B1GA"&:?[VBI\.HO25._L$SRN*4'/:D+7OFXVJ0A(S1%WF-!ON<R8^,I
M;7#,: L&SP-.JLI)*1N"GTCMKI)0X=Q7HRQMS=;-LT:118%!53@WQ55GJ"T[
MU3;#(#2U$U><E$3A6=9]($H7YM]^S>8MAHR6<J >?@S)3AM#;M$&9Y ?G#7X
M*</;&G[A[$H:.;]52=+O",%E/IF[-E-D[^'H%QC6^%'S"S[[XF&EY5Q4@;7M
M\F5'M/253UO+3^=,'Y@3HJJ/2A->*2QEQ.Q]G>X;KG>NT+9?2W7[&7=2;MZ,
M,41<SKPM#Y\SWM4X.-6N(//YXW;@TYGBX05&K_I;1ZSS.P/:&V.2NX0#4W4Z
M<010C?3K;57A_5!Z$DQ>M&*P/;5.+::QGK@J,IH*<[N^'[XECUJ:S>9*1[*A
M?6=?;42V",97#*_//+>QR&./$@LDH]L'Z%<!0V8?K\WMG>[4L=IQ/[=I8B.Q
M^0,# XJ4Q(+$H-9%P2(GQ7%(:A7*0\@KN*9,PHFI"%_56.*JVTDD\<IQ;*>5
M9.7A_\XX%=\@;DS:-4G33<9)IKA3S0ZC(\OAP(XWTRMB,MD)[D%,![<=%H^3
MRU.%GTDJ<Z>AE>%) !QP6J<:Q:0IE5WN"C4!:?Z.MRN%9F$L]301@(%7K4D-
MSFNQDY76JK'J.8&]ICOP"]15MT6\P'V=DW)XOYS5 2S V)%?/G<=&).JMUFA
MC?:@O$$3"1,'S!OQH,7'<##'*6Z;2("J?TNW?'*'M=LF-*UU="(LS41,SVCD
MK <8/\AU/NE/UR)Z,+A\/GW9P&$'EZR)(<_;C23L4"F&O5Z6F7S+3,WQ:I0W
M W%2:I?]>2S A^5UC&K2O^8M/]C4]DO=J[2W+5G+F$_HA6I%M]2!T]->/!BL
MYWMU)!8X*=-V#9EE$_'"4X,2^7!Y]T_@]94R!<ES\#CP=B9C3&C>#)[EYE<-
MV?M<%9B#CN-EK:UYN_OPJY46M53!!VZNYH#9D^_00G=@EL3G2&/=T3V%T/>O
M8*5"\O][)/[+YZ[AM=0@2MA0;2TN3B(1^U3FG_H#[ON3K'/Y*?#U4/(RWUP]
MG.TZ,4TV%W;R5AJ]*O0)2785$,QO4BQ"!O4TB=0*I%5?Z*!C)D#;7].$2E15
M&8)-U%GX7@EK5'U*I$HJ"8&J_E6'-%;F:46[,7HQF *&ZV1U7N+E+Y,6'"Z\
M2/QRS'7F-];JVG59(_XBNIDQ_SJS>;*U]5)41*I6TG9',BP/F&BA7508=L+O
M=@;F),9-@_<@(%T!KZW]&KE8V$,=U._-VV=(.(5+;=Y:&^O[!Z)ID:OAE45D
MM:)71R.A4[Q-Q4\*ED876[G+B$6Z/+EQADFHVFQ=@-X;U2^+RNCL:/=\!3^X
MD'?'U58YUE7Q79PC9O#6:903FSSIO1%!J[('97)]4LLNW;1VE+FCTR=D7C/[
M>M0.K'SDZCDHOKA73-!A@<B#.,4%UG17N)7]=Z3,AL5/;(Z5]K>O-:2:PCU<
M^>"W1*1$K2HUZ[N,1 9:* \E^6284.U:4E_ATWR)D:H37F(+_S"%%! ;0I2=
M684E((VF@"!R#/DH[N!7:Q):!]M[8JP1((R%9KVXDCWNX;;35$_U.G; I'%<
M+!VP3+15>FPE%^-7X'&%8:/%D4KNMFW:\^GTWNC&;>'1&FF9$;U&U]G)AE?@
M/6/M)##G5]=G'")^Y;S3\["QT:ARO--*+[7@7Q_Y40PTRC]K[*[E^#4<DE45
MD>V06H'B=_,[RHHE?J,O.O*M@BA2?6>DR<7(* H?2&8]:2C.#+1&Y7GX_A@$
MD*8-H?L_$D[IW9#D@J_2&\<*MY%A)K=\)T6O7N.D3!Q?:.BD.I0":3 &7SKC
M59=[9$U\CD8"!/RFZV(0R3NLQ=D"D?F9* )D0>2,9R</V)]?),^29W4*@8KU
M'(4U!H@F)'O[6V0R#0JS+@[P>H"D?!I.]M*,>CX:.0QF5(*&;%)JI-)22,9X
M_#4T.L_ @R</&%S[^ 8Y5* 'O9"N.NM/Q5"]MU;QEKX:C5SNPFTC"54%D'W#
M\UC^CWF+:!9?M9N3\MD)N%1P"@Y$RX D%K0[*3]!S%'(=DCM6'%P.F;.'3+=
M(8CD\*)"VDNH"^S;@)N[.WT#T% TKQ^*N^*.;^R?4[NY](K8S2/9HN_AU6R)
MS_TZ9K!=3C,:]7+!EURX UD-CS3^:PD\4@C7WP4#OU"\[UG=VZ\?::3>UTR*
MFSV\(X5L_B_2?:($6YADC$XKG!0;AUU0G!]R<MAQ ?8GLTSHGBC5E @9Y#,Z
MU61*U(;B0/P;75.C/D8A@'>1/[)+^S^9CFU0&M4DPR-9T(O\)"Q4K %^;34>
M*YS@@$"5-PXY*5$<9!X_=XKW> QR5PC,[$/][T"QWN=^#>%&4,P32 WK1! @
MS_Q@[W+%/ST6ID?CXYV4_P&SY=H$J\1/AGM?LB9:^VW>"MQAM0G5*JNO<3?9
M9BA\[!@Z.=#4^.)\GL3L^MS$-I2N<E)^2!P::K=I%!&JR:85+S0V!/7608^&
MLHZ4-^326.8[Y.)>6*QA?7]X[4"X5>#ZL-BH(I,U%\) B,[@?/RRSDK5"LU)
M#CPXV74*W-'%^SECSQC[_.<D1GPZ+-79]I(L1I7Z0-,>Z33#$K2.IG)2&CTA
MXZZ=18HPH_O: 6XQME.ZX^Y&FU+# E&NFY61YB=;,<;'5Y9 #?54<S<<X=J\
M)PT@.LE7PQOZ6N>#(-I;2D;"Z,UU,>6QY)>(U*"S>,!\U\?S],?%3LK)9EM>
M:\P;OA;.IZEMS!P[>8WT\'GQY*!O_K9*N5K>PQ%_4A/I6C0KIMTKU(T"'!RL
MVOO"+)P'Y.BLI!-K LIBK-TAH62PV57I0-4DU-!&W'0+#$)E7$Y,#1YHS!7<
M@KN)?KY5B)HLCFR8'X#/'QP.C_>^Y [%W:5-JP0DLA%$0?1C@V(,YI.+WQ;(
M%">"O[F9D>BDD"5KD+'=4AI#N/7<ENA[RU8"H-%/UL8091:NGZ*V0,-&-%/0
M<_87TLJB=>N?R]\"_]?.K4:D]5E;BC,3LLD;KHU'D)@AJ8'7*NZS\(6_=7;"
M R05)48U.0G)KI[HL[I*;EF>.=YD\W("B/<Y2U"C(44YLY!]&YTAHB\U)M0@
M.'<?44UZ(1$A9$F(9B)YR9Y5QXKV:TME]DP/E"/Z (NRVUQE-O>7*C+O</DV
M?[@\,IN$&.."F]5!Q^YJYJ43L$/!2/JKB;K@0&B \.)Z:+!!,:W)E"/CJ,TC
MY.BDB26XR_TE2;>F@3:9@0/6]ZQ_,VB%4UP':]1:Z7"65%^)K5^+P:)"AL'5
MA^I>Y3[%A)QVN E;2V/<<C"A>/*^S+6E3@*>(]2J^5.<"(NCD; BDLT*4NF@
MN#X"%@N1D4T5\8.$&+^0<M#3%^; +VJ#TL@HPB@..9S;>SB!<X4+"]"4 >"%
MF4Y*7=+$;[)$!0L 5O#QFO]PT,2:2D_%)*RZ*.&KU)(O0E+AE.GI1?V+"BVF
M]Y/BBB!O+0W\0F"@G6+ETB#RP%I(.*XAOSH&QXDA?1D6")))97HD#).DRJG^
MVI309&MI"2PTJZ0:#>;FVHH_[14PW&*9)#B],ST^/2(J44^%T(%Z8O4UT$5O
M1 +SV43 Y2'9%UP']-/\T"U:4N(NM5JET+0F7@N)O<^E*A<\W1>NXDT<AA_4
MPNI>*6YS$"E1/G/6B*O"@%DK37-U;46]0__X1U[?<K5 $HJ%!S/4?+(^:\$U
M10LT;1))'MJ"E7^0W(=_#X32< #M8_N!I.)W"\6"[;%5*+,8[;1>(ZZU+Y 1
MB A:2J=-%B41] P^364&5T^GYG$%0^-J%9':J:&*'7;!]L$>]Q O!V^&G=;=
MU[S,SXLM;'15FW+M?^]FB-0Z =R+S.)MA!]G(C'\DX5,Z](]C3<Y7R/@K\I@
M\HLPM4(H\=  )E!2\>6OC+OV7L)\1J#.:NZ\#B7)\EN#1"/$4?/-'P0'% Y%
M4P]1EEO61B:Q1$)\'7$YHWHGR'.8@?3K]3H=HC$1;I*7 (_O^$RSK#<!]I\A
M_U90UK>4,+M8'SX(2=H%;AK1JU78"$C0!G^$>$(C-VF-5!%?-ZLUQ7A4&?Y"
MOP9Y0QW=+-3>X3-,DA-9S,?T_T@YN^\<+5@J/".T4.>QKA&%ND+X#9E6]U?_
MA\<:TN5_PS*^V @="W:=_8*<E-R3Q(-48A?C+OG$$-!5=O?%>15'(/QC!I[%
M-$<9XO?FFL),[8J>1Q@L;;0KJVI@03L_LSI4";FS><OZ:@/\_HW"^\C!YKH7
M)C*ORD&&F!Q,ZS@V'_T558P>/S]6?C$EN9QJAA@[),+1"Y='Q]:^)18B0IPF
MFG(<0SY,D[)8TP3/9)W141<*A'VL(SO6[#$3WJ\W*[QZUTD]!86> O*V 79C
M#S,&ZP)E"<TT$XY$/Q3N*)H^@KRT61V\$NR,?""3A QSKVU1^/6%57?>R@1B
MOAOX Y3T>-CUH^?JZ;CZNXBI!LR;5/"'!<=2'<;(_O1FYF!"63$)B>R.+(Q@
MYQM;R?":!VL!<N?A[?"O4"^[;LZ7 WB3N5E>6^UXQ1&7%O29"\=7H%=<"Q+#
M9\4R&;P9@\C_]3S/OC#\FN19[)&L"MBP1R[>;&U_E6I*L1:7^'?F">JSS_$$
M!U0&8<\DYVHMP@T0#39!+)-8.KF1?&/ R*\^-+.P(^BB>7[HWDL-18!1WOQZ
MI*Z'G0(#/44C$2EB5N_/VM[W=O^%B^Z*:;T M=6[.@FZF<4AJDQ%$P%5<6)I
M_(@!8+]L6QM??E*Z7!Z9G:PA0I)9536%U_&+T[VVK#3=6PY#N:V3:+L3*M<=
M<(QD_;-%9]T!&X[Q,(5PY"=8C&1-<G;-#2B)?89M"?NB5*'BJW1\VI0RCVSC
MY4WC_F><E$#CQNRQZ.;-CC0['$E[^5&@Q)'EKP>Y3+^W,-]HVGZWJ7F#0G:-
M>U\LV;3XC?(WV+/M&Z%&/NJ63Q>GI<S)"Q7)Z2_A/I%$.$ZP40%Q&0> \+Y"
MQ,^UD=\\,GH*RLGE<_TMY%ZAUGM4JXAM;IJ.P<(;94[*BR0NLJ8**LPBXXT,
MJG8=<VI(4$ZLMPL>&&9^0NR7:^H(6(A"WQUEMC//^ I'BQ$<P(7?2P?OLASN
M^ ;.K#H=I['6T@=)&I\V&NV_X4::7QUCO>((4"*;?TF13+_=XM- #A3M?0)5
MF=0*":XRGL',=HY8PB^ CO _X"\^6NJ)IMWX>TTB9T>:=4Z\PF%B >(R[$P:
MH$82E[6<$*7@W<Z;1X,VW#KKI,R+MH@ KV#+F7K1B7J&3B_[[T3"GF-P!\37
MQO;ZZ 'H*.IJ\[$H7B\)H7L^P1BGT[9] 8]VBR=A<569L'V$MY+L_HV1>"A;
MQZZ03G#<%G[OD2IK[Y7!A7\Z*4$EGJ:M_3Q)\'PX[NWR(;@R'O,)3A?9\3F'
MOUA %GO4D 6)Z^4".]8'O?$!0(,K2]E_H.,&2 2]TYJLI.;2H1=KUC/^C4+[
ML'?J6BW LN7"E3,9A7*-Y^KGO,[U_I&ON8*-=1K!%TZ*U*/E.*WOLU'_<ZL+
MF\WA2)J942.)ZJ_N#C4V6EH7?O:VKT6O4M]R_(P!,?]X)W)4,=@?ON+_&HRK
M1&=3V;R<O<WJTA/)9+)XDW"RW!H%\L=.BN%_W[@+2/3I[#DIH^D7TAAF*OHU
M-+$ ,,.?"_#(0;2Z,^OW H4,,?HVT:;M\6_II>203T/=B_;!I/'H4*(QX1EV
M2("?@@5FX:^]&[=Y/?6>NC%$+KXYU&+=LW6J?T_?7[(50X^2O7RH+=SZECX2
MF)1(@?KQ"'(.<>=Y9[ PYJ-AR"#(]T54O>)]D SYZ\ZDK6%A>O3Q:O)\PCEN
M'6[%J_'^X/>,;&581]1!$(*CK">*>1E)6B=%;1UH%@&"?D1L5%N$P"3]C!@.
M\&4MH_EW\\;67"[C[+_;,"'5"52F$/$">\&14=&!U5PK,*/*H<[DU0D;^H5(
M$<)B%4$MV2&QVBS(H3=C?-2"T0#TT%M-@IKCGLN,WTD%<7<;3$Y*)1C6_>2/
M) 6,+@?ZP6\IMU(\]FZ0JD.#]7+"K&(I^:'>$."H-@BMS<35]I5PU[81_3G>
M,A>M]L1+I_5H]@=VU>/,WU./]D_3?X[?NZ<QJU8CQ#<YRN;>B/M-;NM7SBCN
M)&FJ@'OQP):5%?<V8FZPA&_0H%:4+K;^@6ZJ%#DIJW:-$CVYD%*"Q>/07-AA
MX=_BO1;4!91('>E/!3/DD31[2IVK.!(=JMHE[6]"7@4S;<ATTO3:"49D+2:,
M5@TO*@U^\;EE]F$X.05.OF:;#$%#$&K'G9Y;H6MI35@@>%Y\)L.C>KKXJ<+P
M+7_ %/$2:H1&.8=M4"QM>CQ-S.K$0S2/+7K45Z6-'"F.1)-P.'ELVS7!_7\L
M>83J CQW4+B-VI$A#!1&DNUW%-@7,99F.)U1K."5B.5SMBY.\@V[!)BDS;4(
M/MZ5;#ILLRTNWIJGVZ!0ZLA,?1=0J$N0D7']!^ID)^40OA#U3:Y1F*S4A6R:
M<75?"W"KIB+\#Y0 #/H$1/)I/.Z"2NNYR:#HS)ZS:\.B_5 >4"J[!54(5)*]
M.)%R.?U5E!6^D,?/'_MJ*(U+G2K?:VS('P$R:^RVD9F+KP)QZ7><]W$_N%N_
M1:_I:]^  OOPGB]QCJ0.L11HM5*42RHJC%:(.@0???,#$&(F$'FEXO/M&S@_
MH25I*;?Q[]!7QA5/"B'C*)"J'Y)_*>W,G)[ DE52ZX/ I86#CGU&@H[DT>V.
M8U#N0B:/20(R= L7KR".@>AZQM<IQZ3X\I^QE1E)-OI,@^)L,)R2""NGIT7D
M*I;DGG(8\6M?"S_N4CP0G+_19% \3LH-HOV24$4"3<KO36.9R)1^I)3MPTU<
MC$_&2,QRZGVE]IJ3<@&.&+:8Q5H-M@[_CA#25QQV4MQY[Q\N4IWE,$+Z!3%I
M8]TAR\A5>^ W\:^9]7FC[FN8;;6-2&$ID%R_'&*='E[S;/.Q%M:4!;_@IE3I
MSF-,WHLBZ0!])><KHV<C?#N*IDVB9L 5$_1KY %'<A&VF9S%SQQ#3L$T &Z+
M][Y=NDI\VI?W.,W:6U@JH@_E2?N1>G@@CWP_&_/G/8,_,)\&4,#LY$&HXO9^
M MG7[^<+UZ?6N'VKHAGX-@?LSW*''W\''>1_@*]J-HA$5$I&T!A @O_UIV*8
M4 LGO858!Z2]R5XQ)QW5'14?Z=CRVV9F0XGBF2"A0Q&9$)*HLVU Q"^G./,S
MJ85O.LFS5E?U D%W%:W;O,#<D',+OFX1U7,8!D5TWI/212_JVU9/*$FO@F98
M2<+B TQ)4,*XV,IM= !3V>Q026O?X_D!UKXPS-N6/LEK.]VIH)1.2=7<2XII
M>M[S@,_*7GY"B*5F(HBWP#RG1.O_0P]YWG6P!(YH'T;(VVAG9PK+23D<NEYQ
M6$V>!7-4NEE MG&IHTC0/KH"YFUJQOPT:BF"H%SF7/:U-2V9EK#'\44QS-]8
MMW #_+AW>"5&ZX1^"6+B+4>+7*=&^(E9,#V$;9^;*[;!DQXP0Z-V3""W8'13
MW4XL[AX6G+$G";6Z:A]7BUU]"I9+3>N(XCF"P;*[3LHW#:[V>"K%] 2"<+S+
M;F3O"PGY$"\>HZ\@JGN)8R1Q?$Y@>''W-,-5$_C^3%@\79/'NG_@G=L]UBLU
M.GA<O/R:40L5CA;5$3FW[<>'P_-P#KRFY$*6V5MXC E]+OVOWZ5UFI=<D.R.
MUQ;AY*(Z,WP)^ECT5BES@ P.8801)5X@!XXR!GO?CU,;X0Y7Q<D9FVBJ$ UQ
M(WAAL/@]%%KLI%Q,"=.K*_C3\%8G9:%PL-35O^P[7N\2L2.L2S\;\ 'NSA.<
MAQ\(<_ KK8M&^:XMBR=3PC0#\*%S1H$)/8@4<W8X*7 4H>]VW .Z:Y:3TN)G
M($\/%]O^&XFE:<!D;\5O@:B7.RE_K7%2V$F8=Q"?/.ECB?(J^N:3:40I=[B[
M/GSV(I]!(PU+SO[35CU38?POS5 ;0.M>H<#A$E[R9<VU0T23DB>O$5<]P?U>
MD#LA47$8PTR[9P\FJG.D?XCL.L?2ZLQ9IHUD'@YY\DJ'Z#G+UZJM)OA&%%S!
M\WAHQH_F5KSILEZMPEV?>):[9R\E?W_R+<.KV?7IZ880@OR5@,$?>&+M9'QQ
MC_NZ9SQ_ZS6:4162HA^@'I/JF?@\Y*GD*(VZIG6U5Z,IP5(NU3S]7P@LK.%]
M\'91Z2%D*F:#0KU/([;C=H=4S<#GTY[V3<+S_<S?Q/<TW$H3W"L-XG=*%^#J
MKBM<5C7!<5)J54/CYX>FX!W#,XJU/_$FR&&9T@QT>[9%>'<][?2N4/:;GKEE
M"3_!8ZRTS&R=P*#6VSFLD6*QET9G(@3:?B5- %=YN[KD?*]N3L@M8R>X*^*;
ML)!:08S"GB9B2"I]>A_!=:/1<MZ1TMP5285V@1OYNM0G-RE?, ?W6>^D&+TQ
MIKSVCJO"JD$\SG\JQ \1A9QWL"C.Q_UTCZ-W"<&3H+CS-S7T.:VM&G(Q6=G*
MM#YZ*9P@;M&IG;>=%%%#(5$F:("[!=X*(9R%^8SZY7_2RB?G?9T(2\R(J^5(
ME9ALM-.!2?)WXY9B.NEXDJ9);DFS;+,TBI,0 W2:GP_-#F8;=CUUB#IIBR,/
M'"G<'R65UR3Y;:0-CKPC.&;3,H)_=-MTY-:RS:R@I >94"&2J+C NQ) 7.0-
ML>YZ7L:B,J)5(CJEK\;,..=)=5+R7]64=-TD_VK%?X(@1@JK&SD+2&<8/K:7
M$9,\(CCO6A?]G]'[9XL_$+1M&1_RT:H4416/"-OO^/O2AUR=R8SLX43'YJ7S
MVD(8;G4O1UM_DV\M)KWV0XQ[!$1CQ*(V"RT/6=@*&ZJC&XPT\-CLTN5(WQ32
M]P"NAY]400SC,[4^FAH<5)N3!H_V[!F(9"]QE5<TJE^FB<9F9M;-K5AO?-T]
M-\&U_XS&O*J_J)<.T+(<;KE[NR<+B,(T)^5=HZ73AK,L]P@J[@8R2)7AI(0W
MWS4(=;-&8\<8U"-[D$%K8SNMWB8R.Y@ZZ!%5+K?&H>-5\NB,))$#^B6)? D_
MMYP5:(78"1L978][A]_AWJ=Y'4[\K[]KYZ2 138>RSX2FDEUK"U*"(UP+0@4
M<CTUGL-.2G0;UP?(<>9\;J"VQ>&AD,_]Y55["\M!UD-]X#%:<Y?XUL]R57X_
MRP+_Z]B@(T5^\T^(;)7"E3W4@@"6F7\7=C6%%++XD"$Q7:<?2;I ?O20X/."
M-*PC*#):7'X'G2WR_%B%I3-4Y,K@GQBU6[(\@Z26+S(-U$?^,@47Z6AP)/0@
M#EZ=DS)?@%Y. 7)P*B<D6U65M??"LJCFX_;C#<3\J1^=E#N^FS?83&3]_IH-
M\1W-"6_\P]S]81$A8JG$=D_+\QYJ'@AP[NVW#;*D 5%D=ZV O*=&J5%\67D8
M<>5S<@&*_=]S^+!B%C[?:,-7-//Q%86(X>+DHAMIHK?OX["?Z0*0-<#12)NA
M,YP=(W-V6<^_#/ZF<A_Z*W%I[PM7>1\1K"E:BV\42K84]&O-[61[VP[$.@Z4
MM=C\83\=XO729Q22JX7GZ?,E2=C@,!L2 YX47@L&3NZ]<\0)<IG:QI()%NLL
M?N!ENP5 :KWQD>(C/U+;X)+V-J5X.?H; [W="H^%)[Z=X>HN5_2,%@']^6R*
M?3GOV31^Z?TF,Q;6N%VYQ%5G--OGT_V'FU-9;W;UK'1L,T(/^.<4AI\*'WD$
M]MY%MQF$>XWUXLC(GH/2VFS@&2MXASD13DK.&>CH^:QAU58T;129@WIU*$FZ
M$)KPE>(8[(\;PJT"?[+DH2,=7V<FTP)+7%6,6 RA73QZ1K\O<1$CC?7",\F:
MZ]VK\-=3\Q6&79 \;ZS*^GN0\"E(L<@CMKRSF_T (;VU:5B+V<-KC<PSY4WT
M3XS,_( 6P-8BU>D  :\U&77,)>YID13O$G=%G K?#'S=A:SXK4NJ@!5Y%0H4
M,:"Q4S*;(QL0_+HHVN ]]2J;T+3(>OUMH65ZG58[08JQ\#Q'H QZSA-;[Q!U
MN JW(@&"2^DIY,\]@DA( GS85NN<P!$QW^+#:BR9Q]V@TC8U@%&_4J,BNA4J
MG.>D$)>=E!$^5*_7[;B]-YJ5<539P9I=2W4PSP(9-<:^L$G-%]%+JOUL<'CV
M<>P!5C.Q0-K_N56FR)E$A(_P6T5+ZGVS9![S_^_ARZDLV>"@JV87XR^$!?W
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M:L*851&*OUI-KC[JCQ"'XJ_F*$_9ZZ]N/\P/A _F7(-?PK2MB"5]E@Q*QV?
M.IR5;D-,7I+8OOK_]#SH7[1H4;1#+)'BY&Y86[3[6H$D$XK3H[Q,%8[M*EU/
MBAOL87@6+?H)1EYV*_AMOR9P35D5MD> 26Q(I_D.?-?0'1G6KC#,@1N30Q1
MY_W]NFB9O=R4MJ_&2;EG1K1.BAFR?^"D0 ;ZH^.B7#;5O]=5O/QKC(D[2!Y9
M2IS:VPY2M'"?@TJLVZ/_V4GI(WNL @5\G8^(]Z]%,VIJI%5L>R8<%9Q^94]&
M8;:FW_%68+\Z/R/Q2.T=[Y=>DIY3"!GA"1%17''#J=)B)V6MT.W(_MS&,8^=
M&O*KS=DLM&B0I!4$[<PX/J721G_LF4*.:1C30"DQ_\3:+Q,\^'$=] XY%]^&
MWAKSS18IYK:N&QLZJ AG#P3,26)$=I^>.N'=N^<XT!TW5\C:W+GQH;.G:L\K
M(@!,76S?5RV-[-%/B%TD6PR4:9YN%L:<G71&4+](1G^/0WM(BE^NCZ)UP<;5
M1@\U&(<W3-L*S(?\$ZY3:$/_*:]"U0Z.S*%VPI/(]_V<?=DQ(,NCLK\ELLA-
MYHT]7&@Y'Q8JU(WG$C]/E<=:E^W;=$:^6%10_BYO93\CLOHA,GZE>72SZT/A
M?CPV0'PO2^@MK9 UCK[&[LS\U^5XF7A::@[&NJ(_7NI9EG_'5X?T(4HQ8M='
M^QKK1I%<TC>#UN78C2]T7.Z]-=H3JD78.A(65C&V&JOTGR<-DG$; 08^XM*K
M#,J*%"M N)M^AO,?C1S7\,=9Q1/UXY',"@L^Z%#,6;,M<GP: DKG!&3\0C,,
MH=MJ7"M '>0*X)\"Y="XB4&&"87J(LS["\+\H]T_Q2H\P&54H:7MEXU(USTK
M UCZL7/'%4W\(/BO:W.!'MR*!78*IEU-(Y^VQ[E8GU<"IG>VQ!Q2'=8ZG?A
M@=II1 P0E)<$WQON/)W6$!$P$,ET=$6.3L3J:\T)!PQ3"C+S^X0OV\H[:$8C
M&-R8$IJ3$B?\8Q2R+W4MHH.?_/\(;S<( %[8&X!P+6P-7 \9Q)ZK2VD/B.L:
M;*FKLISB9S7K;S?YY]MYJ=!A\0;Z-:K0\H9I ;GM!JCZV484N,38)>1E_$*G
MS>VEU+%HU!N[;>?%&_FGG10]XY5E.NY&8*/C6('4\/<:>+RS':K:B,.K^USU
MDPIE2?JZA)1C7-<^W6M[PO"&?SK;;^W+#?NM7Y6]4(4\SV).54UHTMXBZ],%
M==NW,&35UGBSDW*J>C19(F&)$^'50)$IW)ZYTV<;A&"0OIP ;UV)\(CL.*1+
M;TUV4BZ5$T6P]C8:":3C&"+S?@Q/KT)CR:XV,#WA<<C55@8(9Z1'</=' >9J
M'=T4N'T?L Y((L,C* L6',4K7(LNWP#T?43<V=Z98U#NP/Y3YZJ&LR7D%*_J
M*.UM&,&E3OB(6[FC5/<,36>IKT%XUARR^0G=H_]326[5C:,_^G:53"4+Z/Z_
M#+D9/\"5?LU/*ALC-&_T#AKCM'S<X8^'F+,?S\VWSDJM"<580 ^H]\ # X[8
MCWF;; '=;YV4I-;?G90_V)RL29&D*CK/B*]CZ6*I^/RSUOFO%<8SBIDDP(:/
M:H)^]1\NOT3.JL-F+@1OO@-=)R%/+6/L(E]Q,67P_@Z"6;#G/K-/'MDDLGP]
M[$@?S-*S26_T]^A0>!UAO0PGF%^T6!S&YX+Q4OK/1*'E/+,37AZ\+G-]H'68
MQY-2ZH-5/[]4J27"1IKV/F((AP=\9I#K0D>0C],,YX$,&;RUBYSU G,_PBP(
M=*1KZPP_]4[_]U\'.D=]OKJ\)6CF,XN^"#TF^K<Q/5'#Q=[J*S#/&FA(-@2-
MP!?Q",ZJ_D^D-0E5=_.^;:K'/J--SY0BS^VJ*CO!UI8$[I5,2$CY^12MXM#_
M/W2^H8V$5,(*.+I?44<#<'O]"'/V#7R5X= OVJ&S7%_F-3YSX]L,M6[_!AJ%
M-SLL?FE5I]_[JXE+?_3Y$O2K0HC\GL>:2"5B["#?_/$)>.2&K-!*[1+F.(0#
M 3U;5;K_<1MZI21(G"]$51%#[,FD4[R5=T'8GLQ:-GM.2G@#L.L,+'XP36_N
MK=+85:5-.F(4%5BW$D6MN[+CH=.\V1G4/06O::OTZU./\Y=@#]-H5]9KX$&6
M]7C]?2P >>RDO-LY\[7]2,5_@"!49!+L+I'9[M:_:HB$\(OXA0QO4<&BYE,G
M@^[(1%8QCN^3N7J";!3^R4)7>^/S16/I3V<%\&6,T1N/4$&'59#4#]_3S84
M<U--,J3O7U)K*KHLZ=/%O$497[S/IYSWI=+.+EU#GX$OO;3]5:H498]ZW6MY
M]_7^$B_JZIWO8-W\Q"?,QLLM?@]'GC@INK^=E ^A.>CUCED!.4K"YP YT.2D
M%(JU!QD<U4:H<DZJ3/086K O8ZY41"[#MM2/GM]%^&CA0S0);AQ&!C_5D[-$
MV*RAUT=_>TW^I9@Y\1MLZ27G/?"*$&1??)L5V_^@%<)FDD]EJ5FY_$-8(.>S
M!DFP IWF=RZ\/M?5V@FJX5*M)W]#H\^VZ'@3M!W7G911OC&B>$<Q>:HM42X&
MI!08P@6JL?TH'E2H]VV]DM:=] #N5EG7VK14Z32.R!(Q<E8W-CM*I8/NBQ\/
MWN,CHY&QTAE81S7<^0!@(^Q/AF\>:23G;6B_2MKLRU-K_A/WZI8B72AF7!G>
ME<N%9I/QZ! >B#Y6 G2DKS/8GK!R TE?0^$%CA_01\TDOSQ9 \1R2%@%-\^X
MF?P #-%['Z+U5D#&"WC/!1_1'R>3/Z<D 4>4J ZMJA(J+4MF(J\<?BB0N=I/
M?<M$VEL&MI,RRR?BM>.EB)Q5A<VXM-9)R8U _<[%DU\MVX$7W6Y/S^<5-B8V
M$!%4[?; 0S;X$9$*/4UZ(I@7G#)675VRJXNW&OVY1F$DKPJ'V%5NDB8WB*P-
M/]@IA"MX#H_0G4V-NLSR+ M E;<.)A84!L).1N1P0)PLKC#$-^)_[4&&(=UN
MX&5_8?,>0X<!H+L+#*QD$60X+<N"V\Z(L0CV#6&<F5L_]?.;*PG:%K*-;X2#
M'@-%F1(_]F4B8#ALF91ODE\XR@Z)):]H!*B712T2FB:SI-A&*NI-U:Y,\#I-
M_H7,;$6FX(Y51QK+0OQUWX$9E4-W6<12_F,^OC(!0F]/DO*N]'49J;4MK,9M
M3DKZGP!UOZG_#P>Q!*E60-,SI];A3>2#NM#:?9-6V8UAFO%0?4.8(T&5!]2[
M1>7!)J[ZPB-@\.^>B%]A_0X-N":P_U[CNNY!(@?05*2<JL6$@]6C[M:]XL$;
MAN-78O'6>_@_=\4_?&;YV@9((HIJO&7TRJ] X6T&7C70)'.VDB;2>R,)=- 5
M>H:3$@S[LVIH][P[$"!V*IM&Q;\H[H<]^K"*/<=)6:%ZT@-O >C$9-FI&?!%
M27O6W"RIXS 8A##MNI2#W<G8Y_CRRU\GTCKVQ%MZV5)\-K89GX/Z)4*CNSD^
M!M8).S2]9K*AGRX8VG-[7TV<+7N0].3%!1A2"PKDX>LUDBD(L-S@(O)])\40
M-C+GCN=:5 +#1O98FZLD8G<WRTXY"I%E)R(VFX72F@WBK<]3L=G4#]2LP68(
MMP].XO Q&MG&'0B&KGL<H&F[MQ,GX.Y/S.3N6[0\\_9'R&!!<?*US/^9>X->
M2D7?5 ]J!0K3=/SUFSZ^67[/,FG_&L[L3Q[*!/%+EK; C'&^8>*3EY4YY#[W
M>(V>=<-&I[U8"=&O'GY]X=Y<)=1[ZT!&6"<]7(Q_;=;C;JP=I+<IX)GE?$EI
M [Z?U3.QGO>3W3#,<R29$T/(4H6JAJ,P2KZ^:V2>Q&.NAUM+MLJ[E@;BF:I&
M'J]4L)\0\COH2[#MB'&%!%%B;<T"^ZG/R,HFC$5!_SLU)=?1E_55@K'/P*R/
M'!C&7,4)S?8FV 1'_$<GD[UM?[\\HMMAGX0_A>H49RHE"4GX.[=#R9)1DW7V
M=IE)>LY)$8@"K.O],V7<!_VTPZYS=O?!OTD]0NI8B Q^Q,K94)C54)%@D'9\
MJWCF5=;^-L3K'9_DUTK:K[6/Z;/QU4]8QB_0]!-? \J(+B??VV-<.)2N'F0U
MO3I]1]?(Z%5,(, <E-:X[2Q8)O0BE_'K#D0E9RJF2>3-L2]C3LW)<WS5TRB[
M)Q#69E%->E9[ ?P^?;$=F5XYZ4'%F_BAI+31_JQFMN"48*Z1AN]P>"]:0IO,
MJ86&:WY$!=5CE[<%)B1(VPNSCF4*XTWX59*%&%A^L_<>H7ER/,9NQD@#EA&\
M :*]5[S%]0E^(\E3>4X@LV)>MEYQ]7>KY9:3CX8"W)6X90$I;@\B?H?B%*?3
MIQO/DQ_@D#%T]D+5WN<)M0Y/.BKT8J'>3.WZ++(;=FL!WN<66YZ$14\@D7]R
M&%WC>P]M71R_ZC"2OU\1V%Z:]S3NRNK=\N;[;<@N//.35W&2-*IYSOQOF["O
MA'CK?G:K)Y)G4N]I];G#ZAGS 6BHC?K?#^:Z>OT 4#!V)C8+[FR%#](<&Z"3
M"C2\RTD1'0$&Y%T;D5_S$5%LC4-W4/]V>S;Z9]Y[*4Y*"#7+\4J9N&H0CH?P
M#VCX15'^:*O?JT19?_<VB]UW<[ES\/\!4$L#!!0    ( ,P^?E8C6#J-4+$
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MD*%("U0;PPS' PL^S^FCA;O''6F<NI:72](<I95 P:BWY@M=T#4X_RK+M5^
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M@DY(_QN:9W([[3#]N3HMN7+10?9#T[[R$MGW=G*3,_^!_'W2G*-@YR)F/GY
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M2J7X52LC2->*SC[7"_[PQ2[EF '!'FRB^_9YM%1]AVKACF]&1)Y$M(KATVF
M@I]G_-7Q4HZ@8?S<0J_9UE_ K7RA(1T33-RSBZKIIR=@3NH>$'C_/J@L2)/6
MA1T))3E7.L1YYM$$TS+]AB*D1D'3,^G"**B&V)@@W4'"4LB#H'.DIOKSR&_/
M@>.!):'M-M%U .S.F$U;AQU!-7?1K."99F !:PU".H*3V+L),F 37:=R?LV%
MJSI!QT(A?P$Q%3OU%K/0!!-SZ7,/GN9WF('VSAPAU<CQ?V?*<*^!N'O]CP2'
M13GYF,[?@/OID?J]O[J^LCI.*8PJN$(%^U0^NQ^]BV!0!B/=VWR7;%#=SMT8
M#\:-#7IOMG\Y%:I=$[!?S'+)ZSE\$ ZJ"26QQ"$0'.16QD8,>^AST(#E-&OQ
MB0R"QFE(+ Q5XC2^[%T4#U(G*QU@^A,>8W,*(M?D,[F]<+4[D8NP.% S,37.
M'<N8+DM?G&VB=VYBLPURS%G+?P6JOS,#ESE.FNMFH'9Z^7Y98DA,OU)UH.V\
ML7Z)?\P%T2[:35EA%+X\HSY#.HS%\F%8F7+Z=2T7IY>6VFFO$=06O2)\QR?&
M0]?:E6.,-Z*7;!=BVH>P0(WL('KA(79<LI8%1I/2^^ZACN[3-[P$^@OR:_Q1
M=K"R$22FBWHI))8S&>BF.MH:+]VKE)#UP;'=P7N]=K>NBZ:.Z1?+[3V%"GXJ
MQ>@^PNUT176>RN9PW<BV%5GT5,D$C,IY?Y71D)T*9*< Z8D641*S PL*2RM)
M&56%\>2E-;!Z2ZQH)B%R@-1@/#60V<>\:@:6L([@19JE=;<YPCZF$4B*D(EI
M[SZ2"5GE8 9."2PPES::)1I;5[E44YJP9J*83 >K^791\<0WB+6.9YP1XP 9
M<6?CB?13X=)ND"97.<A2D $X\]<XUR#B&L$CKF>Y17WE(<H%&QY4Y7O?UGV0
MDC#;FU76$>/R&KN-WX1.2A,91=(J))D N:_@3L8\SF=1X9V=Z*/.,8VOSTNC
M;/&X\JIA9C\=FPN3E$O-[(NL$5B2VWD/);2O&.I;V 'T<: 9F"N8TW':'NES
M&/9&^/-Q2N.#1=^MPQ-ZWQ^=%2#6--$5RL:%"[31D8ZJ<3O>2S/ ';M#H:*1
M?17!530K-1R_X5B,K#:-MNAM. X>TE@+O0IS[ML0W*38]+&;=T>)QJDTL0TD
MZTV!!;D&Y6;#0")4^7O$F-!@!CSL#J4S78B#9H!/E-)C@+?_3>1/NAM!%^CF
M4XRB[[?IK1S'%$38X?6-LF:"+SOZ+,FK,%]W9#T)*(I'B^$?BW6@ &TEY8J2
M%*-Y71+)V ;K<_"/)TYY?U8\,C^WMY%6])%$N]%5T7,-%;"(091*LHK=_[Y1
MM 6AUQAG%!T#.]K]WYKN$M\>&X=C27J<_WB[%ZFT5N"Q["]Z]O7P[Y ,\/$6
MEP?'H1L068D'OAEY89(:KM_CCC/DBT8^T7)3.[--GN,XC*8C6P)TAZ%ZU&5T
M9N7("/SQP,2MR56C+)%62M;%3]!M6W8N<3!"/S:.0^!IZLT_4S.OO,"G3O=4
M7.C"KM+R? W0%&)S9#<^@M60,)J%2*2YN7#N*'?\*U@D1$D0L>I=C<]C'^"-
M<DB,N?8?LZ10MRDVTOB,7+M>.?0F!>PAS:!SI&F2]HYX1(:OKHO\\[<GVSY_
MNP)9@2Q?%&_+OBM*'(=.ZSYYR$OMB6+.(GUTG>A(O(L\"?[RW5_.?TZZNNK.
M?XW5Y3A"47YM=7L>_^<3*/P=#XZAMK/AO<2&?='^^T7MKO* DA@3!Y3G^-VB
M#IJ!, B+U9>J6F-D9B#?VW/9 CA,GS023\N$:5GO9M4TI8JTCT-2A H<%FT7
M<E]S"<[:4(GJ;B9GD8ZHU&E=5$=(83('YQ%S3IN!>00UJE+ZK5I7D8V4B*>;
M@:N)=5YQBNPH>/NR3+X062%S>JS%X%Z++BP2[5 7Z6/1Z'YF(K2 M=GJ<KEK
MK^G8-X,]0Y&,$R;_J7#_/HMZI\PY6<0[;""(8XN3.]M;#L]>R]JLH1"VC(NP
M>B<X4[D1;">FM:PU T^P;9HBT[(!,U"]^3>X?RO=T?OYRT53:+:<)O#I.+8@
M7K;KFFDWIW/V$#@-/LZ82>[Q&:()+.)B%\NW]1?=U9"9GY;\PIH2-Q6FID#W
M82LTH*;'2MUSK8\^8S =YI9ONG.8%#2#G;1K(1,]56? #P#<XB_NVK9XV,<N
M.&?*6P2AOY+*!\(R2VO !,Y\=$<OTP;S1"/Z"C9M5KO'C^VYBX;5=$ZYTS*&
M/ H7V9T=KY=G"[Y+: )=ZA/ (@XD,<1$/#@I<VHT0:6"CUL]Y-J\W<2(SJC'
M(!R^'/TL:<'"V43QGI5MR(Q*7(5DOPU= [WC[,_9,O^A^+ASP]\WGR09+#\3
MC#E+;6]3-X=ROG1- KQ2*K,ZZF*2H]WKMF%\+O%9.G,L#"<5!W@[].481!>I
M"^,HEYXE]HD2)CM"FI4BNH^27T-#!'\:BF*(NUAP(V>6\ .V3@V/<)JAQQ=$
M)W^.DB.@8)'@^[\[]* ;YW51M+0(B:.DZIEH:KA0+CI)]V9[^3633A6.&X>)
MH\;8@!)XK1N#^C]Z4Q8?HR,ED$[Q=VO*B12)7]M/^?;M)UZ@882L:H9W4(E/
M:>/HBPB9MU?X@\JVK+NC),EHG@P%T*2W2&A/D ID^ &!@9"2-<?_?G0W*8>9
M'%0H$2Q62.=99/3_"^[WS=]"<H0%S^3&@0"EN"(,M.GC$G.ZF._?4\0D9:$5
M-Z-YQ)879L"HAIJ>CW ?D>5D6D7I;7<C73LF-\IT'G=L$D8]\_L60D$+I('%
MC1(6&W+9Y9VG/=)OA<W3]D()Q:)%45]UD=P W5;N?>(^+'R5!#\9V0!X!=+>
MF^SF]" [BF<>^NY\.U?E(1L304=38L+\E_8S.R1]+E=M]Y4A)$0CI:<SCYUF
MM->8]LGMY(NQ"K>NK"6H%6/_RLJ0TS$&GY?YWT<-O-][Y+"^[(4D]M!@<8E0
M6]4+H6M\:W<@2><&.1O%8Q5N?2-Z$<8YQ%<=\S-!]Z*(+%1 ^M6*K'7;*J=%
M_27S5TL3^C0[FQZ#W W6,6VC\AJN:15^+MH3T'8]%GRF]L/F:'O=+Q)K?30)
M"XFN-GG;%KPXZT$P<7%3BI7W,Q _C2\K(AGU*VLO D1],/?<HT/GIU:/#)^_
M)QP%./;.MXZ[KE_29NS6*04'V"OAE+Y.],CQN64'WJYY]\*YP$_^GHA& AFH
MLT2UM'\GI/]5X\<;$TQ_SW)7+\0^7^(>SPHER]PR ;H=^NC?O M:,LBR-P-3
MPE&EQE+_$[I'LY?^2-U]HY#F"%?/T?2/J!BC3J>P /]%>I"K9!1Z<3%;H3XV
MHS=9,CQ.[B*''Z*6[M. V$I_1^)-,<GO[E7T7\B*DF?EKL MFEAAM9!ZFZ C
MG5CC4\.95_),3;^ ??WE&M:/??BRWJ@\^R)1Z7<RM;SGB,L6 YCE<**7WM4@
M<ZGE7T2>6B57V@<=9B0R"?MC;.Z.<CENFP0SYV3.$?E<PPZ^GLP)P$A9<_$]
MT<I?2O7-CUI8$P-=P#;D8133U H-Z/?.*VJ<[MF4UM<GS@I3CC7"WQ!6^)7*
MF:SE*"QC6F!>%TD8.\Q,P3Q8FTC]GRM?O AS2T79.UG%#_ZA+C_PG%ZVG5^R
M,ON/X$[&+V:@)((_^Y09&%PBN)H"?5Q#P,9V>ZO!TBKX"J@NIBV-@H3C-Z#V
M--JRM_GDRA[7!^AW5>:FE,]2N\:Y7E#MJ3<AN3YD'@X1T?W/F#-0O^WJ0E[?
M".44--A)N4R2_T>'NPC.;:Z_ZWN=LCVZ9:'VQ)MF&;]P$^@O;8I;?^J_M<@F
MQFKDVLA$5_IAW3P+QFNRVAK?G;RZRB+#Z@$.5?\QZDWJ%:+XX!_7TWX<=QF=
M]%\G[_WW[_<[3$V('.P;:<O?\_44O_]\1]R,51/C(7&&AI">6"*?5#>?T<B5
MZ"#9 ><[,\S J 0S S&W9OU\1]Y*<D:2&M J0#.P!A:-W__G'H/$8[JI6Q/H
M(8\42^TU1EU_?EMD)R:I]8Y;[$T4_Q14CC EF(D#;0<R9^TCM=T#B*?=D/%Y
MCV@CT[G+<P@8EV%XT%J7Y=-.9A#>9>R['O8&/21/I^.W-QHCQY#!R7MZ=KAW
M+C<#>\/.^MY;JW95BDL%WI</:,OY[[MK0O49%XA4/35R,,J8PO7.6XC/'>VO
M'@6?1A_^Z6L9 4&SC%I%(^<,7.4#]>;"%/@$/+WNCZ 8MK".V4FIZSW(6H]N
M[M.: =L0^IXV-S+,#>\2O"S$3IY6<8!3!B6]SQG).Q;&""X,,2K9V$7A'T0W
M7!I9Q6QWZWN@<>+I' NBY$=D?;G5&;$"]#X6W1\6GW/*<?&R\_+%RW#Z@'0X
MT62-<<C@3<+VJ\=5)"V8LJXEPIY2K8]D=$$69.29&D:I[GW6U#GX!4%4XG8@
MKMW3$DWI+9]Z8A!Y),5L??I=7KE<O<%7[P;1+WYL%*40FX*C-+[5@HM^=WC6
MV#PQZGQO;=S6I4>%V1[4V:Y7B2MK:"3)Y ?#J&[4T\BC,PIC)$7B75TCXQPK
MSX0L\,D3<<%3^Z]>MBLVGN>?*'[4\KHE_\LQ+,"T+B#.)C9@T/EA0M,<^])/
M')&>-=O#OBPP5]8UFKO_%Z255V.X^M+R[P!L_?=G9?+W;&Z>MV=+6%P]3<9V
M_HOFQ)'WY?[B74#!..&J03:2Q0Y^-V!*'A-\@3[@HWZ<Y?@X5E5,\8]EPP)8
M\+55%;9375,UVMBU=3*!-%AAOMO_4Q_?P!:;@=\8?;#)DC< &W5#^RRT5L.\
M%<U$DQFP)L24CGM$'2CWL'<>U,@Y\GHL)E:&$?NUS.$;*Q/U;+55UTI2L'U)
M!GO]L'>4X!;"I/_">$KN!0;="T**KB>D_>'#/,XL]Y7Q%\#947X[R>EN/I8]
M<G@?X7&'\O8!DR8*D^\D"[N[U?#&D@!L3)!%HW'>'G8:5N2B,69@?TNQ-9.8
MF_S#8%O)>58&)!8;M,T2>21F"^N?XO<XU&!W8JF&R%.;@7Y> G4-<4'F\HL#
MF0-IT#S0$,?/?3 0+MI@A$Q;HA:,]$/Q3,R=Q(@CRL-5):;)?FFP=AJ5_R8%
MGLM>95E%K(.KOJ;.5',VF6[[;6[=X.W0L%4\\HFU.:@IK5X^>=136&(5>@0L
M0E1O>T6=/KO%X8+)"K\%$O<%B.)\9#Q!;?(B^+FAC!6#L)H.73E_F#WQ&20\
M=@>ITUA[X!,1^<G^V,<WI\@ +5 HA8=',&<S,-D,:$IK*"DT!_2:6E@7P[G2
M]S;"#,QWX@[C1.5->6[A5VY?@[D]KK\MM;8Z]ORF!D_6'PWH,MB.[",<:CY&
M^7>-=V_&W48P;M\>5+O3Q.#JKMQY,?IAP5W5LACX:VAYRKK38$(4KWI!,S_W
M(R K-8Q\[< =,+B2"D&;A>3LS6A*+19^2(%<7N6=OM:(9U";:_09&><X#4H<
M$FXP,&04'ES:=$T#'GRDEE<UNGRO9C]'3&L^"+UMV&6SHW1W**T=V?A[6N0.
MF,,G"J6\^P]/BAIJ.TIE!*WRK1E8"],_2 I@EXFVZ,4L3CMG%7[?!9M)J7Z1
MR+?%\W:_I7,;2[&]_"QV&!%#9 :!2\S V5@INBT;?:"&JCG3U1MS^[Q/=M;4
M+ME@!O3W\B9TY2Q*@#+^VJ_3@+C@YSW=&PED=[9/NT%Z]T6WM$ D3G:I77+@
MT;@TX-WZG=N%.\P 3S#\(A]/DCEZR'2.)=%Y>Z-2ORUZ4H*\8XZ-/2HGC^_<
MJ_(9=L_*Y&L5#"'T$IQ!=#*FPX%P9Z#^4IL.N;)1JLZ*:JASL$9#R4CS,@/8
MBIAQO?"H&6BEI!HEWKUF(!%^FE5A6HTN <%&C4\5M @B%_J+M,M+5 W//JR4
M=E8ZB\EJY3\VP1T51UTBA\S .J@H8Z?/]O2>CW*3'[TUG(4+5 L7,C1RG<R;
M<L8!GG&7I/A3K^0&G9=HH[AT0O1N+=2_\T&&8&SM[:^VV7\US2[03B/JHP^'
M:A;62>?2IA-M/>LT!8(DEG.?K)<_%LS^7K*7>"=V4>\*S]<M!EAW,J^]ZJ[E
M;/71--3Y4]4@]YX9N)3:_XH%YDO;659M4#\[)\A_-7JA^11M.08[C%G@^<DG
MJT?V+6$GO+A[)6ZA^\:3@];[D@+BIK^46>72MRL"DD@2_%C)(Q[+W@]H#'X:
MK6DFJ96?,J] P?3+H/IF5)IP29J*8@8VR&N,+R5/!9:#M(7D&?-&Q*7H#**B
M+WTQTOH&\@_C'8=P_U:+YCU;Y@'_M^- 2)_A\7K:#Y <T]DC,_U_,@,U.E'_
MZ4OBR?B;]R8.0A<KCK8G=NU4$<<=#6[>CT?9L>>L#'+O(>$BDJ3PQ: <4]V'
M/_ P*V/;A@\#C\Q  ],4J6PW [M"49,?[^9'L!UE"$X>"6)42I/'O*P/W5MQ
M)D/[B:X@?.WV06>TE6**; 1E;XW1*1D9Q J\".JCH-D33P\<5G<C^KJ*PNR(
MX,!H,J5MCS12<3@;R^N37I6JCR$)?(I.:HMYJ:V&59HT&5@'S^RVMQN<$'"Y
M^.^;[=%>F[N9\DH/P6^O/<S ER(M[_Z)IY%%C$V<V%-6(W\M;:@\D2XE:%=T
MLL)0W$NF//!3>?JB3RR9/CB8P^F*5A"<6ZH>)%V$DMH/76.EFO9K)VL!S@OG
M72K;>I\F#NZG7!E0^)4<CPU<+!?L;8J:=*-!;T/FZ"M.<YID+M',+[$OK6'.
ME"8=BV*^1%^.V7LCU<A>_?2SO4\1W>,FCA'-D FK1)/;I5*TII]7DVP[#(X:
MHOMW3@O0O9:)^?XZ@T@33\R,)4$.1T/L\23(]A,5SC^4='30P>H1\<[[A7R1
MAUT -4+%\)SXI$@\"PX\R+3)TTCZ>76,Y/3K=9*N3T@)]<>'UB[B;!S"]QN7
MJE.)Z:FFZ:R%#+146I06IV+VOMK@O9?N55AP_EQ8:OYO$/U,9OS1Q5?-P(^_
M'1DMSLU!UMV5R(U@AO\ZTK94);R49H<&R."7!<ZUE=,?M6"^^IGTZ>@3B<G9
M%$LUP30WQA',$D\FID6-]^MYIC-11)-,R%_ZB>I!JX_L;PH7S!BR!$==*,JL
M=^.<YR9O[/-WPV/=<YD &F9R)+&&7BQ>5KS@L-^>)-5+XNC/YSP+R9ATL&S&
MW(-"0G*"X)./2D'-8&@K'III*U4K&:*;K/C$5:$\R?,<_/<//0?0BC.1+PZI
M2@>;6C9Y_IG2U23$O0-;8?Z'GA+'2]\\XX(\PX2DS#K0Y!4K%X ),1$C!YR-
M*Z_COV\:+3!UG#U7(<W#.OP9.B<-\5,.[Y-+"W_+J67_T?JR^(W]RNAWB[7W
MJB.)8[6'R"2XXBGT]V5(<@WREL_-P/<P^#&XD?@"=.HC#[U9A^<2*Z2OU;!=
MH"1S]Q1&/#2Z8T(G' _%2#7N7^%43R/KN6 -2M*Z%4554KT-0^Y?^C7H3+RN
M# >+1#5:]XZZQCJ!G*\FD&36CR0UB]<XU0ILB(:8ZBC+EVW2V5]&[! \(NO3
M>)K/]I81"Q%VN9CID](=JF2$$/5A6]Q?@ES;:,9H;^APM%RA[.)55_J1&UEX
M2I\N'-ZF87R;\<JRRG'?<_$OFBD?=Z7]]'-85VXWK=SN*F"0$=.R PMZ6#,K
M)86LA;U,[@);:>*Q@&K.M!=$J^7!$3ROQJZ7<$RZP"C9>.X6""D6"$N]339P
M#;\-F8/T<MO\-L)%#H]/1!>B8"T_4)-F7".O,9&0;.MBY)UN]_8VA@X%C\]L
M2IB]7(NHW7*':+>?W9G^O61.[4D/^UVPB"KO\L@9Q2K)"J]F$^4$GS_ ?M*T
MF!J_3OO(F^0V:S'=P[<]1_PI[\W GR>5[X_;(/2S/=5QJU ^\?7A$3R&/Q#,
M5R_=X7Z9I#,D$W2(IX9_+)UH^"ZSCB0J*-I\D%L$U[F$C,EY<IU^GD5[M-O.
M65"EGI0C//E(BNO>G4SYEK!9TE'UIE@V)%(F;H(B)9@<8Y?M&8@E$/PT,*IR
MZ976'+,Z0I:!O&_5C(0QZ9P L$MO=,=VANF&HH4>X\+Y[V]O;!G==/.G5SDA
M8=<BF*%#L$OA)OV&QT21%,I% S#Y^@#B)F?B<A__5$NYI4>B._WY\B-'\3()
M/@_^@[\GY=+/TV19Y]8Y@_O0Z%YX[ND%2\9_P=SN*F,^W;H0E-=SJD:5Q_ND
MX>^R"4V:%<;_9A>?A^[S_Z?G>L?F>_H4E#D<<SE-__FE TL*'I2\^U*E\C4>
M]WXFW!6/I7\XCD+J,A%=''Z0:M&W*<39I\S$20O$DW-D.UL]'?=9>EC=P<HT
MO.^X*JH!9^/>"$/8^?24I2@$L^I%=5S-?G["V Z*;8,9<&U@+V*_R/5W%3V'
M]ASCI9G>&&ITI#/Y\%GGK?]3+OZ/\9 (A[1=9L !ZO.]3<'T9D#(0W=/N;H:
MZ50A\G)XO/F>;_0\Y)Q<*21)M_?@I.[YMU?PM<)A,W#-'O< Y<B\Z#1^ST52
ME>9+O](VB(S0F$Z1&8M[#YTX=XV5NITJI=-KC++<[?))'_Q^VW73H8+4:@0[
M^MZVZ'D,EDPAFKCLP\60/,GMI%R2^UQDD%,E7\^C=0QTOF]</T%$<EE)8R!W
MP&K^-\%7LD=9[;[7]0P#:Q!* P=,FPZUK1=8*\3!G!6(>*S1?4?Q0K_#.1^:
M'[<,OPJ5:NM5752_WES59C)Y_WST0G-=]!)$G4;B-E Z?61U0HS$O)(O57 _
MMSG"Q@K;YU7:I^SD/@(%4I+(G:)<0HH$%W64)=A/FJ8KO7Q*T 'DM!4YX2;[
MO0>'IZ;V8<G"96/4< \G)_7"6K[Z>Z@K@YCA)#L"<V'U3I=+I;3IZ+$<I2-=
M(U=-UWS5KHA$.FJ(RQ^<@('47RW&E_F%J)G$-%RS5W]+P^:I;,DU[D>OWV<=
MT;2.!^>CD;T]%\)X7&*^%7_89;C\1(K;2Y''][[,09<JPI)$P!JI]:#_?+4[
M=ZS"MF:)_:-'XC'VVM:#,KKL@QWEN\Q4D?TZJ[4!:2?"OBON"X6"=Z6O3#?H
M/UE]3(@W38^JV?:.Y2KCVV%?.T :XL)==OQ!S;$/A;1VWZ.PVZ#SF%6?J)H_
M*8K6MK2+,AD]VW5P].OGK:KU(5^>3N-F9MV:/"ZTLY%O4!:<L!Z\V6!=]\S;
M,&#;M1CC^I]6E;MM^85D)=Y16(6S=E9JS1N;S;4NX.7*@A?&%V/-@TZXT)CE
M12 C)(H8\<%16-$O&_TSP3.;0 8(6+:#D2,IU/MA,*3$#*]IK\C:ZDJL;TCT
M^ F'1(;&4[+QZ)$D6/8\7PEMPIV:%+BKBBPI^83@*OML!?,9)1WL-@-9KBH<
MNF$]!WY8J@U-L@NX%QN.>1'SX,(,Q SD802GHL.D6%$B8L)*(C3]A3/;OWL3
MIT0J#[C3\L]- ;]_?H1PNSX0OAY[MLQOL=@R;_?$F!+]SVU2+?-JP!L4[G>1
M'CT"UV;PBN3DEEBH4+\__]T9QOY%I@BEEO'\V7.R'*TE>94#+(>XDN;FJ<PJ
MAN%S#JGT'D41Q<K] R3+0 9NHCY$A9]1DC_QS-N3HV*X!F*YFZ+-P':3$_;B
M L$.D\Y7,[ %4/]Y;B^_0WE +:V-M9[!!*)&:_:\+2C<X,-''\:@\(5785*P
M@"WY^YF+2G0A40&C#PUAQ(P.=>!VM,JT/.I5M;RZ+#(Q(AE<(N*NT279KQ;M
M'OB!K\WZW4+#PV93B#F,&9PFPDF]WFO%DI45S'ZW^XSNCKCP%XV0]\]1.J6R
M-8 _.#6(*C*<7 NW)'B7A4KBC1&"*I*K+9/^0JSMX316+A<3ZZ(L?=3715S,
M%T_4-[H0#(C4'*M-D<2,A::M:%XO6&4?HZRZ1<*W&=C7=N;+]<RB+G#,F\HW
MS(@0+A+N30J]D Z8AF)YCWNZ?*PSQZ'.-(;B4-.7:D^G485*E[>N/@3LO*>]
M_-3=JHM'(![@=9BZ9%QU[.^+ZTJOT!:A)*41LT[DF(' =@JE)Q0O]\62O,:M
MM)BR"_F!UQDO] /GKQ<D@$MUR@SGPJW\*:]LKA>:1FU"NY8EI82UQ$%!NA%G
MDZ,?J7N6<=BA\4G$+2SL$$B!!XZ5&OG*0Y54B5,SYAT6%A""Y^@3F4]T9/G:
M!1GE8O[I(G635N5@6Y*!G D5*XRP;M"RY?X])[H0^V+L_U8D6#":N!R(EZL0
M"W)IUP\'E5^!Z*02*\!7D[AXD(:T2M:FC;[/*7ZSUWKCG)^WM"ZY4_5"=-2A
MV\I17!%VX2UT&[S^X1N2@=.XDBY#"\>$"UJ>&XIYCS-.G0TI7)/]S PX8::8
MMM^G!MU-9XYQI)J/9+QY5VQ*>7I(#X>11KO\_2QC6NFG<IYR!"?%X^4#IL!4
M< 1YFPV.:LZ%$7 M,?]CSPJT2BUXJ6EP3Z)]CE)J:HB[#H[-^>>\A9.-/XPK
MKXKQ7..SHSK0"2]^Z X'_^;YF$A.2;.#7>A:'EU$<8"K]D,G7!)^E38^Q#AJ
M3G$8L_$=/V$M4LPIC^%X>X<Q;DF?RC&[Z::-9J!:H*%@;C?2-([]NQXSB0L1
MT3_V>L>:G$M##60>K4T_H4:OHED-3=+"C$5XP%^,:)S2T=/NS]B1X_.0!/7W
MBO-_#"E?ERU>K&B^-O$)7D8ZHX2+S??1G\.32"CIF]>F6ZX)D]VXX]HGNB2=
M)<16<%:WEEG@>>TVN=FR>\Z&BC;:&LY[J'B^I(IDLP&;<)_> SQ98^ P.*<\
MM+\Q$-20)/,6E_AB1)0%S2"N0"=XZ ID6&5R%(;)\ -+><G\IY0DUX*HAGYA
M+8+>U^V]/VL@*FHV_'@K,!A6KY"^F,,UEGPR Q$CE05S.><.<][ ZCU2U/E&
MQ3VT1G]?4R<?OF5:$:@Z[$YFG.6QI2YV47ET\M=KB2E?6=AE!J;\[&:J,[D0
M0K!(,)S6MY0R%9NMMN'^80T1D$[T)'%DSM!A+G6H9_G,W^C?!2X:M&AD[]V0
MZ?[K+S\E#DO'/GE//$%X[8!CPFPJWPE?Q*EX;@2UF1)*R2@&]=Z>>DJ[M\GD
MTKGVQV>RA5GQ=H!W&3GSD8W?[Z3"E1@LJF1#UQUV(L84J2"7=,]G?S[AUB<9
M PR<]18N_]EXGD#2/3]VL!NP.,'_>)CQ]#_'OA>SO<,Q,] ;1^; RU5_/&9)
MBV3C2)!I"[EC1^P?MT?>L7[HS$\8&;]I!OXUT2.92#SO=1YX\,:0P.'0]XUP
M&)',Y(\U[&!H7]/X37&;5CO?N#%Z*D![B3%H)UW:Q*Y04T*E5LC\0%56^'DQ
MR0]<%A'/]*0B2 ;.(F2.!K^I_-P@50NP+4EFX/72W8JQ\1&CS/OQ,;)JU;O)
M8>%SN133=F'!(F*U#V6B&V9K:!Y[)!P=4X[H[LP:N;C-#"PHK>J%10G1XYA7
MJ'^Q_QXUG=C&C<<R9<.68L$H9@HLCJD 6(VFSPUB0B2EX,.0@QF0MX*2.KCW
M+D@AUK&.XNG8";6R]VD9C*TTXJ^?/HI7?>L_KOBT*>F'29XRW@G\MT_+R:0D
M=7>08(U63\GUES)@#N4P)B*%1@OFB4H#U=MK9)$O05XG]Z5T'FOC\\D='1]-
MQ-S\ 6NKQ;)?H^JQ;7<HL\FSW2>,N/@+T>@UGD2S))JSIK:0Z4#GS3$#9P9[
MW,O-P*\%O4JA!*,5FS3]= OTB/#&SX-9;F_7FX'9[>RTX1+)PI**K39>#N]C
MY-=Z$">XEW2='<V)]0-J$0$)>8E>W%K>U</V;1MNNQPJEF]>["%']KX/*$6&
M;]^6=QUW\VD4&< &:KC^#B6#I)<_,#I&=K[[<L-!JG4N_K!',KR 'RA79ODR
M7VM;RF)%'=)>K.<+]7C22G5!J7Z<:P8&K*.G"+!HGG8$]2N'[T:S*QO1  \R
MC KL2%8K,HPI%.A/<20:SHV6JA/1#(+D%C))DIRYQXC'?LQ&F3=9+B&O9:/*
M,>S9AL?]]WTQQYAR;Z(!J\P23GHNY3YI<+^L0MB\(ARR@[,JJ^.\5]J0L3>6
M-]_?1>>H)D[F[_XW2_C_'/OE*A0^_/A0*3R$>'VL]>\\K]!.BAH088^50H-,
M*G;0^9AV4NN7C\*M$>!F87^,#,2C3OZV>(7V7L:PQ"&K78YE4:@1^:<JI?.$
M38]*' D(:19B.REG'-YG4M1W*;'![#(L;O#/<JVCK0\>UM5LFH&%3(A.3I?#
M//SF&&B%.AW1X,A%)A842222<.^V>)"".?:@=N/VGOW/F%TUQ Q=KQFXX/!E
MAIZ%_\YR#S5]1[017UAN?8M9]^T0J(ZY5"-ZUP!'QVNO?+-E_'2:#5PU'PLR
M?7-Z":0B=?@4>_1Z8914?Z&T%>I;I>:3Y7W N4^4X'@-ORR6"&2MO>#WW$]?
M=O.#\T;&5;#P..T@2H;>E C\13CSEW1AE>@R7.1>RTNN='BWIE+:"RV(DCKN
M'_1=%N%P:W*@5;.DE:'.@JLXT*G[M5Y.<;2EA&B)]RO.._RQ&5C.I(L+O3U4
MC")&$7?XV@FU2VW/<DU33C\=_8ZZOW\'XTGGT+5V=D+#-G'9KYY#OD>UDMRI
ME?6F%3V'$J(KWV95(*_EE;2G?H7_B[ W#VOB_-]_8['B!G$7%(@5E;:(2)&R
M9[14<8-H%5$04L2"B! 1D#49EPHJ2*I\%%FCHJ(B1$06%1+V2!6"!@@0)(2H
M,80E(0N39&9RAGYZON?[.^>/<UURZ>5%)K.\YWZ_[GF>YY[R@3W!3_A34B22
M>:  /?$4$Z,<4'Z0<)7!@GCZL[*BU=68D:&7 O/T(%W,H V5B,B0<_'PGS>V
M@PJZYB)RA^8P6GDA^H[". .OV8\[:V1#WWM<A<N*U"U+(RB%PKZS:.%)[K^2
M2'P&HY/0=V.I!AP!,O[LW Q"U@"\5"BJ[ZGO2&^((@3VC.M.%JU9"TFFT/M6
M=:'+-6<OZ9U2%\BS;FZZ(B+_R<:_V$-X/C,7K%5D9[R"!F<5 CDG=?/-0"X(
MA@AT\:7$_WK2QX>O)8/#V\8\_OFFAJ%OD$NT;U.=%0]JLN)\?A1W?IB@"2-G
M1KS6#O?B 0&LD!75T7?KCUD"[X!(9;E'_OE_TC&44MX=S6BRF*C&3OK&+Y>5
MJ#G!%^T)?=L_-\-5;*XQ T2[6=^IV9('.64URN3)R, [G9<^3S7^I"3&%)Q.
M3J'B9=)#(;=#VPVX' 9FD"P!1N_3QH6+\8.Z&5_ UO7K]G]IEND8BO(UMGA7
M XYJP(U:]:G&P.">\ X#[B%9@FJ+N1H$T*E_B=C0P6;+&,JOU,JM*^O:*] 2
M@25[$SO-+>$)-U9?2_]/TJ>%"FV*'A/W0_F=-RAJH>9+B@'G"VRJ_P%-6.D8
M:E0C4I>?L[E!&L(/2K0*[D, 0)]52O0T!I)\UX)(F@C!3.TXEQV=.'G] -_%
MN!#[,"8KI"_H9.=45LQX$=LW=[+W4?.6H>-=.MKL<#GL(I9+_<>/C;@S;+G5
M>@"N2];ISG*53ZV^*QW2^+,0>QIKKPGC9P*Y&]LIAW7*I/Y*Q<S8"IHBL; J
M&2FTW0ENB#HT-#"<1>LO -7L9L](?^_NAVQ$Y1@X*#B*YV 4R"^09*E%(BAG
M8TNH 5?9G>,T?IP7,22()5-_-BK)VL66T/D,60'-,D)-=_KD8,"]C:1]5/8^
M\F%&[&N74-DD%7?@>:P,I9:.$9E594]80KDIY:F]O>Q+W%#,-'PIM-TY>SV\
M&=/.!D*TQA.X,\Y1#<?3,QGS51$>U_PYQ-6\Z-@/4U]IA=POCN/!00GZ@S1N
M<M!D89+B0%,HIHOT*@Q\^\3RI_47 X04WJ=0=;H$2>5F L,/P9J5+>R^C.9@
M/)0C8BXXFLAHRA->]7"X\[%_(/"X =?R\3*Q'F]5%WLQV%G.0.<?P4Z.&:V[
MR%)NC#'3KZ@9_(,BZUH)AH.KD6>QI9&OSDL>=WIN/FTL"B14[<B76VM&]<:7
M4K]3%.LIS4,K,4;YL[B%9E4IV5V_ROGQ&MKA!AU_N9RI60[MT>].S&@6+O<(
M<1Y(=9 /7@,:DCT9\&[V,\P?H:'" 2&=UJ.U EJ>;EIZ)<?T_LSX0'1=]:L
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M0A1%KC86_/H_O'RL;DFEDA0XBT"Q%02-\V'N?(B@=X-_0A@JLQ= &LNLYL.
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M.RA;'&.RBF4\/NR^;_80>=)1@N?+4"I26T[>I]_(7[KZ[>MK>6&[=#H)<="
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MO.H'3$5"-/CGQZQ)E#DSIROHP.G4"M_DZ;>\7F75+U>0Z,:A7B&[N&FCT!3
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MTN<HM%S\!%,EIJ69<;;A23)AMTI&O5/BK!RZ<ENF&]A]Y4ZT;CFIGMQZIW\
M^3,T?3A>WI-MT#A<E.DZMB2,HA ;8-Y#LWS>(7EH.CB^:\;/6LPS-7R-<G55
MA;$T6O>KM9U772ANOM'&=-W*F0,SO,NZ<PP61:WU*QDYZ^M>NRW!L_@Z*ZZ6
MOU.!'(7IE.NC1N Z(%P&3SB^7K76"!RIUV(< ^-[N=%A8?3"Z5C GT?PU5^;
M81@EGVJ&1ZY^>_M&X$W&!.C>*L1LRWO_+]&) [''+.O/)@)V0:-!]_WG)8L:
MGC34-V"8]8HL"D==N,*J=$LW=A*:++"C# 7Q[.$ (7Q&33#L<5Y8JW(DVS3T
M*J8RJ5Y0%BN/O_PN/KR@&)B7U.'V-)<VA)KB  +*)?))XR:NEH;V# VQWIEQ
MK<F;,#"@"3!]L0V:=D?W1*D&!3-8;&7)_Z/^M3H'B46:N$@3>!,!G$=JIC-I
MPQ F/@6P?]D@)LG<"_< ]XG294[?9CCY6%:*K!\@>L0'_>M%)O9=^\RX[1ET
M9^;YM"1I!_//IVGJ),+I$MLZ"9I#1GG9X_$:_? T<)327QN$8&32SIHSF&3&
M7>L";,#RG^D\#+M6D$^K[V)^:4S4*V=OSTA"[S[H]"R.B86F'ZGY8@Q3R&@=
MYL>@(^!SBI^ULK %_4)(MDVM\%?]7G]?0O+]465?Z_WNB[SC-OAE4YM?O&P>
M=PN"4C-IR*V5U<J\R8O*PG!HT_T8-%\5V6;'504GFA+)1GE/8A6CXA]A+79]
MS81W3(?4P1;.[.XI#ZJC(8^BO,K ,M[]Z1V19;X"\V=X2"6%%S\:;+M1R<_&
M#$$N>96!-^*(Y*"+YOI&FG&S/USO\%XVFN'L)6MV<;'T5@9SEV3^)GSH%P^%
MP50A?075C..9<; ;XCR^QW L67HA'=2J>NB%,,FP:YAP*GW_&S^K8838LKNO
M>9]S3R37U0^B7^-O+:]\:F6,B8*6HSW<QT-UL1+"0)3D<(V8.">":?QJ:):E
MG3#_C1DW;EV1/+4-**;GP"N10O0S>&[M&8&8?V(C:=%P/')?1ZV?8%_3N@"Y
M>.N2C*PEHYV]- TSN)5+X;&=,I(C>'J DX-?(653@^D<>#?N<!:CLU$-2Y96
M7N=Q_ECO@XGX%;ON[9^)M/CN H %"&3P)&_=#-@S3&=&@(170P\E_]O>6.T<
M<BJ5R]IXL[$GC-NYZ8O9F""_2I7T@7E:T^ZFD)D.V.COW""YLX<5W+SDHQFW
MQ"679F7(4Y" 6JV5AB<NP!L.-_WGWR*;9R/Q,XWX$:*AT++%]L )7OP@L=Q/
M;^K^@G82G-G6Z&#&[?\EHBYBFS+(CYGKO,#YZ@GU5+IN"B,A9[?><>LQ?K^C
MD5G+;Q5(D][4:)8!!< :K6;>'W'O@!X)LA@L\(ED8[E"3[&4*2= ?@;KK@5A
M86 DG<G "[EU67;,F86 5H9LQ<6\2\/3/)U>\(WZKB#;CJ\9 J/).>!. EMV
M_?N5N0O/C8U*4=(L*WZ<T7I\/NZ( __#^^N8IM$]YY%+BB>$Q82+N@* JM1*
M9?PF^GYX/]+HCA+E0ROS6CA++-,%GJ.$IVA';^,6S)REYU&I:%T$4@C&;>-&
MS\] %]Q_')AEV^:S3SA8A0Y0X)R.]*B)A&P%WQZ'?*Y:)5*Y"&MU&4Q-!)-*
M:87/E T7W3/CQ,NJ<Z,YKQ$?W42:?/J<\&, O,3RGID_F73+L!S$&>)$80VJ
M/-WY4^^N_GC<![P$;G:;B;2(1G5FJB'J5K@AIHWY^6HX5L)<0#"4'=-@G*Z@
M/@+[6@>Y,]/[*CX;"%K]-H:VLP]]:<8=-G5JZX7"*2X_TC38XU[Y^)EO!02]
MRH@)!#67TQ[LR\I]0?=+[$J3<'Q"U!<Q<1" G><EG0]^J?#S58)B?#ZC'7"<
M*/F/G;-+WG,[KO)BGZQ8F?G#G&7R2PV.D5[+6#<R/96@SC(TY<0VPCD@CC(8
M&6A8J7RF,.,&>[G6Z-(/3JZ[L#M))<Y8J0AJJ4GX&#Y>:Y' ]&:P]O"=4OIK
MT;Q,3\FT;6JI&8?^V*  Q2[OP,<8SN7K=?4^IDB1MWS?GDQ2S382Z!X"3D N
M77O34Z^P8?SOG ^4;/1+>ANXG'L,R[_FY7D*R@AE46J@;ILJ-ZEXJ8[V6.6J
MJZH8J7HB;/SO9HD_;$/R#='Y#C/R.+,-(>+5Q&:RE;***6;A#9GSB3\JT>LQ
MY[^9E[Y_8;?V)1[(F]%_&G&"-&5ZBJEG=XN43_P\::5AX4>X,WY$ Z;5]F-\
MH'8GQ.65^XV&3/+R@>$*YB/*J4,SH/@[H=^V6-VOP?<M]8[<VZ,I+C6\^GX.
MT39)&U7'&LS(-/4];%UEXG!"C#3I&+WP\)'1&\NX(P==I9,2^\?V^A?/G93>
M<#XM'FKVDX,:4$.K&=1(9I[K+(-OQ $=?,-J_O,PXN>I)]USGH;D)[DO7GV_
MNJZQ\<T+XL#G^T>M<W@__.&-SQ',,'7)V-V^3G\W$%"PYN&:I'W 3J[A\D-,
M5Y5(VAS-N .$[6#!'^2ZY\C%,VVAIA3*%+T8K+1[XHAGMVY2E&9,UTX+*/)(
MR+VGSFW^&I'"4Z];'EM ,&WE;8^L]HLBS5;<,%)' $4-M"ES@_JAQS119KJ"
M<$V>NDV8G++]U<:7$0>77%O&ZES6B">T5S ,VX CHL&#$HB( E@ZV"J+A;K=
M5Z)D1I5"4)=%4@I:064P\[,TSQOT"C&PZ.ANG:.<O (+A]O/[">XWWXN_=R&
M^4_>B5:Q_EG6)0XGMHD<-W D+6AO77^=?E-!U!ZDB;P1_JEW32*FEX=M;E?V
M8=ZGO62%92#9[BS(&:0&7PD%^D6Z8>3VFM4L=!T<+8"MQ!*^#LC.?O3N&$*)
MY]-_3)-3#\JH=5&3=\H8U4>< 67QN=WOD:*@.FNEO6.RHC,14/81:]/46,R>
MNB]^J!^]23A0D":YI3A3]/)8*2=T6G\,J! ]K)N9RD24>G1..41.W3W2VD9>
M6]=+7I7ZZ#WXHG7D@S^T0R6P=O(Y)!7F1+R\B_X#?-;HJ?IQ4.)\9;CSN\$.
MMAVQKY?-Q*#ZA]IJ4V0)S]M;QMBC90QNT&6>#>QQGT2_2XT;"R,Y[.#:&4E
M>7E$NO0>2_JS&IU+L_2&M?P"@G=2@><#HFRNV 7EHYB/OP>62XT2V;Y$<MT^
MTJ=1G@#P>KQ5^:#CZ-L)+;M(CJ01>_WBP_::<7?]T0J4%%<U1VKM"&D5V27%
M#XCU@9ZF(@BS%S-R+!+U"AX7?(U9R9,5]-?.2Y1 KL>T?6HA OSV!A4E18DA
MZP=9#"$7'$UC6:F(\-)(W3%VX$4Q]TMXLVJ-;_^XJ%P:$>PJ]Z1S#LOS!I+K
MS_)KV>/T4?]50U12/ .4\Z4:K8OZ;QT,MEIK-/*;PF$2#[;;L$NUFZECXC(]
M>U9SWG3+[9J:?"15Y+PSM\VX^6\P,[+E:7WUVSIN'HJK!V:,#U,FO>6\JH0S
MZG][F3\@N3#W#AHUK1T]WM\NW>X+FDP7"U*QZSG(Q1S:47>#V](6:C]WY)#H
MR^E)C[E,Q\$!Y)F"^7O'%82)!K#OC<=@4D+\%7+;[T!2@F<!&"/ZXLB%K$*4
M# -)EGG"&C,.*  7@<?X>'DZH8.QH/6!H44R\NY49Q6F\&=/GW7' RHOF5$J
M%Q4<:3M0$SPHE\^0!T]Y);C5J5,<TEF^29H 3046.%_>ADB&BF9KG@_K#+?&
M'7UEQOW'C.OG?'C 0.O3I(+L&Y@'$[.!HXR!_W3)@Y#K')S\:=Q?<1SL!\ZU
M;>>JOI.4ZY@ZRH$)4L8(Q_W3]F5 +9"#+@A++1]Y37:H4^D*'V;EO%1]4?W"
M]-EL$EJ2YT?O'3?CZ@(F7XJUT&>8'VMZ_(,0]5.HT+R2ZRZ 5#-(R&OKW@>9
M<9C&M,T[H^SWP*/-)46^;LF/V*+*=U.LA)'51'2.5@5)\*</J#P58="6B1M#
MA><8UH853M^D[Z_^_!#JZI1 I<%$Y!P01<C1U8N4IV#O[J[;#(Q*:'*B:J-J
M(3_S(G\8[^W8RX<W!4SR42YJ5V*I)MQ.]XA!'1QTQ]2K:U0[6P]ALETX"A+4
M0T^S\K2(BX13T\]R?SNDIW.SITN[["529'F+R.X)9O<*6QE2S40"?]95T<N9
MCZ\]ER>ZE ]XP;4O%**[!&'S(:0*.'RL#10?38WI0UC ?=C2B@SS1\H5[<JY
M8GXK8&<0!1C.WC;<15\%]*QYN-'2;TED&WA^^QU-42[%[X=CM<DF=QC/'RM,
M6*PZ/UV6!2.4Q^("%'C?ZL$ESBC3FLTXTA-R#QC5N>IBVH=:]((W'Q0R*1\9
MG=/](O1+5V782-YS!,]#O56YA</S,Q34_5RE5B&"@U)=V"!:,])DH=.3%^C_
M^$296/G)ID(D+50/QS?K%X>THB7[F@!61\UB7UV8Z!](9(+)4O9,I+KQ_GE^
M/;W8C&L&SP-=B(C: P+E,GXHW L:OI5.]A_^^FJ+&1>.)<Q-3>Q.@<L]K^E!
MOZ3IB(S[X/,(#DYV5_I2R6J;RX!R$I@?.T/>B;2T&=<^ &._9B#TZR),:%P5
M-6A1$(.<-=\M(_(O4=_SBS)8KQ->2.%XP1FXH C]4JVL&@;;+HNI;>?CI-AY
M:&HFRD[_J 4-;L3+MT0QQV$K0TYIV%P*&V'MJ9,P::^<GD5ZL'N<,MS6Y+._
M>C=A2E3T,"N,O"G@]P,W^JN^SEUV"TMF)DM3E:9[KJW\&0WXM+IC^!;/HR[(
M3%2AEX>AF*R?S;B1KAJ,->>,HRN>\G6$< 95BE!D]#NW++VSC;%)&X>\#'(Q
M]]13\CU ,MBJ(\[,-^-<A(-OSQA_)-KH=\OOLN4QOF#8E4DB*)\"(NO<%Q@R
M @I^ 2OZHIVWK$!*Q^.G_OB-<>RS@'1C!0^L+YP<'+X6![ YKM')PDT84+9T
MR14\ 'W(K/(Y8\B@8$\OP^ 0<0F[XR-"Q3J5:_L %A07NCQ8D\7?2.2F=.)]
MUBT_3^@KM-W9&O)DWHH><N&R'6.6OT3?^4E9CI'=4?("-_<#N;>?I<O+-WL1
M[<'GO\!6&Y <,;65Y9CY$T<6DQ%5AA%\A0 (QZ!-B"<JHJ%X^+=K0<I:79+S
MG#>3J\%ZC_,A;<5):]9O-F5?UI"OL=ZZVX1EVBFS+N2UW$CY4_/J0,R+1W6.
M$O8/\1<OGR.FBS -IWZ^J;=>0)UX2B^*38C1A85MF-8H-#KY7BH!+#:EY[U
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M[?>C'75O)A59(/&5:(;5P^I?.AR0#T11<TR>+=0EJ9=$;5>'EC9 L\X_W#N
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M<,#9+J<E%#BA+?;_$5HB=MW5R+LETUH[_]V-'_<#")G$CZK2L,CN<U*G9W\
M+S540TB)#>8+OF*.@2U/H>C,ON=3 '\<7%Z[#Q>?/TSYLG7E]8UAQPKZ8%)Z
M9#VX_"RZ@(F?+D)7/05IK4K24^?&#/6^]H-I%WA?Z:?H_(+YS\?!>Z-13IR_
MK%YO&P;PU_BPI4$5C#V98;-^UOIT8K/2;6Z DG(J,8LL15<Q5:HD[*Y<Y:#<
M/+&0Y3',K,<K\".$_L%FG?.FMYIH;=,F2:A $U/!,,[X/$<SK0V1+F>& 7&I
M7TRLBB<NS'Y([ASAV\ _*<_GLN\=03SV6?LQ@XU _D8K_2R&F#I_7!^1?.4
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MO%8IU76>:OI8!=0FJD0A9IP-_3%F>\?2OO4L9E1+<,-1-^.9_W""D+_!J&^
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M>*OY,,N,:S/=S2^3I5#C-B6#,_KG:!- 2)]Q/P4^\LAKY9Y?"M@?4*&W*_O
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MJ 4D&.:8^_\?4$L! A0#%     @ S#Y^5@Q$TY[A&0  ;3H! !$
M     ( !     &-A;F8M,C R,C$R,S$N>'-D4$L! A0#%     @ S#Y^5@+;
M;(:("@  C&\  !4              ( !$!H  &-A;F8M,C R,C$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( ,P^?E9]K(QC[T$  +G@ P 5              "
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M+FAT;5!+ 0(4 Q0    ( ,P^?E965X7G@((   CH P <              "
M <'4!0!F,C!F,C R,F5X,2TQ7V-A;F9I=&5B:6\N:'1M4$L! A0#%     @
MS#Y^5GZ>E$,7!P  GR0  !T              ( !>U<& &8R,&8R,#(R97@Q
M,BTQ7V-A;F9I=&5B:6\N:'1M4$L! A0#%     @ S#Y^5JZD4)0?!P  HR4
M !T              ( !S5X& &8R,&8R,#(R97@Q,BTR7V-A;F9I=&5B:6\N
M:'1M4$L! A0#%     @ S#Y^5HE=:?^"!   C0\  !T              ( !
M)V8& &8R,&8R,#(R97@Q,RTQ7V-A;F9I=&5B:6\N:'1M4$L! A0#%     @
MS#Y^5D(0]*Z*!   2!   !T              ( !Y&H& &8R,&8R,#(R97@Q
M,RTR7V-A;F9I=&5B:6\N:'1M4$L! A0#%     @ S#Y^5FE'+O*S P  I10
M !T              ( !J6\& &8R,&8R,#(R97@Q-2TQ7V-A;F9I=&5B:6\N
M:'1M4$L! A0#%     @ S#Y^5K^'X C8R   2.H   T              ( !
MEW,& &EM86=E7S P,2YJ<&=02P$"% ,4    " #,/GY6BH]9YT.>   )J0
M#0              @ &:/ < :6UA9V5?,# R+FIP9U!+ 0(4 Q0    ( ,P^
M?E:BVHE4ADX   ]1   -              "  0C;!P!I;6%G95\P,#,N:G!G
M4$L! A0#%     @ S#Y^5C3+\M4I"0  O D   T              ( !N2D(
M &EM86=E7S P-"YJ<&=02P$"% ,4    " #,/GY6@<L3XN>L  #KO@  #0
M            @ $-,P@ :6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( ,P^?E8(
M1"^2%C<! *Y+ 0 -              "  1_@" !I;6%G95\P,#8N:G!G4$L!
M A0#%     @ S#Y^5B-8.HU0L0  2KP   T              ( !8!<* &EM
A86=E7S P-RYJ<&=02P4&     !, $P#N!   V\@*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
